chembl_id,drug_name,SMILES,KG_relevance,Evidence_strength,ADMET_safety,Composite_score,Confidence,Evidence_Summary,Sources
CHEMBL107,COLCHICINE,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,76.73913043478261,100,100.0,90.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -1.12; logP 2.87",repurposing_candidates.csv:rc_row=21;protein_drug_candidates.csv:rows=821;1554;1989;2228;2333;2397;2704;2768;2832;pathway_drug_candidates.csv:rows=1534;1598;1662;1726;1790;1854;1918;2083;2147;2211;2275;2339;2403;2467;2531;2595;2659;2723;2787;2851;2915;2979;3049;3113;3177;3241;3305;3369;3433;3497;3561;3652;3716;3780;3844;3908;3972;4039;CYP3A4_results.csv:row=21;CYP2C19_results.csv:row=21;CYP2D6_results.csv:row=21;CYP1A2_results.csv:row=21;CYP2C9_results.csv:row=21;hERG_results.csv:row=21;AMES_results.csv:row=21;PGP_results.csv:row=21;PAMPA_results.csv:row=21;BBB_results.csv:row=21;Solubility_results.csv:row=21;Lipophilicity_results.csv:row=21
CHEMBL1201752,IXABEPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,76.73913043478261,100,100.0,90.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -3.06; logP 4.05",repurposing_candidates.csv:rc_row=309;protein_drug_candidates.csv:rows=808;1540;1975;2217;2319;2385;2692;2756;2820;pathway_drug_candidates.csv:rows=1521;1585;1649;1713;1777;1841;1905;2070;2134;2198;2262;2326;2390;2454;2518;2582;2646;2710;2774;2838;2902;2966;3036;3100;3164;3228;3292;3356;3420;3484;3548;3639;3703;3767;3831;3895;3959;4026;CYP3A4_results.csv:row=278;CYP2C19_results.csv:row=278;CYP2D6_results.csv:row=278;CYP1A2_results.csv:row=278;CYP2C9_results.csv:row=278;hERG_results.csv:row=278;AMES_results.csv:row=278;PGP_results.csv:row=278;PAMPA_results.csv:row=278;BBB_results.csv:row=278;Solubility_results.csv:row=278;Lipophilicity_results.csv:row=279
CHEMBL1683544,ERIBULIN MESYLATE,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O,76.73913043478261,100,100.0,90.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -0.19; logP 2.94",repurposing_candidates.csv:rc_row=507;protein_drug_candidates.csv:rows=811;1541;1976;2214;2320;2386;2693;2757;2821;pathway_drug_candidates.csv:rows=1524;1588;1652;1716;1780;1844;1908;2073;2137;2201;2265;2329;2393;2457;2521;2585;2649;2713;2777;2841;2905;2969;3039;3103;3167;3231;3295;3359;3423;3487;3551;3642;3706;3770;3834;3898;3962;4029;CYP3A4_results.csv:row=467;CYP2C19_results.csv:row=467;CYP2D6_results.csv:row=467;CYP1A2_results.csv:row=467;CYP2C9_results.csv:row=467;hERG_results.csv:row=467;AMES_results.csv:row=467;PGP_results.csv:row=467;PAMPA_results.csv:row=467;BBB_results.csv:row=467;Solubility_results.csv:row=467;Lipophilicity_results.csv:row=468
CHEMBL2068724,ACAMPROSATE CALCIUM,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2],79.73684210526315,100,95.0,90.64473684210526,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -0.76; logP -2.27",repurposing_candidates.csv:rc_row=642;protein_drug_candidates.csv:rows=505;713;1434;1520;1611;1658;1704;1746;1779;1800;1873;1934;1957;2065;2111;2185;2472;2559;2581;2606;2629;2650;2674;pathway_drug_candidates.csv:rows=3619;6803;6830;6857;6890;7048;7075;7102;7129;CYP3A4_results.csv:row=588;CYP2C19_results.csv:row=588;CYP2D6_results.csv:row=588;CYP1A2_results.csv:row=588;CYP2C9_results.csv:row=588;hERG_results.csv:row=588;AMES_results.csv:row=588;PGP_results.csv:row=588;PAMPA_results.csv:row=588;BBB_results.csv:row=588;Solubility_results.csv:row=588;Lipophilicity_results.csv:row=589
CHEMBL1200694,SEVOFLURANE,FCOC(C(F)(F)F)C(F)(F)F,80.80091533180779,95,100.0,90.57036613272311,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; logS -1.90; logP 2.42",repurposing_candidates.csv:rc_row=153;protein_drug_candidates.csv:rows=509;524;527;532;537;540;1404;1438;1523;1662;1708;1749;1782;1803;1876;1937;2069;2115;2476;2562;2585;2633;pathway_drug_candidates.csv:rows=0;3;6;9;12;17;22;7724;7729;7904;CYP3A4_results.csv:row=151;CYP2C19_results.csv:row=151;CYP2D6_results.csv:row=151;CYP1A2_results.csv:row=151;CYP2C9_results.csv:row=151;hERG_results.csv:row=151;AMES_results.csv:row=151;PGP_results.csv:row=151;PAMPA_results.csv:row=151;BBB_results.csv:row=151;Solubility_results.csv:row=151;Lipophilicity_results.csv:row=152
CHEMBL428647,PACLITAXEL,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,76.73913043478261,100,85.0,86.94565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -6.18; logP 3.74",repurposing_candidates.csv:rc_row=1154;protein_drug_candidates.csv:rows=810;1544;1978;2218;2322;2384;2691;2758;2819;pathway_drug_candidates.csv:rows=1523;1587;1651;1715;1779;1843;1907;2072;2136;2200;2264;2328;2392;2456;2520;2584;2648;2712;2776;2840;2904;2968;3038;3102;3166;3230;3294;3358;3422;3486;3550;3641;3705;3769;3833;3897;3961;4028;CYP3A4_results.csv:row=1018;CYP2C19_results.csv:row=1018;CYP2D6_results.csv:row=1018;CYP1A2_results.csv:row=1018;CYP2C9_results.csv:row=1018;hERG_results.csv:row=1018;AMES_results.csv:row=1018;PGP_results.csv:row=1018;PAMPA_results.csv:row=1018;BBB_results.csv:row=1018;Solubility_results.csv:row=1018;Lipophilicity_results.csv:row=1019
CHEMBL3545252,DOCETAXEL,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,76.73913043478261,100,85.0,86.94565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -6.30; logP 0.79",repurposing_candidates.csv:rc_row=985;protein_drug_candidates.csv:rows=807;1543;1977;2216;2321;2383;2690;2754;2818;pathway_drug_candidates.csv:rows=1520;1584;1648;1712;1776;1840;1904;2069;2133;2197;2261;2325;2389;2453;2517;2581;2645;2709;2773;2837;2901;2965;3035;3099;3163;3227;3291;3355;3419;3483;3547;3638;3702;3766;3830;3894;3958;4025;CYP3A4_results.csv:row=879;CYP2C19_results.csv:row=879;CYP2D6_results.csv:row=879;CYP1A2_results.csv:row=879;CYP2C9_results.csv:row=879;hERG_results.csv:row=879;AMES_results.csv:row=879;PGP_results.csv:row=879;PAMPA_results.csv:row=879;BBB_results.csv:row=879;Solubility_results.csv:row=879;Lipophilicity_results.csv:row=880
CHEMBL1201748,CABAZITAXEL,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,76.73913043478261,100,85.0,86.94565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -6.01; logP 4.57",repurposing_candidates.csv:rc_row=307;protein_drug_candidates.csv:rows=813;1546;1981;2220;2328;2392;2701;2763;2827;pathway_drug_candidates.csv:rows=1526;1590;1654;1718;1782;1846;1910;2075;2139;2203;2267;2331;2395;2459;2523;2587;2651;2715;2779;2843;2907;2971;3041;3105;3169;3233;3297;3361;3425;3489;3553;3644;3708;3772;3836;3900;3964;4031;CYP3A4_results.csv:row=276;CYP2C19_results.csv:row=276;CYP2D6_results.csv:row=276;CYP1A2_results.csv:row=276;CYP2C9_results.csv:row=276;hERG_results.csv:row=276;AMES_results.csv:row=276;PGP_results.csv:row=276;PAMPA_results.csv:row=276;BBB_results.csv:row=276;Solubility_results.csv:row=276;Lipophilicity_results.csv:row=277
CHEMBL4298167,FILGOTINIB MALEATE,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O,63.649885583524025,100,100.0,85.4599542334096,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -3.06; logP 1.69",repurposing_candidates.csv:rc_row=1246;protein_drug_candidates.csv:rows=760;783;1187;pathway_drug_candidates.csv:rows=185;208;405;647;670;784;4237;4269;4416;4523;4557;4580;4606;4636;4659;4685;4715;4738;4764;4784;4805;4822;4845;4871;4891;4914;4940;4957;4980;5006;5023;5046;5072;5090;5116;5133;5156;5182;5211;5232;5261;5282;5299;5322;5348;5365;5388;5414;5430;5459;5480;6912;6935;7469;8298;8326;8354;8388;8416;8444;CYP3A4_results.csv:row=1068;CYP2C19_results.csv:row=1068;CYP2D6_results.csv:row=1068;CYP1A2_results.csv:row=1068;CYP2C9_results.csv:row=1068;hERG_results.csv:row=1068;AMES_results.csv:row=1068;PGP_results.csv:row=1068;PAMPA_results.csv:row=1068;BBB_results.csv:row=1068;Solubility_results.csv:row=1068;Lipophilicity_results.csv:row=1069
CHEMBL5315119,UPADACITINIB HEMIHYDRATE,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O,63.649885583524025,100,100.0,85.4599542334096,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -4.98; logP 4.99",repurposing_candidates.csv:rc_row=1394;protein_drug_candidates.csv:rows=761;784;1186;pathway_drug_candidates.csv:rows=186;209;404;648;671;783;4238;4268;4417;4522;4558;4581;4605;4637;4660;4684;4716;4739;4763;4785;4804;4823;4846;4870;4892;4915;4939;4958;4981;5005;5024;5047;5071;5091;5115;5134;5157;5181;5212;5231;5262;5281;5300;5323;5347;5366;5389;5413;5429;5460;5479;6913;6936;7470;8299;8327;8355;8389;8417;8445;CYP3A4_results.csv:row=1203;CYP2C19_results.csv:row=1203;CYP2D6_results.csv:row=1203;CYP1A2_results.csv:row=1203;CYP2C9_results.csv:row=1203;hERG_results.csv:row=1203;AMES_results.csv:row=1203;PGP_results.csv:row=1203;PAMPA_results.csv:row=1203;BBB_results.csv:row=1203;Solubility_results.csv:row=1203;Lipophilicity_results.csv:row=1204
CHEMBL3301607,FILGOTINIB,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,63.649885583524025,100,100.0,85.4599542334096,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -3.43; logP 1.98",repurposing_candidates.csv:rc_row=941;protein_drug_candidates.csv:rows=756;778;1183;pathway_drug_candidates.csv:rows=181;203;401;643;665;780;4233;4265;4412;4519;4553;4575;4602;4632;4654;4681;4711;4733;4760;4780;4801;4818;4840;4867;4887;4909;4936;4953;4975;5002;5019;5041;5068;5085;5112;5129;5151;5178;5207;5228;5257;5278;5295;5317;5344;5361;5383;5410;5426;5455;5476;6908;6930;7464;8293;8321;8349;8383;8411;8439;CYP3A4_results.csv:row=845;CYP2C19_results.csv:row=845;CYP2D6_results.csv:row=845;CYP1A2_results.csv:row=845;CYP2C9_results.csv:row=845;hERG_results.csv:row=845;AMES_results.csv:row=845;PGP_results.csv:row=845;PAMPA_results.csv:row=845;BBB_results.csv:row=845;Solubility_results.csv:row=845;Lipophilicity_results.csv:row=846
CHEMBL2105759,BARICITINIB,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,61.81922196796339,100,100.0,84.72768878718536,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -1.71; logP 1.10",repurposing_candidates.csv:rc_row=710;protein_drug_candidates.csv:rows=757;777;pathway_drug_candidates.csv:rows=182;202;644;664;4234;4413;4554;4574;4633;4653;4712;4732;4781;4819;4839;4888;4908;4954;4974;5020;5040;5084;5130;5150;5208;5258;5296;5316;5362;5382;5456;6909;6929;7463;8292;8320;8348;8382;8410;8438;CYP3A4_results.csv:row=655;CYP2C19_results.csv:row=655;CYP2D6_results.csv:row=655;CYP1A2_results.csv:row=655;CYP2C9_results.csv:row=655;hERG_results.csv:row=655;AMES_results.csv:row=655;PGP_results.csv:row=655;PAMPA_results.csv:row=655;BBB_results.csv:row=655;Solubility_results.csv:row=655;Lipophilicity_results.csv:row=656
CHEMBL1795071,RUXOLITINIB PHOSPHATE,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,61.81922196796339,100,100.0,84.72768878718536,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -2.99; logP 2.54",repurposing_candidates.csv:rc_row=577;protein_drug_candidates.csv:rows=762;786;pathway_drug_candidates.csv:rows=187;211;649;673;4239;4418;4559;4583;4638;4662;4717;4741;4786;4824;4848;4893;4917;4959;4983;5025;5049;5093;5135;5159;5213;5263;5301;5325;5367;5391;5461;6914;6938;7472;8301;8329;8357;8391;8419;8447;CYP3A4_results.csv:row=523;CYP2C19_results.csv:row=523;CYP2D6_results.csv:row=523;CYP1A2_results.csv:row=523;CYP2C9_results.csv:row=523;hERG_results.csv:row=523;AMES_results.csv:row=523;PGP_results.csv:row=523;PAMPA_results.csv:row=523;BBB_results.csv:row=523;Solubility_results.csv:row=523;Lipophilicity_results.csv:row=524
CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl,60.69794050343249,100,100.0,84.27917620137299,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -1.76; logP 4.08",repurposing_candidates.csv:rc_row=220;protein_drug_candidates.csv:rows=710;1013;1612;1955;2182;2602;2651;2675;pathway_drug_candidates.csv:rows=3616;6643;6800;6827;6854;6887;7045;7072;7099;7126;CYP3A4_results.csv:row=218;CYP2C19_results.csv:row=218;CYP2D6_results.csv:row=218;CYP1A2_results.csv:row=218;CYP2C9_results.csv:row=218;hERG_results.csv:row=218;AMES_results.csv:row=218;PGP_results.csv:row=218;PAMPA_results.csv:row=218;BBB_results.csv:row=218;Solubility_results.csv:row=218;Lipophilicity_results.csv:row=219
CHEMBL1096380,PLINABULIN,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,76.73913043478261,80,100.0,83.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -5.10; logP 0.74",repurposing_candidates.csv:rc_row=46;protein_drug_candidates.csv:rows=830;1563;2000;2239;2342;2406;2713;2777;2842;pathway_drug_candidates.csv:rows=1543;1607;1671;1735;1799;1863;1927;2092;2156;2220;2284;2348;2412;2476;2540;2604;2668;2732;2796;2860;2924;2988;3058;3122;3186;3250;3314;3378;3442;3506;3570;3661;3725;3789;3853;3917;3981;4048;CYP3A4_results.csv:row=46;CYP2C19_results.csv:row=46;CYP2D6_results.csv:row=46;CYP1A2_results.csv:row=46;CYP2C9_results.csv:row=46;hERG_results.csv:row=46;AMES_results.csv:row=46;PGP_results.csv:row=46;PAMPA_results.csv:row=46;BBB_results.csv:row=46;Solubility_results.csv:row=46;Lipophilicity_results.csv:row=46
CHEMBL538943,VINORELBINE TARTRATE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,76.73913043478261,80,100.0,83.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -4.64; logP 0.51",repurposing_candidates.csv:rc_row=1400;protein_drug_candidates.csv:rows=825;1558;1993;2232;2337;2401;2708;2772;2836;pathway_drug_candidates.csv:rows=1538;1602;1666;1730;1794;1858;1922;2087;2151;2215;2279;2343;2407;2471;2535;2599;2663;2727;2791;2855;2919;2983;3053;3117;3181;3245;3309;3373;3437;3501;3565;3656;3720;3784;3848;3912;3976;4043;CYP3A4_results.csv:row=1209;CYP2C19_results.csv:row=1209;CYP2D6_results.csv:row=1209;CYP1A2_results.csv:row=1209;CYP2C9_results.csv:row=1209;hERG_results.csv:row=1209;AMES_results.csv:row=1209;PGP_results.csv:row=1209;PAMPA_results.csv:row=1209;BBB_results.csv:row=1209;Solubility_results.csv:row=1209;Lipophilicity_results.csv:row=1210
CHEMBL501867,VINCRISTINE SULFATE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,76.73913043478261,80,100.0,83.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -4.09; logP 2.86",repurposing_candidates.csv:rc_row=1345;protein_drug_candidates.csv:rows=824;1556;1992;2231;2336;2399;2706;2771;2835;pathway_drug_candidates.csv:rows=1537;1601;1665;1729;1793;1857;1921;2086;2150;2214;2278;2342;2406;2470;2534;2598;2662;2726;2790;2854;2918;2982;3052;3116;3180;3244;3308;3372;3436;3500;3564;3655;3719;3783;3847;3911;3975;4042;CYP3A4_results.csv:row=1156;CYP2C19_results.csv:row=1156;CYP2D6_results.csv:row=1156;CYP1A2_results.csv:row=1156;CYP2C9_results.csv:row=1156;hERG_results.csv:row=1156;AMES_results.csv:row=1156;PGP_results.csv:row=1156;PAMPA_results.csv:row=1156;BBB_results.csv:row=1156;Solubility_results.csv:row=1156;Lipophilicity_results.csv:row=1157
CHEMBL572284,OMBRABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,76.73913043478261,80,100.0,83.69565217391305,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -4.14; logP 2.15",repurposing_candidates.csv:rc_row=1419;protein_drug_candidates.csv:rows=829;1562;1997;2236;2341;2405;2712;2776;2840;pathway_drug_candidates.csv:rows=1542;1606;1670;1734;1798;1862;1926;2091;2155;2219;2283;2347;2411;2475;2539;2603;2667;2731;2795;2859;2923;2987;3057;3121;3185;3249;3313;3377;3441;3505;3569;3660;3724;3788;3852;3916;3980;4047;CYP3A4_results.csv:row=1228;CYP2C19_results.csv:row=1228;CYP2D6_results.csv:row=1228;CYP1A2_results.csv:row=1228;CYP2C9_results.csv:row=1228;hERG_results.csv:row=1228;AMES_results.csv:row=1228;PGP_results.csv:row=1228;PAMPA_results.csv:row=1228;BBB_results.csv:row=1228;Solubility_results.csv:row=1228;Lipophilicity_results.csv:row=1229
CHEMBL1094,FELBAMATE,NC(=O)OCC(COC(N)=O)c1ccccc1,58.86727688787185,100,100.0,83.54691075514874,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -1.30; logP 0.96",repurposing_candidates.csv:rc_row=42;protein_drug_candidates.csv:rows=703;1602;1948;2175;2596;2639;2665;pathway_drug_candidates.csv:rows=3609;6793;6820;6847;6880;7038;7065;7092;7119;CYP3A4_results.csv:row=42;CYP2C19_results.csv:row=42;CYP2D6_results.csv:row=42;CYP1A2_results.csv:row=42;CYP2C9_results.csv:row=42;hERG_results.csv:row=42;AMES_results.csv:row=42;PGP_results.csv:row=42;PAMPA_results.csv:row=42;BBB_results.csv:row=42;Solubility_results.csv:row=42;Lipophilicity_results.csv:row=42
CHEMBL1569,AMANTADINE HYDROCHLORIDE,Cl.NC12CC3CC(CC(C3)C1)C2,58.86727688787185,100,100.0,83.54691075514874,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -1.36; logP 2.34",repurposing_candidates.csv:rc_row=464;protein_drug_candidates.csv:rows=704;1603;1949;2176;2597;2640;2666;pathway_drug_candidates.csv:rows=3610;6794;6821;6848;6881;7039;7066;7093;7120;CYP3A4_results.csv:row=424;CYP2C19_results.csv:row=424;CYP2D6_results.csv:row=424;CYP1A2_results.csv:row=424;CYP2C9_results.csv:row=424;hERG_results.csv:row=424;AMES_results.csv:row=424;PGP_results.csv:row=424;PAMPA_results.csv:row=424;BBB_results.csv:row=424;Solubility_results.csv:row=424;Lipophilicity_results.csv:row=425
CHEMBL1743082,TRASTUZUMAB EMTANSINE,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=555;protein_drug_candidates.csv:rows=809;1542;1979;2215;2323;2387;2694;2755;2822;pathway_drug_candidates.csv:rows=1522;1586;1650;1714;1778;1842;1906;2071;2135;2199;2263;2327;2391;2455;2519;2583;2647;2711;2775;2839;2903;2967;3037;3101;3165;3229;3293;3357;3421;3485;3549;3640;3704;3768;3832;3896;3960;4027;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297841,TISOTUMAB VEDOTIN,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=1222;protein_drug_candidates.csv:rows=819;1553;1986;2224;2326;2396;2699;2766;2830;pathway_drug_candidates.csv:rows=1532;1596;1660;1724;1788;1852;1916;2081;2145;2209;2273;2337;2401;2465;2529;2593;2657;2721;2785;2849;2913;2977;3047;3111;3175;3239;3303;3367;3431;3495;3559;3650;3714;3778;3842;3906;3970;4037;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3301589,ENFORTUMAB VEDOTIN,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=937;protein_drug_candidates.csv:rows=817;1547;1982;2221;2330;2389;2696;2760;2829;pathway_drug_candidates.csv:rows=1530;1594;1658;1722;1786;1850;1914;2079;2143;2207;2271;2335;2399;2463;2527;2591;2655;2719;2783;2847;2911;2975;3045;3109;3173;3237;3301;3365;3429;3493;3557;3648;3712;3776;3840;3904;3968;4035;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298209,BELANTAMAB MAFODOTIN,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=1248;protein_drug_candidates.csv:rows=820;1551;1987;2225;2332;2390;2703;2767;2831;pathway_drug_candidates.csv:rows=1533;1597;1661;1725;1789;1853;1917;2082;2146;2210;2274;2338;2402;2466;2530;2594;2658;2722;2786;2850;2914;2978;3048;3112;3176;3240;3304;3368;3432;3496;3560;3651;3715;3779;3843;3907;3971;4038;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL90555,VINCRISTINE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -4.88; logP 3.52",repurposing_candidates.csv:rc_row=1548;protein_drug_candidates.csv:rows=814;1549;1985;2227;2325;2395;2697;2765;2826;pathway_drug_candidates.csv:rows=1527;1591;1655;1719;1783;1847;1911;2076;2140;2204;2268;2332;2396;2460;2524;2588;2652;2716;2780;2844;2908;2972;3042;3106;3170;3234;3298;3362;3426;3490;3554;3645;3709;3773;3837;3901;3965;4032;CYP3A4_results.csv:row=1354;CYP2C19_results.csv:row=1354;CYP2D6_results.csv:row=1354;CYP1A2_results.csv:row=1354;CYP2C9_results.csv:row=1354;hERG_results.csv:row=1354;AMES_results.csv:row=1354;PGP_results.csv:row=1354;PAMPA_results.csv:row=1354;BBB_results.csv:row=1354;Solubility_results.csv:row=1354;Lipophilicity_results.csv:row=1355
CHEMBL1683590,ERIBULIN,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -2.15; logP 3.44",repurposing_candidates.csv:rc_row=508;protein_drug_candidates.csv:rows=815;1550;1988;2226;2329;2393;2698;2762;2828;pathway_drug_candidates.csv:rows=1528;1592;1656;1720;1784;1848;1912;2077;2141;2205;2269;2333;2397;2461;2525;2589;2653;2717;2781;2845;2909;2973;3043;3107;3171;3235;3299;3363;3427;3491;3555;3646;3710;3774;3838;3902;3966;4033;CYP3A4_results.csv:row=468;CYP2C19_results.csv:row=468;CYP2D6_results.csv:row=468;CYP1A2_results.csv:row=468;CYP2C9_results.csv:row=468;hERG_results.csv:row=468;AMES_results.csv:row=468;PGP_results.csv:row=468;PAMPA_results.csv:row=468;BBB_results.csv:row=468;Solubility_results.csv:row=468;Lipophilicity_results.csv:row=469
CHEMBL1742994,BRENTUXIMAB VEDOTIN,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=543;protein_drug_candidates.csv:rows=805;1538;1973;2212;2317;2381;2688;2753;2816;pathway_drug_candidates.csv:rows=1518;1582;1646;1710;1774;1838;1902;2067;2131;2195;2259;2323;2387;2451;2515;2579;2643;2707;2771;2835;2899;2963;3033;3097;3161;3225;3289;3353;3417;3481;3545;3636;3700;3764;3828;3892;3956;4023;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3301582,POLATUZUMAB VEDOTIN,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=935;protein_drug_candidates.csv:rows=812;1545;1980;2219;2324;2388;2695;2759;2823;pathway_drug_candidates.csv:rows=1525;1589;1653;1717;1781;1845;1909;2074;2138;2202;2266;2330;2394;2458;2522;2586;2650;2714;2778;2842;2906;2970;3040;3104;3168;3232;3296;3360;3424;3488;3552;3643;3707;3771;3835;3899;3963;4030;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,,58.405797101449274,100,100.0,83.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0",repurposing_candidates.csv:rc_row=972;protein_drug_candidates.csv:rows=822;1555;1990;2229;2334;2398;2705;2769;2833;pathway_drug_candidates.csv:rows=1535;1599;1663;1727;1791;1855;1919;2084;2148;2212;2276;2340;2404;2468;2532;2596;2660;2724;2788;2852;2916;2980;3050;3114;3178;3242;3306;3370;3434;3498;3562;3653;3717;3781;3845;3909;3973;4040;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201293,ACAMPROSATE,CC(=O)NCCCS(=O)(=O)O,61.40350877192982,100,95.0,83.31140350877193,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -0.83; logP -0.60",repurposing_candidates.csv:rc_row=268;protein_drug_candidates.csv:rows=504;712;1433;1518;1610;1657;1703;1745;1778;1799;1872;1933;1956;2064;2110;2184;2471;2558;2580;2605;2630;2649;2673;pathway_drug_candidates.csv:rows=3618;6802;6829;6856;6889;7047;7074;7101;7128;CYP3A4_results.csv:row=265;CYP2C19_results.csv:row=265;CYP2D6_results.csv:row=265;CYP1A2_results.csv:row=265;CYP2C9_results.csv:row=265;hERG_results.csv:row=265;AMES_results.csv:row=265;PGP_results.csv:row=265;PAMPA_results.csv:row=265;BBB_results.csv:row=265;Solubility_results.csv:row=265;Lipophilicity_results.csv:row=266
CHEMBL378544,VINBLASTINE SULFATE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,76.73913043478261,100,70.0,83.19565217391305,H,"KG targets TUBB, TUBB1; clinical phase 4.0; hERG risk; logS -3.75; logP 3.34",repurposing_candidates.csv:rc_row=1037;protein_drug_candidates.csv:rows=806;1539;1974;2213;2318;2382;2689;2752;2817;pathway_drug_candidates.csv:rows=1519;1583;1647;1711;1775;1839;1903;2068;2132;2196;2260;2324;2388;2452;2516;2580;2644;2708;2772;2836;2900;2964;3034;3098;3162;3226;3290;3354;3418;3482;3546;3637;3701;3765;3829;3893;3957;4024;CYP3A4_results.csv:row=912;CYP2C19_results.csv:row=912;CYP2D6_results.csv:row=912;CYP1A2_results.csv:row=912;CYP2C9_results.csv:row=912;hERG_results.csv:row=912;AMES_results.csv:row=912;PGP_results.csv:row=912;PAMPA_results.csv:row=912;BBB_results.csv:row=912;Solubility_results.csv:row=912;Lipophilicity_results.csv:row=913
CHEMBL1256,ISOFLURANE,FC(F)OC(Cl)C(F)(F)F,80.80091533180779,95,70.0,83.07036613272311,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; hERG risk; logS -1.79; logP 2.35",repurposing_candidates.csv:rc_row=355;protein_drug_candidates.csv:rows=515;525;528;533;538;541;1405;1441;1528;1665;1712;1756;1786;1805;1878;1941;2072;2120;2479;2564;2589;2634;pathway_drug_candidates.csv:rows=1;4;7;10;13;18;23;7725;7730;7905;CYP3A4_results.csv:row=317;CYP2C19_results.csv:row=317;CYP2D6_results.csv:row=317;CYP1A2_results.csv:row=317;CYP2C9_results.csv:row=317;hERG_results.csv:row=317;AMES_results.csv:row=317;PGP_results.csv:row=317;PAMPA_results.csv:row=317;BBB_results.csv:row=317;Solubility_results.csv:row=317;Lipophilicity_results.csv:row=318
CHEMBL3989949,CENOBAMATE,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,57.53623188405797,100,100.0,83.01449275362319,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -1.75; logP 1.16",repurposing_candidates.csv:rc_row=1105;protein_drug_candidates.csv:rows=480;1409;1510;1633;1678;1733;1773;1795;1868;1928;2039;2084;2448;2554;2573;2624;CYP3A4_results.csv:row=974;CYP2C19_results.csv:row=974;CYP2D6_results.csv:row=974;CYP1A2_results.csv:row=974;CYP2C9_results.csv:row=974;hERG_results.csv:row=974;AMES_results.csv:row=974;PGP_results.csv:row=974;PAMPA_results.csv:row=974;BBB_results.csv:row=974;Solubility_results.csv:row=974;Lipophilicity_results.csv:row=975
CHEMBL4105630,ZURANOLONE,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,57.53623188405797,100,100.0,83.01449275362319,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -5.01; logP 4.34",repurposing_candidates.csv:rc_row=1132;protein_drug_candidates.csv:rows=501;1425;1517;1647;1693;1742;1777;1797;1871;1932;2062;2100;2461;2557;2579;2628;CYP3A4_results.csv:row=996;CYP2C19_results.csv:row=996;CYP2D6_results.csv:row=996;CYP1A2_results.csv:row=996;CYP2C9_results.csv:row=996;hERG_results.csv:row=996;AMES_results.csv:row=996;PGP_results.csv:row=996;PAMPA_results.csv:row=996;BBB_results.csv:row=996;Solubility_results.csv:row=996;Lipophilicity_results.csv:row=997
CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O,57.35697940503432,100,100.0,82.94279176201373,H,KG targets JAK2; clinical phase 4.0; logS -3.19; logP 4.84,repurposing_candidates.csv:rc_row=1163;protein_drug_candidates.csv:rows=787;pathway_drug_candidates.csv:rows=212;674;4584;4663;4742;4849;4918;4984;5050;5094;5160;5326;5392;6939;7473;8302;8330;8358;8392;8420;8448;CYP3A4_results.csv:row=1026;CYP2C19_results.csv:row=1026;CYP2D6_results.csv:row=1026;CYP1A2_results.csv:row=1026;CYP2C9_results.csv:row=1026;hERG_results.csv:row=1026;AMES_results.csv:row=1026;PGP_results.csv:row=1026;PAMPA_results.csv:row=1026;BBB_results.csv:row=1026;Solubility_results.csv:row=1026;Lipophilicity_results.csv:row=1027
CHEMBL1287853,FEDRATINIB,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,57.35697940503432,100,100.0,82.94279176201373,H,KG targets JAK2; clinical phase 4.0; logS -3.65; logP 4.82,repurposing_candidates.csv:rc_row=375;protein_drug_candidates.csv:rows=781;pathway_drug_candidates.csv:rows=206;668;4578;4657;4736;4843;4912;4978;5044;5088;5154;5320;5386;6933;7467;8296;8324;8352;8386;8414;8442;CYP3A4_results.csv:row=336;CYP2C19_results.csv:row=336;CYP2D6_results.csv:row=336;CYP1A2_results.csv:row=336;CYP2C9_results.csv:row=336;hERG_results.csv:row=336;AMES_results.csv:row=336;PGP_results.csv:row=336;PAMPA_results.csv:row=336;BBB_results.csv:row=336;Solubility_results.csv:row=336;Lipophilicity_results.csv:row=337
CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl,57.03661327231121,100,100.0,82.81464530892448,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -3.58; logP 4.62",repurposing_candidates.csv:rc_row=166;protein_drug_candidates.csv:rows=363;1307;1351;1456;1826;2498;pathway_drug_candidates.csv:rows=826;878;922;982;1026;1086;1138;1182;1370;1414;1474;6488;6688;CYP3A4_results.csv:row=164;CYP2C19_results.csv:row=164;CYP2D6_results.csv:row=164;CYP1A2_results.csv:row=164;CYP2C9_results.csv:row=164;hERG_results.csv:row=164;AMES_results.csv:row=164;PGP_results.csv:row=164;PAMPA_results.csv:row=164;BBB_results.csv:row=164;Solubility_results.csv:row=164;Lipophilicity_results.csv:row=165
CHEMBL3655081,ABROCITINIB,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,56.30434782608695,100,100.0,82.52173913043478,H,KG targets JAK1; clinical phase 4.0; logS -2.72; logP 1.25,repurposing_candidates.csv:rc_row=1010;protein_drug_candidates.csv:rows=755;pathway_drug_candidates.csv:rows=180;642;4232;4411;4552;4631;4710;4779;4817;4886;4952;5018;5128;5206;5256;5294;5360;5454;6907;CYP3A4_results.csv:row=896;CYP2C19_results.csv:row=896;CYP2D6_results.csv:row=896;CYP1A2_results.csv:row=896;CYP2C9_results.csv:row=896;hERG_results.csv:row=896;AMES_results.csv:row=896;PGP_results.csv:row=896;PAMPA_results.csv:row=896;BBB_results.csv:row=896;Solubility_results.csv:row=896;Lipophilicity_results.csv:row=897
CHEMBL112,ACETAMINOPHEN,CC(=O)Nc1ccc(O)cc1,56.006864988558355,100,100.0,82.40274599542334,H,"KG targets FAAH, PTGS1; clinical phase 4.0; logS -1.28; logP 1.35",repurposing_candidates.csv:rc_row=57;protein_drug_candidates.csv:rows=119;687;690;903;pathway_drug_candidates.csv:rows=342;4460;5543;5603;5669;5716;6053;6127;6201;6275;6349;6423;CYP3A4_results.csv:row=57;CYP2C19_results.csv:row=57;CYP2D6_results.csv:row=57;CYP1A2_results.csv:row=57;CYP2C9_results.csv:row=57;hERG_results.csv:row=57;AMES_results.csv:row=57;PGP_results.csv:row=57;PAMPA_results.csv:row=57;BBB_results.csv:row=57;Solubility_results.csv:row=57;Lipophilicity_results.csv:row=57
CHEMBL159,VINBLASTINE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,58.405797101449274,100,95.0,82.11231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -4.61; logP 3.99",repurposing_candidates.csv:rc_row=469;protein_drug_candidates.csv:rows=816;1552;1984;2223;2327;2391;2700;2761;2825;pathway_drug_candidates.csv:rows=1529;1593;1657;1721;1785;1849;1913;2078;2142;2206;2270;2334;2398;2462;2526;2590;2654;2718;2782;2846;2910;2974;3044;3108;3172;3236;3300;3364;3428;3492;3556;3647;3711;3775;3839;3903;3967;4034;CYP3A4_results.csv:row=429;CYP2C19_results.csv:row=429;CYP2D6_results.csv:row=429;CYP1A2_results.csv:row=429;CYP2C9_results.csv:row=429;hERG_results.csv:row=429;AMES_results.csv:row=429;PGP_results.csv:row=429;PAMPA_results.csv:row=429;BBB_results.csv:row=429;Solubility_results.csv:row=429;Lipophilicity_results.csv:row=430
CHEMBL207538,BREXANOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,57.53623188405797,100,95.0,81.76449275362319,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -4.91; logP 4.60",repurposing_candidates.csv:rc_row=645;protein_drug_candidates.csv:rows=494;1424;1515;1646;1692;1741;1776;1798;1870;1931;2055;2099;2460;2556;2578;2627;CYP3A4_results.csv:row=591;CYP2C19_results.csv:row=591;CYP2D6_results.csv:row=591;CYP1A2_results.csv:row=591;CYP2C9_results.csv:row=591;hERG_results.csv:row=591;AMES_results.csv:row=591;PGP_results.csv:row=591;PAMPA_results.csv:row=591;BBB_results.csv:row=591;Solubility_results.csv:row=591;Lipophilicity_results.csv:row=592
CHEMBL1568698,GANAXOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,57.53623188405797,100,95.0,81.76449275362319,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -4.59; logP 4.99",repurposing_candidates.csv:rc_row=463;protein_drug_candidates.csv:rows=478;1407;1509;1632;1676;1732;1772;1793;1867;1926;2037;2088;2446;2552;2571;2623;CYP3A4_results.csv:row=423;CYP2C19_results.csv:row=423;CYP2D6_results.csv:row=423;CYP1A2_results.csv:row=423;CYP2C9_results.csv:row=423;hERG_results.csv:row=423;AMES_results.csv:row=423;PGP_results.csv:row=423;PAMPA_results.csv:row=423;BBB_results.csv:row=423;Solubility_results.csv:row=423;Lipophilicity_results.csv:row=424
CHEMBL159226,MOXISYLYTE,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,57.03661327231121,100,95.0,81.56464530892448,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.41; logP 2.98",repurposing_candidates.csv:rc_row=471;protein_drug_candidates.csv:rows=367;1309;1359;1459;1814;2508;pathway_drug_candidates.csv:rows=830;880;930;984;1034;1088;1140;1190;1372;1422;1476;6492;6692;CYP3A4_results.csv:row=431;CYP2C19_results.csv:row=431;CYP2D6_results.csv:row=431;CYP1A2_results.csv:row=431;CYP2C9_results.csv:row=431;hERG_results.csv:row=431;AMES_results.csv:row=431;PGP_results.csv:row=431;PAMPA_results.csv:row=431;BBB_results.csv:row=431;Solubility_results.csv:row=431;Lipophilicity_results.csv:row=432
CHEMBL6,INDOMETHACIN,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.74; logP 3.93",repurposing_candidates.csv:rc_row=1440;protein_drug_candidates.csv:rows=93;882;pathway_drug_candidates.csv:rows=316;4434;5522;5582;5643;6027;6101;6175;6249;6323;6397;CYP3A4_results.csv:row=1249;CYP2C19_results.csv:row=1249;CYP2D6_results.csv:row=1249;CYP1A2_results.csv:row=1249;CYP2C9_results.csv:row=1249;hERG_results.csv:row=1249;AMES_results.csv:row=1249;PGP_results.csv:row=1249;PAMPA_results.csv:row=1249;BBB_results.csv:row=1249;Solubility_results.csv:row=1249;Lipophilicity_results.csv:row=1250
CHEMBL527,PIROXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.20; logP 1.58",repurposing_candidates.csv:rc_row=1373;protein_drug_candidates.csv:rows=113;899;pathway_drug_candidates.csv:rows=336;4454;5539;5599;5663;6047;6121;6195;6269;6343;6417;CYP3A4_results.csv:row=1184;CYP2C19_results.csv:row=1184;CYP2D6_results.csv:row=1184;CYP1A2_results.csv:row=1184;CYP2C9_results.csv:row=1184;hERG_results.csv:row=1184;AMES_results.csv:row=1184;PGP_results.csv:row=1184;PAMPA_results.csv:row=1184;BBB_results.csv:row=1184;Solubility_results.csv:row=1184;Lipophilicity_results.csv:row=1185
CHEMBL571,KETOPROFEN,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.40; logP 3.11",repurposing_candidates.csv:rc_row=1418;protein_drug_candidates.csv:rows=114;891;pathway_drug_candidates.csv:rows=337;4455;5531;5591;5664;6048;6122;6196;6270;6344;6418;CYP3A4_results.csv:row=1227;CYP2C19_results.csv:row=1227;CYP2D6_results.csv:row=1227;CYP1A2_results.csv:row=1227;CYP2C9_results.csv:row=1227;hERG_results.csv:row=1227;AMES_results.csv:row=1227;PGP_results.csv:row=1227;PAMPA_results.csv:row=1227;BBB_results.csv:row=1227;Solubility_results.csv:row=1227;Lipophilicity_results.csv:row=1228
CHEMBL521,IBUPROFEN,CC(C)Cc1ccc(C(C)C(=O)O)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.87; logP 3.07",repurposing_candidates.csv:rc_row=1367;protein_drug_candidates.csv:rows=92;883;pathway_drug_candidates.csv:rows=315;4433;5523;5583;5642;6026;6100;6174;6248;6322;6396;CYP3A4_results.csv:row=1178;CYP2C19_results.csv:row=1178;CYP2D6_results.csv:row=1178;CYP1A2_results.csv:row=1178;CYP2C9_results.csv:row=1178;hERG_results.csv:row=1178;AMES_results.csv:row=1178;PGP_results.csv:row=1178;PAMPA_results.csv:row=1178;BBB_results.csv:row=1178;Solubility_results.csv:row=1178;Lipophilicity_results.csv:row=1179
CHEMBL3989676,OXYPHENBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.17; logP 2.67",repurposing_candidates.csv:rc_row=1076;protein_drug_candidates.csv:rows=124;920;pathway_drug_candidates.csv:rows=347;4465;5560;5620;5674;6058;6132;6206;6280;6354;6428;CYP3A4_results.csv:row=945;CYP2C19_results.csv:row=945;CYP2D6_results.csv:row=945;CYP1A2_results.csv:row=945;CYP2C9_results.csv:row=945;hERG_results.csv:row=945;AMES_results.csv:row=945;PGP_results.csv:row=945;PAMPA_results.csv:row=945;BBB_results.csv:row=945;Solubility_results.csv:row=945;Lipophilicity_results.csv:row=946
CHEMBL704,MESALAMINE,Nc1ccc(O)c(C(=O)O)c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.06; logP 0.67",repurposing_candidates.csv:rc_row=1492;protein_drug_candidates.csv:rows=108;895;pathway_drug_candidates.csv:rows=331;4449;5535;5595;5658;6042;6116;6190;6264;6338;6412;CYP3A4_results.csv:row=1298;CYP2C19_results.csv:row=1298;CYP2D6_results.csv:row=1298;CYP1A2_results.csv:row=1298;CYP2C9_results.csv:row=1298;hERG_results.csv:row=1298;AMES_results.csv:row=1298;PGP_results.csv:row=1298;PAMPA_results.csv:row=1298;BBB_results.csv:row=1298;Solubility_results.csv:row=1298;Lipophilicity_results.csv:row=1299
CHEMBL1200804,DICLOFENAC POTASSIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.42; logP 0.03",repurposing_candidates.csv:rc_row=173;protein_drug_candidates.csv:rows=98;885;pathway_drug_candidates.csv:rows=321;4439;5525;5585;5648;6032;6106;6180;6254;6328;6402;CYP3A4_results.csv:row=171;CYP2C19_results.csv:row=171;CYP2D6_results.csv:row=171;CYP1A2_results.csv:row=171;CYP2C9_results.csv:row=171;hERG_results.csv:row=171;AMES_results.csv:row=171;PGP_results.csv:row=171;PAMPA_results.csv:row=171;BBB_results.csv:row=171;Solubility_results.csv:row=171;Lipophilicity_results.csv:row=172
CHEMBL1201141,IBUPROFEN LYSINE,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.12; logP 2.60",repurposing_candidates.csv:rc_row=241;protein_drug_candidates.csv:rows=150;930;pathway_drug_candidates.csv:rows=373;4491;5570;5630;5700;6084;6158;6232;6306;6380;6454;CYP3A4_results.csv:row=238;CYP2C19_results.csv:row=238;CYP2D6_results.csv:row=238;CYP1A2_results.csv:row=238;CYP2C9_results.csv:row=238;hERG_results.csv:row=238;AMES_results.csv:row=238;PGP_results.csv:row=238;PAMPA_results.csv:row=238;BBB_results.csv:row=238;Solubility_results.csv:row=238;Lipophilicity_results.csv:row=239
CHEMBL154,NAPROXEN,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.97; logP 3.04",repurposing_candidates.csv:rc_row=455;protein_drug_candidates.csv:rows=100;887;pathway_drug_candidates.csv:rows=323;4441;5527;5587;5650;6034;6108;6182;6256;6330;6404;CYP3A4_results.csv:row=415;CYP2C19_results.csv:row=415;CYP2D6_results.csv:row=415;CYP1A2_results.csv:row=415;CYP2C9_results.csv:row=415;hERG_results.csv:row=415;AMES_results.csv:row=415;PGP_results.csv:row=415;PAMPA_results.csv:row=415;BBB_results.csv:row=415;Solubility_results.csv:row=415;Lipophilicity_results.csv:row=416
CHEMBL139,DICLOFENAC,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.40; logP 4.36",repurposing_candidates.csv:rc_row=400;protein_drug_candidates.csv:rows=99;886;pathway_drug_candidates.csv:rows=322;4440;5526;5586;5649;6033;6107;6181;6255;6329;6403;CYP3A4_results.csv:row=360;CYP2C19_results.csv:row=360;CYP2D6_results.csv:row=360;CYP1A2_results.csv:row=360;CYP2C9_results.csv:row=360;hERG_results.csv:row=360;AMES_results.csv:row=360;PGP_results.csv:row=360;PAMPA_results.csv:row=360;BBB_results.csv:row=360;Solubility_results.csv:row=360;Lipophilicity_results.csv:row=361
CHEMBL15870,INDOPROFEN,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.28; logP 3.04",repurposing_candidates.csv:rc_row=468;protein_drug_candidates.csv:rows=131;912;pathway_drug_candidates.csv:rows=354;4472;5552;5612;5681;6065;6139;6213;6287;6361;6435;CYP3A4_results.csv:row=428;CYP2C19_results.csv:row=428;CYP2D6_results.csv:row=428;CYP1A2_results.csv:row=428;CYP2C9_results.csv:row=428;hERG_results.csv:row=428;AMES_results.csv:row=428;PGP_results.csv:row=428;PAMPA_results.csv:row=428;BBB_results.csv:row=428;Solubility_results.csv:row=428;Lipophilicity_results.csv:row=429
CHEMBL15770,SULINDAC,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.57; logP 4.37",repurposing_candidates.csv:rc_row=466;protein_drug_candidates.csv:rows=111;889;pathway_drug_candidates.csv:rows=334;4452;5529;5589;5661;6045;6119;6193;6267;6341;6415;CYP3A4_results.csv:row=426;CYP2C19_results.csv:row=426;CYP2D6_results.csv:row=426;CYP1A2_results.csv:row=426;CYP2C9_results.csv:row=426;hERG_results.csv:row=426;AMES_results.csv:row=426;PGP_results.csv:row=426;PAMPA_results.csv:row=426;BBB_results.csv:row=426;Solubility_results.csv:row=426;Lipophilicity_results.csv:row=427
CHEMBL1569487,LORNOXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.66; logP 2.30",repurposing_candidates.csv:rc_row=465;protein_drug_candidates.csv:rows=144;924;pathway_drug_candidates.csv:rows=367;4485;5564;5624;5694;6078;6152;6226;6300;6374;6448;CYP3A4_results.csv:row=425;CYP2C19_results.csv:row=425;CYP2D6_results.csv:row=425;CYP1A2_results.csv:row=425;CYP2C9_results.csv:row=425;hERG_results.csv:row=425;AMES_results.csv:row=425;PGP_results.csv:row=425;PAMPA_results.csv:row=425;BBB_results.csv:row=425;Solubility_results.csv:row=425;Lipophilicity_results.csv:row=426
CHEMBL686,MEFENAMIC ACID,Cc1cccc(Nc2ccccc2C(=O)O)c1C,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.22; logP 3.75",repurposing_candidates.csv:rc_row=1487;protein_drug_candidates.csv:rows=135;929;pathway_drug_candidates.csv:rows=358;4476;5569;5629;5685;6069;6143;6217;6291;6365;6439;CYP3A4_results.csv:row=1293;CYP2C19_results.csv:row=1293;CYP2D6_results.csv:row=1293;CYP1A2_results.csv:row=1293;CYP2C9_results.csv:row=1293;hERG_results.csv:row=1293;AMES_results.csv:row=1293;PGP_results.csv:row=1293;PAMPA_results.csv:row=1293;BBB_results.csv:row=1293;Solubility_results.csv:row=1293;Lipophilicity_results.csv:row=1294
CHEMBL1565476,APAZONE,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.43; logP 2.06",repurposing_candidates.csv:rc_row=460;protein_drug_candidates.csv:rows=143;911;pathway_drug_candidates.csv:rows=366;4484;5551;5611;5693;6077;6151;6225;6299;6373;6447;CYP3A4_results.csv:row=420;CYP2C19_results.csv:row=420;CYP2D6_results.csv:row=420;CYP1A2_results.csv:row=420;CYP2C9_results.csv:row=420;hERG_results.csv:row=420;AMES_results.csv:row=420;PGP_results.csv:row=420;PAMPA_results.csv:row=420;BBB_results.csv:row=420;Solubility_results.csv:row=420;Lipophilicity_results.csv:row=421
CHEMBL1201180,DICLOFENAC EPOLAMINE,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.23; logP 4.44",repurposing_candidates.csv:rc_row=251;protein_drug_candidates.csv:rows=120;917;pathway_drug_candidates.csv:rows=343;4461;5557;5617;5670;6054;6128;6202;6276;6350;6424;CYP3A4_results.csv:row=248;CYP2C19_results.csv:row=248;CYP2D6_results.csv:row=248;CYP1A2_results.csv:row=248;CYP2C9_results.csv:row=248;hERG_results.csv:row=248;AMES_results.csv:row=248;PGP_results.csv:row=248;PAMPA_results.csv:row=248;BBB_results.csv:row=248;Solubility_results.csv:row=248;Lipophilicity_results.csv:row=249
CHEMBL898,DIFLUNISAL,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.61; logP 3.04",repurposing_candidates.csv:rc_row=1544;protein_drug_candidates.csv:rows=116;900;pathway_drug_candidates.csv:rows=339;4457;5540;5600;5666;6050;6124;6198;6272;6346;6420;CYP3A4_results.csv:row=1350;CYP2C19_results.csv:row=1350;CYP2D6_results.csv:row=1350;CYP1A2_results.csv:row=1350;CYP2C9_results.csv:row=1350;hERG_results.csv:row=1350;AMES_results.csv:row=1350;PGP_results.csv:row=1350;PAMPA_results.csv:row=1350;BBB_results.csv:row=1350;Solubility_results.csv:row=1350;Lipophilicity_results.csv:row=1351
CHEMBL75435,DEXKETOPROFEN,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.40; logP 3.11",repurposing_candidates.csv:rc_row=1507;protein_drug_candidates.csv:rows=136;913;pathway_drug_candidates.csv:rows=359;4477;5553;5613;5686;6070;6144;6218;6292;6366;6440;CYP3A4_results.csv:row=1313;CYP2C19_results.csv:row=1313;CYP2D6_results.csv:row=1313;CYP1A2_results.csv:row=1313;CYP2C9_results.csv:row=1313;hERG_results.csv:row=1313;AMES_results.csv:row=1313;PGP_results.csv:row=1313;PAMPA_results.csv:row=1313;BBB_results.csv:row=1313;Solubility_results.csv:row=1313;Lipophilicity_results.csv:row=1314
CHEMBL563,FLURBIPROFEN,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.18; logP 3.68",repurposing_candidates.csv:rc_row=1414;protein_drug_candidates.csv:rows=126;910;pathway_drug_candidates.csv:rows=349;4467;5550;5610;5676;6060;6134;6208;6282;6356;6430;CYP3A4_results.csv:row=1223;CYP2C19_results.csv:row=1223;CYP2D6_results.csv:row=1223;CYP1A2_results.csv:row=1223;CYP2C9_results.csv:row=1223;hERG_results.csv:row=1223;AMES_results.csv:row=1223;PGP_results.csv:row=1223;PAMPA_results.csv:row=1223;BBB_results.csv:row=1223;Solubility_results.csv:row=1223;Lipophilicity_results.csv:row=1224
CHEMBL25,ASPIRIN,CC(=O)Oc1ccccc1C(=O)O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -1.71; logP 1.31",repurposing_candidates.csv:rc_row=854;protein_drug_candidates.csv:rows=94;884;pathway_drug_candidates.csv:rows=317;4435;5524;5584;5644;6028;6102;6176;6250;6324;6398;CYP3A4_results.csv:row=762;CYP2C19_results.csv:row=762;CYP2D6_results.csv:row=762;CYP1A2_results.csv:row=762;CYP2C9_results.csv:row=762;hERG_results.csv:row=762;AMES_results.csv:row=762;PGP_results.csv:row=762;PAMPA_results.csv:row=762;BBB_results.csv:row=762;Solubility_results.csv:row=762;Lipophilicity_results.csv:row=763
CHEMBL1034,DICLOFENAC SODIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.41; logP 0.03",repurposing_candidates.csv:rc_row=12;protein_drug_candidates.csv:rows=96;893;pathway_drug_candidates.csv:rows=319;4437;5533;5593;5646;6030;6104;6178;6252;6326;6400;CYP3A4_results.csv:row=12;CYP2C19_results.csv:row=12;CYP2D6_results.csv:row=12;CYP1A2_results.csv:row=12;CYP2C9_results.csv:row=12;hERG_results.csv:row=12;AMES_results.csv:row=12;PGP_results.csv:row=12;PAMPA_results.csv:row=12;BBB_results.csv:row=12;Solubility_results.csv:row=12;Lipophilicity_results.csv:row=12
CHEMBL101,PHENYLBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.38; logP 3.79",repurposing_candidates.csv:rc_row=4;protein_drug_candidates.csv:rows=127;921;pathway_drug_candidates.csv:rows=350;4468;5561;5621;5677;6061;6135;6209;6283;6357;6431;CYP3A4_results.csv:row=4;CYP2C19_results.csv:row=4;CYP2D6_results.csv:row=4;CYP1A2_results.csv:row=4;CYP2C9_results.csv:row=4;hERG_results.csv:row=4;AMES_results.csv:row=4;PGP_results.csv:row=4;PAMPA_results.csv:row=4;BBB_results.csv:row=4;Solubility_results.csv:row=4;Lipophilicity_results.csv:row=4
CHEMBL1120,BISMUTH SUBSALICYLATE,,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0",repurposing_candidates.csv:rc_row=58;protein_drug_candidates.csv:rows=149;931;pathway_drug_candidates.csv:rows=372;4490;5571;5631;5699;6083;6157;6231;6305;6379;6453;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL188952,PIRPROFEN,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.25; logP 2.90",repurposing_candidates.csv:rc_row=587;protein_drug_candidates.csv:rows=145;926;pathway_drug_candidates.csv:rows=368;4486;5566;5626;5695;6079;6153;6227;6301;6375;6449;CYP3A4_results.csv:row=533;CYP2C19_results.csv:row=533;CYP2D6_results.csv:row=533;CYP1A2_results.csv:row=533;CYP2C9_results.csv:row=533;hERG_results.csv:row=533;AMES_results.csv:row=533;PGP_results.csv:row=533;PAMPA_results.csv:row=533;BBB_results.csv:row=533;Solubility_results.csv:row=533;Lipophilicity_results.csv:row=534
CHEMBL175,DEXIBUPROFEN,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.87; logP 3.07",repurposing_candidates.csv:rc_row=557;protein_drug_candidates.csv:rows=132;925;pathway_drug_candidates.csv:rows=355;4473;5565;5625;5682;6066;6140;6214;6288;6362;6436;CYP3A4_results.csv:row=503;CYP2C19_results.csv:row=503;CYP2D6_results.csv:row=503;CYP1A2_results.csv:row=503;CYP2C9_results.csv:row=503;hERG_results.csv:row=503;AMES_results.csv:row=503;PGP_results.csv:row=503;PAMPA_results.csv:row=503;BBB_results.csv:row=503;Solubility_results.csv:row=503;Lipophilicity_results.csv:row=504
CHEMBL189171,ACEMETACIN,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.60; logP 3.47",repurposing_candidates.csv:rc_row=588;protein_drug_candidates.csv:rows=133;927;pathway_drug_candidates.csv:rows=356;4474;5567;5627;5683;6067;6141;6215;6289;6363;6437;CYP3A4_results.csv:row=534;CYP2C19_results.csv:row=534;CYP2D6_results.csv:row=534;CYP1A2_results.csv:row=534;CYP2C9_results.csv:row=534;hERG_results.csv:row=534;AMES_results.csv:row=534;PGP_results.csv:row=534;PAMPA_results.csv:row=534;BBB_results.csv:row=534;Solubility_results.csv:row=534;Lipophilicity_results.csv:row=535
CHEMBL421,SULFASALAZINE,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -5.76; logP 3.70",repurposing_candidates.csv:rc_row=1147;protein_drug_candidates.csv:rows=102;890;pathway_drug_candidates.csv:rows=325;4443;5530;5590;5652;6036;6110;6184;6258;6332;6406;CYP3A4_results.csv:row=1011;CYP2C19_results.csv:row=1011;CYP2D6_results.csv:row=1011;CYP1A2_results.csv:row=1011;CYP2C9_results.csv:row=1011;hERG_results.csv:row=1011;AMES_results.csv:row=1011;PGP_results.csv:row=1011;PAMPA_results.csv:row=1011;BBB_results.csv:row=1011;Solubility_results.csv:row=1011;Lipophilicity_results.csv:row=1012
CHEMBL1071,OXAPROZIN,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.44; logP 4.03",repurposing_candidates.csv:rc_row=23;protein_drug_candidates.csv:rows=107;894;pathway_drug_candidates.csv:rows=330;4448;5534;5594;5657;6041;6115;6189;6263;6337;6411;CYP3A4_results.csv:row=23;CYP2C19_results.csv:row=23;CYP2D6_results.csv:row=23;CYP1A2_results.csv:row=23;CYP2C9_results.csv:row=23;hERG_results.csv:row=23;AMES_results.csv:row=23;PGP_results.csv:row=23;PAMPA_results.csv:row=23;BBB_results.csv:row=23;Solubility_results.csv:row=23;Lipophilicity_results.csv:row=23
CHEMBL956,SUPROFEN,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.42; logP 3.17",repurposing_candidates.csv:rc_row=1565;protein_drug_candidates.csv:rows=148;915;pathway_drug_candidates.csv:rows=371;4489;5555;5615;5698;6082;6156;6230;6304;6378;6452;CYP3A4_results.csv:row=1371;CYP2C19_results.csv:row=1371;CYP2D6_results.csv:row=1371;CYP1A2_results.csv:row=1371;CYP2C9_results.csv:row=1371;hERG_results.csv:row=1371;AMES_results.csv:row=1371;PGP_results.csv:row=1371;PAMPA_results.csv:row=1371;BBB_results.csv:row=1371;Solubility_results.csv:row=1371;Lipophilicity_results.csv:row=1372
CHEMBL1021,NEPAFENAC,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,52.87185354691076,100,100.0,81.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.68; logP 1.53",repurposing_candidates.csv:rc_row=10;protein_drug_candidates.csv:rows=118;902;pathway_drug_candidates.csv:rows=341;4459;5542;5602;5668;6052;6126;6200;6274;6348;6422;CYP3A4_results.csv:row=10;CYP2C19_results.csv:row=10;CYP2D6_results.csv:row=10;CYP1A2_results.csv:row=10;CYP2C9_results.csv:row=10;hERG_results.csv:row=10;AMES_results.csv:row=10;PGP_results.csv:row=10;PAMPA_results.csv:row=10;BBB_results.csv:row=10;Solubility_results.csv:row=10;Lipophilicity_results.csv:row=10
CHEMBL654,MIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3C2C1,52.07093821510297,100,100.0,80.8283752860412,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.88; logP 2.48",repurposing_candidates.csv:rc_row=1474;protein_drug_candidates.csv:rows=1332;1379;2530;pathway_drug_candidates.csv:rows=903;950;1007;1054;1111;1163;1210;1395;1442;1499;CYP3A4_results.csv:row=1280;CYP2C19_results.csv:row=1280;CYP2D6_results.csv:row=1280;CYP1A2_results.csv:row=1280;CYP2C9_results.csv:row=1280;hERG_results.csv:row=1280;AMES_results.csv:row=1280;PGP_results.csv:row=1280;PAMPA_results.csv:row=1280;BBB_results.csv:row=1280;Solubility_results.csv:row=1280;Lipophilicity_results.csv:row=1281
CHEMBL1096,AMLEXANOX,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,51.79633867276888,100,100.0,80.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -4.59; logP 2.75",repurposing_candidates.csv:rc_row=45;protein_drug_candidates.csv:rows=414;1048;1075;2152;pathway_drug_candidates.csv:rows=4326;5736;5765;5792;5831;5859;CYP3A4_results.csv:row=45;CYP2C19_results.csv:row=45;CYP2D6_results.csv:row=45;CYP1A2_results.csv:row=45;CYP2C9_results.csv:row=45;hERG_results.csv:row=45;AMES_results.csv:row=45;PGP_results.csv:row=45;PAMPA_results.csv:row=45;BBB_results.csv:row=45;Solubility_results.csv:row=45;Lipophilicity_results.csv:row=45
CHEMBL514800,APREMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,51.79633867276888,100,100.0,80.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -2.88; logP 2.43",repurposing_candidates.csv:rc_row=1361;protein_drug_candidates.csv:rows=410;1043;1071;2148;pathway_drug_candidates.csv:rows=4322;5732;5760;5788;5827;5855;CYP3A4_results.csv:row=1172;CYP2C19_results.csv:row=1172;CYP2D6_results.csv:row=1172;CYP1A2_results.csv:row=1172;CYP2C9_results.csv:row=1172;hERG_results.csv:row=1172;AMES_results.csv:row=1172;PGP_results.csv:row=1172;PAMPA_results.csv:row=1172;BBB_results.csv:row=1172;Solubility_results.csv:row=1172;Lipophilicity_results.csv:row=1173
CHEMBL628,PENTOXIFYLLINE,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,54.679633867276884,100,95.0,80.62185354691076,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -0.40; logP 0.19",repurposing_candidates.csv:rc_row=1460;protein_drug_candidates.csv:rows=409;870;1042;1070;2146;pathway_drug_candidates.csv:rows=4321;5731;5759;5787;5826;5854;7670;7697;7710;CYP3A4_results.csv:row=1266;CYP2C19_results.csv:row=1266;CYP2D6_results.csv:row=1266;CYP1A2_results.csv:row=1266;CYP2C9_results.csv:row=1266;hERG_results.csv:row=1266;AMES_results.csv:row=1266;PGP_results.csv:row=1266;PAMPA_results.csv:row=1266;BBB_results.csv:row=1266;Solubility_results.csv:row=1266;Lipophilicity_results.csv:row=1267
CHEMBL1091,HYDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.32; logP 2.35,repurposing_candidates.csv:rc_row=40;protein_drug_candidates.csv:rows=21;pathway_drug_candidates.csv:rows=713;2022;5937;7841;7978;8044;8115;8181;8247;CYP3A4_results.csv:row=40;CYP2C19_results.csv:row=40;CYP2D6_results.csv:row=40;CYP1A2_results.csv:row=40;CYP2C9_results.csv:row=40;hERG_results.csv:row=40;AMES_results.csv:row=40;PGP_results.csv:row=40;PAMPA_results.csv:row=40;BBB_results.csv:row=40;Solubility_results.csv:row=40;Lipophilicity_results.csv:row=40
CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.34; logP 4.41,repurposing_candidates.csv:rc_row=186;protein_drug_candidates.csv:rows=46;pathway_drug_candidates.csv:rows=738;2047;5962;7866;8003;8069;8140;8206;8272;CYP3A4_results.csv:row=184;CYP2C19_results.csv:row=184;CYP2D6_results.csv:row=184;CYP1A2_results.csv:row=184;CYP2C9_results.csv:row=184;hERG_results.csv:row=184;AMES_results.csv:row=184;PGP_results.csv:row=184;PAMPA_results.csv:row=184;BBB_results.csv:row=184;Solubility_results.csv:row=184;Lipophilicity_results.csv:row=185
CHEMBL635,PREDNISONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -3.37; logP 1.77,repurposing_candidates.csv:rc_row=1464;protein_drug_candidates.csv:rows=6;pathway_drug_candidates.csv:rows=698;2007;5922;7826;7963;8029;8100;8166;8232;CYP3A4_results.csv:row=1270;CYP2C19_results.csv:row=1270;CYP2D6_results.csv:row=1270;CYP1A2_results.csv:row=1270;CYP2C9_results.csv:row=1270;hERG_results.csv:row=1270;AMES_results.csv:row=1270;PGP_results.csv:row=1270;PAMPA_results.csv:row=1270;BBB_results.csv:row=1270;Solubility_results.csv:row=1270;Lipophilicity_results.csv:row=1271
CHEMBL1200384,BETAMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.09; logP 3.82,repurposing_candidates.csv:rc_row=92;protein_drug_candidates.csv:rows=14;pathway_drug_candidates.csv:rows=706;2015;5930;7834;7971;8037;8108;8174;8240;CYP3A4_results.csv:row=91;CYP2C19_results.csv:row=91;CYP2D6_results.csv:row=91;CYP1A2_results.csv:row=91;CYP2C9_results.csv:row=91;hERG_results.csv:row=91;AMES_results.csv:row=91;PGP_results.csv:row=91;PAMPA_results.csv:row=91;BBB_results.csv:row=91;Solubility_results.csv:row=91;Lipophilicity_results.csv:row=91
CHEMBL1200386,PREDNICARBATE,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.74; logP 3.70,repurposing_candidates.csv:rc_row=93;protein_drug_candidates.csv:rows=22;pathway_drug_candidates.csv:rows=714;2023;5938;7842;7979;8045;8116;8182;8248;CYP3A4_results.csv:row=92;CYP2C19_results.csv:row=92;CYP2D6_results.csv:row=92;CYP1A2_results.csv:row=92;CYP2C9_results.csv:row=92;hERG_results.csv:row=92;AMES_results.csv:row=92;PGP_results.csv:row=92;PAMPA_results.csv:row=92;BBB_results.csv:row=92;Solubility_results.csv:row=92;Lipophilicity_results.csv:row=92
CHEMBL1200908,HALOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.86; logP 4.05,repurposing_candidates.csv:rc_row=191;protein_drug_candidates.csv:rows=20;pathway_drug_candidates.csv:rows=712;2021;5936;7840;7977;8043;8114;8180;8246;CYP3A4_results.csv:row=189;CYP2C19_results.csv:row=189;CYP2D6_results.csv:row=189;CYP1A2_results.csv:row=189;CYP2C9_results.csv:row=189;hERG_results.csv:row=189;AMES_results.csv:row=189;PGP_results.csv:row=189;PAMPA_results.csv:row=189;BBB_results.csv:row=189;Solubility_results.csv:row=189;Lipophilicity_results.csv:row=190
CHEMBL1201891,DEFLAZACORT,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -3.96; logP 2.56,repurposing_candidates.csv:rc_row=325;protein_drug_candidates.csv:rows=47;pathway_drug_candidates.csv:rows=739;2048;5963;7867;8004;8070;8141;8207;8273;CYP3A4_results.csv:row=288;CYP2C19_results.csv:row=288;CYP2D6_results.csv:row=288;CYP1A2_results.csv:row=288;CYP2C9_results.csv:row=288;hERG_results.csv:row=288;AMES_results.csv:row=288;PGP_results.csv:row=288;PAMPA_results.csv:row=288;BBB_results.csv:row=288;Solubility_results.csv:row=288;Lipophilicity_results.csv:row=289
CHEMBL1683,HYDROCORTISONE BUTYRATE,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.14; logP 3.13,repurposing_candidates.csv:rc_row=506;protein_drug_candidates.csv:rows=4;pathway_drug_candidates.csv:rows=696;2005;5920;7824;7961;8027;8098;8164;8230;CYP3A4_results.csv:row=466;CYP2C19_results.csv:row=466;CYP2D6_results.csv:row=466;CYP1A2_results.csv:row=466;CYP2C9_results.csv:row=466;hERG_results.csv:row=466;AMES_results.csv:row=466;PGP_results.csv:row=466;PAMPA_results.csv:row=466;BBB_results.csv:row=466;Solubility_results.csv:row=466;Lipophilicity_results.csv:row=467
CHEMBL1200953,HYDROCORTISONE PROBUTATE,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.29; logP 4.09,repurposing_candidates.csv:rc_row=200;protein_drug_candidates.csv:rows=24;pathway_drug_candidates.csv:rows=716;2025;5940;7844;7981;8047;8118;8184;8250;CYP3A4_results.csv:row=198;CYP2C19_results.csv:row=198;CYP2D6_results.csv:row=198;CYP1A2_results.csv:row=198;CYP2C9_results.csv:row=198;hERG_results.csv:row=198;AMES_results.csv:row=198;PGP_results.csv:row=198;PAMPA_results.csv:row=198;BBB_results.csv:row=198;Solubility_results.csv:row=198;Lipophilicity_results.csv:row=199
CHEMBL1650,CORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.14; logP 2.56,repurposing_candidates.csv:rc_row=493;protein_drug_candidates.csv:rows=3;pathway_drug_candidates.csv:rows=695;2004;5919;7823;7960;8026;8097;8163;8229;CYP3A4_results.csv:row=453;CYP2C19_results.csv:row=453;CYP2D6_results.csv:row=453;CYP1A2_results.csv:row=453;CYP2C9_results.csv:row=453;hERG_results.csv:row=453;AMES_results.csv:row=453;PGP_results.csv:row=453;PAMPA_results.csv:row=453;BBB_results.csv:row=453;Solubility_results.csv:row=453;Lipophilicity_results.csv:row=454
CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -3.14; logP 3.94,repurposing_candidates.csv:rc_row=212;protein_drug_candidates.csv:rows=25;pathway_drug_candidates.csv:rows=717;2026;5941;7845;7982;8048;8119;8185;8251;CYP3A4_results.csv:row=210;CYP2C19_results.csv:row=210;CYP2D6_results.csv:row=210;CYP1A2_results.csv:row=210;CYP2C9_results.csv:row=210;hERG_results.csv:row=210;AMES_results.csv:row=210;PGP_results.csv:row=210;PAMPA_results.csv:row=210;BBB_results.csv:row=210;Solubility_results.csv:row=210;Lipophilicity_results.csv:row=211
CHEMBL2040682,CICLESONIDE,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.56; logP 4.70,repurposing_candidates.csv:rc_row=632;protein_drug_candidates.csv:rows=41;pathway_drug_candidates.csv:rows=733;2042;5957;7861;7998;8064;8135;8201;8267;CYP3A4_results.csv:row=578;CYP2C19_results.csv:row=578;CYP2D6_results.csv:row=578;CYP1A2_results.csv:row=578;CYP2C9_results.csv:row=578;hERG_results.csv:row=578;AMES_results.csv:row=578;PGP_results.csv:row=578;PAMPA_results.csv:row=578;BBB_results.csv:row=578;Solubility_results.csv:row=578;Lipophilicity_results.csv:row=579
CHEMBL1200545,DIFLORASONE DIACETATE,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.35; logP 2.99,repurposing_candidates.csv:rc_row=123;protein_drug_candidates.csv:rows=23;pathway_drug_candidates.csv:rows=715;2024;5939;7843;7980;8046;8117;8183;8249;CYP3A4_results.csv:row=122;CYP2C19_results.csv:row=122;CYP2D6_results.csv:row=122;CYP1A2_results.csv:row=122;CYP2C9_results.csv:row=122;hERG_results.csv:row=122;AMES_results.csv:row=122;PGP_results.csv:row=122;PAMPA_results.csv:row=122;BBB_results.csv:row=122;Solubility_results.csv:row=122;Lipophilicity_results.csv:row=122
CHEMBL1152,PREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.24; logP 2.13,repurposing_candidates.csv:rc_row=63;protein_drug_candidates.csv:rows=43;pathway_drug_candidates.csv:rows=735;2044;5959;7863;8000;8066;8137;8203;8269;CYP3A4_results.csv:row=62;CYP2C19_results.csv:row=62;CYP2D6_results.csv:row=62;CYP1A2_results.csv:row=62;CYP2C9_results.csv:row=62;hERG_results.csv:row=62;AMES_results.csv:row=62;PGP_results.csv:row=62;PAMPA_results.csv:row=62;BBB_results.csv:row=62;Solubility_results.csv:row=62;Lipophilicity_results.csv:row=62
CHEMBL1497,BETAMETHASONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.85; logP 3.64,repurposing_candidates.csv:rc_row=436;protein_drug_candidates.csv:rows=26;pathway_drug_candidates.csv:rows=718;2027;5942;7846;7983;8049;8120;8186;8252;CYP3A4_results.csv:row=396;CYP2C19_results.csv:row=396;CYP2D6_results.csv:row=396;CYP1A2_results.csv:row=396;CYP2C9_results.csv:row=396;hERG_results.csv:row=396;AMES_results.csv:row=396;PGP_results.csv:row=396;PAMPA_results.csv:row=396;BBB_results.csv:row=396;Solubility_results.csv:row=396;Lipophilicity_results.csv:row=397
CHEMBL1501,FLUOCINONIDE,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -5.66; logP 2.94,repurposing_candidates.csv:rc_row=437;protein_drug_candidates.csv:rows=27;pathway_drug_candidates.csv:rows=719;2028;5943;7847;7984;8050;8121;8187;8253;CYP3A4_results.csv:row=397;CYP2C19_results.csv:row=397;CYP2D6_results.csv:row=397;CYP1A2_results.csv:row=397;CYP2C9_results.csv:row=397;hERG_results.csv:row=397;AMES_results.csv:row=397;PGP_results.csv:row=397;PAMPA_results.csv:row=397;BBB_results.csv:row=397;Solubility_results.csv:row=397;Lipophilicity_results.csv:row=398
CHEMBL1159650,CLOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.62; logP 4.10,repurposing_candidates.csv:rc_row=64;protein_drug_candidates.csv:rows=19;pathway_drug_candidates.csv:rows=711;2020;5935;7839;7976;8042;8113;8179;8245;CYP3A4_results.csv:row=63;CYP2C19_results.csv:row=63;CYP2D6_results.csv:row=63;CYP1A2_results.csv:row=63;CYP2C9_results.csv:row=63;hERG_results.csv:row=63;AMES_results.csv:row=63;PGP_results.csv:row=63;PAMPA_results.csv:row=63;BBB_results.csv:row=63;Solubility_results.csv:row=63;Lipophilicity_results.csv:row=63
CHEMBL1200845,HALCINONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1,51.04118993135011,100,100.0,80.41647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.03; logP 3.89,repurposing_candidates.csv:rc_row=181;protein_drug_candidates.csv:rows=29;pathway_drug_candidates.csv:rows=721;2030;5945;7849;7986;8052;8123;8189;8255;CYP3A4_results.csv:row=179;CYP2C19_results.csv:row=179;CYP2D6_results.csv:row=179;CYP1A2_results.csv:row=179;CYP2C9_results.csv:row=179;hERG_results.csv:row=179;AMES_results.csv:row=179;PGP_results.csv:row=179;PAMPA_results.csv:row=179;BBB_results.csv:row=179;Solubility_results.csv:row=179;Lipophilicity_results.csv:row=180
CHEMBL1200699,DOXYCYCLINE,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,53.901601830663616,100,95.0,80.31064073226545,H,"KG targets MMP1, MMP13; clinical phase 4.0; logS -3.56; logP -1.17",repurposing_candidates.csv:rc_row=154;protein_drug_candidates.csv:rows=609;614;620;627;pathway_drug_candidates.csv:rows=25;31;38;43;49;55;62;67;80;86;93;98;111;125;230;3027;CYP3A4_results.csv:row=152;CYP2C19_results.csv:row=152;CYP2D6_results.csv:row=152;CYP1A2_results.csv:row=152;CYP2C9_results.csv:row=152;hERG_results.csv:row=152;AMES_results.csv:row=152;PGP_results.csv:row=152;PAMPA_results.csv:row=152;BBB_results.csv:row=152;Solubility_results.csv:row=152;Lipophilicity_results.csv:row=153
CHEMBL3989740,DOXYCYCLINE HYCLATE,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,53.901601830663616,100,95.0,80.31064073226545,H,"KG targets MMP1, MMP13; clinical phase 4.0; logS -2.03; logP -0.68",repurposing_candidates.csv:rc_row=1084;protein_drug_candidates.csv:rows=610;615;621;628;pathway_drug_candidates.csv:rows=26;32;39;44;50;56;63;68;81;87;94;99;112;126;231;3028;CYP3A4_results.csv:row=953;CYP2C19_results.csv:row=953;CYP2D6_results.csv:row=953;CYP1A2_results.csv:row=953;CYP2C9_results.csv:row=953;hERG_results.csv:row=953;AMES_results.csv:row=953;PGP_results.csv:row=953;PAMPA_results.csv:row=953;BBB_results.csv:row=953;Solubility_results.csv:row=953;Lipophilicity_results.csv:row=954
CHEMBL2110725,VINFLUNINE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,76.73913043478261,80,85.0,79.94565217391305,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -5.87; logP 5.08",repurposing_candidates.csv:rc_row=779;protein_drug_candidates.csv:rows=827;1559;1994;2233;2338;2403;2710;2773;2837;pathway_drug_candidates.csv:rows=1540;1604;1668;1732;1796;1860;1924;2089;2153;2217;2281;2345;2409;2473;2537;2601;2665;2729;2793;2857;2921;2985;3055;3119;3183;3247;3311;3375;3439;3503;3567;3658;3722;3786;3850;3914;3978;4045;CYP3A4_results.csv:row=688;CYP2C19_results.csv:row=688;CYP2D6_results.csv:row=688;CYP1A2_results.csv:row=688;CYP2C9_results.csv:row=688;hERG_results.csv:row=688;AMES_results.csv:row=688;PGP_results.csv:row=688;PAMPA_results.csv:row=688;BBB_results.csv:row=688;Solubility_results.csv:row=688;Lipophilicity_results.csv:row=689
CHEMBL1200613,TOLMETIN SODIUM,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.83; logP -2.14",repurposing_candidates.csv:rc_row=134;protein_drug_candidates.csv:rows=109;896;pathway_drug_candidates.csv:rows=332;4450;5536;5596;5659;6043;6117;6191;6265;6339;6413;CYP3A4_results.csv:row=133;CYP2C19_results.csv:row=133;CYP2D6_results.csv:row=133;CYP1A2_results.csv:row=133;CYP2C9_results.csv:row=133;hERG_results.csv:row=133;AMES_results.csv:row=133;PGP_results.csv:row=133;PAMPA_results.csv:row=133;BBB_results.csv:row=133;Solubility_results.csv:row=133;Lipophilicity_results.csv:row=133
CHEMBL1200806,NAPROXEN SODIUM,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.95; logP -1.29",repurposing_candidates.csv:rc_row=174;protein_drug_candidates.csv:rows=110;897;pathway_drug_candidates.csv:rows=333;4451;5537;5597;5660;6044;6118;6192;6266;6340;6414;CYP3A4_results.csv:row=172;CYP2C19_results.csv:row=172;CYP2D6_results.csv:row=172;CYP1A2_results.csv:row=172;CYP2C9_results.csv:row=172;hERG_results.csv:row=172;AMES_results.csv:row=172;PGP_results.csv:row=172;PAMPA_results.csv:row=172;BBB_results.csv:row=172;Solubility_results.csv:row=172;Lipophilicity_results.csv:row=173
CHEMBL12610,BENZYDAMINE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.35; logP 3.42",repurposing_candidates.csv:rc_row=363;protein_drug_candidates.csv:rows=129;916;pathway_drug_candidates.csv:rows=352;4470;5556;5616;5679;6063;6137;6211;6285;6359;6433;CYP3A4_results.csv:row=325;CYP2C19_results.csv:row=325;CYP2D6_results.csv:row=325;CYP1A2_results.csv:row=325;CYP2C9_results.csv:row=325;hERG_results.csv:row=325;AMES_results.csv:row=325;PGP_results.csv:row=325;PAMPA_results.csv:row=325;BBB_results.csv:row=325;Solubility_results.csv:row=325;Lipophilicity_results.csv:row=326
CHEMBL1201124,KETOROLAC TROMETHAMINE,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -1.53; logP -0.05",repurposing_candidates.csv:rc_row=238;protein_drug_candidates.csv:rows=137;904;pathway_drug_candidates.csv:rows=360;4478;5544;5604;5687;6071;6145;6219;6293;6367;6441;CYP3A4_results.csv:row=235;CYP2C19_results.csv:row=235;CYP2D6_results.csv:row=235;CYP1A2_results.csv:row=235;CYP2C9_results.csv:row=235;hERG_results.csv:row=235;AMES_results.csv:row=235;PGP_results.csv:row=235;PAMPA_results.csv:row=235;BBB_results.csv:row=235;Solubility_results.csv:row=235;Lipophilicity_results.csv:row=236
CHEMBL1201013,OLSALAZINE SODIUM,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -2.66; logP -5.75",repurposing_candidates.csv:rc_row=218;protein_drug_candidates.csv:rows=106;901;pathway_drug_candidates.csv:rows=329;4447;5541;5601;5656;6040;6114;6188;6262;6336;6410;CYP3A4_results.csv:row=216;CYP2C19_results.csv:row=216;CYP2D6_results.csv:row=216;CYP1A2_results.csv:row=216;CYP2C9_results.csv:row=216;hERG_results.csv:row=216;AMES_results.csv:row=216;PGP_results.csv:row=216;PAMPA_results.csv:row=216;BBB_results.csv:row=216;Solubility_results.csv:row=216;Lipophilicity_results.csv:row=217
CHEMBL1562610,MECLOFENAMATE SODIUM,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.32; logP -0.41",repurposing_candidates.csv:rc_row=459;protein_drug_candidates.csv:rows=101;888;pathway_drug_candidates.csv:rows=324;4442;5528;5588;5651;6035;6109;6183;6257;6331;6405;CYP3A4_results.csv:row=419;CYP2C19_results.csv:row=419;CYP2D6_results.csv:row=419;CYP1A2_results.csv:row=419;CYP2C9_results.csv:row=419;hERG_results.csv:row=419;AMES_results.csv:row=419;PGP_results.csv:row=419;PAMPA_results.csv:row=419;BBB_results.csv:row=419;Solubility_results.csv:row=419;Lipophilicity_results.csv:row=420
CHEMBL1200760,BALSALAZIDE DISODIUM,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -1.24; logP -5.95",repurposing_candidates.csv:rc_row=162;protein_drug_candidates.csv:rows=105;892;pathway_drug_candidates.csv:rows=328;4446;5532;5592;5655;6039;6113;6187;6261;6335;6409;CYP3A4_results.csv:row=160;CYP2C19_results.csv:row=160;CYP2D6_results.csv:row=160;CYP1A2_results.csv:row=160;CYP2C9_results.csv:row=160;hERG_results.csv:row=160;AMES_results.csv:row=160;PGP_results.csv:row=160;PAMPA_results.csv:row=160;BBB_results.csv:row=160;Solubility_results.csv:row=160;Lipophilicity_results.csv:row=161
CHEMBL3181947,BROMFENAC SODIUM,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+],52.87185354691076,100,95.0,79.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.79; logP -5.36",repurposing_candidates.csv:rc_row=916;protein_drug_candidates.csv:rows=140;906;pathway_drug_candidates.csv:rows=363;4481;5546;5606;5690;6074;6148;6222;6296;6370;6444;CYP3A4_results.csv:row=823;CYP2C19_results.csv:row=823;CYP2D6_results.csv:row=823;CYP1A2_results.csv:row=823;CYP2C9_results.csv:row=823;hERG_results.csv:row=823;AMES_results.csv:row=823;PGP_results.csv:row=823;PAMPA_results.csv:row=823;BBB_results.csv:row=823;Solubility_results.csv:row=823;Lipophilicity_results.csv:row=824
CHEMBL553025,VINORELBINE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,58.405797101449274,100,85.0,79.61231884057972,H,"KG targets TUBB, TUBB1; clinical phase 4.0; logS -6.02; logP 4.75",repurposing_candidates.csv:rc_row=1410;protein_drug_candidates.csv:rows=818;1548;1983;2222;2331;2394;2702;2764;2824;pathway_drug_candidates.csv:rows=1531;1595;1659;1723;1787;1851;1915;2080;2144;2208;2272;2336;2400;2464;2528;2592;2656;2720;2784;2848;2912;2976;3046;3110;3174;3238;3302;3366;3430;3494;3558;3649;3713;3777;3841;3905;3969;4036;CYP3A4_results.csv:row=1219;CYP2C19_results.csv:row=1219;CYP2D6_results.csv:row=1219;CYP1A2_results.csv:row=1219;CYP2C9_results.csv:row=1219;hERG_results.csv:row=1219;AMES_results.csv:row=1219;PGP_results.csv:row=1219;PAMPA_results.csv:row=1219;BBB_results.csv:row=1219;Solubility_results.csv:row=1219;Lipophilicity_results.csv:row=1220
CHEMBL1752,DYPHYLLINE,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,51.79633867276888,100,95.0,79.46853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -0.06; logP -2.21",repurposing_candidates.csv:rc_row=558;protein_drug_candidates.csv:rows=415;1050;1078;2155;pathway_drug_candidates.csv:rows=4329;5737;5767;5795;5832;5862;CYP3A4_results.csv:row=504;CYP2C19_results.csv:row=504;CYP2D6_results.csv:row=504;CYP1A2_results.csv:row=504;CYP2C9_results.csv:row=504;hERG_results.csv:row=504;AMES_results.csv:row=504;PGP_results.csv:row=504;PAMPA_results.csv:row=504;BBB_results.csv:row=504;Solubility_results.csv:row=504;Lipophilicity_results.csv:row=505
CHEMBL1200434,OXTRIPHYLLINE,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O,51.79633867276888,100,95.0,79.46853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS 0.96; logP -1.73",repurposing_candidates.csv:rc_row=101;protein_drug_candidates.csv:rows=416;1047;1077;2153;pathway_drug_candidates.csv:rows=4328;5738;5764;5794;5833;5861;CYP3A4_results.csv:row=100;CYP2C19_results.csv:row=100;CYP2D6_results.csv:row=100;CYP1A2_results.csv:row=100;CYP2C9_results.csv:row=100;hERG_results.csv:row=100;AMES_results.csv:row=100;PGP_results.csv:row=100;PAMPA_results.csv:row=100;BBB_results.csv:row=100;Solubility_results.csv:row=100;Lipophilicity_results.csv:row=100
CHEMBL932,DIPYRIDAMOLE,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,54.679633867276884,100,90.0,79.37185354691076,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -1.61; logP -0.02",repurposing_candidates.csv:rc_row=1556;protein_drug_candidates.csv:rows=411;871;1044;1072;2149;pathway_drug_candidates.csv:rows=4323;5733;5761;5789;5828;5856;7671;7698;7711;CYP3A4_results.csv:row=1362;CYP2C19_results.csv:row=1362;CYP2D6_results.csv:row=1362;CYP1A2_results.csv:row=1362;CYP2C9_results.csv:row=1362;hERG_results.csv:row=1362;AMES_results.csv:row=1362;PGP_results.csv:row=1362;PAMPA_results.csv:row=1362;BBB_results.csv:row=1362;Solubility_results.csv:row=1362;Lipophilicity_results.csv:row=1363
CHEMBL877,TRANEXAMIC ACID,NC[C@H]1CC[C@H](C(=O)O)CC1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets PLG; clinical phase 4.0; logS 0.14; logP 0.84,repurposing_candidates.csv:rc_row=1541;protein_drug_candidates.csv:rows=680;pathway_drug_candidates.csv:rows=73;104;131;454;CYP3A4_results.csv:row=1347;CYP2C19_results.csv:row=1347;CYP2D6_results.csv:row=1347;CYP1A2_results.csv:row=1347;CYP2C9_results.csv:row=1347;hERG_results.csv:row=1347;AMES_results.csv:row=1347;PGP_results.csv:row=1347;PAMPA_results.csv:row=1347;BBB_results.csv:row=1347;Solubility_results.csv:row=1347;Lipophilicity_results.csv:row=1348
CHEMBL1873475,IBRUTINIB,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets BTK; clinical phase 4.0; logS -4.83; logP 4.22,repurposing_candidates.csv:rc_row=584;protein_drug_candidates.csv:rows=189;pathway_drug_candidates.csv:rows=595;4090;6552;6732;CYP3A4_results.csv:row=530;CYP2C19_results.csv:row=530;CYP2D6_results.csv:row=530;CYP1A2_results.csv:row=530;CYP2C9_results.csv:row=530;hERG_results.csv:row=530;AMES_results.csv:row=530;PGP_results.csv:row=530;PAMPA_results.csv:row=530;BBB_results.csv:row=530;Solubility_results.csv:row=530;Lipophilicity_results.csv:row=531
CHEMBL1200692,OLMESARTAN MEDOXOMIL,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -4.72; logP 4.17,repurposing_candidates.csv:rc_row=152;protein_drug_candidates.csv:rows=579;pathway_drug_candidates.csv:rows=6533;7152;7263;7283;CYP3A4_results.csv:row=150;CYP2C19_results.csv:row=150;CYP2D6_results.csv:row=150;CYP1A2_results.csv:row=150;CYP2C9_results.csv:row=150;hERG_results.csv:row=150;AMES_results.csv:row=150;PGP_results.csv:row=150;PAMPA_results.csv:row=150;BBB_results.csv:row=150;Solubility_results.csv:row=150;Lipophilicity_results.csv:row=151
CHEMBL995,LOSARTAN POTASSIUM,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+],48.40961098398169,100,100.0,79.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -3.69; logP 0.90,repurposing_candidates.csv:rc_row=1580;protein_drug_candidates.csv:rows=586;pathway_drug_candidates.csv:rows=6540;7159;7270;7290;CYP3A4_results.csv:row=1386;CYP2C19_results.csv:row=1386;CYP2D6_results.csv:row=1386;CYP1A2_results.csv:row=1386;CYP2C9_results.csv:row=1386;hERG_results.csv:row=1386;AMES_results.csv:row=1386;PGP_results.csv:row=1386;PAMPA_results.csv:row=1386;BBB_results.csv:row=1386;Solubility_results.csv:row=1386;Lipophilicity_results.csv:row=1387
CHEMBL1513,IRBESARTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -4.43; logP 4.78,repurposing_candidates.csv:rc_row=442;protein_drug_candidates.csv:rows=580;pathway_drug_candidates.csv:rows=6534;7153;7264;7284;CYP3A4_results.csv:row=402;CYP2C19_results.csv:row=402;CYP2D6_results.csv:row=402;CYP1A2_results.csv:row=402;CYP2C9_results.csv:row=402;hERG_results.csv:row=402;AMES_results.csv:row=402;PGP_results.csv:row=402;PAMPA_results.csv:row=402;BBB_results.csv:row=402;Solubility_results.csv:row=402;Lipophilicity_results.csv:row=403
CHEMBL4594293,ACALABRUTINIB MALEATE,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O,48.40961098398169,100,100.0,79.36384439359267,H,KG targets BTK; clinical phase 4.0; logS -3.70; logP 3.02,repurposing_candidates.csv:rc_row=1289;protein_drug_candidates.csv:rows=191;pathway_drug_candidates.csv:rows=597;4092;6554;6734;CYP3A4_results.csv:row=1109;CYP2C19_results.csv:row=1109;CYP2D6_results.csv:row=1109;CYP1A2_results.csv:row=1109;CYP2C9_results.csv:row=1109;hERG_results.csv:row=1109;AMES_results.csv:row=1109;PGP_results.csv:row=1109;PAMPA_results.csv:row=1109;BBB_results.csv:row=1109;Solubility_results.csv:row=1109;Lipophilicity_results.csv:row=1110
CHEMBL1046,AMINOCAPROIC ACID,NCCCCCC(=O)O,48.40961098398169,100,100.0,79.36384439359267,H,KG targets PLG; clinical phase 4.0; logS -0.72; logP 0.59,repurposing_candidates.csv:rc_row=16;protein_drug_candidates.csv:rows=683;pathway_drug_candidates.csv:rows=76;107;134;457;CYP3A4_results.csv:row=16;CYP2C19_results.csv:row=16;CYP2D6_results.csv:row=16;CYP1A2_results.csv:row=16;CYP2C9_results.csv:row=16;hERG_results.csv:row=16;AMES_results.csv:row=16;PGP_results.csv:row=16;PAMPA_results.csv:row=16;BBB_results.csv:row=16;Solubility_results.csv:row=16;Lipophilicity_results.csv:row=16
CHEMBL1200987,EPROSARTAN MESYLATE,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O,48.40961098398169,100,100.0,79.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -2.39; logP 4.25,repurposing_candidates.csv:rc_row=210;protein_drug_candidates.csv:rows=587;pathway_drug_candidates.csv:rows=6541;7160;7271;7291;CYP3A4_results.csv:row=208;CYP2C19_results.csv:row=208;CYP2D6_results.csv:row=208;CYP1A2_results.csv:row=208;CYP2C9_results.csv:row=208;hERG_results.csv:row=208;AMES_results.csv:row=208;PGP_results.csv:row=208;PAMPA_results.csv:row=208;BBB_results.csv:row=208;Solubility_results.csv:row=208;Lipophilicity_results.csv:row=209
CHEMBL3989920,PITAVASTATIN SODIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+],48.40961098398169,100,100.0,79.36384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -2.87; logP 0.19,repurposing_candidates.csv:rc_row=1101;protein_drug_candidates.csv:rows=744;pathway_drug_candidates.csv:rows=7623;7638;7653;7668;CYP3A4_results.csv:row=970;CYP2C19_results.csv:row=970;CYP2D6_results.csv:row=970;CYP1A2_results.csv:row=970;CYP2C9_results.csv:row=970;hERG_results.csv:row=970;AMES_results.csv:row=970;PGP_results.csv:row=970;PAMPA_results.csv:row=970;BBB_results.csv:row=970;Solubility_results.csv:row=970;Lipophilicity_results.csv:row=971
CHEMBL1744447,ROSUVASTATIN CALCIUM,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],48.40961098398169,100,100.0,79.36384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -3.28; logP 1.75,repurposing_candidates.csv:rc_row=556;protein_drug_candidates.csv:rows=740;pathway_drug_candidates.csv:rows=7619;7634;7649;7664;CYP3A4_results.csv:row=502;CYP2C19_results.csv:row=502;CYP2D6_results.csv:row=502;CYP1A2_results.csv:row=502;CYP2C9_results.csv:row=502;hERG_results.csv:row=502;AMES_results.csv:row=502;PGP_results.csv:row=502;PAMPA_results.csv:row=502;BBB_results.csv:row=502;Solubility_results.csv:row=502;Lipophilicity_results.csv:row=503
CHEMBL2218894,FLUVASTATIN SODIUM,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+],48.40961098398169,100,100.0,79.36384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -2.22; logP 0.30,repurposing_candidates.csv:rc_row=809;protein_drug_candidates.csv:rows=741;pathway_drug_candidates.csv:rows=7620;7635;7650;7665;CYP3A4_results.csv:row=718;CYP2C19_results.csv:row=718;CYP2D6_results.csv:row=718;CYP1A2_results.csv:row=718;CYP2C9_results.csv:row=718;hERG_results.csv:row=718;AMES_results.csv:row=718;PGP_results.csv:row=718;PAMPA_results.csv:row=718;BBB_results.csv:row=718;Solubility_results.csv:row=718;Lipophilicity_results.csv:row=719
CHEMBL1069,VALSARTAN,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,48.40961098398169,100,100.0,79.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -3.58; logP 4.16,repurposing_candidates.csv:rc_row=20;protein_drug_candidates.csv:rows=578;pathway_drug_candidates.csv:rows=6532;7151;7262;7282;CYP3A4_results.csv:row=20;CYP2C19_results.csv:row=20;CYP2D6_results.csv:row=20;CYP1A2_results.csv:row=20;CYP2C9_results.csv:row=20;hERG_results.csv:row=20;AMES_results.csv:row=20;PGP_results.csv:row=20;PAMPA_results.csv:row=20;BBB_results.csv:row=20;Solubility_results.csv:row=20;Lipophilicity_results.csv:row=20
CHEMBL3707348,ACALABRUTINIB,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,48.40961098398169,100,100.0,79.36384439359267,H,KG targets BTK; clinical phase 4.0; logS -4.12; logP 3.31,repurposing_candidates.csv:rc_row=1023;protein_drug_candidates.csv:rows=190;pathway_drug_candidates.csv:rows=596;4091;6553;6733;CYP3A4_results.csv:row=903;CYP2C19_results.csv:row=903;CYP2D6_results.csv:row=903;CYP1A2_results.csv:row=903;CYP2C9_results.csv:row=903;hERG_results.csv:row=903;AMES_results.csv:row=903;PGP_results.csv:row=903;PAMPA_results.csv:row=903;BBB_results.csv:row=903;Solubility_results.csv:row=903;Lipophilicity_results.csv:row=904
CHEMBL4650485,PIRTOBRUTINIB,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets BTK; clinical phase 4.0; logS -2.83; logP 3.43,repurposing_candidates.csv:rc_row=1316;protein_drug_candidates.csv:rows=194;pathway_drug_candidates.csv:rows=600;4095;6557;6737;CYP3A4_results.csv:row=1129;CYP2C19_results.csv:row=1129;CYP2D6_results.csv:row=1129;CYP1A2_results.csv:row=1129;CYP2C9_results.csv:row=1129;hERG_results.csv:row=1129;AMES_results.csv:row=1129;PGP_results.csv:row=1129;PAMPA_results.csv:row=1129;BBB_results.csv:row=1129;Solubility_results.csv:row=1129;Lipophilicity_results.csv:row=1130
CHEMBL3936761,ZANUBRUTINIB,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,48.40961098398169,100,100.0,79.36384439359267,H,KG targets BTK; clinical phase 4.0; logS -3.74; logP 4.22,repurposing_candidates.csv:rc_row=1059;protein_drug_candidates.csv:rows=192;pathway_drug_candidates.csv:rows=598;4093;6555;6735;CYP3A4_results.csv:row=928;CYP2C19_results.csv:row=928;CYP2D6_results.csv:row=928;CYP1A2_results.csv:row=928;CYP2C9_results.csv:row=928;hERG_results.csv:row=928;AMES_results.csv:row=928;PGP_results.csv:row=928;PAMPA_results.csv:row=928;BBB_results.csv:row=928;Solubility_results.csv:row=928;Lipophilicity_results.csv:row=929
CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -2.56; logP -5.24,repurposing_candidates.csv:rc_row=163;protein_drug_candidates.csv:rows=33;pathway_drug_candidates.csv:rows=725;2034;5949;7853;7990;8056;8127;8193;8259;CYP3A4_results.csv:row=161;CYP2C19_results.csv:row=161;CYP2D6_results.csv:row=161;CYP1A2_results.csv:row=161;CYP2C9_results.csv:row=161;hERG_results.csv:row=161;AMES_results.csv:row=161;PGP_results.csv:row=161;PAMPA_results.csv:row=161;BBB_results.csv:row=161;Solubility_results.csv:row=161;Lipophilicity_results.csv:row=162
CHEMBL1364144,METHYLPREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.32; logP 2.37,repurposing_candidates.csv:rc_row=393;protein_drug_candidates.csv:rows=17;pathway_drug_candidates.csv:rows=709;2018;5933;7837;7974;8040;8111;8177;8243;CYP3A4_results.csv:row=354;CYP2C19_results.csv:row=354;CYP2D6_results.csv:row=354;CYP1A2_results.csv:row=354;CYP2C9_results.csv:row=354;hERG_results.csv:row=354;AMES_results.csv:row=354;PGP_results.csv:row=354;PAMPA_results.csv:row=354;BBB_results.csv:row=354;Solubility_results.csv:row=354;Lipophilicity_results.csv:row=355
CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -1.96; logP -5.58,repurposing_candidates.csv:rc_row=219;protein_drug_candidates.csv:rows=8;pathway_drug_candidates.csv:rows=700;2009;5924;7828;7965;8031;8102;8168;8234;CYP3A4_results.csv:row=217;CYP2C19_results.csv:row=217;CYP2D6_results.csv:row=217;CYP1A2_results.csv:row=217;CYP2C9_results.csv:row=217;hERG_results.csv:row=217;AMES_results.csv:row=217;PGP_results.csv:row=217;PAMPA_results.csv:row=217;BBB_results.csv:row=217;Solubility_results.csv:row=217;Lipophilicity_results.csv:row=218
CHEMBL1201173,MEDRYSONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -3.62; logP 3.94,repurposing_candidates.csv:rc_row=249;protein_drug_candidates.csv:rows=37;pathway_drug_candidates.csv:rows=729;2038;5953;7857;7994;8060;8131;8197;8263;CYP3A4_results.csv:row=246;CYP2C19_results.csv:row=246;CYP2D6_results.csv:row=246;CYP1A2_results.csv:row=246;CYP2C9_results.csv:row=246;hERG_results.csv:row=246;AMES_results.csv:row=246;PGP_results.csv:row=246;PAMPA_results.csv:row=246;BBB_results.csv:row=246;Solubility_results.csv:row=246;Lipophilicity_results.csv:row=247
CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -3.69; logP 4.09,repurposing_candidates.csv:rc_row=115;protein_drug_candidates.csv:rows=40;pathway_drug_candidates.csv:rows=732;2041;5956;7860;7997;8063;8134;8200;8266;CYP3A4_results.csv:row=114;CYP2C19_results.csv:row=114;CYP2D6_results.csv:row=114;CYP1A2_results.csv:row=114;CYP2C9_results.csv:row=114;hERG_results.csv:row=114;AMES_results.csv:row=114;PGP_results.csv:row=114;PAMPA_results.csv:row=114;BBB_results.csv:row=114;Solubility_results.csv:row=114;Lipophilicity_results.csv:row=114
CHEMBL1161,MOMETASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.09; logP 4.87,repurposing_candidates.csv:rc_row=66;protein_drug_candidates.csv:rows=28;pathway_drug_candidates.csv:rows=720;2029;5944;7848;7985;8051;8122;8188;8254;CYP3A4_results.csv:row=65;CYP2C19_results.csv:row=65;CYP2D6_results.csv:row=65;CYP1A2_results.csv:row=65;CYP2C9_results.csv:row=65;hERG_results.csv:row=65;AMES_results.csv:row=65;PGP_results.csv:row=65;PAMPA_results.csv:row=65;BBB_results.csv:row=65;Solubility_results.csv:row=65;Lipophilicity_results.csv:row=65
CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -2.56; logP -5.24,repurposing_candidates.csv:rc_row=623;protein_drug_candidates.csv:rows=11;pathway_drug_candidates.csv:rows=703;2012;5927;7831;7968;8034;8105;8171;8237;CYP3A4_results.csv:row=569;CYP2C19_results.csv:row=569;CYP2D6_results.csv:row=569;CYP1A2_results.csv:row=569;CYP2C9_results.csv:row=569;hERG_results.csv:row=569;AMES_results.csv:row=569;PGP_results.csv:row=569;PAMPA_results.csv:row=569;BBB_results.csv:row=569;Solubility_results.csv:row=569;Lipophilicity_results.csv:row=570
CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+],51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -2.82; logP -2.13,repurposing_candidates.csv:rc_row=114;protein_drug_candidates.csv:rows=45;pathway_drug_candidates.csv:rows=737;2046;5961;7865;8002;8068;8139;8205;8271;CYP3A4_results.csv:row=113;CYP2C19_results.csv:row=113;CYP2D6_results.csv:row=113;CYP1A2_results.csv:row=113;CYP2C9_results.csv:row=113;hERG_results.csv:row=113;AMES_results.csv:row=113;PGP_results.csv:row=113;PAMPA_results.csv:row=113;BBB_results.csv:row=113;Solubility_results.csv:row=113;Lipophilicity_results.csv:row=113
CHEMBL1200538,BETAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,95.0,79.16647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -4.71; logP 2.47,repurposing_candidates.csv:rc_row=120;protein_drug_candidates.csv:rows=32;pathway_drug_candidates.csv:rows=724;2033;5948;7852;7989;8055;8126;8192;8258;CYP3A4_results.csv:row=119;CYP2C19_results.csv:row=119;CYP2D6_results.csv:row=119;CYP1A2_results.csv:row=119;CYP2C9_results.csv:row=119;hERG_results.csv:row=119;AMES_results.csv:row=119;PGP_results.csv:row=119;PAMPA_results.csv:row=119;BBB_results.csv:row=119;Solubility_results.csv:row=119;Lipophilicity_results.csv:row=119
CHEMBL1339,VARDENAFIL HYDROCHLORIDE,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl,47.88329519450801,100,100.0,79.1533180778032,H,KG targets PDE5A; clinical phase 4.0; logS -3.24; logP 2.90,repurposing_candidates.csv:rc_row=386;protein_drug_candidates.csv:rows=873;pathway_drug_candidates.csv:rows=7673;7700;7713;CYP3A4_results.csv:row=347;CYP2C19_results.csv:row=347;CYP2D6_results.csv:row=347;CYP1A2_results.csv:row=347;CYP2C9_results.csv:row=347;hERG_results.csv:row=347;AMES_results.csv:row=347;PGP_results.csv:row=347;PAMPA_results.csv:row=347;BBB_results.csv:row=347;Solubility_results.csv:row=347;Lipophilicity_results.csv:row=348
CHEMBL1963681,AVANAFIL,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,47.88329519450801,100,100.0,79.1533180778032,H,KG targets PDE5A; clinical phase 4.0; logS -2.80; logP 2.43,repurposing_candidates.csv:rc_row=614;protein_drug_candidates.csv:rows=876;pathway_drug_candidates.csv:rows=7676;7703;7716;CYP3A4_results.csv:row=560;CYP2C19_results.csv:row=560;CYP2D6_results.csv:row=560;CYP1A2_results.csv:row=560;CYP2C9_results.csv:row=560;hERG_results.csv:row=560;AMES_results.csv:row=560;PGP_results.csv:row=560;PAMPA_results.csv:row=560;BBB_results.csv:row=560;Solubility_results.csv:row=560;Lipophilicity_results.csv:row=561
CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl,47.88329519450801,100,100.0,79.1533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -1.41; logP 3.51,repurposing_candidates.csv:rc_row=317;protein_drug_candidates.csv:rows=304;pathway_drug_candidates.csv:rows=274;1308;7221;CYP3A4_results.csv:row=286;CYP2C19_results.csv:row=286;CYP2D6_results.csv:row=286;CYP1A2_results.csv:row=286;CYP2C9_results.csv:row=286;hERG_results.csv:row=286;AMES_results.csv:row=286;PGP_results.csv:row=286;PAMPA_results.csv:row=286;BBB_results.csv:row=286;Solubility_results.csv:row=286;Lipophilicity_results.csv:row=287
CHEMBL3590187,CLASCOTERONE,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -5.13; logP 3.77,repurposing_candidates.csv:rc_row=1002;protein_drug_candidates.csv:rows=556;pathway_drug_candidates.csv:rows=1979;5894;7798;CYP3A4_results.csv:row=888;CYP2C19_results.csv:row=888;CYP2D6_results.csv:row=888;CYP1A2_results.csv:row=888;CYP2C9_results.csv:row=888;hERG_results.csv:row=888;AMES_results.csv:row=888;PGP_results.csv:row=888;PAMPA_results.csv:row=888;BBB_results.csv:row=888;Solubility_results.csv:row=888;Lipophilicity_results.csv:row=889
CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl,47.88329519450801,100,100.0,79.1533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -4.03; logP 4.70,repurposing_candidates.csv:rc_row=350;protein_drug_candidates.csv:rows=283;pathway_drug_candidates.csv:rows=253;1287;7200;CYP3A4_results.csv:row=312;CYP2C19_results.csv:row=312;CYP2D6_results.csv:row=312;CYP1A2_results.csv:row=312;CYP2C9_results.csv:row=312;hERG_results.csv:row=312;AMES_results.csv:row=312;PGP_results.csv:row=312;PAMPA_results.csv:row=312;BBB_results.csv:row=312;Solubility_results.csv:row=312;Lipophilicity_results.csv:row=313
CHEMBL1274,NILUTAMIDE,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -3.29; logP 2.45,repurposing_candidates.csv:rc_row=370;protein_drug_candidates.csv:rows=549;pathway_drug_candidates.csv:rows=1972;5887;7791;CYP3A4_results.csv:row=331;CYP2C19_results.csv:row=331;CYP2D6_results.csv:row=331;CYP1A2_results.csv:row=331;CYP2C9_results.csv:row=331;hERG_results.csv:row=331;AMES_results.csv:row=331;PGP_results.csv:row=331;PAMPA_results.csv:row=331;BBB_results.csv:row=331;Solubility_results.csv:row=331;Lipophilicity_results.csv:row=332
CHEMBL2159122,ELUXADOLINE,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,47.88329519450801,100,100.0,79.1533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -2.69; logP 4.16,repurposing_candidates.csv:rc_row=793;protein_drug_candidates.csv:rows=266;pathway_drug_candidates.csv:rows=236;1270;7183;CYP3A4_results.csv:row=702;CYP2C19_results.csv:row=702;CYP2D6_results.csv:row=702;CYP1A2_results.csv:row=702;CYP2C9_results.csv:row=702;hERG_results.csv:row=702;AMES_results.csv:row=702;PGP_results.csv:row=702;PAMPA_results.csv:row=702;BBB_results.csv:row=702;Solubility_results.csv:row=702;Lipophilicity_results.csv:row=703
CHEMBL806,FLUTAMIDE,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -2.97; logP 3.21,repurposing_candidates.csv:rc_row=1519;protein_drug_candidates.csv:rows=544;pathway_drug_candidates.csv:rows=1967;5882;7786;CYP3A4_results.csv:row=1325;CYP2C19_results.csv:row=1325;CYP2D6_results.csv:row=1325;CYP1A2_results.csv:row=1325;CYP2C9_results.csv:row=1325;hERG_results.csv:row=1325;AMES_results.csv:row=1325;PGP_results.csv:row=1325;PAMPA_results.csv:row=1325;BBB_results.csv:row=1325;Solubility_results.csv:row=1325;Lipophilicity_results.csv:row=1326
CHEMBL3989826,OXYCODONE TEREPHTHALATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1,47.88329519450801,100,100.0,79.1533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -2.74; logP 3.18,repurposing_candidates.csv:rc_row=1090;protein_drug_candidates.csv:rows=311;pathway_drug_candidates.csv:rows=281;1315;7228;CYP3A4_results.csv:row=959;CYP2C19_results.csv:row=959;CYP2D6_results.csv:row=959;CYP1A2_results.csv:row=959;CYP2C9_results.csv:row=959;hERG_results.csv:row=959;AMES_results.csv:row=959;PGP_results.csv:row=959;PAMPA_results.csv:row=959;BBB_results.csv:row=959;Solubility_results.csv:row=959;Lipophilicity_results.csv:row=960
CHEMBL2443262,OLICERIDINE,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,47.88329519450801,100,100.0,79.1533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -1.02; logP 4.69,repurposing_candidates.csv:rc_row=849;protein_drug_candidates.csv:rows=291;pathway_drug_candidates.csv:rows=261;1295;7208;CYP3A4_results.csv:row=757;CYP2C19_results.csv:row=757;CYP2D6_results.csv:row=757;CYP1A2_results.csv:row=757;CYP2C9_results.csv:row=757;hERG_results.csv:row=757;AMES_results.csv:row=757;PGP_results.csv:row=757;PAMPA_results.csv:row=757;BBB_results.csv:row=757;Solubility_results.csv:row=757;Lipophilicity_results.csv:row=758
CHEMBL4297185,DAROLUTAMIDE,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -3.07; logP 2.67,repurposing_candidates.csv:rc_row=1161;protein_drug_candidates.csv:rows=552;pathway_drug_candidates.csv:rows=1975;5890;7794;CYP3A4_results.csv:row=1024;CYP2C19_results.csv:row=1024;CYP2D6_results.csv:row=1024;CYP1A2_results.csv:row=1024;CYP2C9_results.csv:row=1024;hERG_results.csv:row=1024;AMES_results.csv:row=1024;PGP_results.csv:row=1024;PAMPA_results.csv:row=1024;BBB_results.csv:row=1024;Solubility_results.csv:row=1024;Lipophilicity_results.csv:row=1025
CHEMBL3183409,APALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -3.86; logP 3.53,repurposing_candidates.csv:rc_row=918;protein_drug_candidates.csv:rows=554;pathway_drug_candidates.csv:rows=1977;5892;7796;CYP3A4_results.csv:row=825;CYP2C19_results.csv:row=825;CYP2D6_results.csv:row=825;CYP1A2_results.csv:row=825;CYP2C9_results.csv:row=825;hERG_results.csv:row=825;AMES_results.csv:row=825;PGP_results.csv:row=825;PAMPA_results.csv:row=825;BBB_results.csv:row=825;Solubility_results.csv:row=825;Lipophilicity_results.csv:row=826
CHEMBL1082407,ENZALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,47.88329519450801,100,100.0,79.1533180778032,H,KG targets AR; clinical phase 4.0; logS -3.26; logP 3.99,repurposing_candidates.csv:rc_row=30;protein_drug_candidates.csv:rows=543;pathway_drug_candidates.csv:rows=1966;5881;7785;CYP3A4_results.csv:row=30;CYP2C19_results.csv:row=30;CYP2D6_results.csv:row=30;CYP1A2_results.csv:row=30;CYP2C9_results.csv:row=30;hERG_results.csv:row=30;AMES_results.csv:row=30;PGP_results.csv:row=30;PAMPA_results.csv:row=30;BBB_results.csv:row=30;Solubility_results.csv:row=30;Lipophilicity_results.csv:row=30
CHEMBL198362,RIVAROXABAN,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,47.35697940503432,100,100.0,78.94279176201373,H,KG targets F10; clinical phase 4.0; logS -5.08; logP 2.52,repurposing_candidates.csv:rc_row=619;protein_drug_candidates.csv:rows=449;pathway_drug_candidates.csv:rows=7529;7558;CYP3A4_results.csv:row=565;CYP2C19_results.csv:row=565;CYP2D6_results.csv:row=565;CYP1A2_results.csv:row=565;CYP2C9_results.csv:row=565;hERG_results.csv:row=565;AMES_results.csv:row=565;PGP_results.csv:row=565;PAMPA_results.csv:row=565;BBB_results.csv:row=565;Solubility_results.csv:row=565;Lipophilicity_results.csv:row=566
CHEMBL2105682,EDOXABAN TOSYLATE,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1,47.35697940503432,100,100.0,78.94279176201373,H,KG targets F10; clinical phase 4.0; logS -1.81; logP 2.53,repurposing_candidates.csv:rc_row=697;protein_drug_candidates.csv:rows=451;pathway_drug_candidates.csv:rows=7531;7560;CYP3A4_results.csv:row=642;CYP2C19_results.csv:row=642;CYP2D6_results.csv:row=642;CYP1A2_results.csv:row=642;CYP2C9_results.csv:row=642;hERG_results.csv:row=642;AMES_results.csv:row=642;PGP_results.csv:row=642;PAMPA_results.csv:row=642;BBB_results.csv:row=642;Solubility_results.csv:row=642;Lipophilicity_results.csv:row=643
CHEMBL231779,APIXABAN,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,47.35697940503432,100,100.0,78.94279176201373,H,KG targets F10; clinical phase 4.0; logS -4.03; logP 2.70,repurposing_candidates.csv:rc_row=825;protein_drug_candidates.csv:rows=450;pathway_drug_candidates.csv:rows=7530;7559;CYP3A4_results.csv:row=734;CYP2C19_results.csv:row=734;CYP2D6_results.csv:row=734;CYP1A2_results.csv:row=734;CYP2C9_results.csv:row=734;hERG_results.csv:row=734;AMES_results.csv:row=734;PGP_results.csv:row=734;PAMPA_results.csv:row=734;BBB_results.csv:row=734;Solubility_results.csv:row=734;Lipophilicity_results.csv:row=735
CHEMBL515606,CILAZAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -1.42; logP 1.60,repurposing_candidates.csv:rc_row=1363;protein_drug_candidates.csv:rows=636;pathway_drug_candidates.csv:rows=432;CYP3A4_results.csv:row=1174;CYP2C19_results.csv:row=1174;CYP2D6_results.csv:row=1174;CYP1A2_results.csv:row=1174;CYP2C9_results.csv:row=1174;hERG_results.csv:row=1174;AMES_results.csv:row=1174;PGP_results.csv:row=1174;PAMPA_results.csv:row=1174;BBB_results.csv:row=1174;Solubility_results.csv:row=1174;Lipophilicity_results.csv:row=1175
CHEMBL2110372,RANITIDINE HYDROCHLORIDE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl,46.83066361556064,100,100.0,78.73226544622426,H,KG targets HRH2; clinical phase 4.0; logS -1.60; logP 1.88,repurposing_candidates.csv:rc_row=777;protein_drug_candidates.csv:rows=747;pathway_drug_candidates.csv:rows=5816;CYP3A4_results.csv:row=686;CYP2C19_results.csv:row=686;CYP2D6_results.csv:row=686;CYP1A2_results.csv:row=686;CYP2C9_results.csv:row=686;hERG_results.csv:row=686;AMES_results.csv:row=686;PGP_results.csv:row=686;PAMPA_results.csv:row=686;BBB_results.csv:row=686;Solubility_results.csv:row=686;Lipophilicity_results.csv:row=687
CHEMBL4066936,VERICIGUAT,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,46.83066361556064,100,100.0,78.73226544622426,H,KG targets GUCY1B1; clinical phase 4.0; logS -5.10; logP 2.56,repurposing_candidates.csv:rc_row=1120;protein_drug_candidates.csv:rows=69;pathway_drug_candidates.csv:rows=7685;CYP3A4_results.csv:row=984;CYP2C19_results.csv:row=984;CYP2D6_results.csv:row=984;CYP1A2_results.csv:row=984;CYP2C9_results.csv:row=984;hERG_results.csv:row=984;AMES_results.csv:row=984;PGP_results.csv:row=984;PAMPA_results.csv:row=984;BBB_results.csv:row=984;Solubility_results.csv:row=984;Lipophilicity_results.csv:row=985
CHEMBL1168,RAMIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -2.14; logP 2.38,repurposing_candidates.csv:rc_row=69;protein_drug_candidates.csv:rows=638;pathway_drug_candidates.csv:rows=434;CYP3A4_results.csv:row=68;CYP2C19_results.csv:row=68;CYP2D6_results.csv:row=68;CYP1A2_results.csv:row=68;CYP2C9_results.csv:row=68;hERG_results.csv:row=68;AMES_results.csv:row=68;PGP_results.csv:row=68;PAMPA_results.csv:row=68;BBB_results.csv:row=68;Solubility_results.csv:row=68;Lipophilicity_results.csv:row=68
CHEMBL1519,TRANDOLAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -2.49; logP 2.77,repurposing_candidates.csv:rc_row=446;protein_drug_candidates.csv:rows=633;pathway_drug_candidates.csv:rows=429;CYP3A4_results.csv:row=406;CYP2C19_results.csv:row=406;CYP2D6_results.csv:row=406;CYP1A2_results.csv:row=406;CYP2C9_results.csv:row=406;hERG_results.csv:row=406;AMES_results.csv:row=406;PGP_results.csv:row=406;PAMPA_results.csv:row=406;BBB_results.csv:row=406;Solubility_results.csv:row=406;Lipophilicity_results.csv:row=407
CHEMBL1200343,PERINDOPRIL ERBUMINE,CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -0.05; logP 2.68,repurposing_candidates.csv:rc_row=90;protein_drug_candidates.csv:rows=649;pathway_drug_candidates.csv:rows=445;CYP3A4_results.csv:row=89;CYP2C19_results.csv:row=89;CYP2D6_results.csv:row=89;CYP1A2_results.csv:row=89;CYP2C9_results.csv:row=89;hERG_results.csv:row=89;AMES_results.csv:row=89;PGP_results.csv:row=89;PAMPA_results.csv:row=89;BBB_results.csv:row=89;Solubility_results.csv:row=89;Lipophilicity_results.csv:row=89
CHEMBL136478,SODIUM NITROPRUSSIDE,,46.83066361556064,100,100.0,78.73226544622426,H,KG targets GUCY1B1; clinical phase 4.0,repurposing_candidates.csv:rc_row=394;protein_drug_candidates.csv:rows=71;pathway_drug_candidates.csv:rows=7687;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL294199,CAPSAICIN,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets TRPV1; clinical phase 4.0; logS -2.83; logP 3.79,repurposing_candidates.csv:rc_row=884;protein_drug_candidates.csv:rows=691;pathway_drug_candidates.csv:rows=5717;CYP3A4_results.csv:row=792;CYP2C19_results.csv:row=792;CYP2D6_results.csv:row=792;CYP1A2_results.csv:row=792;CYP2C9_results.csv:row=792;hERG_results.csv:row=792;AMES_results.csv:row=792;PGP_results.csv:row=792;PAMPA_results.csv:row=792;BBB_results.csv:row=792;Solubility_results.csv:row=792;Lipophilicity_results.csv:row=793
CHEMBL3183075,NIZATIDINE,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,46.83066361556064,100,100.0,78.73226544622426,H,KG targets HRH2; clinical phase 4.0; logS -1.86; logP 1.32,repurposing_candidates.csv:rc_row=917;protein_drug_candidates.csv:rows=749;pathway_drug_candidates.csv:rows=5818;CYP3A4_results.csv:row=824;CYP2C19_results.csv:row=824;CYP2D6_results.csv:row=824;CYP1A2_results.csv:row=824;CYP2C9_results.csv:row=824;hERG_results.csv:row=824;AMES_results.csv:row=824;PGP_results.csv:row=824;PAMPA_results.csv:row=824;BBB_results.csv:row=824;Solubility_results.csv:row=824;Lipophilicity_results.csv:row=825
CHEMBL1560,CAPTOPRIL,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -1.65; logP 0.63,repurposing_candidates.csv:rc_row=458;protein_drug_candidates.csv:rows=639;pathway_drug_candidates.csv:rows=435;CYP3A4_results.csv:row=418;CYP2C19_results.csv:row=418;CYP2D6_results.csv:row=418;CYP1A2_results.csv:row=418;CYP2C9_results.csv:row=418;hERG_results.csv:row=418;AMES_results.csv:row=418;PGP_results.csv:row=418;PAMPA_results.csv:row=418;BBB_results.csv:row=418;Solubility_results.csv:row=418;Lipophilicity_results.csv:row=419
CHEMBL30,CIMETIDINE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N,46.83066361556064,100,100.0,78.73226544622426,H,KG targets HRH2; clinical phase 4.0; logS -1.63; logP 0.60,repurposing_candidates.csv:rc_row=889;protein_drug_candidates.csv:rows=748;pathway_drug_candidates.csv:rows=5817;CYP3A4_results.csv:row=797;CYP2C19_results.csv:row=797;CYP2D6_results.csv:row=797;CYP1A2_results.csv:row=797;CYP2C9_results.csv:row=797;hERG_results.csv:row=797;AMES_results.csv:row=797;PGP_results.csv:row=797;PAMPA_results.csv:row=797;BBB_results.csv:row=797;Solubility_results.csv:row=797;Lipophilicity_results.csv:row=798
CHEMBL317094,IMIDAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -0.99; logP 0.88,repurposing_candidates.csv:rc_row=915;protein_drug_candidates.csv:rows=643;pathway_drug_candidates.csv:rows=439;CYP3A4_results.csv:row=822;CYP2C19_results.csv:row=822;CYP2D6_results.csv:row=822;CYP1A2_results.csv:row=822;CYP2C9_results.csv:row=822;hERG_results.csv:row=822;AMES_results.csv:row=822;PGP_results.csv:row=822;PAMPA_results.csv:row=822;BBB_results.csv:row=822;Solubility_results.csv:row=822;Lipophilicity_results.csv:row=823
CHEMBL3039596,FOSINOPRIL SODIUM,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+],46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -2.72; logP 1.79,repurposing_candidates.csv:rc_row=898;protein_drug_candidates.csv:rows=651;pathway_drug_candidates.csv:rows=447;CYP3A4_results.csv:row=805;CYP2C19_results.csv:row=805;CYP2D6_results.csv:row=805;CYP1A2_results.csv:row=805;CYP2C9_results.csv:row=805;hERG_results.csv:row=805;AMES_results.csv:row=805;PGP_results.csv:row=805;PAMPA_results.csv:row=805;BBB_results.csv:row=805;Solubility_results.csv:row=805;Lipophilicity_results.csv:row=806
CHEMBL1200659,ENALAPRIL MALEATE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -1.45; logP 1.32,repurposing_candidates.csv:rc_row=144;protein_drug_candidates.csv:rows=646;pathway_drug_candidates.csv:rows=442;CYP3A4_results.csv:row=143;CYP2C19_results.csv:row=143;CYP2D6_results.csv:row=143;CYP1A2_results.csv:row=143;CYP2C9_results.csv:row=143;hERG_results.csv:row=143;AMES_results.csv:row=143;PGP_results.csv:row=143;PAMPA_results.csv:row=143;BBB_results.csv:row=143;Solubility_results.csv:row=143;Lipophilicity_results.csv:row=143
CHEMBL1790041,RANITIDINE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,46.83066361556064,100,100.0,78.73226544622426,H,KG targets HRH2; clinical phase 4.0; logS -2.28; logP 1.46,repurposing_candidates.csv:rc_row=576;protein_drug_candidates.csv:rows=750;pathway_drug_candidates.csv:rows=5819;CYP3A4_results.csv:row=522;CYP2C19_results.csv:row=522;CYP2D6_results.csv:row=522;CYP1A2_results.csv:row=522;CYP2C9_results.csv:row=522;hERG_results.csv:row=522;AMES_results.csv:row=522;PGP_results.csv:row=522;PAMPA_results.csv:row=522;BBB_results.csv:row=522;Solubility_results.csv:row=522;Lipophilicity_results.csv:row=523
CHEMBL1201011,QUINAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -2.10; logP 2.99,repurposing_candidates.csv:rc_row=216;protein_drug_candidates.csv:rows=648;pathway_drug_candidates.csv:rows=444;CYP3A4_results.csv:row=214;CYP2C19_results.csv:row=214;CYP2D6_results.csv:row=214;CYP1A2_results.csv:row=214;CYP2C9_results.csv:row=214;hERG_results.csv:row=214;AMES_results.csv:row=214;PGP_results.csv:row=214;PAMPA_results.csv:row=214;BBB_results.csv:row=214;Solubility_results.csv:row=214;Lipophilicity_results.csv:row=215
CHEMBL1200534,MOEXIPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -1.58; logP 3.01,repurposing_candidates.csv:rc_row=119;protein_drug_candidates.csv:rows=650;pathway_drug_candidates.csv:rows=446;CYP3A4_results.csv:row=118;CYP2C19_results.csv:row=118;CYP2D6_results.csv:row=118;CYP1A2_results.csv:row=118;CYP2C9_results.csv:row=118;hERG_results.csv:row=118;AMES_results.csv:row=118;PGP_results.csv:row=118;PAMPA_results.csv:row=118;BBB_results.csv:row=118;Solubility_results.csv:row=118;Lipophilicity_results.csv:row=118
CHEMBL3544986,PERINDOPRIL ARGININE,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS 0.03; logP 0.60,repurposing_candidates.csv:rc_row=963;protein_drug_candidates.csv:rows=652;pathway_drug_candidates.csv:rows=448;CYP3A4_results.csv:row=865;CYP2C19_results.csv:row=865;CYP2D6_results.csv:row=865;CYP1A2_results.csv:row=865;CYP2C9_results.csv:row=865;hERG_results.csv:row=865;AMES_results.csv:row=865;PGP_results.csv:row=865;PAMPA_results.csv:row=865;BBB_results.csv:row=865;Solubility_results.csv:row=865;Lipophilicity_results.csv:row=866
CHEMBL1694,BENAZEPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl,46.83066361556064,100,100.0,78.73226544622426,H,KG targets ACE; clinical phase 4.0; logS -2.30; logP 2.99,repurposing_candidates.csv:rc_row=514;protein_drug_candidates.csv:rows=647;pathway_drug_candidates.csv:rows=443;CYP3A4_results.csv:row=474;CYP2C19_results.csv:row=474;CYP2D6_results.csv:row=474;CYP1A2_results.csv:row=474;CYP2C9_results.csv:row=474;hERG_results.csv:row=474;AMES_results.csv:row=474;PGP_results.csv:row=474;PAMPA_results.csv:row=474;BBB_results.csv:row=474;Solubility_results.csv:row=474;Lipophilicity_results.csv:row=475
CHEMBL2103736,FENOPROFEN CALCIUM,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2],52.87185354691076,100,90.0,78.6487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -6.79; logP 2.63",repurposing_candidates.csv:rc_row=653;protein_drug_candidates.csv:rows=112;898;pathway_drug_candidates.csv:rows=335;4453;5538;5598;5662;6046;6120;6194;6268;6342;6416;CYP3A4_results.csv:row=598;CYP2C19_results.csv:row=598;CYP2D6_results.csv:row=598;CYP1A2_results.csv:row=598;CYP2C9_results.csv:row=598;hERG_results.csv:row=598;AMES_results.csv:row=598;PGP_results.csv:row=598;PAMPA_results.csv:row=598;BBB_results.csv:row=598;Solubility_results.csv:row=598;Lipophilicity_results.csv:row=599
CHEMBL580,LORAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -3.81; logP 3.10",repurposing_candidates.csv:rc_row=1427;protein_drug_candidates.csv:rows=487;1415;1654;1685;2047;2098;2467;CYP3A4_results.csv:row=1236;CYP2C19_results.csv:row=1236;CYP2D6_results.csv:row=1236;CYP1A2_results.csv:row=1236;CYP2C9_results.csv:row=1236;hERG_results.csv:row=1236;AMES_results.csv:row=1236;PGP_results.csv:row=1236;PAMPA_results.csv:row=1236;BBB_results.csv:row=1236;Solubility_results.csv:row=1236;Lipophilicity_results.csv:row=1237
CHEMBL970,HALAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -5.09; logP 4.09",repurposing_candidates.csv:rc_row=1573;protein_drug_candidates.csv:rows=498;1419;1643;1698;2052;2096;2465;CYP3A4_results.csv:row=1379;CYP2C19_results.csv:row=1379;CYP2D6_results.csv:row=1379;CYP1A2_results.csv:row=1379;CYP2C9_results.csv:row=1379;hERG_results.csv:row=1379;AMES_results.csv:row=1379;PGP_results.csv:row=1379;PAMPA_results.csv:row=1379;BBB_results.csv:row=1379;Solubility_results.csv:row=1379;Lipophilicity_results.csv:row=1380
CHEMBL3989724,FLURAZEPAM HYDROCHLORIDE,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -3.46; logP 4.85",repurposing_candidates.csv:rc_row=1083;protein_drug_candidates.csv:rows=490;1429;1650;1695;2057;2095;2456;CYP3A4_results.csv:row=952;CYP2C19_results.csv:row=952;CYP2D6_results.csv:row=952;CYP1A2_results.csv:row=952;CYP2C9_results.csv:row=952;hERG_results.csv:row=952;AMES_results.csv:row=952;PGP_results.csv:row=952;PAMPA_results.csv:row=952;BBB_results.csv:row=952;Solubility_results.csv:row=952;Lipophilicity_results.csv:row=953
CHEMBL1522,ESZOPICLONE,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -1.39; logP 1.57",repurposing_candidates.csv:rc_row=449;protein_drug_candidates.csv:rows=486;1416;1641;1686;2048;2093;2454;CYP3A4_results.csv:row=409;CYP2C19_results.csv:row=409;CYP2D6_results.csv:row=409;CYP1A2_results.csv:row=409;CYP2C9_results.csv:row=409;hERG_results.csv:row=409;AMES_results.csv:row=409;PGP_results.csv:row=409;PAMPA_results.csv:row=409;BBB_results.csv:row=409;Solubility_results.csv:row=409;Lipophilicity_results.csv:row=410
CHEMBL452,CLONAZEPAM,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -4.60; logP 3.04",repurposing_candidates.csv:rc_row=1274;protein_drug_candidates.csv:rows=481;1410;1631;1679;2042;2085;2449;CYP3A4_results.csv:row=1094;CYP2C19_results.csv:row=1094;CYP2D6_results.csv:row=1094;CYP1A2_results.csv:row=1094;CYP2C9_results.csv:row=1094;hERG_results.csv:row=1094;AMES_results.csv:row=1094;PGP_results.csv:row=1094;PAMPA_results.csv:row=1094;BBB_results.csv:row=1094;Solubility_results.csv:row=1094;Lipophilicity_results.csv:row=1095
CHEMBL451,CHLORDIAZEPOXIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -4.28; logP 2.95",repurposing_candidates.csv:rc_row=1272;protein_drug_candidates.csv:rows=500;1414;1645;1683;2046;2092;2453;CYP3A4_results.csv:row=1092;CYP2C19_results.csv:row=1092;CYP2D6_results.csv:row=1092;CYP1A2_results.csv:row=1092;CYP2C9_results.csv:row=1092;hERG_results.csv:row=1092;AMES_results.csv:row=1092;PGP_results.csv:row=1092;PAMPA_results.csv:row=1092;BBB_results.csv:row=1092;Solubility_results.csv:row=1092;Lipophilicity_results.csv:row=1093
CHEMBL12,DIAZEPAM,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,45.79710144927536,100,100.0,78.31884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -3.63; logP 3.15",repurposing_candidates.csv:rc_row=81;protein_drug_candidates.csv:rows=477;1412;1629;1675;2041;2087;2445;CYP3A4_results.csv:row=80;CYP2C19_results.csv:row=80;CYP2D6_results.csv:row=80;CYP1A2_results.csv:row=80;CYP2C9_results.csv:row=80;hERG_results.csv:row=80;AMES_results.csv:row=80;PGP_results.csv:row=80;PAMPA_results.csv:row=80;BBB_results.csv:row=80;Solubility_results.csv:row=80;Lipophilicity_results.csv:row=80
CHEMBL193240,ROFLUMILAST,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,51.79633867276888,100,90.0,78.21853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -5.55; logP 5.03",repurposing_candidates.csv:rc_row=603;protein_drug_candidates.csv:rows=408;1041;1069;2147;pathway_drug_candidates.csv:rows=4320;5730;5758;5786;5825;5853;CYP3A4_results.csv:row=549;CYP2C19_results.csv:row=549;CYP2D6_results.csv:row=549;CYP1A2_results.csv:row=549;CYP2C9_results.csv:row=549;hERG_results.csv:row=549;AMES_results.csv:row=549;PGP_results.csv:row=549;PAMPA_results.csv:row=549;BBB_results.csv:row=549;Solubility_results.csv:row=549;Lipophilicity_results.csv:row=550
CHEMBL503,LOVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,48.40961098398169,100,95.0,78.11384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -5.37; logP 4.20,repurposing_candidates.csv:rc_row=1347;protein_drug_candidates.csv:rows=738;pathway_drug_candidates.csv:rows=7617;7632;7647;7662;CYP3A4_results.csv:row=1158;CYP2C19_results.csv:row=1158;CYP2D6_results.csv:row=1158;CYP1A2_results.csv:row=1158;CYP2C9_results.csv:row=1158;hERG_results.csv:row=1158;AMES_results.csv:row=1158;PGP_results.csv:row=1158;PAMPA_results.csv:row=1158;BBB_results.csv:row=1158;Solubility_results.csv:row=1158;Lipophilicity_results.csv:row=1159
CHEMBL690,PRAVASTATIN SODIUM,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],48.40961098398169,100,95.0,78.11384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -1.03; logP -1.89,repurposing_candidates.csv:rc_row=1489;protein_drug_candidates.csv:rows=734;pathway_drug_candidates.csv:rows=7613;7628;7643;7658;CYP3A4_results.csv:row=1295;CYP2C19_results.csv:row=1295;CYP2D6_results.csv:row=1295;CYP1A2_results.csv:row=1295;CYP2C9_results.csv:row=1295;hERG_results.csv:row=1295;AMES_results.csv:row=1295;PGP_results.csv:row=1295;PAMPA_results.csv:row=1295;BBB_results.csv:row=1295;Solubility_results.csv:row=1295;Lipophilicity_results.csv:row=1296
CHEMBL163,RITONAVIR,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,51.2700228832952,100,90.0,78.00800915331808,H,"KG targets CYP3A4, CYP3A43; clinical phase 4.0; logS -3.72; logP 5.91",repurposing_candidates.csv:rc_row=487;protein_drug_candidates.csv:rows=212;948;1625;1902;pathway_drug_candidates.csv:rows=7907;7910;7911;7914;CYP3A4_results.csv:row=447;CYP2C19_results.csv:row=447;CYP2D6_results.csv:row=447;CYP1A2_results.csv:row=447;CYP2C9_results.csv:row=447;hERG_results.csv:row=447;AMES_results.csv:row=447;PGP_results.csv:row=447;PAMPA_results.csv:row=447;BBB_results.csv:row=447;Solubility_results.csv:row=447;Lipophilicity_results.csv:row=448
CHEMBL2095208,COBICISTAT,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,51.2700228832952,100,90.0,78.00800915331808,H,"KG targets CYP3A4, CYP3A43; clinical phase 4.0; logS -3.62; logP 6.00",repurposing_candidates.csv:rc_row=650;protein_drug_candidates.csv:rows=213;947;1626;1903;pathway_drug_candidates.csv:rows=7908;7909;7912;7913;CYP3A4_results.csv:row=596;CYP2C19_results.csv:row=596;CYP2D6_results.csv:row=596;CYP1A2_results.csv:row=596;CYP2C9_results.csv:row=596;hERG_results.csv:row=596;AMES_results.csv:row=596;PGP_results.csv:row=596;PAMPA_results.csv:row=596;BBB_results.csv:row=596;Solubility_results.csv:row=596;Lipophilicity_results.csv:row=597
CHEMBL1201749,DIFLUPREDNATE,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,90.0,77.91647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -7.53; logP 3.52,repurposing_candidates.csv:rc_row=308;protein_drug_candidates.csv:rows=42;pathway_drug_candidates.csv:rows=734;2043;5958;7862;7999;8065;8136;8202;8268;CYP3A4_results.csv:row=277;CYP2C19_results.csv:row=277;CYP2D6_results.csv:row=277;CYP1A2_results.csv:row=277;CYP2C9_results.csv:row=277;hERG_results.csv:row=277;AMES_results.csv:row=277;PGP_results.csv:row=277;PAMPA_results.csv:row=277;BBB_results.csv:row=277;Solubility_results.csv:row=277;Lipophilicity_results.csv:row=278
CHEMBL1676,FLUTICASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,51.04118993135011,100,90.0,77.91647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -7.12; logP 4.93,repurposing_candidates.csv:rc_row=505;protein_drug_candidates.csv:rows=10;pathway_drug_candidates.csv:rows=702;2011;5926;7830;7967;8033;8104;8170;8236;CYP3A4_results.csv:row=465;CYP2C19_results.csv:row=465;CYP2D6_results.csv:row=465;CYP1A2_results.csv:row=465;CYP2C9_results.csv:row=465;hERG_results.csv:row=465;AMES_results.csv:row=465;PGP_results.csv:row=465;PAMPA_results.csv:row=465;BBB_results.csv:row=465;Solubility_results.csv:row=465;Lipophilicity_results.csv:row=466
CHEMBL1473,FLUTICASONE PROPIONATE,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,90.0,77.91647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -7.30; logP 4.43,repurposing_candidates.csv:rc_row=426;protein_drug_candidates.csv:rows=2;pathway_drug_candidates.csv:rows=694;2003;5918;7822;7959;8025;8096;8162;8228;CYP3A4_results.csv:row=386;CYP2C19_results.csv:row=386;CYP2D6_results.csv:row=386;CYP1A2_results.csv:row=386;CYP2C9_results.csv:row=386;hERG_results.csv:row=386;AMES_results.csv:row=386;PGP_results.csv:row=386;PAMPA_results.csv:row=386;BBB_results.csv:row=386;Solubility_results.csv:row=386;Lipophilicity_results.csv:row=387
CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+],51.04118993135011,100,90.0,77.91647597254004,H,KG targets NR3C1; clinical phase 4.0; logS -2.84; logP -2.11,repurposing_candidates.csv:rc_row=230;protein_drug_candidates.csv:rows=16;pathway_drug_candidates.csv:rows=708;2017;5932;7836;7973;8039;8110;8176;8242;CYP3A4_results.csv:row=228;CYP2C19_results.csv:row=228;CYP2D6_results.csv:row=228;CYP1A2_results.csv:row=228;CYP2C9_results.csv:row=228;hERG_results.csv:row=228;AMES_results.csv:row=228;PGP_results.csv:row=228;PAMPA_results.csv:row=228;BBB_results.csv:row=228;Solubility_results.csv:row=228;Lipophilicity_results.csv:row=229
CHEMBL1237065,TRAMADOL HYDROCHLORIDE,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,47.88329519450801,100,95.0,77.9033180778032,H,KG targets OPRM1; clinical phase 4.0; logS -1.95; logP 3.06,repurposing_candidates.csv:rc_row=347;protein_drug_candidates.csv:rows=282;pathway_drug_candidates.csv:rows=252;1286;7199;CYP3A4_results.csv:row=309;CYP2C19_results.csv:row=309;CYP2D6_results.csv:row=309;CYP1A2_results.csv:row=309;CYP2C9_results.csv:row=309;hERG_results.csv:row=309;AMES_results.csv:row=309;PGP_results.csv:row=309;PAMPA_results.csv:row=309;BBB_results.csv:row=309;Solubility_results.csv:row=309;Lipophilicity_results.csv:row=310
CHEMBL1701,MEPERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl,47.88329519450801,100,95.0,77.9033180778032,H,KG targets OPRM1; clinical phase 4.0; logS -1.26; logP 2.63,repurposing_candidates.csv:rc_row=517;protein_drug_candidates.csv:rows=286;pathway_drug_candidates.csv:rows=256;1290;7203;CYP3A4_results.csv:row=477;CYP2C19_results.csv:row=477;CYP2D6_results.csv:row=477;CYP1A2_results.csv:row=477;CYP2C9_results.csv:row=477;hERG_results.csv:row=477;AMES_results.csv:row=477;PGP_results.csv:row=477;PAMPA_results.csv:row=477;BBB_results.csv:row=477;Solubility_results.csv:row=477;Lipophilicity_results.csv:row=478
CHEMBL409,BICALUTAMIDE,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,47.88329519450801,100,95.0,77.9033180778032,H,KG targets AR; clinical phase 4.0; logS -2.92; logP 2.88,repurposing_candidates.csv:rc_row=1129;protein_drug_candidates.csv:rows=545;pathway_drug_candidates.csv:rows=1968;5883;7787;CYP3A4_results.csv:row=993;CYP2C19_results.csv:row=993;CYP2D6_results.csv:row=993;CYP1A2_results.csv:row=993;CYP2C9_results.csv:row=993;hERG_results.csv:row=993;AMES_results.csv:row=993;PGP_results.csv:row=993;PAMPA_results.csv:row=993;BBB_results.csv:row=993;Solubility_results.csv:row=993;Lipophilicity_results.csv:row=994
CHEMBL1078178,MOMELOTINIB,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,61.81922196796339,80,100.0,77.72768878718536,H,"KG targets JAK1, JAK2; clinical phase 3.0; logS -4.73; logP 2.98",repurposing_candidates.csv:rc_row=28;protein_drug_candidates.csv:rows=768;792;pathway_drug_candidates.csv:rows=193;217;655;679;4245;4424;4565;4589;4644;4668;4723;4747;4792;4830;4854;4899;4923;4965;4989;5031;5055;5099;5141;5165;5219;5269;5307;5331;5373;5397;5467;6920;6944;7478;8307;8335;8363;8397;8425;8453;CYP3A4_results.csv:row=28;CYP2C19_results.csv:row=28;CYP2D6_results.csv:row=28;CYP1A2_results.csv:row=28;CYP2C9_results.csv:row=28;hERG_results.csv:row=28;AMES_results.csv:row=28;PGP_results.csv:row=28;PAMPA_results.csv:row=28;BBB_results.csv:row=28;Solubility_results.csv:row=28;Lipophilicity_results.csv:row=28
CHEMBL547,ISOTRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,50.49199084668192,100,90.0,77.69679633867277,H,"KG targets RARA, RARB; clinical phase 4.0; logS -4.41; logP 5.60",repurposing_candidates.csv:rc_row=1404;protein_drug_candidates.csv:rows=187;1767;1894;pathway_drug_candidates.csv:rows=5989;6015;6024;CYP3A4_results.csv:row=1213;CYP2C19_results.csv:row=1213;CYP2D6_results.csv:row=1213;CYP1A2_results.csv:row=1213;CYP2C9_results.csv:row=1213;hERG_results.csv:row=1213;AMES_results.csv:row=1213;PGP_results.csv:row=1213;PAMPA_results.csv:row=1213;BBB_results.csv:row=1213;Solubility_results.csv:row=1213;Lipophilicity_results.csv:row=1214
CHEMBL38,TRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,50.49199084668192,100,90.0,77.69679633867277,H,"KG targets RARA, RARB; clinical phase 4.0; logS -4.41; logP 5.60",repurposing_candidates.csv:rc_row=1038;protein_drug_candidates.csv:rows=180;1761;1888;pathway_drug_candidates.csv:rows=5982;6008;6017;CYP3A4_results.csv:row=913;CYP2C19_results.csv:row=913;CYP2D6_results.csv:row=913;CYP1A2_results.csv:row=913;CYP2C9_results.csv:row=913;hERG_results.csv:row=913;AMES_results.csv:row=913;PGP_results.csv:row=913;PAMPA_results.csv:row=913;BBB_results.csv:row=913;Solubility_results.csv:row=913;Lipophilicity_results.csv:row=914
CHEMBL1657,TAZAROTENE,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,50.49199084668192,100,90.0,77.69679633867277,H,"KG targets RARA, RARB; clinical phase 4.0; logS -6.17; logP 4.43",repurposing_candidates.csv:rc_row=499;protein_drug_candidates.csv:rows=182;1763;1890;pathway_drug_candidates.csv:rows=5984;6010;6019;CYP3A4_results.csv:row=459;CYP2C19_results.csv:row=459;CYP2D6_results.csv:row=459;CYP1A2_results.csv:row=459;CYP2C9_results.csv:row=459;hERG_results.csv:row=459;AMES_results.csv:row=459;PGP_results.csv:row=459;PAMPA_results.csv:row=459;BBB_results.csv:row=459;Solubility_results.csv:row=459;Lipophilicity_results.csv:row=460
CHEMBL57242,AZILSARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,48.40961098398169,95,100.0,77.61384439359267,H,KG targets AGTR1; clinical phase 3.0; logS -5.90; logP 4.19,repurposing_candidates.csv:rc_row=1420;protein_drug_candidates.csv:rows=595;pathway_drug_candidates.csv:rows=6549;7168;7279;7299;CYP3A4_results.csv:row=1229;CYP2C19_results.csv:row=1229;CYP2D6_results.csv:row=1229;CYP1A2_results.csv:row=1229;CYP2C9_results.csv:row=1229;hERG_results.csv:row=1229;AMES_results.csv:row=1229;PGP_results.csv:row=1229;PAMPA_results.csv:row=1229;BBB_results.csv:row=1229;Solubility_results.csv:row=1229;Lipophilicity_results.csv:row=1230
CHEMBL1516,OLMESARTAN,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,48.40961098398169,95,100.0,77.61384439359267,H,KG targets AGTR1; clinical phase 3.0; logS -3.88; logP 3.66,repurposing_candidates.csv:rc_row=444;protein_drug_candidates.csv:rows=594;pathway_drug_candidates.csv:rows=6548;7167;7278;7298;CYP3A4_results.csv:row=404;CYP2C19_results.csv:row=404;CYP2D6_results.csv:row=404;CYP1A2_results.csv:row=404;CYP2C9_results.csv:row=404;hERG_results.csv:row=404;AMES_results.csv:row=404;PGP_results.csv:row=404;PAMPA_results.csv:row=404;BBB_results.csv:row=404;Solubility_results.csv:row=404;Lipophilicity_results.csv:row=405
CHEMBL902,FAMOTIDINE,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,46.83066361556064,100,95.0,77.48226544622426,H,KG targets HRH2; clinical phase 4.0; logS -2.49; logP -0.77,repurposing_candidates.csv:rc_row=1547;protein_drug_candidates.csv:rows=746;pathway_drug_candidates.csv:rows=5815;CYP3A4_results.csv:row=1353;CYP2C19_results.csv:row=1353;CYP2D6_results.csv:row=1353;CYP1A2_results.csv:row=1353;CYP2C9_results.csv:row=1353;hERG_results.csv:row=1353;AMES_results.csv:row=1353;PGP_results.csv:row=1353;PAMPA_results.csv:row=1353;BBB_results.csv:row=1353;Solubility_results.csv:row=1353;Lipophilicity_results.csv:row=1354
CHEMBL1200689,NITRIC OXIDE,[N]=O,46.83066361556064,100,95.0,77.48226544622426,H,KG targets GUCY1B1; clinical phase 4.0; logP -0.45,repurposing_candidates.csv:rc_row=151;protein_drug_candidates.csv:rows=74;pathway_drug_candidates.csv:rows=7690;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv:row=150
CHEMBL419213,LISINOPRIL,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,46.83066361556064,100,95.0,77.48226544622426,H,KG targets ACE; clinical phase 4.0; logS -1.03; logP -0.41,repurposing_candidates.csv:rc_row=1141;protein_drug_candidates.csv:rows=634;pathway_drug_candidates.csv:rows=430;CYP3A4_results.csv:row=1005;CYP2C19_results.csv:row=1005;CYP2D6_results.csv:row=1005;CYP1A2_results.csv:row=1005;CYP2C9_results.csv:row=1005;hERG_results.csv:row=1005;AMES_results.csv:row=1005;PGP_results.csv:row=1005;PAMPA_results.csv:row=1005;BBB_results.csv:row=1005;Solubility_results.csv:row=1005;Lipophilicity_results.csv:row=1006
CHEMBL398435,TICAGRELOR,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,46.83066361556064,100,95.0,77.48226544622426,H,KG targets P2RY12; clinical phase 4.0; logS -4.42; logP 2.01,repurposing_candidates.csv:rc_row=1065;protein_drug_candidates.csv:rows=467;pathway_drug_candidates.csv:rows=1352;CYP3A4_results.csv:row=934;CYP2C19_results.csv:row=934;CYP2D6_results.csv:row=934;CYP1A2_results.csv:row=934;CYP2C9_results.csv:row=934;hERG_results.csv:row=934;AMES_results.csv:row=934;PGP_results.csv:row=934;PAMPA_results.csv:row=934;BBB_results.csv:row=934;Solubility_results.csv:row=934;Lipophilicity_results.csv:row=935
CHEMBL146095,GLAFENINE,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,52.87185354691076,100,85.0,77.3987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -6.55; logP 3.14",repurposing_candidates.csv:rc_row=424;protein_drug_candidates.csv:rows=121;918;pathway_drug_candidates.csv:rows=344;4462;5558;5618;5671;6055;6129;6203;6277;6351;6425;CYP3A4_results.csv:row=384;CYP2C19_results.csv:row=384;CYP2D6_results.csv:row=384;CYP1A2_results.csv:row=384;CYP2C9_results.csv:row=384;hERG_results.csv:row=384;AMES_results.csv:row=384;PGP_results.csv:row=384;PAMPA_results.csv:row=384;BBB_results.csv:row=384;Solubility_results.csv:row=384;Lipophilicity_results.csv:row=385
CHEMBL1789941,RUXOLITINIB,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,43.48588863463005,100,100.0,77.39435545385203,H,"KG targets JAK1, JAK2; clinical phase 4.0; logS -3.09; logP 3.47",repurposing_candidates.csv:rc_row=575;protein_drug_candidates.csv:rows=758;780;pathway_drug_candidates.csv:rows=183;205;645;667;4235;4414;4555;4577;4634;4656;4713;4735;4782;4820;4842;4889;4911;4955;4977;5021;5043;5087;5131;5153;5209;5259;5297;5319;5363;5385;5457;6910;6932;7466;8295;8323;8351;8385;8413;8441;CYP3A4_results.csv:row=521;CYP2C19_results.csv:row=521;CYP2D6_results.csv:row=521;CYP1A2_results.csv:row=521;CYP2C9_results.csv:row=521;hERG_results.csv:row=521;AMES_results.csv:row=521;PGP_results.csv:row=521;PAMPA_results.csv:row=521;BBB_results.csv:row=521;Solubility_results.csv:row=521;Lipophilicity_results.csv:row=522
CHEMBL539423,SPARSENTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1,49.713958810068654,100,90.0,77.38558352402747,H,"KG targets AGTR1, EDNRA; clinical phase 4.0; logS -4.28; logP 6.54",repurposing_candidates.csv:rc_row=1401;protein_drug_candidates.csv:rows=589;1914;pathway_drug_candidates.csv:rows=6543;7162;7273;7293;CYP3A4_results.csv:row=1210;CYP2C19_results.csv:row=1210;CYP2D6_results.csv:row=1210;CYP1A2_results.csv:row=1210;CYP2C9_results.csv:row=1210;hERG_results.csv:row=1210;AMES_results.csv:row=1210;PGP_results.csv:row=1210;PAMPA_results.csv:row=1210;BBB_results.csv:row=1210;Solubility_results.csv:row=1210;Lipophilicity_results.csv:row=1211
CHEMBL70418,CLOBAZAM,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,45.79710144927536,100,95.0,77.06884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -2.84; logP 3.37",repurposing_candidates.csv:rc_row=1493;protein_drug_candidates.csv:rows=489;1417;1652;1697;2050;2108;2463;CYP3A4_results.csv:row=1299;CYP2C19_results.csv:row=1299;CYP2D6_results.csv:row=1299;CYP1A2_results.csv:row=1299;CYP2C9_results.csv:row=1299;hERG_results.csv:row=1299;AMES_results.csv:row=1299;PGP_results.csv:row=1299;PAMPA_results.csv:row=1299;BBB_results.csv:row=1299;Solubility_results.csv:row=1299;Lipophilicity_results.csv:row=1300
CHEMBL2096631,CLORAZEPATE DIPOTASSIUM,O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],45.79710144927536,100,95.0,77.06884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -3.98; logP -4.92",repurposing_candidates.csv:rc_row=651;protein_drug_candidates.csv:rows=492;1422;1655;1690;2054;2109;2468;CYP3A4_results.csv:row=597;CYP2C19_results.csv:row=597;CYP2D6_results.csv:row=597;CYP1A2_results.csv:row=597;CYP2C9_results.csv:row=597;hERG_results.csv:row=597;AMES_results.csv:row=597;PGP_results.csv:row=597;PAMPA_results.csv:row=597;BBB_results.csv:row=597;Solubility_results.csv:row=597;Lipophilicity_results.csv:row=598
CHEMBL1237061,PITAVASTATIN CALCIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2],48.40961098398169,100,90.0,76.86384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -5.38; logP 5.99,repurposing_candidates.csv:rc_row=346;protein_drug_candidates.csv:rows=742;pathway_drug_candidates.csv:rows=7621;7636;7651;7666;CYP3A4_results.csv:row=308;CYP2C19_results.csv:row=308;CYP2D6_results.csv:row=308;CYP1A2_results.csv:row=308;CYP2C9_results.csv:row=308;hERG_results.csv:row=308;AMES_results.csv:row=308;PGP_results.csv:row=308;PAMPA_results.csv:row=308;BBB_results.csv:row=308;Solubility_results.csv:row=308;Lipophilicity_results.csv:row=309
CHEMBL1017,TELMISARTAN,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,48.40961098398169,100,90.0,76.86384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -3.93; logP 7.26,repurposing_candidates.csv:rc_row=8;protein_drug_candidates.csv:rows=585;pathway_drug_candidates.csv:rows=6539;7158;7269;7289;CYP3A4_results.csv:row=8;CYP2C19_results.csv:row=8;CYP2D6_results.csv:row=8;CYP1A2_results.csv:row=8;CYP2C9_results.csv:row=8;hERG_results.csv:row=8;AMES_results.csv:row=8;PGP_results.csv:row=8;PAMPA_results.csv:row=8;BBB_results.csv:row=8;Solubility_results.csv:row=8;Lipophilicity_results.csv:row=8
CHEMBL1200395,ORPHENADRINE CITRATE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,60.69794050343249,100,70.0,76.77917620137299,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; hERG risk; logS -1.82; logP 2.41",repurposing_candidates.csv:rc_row=95;protein_drug_candidates.csv:rows=705;953;1604;1950;2177;2598;2641;2667;pathway_drug_candidates.csv:rows=3611;6583;6795;6822;6849;6882;7040;7067;7094;7121;CYP3A4_results.csv:row=94;CYP2C19_results.csv:row=94;CYP2D6_results.csv:row=94;CYP1A2_results.csv:row=94;CYP2C9_results.csv:row=94;hERG_results.csv:row=94;AMES_results.csv:row=94;PGP_results.csv:row=94;PAMPA_results.csv:row=94;BBB_results.csv:row=94;Solubility_results.csv:row=94;Lipophilicity_results.csv:row=94
CHEMBL770,TOLAZOLINE,c1ccc(CC2=NCCN2)cc1,41.83829138062547,100,100.0,76.7353165522502,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.11; logP 1.23",repurposing_candidates.csv:rc_row=1511;protein_drug_candidates.csv:rows=359;745;949;1306;1364;1474;1821;2505;pathway_drug_candidates.csv:rows=822;877;935;981;1039;1085;1137;1195;1369;1427;1473;5814;6484;6579;6684;CYP3A4_results.csv:row=1317;CYP2C19_results.csv:row=1317;CYP2D6_results.csv:row=1317;CYP1A2_results.csv:row=1317;CYP2C9_results.csv:row=1317;hERG_results.csv:row=1317;AMES_results.csv:row=1317;PGP_results.csv:row=1317;PAMPA_results.csv:row=1317;BBB_results.csv:row=1317;Solubility_results.csv:row=1317;Lipophilicity_results.csv:row=1318
CHEMBL552212,LEXIBULIN,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,76.73913043478261,60,100.0,76.69565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.81; logP 4.95",repurposing_candidates.csv:rc_row=1409;protein_drug_candidates.csv:rows=850;1583;2019;2259;2364;2428;2733;2797;2861;pathway_drug_candidates.csv:rows=1563;1627;1691;1755;1819;1883;1947;2112;2176;2240;2304;2368;2432;2496;2560;2624;2688;2752;2816;2880;2944;3008;3078;3142;3206;3270;3334;3398;3462;3526;3590;3681;3745;3809;3873;3937;4001;4068;CYP3A4_results.csv:row=1218;CYP2C19_results.csv:row=1218;CYP2D6_results.csv:row=1218;CYP1A2_results.csv:row=1218;CYP2C9_results.csv:row=1218;hERG_results.csv:row=1218;AMES_results.csv:row=1218;PGP_results.csv:row=1218;PAMPA_results.csv:row=1218;BBB_results.csv:row=1218;Solubility_results.csv:row=1218;Lipophilicity_results.csv:row=1219
CHEMBL3989512,SOBLIDOTIN,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,76.73913043478261,60,100.0,76.69565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.53; logP 3.99",repurposing_candidates.csv:rc_row=1070;protein_drug_candidates.csv:rows=849;1582;2017;2256;2361;2425;2732;2796;2860;pathway_drug_candidates.csv:rows=1562;1626;1690;1754;1818;1882;1946;2111;2175;2239;2303;2367;2431;2495;2559;2623;2687;2751;2815;2879;2943;3007;3077;3141;3205;3269;3333;3397;3461;3525;3589;3680;3744;3808;3872;3936;4000;4067;CYP3A4_results.csv:row=939;CYP2C19_results.csv:row=939;CYP2D6_results.csv:row=939;CYP1A2_results.csv:row=939;CYP2C9_results.csv:row=939;hERG_results.csv:row=939;AMES_results.csv:row=939;PGP_results.csv:row=939;PAMPA_results.csv:row=939;BBB_results.csv:row=939;Solubility_results.csv:row=939;Lipophilicity_results.csv:row=940
CHEMBL4297636,PLOCABULIN,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O,76.73913043478261,60,100.0,76.69565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.83; logP 4.51",repurposing_candidates.csv:rc_row=1202;protein_drug_candidates.csv:rows=856;1592;2027;2263;2368;2434;2741;2803;2867;pathway_drug_candidates.csv:rows=1569;1633;1697;1761;1825;1889;1953;2118;2182;2246;2310;2374;2438;2502;2566;2630;2694;2758;2822;2886;2950;3014;3084;3148;3212;3276;3340;3404;3468;3532;3596;3687;3751;3815;3879;3943;4007;4074;CYP3A4_results.csv:row=1062;CYP2C19_results.csv:row=1062;CYP2D6_results.csv:row=1062;CYP1A2_results.csv:row=1062;CYP2C9_results.csv:row=1062;hERG_results.csv:row=1062;AMES_results.csv:row=1062;PGP_results.csv:row=1062;PAMPA_results.csv:row=1062;BBB_results.csv:row=1062;Solubility_results.csv:row=1062;Lipophilicity_results.csv:row=1063
CHEMBL2107759,MILATAXEL,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C,76.73913043478261,60,100.0,76.69565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -5.00; logP 4.06",repurposing_candidates.csv:rc_row=733;protein_drug_candidates.csv:rows=844;1576;2011;2250;2355;2420;2727;2790;2854;pathway_drug_candidates.csv:rows=1557;1621;1685;1749;1813;1877;1941;2106;2170;2234;2298;2362;2426;2490;2554;2618;2682;2746;2810;2874;2938;3002;3072;3136;3200;3264;3328;3392;3456;3520;3584;3675;3739;3803;3867;3931;3995;4062;CYP3A4_results.csv:row=678;CYP2C19_results.csv:row=678;CYP2D6_results.csv:row=678;CYP1A2_results.csv:row=678;CYP2C9_results.csv:row=678;hERG_results.csv:row=678;AMES_results.csv:row=678;PGP_results.csv:row=678;PAMPA_results.csv:row=678;BBB_results.csv:row=678;Solubility_results.csv:row=678;Lipophilicity_results.csv:row=679
CHEMBL3989716,PROPOXYPHENE NAPSYLATE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1,47.88329519450801,100,90.0,76.6533180778032,H,KG targets OPRM1; clinical phase 4.0; logS -4.24; logP 5.54,repurposing_candidates.csv:rc_row=1082;protein_drug_candidates.csv:rows=310;pathway_drug_candidates.csv:rows=280;1314;7227;CYP3A4_results.csv:row=951;CYP2C19_results.csv:row=951;CYP2D6_results.csv:row=951;CYP1A2_results.csv:row=951;CYP2C9_results.csv:row=951;hERG_results.csv:row=951;AMES_results.csv:row=951;PGP_results.csv:row=951;PAMPA_results.csv:row=951;BBB_results.csv:row=951;Solubility_results.csv:row=951;Lipophilicity_results.csv:row=952
CHEMBL1200666,CALCIPOTRIENE,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,100,90.0,76.6533180778032,H,KG targets VDR; clinical phase 4.0; logS -4.36; logP 5.09,repurposing_candidates.csv:rc_row=146;protein_drug_candidates.csv:rows=239;pathway_drug_candidates.csv:rows=5992;7769;7887;CYP3A4_results.csv:row=145;CYP2C19_results.csv:row=145;CYP2D6_results.csv:row=145;CYP1A2_results.csv:row=145;CYP2C9_results.csv:row=145;hERG_results.csv:row=145;AMES_results.csv:row=145;PGP_results.csv:row=145;PAMPA_results.csv:row=145;BBB_results.csv:row=145;Solubility_results.csv:row=145;Lipophilicity_results.csv:row=145
CHEMBL1200810,DOXERCALCIFEROL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,100,90.0,76.6533180778032,H,KG targets VDR; clinical phase 4.0; logS -5.40; logP 6.61,repurposing_candidates.csv:rc_row=176;protein_drug_candidates.csv:rows=243;pathway_drug_candidates.csv:rows=5996;7773;7891;CYP3A4_results.csv:row=174;CYP2C19_results.csv:row=174;CYP2D6_results.csv:row=174;CYP1A2_results.csv:row=174;CYP2C9_results.csv:row=174;hERG_results.csv:row=174;AMES_results.csv:row=174;PGP_results.csv:row=174;PAMPA_results.csv:row=174;BBB_results.csv:row=174;Solubility_results.csv:row=174;Lipophilicity_results.csv:row=175
CHEMBL1200622,PARICALCITOL,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C,47.88329519450801,100,90.0,76.6533180778032,H,KG targets VDR; clinical phase 4.0; logS -3.66; logP 5.56,repurposing_candidates.csv:rc_row=137;protein_drug_candidates.csv:rows=241;pathway_drug_candidates.csv:rows=5994;7771;7889;CYP3A4_results.csv:row=136;CYP2C19_results.csv:row=136;CYP2D6_results.csv:row=136;CYP1A2_results.csv:row=136;CYP2C9_results.csv:row=136;hERG_results.csv:row=136;AMES_results.csv:row=136;PGP_results.csv:row=136;PAMPA_results.csv:row=136;BBB_results.csv:row=136;Solubility_results.csv:row=136;Lipophilicity_results.csv:row=136
CHEMBL2107771,RALFINAMIDE,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,58.86727688787185,80,100.0,76.54691075514874,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -3.24; logP 2.37",repurposing_candidates.csv:rc_row=735;protein_drug_candidates.csv:rows=717;1616;1962;2189;2610;2655;2679;pathway_drug_candidates.csv:rows=3623;6807;6834;6861;6894;7052;7079;7106;7133;CYP3A4_results.csv:row=680;CYP2C19_results.csv:row=680;CYP2D6_results.csv:row=680;CYP1A2_results.csv:row=680;CYP2C9_results.csv:row=680;hERG_results.csv:row=680;AMES_results.csv:row=680;PGP_results.csv:row=680;PAMPA_results.csv:row=680;BBB_results.csv:row=680;Solubility_results.csv:row=680;Lipophilicity_results.csv:row=681
CHEMBL3545351,AV-101,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O,58.86727688787185,80,100.0,76.54691075514874,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -2.95; logP 0.91",repurposing_candidates.csv:rc_row=992;protein_drug_candidates.csv:rows=716;1615;1961;2188;2609;2654;2678;pathway_drug_candidates.csv:rows=3622;6806;6833;6860;6893;7051;7078;7105;7132;CYP3A4_results.csv:row=883;CYP2C19_results.csv:row=883;CYP2D6_results.csv:row=883;CYP1A2_results.csv:row=883;CYP2C9_results.csv:row=883;hERG_results.csv:row=883;AMES_results.csv:row=883;PGP_results.csv:row=883;PAMPA_results.csv:row=883;BBB_results.csv:row=883;Solubility_results.csv:row=883;Lipophilicity_results.csv:row=884
CHEMBL221959,TOFACITINIB,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,45.31655225019069,95,100.0,76.37662090007628,H,"KG targets JAK1, JAK2; clinical phase 3.0; logS -1.20; logP 1.54",repurposing_candidates.csv:rc_row=814;protein_drug_candidates.csv:rows=765;791;1191;pathway_drug_candidates.csv:rows=190;216;409;652;678;788;4242;4273;4421;4527;4562;4588;4610;4641;4667;4689;4720;4746;4768;4789;4809;4827;4853;4875;4896;4922;4944;4962;4988;5010;5028;5054;5076;5098;5120;5138;5164;5186;5216;5236;5266;5286;5304;5330;5352;5370;5396;5418;5434;5464;5484;6917;6943;7477;8306;8334;8362;8396;8424;8452;CYP3A4_results.csv:row=723;CYP2C19_results.csv:row=723;CYP2D6_results.csv:row=723;CYP1A2_results.csv:row=723;CYP2C9_results.csv:row=723;hERG_results.csv:row=723;AMES_results.csv:row=723;PGP_results.csv:row=723;PAMPA_results.csv:row=723;BBB_results.csv:row=723;Solubility_results.csv:row=723;Lipophilicity_results.csv:row=724
CHEMBL2108628,PACLITAXEL POLIGLUMEX,,58.405797101449274,80,100.0,76.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0",repurposing_candidates.csv:rc_row=751;protein_drug_candidates.csv:rows=828;1561;1996;2235;2340;2404;2711;2775;2839;pathway_drug_candidates.csv:rows=1541;1605;1669;1733;1797;1861;1925;2090;2154;2218;2282;2346;2410;2474;2538;2602;2666;2730;2794;2858;2922;2986;3056;3120;3184;3248;3312;3376;3440;3504;3568;3659;3723;3787;3851;3915;3979;4046;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1206232,FOSBRETABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,58.405797101449274,80,100.0,76.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -4.47; logP 3.36",repurposing_candidates.csv:rc_row=327;protein_drug_candidates.csv:rows=834;1567;2002;2242;2347;2411;2718;2782;2846;pathway_drug_candidates.csv:rows=1547;1611;1675;1739;1803;1867;1931;2096;2160;2224;2288;2352;2416;2480;2544;2608;2672;2736;2800;2864;2928;2992;3062;3126;3190;3254;3318;3382;3446;3510;3574;3665;3729;3793;3857;3921;3985;4052;CYP3A4_results.csv:row=290;CYP2C19_results.csv:row=290;CYP2D6_results.csv:row=290;CYP1A2_results.csv:row=290;CYP2C9_results.csv:row=290;hERG_results.csv:row=290;AMES_results.csv:row=290;PGP_results.csv:row=290;PAMPA_results.csv:row=290;BBB_results.csv:row=290;Solubility_results.csv:row=290;Lipophilicity_results.csv:row=291
CHEMBL3990032,TELISOTUZUMAB VEDOTIN,,58.405797101449274,80,100.0,76.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0",repurposing_candidates.csv:rc_row=1114;protein_drug_candidates.csv:rows=831;1564;1998;2237;2343;2407;2714;2778;2841;pathway_drug_candidates.csv:rows=1544;1608;1672;1736;1800;1864;1928;2093;2157;2221;2285;2349;2413;2477;2541;2605;2669;2733;2797;2861;2925;2989;3059;3123;3187;3251;3315;3379;3443;3507;3571;3662;3726;3790;3854;3918;3982;4049;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298098,TUSAMITAMAB RAVTANSINE,,58.405797101449274,80,100.0,76.36231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0",repurposing_candidates.csv:rc_row=1243;protein_drug_candidates.csv:rows=833;1566;2001;2240;2345;2409;2716;2780;2844;pathway_drug_candidates.csv:rows=1546;1610;1674;1738;1802;1866;1930;2095;2159;2223;2287;2351;2415;2479;2543;2607;2671;2735;2799;2863;2927;2991;3061;3125;3189;3253;3317;3381;3445;3509;3573;3664;3728;3792;3856;3920;3984;4051;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL856,PRIMIDONE,CCC1(c2ccccc2)C(=O)NCNC1=O,40.57971014492753,100,100.0,76.23188405797102,H,"KG targets GABRB1, GABRB2; clinical phase 4.0; logS -2.47; logP 0.54",repurposing_candidates.csv:rc_row=1537;protein_drug_candidates.csv:rows=1508;1736;2570;CYP3A4_results.csv:row=1343;CYP2C19_results.csv:row=1343;CYP2D6_results.csv:row=1343;CYP1A2_results.csv:row=1343;CYP2C9_results.csv:row=1343;hERG_results.csv:row=1343;AMES_results.csv:row=1343;PGP_results.csv:row=1343;PAMPA_results.csv:row=1343;BBB_results.csv:row=1343;Solubility_results.csv:row=1343;Lipophilicity_results.csv:row=1344
CHEMBL454,BUTALBITAL,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,40.57971014492753,100,100.0,76.23188405797102,H,"KG targets GABRB1, GABRB2; clinical phase 4.0; logS -2.53; logP 0.96",repurposing_candidates.csv:rc_row=1277;protein_drug_candidates.csv:rows=1519;1744;2582;CYP3A4_results.csv:row=1097;CYP2C19_results.csv:row=1097;CYP2D6_results.csv:row=1097;CYP1A2_results.csv:row=1097;CYP2C9_results.csv:row=1097;hERG_results.csv:row=1097;AMES_results.csv:row=1097;PGP_results.csv:row=1097;PAMPA_results.csv:row=1097;BBB_results.csv:row=1097;Solubility_results.csv:row=1097;Lipophilicity_results.csv:row=1098
CHEMBL450,METHARBITAL,CCC1(CC)C(=O)NC(=O)N(C)C1=O,40.57971014492753,100,100.0,76.23188405797102,H,"KG targets GABRB1, GABRB2; clinical phase 4.0; logS -2.42; logP 0.50",repurposing_candidates.csv:rc_row=1270;protein_drug_candidates.csv:rows=1511;1734;2574;CYP3A4_results.csv:row=1090;CYP2C19_results.csv:row=1090;CYP2D6_results.csv:row=1090;CYP1A2_results.csv:row=1090;CYP2C9_results.csv:row=1090;hERG_results.csv:row=1090;AMES_results.csv:row=1090;PGP_results.csv:row=1090;PAMPA_results.csv:row=1090;BBB_results.csv:row=1090;Solubility_results.csv:row=1090;Lipophilicity_results.csv:row=1091
CHEMBL448,PENTOBARBITAL,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,40.57971014492753,100,100.0,76.23188405797102,H,"KG targets GABRB1, GABRB2; clinical phase 4.0; logS -2.64; logP 1.18",repurposing_candidates.csv:rc_row=1269;protein_drug_candidates.csv:rows=1516;1739;2576;CYP3A4_results.csv:row=1089;CYP2C19_results.csv:row=1089;CYP2D6_results.csv:row=1089;CYP1A2_results.csv:row=1089;CYP2C9_results.csv:row=1089;hERG_results.csv:row=1089;AMES_results.csv:row=1089;PGP_results.csv:row=1089;PAMPA_results.csv:row=1089;BBB_results.csv:row=1089;Solubility_results.csv:row=1089;Lipophilicity_results.csv:row=1090
CHEMBL660,AMANTADINE,NC12CC3CC(CC(C3)C1)C2,40.53394355453852,100,100.0,76.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -2.03; logP 1.91",repurposing_candidates.csv:rc_row=1479;protein_drug_candidates.csv:rows=711;1609;1958;2183;2604;2648;2672;pathway_drug_candidates.csv:rows=3617;6801;6828;6855;6888;7046;7073;7100;7127;CYP3A4_results.csv:row=1285;CYP2C19_results.csv:row=1285;CYP2D6_results.csv:row=1285;CYP1A2_results.csv:row=1285;CYP2C9_results.csv:row=1285;hERG_results.csv:row=1285;AMES_results.csv:row=1285;PGP_results.csv:row=1285;PAMPA_results.csv:row=1285;BBB_results.csv:row=1285;Solubility_results.csv:row=1285;Lipophilicity_results.csv:row=1286
CHEMBL395091,ESKETAMINE,CN[C@]1(c2ccccc2Cl)CCCCC1=O,40.53394355453852,100,100.0,76.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -0.91; logP 2.90",repurposing_candidates.csv:rc_row=1063;protein_drug_candidates.csv:rows=707;1606;1954;2180;2601;2646;2671;pathway_drug_candidates.csv:rows=3613;6797;6824;6851;6884;7042;7069;7096;7123;CYP3A4_results.csv:row=932;CYP2C19_results.csv:row=932;CYP2D6_results.csv:row=932;CYP1A2_results.csv:row=932;CYP2C9_results.csv:row=932;hERG_results.csv:row=932;AMES_results.csv:row=932;PGP_results.csv:row=932;PAMPA_results.csv:row=932;BBB_results.csv:row=932;Solubility_results.csv:row=932;Lipophilicity_results.csv:row=933
CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl,40.53394355453852,100,100.0,76.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; logS -0.19; logP 3.32",repurposing_candidates.csv:rc_row=835;protein_drug_candidates.csv:rows=708;1608;1953;2181;2603;2647;2670;pathway_drug_candidates.csv:rows=3614;6798;6825;6852;6885;7043;7070;7097;7124;CYP3A4_results.csv:row=744;CYP2C19_results.csv:row=744;CYP2D6_results.csv:row=744;CYP1A2_results.csv:row=744;CYP2C9_results.csv:row=744;hERG_results.csv:row=744;AMES_results.csv:row=744;PGP_results.csv:row=744;PAMPA_results.csv:row=744;BBB_results.csv:row=744;Solubility_results.csv:row=744;Lipophilicity_results.csv:row=745
CHEMBL4594301,REMIMAZOLAM BESYLATE,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1,45.79710144927536,100,90.0,75.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -1.92; logP 5.12",repurposing_candidates.csv:rc_row=1290;protein_drug_candidates.csv:rows=502;1426;1648;1701;2056;2101;2469;CYP3A4_results.csv:row=1110;CYP2C19_results.csv:row=1110;CYP2D6_results.csv:row=1110;CYP1A2_results.csv:row=1110;CYP2C9_results.csv:row=1110;hERG_results.csv:row=1110;AMES_results.csv:row=1110;PGP_results.csv:row=1110;PAMPA_results.csv:row=1110;BBB_results.csv:row=1110;Solubility_results.csv:row=1110;Lipophilicity_results.csv:row=1111
CHEMBL1064,SIMVASTATIN,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,48.40961098398169,100,85.0,75.61384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -6.25; logP 4.59,repurposing_candidates.csv:rc_row=19;protein_drug_candidates.csv:rows=735;pathway_drug_candidates.csv:rows=7614;7629;7644;7659;CYP3A4_results.csv:row=19;CYP2C19_results.csv:row=19;CYP2D6_results.csv:row=19;CYP1A2_results.csv:row=19;CYP2C9_results.csv:row=19;hERG_results.csv:row=19;AMES_results.csv:row=19;PGP_results.csv:row=19;PAMPA_results.csv:row=19;BBB_results.csv:row=19;Solubility_results.csv:row=19;Lipophilicity_results.csv:row=19
CHEMBL3622820,ITACITINIB,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,56.30434782608695,80,100.0,75.52173913043478,H,KG targets JAK1; clinical phase 3.0; logS -3.84; logP 3.60,repurposing_candidates.csv:rc_row=1003;protein_drug_candidates.csv:rows=767;pathway_drug_candidates.csv:rows=192;654;4244;4423;4564;4643;4722;4791;4829;4898;4964;5030;5140;5218;5268;5306;5372;5466;6919;CYP3A4_results.csv:row=889;CYP2C19_results.csv:row=889;CYP2D6_results.csv:row=889;CYP1A2_results.csv:row=889;CYP2C9_results.csv:row=889;hERG_results.csv:row=889;AMES_results.csv:row=889;PGP_results.csv:row=889;PAMPA_results.csv:row=889;BBB_results.csv:row=889;Solubility_results.csv:row=889;Lipophilicity_results.csv:row=890
CHEMBL761,NAPHAZOLINE,c1ccc2c(CC3=NCCN3)cccc2c1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.94; logP 2.38",repurposing_candidates.csv:rc_row=1508;protein_drug_candidates.csv:rows=384;1329;1385;1491;1851;2532;pathway_drug_candidates.csv:rows=847;900;956;1004;1060;1108;1160;1216;1392;1448;1496;6509;6709;CYP3A4_results.csv:row=1314;CYP2C19_results.csv:row=1314;CYP2D6_results.csv:row=1314;CYP1A2_results.csv:row=1314;CYP2C9_results.csv:row=1314;hERG_results.csv:row=1314;AMES_results.csv:row=1314;PGP_results.csv:row=1314;PAMPA_results.csv:row=1314;BBB_results.csv:row=1314;Solubility_results.csv:row=1314;Lipophilicity_results.csv:row=1315
CHEMBL753,PHENOXYBENZAMINE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.28; logP 4.19",repurposing_candidates.csv:rc_row=1506;protein_drug_candidates.csv:rows=358;1305;1356;1464;1833;2504;pathway_drug_candidates.csv:rows=821;876;927;980;1031;1084;1136;1187;1368;1419;1472;6483;6683;CYP3A4_results.csv:row=1312;CYP2C19_results.csv:row=1312;CYP2D6_results.csv:row=1312;CYP1A2_results.csv:row=1312;CYP2C9_results.csv:row=1312;hERG_results.csv:row=1312;AMES_results.csv:row=1312;PGP_results.csv:row=1312;PAMPA_results.csv:row=1312;BBB_results.csv:row=1312;Solubility_results.csv:row=1312;Lipophilicity_results.csv:row=1313
CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,Cl.c1ccc2c(CC3=NCCN3)cccc2c1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.28; logP 2.81",repurposing_candidates.csv:rc_row=520;protein_drug_candidates.csv:rows=379;1324;1377;1483;1845;2529;pathway_drug_candidates.csv:rows=842;895;948;999;1052;1103;1155;1208;1387;1440;1491;6504;6704;CYP3A4_results.csv:row=480;CYP2C19_results.csv:row=480;CYP2D6_results.csv:row=480;CYP1A2_results.csv:row=480;CYP2C9_results.csv:row=480;hERG_results.csv:row=480;AMES_results.csv:row=480;PGP_results.csv:row=480;PAMPA_results.csv:row=480;BBB_results.csv:row=480;Solubility_results.csv:row=480;Lipophilicity_results.csv:row=481
CHEMBL1266,TETRAHYDROZOLINE,c1ccc2c(c1)CCCC2C1=NCCN1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -3.18; logP 2.11",repurposing_candidates.csv:rc_row=365;protein_drug_candidates.csv:rows=383;1327;1381;1487;1843;2524;pathway_drug_candidates.csv:rows=846;898;952;1002;1056;1106;1158;1212;1390;1444;1494;6508;6708;CYP3A4_results.csv:row=327;CYP2C19_results.csv:row=327;CYP2D6_results.csv:row=327;CYP1A2_results.csv:row=327;CYP2C9_results.csv:row=327;hERG_results.csv:row=327;AMES_results.csv:row=327;PGP_results.csv:row=327;PAMPA_results.csv:row=327;BBB_results.csv:row=327;Solubility_results.csv:row=327;Lipophilicity_results.csv:row=328
CHEMBL1201234,MEPHENTERMINE,CNC(C)(C)Cc1ccccc1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.79; logP 2.23",repurposing_candidates.csv:rc_row=261;protein_drug_candidates.csv:rows=350;1300;1357;1467;1812;2507;pathway_drug_candidates.csv:rows=813;871;928;975;1032;1079;1131;1188;1363;1420;1467;6475;6675;CYP3A4_results.csv:row=258;CYP2C19_results.csv:row=258;CYP2D6_results.csv:row=258;CYP1A2_results.csv:row=258;CYP2C9_results.csv:row=258;hERG_results.csv:row=258;AMES_results.csv:row=258;PGP_results.csv:row=258;PAMPA_results.csv:row=258;BBB_results.csv:row=258;Solubility_results.csv:row=258;Lipophilicity_results.csv:row=259
CHEMBL1437,NOREPINEPHRINE,NC[C@H](O)c1ccc(O)c(O)c1,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -0.31; logP 0.09",repurposing_candidates.csv:rc_row=415;protein_drug_candidates.csv:rows=366;1308;1358;1469;1829;2499;pathway_drug_candidates.csv:rows=829;879;929;983;1033;1087;1139;1189;1371;1421;1475;6491;6691;CYP3A4_results.csv:row=375;CYP2C19_results.csv:row=375;CYP2D6_results.csv:row=375;CYP1A2_results.csv:row=375;CYP2C9_results.csv:row=375;hERG_results.csv:row=375;AMES_results.csv:row=375;PGP_results.csv:row=375;PAMPA_results.csv:row=375;BBB_results.csv:row=375;Solubility_results.csv:row=375;Lipophilicity_results.csv:row=376
CHEMBL3559672,RAUWOLFIA SERPENTINA,,38.70327993897788,100,100.0,75.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0",repurposing_candidates.csv:rc_row=999;protein_drug_candidates.csv:rows=375;1319;1371;1479;1838;2518;pathway_drug_candidates.csv:rows=838;890;942;994;1046;1098;1150;1202;1382;1434;1486;6500;6700;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL289351,FOSBRETABULIN DISODIUM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],76.73913043478261,60,95.0,75.44565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.88; logP -3.89",repurposing_candidates.csv:rc_row=883;protein_drug_candidates.csv:rows=843;1579;2015;2253;2357;2419;2726;2791;2856;pathway_drug_candidates.csv:rows=1556;1620;1684;1748;1812;1876;1940;2105;2169;2233;2297;2361;2425;2489;2553;2617;2681;2745;2809;2873;2937;3001;3071;3135;3199;3263;3327;3391;3455;3519;3583;3674;3738;3802;3866;3930;3994;4061;CYP3A4_results.csv:row=791;CYP2C19_results.csv:row=791;CYP2D6_results.csv:row=791;CYP1A2_results.csv:row=791;CYP2C9_results.csv:row=791;hERG_results.csv:row=791;AMES_results.csv:row=791;PGP_results.csv:row=791;PAMPA_results.csv:row=791;BBB_results.csv:row=791;Solubility_results.csv:row=791;Lipophilicity_results.csv:row=792
CHEMBL5095049,PACRITINIB CITRATE,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O,57.35697940503432,100,70.0,75.44279176201373,H,KG targets JAK2; clinical phase 4.0; hERG risk; logS -4.05; logP 3.72,repurposing_candidates.csv:rc_row=1353;protein_drug_candidates.csv:rows=785;pathway_drug_candidates.csv:rows=210;672;4582;4661;4740;4847;4916;4982;5048;5092;5158;5324;5390;6937;7471;8300;8328;8356;8390;8418;8446;CYP3A4_results.csv:row=1164;CYP2C19_results.csv:row=1164;CYP2D6_results.csv:row=1164;CYP1A2_results.csv:row=1164;CYP2C9_results.csv:row=1164;hERG_results.csv:row=1164;AMES_results.csv:row=1164;PGP_results.csv:row=1164;PAMPA_results.csv:row=1164;BBB_results.csv:row=1164;Solubility_results.csv:row=1164;Lipophilicity_results.csv:row=1165
CHEMBL2035187,PACRITINIB,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,57.35697940503432,100,70.0,75.44279176201373,H,KG targets JAK2; clinical phase 4.0; hERG risk; logS -5.38; logP 4.47,repurposing_candidates.csv:rc_row=630;protein_drug_candidates.csv:rows=779;pathway_drug_candidates.csv:rows=204;666;4576;4655;4734;4841;4910;4976;5042;5086;5152;5318;5384;6931;7465;8294;8322;8350;8384;8412;8440;CYP3A4_results.csv:row=576;CYP2C19_results.csv:row=576;CYP2D6_results.csv:row=576;CYP1A2_results.csv:row=576;CYP2C9_results.csv:row=576;hERG_results.csv:row=576;AMES_results.csv:row=576;PGP_results.csv:row=576;PAMPA_results.csv:row=576;BBB_results.csv:row=576;Solubility_results.csv:row=576;Lipophilicity_results.csv:row=577
CHEMBL1946170,REGORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,51.01830663615561,100,80.0,75.40732265446225,H,"KG targets ABL1, KIT; clinical phase 4.0; logS -6.84; logP 5.69",repurposing_candidates.csv:rc_row=608;protein_drug_candidates.csv:rows=1101;1148;1207;pathway_drug_candidates.csv:rows=553;4298;6965;6999;7499;CYP3A4_results.csv:row=554;CYP2C19_results.csv:row=554;CYP2D6_results.csv:row=554;CYP1A2_results.csv:row=554;CYP2C9_results.csv:row=554;hERG_results.csv:row=554;AMES_results.csv:row=554;PGP_results.csv:row=554;PAMPA_results.csv:row=554;BBB_results.csv:row=554;Solubility_results.csv:row=554;Lipophilicity_results.csv:row=555
CHEMBL846,CALCITRIOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,100,85.0,75.4033180778032,H,KG targets VDR; clinical phase 4.0; logS -3.84; logP 5.70,repurposing_candidates.csv:rc_row=1534;protein_drug_candidates.csv:rows=238;pathway_drug_candidates.csv:rows=5991;7768;7886;CYP3A4_results.csv:row=1340;CYP2C19_results.csv:row=1340;CYP2D6_results.csv:row=1340;CYP1A2_results.csv:row=1340;CYP2C9_results.csv:row=1340;hERG_results.csv:row=1340;AMES_results.csv:row=1340;PGP_results.csv:row=1340;PAMPA_results.csv:row=1340;BBB_results.csv:row=1340;Solubility_results.csv:row=1340;Lipophilicity_results.csv:row=1341
CHEMBL3544909,CALCIFEDIOL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O,47.88329519450801,100,85.0,75.4033180778032,H,KG targets VDR; clinical phase 4.0; logS -4.99; logP 5.91,repurposing_candidates.csv:rc_row=955;protein_drug_candidates.csv:rows=242;pathway_drug_candidates.csv:rows=5995;7772;7890;CYP3A4_results.csv:row=859;CYP2C19_results.csv:row=859;CYP2D6_results.csv:row=859;CYP1A2_results.csv:row=859;CYP2C9_results.csv:row=859;hERG_results.csv:row=859;AMES_results.csv:row=859;PGP_results.csv:row=859;PAMPA_results.csv:row=859;BBB_results.csv:row=859;Solubility_results.csv:row=859;Lipophilicity_results.csv:row=860
CHEMBL4435170,DEUCRAVACITINIB,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,38.49733028222731,100,100.0,75.39893211289092,H,KG targets TYK2; clinical phase 4.0; logS -4.34; logP 1.73,repurposing_candidates.csv:rc_row=1262;protein_drug_candidates.csv:rows=1184;pathway_drug_candidates.csv:rows=402;781;4266;4520;4603;4682;4761;4802;4868;4937;5003;5069;5113;5179;5229;5279;5345;5411;5427;5477;CYP3A4_results.csv:row=1082;CYP2C19_results.csv:row=1082;CYP2D6_results.csv:row=1082;CYP1A2_results.csv:row=1082;CYP2C9_results.csv:row=1082;hERG_results.csv:row=1082;AMES_results.csv:row=1082;PGP_results.csv:row=1082;PAMPA_results.csv:row=1082;BBB_results.csv:row=1082;Solubility_results.csv:row=1082;Lipophilicity_results.csv:row=1083
CHEMBL1016,CANDESARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,48.40961098398169,95,90.0,75.11384439359267,H,KG targets AGTR1; clinical phase 3.0; logS -6.17; logP 4.03,repurposing_candidates.csv:rc_row=7;protein_drug_candidates.csv:rows=591;pathway_drug_candidates.csv:rows=6545;7164;7275;7295;CYP3A4_results.csv:row=7;CYP2C19_results.csv:row=7;CYP2D6_results.csv:row=7;CYP1A2_results.csv:row=7;CYP2C9_results.csv:row=7;hERG_results.csv:row=7;AMES_results.csv:row=7;PGP_results.csv:row=7;PAMPA_results.csv:row=7;BBB_results.csv:row=7;Solubility_results.csv:row=7;Lipophilicity_results.csv:row=7
CHEMBL92,DOCETAXEL ANHYDROUS,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,58.405797101449274,80,95.0,75.11231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -5.31; logP 3.26",repurposing_candidates.csv:rc_row=1554;protein_drug_candidates.csv:rows=823;1557;1991;2230;2335;2400;2707;2770;2834;pathway_drug_candidates.csv:rows=1536;1600;1664;1728;1792;1856;1920;2085;2149;2213;2277;2341;2405;2469;2533;2597;2661;2725;2789;2853;2917;2981;3051;3115;3179;3243;3307;3371;3435;3499;3563;3654;3718;3782;3846;3910;3974;4041;CYP3A4_results.csv:row=1360;CYP2C19_results.csv:row=1360;CYP2D6_results.csv:row=1360;CYP1A2_results.csv:row=1360;CYP2C9_results.csv:row=1360;hERG_results.csv:row=1360;AMES_results.csv:row=1360;PGP_results.csv:row=1360;PAMPA_results.csv:row=1360;BBB_results.csv:row=1360;Solubility_results.csv:row=1360;Lipophilicity_results.csv:row=1361
CHEMBL94657,PATUPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,58.405797101449274,80,95.0,75.11231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -3.94; logP 4.48",repurposing_candidates.csv:rc_row=1563;protein_drug_candidates.csv:rows=835;1568;2003;2241;2346;2410;2717;2781;2845;pathway_drug_candidates.csv:rows=1548;1612;1676;1740;1804;1868;1932;2097;2161;2225;2289;2353;2417;2481;2545;2609;2673;2737;2801;2865;2929;2993;3063;3127;3191;3255;3319;3383;3447;3511;3575;3666;3730;3794;3858;3922;3986;4053;CYP3A4_results.csv:row=1369;CYP2C19_results.csv:row=1369;CYP2D6_results.csv:row=1369;CYP1A2_results.csv:row=1369;CYP2C9_results.csv:row=1369;hERG_results.csv:row=1369;AMES_results.csv:row=1369;PGP_results.csv:row=1369;PAMPA_results.csv:row=1369;BBB_results.csv:row=1369;Solubility_results.csv:row=1369;Lipophilicity_results.csv:row=1370
CHEMBL4594417,PRUXELUTAMIDE,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1,47.88329519450801,95,90.0,74.9033180778032,H,KG targets AR; clinical phase 3.0; logS -3.48; logP 5.19,repurposing_candidates.csv:rc_row=1295;protein_drug_candidates.csv:rows=560;pathway_drug_candidates.csv:rows=1983;5898;7802;CYP3A4_results.csv:row=1114;CYP2C19_results.csv:row=1114;CYP2D6_results.csv:row=1114;CYP1A2_results.csv:row=1114;CYP2C9_results.csv:row=1114;hERG_results.csv:row=1114;AMES_results.csv:row=1114;PGP_results.csv:row=1114;PAMPA_results.csv:row=1114;BBB_results.csv:row=1114;Solubility_results.csv:row=1114;Lipophilicity_results.csv:row=1115
CHEMBL19449,IBUDILAST,CC(C)C(=O)c1c(C(C)C)nn2ccccc12,54.679633867276884,80,100.0,74.87185354691076,H,"KG targets PDE4A, PDE4B; clinical phase 3.0; logS -2.06; logP 3.30",repurposing_candidates.csv:rc_row=607;protein_drug_candidates.csv:rows=423;878;1056;1085;2162;pathway_drug_candidates.csv:rows=4336;5745;5773;5802;5840;5869;7678;7705;7718;CYP3A4_results.csv:row=553;CYP2C19_results.csv:row=553;CYP2D6_results.csv:row=553;CYP1A2_results.csv:row=553;CYP2C9_results.csv:row=553;hERG_results.csv:row=553;AMES_results.csv:row=553;PGP_results.csv:row=553;PAMPA_results.csv:row=553;BBB_results.csv:row=553;Solubility_results.csv:row=553;Lipophilicity_results.csv:row=554
CHEMBL526,PROPOFOL,CC(C)c1cccc(C(C)C)c1O,57.53623188405797,80,95.0,74.76449275362319,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; logS -3.54; logP 3.64",repurposing_candidates.csv:rc_row=1372;protein_drug_candidates.csv:rows=507;1436;1521;1660;1706;1747;1780;1801;1874;1935;2066;2112;2474;2560;2583;2631;CYP3A4_results.csv:row=1183;CYP2C19_results.csv:row=1183;CYP2D6_results.csv:row=1183;CYP1A2_results.csv:row=1183;CYP2C9_results.csv:row=1183;hERG_results.csv:row=1183;AMES_results.csv:row=1183;PGP_results.csv:row=1183;PAMPA_results.csv:row=1183;BBB_results.csv:row=1183;Solubility_results.csv:row=1183;Lipophilicity_results.csv:row=1184
CHEMBL2107339,ESMIRTAZAPINE MALEATE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O,53.901601830663616,80,100.0,74.56064073226545,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; logS -2.44; logP 2.19",repurposing_candidates.csv:rc_row=724;protein_drug_candidates.csv:rows=1028;1344;1396;2544;pathway_drug_candidates.csv:rows=915;967;1019;1071;1123;1175;1227;1407;1459;1511;6658;CYP3A4_results.csv:row=669;CYP2C19_results.csv:row=669;CYP2D6_results.csv:row=669;CYP1A2_results.csv:row=669;CYP2C9_results.csv:row=669;hERG_results.csv:row=669;AMES_results.csv:row=669;PGP_results.csv:row=669;PAMPA_results.csv:row=669;BBB_results.csv:row=669;Solubility_results.csv:row=669;Lipophilicity_results.csv:row=670
CHEMBL3989923,PITAVASTATIN MAGNESIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2],48.40961098398169,100,80.0,74.36384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -6.07; logP 5.99,repurposing_candidates.csv:rc_row=1102;protein_drug_candidates.csv:rows=743;pathway_drug_candidates.csv:rows=7622;7637;7652;7667;CYP3A4_results.csv:row=971;CYP2C19_results.csv:row=971;CYP2D6_results.csv:row=971;CYP1A2_results.csv:row=971;CYP2C9_results.csv:row=971;hERG_results.csv:row=971;AMES_results.csv:row=971;PGP_results.csv:row=971;PAMPA_results.csv:row=971;BBB_results.csv:row=971;Solubility_results.csv:row=971;Lipophilicity_results.csv:row=972
CHEMBL1014,CANDESARTAN CILEXETIL,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,48.40961098398169,100,80.0,74.36384439359267,H,KG targets AGTR1; clinical phase 4.0; logS -7.69; logP 6.32,repurposing_candidates.csv:rc_row=6;protein_drug_candidates.csv:rows=584;pathway_drug_candidates.csv:rows=6538;7157;7268;7288;CYP3A4_results.csv:row=6;CYP2C19_results.csv:row=6;CYP2D6_results.csv:row=6;CYP1A2_results.csv:row=6;CYP2C9_results.csv:row=6;hERG_results.csv:row=6;AMES_results.csv:row=6;PGP_results.csv:row=6;PAMPA_results.csv:row=6;BBB_results.csv:row=6;Solubility_results.csv:row=6;Lipophilicity_results.csv:row=6
CHEMBL393220,ATORVASTATIN CALCIUM,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],48.40961098398169,100,80.0,74.36384439359267,H,KG targets HMGCR; clinical phase 4.0; logS -7.00; logP 9.58,repurposing_candidates.csv:rc_row=1058;protein_drug_candidates.csv:rows=739;pathway_drug_candidates.csv:rows=7618;7633;7648;7663;CYP3A4_results.csv:row=927;CYP2C19_results.csv:row=927;CYP2D6_results.csv:row=927;CYP1A2_results.csv:row=927;CYP2C9_results.csv:row=927;hERG_results.csv:row=927;AMES_results.csv:row=927;PGP_results.csv:row=927;PAMPA_results.csv:row=927;BBB_results.csv:row=927;Solubility_results.csv:row=927;Lipophilicity_results.csv:row=928
CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.71; logP 3.27",repurposing_candidates.csv:rc_row=168;protein_drug_candidates.csv:rows=387;1323;1376;1489;1844;2522;pathway_drug_candidates.csv:rows=850;894;947;998;1051;1102;1154;1207;1386;1439;1490;6512;6712;CYP3A4_results.csv:row=166;CYP2C19_results.csv:row=166;CYP2D6_results.csv:row=166;CYP1A2_results.csv:row=166;CYP2C9_results.csv:row=166;hERG_results.csv:row=166;AMES_results.csv:row=166;PGP_results.csv:row=166;PAMPA_results.csv:row=166;BBB_results.csv:row=166;Solubility_results.csv:row=166;Lipophilicity_results.csv:row=167
CHEMBL1256958,EPINEPHRINE BITARTRATE,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -0.29; logP -1.77",repurposing_candidates.csv:rc_row=357;protein_drug_candidates.csv:rows=377;1322;1374;1481;1847;2528;pathway_drug_candidates.csv:rows=840;893;945;997;1049;1101;1153;1205;1385;1437;1489;6502;6702;CYP3A4_results.csv:row=319;CYP2C19_results.csv:row=319;CYP2D6_results.csv:row=319;CYP1A2_results.csv:row=319;CYP2C9_results.csv:row=319;hERG_results.csv:row=319;AMES_results.csv:row=319;PGP_results.csv:row=319;PAMPA_results.csv:row=319;BBB_results.csv:row=319;Solubility_results.csv:row=319;Lipophilicity_results.csv:row=320
CHEMBL597,PHENTOLAMINE,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.43; logP 2.84",repurposing_candidates.csv:rc_row=1438;protein_drug_candidates.csv:rows=369;1303;1355;1471;1818;2503;pathway_drug_candidates.csv:rows=832;874;926;978;1030;1082;1134;1186;1366;1418;1470;6494;6694;CYP3A4_results.csv:row=1247;CYP2C19_results.csv:row=1247;CYP2D6_results.csv:row=1247;CYP1A2_results.csv:row=1247;CYP2C9_results.csv:row=1247;hERG_results.csv:row=1247;AMES_results.csv:row=1247;PGP_results.csv:row=1247;PAMPA_results.csv:row=1247;BBB_results.csv:row=1247;Solubility_results.csv:row=1247;Lipophilicity_results.csv:row=1248
CHEMBL442,ERGOTAMINE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.87; logP 1.99",repurposing_candidates.csv:rc_row=1261;protein_drug_candidates.csv:rows=396;1339;1391;1497;1856;2538;pathway_drug_candidates.csv:rows=859;910;962;1014;1066;1118;1170;1222;1402;1454;1506;6521;6721;CYP3A4_results.csv:row=1081;CYP2C19_results.csv:row=1081;CYP2D6_results.csv:row=1081;CYP1A2_results.csv:row=1081;CYP2C9_results.csv:row=1081;hERG_results.csv:row=1081;AMES_results.csv:row=1081;PGP_results.csv:row=1081;PAMPA_results.csv:row=1081;BBB_results.csv:row=1081;Solubility_results.csv:row=1081;Lipophilicity_results.csv:row=1082
CHEMBL762,OXYMETAZOLINE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -3.37; logP 2.85",repurposing_candidates.csv:rc_row=1509;protein_drug_candidates.csv:rows=385;1334;1386;1492;1852;2526;pathway_drug_candidates.csv:rows=848;905;957;1009;1061;1113;1165;1217;1397;1449;1501;6510;6710;CYP3A4_results.csv:row=1315;CYP2C19_results.csv:row=1315;CYP2D6_results.csv:row=1315;CYP1A2_results.csv:row=1315;CYP2C9_results.csv:row=1315;hERG_results.csv:row=1315;AMES_results.csv:row=1315;PGP_results.csv:row=1315;PAMPA_results.csv:row=1315;BBB_results.csv:row=1315;Solubility_results.csv:row=1315;Lipophilicity_results.csv:row=1316
CHEMBL2103827,DROXIDOPA,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -0.60; logP -0.46",repurposing_candidates.csv:rc_row=664;protein_drug_candidates.csv:rows=368;1310;1360;1470;1815;2509;pathway_drug_candidates.csv:rows=831;881;931;985;1035;1089;1141;1191;1373;1423;1477;6493;6693;CYP3A4_results.csv:row=609;CYP2C19_results.csv:row=609;CYP2D6_results.csv:row=609;CYP1A2_results.csv:row=609;CYP2C9_results.csv:row=609;hERG_results.csv:row=609;AMES_results.csv:row=609;PGP_results.csv:row=609;PAMPA_results.csv:row=609;BBB_results.csv:row=609;Solubility_results.csv:row=609;Lipophilicity_results.csv:row=610
CHEMBL679,EPINEPHRINE,CNC[C@H](O)c1ccc(O)c(O)c1,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -0.78; logP 0.35",repurposing_candidates.csv:rc_row=1483;protein_drug_candidates.csv:rows=356;1304;1363;1472;1832;2511;pathway_drug_candidates.csv:rows=819;875;934;979;1038;1083;1135;1194;1367;1426;1471;6481;6681;CYP3A4_results.csv:row=1289;CYP2C19_results.csv:row=1289;CYP2D6_results.csv:row=1289;CYP1A2_results.csv:row=1289;CYP2C9_results.csv:row=1289;hERG_results.csv:row=1289;AMES_results.csv:row=1289;PGP_results.csv:row=1289;PAMPA_results.csv:row=1289;BBB_results.csv:row=1289;Solubility_results.csv:row=1289;Lipophilicity_results.csv:row=1290
CHEMBL1201262,DIPIVEFRIN,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -3.62; logP 2.84",repurposing_candidates.csv:rc_row=263;protein_drug_candidates.csv:rows=394;1338;1389;1496;1855;2537;pathway_drug_candidates.csv:rows=857;909;960;1013;1064;1117;1169;1220;1401;1452;1505;6519;6719;CYP3A4_results.csv:row=260;CYP2C19_results.csv:row=260;CYP2D6_results.csv:row=260;CYP1A2_results.csv:row=260;CYP2C9_results.csv:row=260;hERG_results.csv:row=260;AMES_results.csv:row=260;PGP_results.csv:row=260;PAMPA_results.csv:row=260;BBB_results.csv:row=260;Solubility_results.csv:row=260;Lipophilicity_results.csv:row=261
CHEMBL1434513,NOREPINEPHRINE BITARTRATE,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O,38.70327993897788,100,95.0,74.23131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -0.38; logP -2.86",repurposing_candidates.csv:rc_row=414;protein_drug_candidates.csv:rows=381;1321;1373;1485;1841;2520;pathway_drug_candidates.csv:rows=844;892;944;996;1048;1100;1152;1204;1384;1436;1488;6506;6706;CYP3A4_results.csv:row=374;CYP2C19_results.csv:row=374;CYP2D6_results.csv:row=374;CYP1A2_results.csv:row=374;CYP2C9_results.csv:row=374;hERG_results.csv:row=374;AMES_results.csv:row=374;PGP_results.csv:row=374;PAMPA_results.csv:row=374;BBB_results.csv:row=374;Solubility_results.csv:row=374;Lipophilicity_results.csv:row=375
CHEMBL39541,DOLASTATIN-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,76.73913043478261,60,90.0,74.19565217391305,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.18; logP 5.19",repurposing_candidates.csv:rc_row=1064;protein_drug_candidates.csv:rows=841;1574;2009;2249;2354;2418;2723;2789;2853;pathway_drug_candidates.csv:rows=1554;1618;1682;1746;1810;1874;1938;2103;2167;2231;2295;2359;2423;2487;2551;2615;2679;2743;2807;2871;2935;2999;3069;3133;3197;3261;3325;3389;3453;3517;3581;3672;3736;3800;3864;3928;3992;4059;CYP3A4_results.csv:row=933;CYP2C19_results.csv:row=933;CYP2D6_results.csv:row=933;CYP1A2_results.csv:row=933;CYP2C9_results.csv:row=933;hERG_results.csv:row=933;AMES_results.csv:row=933;PGP_results.csv:row=933;PAMPA_results.csv:row=933;BBB_results.csv:row=933;Solubility_results.csv:row=933;Lipophilicity_results.csv:row=934
CHEMBL3,NICOTINE,CN1CCC[C@H]1c1cccnc1,54.18764302059497,100,70.0,74.17505720823799,H,"KG targets CHRNA4, CHRNB2; clinical phase 4.0; hERG risk; logS 0.63; logP 1.85",repurposing_candidates.csv:rc_row=888;protein_drug_candidates.csv:rows=436;2132;pathway_drug_candidates.csv:rows=7916;7930;7944;CYP3A4_results.csv:row=796;CYP2C19_results.csv:row=796;CYP2D6_results.csv:row=796;CYP1A2_results.csv:row=796;CYP2C9_results.csv:row=796;hERG_results.csv:row=796;AMES_results.csv:row=796;PGP_results.csv:row=796;PAMPA_results.csv:row=796;BBB_results.csv:row=796;Solubility_results.csv:row=796;Lipophilicity_results.csv:row=797
CHEMBL1536,ERGOCALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12,47.88329519450801,100,80.0,74.1533180778032,H,KG targets VDR; clinical phase 4.0; logS -6.11; logP 7.64,repurposing_candidates.csv:rc_row=454;protein_drug_candidates.csv:rows=244;pathway_drug_candidates.csv:rows=5997;7774;7892;CYP3A4_results.csv:row=414;CYP2C19_results.csv:row=414;CYP2D6_results.csv:row=414;CYP1A2_results.csv:row=414;CYP2C9_results.csv:row=414;hERG_results.csv:row=414;AMES_results.csv:row=414;PGP_results.csv:row=414;PAMPA_results.csv:row=414;BBB_results.csv:row=414;Solubility_results.csv:row=414;Lipophilicity_results.csv:row=415
CHEMBL19299,LOXOPROFEN,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,52.87185354691076,80,100.0,74.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; logS -3.29; logP 2.79",repurposing_candidates.csv:rc_row=602;protein_drug_candidates.csv:rows=157;933;pathway_drug_candidates.csv:rows=380;4498;5573;5633;5707;6091;6165;6239;6313;6387;6461;CYP3A4_results.csv:row=548;CYP2C19_results.csv:row=548;CYP2D6_results.csv:row=548;CYP1A2_results.csv:row=548;CYP2C9_results.csv:row=548;hERG_results.csv:row=548;AMES_results.csv:row=548;PGP_results.csv:row=548;PAMPA_results.csv:row=548;BBB_results.csv:row=548;Solubility_results.csv:row=548;Lipophilicity_results.csv:row=549
CHEMBL435298,ESFLURBIPROFEN,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,52.87185354691076,80,100.0,74.1487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; logS -4.18; logP 3.68",repurposing_candidates.csv:rc_row=1256;protein_drug_candidates.csv:rows=160;938;pathway_drug_candidates.csv:rows=383;4501;5578;5638;5710;6094;6168;6242;6316;6390;6464;CYP3A4_results.csv:row=1076;CYP2C19_results.csv:row=1076;CYP2D6_results.csv:row=1076;CYP1A2_results.csv:row=1076;CYP2C9_results.csv:row=1076;hERG_results.csv:row=1076;AMES_results.csv:row=1076;PGP_results.csv:row=1076;PAMPA_results.csv:row=1076;BBB_results.csv:row=1076;Solubility_results.csv:row=1076;Lipophilicity_results.csv:row=1077
CHEMBL1421,DASATINIB,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,35.293668954996186,100,100.0,74.11746758199848,H,"KG targets ABL1, BCR; clinical phase 4.0; logS -2.73; logP 3.31",repurposing_candidates.csv:rc_row=407;protein_drug_candidates.csv:rows=942;1097;1140;1199;2199;pathway_drug_candidates.csv:rows=545;4290;6957;6995;7491;CYP3A4_results.csv:row=367;CYP2C19_results.csv:row=367;CYP2D6_results.csv:row=367;CYP1A2_results.csv:row=367;CYP2C9_results.csv:row=367;hERG_results.csv:row=367;AMES_results.csv:row=367;PGP_results.csv:row=367;PAMPA_results.csv:row=367;BBB_results.csv:row=367;Solubility_results.csv:row=367;Lipophilicity_results.csv:row=368
CHEMBL1200873,PHENTOLAMINE MESYLATE,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,57.03661327231121,100,65.0,74.06464530892448,M,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -0.38; logP 2.34",repurposing_candidates.csv:rc_row=183;protein_drug_candidates.csv:rows=364;1299;1352;1457;1811;2506;pathway_drug_candidates.csv:rows=827;870;923;974;1027;1078;1130;1183;1362;1415;1466;6489;6689;CYP3A4_results.csv:row=181;CYP2C19_results.csv:row=181;CYP2D6_results.csv:row=181;CYP1A2_results.csv:row=181;CYP2C9_results.csv:row=181;hERG_results.csv:row=181;AMES_results.csv:row=181;PGP_results.csv:row=181;PAMPA_results.csv:row=181;BBB_results.csv:row=181;Solubility_results.csv:row=181;Lipophilicity_results.csv:row=182
CHEMBL509,MECLOFENAMIC ACID,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.73; logP 4.74",repurposing_candidates.csv:rc_row=1350;protein_drug_candidates.csv:rows=147;928;pathway_drug_candidates.csv:rows=370;4488;5568;5628;5697;6081;6155;6229;6303;6377;6451;CYP3A4_results.csv:row=1161;CYP2C19_results.csv:row=1161;CYP2D6_results.csv:row=1161;CYP1A2_results.csv:row=1161;CYP2C9_results.csv:row=1161;hERG_results.csv:row=1161;AMES_results.csv:row=1161;PGP_results.csv:row=1161;PAMPA_results.csv:row=1161;BBB_results.csv:row=1161;Solubility_results.csv:row=1161;Lipophilicity_results.csv:row=1162
CHEMBL2108222,ALOXIPRIN,,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0",repurposing_candidates.csv:rc_row=746;protein_drug_candidates.csv:rows=138;919;pathway_drug_candidates.csv:rows=361;4479;5559;5619;5688;6072;6146;6220;6294;6368;6442;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1020,TOLMETIN,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.83; logP 2.19",repurposing_candidates.csv:rc_row=9;protein_drug_candidates.csv:rows=141;922;pathway_drug_candidates.csv:rows=364;4482;5562;5622;5691;6075;6149;6223;6297;6371;6445;CYP3A4_results.csv:row=9;CYP2C19_results.csv:row=9;CYP2D6_results.csv:row=9;CYP1A2_results.csv:row=9;CYP2C9_results.csv:row=9;hERG_results.csv:row=9;AMES_results.csv:row=9;PGP_results.csv:row=9;PAMPA_results.csv:row=9;BBB_results.csv:row=9;Solubility_results.csv:row=9;Lipophilicity_results.csv:row=9
CHEMBL1077,BROMFENAC,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.66; logP 2.89",repurposing_candidates.csv:rc_row=27;protein_drug_candidates.csv:rows=123;908;pathway_drug_candidates.csv:rows=346;4464;5548;5608;5673;6057;6131;6205;6279;6353;6427;CYP3A4_results.csv:row=27;CYP2C19_results.csv:row=27;CYP2D6_results.csv:row=27;CYP1A2_results.csv:row=27;CYP2C9_results.csv:row=27;hERG_results.csv:row=27;AMES_results.csv:row=27;PGP_results.csv:row=27;PAMPA_results.csv:row=27;BBB_results.csv:row=27;Solubility_results.csv:row=27;Lipophilicity_results.csv:row=27
CHEMBL1297,FENOPROFEN,CC(C(=O)O)c1cccc(Oc2ccccc2)c1,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -4.00; logP 3.67",repurposing_candidates.csv:rc_row=377;protein_drug_candidates.csv:rows=130;923;pathway_drug_candidates.csv:rows=353;4471;5563;5623;5680;6064;6138;6212;6286;6360;6434;CYP3A4_results.csv:row=338;CYP2C19_results.csv:row=338;CYP2D6_results.csv:row=338;CYP1A2_results.csv:row=338;CYP2C9_results.csv:row=338;hERG_results.csv:row=338;AMES_results.csv:row=338;PGP_results.csv:row=338;PAMPA_results.csv:row=338;BBB_results.csv:row=338;Solubility_results.csv:row=338;Lipophilicity_results.csv:row=339
CHEMBL469,KETOROLAC,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,34.53852021357742,100,100.0,73.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 4.0; logS -3.13; logP 2.29",repurposing_candidates.csv:rc_row=1324;protein_drug_candidates.csv:rows=125;909;pathway_drug_candidates.csv:rows=348;4466;5549;5609;5675;6059;6133;6207;6281;6355;6429;CYP3A4_results.csv:row=1135;CYP2C19_results.csv:row=1135;CYP2D6_results.csv:row=1135;CYP1A2_results.csv:row=1135;CYP2C9_results.csv:row=1135;hERG_results.csv:row=1135;AMES_results.csv:row=1135;PGP_results.csv:row=1135;PAMPA_results.csv:row=1135;BBB_results.csv:row=1135;Solubility_results.csv:row=1135;Lipophilicity_results.csv:row=1136
CHEMBL511115,CILOMILAST,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1,51.79633867276888,80,100.0,73.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 3.0; logS -3.49; logP 4.05",repurposing_candidates.csv:rc_row=1356;protein_drug_candidates.csv:rows=420;1053;1080;2159;pathway_drug_candidates.csv:rows=4331;5742;5770;5797;5837;5864;CYP3A4_results.csv:row=1167;CYP2C19_results.csv:row=1167;CYP2D6_results.csv:row=1167;CYP1A2_results.csv:row=1167;CYP2C9_results.csv:row=1167;hERG_results.csv:row=1167;AMES_results.csv:row=1167;PGP_results.csv:row=1167;PAMPA_results.csv:row=1167;BBB_results.csv:row=1167;Solubility_results.csv:row=1167;Lipophilicity_results.csv:row=1168
CHEMBL332750,TETOMILAST,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,51.79633867276888,80,100.0,73.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 3.0; logS -4.16; logP 4.37",repurposing_candidates.csv:rc_row=946;protein_drug_candidates.csv:rows=422;1055;1083;2160;pathway_drug_candidates.csv:rows=4334;5744;5772;5800;5839;5867;CYP3A4_results.csv:row=850;CYP2C19_results.csv:row=850;CYP2D6_results.csv:row=850;CYP1A2_results.csv:row=850;CYP2C9_results.csv:row=850;hERG_results.csv:row=850;AMES_results.csv:row=850;PGP_results.csv:row=850;PAMPA_results.csv:row=850;BBB_results.csv:row=850;Solubility_results.csv:row=850;Lipophilicity_results.csv:row=851
CHEMBL551978,DROTAVERINE,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC,51.79633867276888,80,100.0,73.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 3.0; logS -5.06; logP 4.93",repurposing_candidates.csv:rc_row=1408;protein_drug_candidates.csv:rows=424;1057;1084;2161;pathway_drug_candidates.csv:rows=4335;5746;5774;5801;5841;5868;CYP3A4_results.csv:row=1217;CYP2C19_results.csv:row=1217;CYP2D6_results.csv:row=1217;CYP1A2_results.csv:row=1217;CYP2C9_results.csv:row=1217;hERG_results.csv:row=1217;AMES_results.csv:row=1217;PGP_results.csv:row=1217;PAMPA_results.csv:row=1217;BBB_results.csv:row=1217;Solubility_results.csv:row=1217;Lipophilicity_results.csv:row=1218
CHEMBL4594287,ENSIFENTRINE,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2,51.79633867276888,80,100.0,73.71853546910755,H,"KG targets PDE4A, PDE4B; clinical phase 3.0; logS -3.26; logP 2.72",repurposing_candidates.csv:rc_row=1288;protein_drug_candidates.csv:rows=419;1054;1082;2158;pathway_drug_candidates.csv:rows=4333;5741;5771;5799;5836;5866;CYP3A4_results.csv:row=1108;CYP2C19_results.csv:row=1108;CYP2D6_results.csv:row=1108;CYP1A2_results.csv:row=1108;CYP2C9_results.csv:row=1108;hERG_results.csv:row=1108;AMES_results.csv:row=1108;PGP_results.csv:row=1108;PAMPA_results.csv:row=1108;BBB_results.csv:row=1108;Solubility_results.csv:row=1108;Lipophilicity_results.csv:row=1109
CHEMBL1642,IMATINIB MESYLATE,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,33.989321128909225,100,100.0,73.59572845156369,H,"KG targets ABL1, BCR; clinical phase 4.0; logS 1.52; logP 4.09",repurposing_candidates.csv:rc_row=490;protein_drug_candidates.csv:rows=1099;1142;1201;2200;pathway_drug_candidates.csv:rows=547;4292;6959;6997;7493;CYP3A4_results.csv:row=450;CYP2C19_results.csv:row=450;CYP2D6_results.csv:row=450;CYP1A2_results.csv:row=450;CYP2C9_results.csv:row=450;hERG_results.csv:row=450;AMES_results.csv:row=450;PGP_results.csv:row=450;PAMPA_results.csv:row=450;BBB_results.csv:row=450;Solubility_results.csv:row=450;Lipophilicity_results.csv:row=451
CHEMBL1282,IMIQUIMOD,CC(C)Cn1cnc2c(N)nc3ccccc3c21,33.760488176964145,100,100.0,73.50419527078566,H,KG targets TLR7; clinical phase 4.0; logS -2.76; logP 2.82,repurposing_candidates.csv:rc_row=373;protein_drug_candidates.csv:rows=600;pathway_drug_candidates.csv:rows=760;4256;7322;7344;7355;7366;7377;7399;7421;7443;7454;CYP3A4_results.csv:row=334;CYP2C19_results.csv:row=334;CYP2D6_results.csv:row=334;CYP1A2_results.csv:row=334;CYP2C9_results.csv:row=334;hERG_results.csv:row=334;AMES_results.csv:row=334;PGP_results.csv:row=334;PAMPA_results.csv:row=334;BBB_results.csv:row=334;Solubility_results.csv:row=334;Lipophilicity_results.csv:row=335
CHEMBL17860,LOFEXIDINE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.81; logP 2.76",repurposing_candidates.csv:rc_row=572;protein_drug_candidates.csv:rows=1331;1375;2521;pathway_drug_candidates.csv:rows=902;946;1006;1050;1110;1162;1206;1394;1438;1498;CYP3A4_results.csv:row=518;CYP2C19_results.csv:row=518;CYP2D6_results.csv:row=518;CYP1A2_results.csv:row=518;CYP2C9_results.csv:row=518;hERG_results.csv:row=518;AMES_results.csv:row=518;PGP_results.csv:row=518;PAMPA_results.csv:row=518;BBB_results.csv:row=518;Solubility_results.csv:row=518;Lipophilicity_results.csv:row=519
CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.18; logP 3.18",repurposing_candidates.csv:rc_row=574;protein_drug_candidates.csv:rows=1333;1384;2527;pathway_drug_candidates.csv:rows=904;955;1008;1059;1112;1164;1215;1396;1447;1500;CYP3A4_results.csv:row=520;CYP2C19_results.csv:row=520;CYP2D6_results.csv:row=520;CYP1A2_results.csv:row=520;CYP2C9_results.csv:row=520;hERG_results.csv:row=520;AMES_results.csv:row=520;PGP_results.csv:row=520;PAMPA_results.csv:row=520;BBB_results.csv:row=520;Solubility_results.csv:row=520;Lipophilicity_results.csv:row=521
CHEMBL27810,CELIPROLOL,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.08; logP 2.89",repurposing_candidates.csv:rc_row=874;protein_drug_candidates.csv:rows=1302;1353;2502;pathway_drug_candidates.csv:rows=873;924;977;1028;1081;1133;1184;1365;1416;1469;CYP3A4_results.csv:row=782;CYP2C19_results.csv:row=782;CYP2D6_results.csv:row=782;CYP1A2_results.csv:row=782;CYP2C9_results.csv:row=782;hERG_results.csv:row=782;AMES_results.csv:row=782;PGP_results.csv:row=782;PAMPA_results.csv:row=782;BBB_results.csv:row=782;Solubility_results.csv:row=782;Lipophilicity_results.csv:row=783
CHEMBL647,APRACLONIDINE,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.34; logP 1.76",repurposing_candidates.csv:rc_row=1470;protein_drug_candidates.csv:rows=1337;1390;2536;pathway_drug_candidates.csv:rows=908;961;1012;1065;1116;1168;1221;1400;1453;1504;CYP3A4_results.csv:row=1276;CYP2C19_results.csv:row=1276;CYP2D6_results.csv:row=1276;CYP1A2_results.csv:row=1276;CYP2C9_results.csv:row=1276;hERG_results.csv:row=1276;AMES_results.csv:row=1276;PGP_results.csv:row=1276;PAMPA_results.csv:row=1276;BBB_results.csv:row=1276;Solubility_results.csv:row=1276;Lipophilicity_results.csv:row=1277
CHEMBL459,METHYLDOPA,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -0.91; logP 0.44",repurposing_candidates.csv:rc_row=1282;protein_drug_candidates.csv:rows=1320;1372;2519;pathway_drug_candidates.csv:rows=891;943;995;1047;1099;1151;1203;1383;1435;1487;CYP3A4_results.csv:row=1102;CYP2C19_results.csv:row=1102;CYP2D6_results.csv:row=1102;CYP1A2_results.csv:row=1102;CYP2C9_results.csv:row=1102;hERG_results.csv:row=1102;AMES_results.csv:row=1102;PGP_results.csv:row=1102;PAMPA_results.csv:row=1102;BBB_results.csv:row=1102;Solubility_results.csv:row=1102;Lipophilicity_results.csv:row=1103
CHEMBL1200494,GUANFACINE HYDROCHLORIDE,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.35; logP 1.97",repurposing_candidates.csv:rc_row=113;protein_drug_candidates.csv:rows=1314;1367;2516;pathway_drug_candidates.csv:rows=885;938;989;1042;1093;1145;1198;1377;1430;1481;CYP3A4_results.csv:row=112;CYP2C19_results.csv:row=112;CYP2D6_results.csv:row=112;CYP1A2_results.csv:row=112;CYP2C9_results.csv:row=112;hERG_results.csv:row=112;AMES_results.csv:row=112;PGP_results.csv:row=112;PAMPA_results.csv:row=112;BBB_results.csv:row=112;Solubility_results.csv:row=112;Lipophilicity_results.csv:row=112
CHEMBL1705,CLONIDINE HYDROCHLORIDE,Cl.Clc1cccc(Cl)c1NC1=NCCN1,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -2.55; logP 2.79",repurposing_candidates.csv:rc_row=519;protein_drug_candidates.csv:rows=1317;1369;2515;pathway_drug_candidates.csv:rows=888;940;992;1044;1096;1148;1200;1380;1432;1484;CYP3A4_results.csv:row=479;CYP2C19_results.csv:row=479;CYP2D6_results.csv:row=479;CYP1A2_results.csv:row=479;CYP2C9_results.csv:row=479;hERG_results.csv:row=479;AMES_results.csv:row=479;PGP_results.csv:row=479;PAMPA_results.csv:row=479;BBB_results.csv:row=479;Solubility_results.csv:row=479;Lipophilicity_results.csv:row=480
CHEMBL134,CLONIDINE,Clc1cccc(Cl)c1NC1=NCCN1,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -3.17; logP 2.36",repurposing_candidates.csv:rc_row=387;protein_drug_candidates.csv:rows=1315;1368;2513;pathway_drug_candidates.csv:rows=886;939;990;1043;1094;1146;1199;1378;1431;1482;CYP3A4_results.csv:row=348;CYP2C19_results.csv:row=348;CYP2D6_results.csv:row=348;CYP1A2_results.csv:row=348;CYP2C9_results.csv:row=348;hERG_results.csv:row=348;AMES_results.csv:row=348;PGP_results.csv:row=348;PAMPA_results.csv:row=348;BBB_results.csv:row=348;Solubility_results.csv:row=348;Lipophilicity_results.csv:row=349
CHEMBL862,GUANFACINE,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,33.737604881769634,100,100.0,73.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; logS -3.11; logP 1.55",repurposing_candidates.csv:rc_row=1538;protein_drug_candidates.csv:rows=1313;1365;2512;pathway_drug_candidates.csv:rows=884;936;988;1040;1092;1144;1196;1376;1428;1480;CYP3A4_results.csv:row=1344;CYP2C19_results.csv:row=1344;CYP2D6_results.csv:row=1344;CYP1A2_results.csv:row=1344;CYP2C9_results.csv:row=1344;hERG_results.csv:row=1344;AMES_results.csv:row=1344;PGP_results.csv:row=1344;PAMPA_results.csv:row=1344;BBB_results.csv:row=1344;Solubility_results.csv:row=1344;Lipophilicity_results.csv:row=1345
CHEMBL644,TRIMIPRAMINE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,33.46300533943554,100,100.0,73.38520213577422,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.40; logP 4.12",repurposing_candidates.csv:rc_row=1468;protein_drug_candidates.csv:rows=395;991;1495;1853;pathway_drug_candidates.csv:rows=858;6520;6621;6720;CYP3A4_results.csv:row=1274;CYP2C19_results.csv:row=1274;CYP2D6_results.csv:row=1274;CYP1A2_results.csv:row=1274;CYP2C9_results.csv:row=1274;hERG_results.csv:row=1274;AMES_results.csv:row=1274;PGP_results.csv:row=1274;PAMPA_results.csv:row=1274;BBB_results.csv:row=1274;Solubility_results.csv:row=1274;Lipophilicity_results.csv:row=1275
CHEMBL1201174,SITAGLIPTIN PHOSPHATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -1.51; logP 0.26,repurposing_candidates.csv:rc_row=250;protein_drug_candidates.csv:rows=660;CYP3A4_results.csv:row=247;CYP2C19_results.csv:row=247;CYP2D6_results.csv:row=247;CYP1A2_results.csv:row=247;CYP2C9_results.csv:row=247;hERG_results.csv:row=247;AMES_results.csv:row=247;PGP_results.csv:row=247;PAMPA_results.csv:row=247;BBB_results.csv:row=247;Solubility_results.csv:row=247;Lipophilicity_results.csv:row=248
CHEMBL237500,LINAGLIPTIN,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -3.34; logP 1.15,repurposing_candidates.csv:rc_row=845;protein_drug_candidates.csv:rows=659;CYP3A4_results.csv:row=753;CYP2C19_results.csv:row=753;CYP2D6_results.csv:row=753;CYP1A2_results.csv:row=753;CYP2C9_results.csv:row=753;hERG_results.csv:row=753;AMES_results.csv:row=753;PGP_results.csv:row=753;PAMPA_results.csv:row=753;BBB_results.csv:row=753;Solubility_results.csv:row=753;Lipophilicity_results.csv:row=754
CHEMBL227529,ALOGLIPTIN BENZOATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -2.11; logP 1.78,repurposing_candidates.csv:rc_row=821;protein_drug_candidates.csv:rows=662;CYP3A4_results.csv:row=730;CYP2C19_results.csv:row=730;CYP2D6_results.csv:row=730;CYP1A2_results.csv:row=730;CYP2C9_results.csv:row=730;hERG_results.csv:row=730;AMES_results.csv:row=730;PGP_results.csv:row=730;PAMPA_results.csv:row=730;BBB_results.csv:row=730;Solubility_results.csv:row=730;Lipophilicity_results.csv:row=731
CHEMBL142703,VILDAGLIPTIN,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -1.98; logP 1.17,repurposing_candidates.csv:rc_row=411;protein_drug_candidates.csv:rows=658;CYP3A4_results.csv:row=371;CYP2C19_results.csv:row=371;CYP2D6_results.csv:row=371;CYP1A2_results.csv:row=371;CYP2C9_results.csv:row=371;hERG_results.csv:row=371;AMES_results.csv:row=371;PGP_results.csv:row=371;PAMPA_results.csv:row=371;BBB_results.csv:row=371;Solubility_results.csv:row=371;Lipophilicity_results.csv:row=372
CHEMBL5315049,SITAGLIPTIN FUMARATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -0.74; logP 1.73,repurposing_candidates.csv:rc_row=1389;protein_drug_candidates.csv:rows=663;CYP3A4_results.csv:row=1199;CYP2C19_results.csv:row=1199;CYP2D6_results.csv:row=1199;CYP1A2_results.csv:row=1199;CYP2C9_results.csv:row=1199;hERG_results.csv:row=1199;AMES_results.csv:row=1199;PGP_results.csv:row=1199;PAMPA_results.csv:row=1199;BBB_results.csv:row=1199;Solubility_results.csv:row=1199;Lipophilicity_results.csv:row=1200
CHEMBL1201743,SAXAGLIPTIN HYDROCHLORIDE,Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,32.971014492753625,100,100.0,73.18840579710145,H,KG targets DPP4; clinical phase 4.0; logS -0.95; logP 1.58,repurposing_candidates.csv:rc_row=305;protein_drug_candidates.csv:rows=661;CYP3A4_results.csv:row=274;CYP2C19_results.csv:row=274;CYP2D6_results.csv:row=274;CYP1A2_results.csv:row=274;CYP2C9_results.csv:row=274;hERG_results.csv:row=274;AMES_results.csv:row=274;PGP_results.csv:row=274;PAMPA_results.csv:row=274;BBB_results.csv:row=274;Solubility_results.csv:row=274;Lipophilicity_results.csv:row=275
CHEMBL3707311,VAMOROLONE,,32.707856598016775,100,100.0,73.08314263920671,H,KG targets NR3C1; clinical phase 4.0,repurposing_candidates.csv:rc_row=1019;protein_drug_candidates.csv:rows=48;pathway_drug_candidates.csv:rows=740;2049;5964;7868;8005;8071;8142;8208;8274;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL93645,ACECLOFENAC,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,32.707856598016775,100,100.0,73.08314263920671,H,KG targets PTGS2; clinical phase 4.0; logS -3.30; logP 3.91,repurposing_candidates.csv:rc_row=1557;protein_drug_candidates.csv:rows=117;pathway_drug_candidates.csv:rows=340;4458;5667;6051;6125;6199;6273;6347;6421;CYP3A4_results.csv:row=1363;CYP2C19_results.csv:row=1363;CYP2D6_results.csv:row=1363;CYP1A2_results.csv:row=1363;CYP2C9_results.csv:row=1363;hERG_results.csv:row=1363;AMES_results.csv:row=1363;PGP_results.csv:row=1363;PAMPA_results.csv:row=1363;BBB_results.csv:row=1363;Solubility_results.csv:row=1363;Lipophilicity_results.csv:row=1364
CHEMBL122,ROFECOXIB,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,32.707856598016775,100,100.0,73.08314263920671,H,KG targets PTGS2; clinical phase 4.0; logS -4.92; logP 2.56,repurposing_candidates.csv:rc_row=335;protein_drug_candidates.csv:rows=128;pathway_drug_candidates.csv:rows=351;4469;5678;6062;6136;6210;6284;6358;6432;CYP3A4_results.csv:row=298;CYP2C19_results.csv:row=298;CYP2D6_results.csv:row=298;CYP1A2_results.csv:row=298;CYP2C9_results.csv:row=298;hERG_results.csv:row=298;AMES_results.csv:row=298;PGP_results.csv:row=298;PAMPA_results.csv:row=298;BBB_results.csv:row=298;Solubility_results.csv:row=298;Lipophilicity_results.csv:row=299
CHEMBL622,ETODOLAC,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,32.707856598016775,100,100.0,73.08314263920671,H,KG targets PTGS2; clinical phase 4.0; logS -3.18; logP 3.38,repurposing_candidates.csv:rc_row=1457;protein_drug_candidates.csv:rows=115;pathway_drug_candidates.csv:rows=338;4456;5665;6049;6123;6197;6271;6345;6419;CYP3A4_results.csv:row=1264;CYP2C19_results.csv:row=1264;CYP2D6_results.csv:row=1264;CYP1A2_results.csv:row=1264;CYP2C9_results.csv:row=1264;hERG_results.csv:row=1264;AMES_results.csv:row=1264;PGP_results.csv:row=1264;PAMPA_results.csv:row=1264;BBB_results.csv:row=1264;Solubility_results.csv:row=1264;Lipophilicity_results.csv:row=1265
CHEMBL296913,PARECOXIB SODIUM,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+],32.707856598016775,100,100.0,73.08314263920671,H,KG targets PTGS2; clinical phase 4.0; logS -3.20; logP 1.32,repurposing_candidates.csv:rc_row=886;protein_drug_candidates.csv:rows=139;pathway_drug_candidates.csv:rows=362;4480;5689;6073;6147;6221;6295;6369;6443;CYP3A4_results.csv:row=794;CYP2C19_results.csv:row=794;CYP2D6_results.csv:row=794;CYP1A2_results.csv:row=794;CYP2C9_results.csv:row=794;hERG_results.csv:row=794;AMES_results.csv:row=794;PGP_results.csv:row=794;PAMPA_results.csv:row=794;BBB_results.csv:row=794;Solubility_results.csv:row=794;Lipophilicity_results.csv:row=795
CHEMBL404108,LUMIRACOXIB,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,32.707856598016775,100,100.0,73.08314263920671,H,KG targets PTGS2; clinical phase 4.0; logS -2.84; logP 4.16,repurposing_candidates.csv:rc_row=1117;protein_drug_candidates.csv:rows=146;pathway_drug_candidates.csv:rows=369;4487;5696;6080;6154;6228;6302;6376;6450;CYP3A4_results.csv:row=981;CYP2C19_results.csv:row=981;CYP2D6_results.csv:row=981;CYP1A2_results.csv:row=981;CYP2C9_results.csv:row=981;hERG_results.csv:row=981;AMES_results.csv:row=981;PGP_results.csv:row=981;PAMPA_results.csv:row=981;BBB_results.csv:row=981;Solubility_results.csv:row=981;Lipophilicity_results.csv:row=982
CHEMBL1504,TRIAMCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -4.09; logP 2.42,repurposing_candidates.csv:rc_row=438;protein_drug_candidates.csv:rows=15;pathway_drug_candidates.csv:rows=707;2016;5931;7835;7972;8038;8109;8175;8241;CYP3A4_results.csv:row=398;CYP2C19_results.csv:row=398;CYP2D6_results.csv:row=398;CYP1A2_results.csv:row=398;CYP2C9_results.csv:row=398;hERG_results.csv:row=398;AMES_results.csv:row=398;PGP_results.csv:row=398;PAMPA_results.csv:row=398;BBB_results.csv:row=398;Solubility_results.csv:row=398;Lipophilicity_results.csv:row=399
CHEMBL1766,DESOXIMETASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.73; logP 2.78,repurposing_candidates.csv:rc_row=563;protein_drug_candidates.csv:rows=18;pathway_drug_candidates.csv:rows=710;2019;5934;7838;7975;8041;8112;8178;8244;CYP3A4_results.csv:row=509;CYP2C19_results.csv:row=509;CYP2D6_results.csv:row=509;CYP1A2_results.csv:row=509;CYP2C9_results.csv:row=509;hERG_results.csv:row=509;AMES_results.csv:row=509;PGP_results.csv:row=509;PAMPA_results.csv:row=509;BBB_results.csv:row=509;Solubility_results.csv:row=509;Lipophilicity_results.csv:row=510
CHEMBL632,BETAMETHASONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -4.08; logP 1.90,repurposing_candidates.csv:rc_row=1463;protein_drug_candidates.csv:rows=38;pathway_drug_candidates.csv:rows=730;2039;5954;7858;7995;8061;8132;8198;8264;CYP3A4_results.csv:row=1269;CYP2C19_results.csv:row=1269;CYP2D6_results.csv:row=1269;CYP1A2_results.csv:row=1269;CYP2C9_results.csv:row=1269;hERG_results.csv:row=1269;AMES_results.csv:row=1269;PGP_results.csv:row=1269;PAMPA_results.csv:row=1269;BBB_results.csv:row=1269;Solubility_results.csv:row=1269;Lipophilicity_results.csv:row=1270
CHEMBL1200865,LOTEPREDNOL ETABONATE,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -5.01; logP 3.92,repurposing_candidates.csv:rc_row=182;protein_drug_candidates.csv:rows=39;pathway_drug_candidates.csv:rows=731;2040;5955;7859;7996;8062;8133;8199;8265;CYP3A4_results.csv:row=180;CYP2C19_results.csv:row=180;CYP2D6_results.csv:row=180;CYP1A2_results.csv:row=180;CYP2C9_results.csv:row=180;hERG_results.csv:row=180;AMES_results.csv:row=180;PGP_results.csv:row=180;PAMPA_results.csv:row=180;BBB_results.csv:row=180;Solubility_results.csv:row=180;Lipophilicity_results.csv:row=181
CHEMBL989,FLUOCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -5.34; logP 2.37,repurposing_candidates.csv:rc_row=1579;protein_drug_candidates.csv:rows=13;pathway_drug_candidates.csv:rows=705;2014;5929;7833;7970;8036;8107;8173;8239;CYP3A4_results.csv:row=1385;CYP2C19_results.csv:row=1385;CYP2D6_results.csv:row=1385;CYP1A2_results.csv:row=1385;CYP2C9_results.csv:row=1385;hERG_results.csv:row=1385;AMES_results.csv:row=1385;PGP_results.csv:row=1385;PAMPA_results.csv:row=1385;BBB_results.csv:row=1385;Solubility_results.csv:row=1385;Lipophilicity_results.csv:row=1386
CHEMBL131,PREDNISOLONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.32; logP 1.56,repurposing_candidates.csv:rc_row=380;protein_drug_candidates.csv:rows=1;pathway_drug_candidates.csv:rows=693;2002;5917;7821;7958;8024;8095;8161;8227;CYP3A4_results.csv:row=341;CYP2C19_results.csv:row=341;CYP2D6_results.csv:row=341;CYP1A2_results.csv:row=341;CYP2C9_results.csv:row=341;hERG_results.csv:row=341;AMES_results.csv:row=341;PGP_results.csv:row=341;PAMPA_results.csv:row=341;BBB_results.csv:row=341;Solubility_results.csv:row=341;Lipophilicity_results.csv:row=342
CHEMBL1370,BUDESONIDE,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -4.12; logP 2.72,repurposing_candidates.csv:rc_row=396;protein_drug_candidates.csv:rows=9;pathway_drug_candidates.csv:rows=701;2010;5925;7829;7966;8032;8103;8169;8235;CYP3A4_results.csv:row=356;CYP2C19_results.csv:row=356;CYP2D6_results.csv:row=356;CYP1A2_results.csv:row=356;CYP2C9_results.csv:row=356;hERG_results.csv:row=356;AMES_results.csv:row=356;PGP_results.csv:row=356;PAMPA_results.csv:row=356;BBB_results.csv:row=356;Solubility_results.csv:row=356;Lipophilicity_results.csv:row=357
CHEMBL384467,DEXAMETHASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -4.08; logP 1.90,repurposing_candidates.csv:rc_row=1051;protein_drug_candidates.csv:rows=12;pathway_drug_candidates.csv:rows=704;2013;5928;7832;7969;8035;8106;8172;8238;CYP3A4_results.csv:row=920;CYP2C19_results.csv:row=920;CYP2D6_results.csv:row=920;CYP1A2_results.csv:row=920;CYP2C9_results.csv:row=920;hERG_results.csv:row=920;AMES_results.csv:row=920;PGP_results.csv:row=920;PAMPA_results.csv:row=920;BBB_results.csv:row=920;Solubility_results.csv:row=920;Lipophilicity_results.csv:row=921
CHEMBL1201012,FLURANDRENOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.62; logP 2.50,repurposing_candidates.csv:rc_row=217;protein_drug_candidates.csv:rows=30;pathway_drug_candidates.csv:rows=722;2031;5946;7850;7987;8053;8124;8190;8256;CYP3A4_results.csv:row=215;CYP2C19_results.csv:row=215;CYP2D6_results.csv:row=215;CYP1A2_results.csv:row=215;CYP2C9_results.csv:row=215;hERG_results.csv:row=215;AMES_results.csv:row=215;PGP_results.csv:row=215;PAMPA_results.csv:row=215;BBB_results.csv:row=215;Solubility_results.csv:row=215;Lipophilicity_results.csv:row=216
CHEMBL1201109,DESONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.36; logP 2.33,repurposing_candidates.csv:rc_row=236;protein_drug_candidates.csv:rows=0;pathway_drug_candidates.csv:rows=692;2001;5916;7820;7957;8023;8094;8160;8226;CYP3A4_results.csv:row=233;CYP2C19_results.csv:row=233;CYP2D6_results.csv:row=233;CYP1A2_results.csv:row=233;CYP2C9_results.csv:row=233;hERG_results.csv:row=233;AMES_results.csv:row=233;PGP_results.csv:row=233;PAMPA_results.csv:row=233;BBB_results.csv:row=233;Solubility_results.csv:row=233;Lipophilicity_results.csv:row=234
CHEMBL1200600,FLUOROMETHOLONE,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -4.77; logP 2.92,repurposing_candidates.csv:rc_row=132;protein_drug_candidates.csv:rows=35;pathway_drug_candidates.csv:rows=727;2036;5951;7855;7992;8058;8129;8195;8261;CYP3A4_results.csv:row=131;CYP2C19_results.csv:row=131;CYP2D6_results.csv:row=131;CYP1A2_results.csv:row=131;CYP2C9_results.csv:row=131;hERG_results.csv:row=131;AMES_results.csv:row=131;PGP_results.csv:row=131;PAMPA_results.csv:row=131;BBB_results.csv:row=131;Solubility_results.csv:row=131;Lipophilicity_results.csv:row=131
CHEMBL1200617,RIMEXOLONE,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.90; logP 4.50,repurposing_candidates.csv:rc_row=135;protein_drug_candidates.csv:rows=36;pathway_drug_candidates.csv:rows=728;2037;5952;7856;7993;8059;8130;8196;8262;CYP3A4_results.csv:row=134;CYP2C19_results.csv:row=134;CYP2D6_results.csv:row=134;CYP1A2_results.csv:row=134;CYP2C9_results.csv:row=134;hERG_results.csv:row=134;AMES_results.csv:row=134;PGP_results.csv:row=134;PAMPA_results.csv:row=134;BBB_results.csv:row=134;Solubility_results.csv:row=134;Lipophilicity_results.csv:row=134
CHEMBL1451,TRIAMCINOLONE,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.49; logP 0.62,repurposing_candidates.csv:rc_row=422;protein_drug_candidates.csv:rows=31;pathway_drug_candidates.csv:rows=723;2032;5947;7851;7988;8054;8125;8191;8257;CYP3A4_results.csv:row=382;CYP2C19_results.csv:row=382;CYP2D6_results.csv:row=382;CYP1A2_results.csv:row=382;CYP2C9_results.csv:row=382;hERG_results.csv:row=382;AMES_results.csv:row=382;PGP_results.csv:row=382;PAMPA_results.csv:row=382;BBB_results.csv:row=382;Solubility_results.csv:row=382;Lipophilicity_results.csv:row=383
CHEMBL1512,FLUNISOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.73; logP 2.27,repurposing_candidates.csv:rc_row=441;protein_drug_candidates.csv:rows=44;pathway_drug_candidates.csv:rows=736;2045;5960;7864;8001;8067;8138;8204;8270;CYP3A4_results.csv:row=401;CYP2C19_results.csv:row=401;CYP2D6_results.csv:row=401;CYP1A2_results.csv:row=401;CYP2C9_results.csv:row=401;hERG_results.csv:row=401;AMES_results.csv:row=401;PGP_results.csv:row=401;PAMPA_results.csv:row=401;BBB_results.csv:row=401;Solubility_results.csv:row=401;Lipophilicity_results.csv:row=402
CHEMBL389621,HYDROCORTISONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,51.04118993135011,100,70.0,72.91647597254004,H,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.40; logP 1.78,repurposing_candidates.csv:rc_row=1055;protein_drug_candidates.csv:rows=5;pathway_drug_candidates.csv:rows=697;2006;5921;7825;7962;8028;8099;8165;8231;CYP3A4_results.csv:row=924;CYP2C19_results.csv:row=924;CYP2D6_results.csv:row=924;CYP1A2_results.csv:row=924;CYP2C9_results.csv:row=924;hERG_results.csv:row=924;AMES_results.csv:row=924;PGP_results.csv:row=924;PAMPA_results.csv:row=924;BBB_results.csv:row=924;Solubility_results.csv:row=924;Lipophilicity_results.csv:row=925
CHEMBL1042,CHOLECALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12,47.88329519450801,100,75.0,72.9033180778032,H,KG targets VDR; clinical phase 4.0; logS -6.01; logP 7.62,repurposing_candidates.csv:rc_row=15;protein_drug_candidates.csv:rows=240;pathway_drug_candidates.csv:rows=5993;7770;7888;CYP3A4_results.csv:row=15;CYP2C19_results.csv:row=15;CYP2D6_results.csv:row=15;CYP1A2_results.csv:row=15;CYP2C9_results.csv:row=15;hERG_results.csv:row=15;AMES_results.csv:row=15;PGP_results.csv:row=15;PAMPA_results.csv:row=15;BBB_results.csv:row=15;Solubility_results.csv:row=15;Lipophilicity_results.csv:row=15
CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,52.87185354691076,80,95.0,72.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; logS -2.68; logP 3.84",repurposing_candidates.csv:rc_row=451;protein_drug_candidates.csv:rows=159;937;pathway_drug_candidates.csv:rows=382;4500;5577;5637;5709;6093;6167;6241;6315;6389;6463;CYP3A4_results.csv:row=411;CYP2C19_results.csv:row=411;CYP2D6_results.csv:row=411;CYP1A2_results.csv:row=411;CYP2C9_results.csv:row=411;hERG_results.csv:row=411;AMES_results.csv:row=411;PGP_results.csv:row=411;PAMPA_results.csv:row=411;BBB_results.csv:row=411;Solubility_results.csv:row=411;Lipophilicity_results.csv:row=412
CHEMBL3989408,IBUPROFEN SODIUM,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+],52.87185354691076,80,95.0,72.8987414187643,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; logS -3.68; logP -2.91",repurposing_candidates.csv:rc_row=1068;protein_drug_candidates.csv:rows=154;934;pathway_drug_candidates.csv:rows=377;4495;5574;5634;5704;6088;6162;6236;6310;6384;6458;CYP3A4_results.csv:row=937;CYP2C19_results.csv:row=937;CYP2D6_results.csv:row=937;CYP1A2_results.csv:row=937;CYP2C9_results.csv:row=937;hERG_results.csv:row=937;AMES_results.csv:row=937;PGP_results.csv:row=937;PAMPA_results.csv:row=937;BBB_results.csv:row=937;Solubility_results.csv:row=937;Lipophilicity_results.csv:row=938
CHEMBL1201319,METARAMINOL,C[C@H](N)[C@H](O)c1cccc(O)c1,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.07; logP 0.77",repurposing_candidates.csv:rc_row=271;protein_drug_candidates.csv:rows=351;1468;1828;pathway_drug_candidates.csv:rows=814;6476;6676;CYP3A4_results.csv:row=268;CYP2C19_results.csv:row=268;CYP2D6_results.csv:row=268;CYP1A2_results.csv:row=268;CYP2C9_results.csv:row=268;hERG_results.csv:row=268;AMES_results.csv:row=268;PGP_results.csv:row=268;PAMPA_results.csv:row=268;BBB_results.csv:row=268;Solubility_results.csv:row=268;Lipophilicity_results.csv:row=269
CHEMBL707,DOXAZOSIN,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.35; logP 1.72",repurposing_candidates.csv:rc_row=1495;protein_drug_candidates.csv:rows=376;1480;1839;pathway_drug_candidates.csv:rows=839;6501;6701;CYP3A4_results.csv:row=1301;CYP2C19_results.csv:row=1301;CYP2D6_results.csv:row=1301;CYP1A2_results.csv:row=1301;CYP2C9_results.csv:row=1301;hERG_results.csv:row=1301;AMES_results.csv:row=1301;PGP_results.csv:row=1301;PAMPA_results.csv:row=1301;BBB_results.csv:row=1301;Solubility_results.csv:row=1301;Lipophilicity_results.csv:row=1302
CHEMBL611,TERAZOSIN,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.09; logP 1.06",repurposing_candidates.csv:rc_row=1454;protein_drug_candidates.csv:rows=347;1453;1824;pathway_drug_candidates.csv:rows=810;6472;6672;CYP3A4_results.csv:row=1261;CYP2C19_results.csv:row=1261;CYP2D6_results.csv:row=1261;CYP1A2_results.csv:row=1261;CYP2C9_results.csv:row=1261;hERG_results.csv:row=1261;AMES_results.csv:row=1261;PGP_results.csv:row=1261;PAMPA_results.csv:row=1261;BBB_results.csv:row=1261;Solubility_results.csv:row=1261;Lipophilicity_results.csv:row=1262
CHEMBL709,ALFUZOSIN,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.61; logP 1.35",repurposing_candidates.csv:rc_row=1496;protein_drug_candidates.csv:rows=362;1454;1825;pathway_drug_candidates.csv:rows=825;6487;6687;CYP3A4_results.csv:row=1302;CYP2C19_results.csv:row=1302;CYP2D6_results.csv:row=1302;CYP1A2_results.csv:row=1302;CYP2C9_results.csv:row=1302;hERG_results.csv:row=1302;AMES_results.csv:row=1302;PGP_results.csv:row=1302;PAMPA_results.csv:row=1302;BBB_results.csv:row=1302;Solubility_results.csv:row=1302;Lipophilicity_results.csv:row=1303
CHEMBL2,PRAZOSIN,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.77; logP 1.78",repurposing_candidates.csv:rc_row=620;protein_drug_candidates.csv:rows=374;1478;1836;pathway_drug_candidates.csv:rows=837;6499;6699;CYP3A4_results.csv:row=566;CYP2C19_results.csv:row=566;CYP2D6_results.csv:row=566;CYP1A2_results.csv:row=566;CYP2C9_results.csv:row=566;hERG_results.csv:row=566;AMES_results.csv:row=566;PGP_results.csv:row=566;PAMPA_results.csv:row=566;BBB_results.csv:row=566;Solubility_results.csv:row=566;Lipophilicity_results.csv:row=567
CHEMBL1558,PRAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.09; logP 2.21",repurposing_candidates.csv:rc_row=457;protein_drug_candidates.csv:rows=371;1475;1834;pathway_drug_candidates.csv:rows=834;6496;6696;CYP3A4_results.csv:row=417;CYP2C19_results.csv:row=417;CYP2D6_results.csv:row=417;CYP1A2_results.csv:row=417;CYP2C9_results.csv:row=417;hERG_results.csv:row=417;AMES_results.csv:row=417;PGP_results.csv:row=417;PAMPA_results.csv:row=417;BBB_results.csv:row=417;Solubility_results.csv:row=417;Lipophilicity_results.csv:row=418
CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl,32.15865751334859,100,100.0,72.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.86; logP 1.77",repurposing_candidates.csv:rc_row=532;protein_drug_candidates.csv:rows=360;1452;1822;pathway_drug_candidates.csv:rows=823;6485;6685;CYP3A4_results.csv:row=492;CYP2C19_results.csv:row=492;CYP2D6_results.csv:row=492;CYP1A2_results.csv:row=492;CYP2C9_results.csv:row=492;hERG_results.csv:row=492;AMES_results.csv:row=492;PGP_results.csv:row=492;PAMPA_results.csv:row=492;BBB_results.csv:row=492;Solubility_results.csv:row=492;Lipophilicity_results.csv:row=493
CHEMBL1265,ADAPALENE,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,50.49199084668192,100,70.0,72.69679633867277,H,"KG targets RARA, RARB; clinical phase 4.0; logS -8.30; logP 6.68",repurposing_candidates.csv:rc_row=364;protein_drug_candidates.csv:rows=185;1766;1893;pathway_drug_candidates.csv:rows=5987;6013;6022;CYP3A4_results.csv:row=326;CYP2C19_results.csv:row=326;CYP2D6_results.csv:row=326;CYP1A2_results.csv:row=326;CYP2C9_results.csv:row=326;hERG_results.csv:row=326;AMES_results.csv:row=326;PGP_results.csv:row=326;PAMPA_results.csv:row=326;BBB_results.csv:row=326;Solubility_results.csv:row=326;Lipophilicity_results.csv:row=327
CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1,58.405797101449274,80,85.0,72.61231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -0.23; logP 10.76",repurposing_candidates.csv:rc_row=1176;protein_drug_candidates.csv:rows=832;1565;1999;2238;2344;2408;2715;2779;2843;pathway_drug_candidates.csv:rows=1545;1609;1673;1737;1801;1865;1929;2094;2158;2222;2286;2350;2414;2478;2542;2606;2670;2734;2798;2862;2926;2990;3060;3124;3188;3252;3316;3380;3444;3508;3572;3663;3727;3791;3855;3919;3983;4050;CYP3A4_results.csv:row=1039;CYP2C19_results.csv:row=1039;CYP2D6_results.csv:row=1039;CYP1A2_results.csv:row=1039;CYP2C9_results.csv:row=1039;hERG_results.csv:row=1039;AMES_results.csv:row=1039;PGP_results.csv:row=1039;PAMPA_results.csv:row=1039;BBB_results.csv:row=1039;Solubility_results.csv:row=1039;Lipophilicity_results.csv:row=1040
CHEMBL4279455,LAROTAXEL,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,58.405797101449274,80,85.0,72.61231884057972,H,"KG targets TUBB, TUBB1; clinical phase 3.0; logS -6.02; logP 4.47",repurposing_candidates.csv:rc_row=1153;protein_drug_candidates.csv:rows=826;1560;1995;2234;2339;2402;2709;2774;2838;pathway_drug_candidates.csv:rows=1539;1603;1667;1731;1795;1859;1923;2088;2152;2216;2280;2344;2408;2472;2536;2600;2664;2728;2792;2856;2920;2984;3054;3118;3182;3246;3310;3374;3438;3502;3566;3657;3721;3785;3849;3913;3977;4044;CYP3A4_results.csv:row=1017;CYP2C19_results.csv:row=1017;CYP2D6_results.csv:row=1017;CYP1A2_results.csv:row=1017;CYP2C9_results.csv:row=1017;hERG_results.csv:row=1017;AMES_results.csv:row=1017;PGP_results.csv:row=1017;PAMPA_results.csv:row=1017;BBB_results.csv:row=1017;Solubility_results.csv:row=1017;Lipophilicity_results.csv:row=1018
CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,53.39816933638444,100,65.0,72.60926773455378,M,"KG targets TLR7, TLR9; clinical phase 4.0; hERG risk; logS -1.80; logP 3.13",repurposing_candidates.csv:rc_row=512;protein_drug_candidates.csv:rows=255;598;pathway_drug_candidates.csv:rows=758;769;4254;7320;7331;7342;7353;7364;7375;7386;7397;7408;7419;7430;7441;7452;CYP3A4_results.csv:row=472;CYP2C19_results.csv:row=472;CYP2D6_results.csv:row=472;CYP1A2_results.csv:row=472;CYP2C9_results.csv:row=472;hERG_results.csv:row=472;AMES_results.csv:row=472;PGP_results.csv:row=472;PAMPA_results.csv:row=472;BBB_results.csv:row=472;Solubility_results.csv:row=472;Lipophilicity_results.csv:row=473
CHEMBL1981592,AVIPTADIL,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O,38.70327993897788,95,95.0,72.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 3.0; logS 0.41; logP -14.62",repurposing_candidates.csv:rc_row=618;protein_drug_candidates.csv:rows=398;1342;1393;1500;1858;2541;pathway_drug_candidates.csv:rows=861;913;964;1017;1068;1121;1173;1224;1405;1456;1509;6523;6723;CYP3A4_results.csv:row=564;CYP2C19_results.csv:row=564;CYP2D6_results.csv:row=564;CYP1A2_results.csv:row=564;CYP2C9_results.csv:row=564;hERG_results.csv:row=564;AMES_results.csv:row=564;PGP_results.csv:row=564;PAMPA_results.csv:row=564;BBB_results.csv:row=564;Solubility_results.csv:row=564;Lipophilicity_results.csv:row=565
CHEMBL220492,TOPIRAMATE,CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1,34.20289855072463,100,95.0,72.43115942028984,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -0.94; logP -0.40",repurposing_candidates.csv:rc_row=803;protein_drug_candidates.csv:rows=479;1408;1512;1630;1677;1735;1771;1794;1866;1927;2038;2083;2447;2553;2572;2625;CYP3A4_results.csv:row=712;CYP2C19_results.csv:row=712;CYP2D6_results.csv:row=712;CYP1A2_results.csv:row=712;CYP2C9_results.csv:row=712;hERG_results.csv:row=712;AMES_results.csv:row=712;PGP_results.csv:row=712;PAMPA_results.csv:row=712;BBB_results.csv:row=712;Solubility_results.csv:row=712;Lipophilicity_results.csv:row=713
CHEMBL3989803,DIPYRONE,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+],52.87185354691076,100,65.0,72.3987414187643,M,"KG targets PTGS1, PTGS2; clinical phase 4.0; hERG risk; logS 0.91; logP -3.40",repurposing_candidates.csv:rc_row=1087;protein_drug_candidates.csv:rows=122;907;pathway_drug_candidates.csv:rows=345;4463;5547;5607;5672;6056;6130;6204;6278;6352;6426;CYP3A4_results.csv:row=956;CYP2C19_results.csv:row=956;CYP2D6_results.csv:row=956;CYP1A2_results.csv:row=956;CYP2C9_results.csv:row=956;hERG_results.csv:row=956;AMES_results.csv:row=956;PGP_results.csv:row=956;PAMPA_results.csv:row=956;BBB_results.csv:row=956;Solubility_results.csv:row=956;Lipophilicity_results.csv:row=957
CHEMBL1951143,FIMASARTAN,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,48.40961098398169,80,100.0,72.36384439359267,H,KG targets AGTR1; clinical phase 3.0; logS -4.19; logP 4.22,repurposing_candidates.csv:rc_row=610;protein_drug_candidates.csv:rows=593;pathway_drug_candidates.csv:rows=6547;7166;7277;7297;CYP3A4_results.csv:row=556;CYP2C19_results.csv:row=556;CYP2D6_results.csv:row=556;CYP1A2_results.csv:row=556;CYP2C9_results.csv:row=556;hERG_results.csv:row=556;AMES_results.csv:row=556;PGP_results.csv:row=556;PAMPA_results.csv:row=556;BBB_results.csv:row=556;Solubility_results.csv:row=556;Lipophilicity_results.csv:row=557
CHEMBL4065122,FENEBRUTINIB,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,48.40961098398169,80,100.0,72.36384439359267,H,KG targets BTK; clinical phase 3.0; logS -3.73; logP 3.57,repurposing_candidates.csv:rc_row=1119;protein_drug_candidates.csv:rows=196;pathway_drug_candidates.csv:rows=602;4097;6559;6739;CYP3A4_results.csv:row=983;CYP2C19_results.csv:row=983;CYP2D6_results.csv:row=983;CYP1A2_results.csv:row=983;CYP2C9_results.csv:row=983;hERG_results.csv:row=983;AMES_results.csv:row=983;PGP_results.csv:row=983;PAMPA_results.csv:row=983;BBB_results.csv:row=983;Solubility_results.csv:row=983;Lipophilicity_results.csv:row=984
CHEMBL4650321,ORELABRUTINIB,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,48.40961098398169,80,100.0,72.36384439359267,H,KG targets BTK; clinical phase 3.0; logS -3.67; logP 4.53,repurposing_candidates.csv:rc_row=1307;protein_drug_candidates.csv:rows=195;pathway_drug_candidates.csv:rows=601;4096;6558;6738;CYP3A4_results.csv:row=1121;CYP2C19_results.csv:row=1121;CYP2D6_results.csv:row=1121;CYP1A2_results.csv:row=1121;CYP2C9_results.csv:row=1121;hERG_results.csv:row=1121;AMES_results.csv:row=1121;PGP_results.csv:row=1121;PAMPA_results.csv:row=1121;BBB_results.csv:row=1121;Solubility_results.csv:row=1121;Lipophilicity_results.csv:row=1122
CHEMBL1076903,VARENICLINE,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,30.85430968726163,100,100.0,72.34172387490466,H,"KG targets CHRNA4, CHRNB2; clinical phase 4.0; logS -0.24; logP 1.80",repurposing_candidates.csv:rc_row=26;protein_drug_candidates.csv:rows=435;2131;pathway_drug_candidates.csv:rows=7915;7929;7943;CYP3A4_results.csv:row=26;CYP2C19_results.csv:row=26;CYP2D6_results.csv:row=26;CYP1A2_results.csv:row=26;CYP2C9_results.csv:row=26;hERG_results.csv:row=26;AMES_results.csv:row=26;PGP_results.csv:row=26;PAMPA_results.csv:row=26;BBB_results.csv:row=26;Solubility_results.csv:row=26;Lipophilicity_results.csv:row=26
CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,30.85430968726163,100,100.0,72.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -2.00; logP 3.56",repurposing_candidates.csv:rc_row=303;protein_drug_candidates.csv:rows=1106;1149;pathway_drug_candidates.csv:rows=554;6966;7004;7500;CYP3A4_results.csv:row=272;CYP2C19_results.csv:row=272;CYP2D6_results.csv:row=272;CYP1A2_results.csv:row=272;CYP2C9_results.csv:row=272;hERG_results.csv:row=272;AMES_results.csv:row=272;PGP_results.csv:row=272;PAMPA_results.csv:row=272;BBB_results.csv:row=272;Solubility_results.csv:row=272;Lipophilicity_results.csv:row=273
CHEMBL1567,SUNITINIB MALATE,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,30.85430968726163,100,100.0,72.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -0.59; logP 2.24",repurposing_candidates.csv:rc_row=461;protein_drug_candidates.csv:rows=1104;1150;pathway_drug_candidates.csv:rows=555;6967;7002;7501;CYP3A4_results.csv:row=421;CYP2C19_results.csv:row=421;CYP2D6_results.csv:row=421;CYP1A2_results.csv:row=421;CYP2C9_results.csv:row=421;hERG_results.csv:row=421;AMES_results.csv:row=421;PGP_results.csv:row=421;PAMPA_results.csv:row=421;BBB_results.csv:row=421;Solubility_results.csv:row=421;Lipophilicity_results.csv:row=422
CHEMBL1341,METHOXYFLURANE,COC(F)(F)C(Cl)Cl,49.36689549961861,100,70.0,72.24675819984745,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -2.03; logP 2.03",repurposing_candidates.csv:rc_row=388;protein_drug_candidates.csv:rows=483;1403;1423;1513;1635;1681;1737;1775;1796;1869;1929;2043;2089;2459;2555;2575;2626;pathway_drug_candidates.csv:rows=7903;CYP3A4_results.csv:row=349;CYP2C19_results.csv:row=349;CYP2D6_results.csv:row=349;CYP1A2_results.csv:row=349;CYP2C9_results.csv:row=349;hERG_results.csv:row=349;AMES_results.csv:row=349;PGP_results.csv:row=349;PAMPA_results.csv:row=349;BBB_results.csv:row=349;Solubility_results.csv:row=349;Lipophilicity_results.csv:row=350
CHEMBL1530428,DEXAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,51.04118993135011,80,95.0,72.16647597254004,H,KG targets NR3C1; clinical phase 3.0; logS -4.71; logP 2.47,repurposing_candidates.csv:rc_row=452;protein_drug_candidates.csv:rows=50;pathway_drug_candidates.csv:rows=742;2051;5966;7870;8007;8073;8144;8210;8276;CYP3A4_results.csv:row=412;CYP2C19_results.csv:row=412;CYP2D6_results.csv:row=412;CYP1A2_results.csv:row=412;CYP2C9_results.csv:row=412;hERG_results.csv:row=412;AMES_results.csv:row=412;PGP_results.csv:row=412;PAMPA_results.csv:row=412;BBB_results.csv:row=412;Solubility_results.csv:row=412;Lipophilicity_results.csv:row=413
CHEMBL2103849,UDENAFIL,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1,47.88329519450801,80,100.0,72.1533180778032,H,KG targets PDE5A; clinical phase 3.0; logS -4.92; logP 2.83,repurposing_candidates.csv:rc_row=670;protein_drug_candidates.csv:rows=877;pathway_drug_candidates.csv:rows=7677;7704;7717;CYP3A4_results.csv:row=615;CYP2C19_results.csv:row=615;CYP2D6_results.csv:row=615;CYP1A2_results.csv:row=615;CYP2C9_results.csv:row=615;hERG_results.csv:row=615;AMES_results.csv:row=615;PGP_results.csv:row=615;PAMPA_results.csv:row=615;BBB_results.csv:row=615;Solubility_results.csv:row=615;Lipophilicity_results.csv:row=616
CHEMBL4650276,SHR3680,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1,47.88329519450801,80,100.0,72.1533180778032,H,KG targets AR; clinical phase 3.0; logS -3.52; logP 3.23,repurposing_candidates.csv:rc_row=1303;protein_drug_candidates.csv:rows=562;pathway_drug_candidates.csv:rows=1985;5900;7804;CYP3A4_results.csv:row=1119;CYP2C19_results.csv:row=1119;CYP2D6_results.csv:row=1119;CYP1A2_results.csv:row=1119;CYP2C9_results.csv:row=1119;hERG_results.csv:row=1119;AMES_results.csv:row=1119;PGP_results.csv:row=1119;PAMPA_results.csv:row=1119;BBB_results.csv:row=1119;Solubility_results.csv:row=1119;Lipophilicity_results.csv:row=1120
CHEMBL3989862,PEFCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,80,100.0,72.1533180778032,H,KG targets VDR; clinical phase 3.0; logS -4.54; logP 4.77,repurposing_candidates.csv:rc_row=1096;protein_drug_candidates.csv:rows=247;pathway_drug_candidates.csv:rows=6000;7777;7895;CYP3A4_results.csv:row=965;CYP2C19_results.csv:row=965;CYP2D6_results.csv:row=965;CYP1A2_results.csv:row=965;CYP2C9_results.csv:row=965;hERG_results.csv:row=965;AMES_results.csv:row=965;PGP_results.csv:row=965;PAMPA_results.csv:row=965;BBB_results.csv:row=965;Solubility_results.csv:row=965;Lipophilicity_results.csv:row=966
CHEMBL190,THEOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O,33.46300533943554,100,95.0,72.13520213577422,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -1.58; logP -1.04",repurposing_candidates.csv:rc_row=590;protein_drug_candidates.csv:rows=413;1046;1074;2151;pathway_drug_candidates.csv:rows=4325;5735;5763;5791;5830;5858;CYP3A4_results.csv:row=536;CYP2C19_results.csv:row=536;CYP2D6_results.csv:row=536;CYP1A2_results.csv:row=536;CYP2C9_results.csv:row=536;hERG_results.csv:row=536;AMES_results.csv:row=536;PGP_results.csv:row=536;PAMPA_results.csv:row=536;BBB_results.csv:row=536;Solubility_results.csv:row=536;Lipophilicity_results.csv:row=537
CHEMBL1370561,AMINOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,33.46300533943554,100,95.0,72.13520213577422,H,"KG targets PDE4A, PDE4B; clinical phase 4.0; logS -0.28; logP -3.18",repurposing_candidates.csv:rc_row=397;protein_drug_candidates.csv:rows=417;1049;1076;2154;pathway_drug_candidates.csv:rows=4327;5739;5766;5793;5834;5860;CYP3A4_results.csv:row=357;CYP2C19_results.csv:row=357;CYP2D6_results.csv:row=357;CYP1A2_results.csv:row=357;CYP2C9_results.csv:row=357;hERG_results.csv:row=357;AMES_results.csv:row=357;PGP_results.csv:row=357;PAMPA_results.csv:row=357;BBB_results.csv:row=357;Solubility_results.csv:row=357;Lipophilicity_results.csv:row=358
CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O,30.327993897787948,100,100.0,72.13119755911518,H,"KG targets KCNK3, KCNK9; clinical phase 4.0; logS -1.73; logP 2.77",repurposing_candidates.csv:rc_row=1071;protein_drug_candidates.csv:rows=531;536;pathway_drug_candidates.csv:rows=16;21;7723;7728;CYP3A4_results.csv:row=940;CYP2C19_results.csv:row=940;CYP2D6_results.csv:row=940;CYP1A2_results.csv:row=940;CYP2C9_results.csv:row=940;hERG_results.csv:row=940;AMES_results.csv:row=940;PGP_results.csv:row=940;PAMPA_results.csv:row=940;BBB_results.csv:row=940;Solubility_results.csv:row=940;Lipophilicity_results.csv:row=941
CHEMBL1754,DOXAPRAM,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,30.327993897787948,100,100.0,72.13119755911518,H,"KG targets KCNK3, KCNK9; clinical phase 4.0; logS -1.85; logP 3.17",repurposing_candidates.csv:rc_row=559;protein_drug_candidates.csv:rows=530;535;pathway_drug_candidates.csv:rows=15;20;7722;7727;CYP3A4_results.csv:row=505;CYP2C19_results.csv:row=505;CYP2D6_results.csv:row=505;CYP1A2_results.csv:row=505;CYP2C9_results.csv:row=505;hERG_results.csv:row=505;AMES_results.csv:row=505;PGP_results.csv:row=505;PAMPA_results.csv:row=505;BBB_results.csv:row=505;Solubility_results.csv:row=505;Lipophilicity_results.csv:row=506
CHEMBL1200472,QUAZEPAM,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,45.79710144927536,100,75.0,72.06884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -6.01; logP 5.03",repurposing_candidates.csv:rc_row=108;protein_drug_candidates.csv:rows=495;1427;1638;1694;2045;2102;2462;CYP3A4_results.csv:row=107;CYP2C19_results.csv:row=107;CYP2D6_results.csv:row=107;CYP1A2_results.csv:row=107;CYP2C9_results.csv:row=107;hERG_results.csv:row=107;AMES_results.csv:row=107;PGP_results.csv:row=107;PAMPA_results.csv:row=107;BBB_results.csv:row=107;Solubility_results.csv:row=107;Lipophilicity_results.csv:row=107
CHEMBL279785,MARIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,50.76659038901602,80,95.0,72.05663615560641,H,"KG targets MMP1, MMP7; clinical phase 3.0; logS 0.83; logP -0.21",repurposing_candidates.csv:rc_row=876;protein_drug_candidates.csv:rows=612;630;pathway_drug_candidates.csv:rows=28;41;52;65;83;96;114;128;233;CYP3A4_results.csv:row=784;CYP2C19_results.csv:row=784;CYP2D6_results.csv:row=784;CYP1A2_results.csv:row=784;CYP2C9_results.csv:row=784;hERG_results.csv:row=784;AMES_results.csv:row=784;PGP_results.csv:row=784;PAMPA_results.csv:row=784;BBB_results.csv:row=784;Solubility_results.csv:row=784;Lipophilicity_results.csv:row=785
CHEMBL191,LOSARTAN,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,30.076277650648358,100,100.0,72.03051106025934,H,KG targets AGTR1; clinical phase 4.0; logS -4.67; logP 4.27,repurposing_candidates.csv:rc_row=596;protein_drug_candidates.csv:rows=583;pathway_drug_candidates.csv:rows=6537;7156;7267;7287;CYP3A4_results.csv:row=542;CYP2C19_results.csv:row=542;CYP2D6_results.csv:row=542;CYP1A2_results.csv:row=542;CYP2C9_results.csv:row=542;hERG_results.csv:row=542;AMES_results.csv:row=542;PGP_results.csv:row=542;PAMPA_results.csv:row=542;BBB_results.csv:row=542;Solubility_results.csv:row=542;Lipophilicity_results.csv:row=543
CHEMBL1201414,TINZAPARIN SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets SERPINC1; clinical phase 4.0,repurposing_candidates.csv:rc_row=274;protein_drug_candidates.csv:rows=169;pathway_drug_candidates.csv:rows=141;7547;7576;7598;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1144,PRAVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,30.076277650648358,100,100.0,72.03051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -1.98; logP 2.44,repurposing_candidates.csv:rc_row=62;protein_drug_candidates.csv:rows=730;pathway_drug_candidates.csv:rows=7609;7624;7639;7654;CYP3A4_results.csv:row=61;CYP2C19_results.csv:row=61;CYP2D6_results.csv:row=61;CYP1A2_results.csv:row=61;CYP2C9_results.csv:row=61;hERG_results.csv:row=61;AMES_results.csv:row=61;PGP_results.csv:row=61;PAMPA_results.csv:row=61;BBB_results.csv:row=61;Solubility_results.csv:row=61;Lipophilicity_results.csv:row=61
CHEMBL2108250,ANISTREPLASE,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets PLG; clinical phase 4.0,repurposing_candidates.csv:rc_row=747;protein_drug_candidates.csv:rows=682;pathway_drug_candidates.csv:rows=75;106;133;456;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201657,HEPARIN SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets SERPINC1; clinical phase 4.0,repurposing_candidates.csv:rc_row=301;protein_drug_candidates.csv:rows=166;pathway_drug_candidates.csv:rows=138;7544;7573;7595;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201572,ETANERCEPT,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets TNF; clinical phase 4.0,repurposing_candidates.csv:rc_row=295;protein_drug_candidates.csv:rows=83;pathway_drug_candidates.csv:rows=392;4146;4161;4510;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1496,ROSUVASTATIN,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,30.076277650648358,100,100.0,72.03051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -2.53; logP 2.40,repurposing_candidates.csv:rc_row=435;protein_drug_candidates.csv:rows=733;pathway_drug_candidates.csv:rows=7612;7627;7642;7657;CYP3A4_results.csv:row=395;CYP2C19_results.csv:row=395;CYP2D6_results.csv:row=395;CYP1A2_results.csv:row=395;CYP2C9_results.csv:row=395;hERG_results.csv:row=395;AMES_results.csv:row=395;PGP_results.csv:row=395;PAMPA_results.csv:row=395;BBB_results.csv:row=395;Solubility_results.csv:row=395;Lipophilicity_results.csv:row=396
CHEMBL1201580,ADALIMUMAB,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets TNF; clinical phase 4.0,repurposing_candidates.csv:rc_row=296;protein_drug_candidates.csv:rows=80;pathway_drug_candidates.csv:rows=389;4143;4158;4507;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1477,CERIVASTATIN,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,30.076277650648358,100,100.0,72.03051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -2.70; logP 4.88,repurposing_candidates.csv:rc_row=427;protein_drug_candidates.csv:rows=731;pathway_drug_candidates.csv:rows=7610;7625;7640;7655;CYP3A4_results.csv:row=387;CYP2C19_results.csv:row=387;CYP2D6_results.csv:row=387;CYP1A2_results.csv:row=387;CYP2C9_results.csv:row=387;hERG_results.csv:row=387;AMES_results.csv:row=387;PGP_results.csv:row=387;PAMPA_results.csv:row=387;BBB_results.csv:row=387;Solubility_results.csv:row=387;Lipophilicity_results.csv:row=388
CHEMBL813,EPROSARTAN,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,30.076277650648358,100,100.0,72.03051106025934,H,KG targets AGTR1; clinical phase 4.0; logS -4.43; logP 4.74,repurposing_candidates.csv:rc_row=1523;protein_drug_candidates.csv:rows=582;pathway_drug_candidates.csv:rows=6536;7155;7266;7286;CYP3A4_results.csv:row=1329;CYP2C19_results.csv:row=1329;CYP2D6_results.csv:row=1329;CYP1A2_results.csv:row=1329;CYP2C9_results.csv:row=1329;hERG_results.csv:row=1329;AMES_results.csv:row=1329;PGP_results.csv:row=1329;PAMPA_results.csv:row=1329;BBB_results.csv:row=1329;Solubility_results.csv:row=1329;Lipophilicity_results.csv:row=1330
CHEMBL1201581,INFLIXIMAB,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets TNF; clinical phase 4.0,repurposing_candidates.csv:rc_row=297;protein_drug_candidates.csv:rows=81;pathway_drug_candidates.csv:rows=390;4144;4159;4508;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL5314649,RITLECITINIB TOSYLATE,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1,30.076277650648358,100,100.0,72.03051106025934,H,KG targets BTK; clinical phase 4.0; logS -0.63; logP 3.18,repurposing_candidates.csv:rc_row=1386;protein_drug_candidates.csv:rows=193;pathway_drug_candidates.csv:rows=599;4094;6556;6736;CYP3A4_results.csv:row=1197;CYP2C19_results.csv:row=1197;CYP2D6_results.csv:row=1197;CYP1A2_results.csv:row=1197;CYP2C9_results.csv:row=1197;hERG_results.csv:row=1197;AMES_results.csv:row=1197;PGP_results.csv:row=1197;PAMPA_results.csv:row=1197;BBB_results.csv:row=1197;Solubility_results.csv:row=1197;Lipophilicity_results.csv:row=1198
CHEMBL1201753,PITAVASTATIN,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,30.076277650648358,100,100.0,72.03051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -3.86; logP 4.52,repurposing_candidates.csv:rc_row=310;protein_drug_candidates.csv:rows=736;pathway_drug_candidates.csv:rows=7615;7630;7645;7660;CYP3A4_results.csv:row=279;CYP2C19_results.csv:row=279;CYP2D6_results.csv:row=279;CYP1A2_results.csv:row=279;CYP2C9_results.csv:row=279;hERG_results.csv:row=279;AMES_results.csv:row=279;PGP_results.csv:row=279;PAMPA_results.csv:row=279;BBB_results.csv:row=279;Solubility_results.csv:row=279;Lipophilicity_results.csv:row=280
CHEMBL1201619,APROTININ,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets PLG; clinical phase 4.0,repurposing_candidates.csv:rc_row=299;protein_drug_candidates.csv:rows=684;pathway_drug_candidates.csv:rows=77;108;135;458;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2220442,FLUVASTATIN,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,30.076277650648358,100,100.0,72.03051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -3.20; logP 4.63,repurposing_candidates.csv:rc_row=815;protein_drug_candidates.csv:rows=737;pathway_drug_candidates.csv:rows=7616;7631;7646;7661;CYP3A4_results.csv:row=724;CYP2C19_results.csv:row=724;CYP2D6_results.csv:row=724;CYP1A2_results.csv:row=724;CYP2C9_results.csv:row=724;hERG_results.csv:row=724;AMES_results.csv:row=724;PGP_results.csv:row=724;PAMPA_results.csv:row=724;BBB_results.csv:row=724;Solubility_results.csv:row=724;Lipophilicity_results.csv:row=725
CHEMBL2108147,STREPTOKINASE,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets PLG; clinical phase 4.0,repurposing_candidates.csv:rc_row=745;protein_drug_candidates.csv:rows=681;pathway_drug_candidates.csv:rows=74;105;132;455;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201833,GOLIMUMAB,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets TNF; clinical phase 4.0,repurposing_candidates.csv:rc_row=323;protein_drug_candidates.csv:rows=84;pathway_drug_candidates.csv:rows=393;4147;4162;4511;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3707226,DEFIBROTIDE SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets PLG; clinical phase 4.0,repurposing_candidates.csv:rc_row=1014;protein_drug_candidates.csv:rows=685;pathway_drug_candidates.csv:rows=78;109;136;459;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201476,ENOXAPARIN SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets SERPINC1; clinical phase 4.0,repurposing_candidates.csv:rc_row=281;protein_drug_candidates.csv:rows=167;pathway_drug_candidates.csv:rows=139;7545;7574;7596;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201534,DANAPAROID SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets SERPINC1; clinical phase 4.0,repurposing_candidates.csv:rc_row=284;protein_drug_candidates.csv:rows=172;pathway_drug_candidates.csv:rows=144;7550;7579;7601;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201831,CERTOLIZUMAB PEGOL,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets TNF; clinical phase 4.0,repurposing_candidates.csv:rc_row=322;protein_drug_candidates.csv:rows=82;pathway_drug_candidates.csv:rows=391;4145;4160;4509;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201460,DALTEPARIN SODIUM,,30.076277650648358,100,100.0,72.03051106025934,H,KG targets SERPINC1; clinical phase 4.0,repurposing_candidates.csv:rc_row=276;protein_drug_candidates.csv:rows=170;pathway_drug_candidates.csv:rows=142;7548;7577;7599;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL484785,CRISABOROLE,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,51.79633867276888,100,65.0,71.96853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 4.0; hERG risk; logS -4.46; logP 1.57",repurposing_candidates.csv:rc_row=1334;protein_drug_candidates.csv:rows=407;1040;1068;2145;pathway_drug_candidates.csv:rows=4319;5729;5757;5785;5824;5852;CYP3A4_results.csv:row=1145;CYP2C19_results.csv:row=1145;CYP2D6_results.csv:row=1145;CYP1A2_results.csv:row=1145;CYP2C9_results.csv:row=1145;hERG_results.csv:row=1145;AMES_results.csv:row=1145;PGP_results.csv:row=1145;PAMPA_results.csv:row=1145;BBB_results.csv:row=1145;Solubility_results.csv:row=1145;Lipophilicity_results.csv:row=1146
CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl,51.79633867276888,100,65.0,71.96853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 4.0; hERG risk; logS -3.31; logP 4.83",repurposing_candidates.csv:rc_row=184;protein_drug_candidates.csv:rows=412;1045;1073;2150;pathway_drug_candidates.csv:rows=4324;5734;5762;5790;5829;5857;CYP3A4_results.csv:row=182;CYP2C19_results.csv:row=182;CYP2D6_results.csv:row=182;CYP1A2_results.csv:row=182;CYP2C9_results.csv:row=182;hERG_results.csv:row=182;AMES_results.csv:row=182;PGP_results.csv:row=182;PAMPA_results.csv:row=182;BBB_results.csv:row=182;Solubility_results.csv:row=182;Lipophilicity_results.csv:row=183
CHEMBL46618,OTAMIXABAN,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,47.35697940503432,80,100.0,71.94279176201373,H,KG targets F10; clinical phase 3.0; logS -2.64; logP 2.42,repurposing_candidates.csv:rc_row=1319;protein_drug_candidates.csv:rows=462;pathway_drug_candidates.csv:rows=7542;7571;CYP3A4_results.csv:row=1130;CYP2C19_results.csv:row=1130;CYP2D6_results.csv:row=1130;CYP1A2_results.csv:row=1130;CYP2C9_results.csv:row=1130;hERG_results.csv:row=1130;AMES_results.csv:row=1130;PGP_results.csv:row=1130;PAMPA_results.csv:row=1130;BBB_results.csv:row=1130;Solubility_results.csv:row=1130;Lipophilicity_results.csv:row=1131
CHEMBL4208229,ASCIMINIB,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,29.801678108314263,100,100.0,71.9206712433257,H,"KG targets ABL1, BCR; clinical phase 4.0; logS -5.93; logP 3.46",repurposing_candidates.csv:rc_row=1145;protein_drug_candidates.csv:rows=1206;2204;pathway_drug_candidates.csv:rows=4297;CYP3A4_results.csv:row=1009;CYP2C19_results.csv:row=1009;CYP2D6_results.csv:row=1009;CYP1A2_results.csv:row=1009;CYP2C9_results.csv:row=1009;hERG_results.csv:row=1009;AMES_results.csv:row=1009;PGP_results.csv:row=1009;PAMPA_results.csv:row=1009;BBB_results.csv:row=1009;Solubility_results.csv:row=1009;Lipophilicity_results.csv:row=1010
CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,29.801678108314263,100,100.0,71.9206712433257,H,"KG targets ABL1, BCR; clinical phase 4.0; logS -5.24; logP 3.88",repurposing_candidates.csv:rc_row=1165;protein_drug_candidates.csv:rows=1204;2202;pathway_drug_candidates.csv:rows=4295;CYP3A4_results.csv:row=1028;CYP2C19_results.csv:row=1028;CYP2D6_results.csv:row=1028;CYP1A2_results.csv:row=1028;CYP2C9_results.csv:row=1028;hERG_results.csv:row=1028;AMES_results.csv:row=1028;PGP_results.csv:row=1028;PAMPA_results.csv:row=1028;BBB_results.csv:row=1028;Solubility_results.csv:row=1028;Lipophilicity_results.csv:row=1029
CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+],48.40961098398169,100,70.0,71.86384439359267,H,KG targets AGTR1; clinical phase 4.0; hERG risk; logS -5.97; logP 1.34,repurposing_candidates.csv:rc_row=661;protein_drug_candidates.csv:rows=588;pathway_drug_candidates.csv:rows=6542;7161;7272;7292;CYP3A4_results.csv:row=606;CYP2C19_results.csv:row=606;CYP2D6_results.csv:row=606;CYP1A2_results.csv:row=606;CYP2C9_results.csv:row=606;hERG_results.csv:row=606;AMES_results.csv:row=606;PGP_results.csv:row=606;PAMPA_results.csv:row=606;BBB_results.csv:row=606;Solubility_results.csv:row=606;Lipophilicity_results.csv:row=607
CHEMBL1520,VARDENAFIL,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,29.549961861174673,100,100.0,71.81998474446988,H,KG targets PDE5A; clinical phase 4.0; logS -4.74; logP 2.07,repurposing_candidates.csv:rc_row=447;protein_drug_candidates.csv:rows=874;pathway_drug_candidates.csv:rows=7674;7701;7714;CYP3A4_results.csv:row=407;CYP2C19_results.csv:row=407;CYP2D6_results.csv:row=407;CYP1A2_results.csv:row=407;CYP2C9_results.csv:row=407;hERG_results.csv:row=407;AMES_results.csv:row=407;PGP_results.csv:row=407;PAMPA_results.csv:row=407;BBB_results.csv:row=407;Solubility_results.csv:row=407;Lipophilicity_results.csv:row=408
CHEMBL1685,DEZOCINE,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -2.99; logP 3.11,repurposing_candidates.csv:rc_row=509;protein_drug_candidates.csv:rows=285;pathway_drug_candidates.csv:rows=255;1289;7202;CYP3A4_results.csv:row=469;CYP2C19_results.csv:row=469;CYP2D6_results.csv:row=469;CYP1A2_results.csv:row=469;CYP2C9_results.csv:row=469;hERG_results.csv:row=469;AMES_results.csv:row=469;PGP_results.csv:row=469;PAMPA_results.csv:row=469;BBB_results.csv:row=469;Solubility_results.csv:row=469;Lipophilicity_results.csv:row=470
CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.26; logP 0.07,repurposing_candidates.csv:rc_row=1392;protein_drug_candidates.csv:rows=313;pathway_drug_candidates.csv:rows=283;1317;7230;CYP3A4_results.csv:row=1202;CYP2C19_results.csv:row=1202;CYP2D6_results.csv:row=1202;CYP1A2_results.csv:row=1202;CYP2C9_results.csv:row=1202;hERG_results.csv:row=1202;AMES_results.csv:row=1202;PGP_results.csv:row=1202;PAMPA_results.csv:row=1202;BBB_results.csv:row=1202;Solubility_results.csv:row=1202;Lipophilicity_results.csv:row=1203
CHEMBL3833389,DEXTROMORAMIDE,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.04; logP 3.71,repurposing_candidates.csv:rc_row=1047;protein_drug_candidates.csv:rows=293;pathway_drug_candidates.csv:rows=263;1297;7210;CYP3A4_results.csv:row=917;CYP2C19_results.csv:row=917;CYP2D6_results.csv:row=917;CYP1A2_results.csv:row=917;CYP2C9_results.csv:row=917;hERG_results.csv:row=917;AMES_results.csv:row=917;PGP_results.csv:row=917;PAMPA_results.csv:row=917;BBB_results.csv:row=917;Solubility_results.csv:row=917;Lipophilicity_results.csv:row=918
CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.11; logP 4.14,repurposing_candidates.csv:rc_row=908;protein_drug_candidates.csv:rows=292;pathway_drug_candidates.csv:rows=262;1296;7209;CYP3A4_results.csv:row=815;CYP2C19_results.csv:row=815;CYP2D6_results.csv:row=815;CYP1A2_results.csv:row=815;CYP2C9_results.csv:row=815;hERG_results.csv:row=815;AMES_results.csv:row=815;PGP_results.csv:row=815;PAMPA_results.csv:row=815;BBB_results.csv:row=815;Solubility_results.csv:row=815;Lipophilicity_results.csv:row=816
CHEMBL1213351,PROPOXYPHENE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -4.70; logP 4.28,repurposing_candidates.csv:rc_row=331;protein_drug_candidates.csv:rows=305;pathway_drug_candidates.csv:rows=275;1309;7222;CYP3A4_results.csv:row=294;CYP2C19_results.csv:row=294;CYP2D6_results.csv:row=294;CYP1A2_results.csv:row=294;CYP2C9_results.csv:row=294;hERG_results.csv:row=294;AMES_results.csv:row=294;PGP_results.csv:row=294;PAMPA_results.csv:row=294;BBB_results.csv:row=294;Solubility_results.csv:row=294;Lipophilicity_results.csv:row=295
CHEMBL192,SILDENAFIL,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,29.549961861174673,100,100.0,71.81998474446988,H,KG targets PDE5A; clinical phase 4.0; logS -4.14; logP 1.61,repurposing_candidates.csv:rc_row=598;protein_drug_candidates.csv:rows=875;pathway_drug_candidates.csv:rows=7675;7702;7715;CYP3A4_results.csv:row=544;CYP2C19_results.csv:row=544;CYP2D6_results.csv:row=544;CYP1A2_results.csv:row=544;CYP2C9_results.csv:row=544;hERG_results.csv:row=544;AMES_results.csv:row=544;PGP_results.csv:row=544;PAMPA_results.csv:row=544;BBB_results.csv:row=544;Solubility_results.csv:row=544;Lipophilicity_results.csv:row=545
CHEMBL1718,NALOXONE HYDROCHLORIDE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -2.47; logP 1.72,repurposing_candidates.csv:rc_row=529;protein_drug_candidates.csv:rows=287;pathway_drug_candidates.csv:rows=257;1291;7204;CYP3A4_results.csv:row=489;CYP2C19_results.csv:row=489;CYP2D6_results.csv:row=489;CYP1A2_results.csv:row=489;CYP2C9_results.csv:row=489;hERG_results.csv:row=489;AMES_results.csv:row=489;PGP_results.csv:row=489;PAMPA_results.csv:row=489;BBB_results.csv:row=489;Solubility_results.csv:row=489;Lipophilicity_results.csv:row=490
CHEMBL299400,BUTORPHANOL TARTRATE,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -2.69; logP 1.24,repurposing_candidates.csv:rc_row=887;protein_drug_candidates.csv:rows=312;pathway_drug_candidates.csv:rows=282;1316;7229;CYP3A4_results.csv:row=795;CYP2C19_results.csv:row=795;CYP2D6_results.csv:row=795;CYP1A2_results.csv:row=795;CYP2C9_results.csv:row=795;hERG_results.csv:row=795;AMES_results.csv:row=795;PGP_results.csv:row=795;PAMPA_results.csv:row=795;BBB_results.csv:row=795;Solubility_results.csv:row=795;Lipophilicity_results.csv:row=796
CHEMBL1201776,TAPENTADOL,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -1.99; logP 3.08,repurposing_candidates.csv:rc_row=316;protein_drug_candidates.csv:rows=303;pathway_drug_candidates.csv:rows=273;1307;7220;CYP3A4_results.csv:row=285;CYP2C19_results.csv:row=285;CYP2D6_results.csv:row=285;CYP1A2_results.csv:row=285;CYP2C9_results.csv:row=285;hERG_results.csv:row=285;AMES_results.csv:row=285;PGP_results.csv:row=285;PAMPA_results.csv:row=285;BBB_results.csv:row=285;Solubility_results.csv:row=285;Lipophilicity_results.csv:row=286
CHEMBL1237044,TRAMADOL,COc1cccc(C2(O)CCCCC2CN(C)C)c1,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -2.67; logP 2.63,repurposing_candidates.csv:rc_row=344;protein_drug_candidates.csv:rows=280;pathway_drug_candidates.csv:rows=250;1284;7197;CYP3A4_results.csv:row=306;CYP2C19_results.csv:row=306;CYP2D6_results.csv:row=306;CYP1A2_results.csv:row=306;CYP2C9_results.csv:row=306;hERG_results.csv:row=306;AMES_results.csv:row=306;PGP_results.csv:row=306;PAMPA_results.csv:row=306;BBB_results.csv:row=306;Solubility_results.csv:row=306;Lipophilicity_results.csv:row=307
CHEMBL1201099,CODEINE PHOSPHATE,,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0,repurposing_candidates.csv:rc_row=233;protein_drug_candidates.csv:rows=299;pathway_drug_candidates.csv:rows=269;1303;7216;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL80,NALOXONE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.15; logP 1.30,repurposing_candidates.csv:rc_row=1517;protein_drug_candidates.csv:rows=316;pathway_drug_candidates.csv:rows=286;1320;7233;CYP3A4_results.csv:row=1323;CYP2C19_results.csv:row=1323;CYP2D6_results.csv:row=1323;CYP1A2_results.csv:row=1323;CYP2C9_results.csv:row=1323;hERG_results.csv:row=1323;AMES_results.csv:row=1323;PGP_results.csv:row=1323;PAMPA_results.csv:row=1323;BBB_results.csv:row=1323;Solubility_results.csv:row=1323;Lipophilicity_results.csv:row=1324
CHEMBL2105749,SAMIDORPHAN L-MALATE,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -1.50; logP 0.16,repurposing_candidates.csv:rc_row=706;protein_drug_candidates.csv:rows=318;pathway_drug_candidates.csv:rows=288;1322;7235;CYP3A4_results.csv:row=651;CYP2C19_results.csv:row=651;CYP2D6_results.csv:row=651;CYP1A2_results.csv:row=651;CYP2C9_results.csv:row=651;hERG_results.csv:row=651;AMES_results.csv:row=651;PGP_results.csv:row=651;PAMPA_results.csv:row=651;BBB_results.csv:row=651;Solubility_results.csv:row=651;Lipophilicity_results.csv:row=652
CHEMBL33986,BUTORPHANOL,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.14; logP 3.37,repurposing_candidates.csv:rc_row=951;protein_drug_candidates.csv:rows=309;pathway_drug_candidates.csv:rows=279;1313;7226;CYP3A4_results.csv:row=855;CYP2C19_results.csv:row=855;CYP2D6_results.csv:row=855;CYP1A2_results.csv:row=855;CYP2C9_results.csv:row=855;hERG_results.csv:row=855;AMES_results.csv:row=855;PGP_results.csv:row=855;PAMPA_results.csv:row=855;BBB_results.csv:row=855;Solubility_results.csv:row=855;Lipophilicity_results.csv:row=856
CHEMBL270190,ALVIMOPAN,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.32; logP 3.05,repurposing_candidates.csv:rc_row=866;protein_drug_candidates.csv:rows=315;pathway_drug_candidates.csv:rows=285;1319;7232;CYP3A4_results.csv:row=774;CYP2C19_results.csv:row=774;CYP2D6_results.csv:row=774;CYP1A2_results.csv:row=774;CYP2C9_results.csv:row=774;hERG_results.csv:row=774;AMES_results.csv:row=774;PGP_results.csv:row=774;PAMPA_results.csv:row=774;BBB_results.csv:row=774;Solubility_results.csv:row=774;Lipophilicity_results.csv:row=775
CHEMBL3039508,NALDEMEDINE TOSYLATE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1,29.549961861174673,100,100.0,71.81998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -3.91; logP 4.72,repurposing_candidates.csv:rc_row=894;protein_drug_candidates.csv:rows=307;pathway_drug_candidates.csv:rows=277;1311;7224;CYP3A4_results.csv:row=802;CYP2C19_results.csv:row=802;CYP2D6_results.csv:row=802;CYP1A2_results.csv:row=802;CYP2C9_results.csv:row=802;hERG_results.csv:row=802;AMES_results.csv:row=802;PGP_results.csv:row=802;PAMPA_results.csv:row=802;BBB_results.csv:row=802;Solubility_results.csv:row=802;Lipophilicity_results.csv:row=803
CHEMBL589583,DELAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,46.83066361556064,80,100.0,71.73226544622426,H,KG targets ACE; clinical phase 3.0; logS -2.97; logP 2.61,repurposing_candidates.csv:rc_row=1430;protein_drug_candidates.csv:rows=654;pathway_drug_candidates.csv:rows=450;CYP3A4_results.csv:row=1239;CYP2C19_results.csv:row=1239;CYP2D6_results.csv:row=1239;CYP1A2_results.csv:row=1239;CYP2C9_results.csv:row=1239;hERG_results.csv:row=1239;AMES_results.csv:row=1239;PGP_results.csv:row=1239;PAMPA_results.csv:row=1239;BBB_results.csv:row=1239;Solubility_results.csv:row=1239;Lipophilicity_results.csv:row=1240
CHEMBL1742461,LAFUTIDINE,O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,46.83066361556064,80,100.0,71.73226544622426,H,KG targets HRH2; clinical phase 3.0; logS 0.05; logP 2.66,repurposing_candidates.csv:rc_row=540;protein_drug_candidates.csv:rows=753;pathway_drug_candidates.csv:rows=5822;CYP3A4_results.csv:row=500;CYP2C19_results.csv:row=500;CYP2D6_results.csv:row=500;CYP1A2_results.csv:row=500;CYP2C9_results.csv:row=500;hERG_results.csv:row=500;AMES_results.csv:row=500;PGP_results.csv:row=500;PAMPA_results.csv:row=500;BBB_results.csv:row=500;Solubility_results.csv:row=500;Lipophilicity_results.csv:row=501
CHEMBL2448612,ERGOTAMINE TARTRATE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O,38.70327993897788,100,85.0,71.73131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -6.59; logP 1.86",repurposing_candidates.csv:rc_row=851;protein_drug_candidates.csv:rows=392;1336;1388;1494;1854;2534;pathway_drug_candidates.csv:rows=855;907;959;1011;1063;1115;1167;1219;1399;1451;1503;6517;6717;CYP3A4_results.csv:row=759;CYP2C19_results.csv:row=759;CYP2D6_results.csv:row=759;CYP1A2_results.csv:row=759;CYP2C9_results.csv:row=759;hERG_results.csv:row=759;AMES_results.csv:row=759;PGP_results.csv:row=759;PAMPA_results.csv:row=759;BBB_results.csv:row=759;Solubility_results.csv:row=759;Lipophilicity_results.csv:row=760
CHEMBL650,METHYLPREDNISOLONE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12,51.04118993135011,100,65.0,71.66647597254004,M,KG targets NR3C1; clinical phase 4.0; hERG risk; logS -3.39; logP 1.80,repurposing_candidates.csv:rc_row=1472;protein_drug_candidates.csv:rows=7;pathway_drug_candidates.csv:rows=699;2008;5923;7827;7964;8030;8101;8167;8233;CYP3A4_results.csv:row=1278;CYP2C19_results.csv:row=1278;CYP2D6_results.csv:row=1278;CYP1A2_results.csv:row=1278;CYP2C9_results.csv:row=1278;hERG_results.csv:row=1278;AMES_results.csv:row=1278;PGP_results.csv:row=1278;PAMPA_results.csv:row=1278;BBB_results.csv:row=1278;Solubility_results.csv:row=1278;Lipophilicity_results.csv:row=1279
CHEMBL779,TADALAFIL,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,47.88329519450801,100,70.0,71.6533180778032,H,KG targets PDE5A; clinical phase 4.0; hERG risk; logS -3.57; logP 2.21,repurposing_candidates.csv:rc_row=1513;protein_drug_candidates.csv:rows=869;pathway_drug_candidates.csv:rows=7669;7696;7709;CYP3A4_results.csv:row=1319;CYP2C19_results.csv:row=1319;CYP2D6_results.csv:row=1319;CYP1A2_results.csv:row=1319;CYP2C9_results.csv:row=1319;hERG_results.csv:row=1319;AMES_results.csv:row=1319;PGP_results.csv:row=1319;PAMPA_results.csv:row=1319;BBB_results.csv:row=1319;Solubility_results.csv:row=1319;Lipophilicity_results.csv:row=1320
CHEMBL511142,BUPRENORPHINE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -4.32; logP 4.41,repurposing_candidates.csv:rc_row=1357;protein_drug_candidates.csv:rows=298;pathway_drug_candidates.csv:rows=268;1302;7215;CYP3A4_results.csv:row=1168;CYP2C19_results.csv:row=1168;CYP2D6_results.csv:row=1168;CYP1A2_results.csv:row=1168;CYP2C9_results.csv:row=1168;hERG_results.csv:row=1168;AMES_results.csv:row=1168;PGP_results.csv:row=1168;PAMPA_results.csv:row=1168;BBB_results.csv:row=1168;Solubility_results.csv:row=1168;Lipophilicity_results.csv:row=1169
CHEMBL1201163,SUFENTANIL CITRATE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.12; logP 2.97,repurposing_candidates.csv:rc_row=247;protein_drug_candidates.csv:rows=279;pathway_drug_candidates.csv:rows=249;1283;7196;CYP3A4_results.csv:row=244;CYP2C19_results.csv:row=244;CYP2D6_results.csv:row=244;CYP1A2_results.csv:row=244;CYP2C9_results.csv:row=244;hERG_results.csv:row=244;AMES_results.csv:row=244;PGP_results.csv:row=244;PAMPA_results.csv:row=244;BBB_results.csv:row=244;Solubility_results.csv:row=244;Lipophilicity_results.csv:row=245
CHEMBL1737,SILDENAFIL CITRATE,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,47.88329519450801,100,70.0,71.6533180778032,H,KG targets PDE5A; clinical phase 4.0; hERG risk; logS -3.77; logP 0.36,repurposing_candidates.csv:rc_row=535;protein_drug_candidates.csv:rows=872;pathway_drug_candidates.csv:rows=7672;7699;7712;CYP3A4_results.csv:row=495;CYP2C19_results.csv:row=495;CYP2D6_results.csv:row=495;CYP1A2_results.csv:row=495;CYP2C9_results.csv:row=495;hERG_results.csv:row=495;AMES_results.csv:row=495;PGP_results.csv:row=495;PAMPA_results.csv:row=495;BBB_results.csv:row=495;Solubility_results.csv:row=495;Lipophilicity_results.csv:row=496
CHEMBL656,OXYCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.61; logP 1.05,repurposing_candidates.csv:rc_row=1476;protein_drug_candidates.csv:rows=270;pathway_drug_candidates.csv:rows=240;1274;7187;CYP3A4_results.csv:row=1282;CYP2C19_results.csv:row=1282;CYP2D6_results.csv:row=1282;CYP1A2_results.csv:row=1282;CYP2C9_results.csv:row=1282;hERG_results.csv:row=1282;AMES_results.csv:row=1282;PGP_results.csv:row=1282;PAMPA_results.csv:row=1282;BBB_results.csv:row=1282;Solubility_results.csv:row=1282;Lipophilicity_results.csv:row=1283
CHEMBL1514,LEVOMETHADYL ACETATE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.88; logP 4.65,repurposing_candidates.csv:rc_row=443;protein_drug_candidates.csv:rows=302;pathway_drug_candidates.csv:rows=272;1306;7219;CYP3A4_results.csv:row=403;CYP2C19_results.csv:row=403;CYP2D6_results.csv:row=403;CYP1A2_results.csv:row=403;CYP2C9_results.csv:row=403;hERG_results.csv:row=403;AMES_results.csv:row=403;PGP_results.csv:row=403;PAMPA_results.csv:row=403;BBB_results.csv:row=403;Solubility_results.csv:row=403;Lipophilicity_results.csv:row=404
CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.71; logP 4.84,repurposing_candidates.csv:rc_row=844;protein_drug_candidates.csv:rows=300;pathway_drug_candidates.csv:rows=270;1304;7217;CYP3A4_results.csv:row=752;CYP2C19_results.csv:row=752;CYP2D6_results.csv:row=752;CYP1A2_results.csv:row=752;CYP2C9_results.csv:row=752;hERG_results.csv:row=752;AMES_results.csv:row=752;PGP_results.csv:row=752;PAMPA_results.csv:row=752;BBB_results.csv:row=752;Solubility_results.csv:row=752;Lipophilicity_results.csv:row=753
CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.61; logP 2.05,repurposing_candidates.csv:rc_row=345;protein_drug_candidates.csv:rows=281;pathway_drug_candidates.csv:rows=251;1285;7198;CYP3A4_results.csv:row=307;CYP2C19_results.csv:row=307;CYP2D6_results.csv:row=307;CYP1A2_results.csv:row=307;CYP2C9_results.csv:row=307;hERG_results.csv:row=307;AMES_results.csv:row=307;PGP_results.csv:row=307;PAMPA_results.csv:row=307;BBB_results.csv:row=307;Solubility_results.csv:row=307;Lipophilicity_results.csv:row=308
CHEMBL1200890,OXYCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -0.91; logP 1.47,repurposing_candidates.csv:rc_row=188;protein_drug_candidates.csv:rows=276;pathway_drug_candidates.csv:rows=246;1280;7193;CYP3A4_results.csv:row=186;CYP2C19_results.csv:row=186;CYP2D6_results.csv:row=186;CYP1A2_results.csv:row=186;CYP2C9_results.csv:row=186;hERG_results.csv:row=186;AMES_results.csv:row=186;PGP_results.csv:row=186;PAMPA_results.csv:row=186;BBB_results.csv:row=186;Solubility_results.csv:row=186;Lipophilicity_results.csv:row=187
CHEMBL688,FENTANYL CITRATE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.65; logP 2.89,repurposing_candidates.csv:rc_row=1488;protein_drug_candidates.csv:rows=271;pathway_drug_candidates.csv:rows=241;1275;7188;CYP3A4_results.csv:row=1294;CYP2C19_results.csv:row=1294;CYP2D6_results.csv:row=1294;CYP1A2_results.csv:row=1294;CYP2C9_results.csv:row=1294;hERG_results.csv:row=1294;AMES_results.csv:row=1294;PGP_results.csv:row=1294;PAMPA_results.csv:row=1294;BBB_results.csv:row=1294;Solubility_results.csv:row=1294;Lipophilicity_results.csv:row=1295
CHEMBL1200825,METHADONE HYDROCHLORIDE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,47.88329519450801,100,70.0,71.6533180778032,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.44; logP 4.71,repurposing_candidates.csv:rc_row=178;protein_drug_candidates.csv:rows=275;pathway_drug_candidates.csv:rows=245;1279;7192;CYP3A4_results.csv:row=176;CYP2C19_results.csv:row=176;CYP2D6_results.csv:row=176;CYP1A2_results.csv:row=176;CYP2C9_results.csv:row=176;hERG_results.csv:row=176;AMES_results.csv:row=176;PGP_results.csv:row=176;PAMPA_results.csv:row=176;BBB_results.csv:row=176;Solubility_results.csv:row=176;Lipophilicity_results.csv:row=177
CHEMBL1201212,MIDODRINE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1,32.15865751334859,100,95.0,71.61346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.61; logP -0.19",repurposing_candidates.csv:rc_row=258;protein_drug_candidates.csv:rows=349;1466;1827;pathway_drug_candidates.csv:rows=812;6474;6674;CYP3A4_results.csv:row=255;CYP2C19_results.csv:row=255;CYP2D6_results.csv:row=255;CYP1A2_results.csv:row=255;CYP2C9_results.csv:row=255;hERG_results.csv:row=255;AMES_results.csv:row=255;PGP_results.csv:row=255;PAMPA_results.csv:row=255;BBB_results.csv:row=255;Solubility_results.csv:row=255;Lipophilicity_results.csv:row=256
CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O,32.15865751334859,100,95.0,71.61346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -2.15; logP -0.17",repurposing_candidates.csv:rc_row=1073;protein_drug_candidates.csv:rows=361;1465;1823;pathway_drug_candidates.csv:rows=824;6486;6686;CYP3A4_results.csv:row=942;CYP2C19_results.csv:row=942;CYP2D6_results.csv:row=942;CYP1A2_results.csv:row=942;CYP2C9_results.csv:row=942;hERG_results.csv:row=942;AMES_results.csv:row=942;PGP_results.csv:row=942;PAMPA_results.csv:row=942;BBB_results.csv:row=942;Solubility_results.csv:row=942;Lipophilicity_results.csv:row=943
CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,CNC[C@H](O)c1cccc(O)c1.Cl,32.15865751334859,100,95.0,71.61346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.17; logP 1.07",repurposing_candidates.csv:rc_row=88;protein_drug_candidates.csv:rows=386;1482;1842;pathway_drug_candidates.csv:rows=849;6511;6711;CYP3A4_results.csv:row=87;CYP2C19_results.csv:row=87;CYP2D6_results.csv:row=87;CYP1A2_results.csv:row=87;CYP2C9_results.csv:row=87;hERG_results.csv:row=87;AMES_results.csv:row=87;PGP_results.csv:row=87;PAMPA_results.csv:row=87;BBB_results.csv:row=87;Solubility_results.csv:row=87;Lipophilicity_results.csv:row=87
CHEMBL12713,SERTINDOLE,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,32.15865751334859,100,95.0,71.61346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -4.76; logP 4.63",repurposing_candidates.csv:rc_row=369;protein_drug_candidates.csv:rows=388;1490;1849;pathway_drug_candidates.csv:rows=851;6513;6713;CYP3A4_results.csv:row=330;CYP2C19_results.csv:row=330;CYP2D6_results.csv:row=330;CYP1A2_results.csv:row=330;CYP2C9_results.csv:row=330;hERG_results.csv:row=330;AMES_results.csv:row=330;PGP_results.csv:row=330;PAMPA_results.csv:row=330;BBB_results.csv:row=330;Solubility_results.csv:row=330;Lipophilicity_results.csv:row=331
CHEMBL1215,PHENYLEPHRINE,CNC[C@H](O)c1cccc(O)c1,32.15865751334859,100,95.0,71.61346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.86; logP 0.65",repurposing_candidates.csv:rc_row=333;protein_drug_candidates.csv:rows=365;1458;1813;pathway_drug_candidates.csv:rows=828;6490;6690;CYP3A4_results.csv:row=296;CYP2C19_results.csv:row=296;CYP2D6_results.csv:row=296;CYP1A2_results.csv:row=296;CYP2C9_results.csv:row=296;hERG_results.csv:row=296;AMES_results.csv:row=296;PGP_results.csv:row=296;PAMPA_results.csv:row=296;BBB_results.csv:row=296;Solubility_results.csv:row=296;Lipophilicity_results.csv:row=297
CHEMBL1201554,ANTITHROMBIN ALFA,,29.02364607170099,100,100.0,71.6094584286804,H,KG targets F10; clinical phase 4.0,repurposing_candidates.csv:rc_row=286;protein_drug_candidates.csv:rows=455;pathway_drug_candidates.csv:rows=7535;7564;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297951,COAGULATION FACTOR X HUMAN,,29.02364607170099,100,100.0,71.6094584286804,H,KG targets F10; clinical phase 4.0,repurposing_candidates.csv:rc_row=1234;protein_drug_candidates.csv:rows=454;pathway_drug_candidates.csv:rows=7534;7563;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL277474,ANTIPYRINE,Cc1cc(=O)n(-c2ccccc2)n1C,29.02364607170099,100,100.0,71.6094584286804,H,KG targets PTGS1; clinical phase 4.0; logS -0.75; logP 1.48,repurposing_candidates.csv:rc_row=872;protein_drug_candidates.csv:rows=905;pathway_drug_candidates.csv:rows=5545;5605;CYP3A4_results.csv:row=780;CYP2C19_results.csv:row=780;CYP2D6_results.csv:row=780;CYP1A2_results.csv:row=780;CYP2C9_results.csv:row=780;hERG_results.csv:row=780;AMES_results.csv:row=780;PGP_results.csv:row=780;PAMPA_results.csv:row=780;BBB_results.csv:row=780;Solubility_results.csv:row=780;Lipophilicity_results.csv:row=781
CHEMBL94081,ALCLOFENAC,C=CCOc1ccc(CC(=O)O)cc1Cl,29.02364607170099,100,100.0,71.6094584286804,H,KG targets PTGS1; clinical phase 4.0; logS -2.84; logP 2.53,repurposing_candidates.csv:rc_row=1559;protein_drug_candidates.csv:rows=914;pathway_drug_candidates.csv:rows=5554;5614;CYP3A4_results.csv:row=1365;CYP2C19_results.csv:row=1365;CYP2D6_results.csv:row=1365;CYP1A2_results.csv:row=1365;CYP2C9_results.csv:row=1365;hERG_results.csv:row=1365;AMES_results.csv:row=1365;PGP_results.csv:row=1365;PAMPA_results.csv:row=1365;BBB_results.csv:row=1365;Solubility_results.csv:row=1365;Lipophilicity_results.csv:row=1366
CHEMBL3833393,EMICIZUMAB,,29.02364607170099,100,100.0,71.6094584286804,H,KG targets F10; clinical phase 4.0,repurposing_candidates.csv:rc_row=1048;protein_drug_candidates.csv:rows=456;pathway_drug_candidates.csv:rows=7536;7565;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL139835,CYPROTERONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,52.34553775743707,80,90.0,71.43821510297482,H,"KG targets AR, NR3C1; clinical phase 3.0; logS -6.59; logP 4.61",repurposing_candidates.csv:rc_row=402;protein_drug_candidates.csv:rows=51;559;pathway_drug_candidates.csv:rows=743;1982;2052;5897;5967;7801;7871;8008;8074;8145;8211;8277;CYP3A4_results.csv:row=362;CYP2C19_results.csv:row=362;CYP2D6_results.csv:row=362;CYP1A2_results.csv:row=362;CYP2C9_results.csv:row=362;hERG_results.csv:row=362;AMES_results.csv:row=362;PGP_results.csv:row=362;PAMPA_results.csv:row=362;BBB_results.csv:row=362;Solubility_results.csv:row=362;Lipophilicity_results.csv:row=363
CHEMBL1200638,DEXBROMPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.22; logP 3.64,repurposing_candidates.csv:rc_row=141;protein_drug_candidates.csv:rows=974;pathway_drug_candidates.csv:rows=6604;CYP3A4_results.csv:row=140;CYP2C19_results.csv:row=140;CYP2D6_results.csv:row=140;CYP1A2_results.csv:row=140;CYP2C9_results.csv:row=140;hERG_results.csv:row=140;AMES_results.csv:row=140;PGP_results.csv:row=140;PAMPA_results.csv:row=140;BBB_results.csv:row=140;Solubility_results.csv:row=140;Lipophilicity_results.csv:row=140
CHEMBL1106,EPINASTINE,NC1=NCC2c3ccccc3Cc3ccccc3N12,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -4.36; logP 2.47,repurposing_candidates.csv:rc_row=50;protein_drug_candidates.csv:rows=967;pathway_drug_candidates.csv:rows=6597;CYP3A4_results.csv:row=50;CYP2C19_results.csv:row=50;CYP2D6_results.csv:row=50;CYP1A2_results.csv:row=50;CYP2C9_results.csv:row=50;hERG_results.csv:row=50;AMES_results.csv:row=50;PGP_results.csv:row=50;PAMPA_results.csv:row=50;BBB_results.csv:row=50;Solubility_results.csv:row=50;Lipophilicity_results.csv:row=50
CHEMBL578,ENALAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets ACE; clinical phase 4.0; logS -1.36; logP 1.60,repurposing_candidates.csv:rc_row=1426;protein_drug_candidates.csv:rows=644;pathway_drug_candidates.csv:rows=440;CYP3A4_results.csv:row=1235;CYP2C19_results.csv:row=1235;CYP2D6_results.csv:row=1235;CYP1A2_results.csv:row=1235;CYP2C9_results.csv:row=1235;hERG_results.csv:row=1235;AMES_results.csv:row=1235;PGP_results.csv:row=1235;PAMPA_results.csv:row=1235;BBB_results.csv:row=1235;Solubility_results.csv:row=1235;Lipophilicity_results.csv:row=1236
CHEMBL1201556,BECAPLERMIN,,28.497330282227306,100,100.0,71.39893211289092,H,KG targets PDGFRB; clinical phase 4.0,repurposing_candidates.csv:rc_row=287;protein_drug_candidates.csv:rows=1108;pathway_drug_candidates.csv:rows=7006;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2097081,NITROPRUSSIDE,,28.497330282227306,100,100.0,71.39893211289092,H,KG targets GUCY1B1; clinical phase 4.0,repurposing_candidates.csv:rc_row=652;protein_drug_candidates.csv:rows=72;pathway_drug_candidates.csv:rows=7688;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1083385,CLOPIDOGREL BISULFATE,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets P2RY12; clinical phase 4.0; logS -2.78; logP 3.02,repurposing_candidates.csv:rc_row=32;protein_drug_candidates.csv:rows=464;pathway_drug_candidates.csv:rows=1349;CYP3A4_results.csv:row=32;CYP2C19_results.csv:row=32;CYP2D6_results.csv:row=32;CYP1A2_results.csv:row=32;CYP2C9_results.csv:row=32;hERG_results.csv:row=32;AMES_results.csv:row=32;PGP_results.csv:row=32;PAMPA_results.csv:row=32;BBB_results.csv:row=32;Solubility_results.csv:row=32;Lipophilicity_results.csv:row=32
CHEMBL838,BENAZEPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets ACE; clinical phase 4.0; logS -2.96; logP 2.57,repurposing_candidates.csv:rc_row=1531;protein_drug_candidates.csv:rows=645;pathway_drug_candidates.csv:rows=441;CYP3A4_results.csv:row=1337;CYP2C19_results.csv:row=1337;CYP2D6_results.csv:row=1337;CYP1A2_results.csv:row=1337;CYP2C9_results.csv:row=1337;hERG_results.csv:row=1337;AMES_results.csv:row=1337;PGP_results.csv:row=1337;PAMPA_results.csv:row=1337;BBB_results.csv:row=1337;Solubility_results.csv:row=1337;Lipophilicity_results.csv:row=1338
CHEMBL3039504,NINTEDANIB ESYLATE,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets PDGFRB; clinical phase 4.0; logS -2.14; logP 3.51,repurposing_candidates.csv:rc_row=892;protein_drug_candidates.csv:rows=1107;pathway_drug_candidates.csv:rows=7005;CYP3A4_results.csv:row=800;CYP2C19_results.csv:row=800;CYP2D6_results.csv:row=800;CYP1A2_results.csv:row=800;CYP2C9_results.csv:row=800;hERG_results.csv:row=800;AMES_results.csv:row=800;PGP_results.csv:row=800;PAMPA_results.csv:row=800;BBB_results.csv:row=800;Solubility_results.csv:row=800;Lipophilicity_results.csv:row=801
CHEMBL1200961,BROMPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.22; logP 3.64,repurposing_candidates.csv:rc_row=202;protein_drug_candidates.csv:rows=957;pathway_drug_candidates.csv:rows=6587;CYP3A4_results.csv:row=200;CYP2C19_results.csv:row=200;CYP2D6_results.csv:row=200;CYP1A2_results.csv:row=200;CYP2C9_results.csv:row=200;hERG_results.csv:row=200;AMES_results.csv:row=200;PGP_results.csv:row=200;PAMPA_results.csv:row=200;BBB_results.csv:row=200;Solubility_results.csv:row=200;Lipophilicity_results.csv:row=201
CHEMBL2107834,RIOCIGUAT,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,28.497330282227306,100,100.0,71.39893211289092,H,KG targets GUCY1B1; clinical phase 4.0; logS -3.81; logP 2.44,repurposing_candidates.csv:rc_row=740;protein_drug_candidates.csv:rows=73;pathway_drug_candidates.csv:rows=7689;CYP3A4_results.csv:row=685;CYP2C19_results.csv:row=685;CYP2D6_results.csv:row=685;CYP1A2_results.csv:row=685;CYP2C9_results.csv:row=685;hERG_results.csv:row=685;AMES_results.csv:row=685;PGP_results.csv:row=685;PAMPA_results.csv:row=685;BBB_results.csv:row=685;Solubility_results.csv:row=685;Lipophilicity_results.csv:row=686
CHEMBL2105458,THENALIDINE,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.43; logP 3.85,repurposing_candidates.csv:rc_row=689;protein_drug_candidates.csv:rows=986;pathway_drug_candidates.csv:rows=6616;CYP3A4_results.csv:row=634;CYP2C19_results.csv:row=634;CYP2D6_results.csv:row=634;CYP1A2_results.csv:row=634;CYP2C9_results.csv:row=634;hERG_results.csv:row=634;AMES_results.csv:row=634;PGP_results.csv:row=634;PAMPA_results.csv:row=634;BBB_results.csv:row=634;Solubility_results.csv:row=634;Lipophilicity_results.csv:row=635
CHEMBL431,SPIRAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,28.497330282227306,100,100.0,71.39893211289092,H,KG targets ACE; clinical phase 4.0; logS -2.67; logP 2.39,repurposing_candidates.csv:rc_row=1254;protein_drug_candidates.csv:rows=635;pathway_drug_candidates.csv:rows=431;CYP3A4_results.csv:row=1074;CYP2C19_results.csv:row=1074;CYP2D6_results.csv:row=1074;CYP1A2_results.csv:row=1074;CYP2C9_results.csv:row=1074;hERG_results.csv:row=1074;AMES_results.csv:row=1074;PGP_results.csv:row=1074;PAMPA_results.csv:row=1074;BBB_results.csv:row=1074;Solubility_results.csv:row=1074;Lipophilicity_results.csv:row=1075
CHEMBL534,KETOTIFEN,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.51; logP 4.01,repurposing_candidates.csv:rc_row=1397;protein_drug_candidates.csv:rows=970;pathway_drug_candidates.csv:rows=6600;CYP3A4_results.csv:row=1206;CYP2C19_results.csv:row=1206;CYP2D6_results.csv:row=1206;CYP1A2_results.csv:row=1206;CYP2C9_results.csv:row=1206;hERG_results.csv:row=1206;AMES_results.csv:row=1206;PGP_results.csv:row=1206;PAMPA_results.csv:row=1206;BBB_results.csv:row=1206;Solubility_results.csv:row=1206;Lipophilicity_results.csv:row=1207
CHEMBL24441,BETAHISTINE,CNCCc1ccccn1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS 0.95; logP 0.84,repurposing_candidates.csv:rc_row=850;protein_drug_candidates.csv:rows=990;pathway_drug_candidates.csv:rows=6620;CYP3A4_results.csv:row=758;CYP2C19_results.csv:row=758;CYP2D6_results.csv:row=758;CYP1A2_results.csv:row=758;CYP2C9_results.csv:row=758;hERG_results.csv:row=758;AMES_results.csv:row=758;PGP_results.csv:row=758;PAMPA_results.csv:row=758;BBB_results.csv:row=758;Solubility_results.csv:row=758;Lipophilicity_results.csv:row=759
CHEMBL833,TICLOPIDINE,Clc1ccccc1CN1CCc2sccc2C1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets P2RY12; clinical phase 4.0; logS -3.37; logP 3.96,repurposing_candidates.csv:rc_row=1529;protein_drug_candidates.csv:rows=470;pathway_drug_candidates.csv:rows=1355;CYP3A4_results.csv:row=1335;CYP2C19_results.csv:row=1335;CYP2D6_results.csv:row=1335;CYP1A2_results.csv:row=1335;CYP2C9_results.csv:row=1335;hERG_results.csv:row=1335;AMES_results.csv:row=1335;PGP_results.csv:row=1335;PAMPA_results.csv:row=1335;BBB_results.csv:row=1335;Solubility_results.csv:row=1335;Lipophilicity_results.csv:row=1336
CHEMBL1200406,DIMENHYDRINATE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.32; logP 2.97,repurposing_candidates.csv:rc_row=96;protein_drug_candidates.csv:rows=1014;pathway_drug_candidates.csv:rows=6644;CYP3A4_results.csv:row=95;CYP2C19_results.csv:row=95;CYP2D6_results.csv:row=95;CYP1A2_results.csv:row=95;CYP2C9_results.csv:row=95;hERG_results.csv:row=95;AMES_results.csv:row=95;PGP_results.csv:row=95;PAMPA_results.csv:row=95;BBB_results.csv:row=95;Solubility_results.csv:row=95;Lipophilicity_results.csv:row=95
CHEMBL864,CARBINOXAMINE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.03; logP 3.40,repurposing_candidates.csv:rc_row=1539;protein_drug_candidates.csv:rows=1010;pathway_drug_candidates.csv:rows=6640;CYP3A4_results.csv:row=1345;CYP2C19_results.csv:row=1345;CYP2D6_results.csv:row=1345;CYP1A2_results.csv:row=1345;CYP2C9_results.csv:row=1345;hERG_results.csv:row=1345;AMES_results.csv:row=1345;PGP_results.csv:row=1345;PAMPA_results.csv:row=1345;BBB_results.csv:row=1345;Solubility_results.csv:row=1345;Lipophilicity_results.csv:row=1346
CHEMBL1771,CLOPIDOGREL,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets P2RY12; clinical phase 4.0; logS -3.66; logP 3.67,repurposing_candidates.csv:rc_row=567;protein_drug_candidates.csv:rows=469;pathway_drug_candidates.csv:rows=1354;CYP3A4_results.csv:row=513;CYP2C19_results.csv:row=513;CYP2D6_results.csv:row=513;CYP1A2_results.csv:row=513;CYP2C9_results.csv:row=513;hERG_results.csv:row=513;AMES_results.csv:row=513;PGP_results.csv:row=513;PAMPA_results.csv:row=513;BBB_results.csv:row=513;Solubility_results.csv:row=513;Lipophilicity_results.csv:row=514
CHEMBL811,BROMPHENIRAMINE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.67; logP 3.93,repurposing_candidates.csv:rc_row=1522;protein_drug_candidates.csv:rows=1019;pathway_drug_candidates.csv:rows=6649;CYP3A4_results.csv:row=1328;CYP2C19_results.csv:row=1328;CYP2D6_results.csv:row=1328;CYP1A2_results.csv:row=1328;CYP2C9_results.csv:row=1328;hERG_results.csv:row=1328;AMES_results.csv:row=1328;PGP_results.csv:row=1328;PAMPA_results.csv:row=1328;BBB_results.csv:row=1328;Solubility_results.csv:row=1328;Lipophilicity_results.csv:row=1329
CHEMBL1592,QUINAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets ACE; clinical phase 4.0; logS -2.75; logP 2.57,repurposing_candidates.csv:rc_row=470;protein_drug_candidates.csv:rows=641;pathway_drug_candidates.csv:rows=437;CYP3A4_results.csv:row=430;CYP2C19_results.csv:row=430;CYP2D6_results.csv:row=430;CYP1A2_results.csv:row=430;CYP2C9_results.csv:row=430;hERG_results.csv:row=430;AMES_results.csv:row=430;PGP_results.csv:row=430;PAMPA_results.csv:row=430;BBB_results.csv:row=430;Solubility_results.csv:row=430;Lipophilicity_results.csv:row=431
CHEMBL1742423,BILASTINE,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.91; logP 4.86,repurposing_candidates.csv:rc_row=539;protein_drug_candidates.csv:rows=969;pathway_drug_candidates.csv:rows=6599;CYP3A4_results.csv:row=499;CYP2C19_results.csv:row=499;CYP2D6_results.csv:row=499;CYP1A2_results.csv:row=499;CYP2C9_results.csv:row=499;hERG_results.csv:row=499;AMES_results.csv:row=499;PGP_results.csv:row=499;PAMPA_results.csv:row=499;BBB_results.csv:row=499;Solubility_results.csv:row=499;Lipophilicity_results.csv:row=500
CHEMBL1193,PHENIRAMINE,CN(C)CCC(c1ccccc1)c1ccccn1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -1.50; logP 3.17,repurposing_candidates.csv:rc_row=77;protein_drug_candidates.csv:rows=984;pathway_drug_candidates.csv:rows=6614;CYP3A4_results.csv:row=76;CYP2C19_results.csv:row=76;CYP2D6_results.csv:row=76;CYP1A2_results.csv:row=76;CYP2C9_results.csv:row=76;hERG_results.csv:row=76;AMES_results.csv:row=76;PGP_results.csv:row=76;PAMPA_results.csv:row=76;BBB_results.csv:row=76;Solubility_results.csv:row=76;Lipophilicity_results.csv:row=76
CHEMBL1620,DIPHENHYDRAMINE HYDROCHLORIDE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.07; logP 3.78,repurposing_candidates.csv:rc_row=481;protein_drug_candidates.csv:rows=963;pathway_drug_candidates.csv:rows=6593;CYP3A4_results.csv:row=441;CYP2C19_results.csv:row=441;CYP2D6_results.csv:row=441;CYP1A2_results.csv:row=441;CYP2C9_results.csv:row=441;hERG_results.csv:row=441;AMES_results.csv:row=441;PGP_results.csv:row=441;PAMPA_results.csv:row=441;BBB_results.csv:row=441;Solubility_results.csv:row=441;Lipophilicity_results.csv:row=442
CHEMBL1200491,EPINASTINE HYDROCHLORIDE,Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.77; logP 2.89,repurposing_candidates.csv:rc_row=111;protein_drug_candidates.csv:rows=982;pathway_drug_candidates.csv:rows=6612;CYP3A4_results.csv:row=110;CYP2C19_results.csv:row=110;CYP2D6_results.csv:row=110;CYP1A2_results.csv:row=110;CYP2C9_results.csv:row=110;hERG_results.csv:row=110;AMES_results.csv:row=110;PGP_results.csv:row=110;PAMPA_results.csv:row=110;BBB_results.csv:row=110;Solubility_results.csv:row=110;Lipophilicity_results.csv:row=110
CHEMBL1201287,DEXBROMPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.67; logP 3.93,repurposing_candidates.csv:rc_row=267;protein_drug_candidates.csv:rows=999;pathway_drug_candidates.csv:rows=6629;CYP3A4_results.csv:row=264;CYP2C19_results.csv:row=264;CYP2D6_results.csv:row=264;CYP1A2_results.csv:row=264;CYP2C9_results.csv:row=264;hERG_results.csv:row=264;AMES_results.csv:row=264;PGP_results.csv:row=264;PAMPA_results.csv:row=264;BBB_results.csv:row=264;Solubility_results.csv:row=264;Lipophilicity_results.csv:row=265
CHEMBL1581,PERINDOPRIL,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,28.497330282227306,100,100.0,71.39893211289092,H,KG targets ACE; clinical phase 4.0; logS -1.38; logP 1.94,repurposing_candidates.csv:rc_row=467;protein_drug_candidates.csv:rows=640;pathway_drug_candidates.csv:rows=436;CYP3A4_results.csv:row=427;CYP2C19_results.csv:row=427;CYP2D6_results.csv:row=427;CYP1A2_results.csv:row=427;CYP2C9_results.csv:row=427;hERG_results.csv:row=427;AMES_results.csv:row=427;PGP_results.csv:row=427;PAMPA_results.csv:row=427;BBB_results.csv:row=427;Solubility_results.csv:row=427;Lipophilicity_results.csv:row=428
CHEMBL1200974,CARBINOXAMINE MALEATE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -1.57; logP 3.11,repurposing_candidates.csv:rc_row=205;protein_drug_candidates.csv:rows=975;pathway_drug_candidates.csv:rows=6605;CYP3A4_results.csv:row=203;CYP2C19_results.csv:row=203;CYP2D6_results.csv:row=203;CYP1A2_results.csv:row=203;CYP2C9_results.csv:row=203;hERG_results.csv:row=203;AMES_results.csv:row=203;PGP_results.csv:row=203;PAMPA_results.csv:row=203;BBB_results.csv:row=203;Solubility_results.csv:row=203;Lipophilicity_results.csv:row=204
CHEMBL1717,TICLOPIDINE HYDROCHLORIDE,Cl.Clc1ccccc1CN1CCc2sccc2C1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets P2RY12; clinical phase 4.0; logS -2.67; logP 4.38,repurposing_candidates.csv:rc_row=528;protein_drug_candidates.csv:rows=468;pathway_drug_candidates.csv:rows=1353;CYP3A4_results.csv:row=488;CYP2C19_results.csv:row=488;CYP2D6_results.csv:row=488;CYP1A2_results.csv:row=488;CYP2C9_results.csv:row=488;hERG_results.csv:row=488;AMES_results.csv:row=488;PGP_results.csv:row=488;PAMPA_results.csv:row=488;BBB_results.csv:row=488;Solubility_results.csv:row=488;Lipophilicity_results.csv:row=489
CHEMBL1442422,DIBENZEPIN,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.84; logP 2.98,repurposing_candidates.csv:rc_row=418;protein_drug_candidates.csv:rows=1012;pathway_drug_candidates.csv:rows=6642;CYP3A4_results.csv:row=378;CYP2C19_results.csv:row=378;CYP2D6_results.csv:row=378;CYP1A2_results.csv:row=378;CYP2C9_results.csv:row=378;hERG_results.csv:row=378;AMES_results.csv:row=378;PGP_results.csv:row=378;PAMPA_results.csv:row=378;BBB_results.csv:row=378;Solubility_results.csv:row=378;Lipophilicity_results.csv:row=379
CHEMBL1201264,METHANTHELINE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH2; clinical phase 4.0; logS -1.65; logP 3.95,repurposing_candidates.csv:rc_row=264;protein_drug_candidates.csv:rows=752;pathway_drug_candidates.csv:rows=5821;CYP3A4_results.csv:row=261;CYP2C19_results.csv:row=261;CYP2D6_results.csv:row=261;CYP1A2_results.csv:row=261;CYP2C9_results.csv:row=261;hERG_results.csv:row=261;AMES_results.csv:row=261;PGP_results.csv:row=261;PAMPA_results.csv:row=261;BBB_results.csv:row=261;Solubility_results.csv:row=261;Lipophilicity_results.csv:row=262
CHEMBL657,DIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccccc1,28.497330282227306,100,100.0,71.39893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.74; logP 3.35,repurposing_candidates.csv:rc_row=1477;protein_drug_candidates.csv:rows=989;pathway_drug_candidates.csv:rows=6619;CYP3A4_results.csv:row=1283;CYP2C19_results.csv:row=1283;CYP2D6_results.csv:row=1283;CYP1A2_results.csv:row=1283;CYP2C9_results.csv:row=1283;hERG_results.csv:row=1283;AMES_results.csv:row=1283;PGP_results.csv:row=1283;PAMPA_results.csv:row=1283;BBB_results.csv:row=1283;Solubility_results.csv:row=1283;Lipophilicity_results.csv:row=1284
CHEMBL1433,DOXYCYCLINE ANHYDROUS,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,35.56826849733028,95,95.0,71.22730739893211,H,"KG targets MMP1, MMP13; clinical phase 3.0; logS -3.03; logP -0.35",repurposing_candidates.csv:rc_row=413;protein_drug_candidates.csv:rows=611;616;622;629;pathway_drug_candidates.csv:rows=27;33;40;45;51;57;64;69;82;88;95;100;113;127;232;3029;CYP3A4_results.csv:row=373;CYP2C19_results.csv:row=373;CYP2D6_results.csv:row=373;CYP1A2_results.csv:row=373;CYP2C9_results.csv:row=373;hERG_results.csv:row=373;AMES_results.csv:row=373;PGP_results.csv:row=373;PAMPA_results.csv:row=373;BBB_results.csv:row=373;Solubility_results.csv:row=373;Lipophilicity_results.csv:row=374
CHEMBL3137308,PEFICITINIB,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2,45.31655225019069,80,100.0,71.12662090007628,H,"KG targets JAK1, JAK2; clinical phase 3.0; logS -2.89; logP 2.01",repurposing_candidates.csv:rc_row=907;protein_drug_candidates.csv:rows=766;790;1190;pathway_drug_candidates.csv:rows=191;215;408;653;677;787;4243;4272;4422;4526;4563;4587;4609;4642;4666;4688;4721;4745;4767;4790;4808;4828;4852;4874;4897;4921;4943;4963;4987;5009;5029;5053;5075;5097;5119;5139;5163;5185;5217;5235;5267;5285;5305;5329;5351;5371;5395;5417;5433;5465;5483;6918;6942;7476;8305;8333;8361;8395;8423;8451;CYP3A4_results.csv:row=814;CYP2C19_results.csv:row=814;CYP2D6_results.csv:row=814;CYP1A2_results.csv:row=814;CYP2C9_results.csv:row=814;hERG_results.csv:row=814;AMES_results.csv:row=814;PGP_results.csv:row=814;PAMPA_results.csv:row=814;BBB_results.csv:row=814;Solubility_results.csv:row=814;Lipophilicity_results.csv:row=815
CHEMBL1200733,DESFLURANE,FC(F)OC(F)C(F)(F)F,80.80091533180779,60,70.0,70.82036613272311,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; hERG risk; logS -1.82; logP 2.08",repurposing_candidates.csv:rc_row=159;protein_drug_candidates.csv:rows=521;526;529;534;539;542;1406;1446;1531;1671;1719;1758;1788;1807;1880;1943;2080;2126;2485;2566;2593;2637;pathway_drug_candidates.csv:rows=2;5;8;11;14;19;24;7726;7731;7906;CYP3A4_results.csv:row=157;CYP2C19_results.csv:row=157;CYP2D6_results.csv:row=157;CYP1A2_results.csv:row=157;CYP2C9_results.csv:row=157;hERG_results.csv:row=157;AMES_results.csv:row=157;PGP_results.csv:row=157;PAMPA_results.csv:row=157;BBB_results.csv:row=157;Solubility_results.csv:row=157;Lipophilicity_results.csv:row=158
CHEMBL969,PRAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -5.03; logP 3.93",repurposing_candidates.csv:rc_row=1572;protein_drug_candidates.csv:rows=497;1418;1653;1688;2051;2104;2464;CYP3A4_results.csv:row=1378;CYP2C19_results.csv:row=1378;CYP2D6_results.csv:row=1378;CYP1A2_results.csv:row=1378;CYP2C9_results.csv:row=1378;hERG_results.csv:row=1378;AMES_results.csv:row=1378;PGP_results.csv:row=1378;PAMPA_results.csv:row=1378;BBB_results.csv:row=1378;Solubility_results.csv:row=1378;Lipophilicity_results.csv:row=1379
CHEMBL568,OXAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -3.84; logP 2.45",repurposing_candidates.csv:rc_row=1416;protein_drug_candidates.csv:rows=485;1432;1640;1684;2061;2107;2466;CYP3A4_results.csv:row=1225;CYP2C19_results.csv:row=1225;CYP2D6_results.csv:row=1225;CYP1A2_results.csv:row=1225;CYP2C9_results.csv:row=1225;hERG_results.csv:row=1225;AMES_results.csv:row=1225;PGP_results.csv:row=1225;PAMPA_results.csv:row=1225;BBB_results.csv:row=1225;Solubility_results.csv:row=1225;Lipophilicity_results.csv:row=1226
CHEMBL646,TRIAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -3.91; logP 4.23",repurposing_candidates.csv:rc_row=1469;protein_drug_candidates.csv:rows=496;1420;1644;1696;2053;2103;2457;CYP3A4_results.csv:row=1275;CYP2C19_results.csv:row=1275;CYP2D6_results.csv:row=1275;CYP1A2_results.csv:row=1275;CYP2C9_results.csv:row=1275;hERG_results.csv:row=1275;AMES_results.csv:row=1275;PGP_results.csv:row=1275;PAMPA_results.csv:row=1275;BBB_results.csv:row=1275;Solubility_results.csv:row=1275;Lipophilicity_results.csv:row=1276
CHEMBL661,ALPRAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -3.89; logP 3.58",repurposing_candidates.csv:rc_row=1480;protein_drug_candidates.csv:rows=484;1413;1636;1682;2044;2090;2451;CYP3A4_results.csv:row=1286;CYP2C19_results.csv:row=1286;CYP2D6_results.csv:row=1286;CYP1A2_results.csv:row=1286;CYP2C9_results.csv:row=1286;hERG_results.csv:row=1286;AMES_results.csv:row=1286;PGP_results.csv:row=1286;PAMPA_results.csv:row=1286;BBB_results.csv:row=1286;Solubility_results.csv:row=1286;Lipophilicity_results.csv:row=1287
CHEMBL967,TEMAZEPAM,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -2.85; logP 2.47",repurposing_candidates.csv:rc_row=1570;protein_drug_candidates.csv:rows=491;1421;1651;1689;2058;2097;2458;CYP3A4_results.csv:row=1376;CYP2C19_results.csv:row=1376;CYP2D6_results.csv:row=1376;CYP1A2_results.csv:row=1376;CYP2C9_results.csv:row=1376;hERG_results.csv:row=1376;AMES_results.csv:row=1376;PGP_results.csv:row=1376;PAMPA_results.csv:row=1376;BBB_results.csv:row=1376;Solubility_results.csv:row=1376;Lipophilicity_results.csv:row=1377
CHEMBL1697737,CLOTIAZEPAM,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -4.43; logP 3.78",repurposing_candidates.csv:rc_row=515;protein_drug_candidates.csv:rows=499;1430;1637;1699;2060;2091;2452;CYP3A4_results.csv:row=475;CYP2C19_results.csv:row=475;CYP2D6_results.csv:row=475;CYP1A2_results.csv:row=475;CYP2C9_results.csv:row=475;hERG_results.csv:row=475;AMES_results.csv:row=475;PGP_results.csv:row=475;PAMPA_results.csv:row=475;BBB_results.csv:row=475;Solubility_results.csv:row=475;Lipophilicity_results.csv:row=476
CHEMBL285674,ESTAZOLAM,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,45.79710144927536,100,70.0,70.81884057971014,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -4.40; logP 3.27",repurposing_candidates.csv:rc_row=881;protein_drug_candidates.csv:rows=488;1428;1649;1687;2049;2094;2455;CYP3A4_results.csv:row=789;CYP2C19_results.csv:row=789;CYP2D6_results.csv:row=789;CYP1A2_results.csv:row=789;CYP2C9_results.csv:row=789;hERG_results.csv:row=789;AMES_results.csv:row=789;PGP_results.csv:row=789;PAMPA_results.csv:row=789;BBB_results.csv:row=789;Solubility_results.csv:row=789;Lipophilicity_results.csv:row=790
CHEMBL3989932,ANGIOTENSIN II ACETATE,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,30.076277650648358,100,95.0,70.78051106025934,H,KG targets AGTR1; clinical phase 4.0; logS -1.27; logP -1.01,repurposing_candidates.csv:rc_row=1103;protein_drug_candidates.csv:rows=590;pathway_drug_candidates.csv:rows=6544;7163;7274;7294;CYP3A4_results.csv:row=972;CYP2C19_results.csv:row=972;CYP2D6_results.csv:row=972;CYP1A2_results.csv:row=972;CYP2C9_results.csv:row=972;hERG_results.csv:row=972;AMES_results.csv:row=972;PGP_results.csv:row=972;PAMPA_results.csv:row=972;BBB_results.csv:row=972;Solubility_results.csv:row=972;Lipophilicity_results.csv:row=973
CHEMBL1200644,FONDAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],30.076277650648358,100,95.0,70.78051106025934,H,KG targets SERPINC1; clinical phase 4.0; logS 9.24; logP -49.12,repurposing_candidates.csv:rc_row=142;protein_drug_candidates.csv:rows=168;pathway_drug_candidates.csv:rows=140;7546;7575;7597;CYP3A4_results.csv:row=141;CYP2C19_results.csv:row=141;CYP2D6_results.csv:row=141;CYP1A2_results.csv:row=141;CYP2C9_results.csv:row=141;hERG_results.csv:row=141;AMES_results.csv:row=141;PGP_results.csv:row=141;PAMPA_results.csv:row=141;BBB_results.csv:row=141;Solubility_results.csv:row=141;Lipophilicity_results.csv:row=141
CHEMBL408403,ANGIOTENSIN II,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,30.076277650648358,100,95.0,70.78051106025934,H,KG targets AGTR1; clinical phase 4.0; logS -1.80; logP -1.11,repurposing_candidates.csv:rc_row=1127;protein_drug_candidates.csv:rows=581;pathway_drug_candidates.csv:rows=6535;7154;7265;7285;CYP3A4_results.csv:row=991;CYP2C19_results.csv:row=991;CYP2D6_results.csv:row=991;CYP1A2_results.csv:row=991;CYP2C9_results.csv:row=991;hERG_results.csv:row=991;AMES_results.csv:row=991;PGP_results.csv:row=991;PAMPA_results.csv:row=991;BBB_results.csv:row=991;Solubility_results.csv:row=991;Lipophilicity_results.csv:row=992
CHEMBL1922235,DAREXABAN,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1,47.35697940503432,80,95.0,70.69279176201373,H,KG targets F10; clinical phase 3.0; logS -3.32; logP 4.05,repurposing_candidates.csv:rc_row=599;protein_drug_candidates.csv:rows=461;pathway_drug_candidates.csv:rows=7541;7570;CYP3A4_results.csv:row=545;CYP2C19_results.csv:row=545;CYP2D6_results.csv:row=545;CYP1A2_results.csv:row=545;CYP2C9_results.csv:row=545;hERG_results.csv:row=545;AMES_results.csv:row=545;PGP_results.csv:row=545;PAMPA_results.csv:row=545;BBB_results.csv:row=545;Solubility_results.csv:row=545;Lipophilicity_results.csv:row=546
CHEMBL2105708,PONATINIB HYDROCHLORIDE,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl,29.801678108314263,100,95.0,70.6706712433257,H,"KG targets ABL1, BCR; clinical phase 4.0; logS -2.32; logP 4.88",repurposing_candidates.csv:rc_row=700;protein_drug_candidates.csv:rows=1200;2198;pathway_drug_candidates.csv:rows=4291;CYP3A4_results.csv:row=645;CYP2C19_results.csv:row=645;CYP2D6_results.csv:row=645;CYP1A2_results.csv:row=645;CYP2C9_results.csv:row=645;hERG_results.csv:row=645;AMES_results.csv:row=645;PGP_results.csv:row=645;PAMPA_results.csv:row=645;BBB_results.csv:row=645;Solubility_results.csv:row=645;Lipophilicity_results.csv:row=646
CHEMBL2103743,TOFACITINIB CITRATE,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,45.31655225019069,100,70.0,70.62662090007628,H,"KG targets JAK1, JAK2; clinical phase 4.0; hERG risk; logS -0.83; logP 0.30",repurposing_candidates.csv:rc_row=656;protein_drug_candidates.csv:rows=759;782;1185;pathway_drug_candidates.csv:rows=184;207;403;646;669;782;4236;4267;4415;4521;4556;4579;4604;4635;4658;4683;4714;4737;4762;4783;4803;4821;4844;4869;4890;4913;4938;4956;4979;5004;5022;5045;5070;5089;5114;5132;5155;5180;5210;5230;5260;5280;5298;5321;5346;5364;5387;5412;5428;5458;5478;6911;6934;7468;8297;8325;8353;8387;8415;8443;CYP3A4_results.csv:row=601;CYP2C19_results.csv:row=601;CYP2D6_results.csv:row=601;CYP1A2_results.csv:row=601;CYP2C9_results.csv:row=601;hERG_results.csv:row=601;AMES_results.csv:row=601;PGP_results.csv:row=601;PAMPA_results.csv:row=601;BBB_results.csv:row=601;Solubility_results.csv:row=601;Lipophilicity_results.csv:row=602
CHEMBL941,IMATINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,33.989321128909225,95,95.0,70.59572845156369,H,"KG targets ABL1, BCR; clinical phase 3.0; logS -0.52; logP 4.59",repurposing_candidates.csv:rc_row=1560;protein_drug_candidates.csv:rows=1113;1156;1209;2205;pathway_drug_candidates.csv:rows=561;4300;6973;7011;7507;CYP3A4_results.csv:row=1366;CYP2C19_results.csv:row=1366;CYP2D6_results.csv:row=1366;CYP1A2_results.csv:row=1366;CYP2C9_results.csv:row=1366;hERG_results.csv:row=1366;AMES_results.csv:row=1366;PGP_results.csv:row=1366;PAMPA_results.csv:row=1366;BBB_results.csv:row=1366;Solubility_results.csv:row=1366;Lipophilicity_results.csv:row=1367
CHEMBL607,MEPERIDINE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,29.549961861174673,100,95.0,70.56998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -1.96; logP 2.21,repurposing_candidates.csv:rc_row=1451;protein_drug_candidates.csv:rows=268;pathway_drug_candidates.csv:rows=238;1272;7185;CYP3A4_results.csv:row=1258;CYP2C19_results.csv:row=1258;CYP2D6_results.csv:row=1258;CYP1A2_results.csv:row=1258;CYP2C9_results.csv:row=1258;hERG_results.csv:row=1258;AMES_results.csv:row=1258;PGP_results.csv:row=1258;PAMPA_results.csv:row=1258;BBB_results.csv:row=1258;Solubility_results.csv:row=1258;Lipophilicity_results.csv:row=1259
CHEMBL314437,MEPTAZINOL,CCC1(c2cccc(O)c2)CCCCN(C)C1,29.549961861174673,100,95.0,70.56998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -1.61; logP 3.16,repurposing_candidates.csv:rc_row=912;protein_drug_candidates.csv:rows=308;pathway_drug_candidates.csv:rows=278;1312;7225;CYP3A4_results.csv:row=819;CYP2C19_results.csv:row=819;CYP2D6_results.csv:row=819;CYP1A2_results.csv:row=819;CYP2C9_results.csv:row=819;hERG_results.csv:row=819;AMES_results.csv:row=819;PGP_results.csv:row=819;PAMPA_results.csv:row=819;BBB_results.csv:row=819;Solubility_results.csv:row=819;Lipophilicity_results.csv:row=820
CHEMBL1201770,METHYLNALTREXONE BROMIDE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-],29.549961861174673,100,95.0,70.56998474446988,H,KG targets OPRM1; clinical phase 4.0; logS -1.17; logP -1.33,repurposing_candidates.csv:rc_row=313;protein_drug_candidates.csv:rows=301;pathway_drug_candidates.csv:rows=271;1305;7218;CYP3A4_results.csv:row=282;CYP2C19_results.csv:row=282;CYP2D6_results.csv:row=282;CYP1A2_results.csv:row=282;CYP2C9_results.csv:row=282;hERG_results.csv:row=282;AMES_results.csv:row=282;PGP_results.csv:row=282;PAMPA_results.csv:row=282;BBB_results.csv:row=282;Solubility_results.csv:row=282;Lipophilicity_results.csv:row=283
CHEMBL4297680,1018 ISS,,30.602593440122043,95,100.0,70.49103737604881,H,KG targets TLR9; clinical phase 3.0,repurposing_candidates.csv:rc_row=1206;protein_drug_candidates.csv:rows=261;pathway_drug_candidates.csv:rows=775;7337;7392;7414;7436;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3989406,ENALAPRILAT,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,46.83066361556064,80,95.0,70.48226544622426,H,KG targets ACE; clinical phase 3.0; logS -2.09; logP -0.52,repurposing_candidates.csv:rc_row=1067;protein_drug_candidates.csv:rows=655;pathway_drug_candidates.csv:rows=451;CYP3A4_results.csv:row=936;CYP2C19_results.csv:row=936;CYP2D6_results.csv:row=936;CYP1A2_results.csv:row=936;CYP2C9_results.csv:row=936;hERG_results.csv:row=936;AMES_results.csv:row=936;PGP_results.csv:row=936;PAMPA_results.csv:row=936;BBB_results.csv:row=936;Solubility_results.csv:row=936;Lipophilicity_results.csv:row=937
CHEMBL2103744,MORPHINE SULFATE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O,47.88329519450801,100,65.0,70.4033180778032,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.17; logP -2.38,repurposing_candidates.csv:rc_row=657;protein_drug_candidates.csv:rows=289;pathway_drug_candidates.csv:rows=259;1293;7206;CYP3A4_results.csv:row=602;CYP2C19_results.csv:row=602;CYP2D6_results.csv:row=602;CYP1A2_results.csv:row=602;CYP2C9_results.csv:row=602;hERG_results.csv:row=602;AMES_results.csv:row=602;PGP_results.csv:row=602;PAMPA_results.csv:row=602;BBB_results.csv:row=602;Solubility_results.csv:row=602;Lipophilicity_results.csv:row=603
CHEMBL596,FENTANYL,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,47.88329519450801,100,65.0,70.4033180778032,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -4.02; logP 4.14,repurposing_candidates.csv:rc_row=1437;protein_drug_candidates.csv:rows=267;pathway_drug_candidates.csv:rows=237;1271;7184;CYP3A4_results.csv:row=1246;CYP2C19_results.csv:row=1246;CYP2D6_results.csv:row=1246;CYP1A2_results.csv:row=1246;CYP2C9_results.csv:row=1246;hERG_results.csv:row=1246;AMES_results.csv:row=1246;PGP_results.csv:row=1246;PAMPA_results.csv:row=1246;BBB_results.csv:row=1246;Solubility_results.csv:row=1246;Lipophilicity_results.csv:row=1247
CHEMBL2062266,DIHYDROCODEINE BITARTRATE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O,47.88329519450801,100,65.0,70.4033180778032,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -0.79; logP -0.40,repurposing_candidates.csv:rc_row=637;protein_drug_candidates.csv:rows=288;pathway_drug_candidates.csv:rows=258;1292;7205;CYP3A4_results.csv:row=583;CYP2C19_results.csv:row=583;CYP2D6_results.csv:row=583;CYP1A2_results.csv:row=583;CYP2C9_results.csv:row=583;hERG_results.csv:row=583;AMES_results.csv:row=583;PGP_results.csv:row=583;PAMPA_results.csv:row=583;BBB_results.csv:row=583;Solubility_results.csv:row=583;Lipophilicity_results.csv:row=584
CHEMBL1131,ACITRETIN,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,32.15865751334859,100,90.0,70.36346300533944,H,"KG targets RARA, RARB; clinical phase 4.0; logS -3.98; logP 5.17",repurposing_candidates.csv:rc_row=59;protein_drug_candidates.csv:rows=183;1765;1891;pathway_drug_candidates.csv:rows=5985;6011;6020;CYP3A4_results.csv:row=58;CYP2C19_results.csv:row=58;CYP2D6_results.csv:row=58;CYP1A2_results.csv:row=58;CYP2C9_results.csv:row=58;hERG_results.csv:row=58;AMES_results.csv:row=58;PGP_results.csv:row=58;PAMPA_results.csv:row=58;BBB_results.csv:row=58;Solubility_results.csv:row=58;Lipophilicity_results.csv:row=58
CHEMBL2062264,PHENYLEPHRINE BITARTRATE,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O,32.15865751334859,100,90.0,70.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; logS -1.34; logP -1.48",repurposing_candidates.csv:rc_row=636;protein_drug_candidates.csv:rows=390;1493;1846;pathway_drug_candidates.csv:rows=853;6515;6715;CYP3A4_results.csv:row=582;CYP2C19_results.csv:row=582;CYP2D6_results.csv:row=582;CYP1A2_results.csv:row=582;CYP2C9_results.csv:row=582;hERG_results.csv:row=582;AMES_results.csv:row=582;PGP_results.csv:row=582;PAMPA_results.csv:row=582;BBB_results.csv:row=582;Solubility_results.csv:row=582;Lipophilicity_results.csv:row=583
CHEMBL705,ALITRETINOIN,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,32.15865751334859,100,90.0,70.36346300533944,H,"KG targets RARA, RARB; clinical phase 4.0; logS -4.41; logP 5.60",repurposing_candidates.csv:rc_row=1494;protein_drug_candidates.csv:rows=181;1762;1889;pathway_drug_candidates.csv:rows=5983;6009;6018;CYP3A4_results.csv:row=1300;CYP2C19_results.csv:row=1300;CYP2D6_results.csv:row=1300;CYP1A2_results.csv:row=1300;CYP2C9_results.csv:row=1300;hERG_results.csv:row=1300;AMES_results.csv:row=1300;PGP_results.csv:row=1300;PAMPA_results.csv:row=1300;BBB_results.csv:row=1300;Solubility_results.csv:row=1300;Lipophilicity_results.csv:row=1301
CHEMBL2108806,BEMIPARIN SODIUM,,30.076277650648358,95,100.0,70.28051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=758;protein_drug_candidates.csv:rows=175;pathway_drug_candidates.csv:rows=147;7553;7582;7604;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109343,LERONLIMAB,,30.076277650648358,95,100.0,70.28051106025934,H,KG targets CCR5; clinical phase 3.0,repurposing_candidates.csv:rc_row=766;protein_drug_candidates.csv:rows=219;pathway_drug_candidates.csv:rows=1261;4378;6760;6784;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4650299,HEPARIN,,30.076277650648358,95,100.0,70.28051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=1305;protein_drug_candidates.csv:rows=173;pathway_drug_candidates.csv:rows=145;7551;7580;7602;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL512351,BETRIXABAN,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,47.35697940503432,100,65.0,70.19279176201373,M,KG targets F10; clinical phase 4.0; hERG risk; logS -3.78; logP 4.14,repurposing_candidates.csv:rc_row=1358;protein_drug_candidates.csv:rows=452;pathway_drug_candidates.csv:rows=7532;7561;CYP3A4_results.csv:row=1169;CYP2C19_results.csv:row=1169;CYP2D6_results.csv:row=1169;CYP1A2_results.csv:row=1169;CYP2C9_results.csv:row=1169;hERG_results.csv:row=1169;AMES_results.csv:row=1169;PGP_results.csv:row=1169;PAMPA_results.csv:row=1169;BBB_results.csv:row=1169;Solubility_results.csv:row=1169;Lipophilicity_results.csv:row=1170
CHEMBL829,METHYLPROMAZINE,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -4.51; logP 4.49,repurposing_candidates.csv:rc_row=1526;protein_drug_candidates.csv:rows=1008;pathway_drug_candidates.csv:rows=6638;CYP3A4_results.csv:row=1332;CYP2C19_results.csv:row=1332;CYP2D6_results.csv:row=1332;CYP1A2_results.csv:row=1332;CYP2C9_results.csv:row=1332;hERG_results.csv:row=1332;AMES_results.csv:row=1332;PGP_results.csv:row=1332;PAMPA_results.csv:row=1332;BBB_results.csv:row=1332;Solubility_results.csv:row=1332;Lipophilicity_results.csv:row=1333
CHEMBL1172,DESLORATADINE,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.39; logP 4.02,repurposing_candidates.csv:rc_row=72;protein_drug_candidates.csv:rows=964;pathway_drug_candidates.csv:rows=6594;CYP3A4_results.csv:row=71;CYP2C19_results.csv:row=71;CYP2D6_results.csv:row=71;CYP1A2_results.csv:row=71;CYP2C9_results.csv:row=71;hERG_results.csv:row=71;AMES_results.csv:row=71;PGP_results.csv:row=71;PAMPA_results.csv:row=71;BBB_results.csv:row=71;Solubility_results.csv:row=71;Lipophilicity_results.csv:row=71
CHEMBL1719,OLOPATADINE HYDROCHLORIDE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.89; logP 4.01,repurposing_candidates.csv:rc_row=530;protein_drug_candidates.csv:rows=960;pathway_drug_candidates.csv:rows=6590;CYP3A4_results.csv:row=490;CYP2C19_results.csv:row=490;CYP2D6_results.csv:row=490;CYP1A2_results.csv:row=490;CYP2C9_results.csv:row=490;hERG_results.csv:row=490;AMES_results.csv:row=490;PGP_results.csv:row=490;PAMPA_results.csv:row=490;BBB_results.csv:row=490;Solubility_results.csv:row=490;Lipophilicity_results.csv:row=491
CHEMBL1189432,OLOPATADINE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.55; logP 3.59,repurposing_candidates.csv:rc_row=76;protein_drug_candidates.csv:rows=978;pathway_drug_candidates.csv:rows=6608;CYP3A4_results.csv:row=75;CYP2C19_results.csv:row=75;CYP2D6_results.csv:row=75;CYP1A2_results.csv:row=75;CYP2C9_results.csv:row=75;hERG_results.csv:row=75;AMES_results.csv:row=75;PGP_results.csv:row=75;PAMPA_results.csv:row=75;BBB_results.csv:row=75;Solubility_results.csv:row=75;Lipophilicity_results.csv:row=75
CHEMBL648,CYCLIZINE,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.07; logP 3.02,repurposing_candidates.csv:rc_row=1471;protein_drug_candidates.csv:rows=1007;pathway_drug_candidates.csv:rows=6637;CYP3A4_results.csv:row=1277;CYP2C19_results.csv:row=1277;CYP2D6_results.csv:row=1277;CYP1A2_results.csv:row=1277;CYP2C9_results.csv:row=1277;hERG_results.csv:row=1277;AMES_results.csv:row=1277;PGP_results.csv:row=1277;PAMPA_results.csv:row=1277;BBB_results.csv:row=1277;Solubility_results.csv:row=1277;Lipophilicity_results.csv:row=1278
CHEMBL1201773,PRASUGREL HYDROCHLORIDE,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl,28.497330282227306,100,95.0,70.14893211289092,H,KG targets P2RY12; clinical phase 4.0; logS -3.62; logP 4.31,repurposing_candidates.csv:rc_row=315;protein_drug_candidates.csv:rows=466;pathway_drug_candidates.csv:rows=1351;CYP3A4_results.csv:row=284;CYP2C19_results.csv:row=284;CYP2D6_results.csv:row=284;CYP1A2_results.csv:row=284;CYP2C9_results.csv:row=284;hERG_results.csv:row=284;AMES_results.csv:row=284;PGP_results.csv:row=284;PAMPA_results.csv:row=284;BBB_results.csv:row=284;Solubility_results.csv:row=284;Lipophilicity_results.csv:row=285
CHEMBL516,CYPROHEPTADINE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -3.07; logP 4.70,repurposing_candidates.csv:rc_row=1365;protein_drug_candidates.csv:rows=1017;pathway_drug_candidates.csv:rows=6647;CYP3A4_results.csv:row=1176;CYP2C19_results.csv:row=1176;CYP2D6_results.csv:row=1176;CYP1A2_results.csv:row=1176;CYP2C9_results.csv:row=1176;hERG_results.csv:row=1176;AMES_results.csv:row=1176;PGP_results.csv:row=1176;PAMPA_results.csv:row=1176;BBB_results.csv:row=1176;Solubility_results.csv:row=1176;Lipophilicity_results.csv:row=1177
CHEMBL946,AZATADINE,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.94; logP 3.71,repurposing_candidates.csv:rc_row=1562;protein_drug_candidates.csv:rows=1021;pathway_drug_candidates.csv:rows=6651;CYP3A4_results.csv:row=1368;CYP2C19_results.csv:row=1368;CYP2D6_results.csv:row=1368;CYP1A2_results.csv:row=1368;CYP2C9_results.csv:row=1368;hERG_results.csv:row=1368;AMES_results.csv:row=1368;PGP_results.csv:row=1368;PAMPA_results.csv:row=1368;BBB_results.csv:row=1368;Solubility_results.csv:row=1368;Lipophilicity_results.csv:row=1369
CHEMBL13828,OXATOMIDE,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -4.58; logP 4.13,repurposing_candidates.csv:rc_row=399;protein_drug_candidates.csv:rows=1001;pathway_drug_candidates.csv:rows=6631;CYP3A4_results.csv:row=359;CYP2C19_results.csv:row=359;CYP2D6_results.csv:row=359;CYP1A2_results.csv:row=359;CYP2C9_results.csv:row=359;hERG_results.csv:row=359;AMES_results.csv:row=359;PGP_results.csv:row=359;PAMPA_results.csv:row=359;BBB_results.csv:row=359;Solubility_results.csv:row=359;Lipophilicity_results.csv:row=360
CHEMBL1201747,ALCAFTADINE,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.78; logP 2.78,repurposing_candidates.csv:rc_row=306;protein_drug_candidates.csv:rows=968;pathway_drug_candidates.csv:rows=6598;CYP3A4_results.csv:row=275;CYP2C19_results.csv:row=275;CYP2D6_results.csv:row=275;CYP1A2_results.csv:row=275;CYP2C9_results.csv:row=275;hERG_results.csv:row=275;AMES_results.csv:row=275;PGP_results.csv:row=275;PAMPA_results.csv:row=275;BBB_results.csv:row=275;Solubility_results.csv:row=275;Lipophilicity_results.csv:row=276
CHEMBL1097279,CANGRELOR TETRASODIUM,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+],28.497330282227306,100,95.0,70.14893211289092,H,KG targets P2RY12; clinical phase 4.0; logS 1.03; logP -11.66,repurposing_candidates.csv:rc_row=48;protein_drug_candidates.csv:rows=465;pathway_drug_candidates.csv:rows=1350;CYP3A4_results.csv:row=48;CYP2C19_results.csv:row=48;CYP2D6_results.csv:row=48;CYP1A2_results.csv:row=48;CYP2C9_results.csv:row=48;hERG_results.csv:row=48;AMES_results.csv:row=48;PGP_results.csv:row=48;PAMPA_results.csv:row=48;BBB_results.csv:row=48;Solubility_results.csv:row=48;Lipophilicity_results.csv:row=48
CHEMBL1165,MOEXIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O,28.497330282227306,100,95.0,70.14893211289092,H,KG targets ACE; clinical phase 4.0; logS -2.19; logP 2.58,repurposing_candidates.csv:rc_row=68;protein_drug_candidates.csv:rows=637;pathway_drug_candidates.csv:rows=433;CYP3A4_results.csv:row=67;CYP2C19_results.csv:row=67;CYP2D6_results.csv:row=67;CYP1A2_results.csv:row=67;CYP2C9_results.csv:row=67;hERG_results.csv:row=67;AMES_results.csv:row=67;PGP_results.csv:row=67;PAMPA_results.csv:row=67;BBB_results.csv:row=67;Solubility_results.csv:row=67;Lipophilicity_results.csv:row=67
CHEMBL998,LORATADINE,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,28.497330282227306,100,95.0,70.14893211289092,H,KG targets HRH1; clinical phase 4.0; logS -4.07; logP 4.89,repurposing_candidates.csv:rc_row=1582;protein_drug_candidates.csv:rows=962;pathway_drug_candidates.csv:rows=6592;CYP3A4_results.csv:row=1388;CYP2C19_results.csv:row=1388;CYP2D6_results.csv:row=1388;CYP1A2_results.csv:row=1388;CYP2C9_results.csv:row=1388;hERG_results.csv:row=1388;AMES_results.csv:row=1388;PGP_results.csv:row=1388;PAMPA_results.csv:row=1388;BBB_results.csv:row=1388;Solubility_results.csv:row=1388;Lipophilicity_results.csv:row=1389
CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12,32.707856598016775,95,95.0,70.08314263920671,H,KG targets NR3C1; clinical phase 3.0; logS -3.82; logP 2.22,repurposing_candidates.csv:rc_row=265;protein_drug_candidates.csv:rows=49;pathway_drug_candidates.csv:rows=741;2050;5965;7869;8006;8072;8143;8209;8275;CYP3A4_results.csv:row=262;CYP2C19_results.csv:row=262;CYP2D6_results.csv:row=262;CYP1A2_results.csv:row=262;CYP2C9_results.csv:row=262;hERG_results.csv:row=262;AMES_results.csv:row=262;PGP_results.csv:row=262;PAMPA_results.csv:row=262;BBB_results.csv:row=262;Solubility_results.csv:row=262;Lipophilicity_results.csv:row=263
CHEMBL979,MEPROBAMATE,CCCC(C)(COC(N)=O)COC(N)=O,25.072463768115938,100,100.0,70.02898550724638,H,"KG targets GABRA1, GABRA2; clinical phase 4.0; logS -1.60; logP 0.98",repurposing_candidates.csv:rc_row=1577;protein_drug_candidates.csv:rows=493;1514;1691;1740;1774;1930;2059;2105;2577;CYP3A4_results.csv:row=1383;CYP2C19_results.csv:row=1383;CYP2D6_results.csv:row=1383;CYP1A2_results.csv:row=1383;CYP2C9_results.csv:row=1383;hERG_results.csv:row=1383;AMES_results.csv:row=1383;PGP_results.csv:row=1383;PAMPA_results.csv:row=1383;BBB_results.csv:row=1383;Solubility_results.csv:row=1383;Lipophilicity_results.csv:row=1384
CHEMBL1311,ISOSORBIDE MONONITRATE,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,46.83066361556064,100,65.0,69.98226544622426,M,KG targets GUCY1B1; clinical phase 4.0; hERG risk; logS -0.71; logP -1.28,repurposing_candidates.csv:rc_row=381;protein_drug_candidates.csv:rows=68;pathway_drug_candidates.csv:rows=7684;CYP3A4_results.csv:row=342;CYP2C19_results.csv:row=342;CYP2D6_results.csv:row=342;CYP1A2_results.csv:row=342;CYP2C9_results.csv:row=342;hERG_results.csv:row=342;AMES_results.csv:row=342;PGP_results.csv:row=342;PAMPA_results.csv:row=342;BBB_results.csv:row=342;Solubility_results.csv:row=342;Lipophilicity_results.csv:row=343
CHEMBL466659,PENTAERYTHRITOL TETRANITRATE,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],46.83066361556064,100,65.0,69.98226544622426,M,KG targets GUCY1B1; clinical phase 4.0; hERG risk; logS -3.13; logP -1.19,repurposing_candidates.csv:rc_row=1320;protein_drug_candidates.csv:rows=70;pathway_drug_candidates.csv:rows=7686;CYP3A4_results.csv:row=1131;CYP2C19_results.csv:row=1131;CYP2D6_results.csv:row=1131;CYP1A2_results.csv:row=1131;CYP2C9_results.csv:row=1131;hERG_results.csv:row=1131;AMES_results.csv:row=1131;PGP_results.csv:row=1131;PAMPA_results.csv:row=1131;BBB_results.csv:row=1131;Solubility_results.csv:row=1131;Lipophilicity_results.csv:row=1132
CHEMBL6622,ISOSORBIDE DINITRATE,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],46.83066361556064,100,65.0,69.98226544622426,M,KG targets GUCY1B1; clinical phase 4.0; hERG risk; logS -2.49; logP -1.06,repurposing_candidates.csv:rc_row=1481;protein_drug_candidates.csv:rows=66;pathway_drug_candidates.csv:rows=7682;CYP3A4_results.csv:row=1287;CYP2C19_results.csv:row=1287;CYP2D6_results.csv:row=1287;CYP1A2_results.csv:row=1287;CYP2C9_results.csv:row=1287;hERG_results.csv:row=1287;AMES_results.csv:row=1287;PGP_results.csv:row=1287;PAMPA_results.csv:row=1287;BBB_results.csv:row=1287;Solubility_results.csv:row=1287;Lipophilicity_results.csv:row=1288
CHEMBL730,NITROGLYCERIN,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],46.83066361556064,100,65.0,69.98226544622426,M,KG targets GUCY1B1; clinical phase 4.0; hERG risk; logS -2.26; logP -1.02,repurposing_candidates.csv:rc_row=1501;protein_drug_candidates.csv:rows=67;pathway_drug_candidates.csv:rows=7683;CYP3A4_results.csv:row=1307;CYP2C19_results.csv:row=1307;CYP2D6_results.csv:row=1307;CYP1A2_results.csv:row=1307;CYP2C9_results.csv:row=1307;hERG_results.csv:row=1307;AMES_results.csv:row=1307;PGP_results.csv:row=1307;PAMPA_results.csv:row=1307;BBB_results.csv:row=1307;Solubility_results.csv:row=1307;Lipophilicity_results.csv:row=1308
CHEMBL2111286,RANITIDINE BISMUTH CITRATE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3],46.83066361556064,100,65.0,69.98226544622426,M,KG targets HRH2; clinical phase 4.0; hERG risk; logS -4.41; logP -4.17,repurposing_candidates.csv:rc_row=785;protein_drug_candidates.csv:rows=751;pathway_drug_candidates.csv:rows=5820;CYP3A4_results.csv:row=694;CYP2C19_results.csv:row=694;CYP2D6_results.csv:row=694;CYP1A2_results.csv:row=694;CYP2C9_results.csv:row=694;hERG_results.csv:row=694;AMES_results.csv:row=694;PGP_results.csv:row=694;PAMPA_results.csv:row=694;BBB_results.csv:row=694;Solubility_results.csv:row=694;Lipophilicity_results.csv:row=695
CHEMBL900,ORPHENADRINE,Cc1ccccc1C(OCCN(C)C)c1ccccc1,42.364607170099156,80,100.0,69.94584286803966,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -2.42; logP 3.66",repurposing_candidates.csv:rc_row=1546;protein_drug_candidates.csv:rows=721;1033;1620;1965;2192;2612;2657;2682;pathway_drug_candidates.csv:rows=3627;6663;6811;6838;6865;6898;7056;7083;7110;7137;CYP3A4_results.csv:row=1352;CYP2C19_results.csv:row=1352;CYP2D6_results.csv:row=1352;CYP1A2_results.csv:row=1352;CYP2C9_results.csv:row=1352;hERG_results.csv:row=1352;AMES_results.csv:row=1352;PGP_results.csv:row=1352;PAMPA_results.csv:row=1352;BBB_results.csv:row=1352;Solubility_results.csv:row=1352;Lipophilicity_results.csv:row=1353
CHEMBL3702854,RILZABRUTINIB,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,48.40961098398169,80,90.0,69.86384439359267,H,KG targets BTK; clinical phase 3.0; logS -6.80; logP 4.42,repurposing_candidates.csv:rc_row=1013;protein_drug_candidates.csv:rows=201;pathway_drug_candidates.csv:rows=607;4102;6564;6744;CYP3A4_results.csv:row=899;CYP2C19_results.csv:row=899;CYP2D6_results.csv:row=899;CYP1A2_results.csv:row=899;CYP2C9_results.csv:row=899;hERG_results.csv:row=899;AMES_results.csv:row=899;PGP_results.csv:row=899;PAMPA_results.csv:row=899;BBB_results.csv:row=899;Solubility_results.csv:row=899;Lipophilicity_results.csv:row=900
CHEMBL608533,MIDOSTAURIN,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,30.85430968726163,100,90.0,69.84172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -5.99; logP 5.91",repurposing_candidates.csv:rc_row=1452;protein_drug_candidates.csv:rows=1098;1141;pathway_drug_candidates.csv:rows=546;6958;6996;7492;CYP3A4_results.csv:row=1259;CYP2C19_results.csv:row=1259;CYP2D6_results.csv:row=1259;CYP1A2_results.csv:row=1259;CYP2C9_results.csv:row=1259;hERG_results.csv:row=1259;AMES_results.csv:row=1259;PGP_results.csv:row=1259;PAMPA_results.csv:row=1259;BBB_results.csv:row=1259;Solubility_results.csv:row=1259;Lipophilicity_results.csv:row=1260
CHEMBL1200485,SORAFENIB TOSYLATE,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,30.85430968726163,100,90.0,69.84172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -5.09; logP 6.79",repurposing_candidates.csv:rc_row=110;protein_drug_candidates.csv:rows=1103;1152;pathway_drug_candidates.csv:rows=557;6969;7001;7503;CYP3A4_results.csv:row=109;CYP2C19_results.csv:row=109;CYP2D6_results.csv:row=109;CYP1A2_results.csv:row=109;CYP2C9_results.csv:row=109;hERG_results.csv:row=109;AMES_results.csv:row=109;PGP_results.csv:row=109;PAMPA_results.csv:row=109;BBB_results.csv:row=109;Solubility_results.csv:row=109;Lipophilicity_results.csv:row=109
CHEMBL495727,AT-9283,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,59.18764302059497,60,100.0,69.67505720823799,M,"KG targets ABL1, JAK2; clinical phase 2.0; logS -0.99; logP 2.07",repurposing_candidates.csv:rc_row=1342;protein_drug_candidates.csv:rows=797;1219;pathway_drug_candidates.csv:rows=222;684;4310;4594;4673;4752;4859;4928;4994;5060;5104;5170;5336;5402;6949;7483;8312;8340;8368;8402;8430;8458;CYP3A4_results.csv:row=1153;CYP2C19_results.csv:row=1153;CYP2D6_results.csv:row=1153;CYP1A2_results.csv:row=1153;CYP2C9_results.csv:row=1153;hERG_results.csv:row=1153;AMES_results.csv:row=1153;PGP_results.csv:row=1153;PAMPA_results.csv:row=1153;BBB_results.csv:row=1153;Solubility_results.csv:row=1153;Lipophilicity_results.csv:row=1154
CHEMBL2103876,MAPRACORAT,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1,51.04118993135011,80,85.0,69.66647597254004,H,KG targets NR3C1; clinical phase 3.0; logS -4.47; logP 5.69,repurposing_candidates.csv:rc_row=675;protein_drug_candidates.csv:rows=57;pathway_drug_candidates.csv:rows=749;2058;5973;7877;8014;8080;8151;8217;8283;CYP3A4_results.csv:row=620;CYP2C19_results.csv:row=620;CYP2D6_results.csv:row=620;CYP1A2_results.csv:row=620;CYP2C9_results.csv:row=620;hERG_results.csv:row=620;AMES_results.csv:row=620;PGP_results.csv:row=620;PAMPA_results.csv:row=620;BBB_results.csv:row=620;Solubility_results.csv:row=620;Lipophilicity_results.csv:row=621
CHEMBL4297608,ELDECALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O,47.88329519450801,80,90.0,69.6533180778032,H,KG targets VDR; clinical phase 3.0; logS -2.46; logP 5.08,repurposing_candidates.csv:rc_row=1196;protein_drug_candidates.csv:rows=249;pathway_drug_candidates.csv:rows=6002;7779;7897;CYP3A4_results.csv:row=1056;CYP2C19_results.csv:row=1056;CYP2D6_results.csv:row=1056;CYP1A2_results.csv:row=1056;CYP2C9_results.csv:row=1056;hERG_results.csv:row=1056;AMES_results.csv:row=1056;PGP_results.csv:row=1056;PAMPA_results.csv:row=1056;BBB_results.csv:row=1056;Solubility_results.csv:row=1056;Lipophilicity_results.csv:row=1057
CHEMBL2105738,GALETERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,47.88329519450801,80,90.0,69.6533180778032,H,KG targets AR; clinical phase 3.0; logS -5.69; logP 5.81,repurposing_candidates.csv:rc_row=704;protein_drug_candidates.csv:rows=563;pathway_drug_candidates.csv:rows=1986;5901;7805;CYP3A4_results.csv:row=649;CYP2C19_results.csv:row=649;CYP2D6_results.csv:row=649;CYP1A2_results.csv:row=649;CYP2C9_results.csv:row=649;hERG_results.csv:row=649;AMES_results.csv:row=649;PGP_results.csv:row=649;PAMPA_results.csv:row=649;BBB_results.csv:row=649;Solubility_results.csv:row=649;Lipophilicity_results.csv:row=650
CHEMBL502835,NINTEDANIB,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,28.497330282227306,95,100.0,69.64893211289092,H,KG targets PDGFRB; clinical phase 3.0; logS -3.58; logP 3.62,repurposing_candidates.csv:rc_row=1346;protein_drug_candidates.csv:rows=1120;pathway_drug_candidates.csv:rows=7018;CYP3A4_results.csv:row=1157;CYP2C19_results.csv:row=1157;CYP2D6_results.csv:row=1157;CYP1A2_results.csv:row=1157;CYP2C9_results.csv:row=1157;hERG_results.csv:row=1157;AMES_results.csv:row=1157;PGP_results.csv:row=1157;PAMPA_results.csv:row=1157;BBB_results.csv:row=1157;Solubility_results.csv:row=1157;Lipophilicity_results.csv:row=1158
CHEMBL655,MIDAZOLAM,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,45.79710144927536,100,65.0,69.56884057971014,M,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -5.32; logP 4.32",repurposing_candidates.csv:rc_row=1475;protein_drug_candidates.csv:rows=482;1411;1634;1680;2040;2086;2450;CYP3A4_results.csv:row=1281;CYP2C19_results.csv:row=1281;CYP2D6_results.csv:row=1281;CYP1A2_results.csv:row=1281;CYP2C9_results.csv:row=1281;hERG_results.csv:row=1281;AMES_results.csv:row=1281;PGP_results.csv:row=1281;PAMPA_results.csv:row=1281;BBB_results.csv:row=1281;Solubility_results.csv:row=1281;Lipophilicity_results.csv:row=1282
CHEMBL1200420,MIDAZOLAM HYDROCHLORIDE,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl,45.79710144927536,100,65.0,69.56884057971014,M,"KG targets GABRA1, GABRA2; clinical phase 4.0; hERG risk; logS -4.68; logP 4.75",repurposing_candidates.csv:rc_row=99;protein_drug_candidates.csv:rows=503;1431;1656;1702;2063;2106;2470;CYP3A4_results.csv:row=98;CYP2C19_results.csv:row=98;CYP2D6_results.csv:row=98;CYP1A2_results.csv:row=98;CYP2C9_results.csv:row=98;hERG_results.csv:row=98;AMES_results.csv:row=98;PGP_results.csv:row=98;PAMPA_results.csv:row=98;BBB_results.csv:row=98;Solubility_results.csv:row=98;Lipophilicity_results.csv:row=98
CHEMBL1207366,GW468816,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1,58.86727688787185,60,100.0,69.54691075514874,M,"KG targets GRIN1, GRIN2A; clinical phase 2.0; logS -4.60; logP 3.80",repurposing_candidates.csv:rc_row=329;protein_drug_candidates.csv:rows=723;1621;1967;2195;2618;2660;2684;pathway_drug_candidates.csv:rows=3629;6813;6840;6867;6900;7058;7085;7112;7139;CYP3A4_results.csv:row=292;CYP2C19_results.csv:row=292;CYP2D6_results.csv:row=292;CYP1A2_results.csv:row=292;CYP2C9_results.csv:row=292;hERG_results.csv:row=292;AMES_results.csv:row=292;PGP_results.csv:row=292;PAMPA_results.csv:row=292;BBB_results.csv:row=292;Solubility_results.csv:row=292;Lipophilicity_results.csv:row=293
CHEMBL1201187,MARAVIROC,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,30.076277650648358,100,90.0,69.53051106025934,H,KG targets CCR5; clinical phase 4.0; logS -3.44; logP 5.95,repurposing_candidates.csv:rc_row=252;protein_drug_candidates.csv:rows=214;pathway_drug_candidates.csv:rows=1256;4373;6755;6779;CYP3A4_results.csv:row=249;CYP2C19_results.csv:row=249;CYP2D6_results.csv:row=249;CYP1A2_results.csv:row=249;CYP2C9_results.csv:row=249;hERG_results.csv:row=249;AMES_results.csv:row=249;PGP_results.csv:row=249;PAMPA_results.csv:row=249;BBB_results.csv:row=249;Solubility_results.csv:row=249;Lipophilicity_results.csv:row=250
CHEMBL1487,ATORVASTATIN,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,30.076277650648358,100,90.0,69.53051106025934,H,KG targets HMGCR; clinical phase 4.0; logS -4.78; logP 6.31,repurposing_candidates.csv:rc_row=430;protein_drug_candidates.csv:rows=732;pathway_drug_candidates.csv:rows=7611;7626;7641;7656;CYP3A4_results.csv:row=390;CYP2C19_results.csv:row=390;CYP2D6_results.csv:row=390;CYP1A2_results.csv:row=390;CYP2C9_results.csv:row=390;hERG_results.csv:row=390;AMES_results.csv:row=390;PGP_results.csv:row=390;PAMPA_results.csv:row=390;BBB_results.csv:row=390;Solubility_results.csv:row=390;Lipophilicity_results.csv:row=391
CHEMBL4116008,CERDULATINIB,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,58.661327231121284,60,100.0,69.46453089244852,M,"KG targets JAK1, TYK2; clinical phase 2.0; logS -3.48; logP 1.37",repurposing_candidates.csv:rc_row=1134;protein_drug_candidates.csv:rows=775;1197;pathway_drug_candidates.csv:rows=200;415;662;794;4252;4279;4431;4533;4572;4616;4651;4695;4730;4774;4799;4815;4837;4881;4906;4950;4972;5016;5038;5082;5126;5148;5192;5226;5242;5276;5292;5314;5358;5380;5424;5440;5474;5490;6927;CYP3A4_results.csv:row=998;CYP2C19_results.csv:row=998;CYP2D6_results.csv:row=998;CYP1A2_results.csv:row=998;CYP2C9_results.csv:row=998;hERG_results.csv:row=998;AMES_results.csv:row=998;PGP_results.csv:row=998;PAMPA_results.csv:row=998;BBB_results.csv:row=998;Solubility_results.csv:row=998;Lipophilicity_results.csv:row=999
CHEMBL4297892,ANVATABART OPADOTIN,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1228;protein_drug_candidates.csv:rows=846;1578;2013;2251;2356;2423;2729;2792;2857;pathway_drug_candidates.csv:rows=1559;1623;1687;1751;1815;1879;1943;2108;2172;2236;2300;2364;2428;2492;2556;2620;2684;2748;2812;2876;2940;3004;3074;3138;3202;3266;3330;3394;3458;3522;3586;3677;3741;3805;3869;3933;3997;4064;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297268,BMS-275183,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -4.33; logP 3.72",repurposing_candidates.csv:rc_row=1166;protein_drug_candidates.csv:rows=853;1584;2020;2257;2362;2426;2734;2798;2862;pathway_drug_candidates.csv:rows=1566;1630;1694;1758;1822;1886;1950;2115;2179;2243;2307;2371;2435;2499;2563;2627;2691;2755;2819;2883;2947;3011;3081;3145;3209;3273;3337;3401;3465;3529;3593;3684;3748;3812;3876;3940;4004;4071;CYP3A4_results.csv:row=1029;CYP2C19_results.csv:row=1029;CYP2D6_results.csv:row=1029;CYP1A2_results.csv:row=1029;CYP2C9_results.csv:row=1029;hERG_results.csv:row=1029;AMES_results.csv:row=1029;PGP_results.csv:row=1029;PAMPA_results.csv:row=1029;BBB_results.csv:row=1029;Solubility_results.csv:row=1029;Lipophilicity_results.csv:row=1030
CHEMBL1743037,LORVOTUZUMAB MERTANSINE,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=547;protein_drug_candidates.csv:rows=842;1575;2010;2247;2352;2415;2725;2786;2850;pathway_drug_candidates.csv:rows=1555;1619;1683;1747;1811;1875;1939;2104;2168;2232;2296;2360;2424;2488;2552;2616;2680;2744;2808;2872;2936;3000;3070;3134;3198;3262;3326;3390;3454;3518;3582;3673;3737;3801;3865;3929;3993;4060;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=545;protein_drug_candidates.csv:rows=848;1577;2012;2255;2359;2421;2728;2795;2858;pathway_drug_candidates.csv:rows=1561;1625;1689;1753;1817;1881;1945;2110;2174;2238;2302;2366;2430;2494;2558;2622;2686;2750;2814;2878;2942;3006;3076;3140;3204;3268;3332;3396;3460;3524;3588;3679;3743;3807;3871;3935;3999;4066;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4594455,AGS-16C3F,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1297;protein_drug_candidates.csv:rows=847;1581;2016;2254;2360;2424;2731;2794;2859;pathway_drug_candidates.csv:rows=1560;1624;1688;1752;1816;1880;1944;2109;2173;2237;2301;2365;2429;2493;2557;2621;2685;2749;2813;2877;2941;3005;3075;3139;3203;3267;3331;3395;3459;3523;3587;3678;3742;3806;3870;3934;3998;4065;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -2.45; logP 1.02",repurposing_candidates.csv:rc_row=692;protein_drug_candidates.csv:rows=854;1587;2022;2262;2366;2430;2738;2801;2866;pathway_drug_candidates.csv:rows=1567;1631;1695;1759;1823;1887;1951;2116;2180;2244;2308;2372;2436;2500;2564;2628;2692;2756;2820;2884;2948;3012;3082;3146;3210;3274;3338;3402;3466;3530;3594;3685;3749;3813;3877;3941;4005;4072;CYP3A4_results.csv:row=637;CYP2C19_results.csv:row=637;CYP2D6_results.csv:row=637;CYP1A2_results.csv:row=637;CYP2C9_results.csv:row=637;hERG_results.csv:row=637;AMES_results.csv:row=637;PGP_results.csv:row=637;PAMPA_results.csv:row=637;BBB_results.csv:row=637;Solubility_results.csv:row=637;Lipophilicity_results.csv:row=638
CHEMBL4297440,T-900607,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -3.44; logP 2.68",repurposing_candidates.csv:rc_row=1175;protein_drug_candidates.csv:rows=836;1569;2004;2243;2348;2412;2719;2783;2847;pathway_drug_candidates.csv:rows=1549;1613;1677;1741;1805;1869;1933;2098;2162;2226;2290;2354;2418;2482;2546;2610;2674;2738;2802;2866;2930;2994;3064;3128;3192;3256;3320;3384;3448;3512;3576;3667;3731;3795;3859;3923;3987;4054;CYP3A4_results.csv:row=1038;CYP2C19_results.csv:row=1038;CYP2D6_results.csv:row=1038;CYP1A2_results.csv:row=1038;CYP2C9_results.csv:row=1038;hERG_results.csv:row=1038;AMES_results.csv:row=1038;PGP_results.csv:row=1038;PAMPA_results.csv:row=1038;BBB_results.csv:row=1038;Solubility_results.csv:row=1038;Lipophilicity_results.csv:row=1039
CHEMBL4298045,INDUSATUMAB VEDOTIN,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1240;protein_drug_candidates.csv:rows=837;1570;2005;2248;2353;2417;2720;2788;2852;pathway_drug_candidates.csv:rows=1550;1614;1678;1742;1806;1870;1934;2099;2163;2227;2291;2355;2419;2483;2547;2611;2675;2739;2803;2867;2931;2995;3065;3129;3193;3257;3321;3385;3449;3513;3577;3668;3732;3796;3860;3924;3988;4055;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297938,LIFASTUZUMAB VEDOTIN,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1233;protein_drug_candidates.csv:rows=857;1591;2025;2266;2371;2435;2742;2806;2870;pathway_drug_candidates.csv:rows=1570;1634;1698;1762;1826;1890;1954;2119;2183;2247;2311;2375;2439;2503;2567;2631;2695;2759;2823;2887;2951;3015;3085;3149;3213;3277;3341;3405;3469;3533;3597;3688;3752;3816;3880;3944;4008;4075;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298101,LADIRATUZUMAB VEDOTIN,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1244;protein_drug_candidates.csv:rows=852;1586;2021;2260;2365;2427;2736;2800;2863;pathway_drug_candidates.csv:rows=1565;1629;1693;1757;1821;1885;1949;2114;2178;2242;2306;2370;2434;2498;2562;2626;2690;2754;2818;2882;2946;3010;3080;3144;3208;3272;3336;3400;3464;3528;3592;3683;3747;3811;3875;3939;4003;4070;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL20684,ABT-751,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -3.06; logP 3.34",repurposing_candidates.csv:rc_row=641;protein_drug_candidates.csv:rows=845;1580;2014;2252;2358;2422;2730;2793;2855;pathway_drug_candidates.csv:rows=1558;1622;1686;1750;1814;1878;1942;2107;2171;2235;2299;2363;2427;2491;2555;2619;2683;2747;2811;2875;2939;3003;3073;3137;3201;3265;3329;3393;3457;3521;3585;3676;3740;3804;3868;3932;3996;4063;CYP3A4_results.csv:row=587;CYP2C19_results.csv:row=587;CYP2D6_results.csv:row=587;CYP1A2_results.csv:row=587;CYP2C9_results.csv:row=587;hERG_results.csv:row=587;AMES_results.csv:row=587;PGP_results.csv:row=587;PAMPA_results.csv:row=587;BBB_results.csv:row=587;Solubility_results.csv:row=587;Lipophilicity_results.csv:row=588
CHEMBL4297736,PRALUZATAMAB RAVTANSINE,,58.405797101449274,60,100.0,69.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0",repurposing_candidates.csv:rc_row=1212;protein_drug_candidates.csv:rows=859;1590;2024;2265;2370;2432;2740;2805;2869;pathway_drug_candidates.csv:rows=1572;1636;1700;1764;1828;1892;1956;2121;2185;2249;2313;2377;2441;2505;2569;2633;2697;2761;2825;2889;2953;3017;3087;3151;3215;3279;3343;3407;3471;3535;3599;3690;3754;3818;3882;3946;4010;4077;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,29.549961861174673,100,90.0,69.31998474446988,H,KG targets KIT; clinical phase 4.0; logS -5.18; logP 5.65,repurposing_candidates.csv:rc_row=1109;protein_drug_candidates.csv:rows=1153;pathway_drug_candidates.csv:rows=558;6970;7504;CYP3A4_results.csv:row=978;CYP2C19_results.csv:row=978;CYP2D6_results.csv:row=978;CYP1A2_results.csv:row=978;CYP2C9_results.csv:row=978;hERG_results.csv:row=978;AMES_results.csv:row=978;PGP_results.csv:row=978;PAMPA_results.csv:row=978;BBB_results.csv:row=978;Solubility_results.csv:row=978;Lipophilicity_results.csv:row=979
CHEMBL3813873,PEXIDARTINIB,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,29.549961861174673,100,90.0,69.31998474446988,H,KG targets KIT; clinical phase 4.0; logS -5.87; logP 5.23,repurposing_candidates.csv:rc_row=1039;protein_drug_candidates.csv:rows=1143;pathway_drug_candidates.csv:rows=548;6960;7494;CYP3A4_results.csv:row=914;CYP2C19_results.csv:row=914;CYP2D6_results.csv:row=914;CYP1A2_results.csv:row=914;CYP2C9_results.csv:row=914;hERG_results.csv:row=914;AMES_results.csv:row=914;PGP_results.csv:row=914;PAMPA_results.csv:row=914;BBB_results.csv:row=914;Solubility_results.csv:row=914;Lipophilicity_results.csv:row=915
CHEMBL315795,CLOMETHIAZOLE,Cc1ncsc1CCCl,40.57971014492753,80,100.0,69.23188405797102,H,"KG targets GABRB1, GABRB2; clinical phase 3.0; logS -1.84; logP 2.23",repurposing_candidates.csv:rc_row=914;protein_drug_candidates.csv:rows=1525;1755;2587;CYP3A4_results.csv:row=821;CYP2C19_results.csv:row=821;CYP2D6_results.csv:row=821;CYP1A2_results.csv:row=821;CYP2C9_results.csv:row=821;hERG_results.csv:row=821;AMES_results.csv:row=821;PGP_results.csv:row=821;PAMPA_results.csv:row=821;BBB_results.csv:row=821;Solubility_results.csv:row=821;Lipophilicity_results.csv:row=822
CHEMBL742,KETAMINE,CNC1(c2ccccc2Cl)CCCCC1=O,40.53394355453852,80,100.0,69.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -0.91; logP 2.90",repurposing_candidates.csv:rc_row=1504;protein_drug_candidates.csv:rows=715;1614;1959;2186;2607;2653;2677;pathway_drug_candidates.csv:rows=3621;6805;6832;6859;6892;7050;7077;7104;7131;CYP3A4_results.csv:row=1310;CYP2C19_results.csv:row=1310;CYP2D6_results.csv:row=1310;CYP1A2_results.csv:row=1310;CYP2C9_results.csv:row=1310;hERG_results.csv:row=1310;AMES_results.csv:row=1310;PGP_results.csv:row=1310;PAMPA_results.csv:row=1310;BBB_results.csv:row=1310;Solubility_results.csv:row=1310;Lipophilicity_results.csv:row=1311
CHEMBL2110954,NERAMEXANE,CC1(C)CC(C)(C)CC(C)(N)C1,40.53394355453852,80,100.0,69.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -2.10; logP 2.94",repurposing_candidates.csv:rc_row=784;protein_drug_candidates.csv:rows=720;1618;1964;2191;2614;2656;2681;pathway_drug_candidates.csv:rows=3626;6810;6837;6864;6897;7055;7082;7109;7136;CYP3A4_results.csv:row=693;CYP2C19_results.csv:row=693;CYP2D6_results.csv:row=693;CYP1A2_results.csv:row=693;CYP2C9_results.csv:row=693;hERG_results.csv:row=693;AMES_results.csv:row=693;PGP_results.csv:row=693;PAMPA_results.csv:row=693;BBB_results.csv:row=693;Solubility_results.csv:row=693;Lipophilicity_results.csv:row=694
CHEMBL1714,KETAMINE HYDROCHLORIDE,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,40.53394355453852,80,100.0,69.21357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS -0.19; logP 3.32",repurposing_candidates.csv:rc_row=525;protein_drug_candidates.csv:rows=714;1613;1960;2187;2608;2652;2676;pathway_drug_candidates.csv:rows=3620;6804;6831;6858;6891;7049;7076;7103;7130;CYP3A4_results.csv:row=485;CYP2C19_results.csv:row=485;CYP2D6_results.csv:row=485;CYP1A2_results.csv:row=485;CYP2C9_results.csv:row=485;hERG_results.csv:row=485;AMES_results.csv:row=485;PGP_results.csv:row=485;PAMPA_results.csv:row=485;BBB_results.csv:row=485;Solubility_results.csv:row=485;Lipophilicity_results.csv:row=486
CHEMBL254328,ABIRATERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,47.88329519450801,100,60.0,69.1533180778032,M,KG targets AR; clinical phase 4.0; hERG risk; logS -4.19; logP 5.40,repurposing_candidates.csv:rc_row=857;protein_drug_candidates.csv:rows=553;pathway_drug_candidates.csv:rows=1976;5891;7795;CYP3A4_results.csv:row=765;CYP2C19_results.csv:row=765;CYP2D6_results.csv:row=765;CYP1A2_results.csv:row=765;CYP2C9_results.csv:row=765;hERG_results.csv:row=765;AMES_results.csv:row=765;PGP_results.csv:row=765;PAMPA_results.csv:row=765;BBB_results.csv:row=765;Solubility_results.csv:row=765;Lipophilicity_results.csv:row=766
CHEMBL464,ETRETINATE,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,32.15865751334859,100,85.0,69.11346300533944,H,"KG targets RARA, RARB; clinical phase 4.0; logS -4.64; logP 5.65",repurposing_candidates.csv:rc_row=1302;protein_drug_candidates.csv:rows=184;1764;1892;pathway_drug_candidates.csv:rows=5986;6012;6021;CYP3A4_results.csv:row=1118;CYP2C19_results.csv:row=1118;CYP2D6_results.csv:row=1118;CYP1A2_results.csv:row=1118;CYP2C9_results.csv:row=1118;hERG_results.csv:row=1118;AMES_results.csv:row=1118;PGP_results.csv:row=1118;PAMPA_results.csv:row=1118;BBB_results.csv:row=1118;Solubility_results.csv:row=1118;Lipophilicity_results.csv:row=1119
CHEMBL603,ZAFIRLUKAST,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,29.02364607170099,100,90.0,69.1094584286804,H,KG targets CYSLTR1; clinical phase 4.0; logS -5.70; logP 5.70,repurposing_candidates.csv:rc_row=1441;protein_drug_candidates.csv:rows=1230;pathway_drug_candidates.csv:rows=620;6577;CYP3A4_results.csv:row=1250;CYP2C19_results.csv:row=1250;CYP2D6_results.csv:row=1250;CYP1A2_results.csv:row=1250;CYP2C9_results.csv:row=1250;hERG_results.csv:row=1250;AMES_results.csv:row=1250;PGP_results.csv:row=1250;PAMPA_results.csv:row=1250;BBB_results.csv:row=1250;Solubility_results.csv:row=1250;Lipophilicity_results.csv:row=1251
CHEMBL1200681,MONTELUKAST SODIUM,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],29.02364607170099,100,90.0,69.1094584286804,H,KG targets CYSLTR1; clinical phase 4.0; logS -6.32; logP 4.62,repurposing_candidates.csv:rc_row=149;protein_drug_candidates.csv:rows=1229;pathway_drug_candidates.csv:rows=619;6576;CYP3A4_results.csv:row=148;CYP2C19_results.csv:row=148;CYP2D6_results.csv:row=148;CYP1A2_results.csv:row=148;CYP2C9_results.csv:row=148;hERG_results.csv:row=148;AMES_results.csv:row=148;PGP_results.csv:row=148;PAMPA_results.csv:row=148;BBB_results.csv:row=148;Solubility_results.csv:row=148;Lipophilicity_results.csv:row=148
CHEMBL2106798,NERAMEXANE MESYLATE,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,58.86727688787185,80,70.0,69.04691075514874,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; hERG risk; logS -0.07; logP 2.44",repurposing_candidates.csv:rc_row=720;protein_drug_candidates.csv:rows=718;1617;1963;2190;2611;2659;2680;pathway_drug_candidates.csv:rows=3624;6808;6835;6862;6895;7053;7080;7107;7134;CYP3A4_results.csv:row=665;CYP2C19_results.csv:row=665;CYP2D6_results.csv:row=665;CYP1A2_results.csv:row=665;CYP2C9_results.csv:row=665;hERG_results.csv:row=665;AMES_results.csv:row=665;PGP_results.csv:row=665;PAMPA_results.csv:row=665;BBB_results.csv:row=665;Solubility_results.csv:row=665;Lipophilicity_results.csv:row=666
CHEMBL4297477,BREPOCITINIB,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,58.661327231121284,80,70.0,68.96453089244852,H,"KG targets JAK1, TYK2; clinical phase 3.0; hERG risk; logS -3.25; logP 1.79",repurposing_candidates.csv:rc_row=1180;protein_drug_candidates.csv:rows=764;1189;pathway_drug_candidates.csv:rows=189;407;651;786;4241;4271;4420;4525;4561;4608;4640;4687;4719;4766;4788;4807;4826;4873;4895;4942;4961;5008;5027;5074;5118;5137;5184;5215;5234;5265;5284;5303;5350;5369;5416;5432;5463;5482;6916;CYP3A4_results.csv:row=1043;CYP2C19_results.csv:row=1043;CYP2D6_results.csv:row=1043;CYP1A2_results.csv:row=1043;CYP2C9_results.csv:row=1043;hERG_results.csv:row=1043;AMES_results.csv:row=1043;PGP_results.csv:row=1043;PAMPA_results.csv:row=1043;BBB_results.csv:row=1043;Solubility_results.csv:row=1043;Lipophilicity_results.csv:row=1044
CHEMBL2107823,GANDOTINIB,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1,57.35697940503432,60,100.0,68.94279176201373,M,KG targets JAK2; clinical phase 2.0; logS -3.05; logP 4.03,repurposing_candidates.csv:rc_row=738;protein_drug_candidates.csv:rows=796;pathway_drug_candidates.csv:rows=221;683;4593;4672;4751;4858;4927;4993;5059;5103;5169;5335;5401;6948;7482;8311;8339;8367;8401;8429;8457;CYP3A4_results.csv:row=683;CYP2C19_results.csv:row=683;CYP2D6_results.csv:row=683;CYP1A2_results.csv:row=683;CYP2C9_results.csv:row=683;hERG_results.csv:row=683;AMES_results.csv:row=683;PGP_results.csv:row=683;PAMPA_results.csv:row=683;BBB_results.csv:row=683;Solubility_results.csv:row=683;Lipophilicity_results.csv:row=684
CHEMBL3989869,UMBRALISIB TOSYLATE,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1,28.497330282227306,100,90.0,68.89893211289092,H,KG targets ABL1; clinical phase 4.0; logS -5.53; logP 7.90,repurposing_candidates.csv:rc_row=1097;protein_drug_candidates.csv:rows=1208;pathway_drug_candidates.csv:rows=4299;CYP3A4_results.csv:row=966;CYP2C19_results.csv:row=966;CYP2D6_results.csv:row=966;CYP1A2_results.csv:row=966;CYP2C9_results.csv:row=966;hERG_results.csv:row=966;AMES_results.csv:row=966;PGP_results.csv:row=966;PAMPA_results.csv:row=966;BBB_results.csv:row=966;Solubility_results.csv:row=966;Lipophilicity_results.csv:row=967
CHEMBL3039598,FOSINOPRIL,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,28.497330282227306,100,90.0,68.89893211289092,H,KG targets ACE; clinical phase 4.0; logS -3.76; logP 6.12,repurposing_candidates.csv:rc_row=899;protein_drug_candidates.csv:rows=642;pathway_drug_candidates.csv:rows=438;CYP3A4_results.csv:row=806;CYP2C19_results.csv:row=806;CYP2D6_results.csv:row=806;CYP1A2_results.csv:row=806;CYP2C9_results.csv:row=806;hERG_results.csv:row=806;AMES_results.csv:row=806;PGP_results.csv:row=806;PAMPA_results.csv:row=806;BBB_results.csv:row=806;Solubility_results.csv:row=806;Lipophilicity_results.csv:row=807
CHEMBL807,MEMANTINE,CC12CC3CC(C)(C1)CC(N)(C3)C2,40.53394355453852,100,70.0,68.71357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; hERG risk; logS -1.77; logP 2.69",repurposing_candidates.csv:rc_row=1520;protein_drug_candidates.csv:rows=709;1607;1952;2179;2600;2644;2669;pathway_drug_candidates.csv:rows=3615;6799;6826;6853;6886;7044;7071;7098;7125;CYP3A4_results.csv:row=1326;CYP2C19_results.csv:row=1326;CYP2D6_results.csv:row=1326;CYP1A2_results.csv:row=1326;CYP2C9_results.csv:row=1326;hERG_results.csv:row=1326;AMES_results.csv:row=1326;PGP_results.csv:row=1326;PAMPA_results.csv:row=1326;BBB_results.csv:row=1326;Solubility_results.csv:row=1326;Lipophilicity_results.csv:row=1327
CHEMBL1699,MEMANTINE HYDROCHLORIDE,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,40.53394355453852,100,70.0,68.71357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 4.0; hERG risk; logS -1.10; logP 3.12",repurposing_candidates.csv:rc_row=516;protein_drug_candidates.csv:rows=706;1605;1951;2178;2599;2643;2668;pathway_drug_candidates.csv:rows=3612;6796;6823;6850;6883;7041;7068;7095;7122;CYP3A4_results.csv:row=476;CYP2C19_results.csv:row=476;CYP2D6_results.csv:row=476;CYP1A2_results.csv:row=476;CYP2C9_results.csv:row=476;hERG_results.csv:row=476;AMES_results.csv:row=476;PGP_results.csv:row=476;PAMPA_results.csv:row=476;BBB_results.csv:row=476;Solubility_results.csv:row=476;Lipophilicity_results.csv:row=477
CHEMBL1908391,MASITINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,30.85430968726163,100,85.0,68.59172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -0.88; logP 5.26",repurposing_candidates.csv:rc_row=594;protein_drug_candidates.csv:rows=1102;1147;pathway_drug_candidates.csv:rows=552;6964;7000;7498;CYP3A4_results.csv:row=540;CYP2C19_results.csv:row=540;CYP2D6_results.csv:row=540;CYP1A2_results.csv:row=540;CYP2C9_results.csv:row=540;hERG_results.csv:row=540;AMES_results.csv:row=540;PGP_results.csv:row=540;PAMPA_results.csv:row=540;BBB_results.csv:row=540;Solubility_results.csv:row=540;Lipophilicity_results.csv:row=541
CHEMBL4577523,GOLIDOCITINIB,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,56.30434782608695,60,100.0,68.52173913043478,M,KG targets JAK1; clinical phase 2.0; logS -2.33; logP 2.69,repurposing_candidates.csv:rc_row=1281;protein_drug_candidates.csv:rows=770;pathway_drug_candidates.csv:rows=195;657;4247;4426;4567;4646;4725;4794;4832;4901;4967;5033;5143;5221;5271;5309;5375;5469;6922;CYP3A4_results.csv:row=1101;CYP2C19_results.csv:row=1101;CYP2D6_results.csv:row=1101;CYP1A2_results.csv:row=1101;CYP2C9_results.csv:row=1101;hERG_results.csv:row=1101;AMES_results.csv:row=1101;PGP_results.csv:row=1101;PAMPA_results.csv:row=1101;BBB_results.csv:row=1101;Solubility_results.csv:row=1101;Lipophilicity_results.csv:row=1102
CHEMBL3301606,SOLCITINIB,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1,56.30434782608695,60,100.0,68.52173913043478,M,KG targets JAK1; clinical phase 2.0; logS -4.43; logP 3.23,repurposing_candidates.csv:rc_row=940;protein_drug_candidates.csv:rows=773;pathway_drug_candidates.csv:rows=198;660;4250;4429;4570;4649;4728;4797;4835;4904;4970;5036;5146;5224;5274;5312;5378;5472;6925;CYP3A4_results.csv:row=844;CYP2C19_results.csv:row=844;CYP2D6_results.csv:row=844;CYP1A2_results.csv:row=844;CYP2C9_results.csv:row=844;hERG_results.csv:row=844;AMES_results.csv:row=844;PGP_results.csv:row=844;PAMPA_results.csv:row=844;BBB_results.csv:row=844;Solubility_results.csv:row=844;Lipophilicity_results.csv:row=845
CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,Cl.c1ccc2c(c1)CCCC2C1=NCCN1,38.70327993897788,80,100.0,68.48131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 3.0; logS -2.54; logP 2.53",repurposing_candidates.csv:rc_row=97;protein_drug_candidates.csv:rows=397;1341;1394;1499;1857;2540;pathway_drug_candidates.csv:rows=860;912;965;1016;1069;1120;1172;1225;1404;1457;1508;6522;6722;CYP3A4_results.csv:row=96;CYP2C19_results.csv:row=96;CYP2D6_results.csv:row=96;CYP1A2_results.csv:row=96;CYP2C9_results.csv:row=96;hERG_results.csv:row=96;AMES_results.csv:row=96;PGP_results.csv:row=96;PAMPA_results.csv:row=96;BBB_results.csv:row=96;Solubility_results.csv:row=96;Lipophilicity_results.csv:row=96
CHEMBL2103852,CROLIBULIN,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,76.73913043478261,40,95.0,68.44565217391305,L,"KG targets TUBB, TUBB1; clinical phase 1.0; logS -4.39; logP 2.85",repurposing_candidates.csv:rc_row=672;protein_drug_candidates.csv:rows=867;1599;2034;2274;2378;2443;2749;2813;2877;pathway_drug_candidates.csv:rows=1580;1644;1708;1772;1836;1900;1964;2129;2193;2257;2321;2385;2449;2513;2577;2641;2705;2769;2833;2897;2961;3025;3095;3159;3223;3287;3351;3415;3479;3543;3607;3698;3762;3826;3890;3954;4018;4085;CYP3A4_results.csv:row=617;CYP2C19_results.csv:row=617;CYP2D6_results.csv:row=617;CYP1A2_results.csv:row=617;CYP2C9_results.csv:row=617;hERG_results.csv:row=617;AMES_results.csv:row=617;PGP_results.csv:row=617;PAMPA_results.csv:row=617;BBB_results.csv:row=617;Solubility_results.csv:row=617;Lipophilicity_results.csv:row=618
CHEMBL603469,LESTAURTINIB,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,57.35697940503432,80,70.0,68.44279176201373,H,KG targets JAK2; clinical phase 3.0; hERG risk; logS -4.77; logP 3.47,repurposing_candidates.csv:rc_row=1442;protein_drug_candidates.csv:rows=788;pathway_drug_candidates.csv:rows=213;675;4585;4664;4743;4850;4919;4985;5051;5095;5161;5327;5393;6940;7474;8303;8331;8359;8393;8421;8449;CYP3A4_results.csv:row=1251;CYP2C19_results.csv:row=1251;CYP2D6_results.csv:row=1251;CYP1A2_results.csv:row=1251;CYP2C9_results.csv:row=1251;hERG_results.csv:row=1251;AMES_results.csv:row=1251;PGP_results.csv:row=1251;PAMPA_results.csv:row=1251;BBB_results.csv:row=1251;Solubility_results.csv:row=1251;Lipophilicity_results.csv:row=1252
CHEMBL1601669,ALFACALCIDOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,80,85.0,68.4033180778032,H,KG targets VDR; clinical phase 3.0; logS -5.34; logP 6.59,repurposing_candidates.csv:rc_row=473;protein_drug_candidates.csv:rows=248;pathway_drug_candidates.csv:rows=6001;7778;7896;CYP3A4_results.csv:row=433;CYP2C19_results.csv:row=433;CYP2D6_results.csv:row=433;CYP1A2_results.csv:row=433;CYP2C9_results.csv:row=433;hERG_results.csv:row=433;AMES_results.csv:row=433;PGP_results.csv:row=433;PAMPA_results.csv:row=433;BBB_results.csv:row=433;Solubility_results.csv:row=433;Lipophilicity_results.csv:row=434
CHEMBL1908376,SEOCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,80,85.0,68.4033180778032,H,KG targets VDR; clinical phase 3.0; logS -5.04; logP 6.43,repurposing_candidates.csv:rc_row=593;protein_drug_candidates.csv:rows=245;pathway_drug_candidates.csv:rows=5998;7775;7893;CYP3A4_results.csv:row=539;CYP2C19_results.csv:row=539;CYP2D6_results.csv:row=539;CYP1A2_results.csv:row=539;CYP2C9_results.csv:row=539;hERG_results.csv:row=539;AMES_results.csv:row=539;PGP_results.csv:row=539;PAMPA_results.csv:row=539;BBB_results.csv:row=539;Solubility_results.csv:row=539;Lipophilicity_results.csv:row=540
CHEMBL1201772,PRASUGREL,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,28.497330282227306,95,95.0,68.39893211289092,H,KG targets P2RY12; clinical phase 3.0; logS -4.30; logP 3.89,repurposing_candidates.csv:rc_row=314;protein_drug_candidates.csv:rows=471;pathway_drug_candidates.csv:rows=1356;CYP3A4_results.csv:row=283;CYP2C19_results.csv:row=283;CYP2D6_results.csv:row=283;CYP1A2_results.csv:row=283;CYP2C9_results.csv:row=283;hERG_results.csv:row=283;AMES_results.csv:row=283;PGP_results.csv:row=283;PAMPA_results.csv:row=283;BBB_results.csv:row=283;Solubility_results.csv:row=283;Lipophilicity_results.csv:row=284
CHEMBL4596392,CRAVACITINIB,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,38.49733028222731,80,100.0,68.39893211289092,H,KG targets TYK2; clinical phase 3.0; logS -3.43; logP 1.73,repurposing_candidates.csv:rc_row=1300;protein_drug_candidates.csv:rows=1192;pathway_drug_candidates.csv:rows=410;789;4274;4528;4611;4690;4769;4810;4876;4945;5011;5077;5121;5187;5237;5287;5353;5419;5435;5485;CYP3A4_results.csv:row=1116;CYP2C19_results.csv:row=1116;CYP2D6_results.csv:row=1116;CYP1A2_results.csv:row=1116;CYP2C9_results.csv:row=1116;hERG_results.csv:row=1116;AMES_results.csv:row=1116;PGP_results.csv:row=1116;PAMPA_results.csv:row=1116;BBB_results.csv:row=1116;Solubility_results.csv:row=1116;Lipophilicity_results.csv:row=1117
CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O,29.801678108314263,100,85.0,68.1706712433257,H,"KG targets ABL1, BCR; clinical phase 4.0; logS -3.36; logP 5.95",repurposing_candidates.csv:rc_row=304;protein_drug_candidates.csv:rows=1202;2203;pathway_drug_candidates.csv:rows=4293;CYP3A4_results.csv:row=273;CYP2C19_results.csv:row=273;CYP2D6_results.csv:row=273;CYP1A2_results.csv:row=273;CYP2C9_results.csv:row=273;hERG_results.csv:row=273;AMES_results.csv:row=273;PGP_results.csv:row=273;PAMPA_results.csv:row=273;BBB_results.csv:row=273;Solubility_results.csv:row=273;Lipophilicity_results.csv:row=274
CHEMBL2103826,DAVUNETIDE,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O,58.405797101449274,60,95.0,68.11231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -1.10; logP -4.34",repurposing_candidates.csv:rc_row=663;protein_drug_candidates.csv:rows=855;1588;2023;2261;2367;2431;2737;2802;2865;pathway_drug_candidates.csv:rows=1568;1632;1696;1760;1824;1888;1952;2117;2181;2245;2309;2373;2437;2501;2565;2629;2693;2757;2821;2885;2949;3013;3083;3147;3211;3275;3339;3403;3467;3531;3595;3686;3750;3814;3878;3942;4006;4073;CYP3A4_results.csv:row=608;CYP2C19_results.csv:row=608;CYP2D6_results.csv:row=608;CYP1A2_results.csv:row=608;CYP2C9_results.csv:row=608;hERG_results.csv:row=608;AMES_results.csv:row=608;PGP_results.csv:row=608;PAMPA_results.csv:row=608;BBB_results.csv:row=608;Solubility_results.csv:row=608;Lipophilicity_results.csv:row=609
CHEMBL492399,VERUBULIN,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,58.405797101449274,60,95.0,68.11231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -3.08; logP 3.71",repurposing_candidates.csv:rc_row=1341;protein_drug_candidates.csv:rows=840;1572;2007;2246;2351;2416;2722;2785;2851;pathway_drug_candidates.csv:rows=1553;1617;1681;1745;1809;1873;1937;2102;2166;2230;2294;2358;2422;2486;2550;2614;2678;2742;2806;2870;2934;2998;3068;3132;3196;3260;3324;3388;3452;3516;3580;3671;3735;3799;3863;3927;3991;4058;CYP3A4_results.csv:row=1152;CYP2C19_results.csv:row=1152;CYP2D6_results.csv:row=1152;CYP1A2_results.csv:row=1152;CYP2C9_results.csv:row=1152;hERG_results.csv:row=1152;AMES_results.csv:row=1152;PGP_results.csv:row=1152;PAMPA_results.csv:row=1152;BBB_results.csv:row=1152;Solubility_results.csv:row=1152;Lipophilicity_results.csv:row=1153
CHEMBL3707313,TRIFAROTENE,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,29.549961861174673,100,85.0,68.06998474446988,H,KG targets RARG; clinical phase 4.0; logS -5.90; logP 5.99,repurposing_candidates.csv:rc_row=1020;protein_drug_candidates.csv:rows=186;pathway_drug_candidates.csv:rows=5988;6014;6023;CYP3A4_results.csv:row=901;CYP2C19_results.csv:row=901;CYP2D6_results.csv:row=901;CYP1A2_results.csv:row=901;CYP2C9_results.csv:row=901;hERG_results.csv:row=901;AMES_results.csv:row=901;PGP_results.csv:row=901;PAMPA_results.csv:row=901;BBB_results.csv:row=901;Solubility_results.csv:row=901;Lipophilicity_results.csv:row=902
CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,CN[C@@H](C)[C@H](O)c1ccccc1.Cl,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -0.12; logP 1.75",repurposing_candidates.csv:rc_row=789;protein_drug_candidates.csv:rows=380;1325;1378;1484;1840;2523;pathway_drug_candidates.csv:rows=843;896;949;1000;1053;1104;1156;1209;1388;1441;1492;6505;6705;CYP3A4_results.csv:row=698;CYP2C19_results.csv:row=698;CYP2D6_results.csv:row=698;CYP1A2_results.csv:row=698;CYP2C9_results.csv:row=698;hERG_results.csv:row=698;AMES_results.csv:row=698;PGP_results.csv:row=698;PAMPA_results.csv:row=698;BBB_results.csv:row=698;Solubility_results.csv:row=698;Lipophilicity_results.csv:row=699
CHEMBL429,LABETALOL,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -3.25; logP 2.14",repurposing_candidates.csv:rc_row=1155;protein_drug_candidates.csv:rows=354;1312;1354;1462;1817;2510;pathway_drug_candidates.csv:rows=817;883;925;987;1029;1091;1143;1185;1375;1417;1479;6479;6679;CYP3A4_results.csv:row=1019;CYP2C19_results.csv:row=1019;CYP2D6_results.csv:row=1019;CYP1A2_results.csv:row=1019;CYP2C9_results.csv:row=1019;hERG_results.csv:row=1019;AMES_results.csv:row=1019;PGP_results.csv:row=1019;PAMPA_results.csv:row=1019;BBB_results.csv:row=1019;Solubility_results.csv:row=1019;Lipophilicity_results.csv:row=1020
CHEMBL312448,XYLOMETAZOLINE,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -3.94; logP 3.15",repurposing_candidates.csv:rc_row=905;protein_drug_candidates.csv:rows=389;1328;1382;1488;1850;2525;pathway_drug_candidates.csv:rows=852;899;953;1003;1057;1107;1159;1213;1391;1445;1495;6514;6714;CYP3A4_results.csv:row=812;CYP2C19_results.csv:row=812;CYP2D6_results.csv:row=812;CYP1A2_results.csv:row=812;CYP2C9_results.csv:row=812;hERG_results.csv:row=812;AMES_results.csv:row=812;PGP_results.csv:row=812;PAMPA_results.csv:row=812;BBB_results.csv:row=812;Solubility_results.csv:row=812;Lipophilicity_results.csv:row=813
CHEMBL1200323,LABETALOL HYDROCHLORIDE,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -2.58; logP 2.56",repurposing_candidates.csv:rc_row=83;protein_drug_candidates.csv:rows=373;1316;1366;1476;1835;2514;pathway_drug_candidates.csv:rows=836;887;937;991;1041;1095;1147;1197;1379;1429;1483;6498;6698;CYP3A4_results.csv:row=82;CYP2C19_results.csv:row=82;CYP2D6_results.csv:row=82;CYP1A2_results.csv:row=82;CYP2C9_results.csv:row=82;hERG_results.csv:row=82;AMES_results.csv:row=82;PGP_results.csv:row=82;PAMPA_results.csv:row=82;BBB_results.csv:row=82;Solubility_results.csv:row=82;Lipophilicity_results.csv:row=82
CHEMBL1523964,EPHEDRINE SULFATE,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS 0.21; logP 2.00",repurposing_candidates.csv:rc_row=450;protein_drug_candidates.csv:rows=382;1326;1380;1486;1848;2531;pathway_drug_candidates.csv:rows=845;897;951;1001;1055;1105;1157;1211;1389;1443;1493;6507;6707;CYP3A4_results.csv:row=410;CYP2C19_results.csv:row=410;CYP2D6_results.csv:row=410;CYP1A2_results.csv:row=410;CYP2C9_results.csv:row=410;hERG_results.csv:row=410;AMES_results.csv:row=410;PGP_results.csv:row=410;PAMPA_results.csv:row=410;BBB_results.csv:row=410;Solubility_results.csv:row=410;Lipophilicity_results.csv:row=411
CHEMBL211456,EPHEDRINE,CN[C@@H](C)[C@H](O)c1ccccc1,38.70327993897788,100,70.0,67.98131197559115,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -0.81; logP 1.33",repurposing_candidates.csv:rc_row=786;protein_drug_candidates.csv:rows=352;1301;1361;1460;1830;2500;pathway_drug_candidates.csv:rows=815;872;932;976;1036;1080;1132;1192;1364;1424;1468;6477;6677;CYP3A4_results.csv:row=695;CYP2C19_results.csv:row=695;CYP2D6_results.csv:row=695;CYP1A2_results.csv:row=695;CYP2C9_results.csv:row=695;hERG_results.csv:row=695;AMES_results.csv:row=695;PGP_results.csv:row=695;PAMPA_results.csv:row=695;BBB_results.csv:row=695;Solubility_results.csv:row=695;Lipophilicity_results.csv:row=696
CHEMBL3544917,RAPASTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,40.53394355453852,80,95.0,67.96357742181542,H,"KG targets GRIN1, GRIN2A; clinical phase 3.0; logS 0.57; logP -2.97",repurposing_candidates.csv:rc_row=956;protein_drug_candidates.csv:rows=719;1619;1966;2193;2613;2658;2683;pathway_drug_candidates.csv:rows=3625;6809;6836;6863;6896;7054;7081;7108;7135;CYP3A4_results.csv:row=860;CYP2C19_results.csv:row=860;CYP2D6_results.csv:row=860;CYP1A2_results.csv:row=860;CYP2C9_results.csv:row=860;hERG_results.csv:row=860;AMES_results.csv:row=860;PGP_results.csv:row=860;PAMPA_results.csv:row=860;BBB_results.csv:row=860;Solubility_results.csv:row=860;Lipophilicity_results.csv:row=861
CHEMBL1201825,RANIBIZUMAB,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=319;pathway_drug_candidates.csv:rows=419;463;475;487;499;511;523;535;585;798;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297750,FARICIMAB,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=1214;pathway_drug_candidates.csv:rows=421;465;477;489;501;513;525;537;587;800;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201421,PEGAPTANIB SODIUM,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=275;pathway_drug_candidates.csv:rows=422;466;478;490;502;514;526;538;588;801;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1742982,AFLIBERCEPT,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=542;pathway_drug_candidates.csv:rows=418;462;474;486;498;510;522;534;584;797;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3707357,BROLUCIZUMAB,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=1025;pathway_drug_candidates.csv:rows=420;464;476;488;500;512;524;536;586;799;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201583,BEVACIZUMAB,,19.90083905415713,100,100.0,67.96033562166285,H,KG targets VEGFA; clinical phase 4.0,repurposing_candidates.csv:rc_row=298;pathway_drug_candidates.csv:rows=417;461;473;485;497;509;521;533;583;796;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl,47.88329519450801,100,55.0,67.9033180778032,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.37; logP 5.51,repurposing_candidates.csv:rc_row=521;protein_drug_candidates.csv:rows=317;pathway_drug_candidates.csv:rows=287;1321;7234;CYP3A4_results.csv:row=481;CYP2C19_results.csv:row=481;CYP2D6_results.csv:row=481;CYP1A2_results.csv:row=481;CYP2C9_results.csv:row=481;hERG_results.csv:row=481;AMES_results.csv:row=481;PGP_results.csv:row=481;PAMPA_results.csv:row=481;BBB_results.csv:row=481;Solubility_results.csv:row=481;Lipophilicity_results.csv:row=482
CHEMBL4594254,SIMPINICLINE,C(=C/[C@H]1CCNC1)\c1cncnc1,54.18764302059497,60,100.0,67.67505720823799,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0; logS -0.67; logP 1.10",repurposing_candidates.csv:rc_row=1285;protein_drug_candidates.csv:rows=443;2139;pathway_drug_candidates.csv:rows=7923;7937;7951;CYP3A4_results.csv:row=1105;CYP2C19_results.csv:row=1105;CYP2D6_results.csv:row=1105;CYP1A2_results.csv:row=1105;CYP2C9_results.csv:row=1105;hERG_results.csv:row=1105;AMES_results.csv:row=1105;PGP_results.csv:row=1105;PAMPA_results.csv:row=1105;BBB_results.csv:row=1105;Solubility_results.csv:row=1105;Lipophilicity_results.csv:row=1106
CHEMBL1716,CYPROHEPTADINE HYDROCHLORIDE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,28.497330282227306,100,85.0,67.64893211289092,H,KG targets HRH1; clinical phase 4.0; logS -2.33; logP 5.12,repurposing_candidates.csv:rc_row=527;protein_drug_candidates.csv:rows=959;pathway_drug_candidates.csv:rows=6589;CYP3A4_results.csv:row=487;CYP2C19_results.csv:row=487;CYP2D6_results.csv:row=487;CYP1A2_results.csv:row=487;CYP2C9_results.csv:row=487;hERG_results.csv:row=487;AMES_results.csv:row=487;PGP_results.csv:row=487;PAMPA_results.csv:row=487;BBB_results.csv:row=487;Solubility_results.csv:row=487;Lipophilicity_results.csv:row=488
CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O,30.85430968726163,100,80.0,67.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 4.0; logS -6.06; logP 5.24",repurposing_candidates.csv:rc_row=709;protein_drug_candidates.csv:rows=1105;1151;pathway_drug_candidates.csv:rows=556;6968;7003;7502;CYP3A4_results.csv:row=654;CYP2C19_results.csv:row=654;CYP2D6_results.csv:row=654;CYP1A2_results.csv:row=654;CYP2C9_results.csv:row=654;hERG_results.csv:row=654;AMES_results.csv:row=654;PGP_results.csv:row=654;PAMPA_results.csv:row=654;BBB_results.csv:row=654;Solubility_results.csv:row=654;Lipophilicity_results.csv:row=655
CHEMBL1743070,SILTUXIMAB,,18.321891685736077,100,100.0,67.32875667429443,H,KG targets IL6; clinical phase 4.0,repurposing_candidates.csv:rc_row=553;pathway_drug_candidates.csv:rows=117;167;4403;4539;4618;4697;7587;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201834,CANAKINUMAB,,18.321891685736077,100,100.0,67.32875667429443,H,KG targets IL1B; clinical phase 4.0,repurposing_candidates.csv:rc_row=324;pathway_drug_candidates.csv:rows=164;4189;4352;4356;4360;4397;4536;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201830,RILONACEPT,,18.321891685736077,100,100.0,67.32875667429443,H,KG targets IL1B; clinical phase 4.0,repurposing_candidates.csv:rc_row=321;pathway_drug_candidates.csv:rows=163;4188;4351;4355;4359;4396;4535;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1366933,ESMIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,35.56826849733028,80,100.0,67.22730739893211,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; logS -2.88; logP 2.48",repurposing_candidates.csv:rc_row=395;protein_drug_candidates.csv:rows=1030;1345;1397;2543;pathway_drug_candidates.csv:rows=916;968;1020;1072;1124;1176;1228;1408;1460;1512;6660;CYP3A4_results.csv:row=355;CYP2C19_results.csv:row=355;CYP2D6_results.csv:row=355;CYP1A2_results.csv:row=355;CYP2C9_results.csv:row=355;hERG_results.csv:row=355;AMES_results.csv:row=355;PGP_results.csv:row=355;PAMPA_results.csv:row=355;BBB_results.csv:row=355;Solubility_results.csv:row=355;Lipophilicity_results.csv:row=356
CHEMBL2105683,NAPROXEN ETEMESIL,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1,52.87185354691076,60,100.0,67.1487414187643,M,"KG targets PTGS1, PTGS2; clinical phase 2.0; logS -4.59; logP 2.54",repurposing_candidates.csv:rc_row=698;protein_drug_candidates.csv:rows=164;940;pathway_drug_candidates.csv:rows=387;4505;5580;5640;5714;6098;6172;6246;6320;6394;6468;CYP3A4_results.csv:row=643;CYP2C19_results.csv:row=643;CYP2D6_results.csv:row=643;CYP1A2_results.csv:row=643;CYP2C9_results.csv:row=643;hERG_results.csv:row=643;AMES_results.csv:row=643;PGP_results.csv:row=643;PAMPA_results.csv:row=643;BBB_results.csv:row=643;Solubility_results.csv:row=643;Lipophilicity_results.csv:row=644
CHEMBL3833307,SATRALIZUMAB,,17.795575896262395,100,100.0,67.11823035850496,H,KG targets IL6R; clinical phase 4.0,repurposing_candidates.csv:rc_row=1042;pathway_drug_candidates.csv:rows=176;638;4548;4627;4706;7147;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1237022,TOCILIZUMAB,,17.795575896262395,100,100.0,67.11823035850496,H,KG targets IL6R; clinical phase 4.0,repurposing_candidates.csv:rc_row=343;pathway_drug_candidates.csv:rows=177;639;4549;4628;4707;7148;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108730,SARILUMAB,,17.795575896262395,100,100.0,67.11823035850496,H,KG targets IL6R; clinical phase 4.0,repurposing_candidates.csv:rc_row=755;pathway_drug_candidates.csv:rows=175;637;4547;4626;4705;7146;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL76222,REBIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,52.597254004576655,60,100.0,67.03890160183066,M,"KG targets MMP1, MMP13; clinical phase 2.0; logS -0.77; logP 1.16",repurposing_candidates.csv:rc_row=1510;protein_drug_candidates.csv:rows=617;623;631;pathway_drug_candidates.csv:rows=29;34;46;53;58;70;84;89;101;115;129;234;3030;CYP3A4_results.csv:row=1316;CYP2C19_results.csv:row=1316;CYP2D6_results.csv:row=1316;CYP1A2_results.csv:row=1316;CYP2C9_results.csv:row=1316;hERG_results.csv:row=1316;AMES_results.csv:row=1316;PGP_results.csv:row=1316;PAMPA_results.csv:row=1316;BBB_results.csv:row=1316;Solubility_results.csv:row=1316;Lipophilicity_results.csv:row=1317
CHEMBL2108508,INTERFERON ALFA-2A,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=749;pathway_drug_candidates.csv:rows=629;4214;5201;5251;5449;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201558,INTERFERON ALFA-2B,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=289;pathway_drug_candidates.csv:rows=623;4208;5195;5245;5443;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL5315048,ZILUCOPLAN SODIUM,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets C5; clinical phase 4.0,repurposing_candidates.csv:rc_row=1388;pathway_drug_candidates.csv:rows=1236;7173;7734;7746;7758;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2364653,ANIFROLUMAB,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=842;pathway_drug_candidates.csv:rows=622;4207;5194;5244;5442;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201557,INTERFERON ALFACON-1,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=288;pathway_drug_candidates.csv:rows=624;4209;5196;5246;5444;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201560,PEGINTERFERON ALFA-2A,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=290;pathway_drug_candidates.csv:rows=627;4212;5199;5249;5447;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298086,POZELIMAB,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets C5; clinical phase 4.0,repurposing_candidates.csv:rc_row=1242;pathway_drug_candidates.csv:rows=1237;7174;7735;7747;7759;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3989986,RAVULIZUMAB,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets C5; clinical phase 4.0,repurposing_candidates.csv:rc_row=1110;pathway_drug_candidates.csv:rows=1235;7172;7733;7745;7757;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201561,PEGINTERFERON ALFA-2B,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=291;pathway_drug_candidates.csv:rows=625;4210;5197;5247;5445;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201828,ECULIZUMAB,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets C5; clinical phase 4.0,repurposing_candidates.csv:rc_row=320;pathway_drug_candidates.csv:rows=1234;7171;7732;7744;7756;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297819,ROPEGINTERFERON ALFA-2B,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=1220;pathway_drug_candidates.csv:rows=631;4216;5203;5253;5451;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201562,INTERFERON BETA-1A,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=292;pathway_drug_candidates.csv:rows=626;4211;5198;5248;5446;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201563,INTERFERON BETA-1B,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=293;pathway_drug_candidates.csv:rows=628;4213;5200;5250;5448;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108677,PEGINTERFERON BETA-1A,,17.26926010678871,100,100.0,66.9077040427155,H,KG targets IFNAR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=752;pathway_drug_candidates.csv:rows=630;4215;5202;5252;5450;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2304041,SAGOPILONE,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,58.405797101449274,60,90.0,66.86231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -4.83; logP 5.46",repurposing_candidates.csv:rc_row=822;protein_drug_candidates.csv:rows=839;1571;2006;2245;2350;2414;2721;2787;2849;pathway_drug_candidates.csv:rows=1552;1616;1680;1744;1808;1872;1936;2101;2165;2229;2293;2357;2421;2485;2549;2613;2677;2741;2805;2869;2933;2997;3067;3131;3195;3259;3323;3387;3451;3515;3579;3670;3734;3798;3862;3926;3990;4057;CYP3A4_results.csv:row=731;CYP2C19_results.csv:row=731;CYP2D6_results.csv:row=731;CYP1A2_results.csv:row=731;CYP2C9_results.csv:row=731;hERG_results.csv:row=731;AMES_results.csv:row=731;PGP_results.csv:row=731;PAMPA_results.csv:row=731;BBB_results.csv:row=731;Solubility_results.csv:row=731;Lipophilicity_results.csv:row=732
CHEMBL1276308,MIFEPRISTONE,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,32.707856598016775,100,75.0,66.83314263920671,H,KG targets NR3C1; clinical phase 4.0; logS -6.26; logP 5.41,repurposing_candidates.csv:rc_row=371;protein_drug_candidates.csv:rows=34;pathway_drug_candidates.csv:rows=726;2035;5950;7854;7991;8057;8128;8194;8260;CYP3A4_results.csv:row=332;CYP2C19_results.csv:row=332;CYP2D6_results.csv:row=332;CYP1A2_results.csv:row=332;CYP2C9_results.csv:row=332;hERG_results.csv:row=332;AMES_results.csv:row=332;PGP_results.csv:row=332;PAMPA_results.csv:row=332;BBB_results.csv:row=332;Solubility_results.csv:row=332;Lipophilicity_results.csv:row=333
CHEMBL4216467,RIPRETINIB,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,29.549961861174673,100,80.0,66.81998474446988,H,KG targets KIT; clinical phase 4.0; logS -6.62; logP 5.67,repurposing_candidates.csv:rc_row=1149;protein_drug_candidates.csv:rows=1146;pathway_drug_candidates.csv:rows=551;6963;7497;CYP3A4_results.csv:row=1013;CYP2C19_results.csv:row=1013;CYP2D6_results.csv:row=1013;CYP1A2_results.csv:row=1013;CYP2C9_results.csv:row=1013;hERG_results.csv:row=1013;AMES_results.csv:row=1013;PGP_results.csv:row=1013;PAMPA_results.csv:row=1013;BBB_results.csv:row=1013;Solubility_results.csv:row=1013;Lipophilicity_results.csv:row=1014
CHEMBL2105648,PALOVAROTENE,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,29.549961861174673,100,80.0,66.81998474446988,H,KG targets RARG; clinical phase 4.0; logS -6.30; logP 6.15,repurposing_candidates.csv:rc_row=693;protein_drug_candidates.csv:rows=188;pathway_drug_candidates.csv:rows=5990;6016;6025;CYP3A4_results.csv:row=638;CYP2C19_results.csv:row=638;CYP2D6_results.csv:row=638;CYP1A2_results.csv:row=638;CYP2C9_results.csv:row=638;hERG_results.csv:row=638;AMES_results.csv:row=638;PGP_results.csv:row=638;PAMPA_results.csv:row=638;BBB_results.csv:row=638;Solubility_results.csv:row=638;Lipophilicity_results.csv:row=639
CHEMBL1201346,BALSALAZIDE,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,34.53852021357742,80,100.0,66.81540808543096,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; logS -2.80; logP 2.71",repurposing_candidates.csv:rc_row=272;protein_drug_candidates.csv:rows=153;932;pathway_drug_candidates.csv:rows=376;4494;5572;5632;5703;6087;6161;6235;6309;6383;6457;CYP3A4_results.csv:row=269;CYP2C19_results.csv:row=269;CYP2D6_results.csv:row=269;CYP1A2_results.csv:row=269;CYP2C9_results.csv:row=269;hERG_results.csv:row=269;AMES_results.csv:row=269;PGP_results.csv:row=269;PAMPA_results.csv:row=269;BBB_results.csv:row=269;Solubility_results.csv:row=269;Lipophilicity_results.csv:row=270
CHEMBL570015,GSK-256066,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,51.79633867276888,60,100.0,66.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -3.54; logP 3.93",repurposing_candidates.csv:rc_row=1417;protein_drug_candidates.csv:rows=426;1062;1089;2167;pathway_drug_candidates.csv:rows=4340;5748;5779;5806;5843;5873;CYP3A4_results.csv:row=1226;CYP2C19_results.csv:row=1226;CYP2D6_results.csv:row=1226;CYP1A2_results.csv:row=1226;CYP2C9_results.csv:row=1226;hERG_results.csv:row=1226;AMES_results.csv:row=1226;PGP_results.csv:row=1226;PAMPA_results.csv:row=1226;BBB_results.csv:row=1226;Solubility_results.csv:row=1226;Lipophilicity_results.csv:row=1227
CHEMBL485629,MK-0873,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,51.79633867276888,60,100.0,66.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -2.27; logP 2.31",repurposing_candidates.csv:rc_row=1336;protein_drug_candidates.csv:rows=429;1061;1091;2166;pathway_drug_candidates.csv:rows=4342;5751;5778;5808;5846;5875;CYP3A4_results.csv:row=1147;CYP2C19_results.csv:row=1147;CYP2D6_results.csv:row=1147;CYP1A2_results.csv:row=1147;CYP2C9_results.csv:row=1147;hERG_results.csv:row=1147;AMES_results.csv:row=1147;PGP_results.csv:row=1147;PAMPA_results.csv:row=1147;BBB_results.csv:row=1147;Solubility_results.csv:row=1147;Lipophilicity_results.csv:row=1148
CHEMBL4297527,REVAMILAST,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12,51.79633867276888,60,100.0,66.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -4.28; logP 4.77",repurposing_candidates.csv:rc_row=1190;protein_drug_candidates.csv:rows=430;1063;1092;2168;pathway_drug_candidates.csv:rows=4343;5752;5780;5809;5847;5876;CYP3A4_results.csv:row=1053;CYP2C19_results.csv:row=1053;CYP2D6_results.csv:row=1053;CYP1A2_results.csv:row=1053;CYP2C9_results.csv:row=1053;hERG_results.csv:row=1053;AMES_results.csv:row=1053;PGP_results.csv:row=1053;PAMPA_results.csv:row=1053;BBB_results.csv:row=1053;Solubility_results.csv:row=1053;Lipophilicity_results.csv:row=1054
CHEMBL217899,TOFIMILAST,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2,51.79633867276888,60,100.0,66.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -2.84; logP 4.10",repurposing_candidates.csv:rc_row=799;protein_drug_candidates.csv:rows=425;1058;1087;2165;pathway_drug_candidates.csv:rows=4338;5747;5775;5804;5842;5871;CYP3A4_results.csv:row=708;CYP2C19_results.csv:row=708;CYP2D6_results.csv:row=708;CYP1A2_results.csv:row=708;CYP2C9_results.csv:row=708;hERG_results.csv:row=708;AMES_results.csv:row=708;PGP_results.csv:row=708;PAMPA_results.csv:row=708;BBB_results.csv:row=708;Solubility_results.csv:row=708;Lipophilicity_results.csv:row=709
CHEMBL2103831,NAPROXCINOD,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1,52.87185354691076,80,70.0,66.6487414187643,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; hERG risk; logS -5.20; logP 3.48",repurposing_candidates.csv:rc_row=667;protein_drug_candidates.csv:rows=156;936;pathway_drug_candidates.csv:rows=379;4497;5576;5636;5706;6090;6164;6238;6312;6386;6460;CYP3A4_results.csv:row=612;CYP2C19_results.csv:row=612;CYP2D6_results.csv:row=612;CYP1A2_results.csv:row=612;CYP2C9_results.csv:row=612;hERG_results.csv:row=612;AMES_results.csv:row=612;PGP_results.csv:row=612;PAMPA_results.csv:row=612;BBB_results.csv:row=612;Solubility_results.csv:row=612;Lipophilicity_results.csv:row=613
CHEMBL787,MONTELUKAST,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,29.02364607170099,100,80.0,66.6094584286804,H,KG targets CYSLTR1; clinical phase 4.0; logS -7.32; logP 8.95,repurposing_candidates.csv:rc_row=1516;protein_drug_candidates.csv:rows=1228;pathway_drug_candidates.csv:rows=618;6575;CYP3A4_results.csv:row=1322;CYP2C19_results.csv:row=1322;CYP2D6_results.csv:row=1322;CYP1A2_results.csv:row=1322;CYP2C9_results.csv:row=1322;hERG_results.csv:row=1322;AMES_results.csv:row=1322;PGP_results.csv:row=1322;PAMPA_results.csv:row=1322;BBB_results.csv:row=1322;Solubility_results.csv:row=1322;Lipophilicity_results.csv:row=1323
CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,33.737604881769634,80,100.0,66.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; logS -3.16; logP 3.60",repurposing_candidates.csv:rc_row=715;protein_drug_candidates.csv:rows=1343;1395;2542;pathway_drug_candidates.csv:rows=914;966;1018;1070;1122;1174;1226;1406;1458;1510;CYP3A4_results.csv:row=660;CYP2C19_results.csv:row=660;CYP2D6_results.csv:row=660;CYP1A2_results.csv:row=660;CYP2C9_results.csv:row=660;hERG_results.csv:row=660;AMES_results.csv:row=660;PGP_results.csv:row=660;PAMPA_results.csv:row=660;BBB_results.csv:row=660;Solubility_results.csv:row=660;Lipophilicity_results.csv:row=661
CHEMBL10316,IDAZOXAN,c1ccc2c(c1)OCC(C1=NCCN1)O2,33.737604881769634,80,100.0,66.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; logS -2.27; logP 0.83",repurposing_candidates.csv:rc_row=11;protein_drug_candidates.csv:rows=1346;1399;2546;pathway_drug_candidates.csv:rows=917;970;1021;1074;1125;1177;1230;1409;1462;1513;CYP3A4_results.csv:row=11;CYP2C19_results.csv:row=11;CYP2D6_results.csv:row=11;CYP1A2_results.csv:row=11;CYP2C9_results.csv:row=11;hERG_results.csv:row=11;AMES_results.csv:row=11;PGP_results.csv:row=11;PAMPA_results.csv:row=11;BBB_results.csv:row=11;Solubility_results.csv:row=11;Lipophilicity_results.csv:row=11
CHEMBL778,DEXMEDETOMIDINE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,33.737604881769634,80,100.0,66.49504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; logS -3.75; logP 3.18",repurposing_candidates.csv:rc_row=1512;protein_drug_candidates.csv:rows=1340;1392;2539;pathway_drug_candidates.csv:rows=911;963;1015;1067;1119;1171;1223;1403;1455;1507;CYP3A4_results.csv:row=1318;CYP2C19_results.csv:row=1318;CYP2D6_results.csv:row=1318;CYP1A2_results.csv:row=1318;CYP2C9_results.csv:row=1318;hERG_results.csv:row=1318;AMES_results.csv:row=1318;PGP_results.csv:row=1318;PAMPA_results.csv:row=1318;BBB_results.csv:row=1318;Solubility_results.csv:row=1318;Lipophilicity_results.csv:row=1319
CHEMBL1201570,ANAKINRA,,16.21662852784134,100,100.0,66.48665141113653,H,KG targets IL1R1; clinical phase 4.0,repurposing_candidates.csv:rc_row=294;pathway_drug_candidates.csv:rows=634;4192;4400;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297700,BIMEKIZUMAB,,16.21662852784134,100,100.0,66.48665141113653,H,KG targets IL17A; clinical phase 4.0,repurposing_candidates.csv:rc_row=1209;pathway_drug_candidates.csv:rows=155;4224;7304;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743068,SECUKINUMAB,,16.21662852784134,100,100.0,66.48665141113653,H,KG targets IL17A; clinical phase 4.0,repurposing_candidates.csv:rc_row=552;pathway_drug_candidates.csv:rows=154;4223;7303;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743034,IXEKIZUMAB,,16.21662852784134,100,100.0,66.48665141113653,H,KG targets IL17A; clinical phase 4.0,repurposing_candidates.csv:rc_row=546;pathway_drug_candidates.csv:rows=153;4222;7302;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201148,MEPREDNISONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,51.04118993135011,60,100.0,66.41647597254004,M,KG targets NR3C1; clinical phase 2.0; logS -3.44; logP 2.01,repurposing_candidates.csv:rc_row=242;protein_drug_candidates.csv:rows=62;pathway_drug_candidates.csv:rows=754;2063;5978;7882;8019;8085;8156;8222;8288;CYP3A4_results.csv:row=239;CYP2C19_results.csv:row=239;CYP2D6_results.csv:row=239;CYP1A2_results.csv:row=239;CYP2C9_results.csv:row=239;hERG_results.csv:row=239;AMES_results.csv:row=239;PGP_results.csv:row=239;PAMPA_results.csv:row=239;BBB_results.csv:row=239;Solubility_results.csv:row=239;Lipophilicity_results.csv:row=240
CHEMBL473159,PHLOROGLUCINOL,Oc1cc(O)cc(O)c1,15.942028985507244,100,100.0,66.3768115942029,H,"KG targets CACNA1A, CACNA2D1; clinical phase 4.0; logS -0.40; logP 0.80",repurposing_candidates.csv:rc_row=1325;protein_drug_candidates.csv:rows=1907;2493;CYP3A4_results.csv:row=1136;CYP2C19_results.csv:row=1136;CYP2D6_results.csv:row=1136;CYP1A2_results.csv:row=1136;CYP2C9_results.csv:row=1136;hERG_results.csv:row=1136;AMES_results.csv:row=1136;PGP_results.csv:row=1136;PAMPA_results.csv:row=1136;BBB_results.csv:row=1136;Solubility_results.csv:row=1136;Lipophilicity_results.csv:row=1137
CHEMBL3989820,ZOLPIDEM TARTRATE,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O,15.942028985507244,100,100.0,66.3768115942029,H,"KG targets GABRB1, GABRG2; clinical phase 4.0; logS -0.88; logP 4.38",repurposing_candidates.csv:rc_row=1088;protein_drug_candidates.csv:rows=1642;1738;CYP3A4_results.csv:row=957;CYP2C19_results.csv:row=957;CYP2D6_results.csv:row=957;CYP1A2_results.csv:row=957;CYP2C9_results.csv:row=957;hERG_results.csv:row=957;AMES_results.csv:row=957;PGP_results.csv:row=957;PAMPA_results.csv:row=957;BBB_results.csv:row=957;Solubility_results.csv:row=957;Lipophilicity_results.csv:row=958
CHEMBL2105754,TRELAGLIPTIN SUCCINATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -1.92; logP 0.47,repurposing_candidates.csv:rc_row=707;protein_drug_candidates.csv:rows=669;CYP3A4_results.csv:row=652;CYP2C19_results.csv:row=652;CYP2D6_results.csv:row=652;CYP1A2_results.csv:row=652;CYP2C9_results.csv:row=652;hERG_results.csv:row=652;AMES_results.csv:row=652;PGP_results.csv:row=652;PAMPA_results.csv:row=652;BBB_results.csv:row=652;Solubility_results.csv:row=652;Lipophilicity_results.csv:row=653
CHEMBL3707235,GEMIGLIPTIN,N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -1.67; logP 2.37,repurposing_candidates.csv:rc_row=1016;protein_drug_candidates.csv:rows=670;CYP3A4_results.csv:row=900;CYP2C19_results.csv:row=900;CYP2D6_results.csv:row=900;CYP1A2_results.csv:row=900;CYP2C9_results.csv:row=900;hERG_results.csv:row=900;AMES_results.csv:row=900;PGP_results.csv:row=900;PAMPA_results.csv:row=900;BBB_results.csv:row=900;Solubility_results.csv:row=900;Lipophilicity_results.csv:row=901
CHEMBL2105762,OMARIGLIPTIN,CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -2.09; logP 1.14,repurposing_candidates.csv:rc_row=712;protein_drug_candidates.csv:rows=666;CYP3A4_results.csv:row=657;CYP2C19_results.csv:row=657;CYP2D6_results.csv:row=657;CYP1A2_results.csv:row=657;CYP2C9_results.csv:row=657;hERG_results.csv:row=657;AMES_results.csv:row=657;PGP_results.csv:row=657;PAMPA_results.csv:row=657;BBB_results.csv:row=657;Solubility_results.csv:row=657;Lipophilicity_results.csv:row=658
CHEMBL1929396,ANAGLIPTIN,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -1.30; logP 0.65,repurposing_candidates.csv:rc_row=601;protein_drug_candidates.csv:rows=675;CYP3A4_results.csv:row=547;CYP2C19_results.csv:row=547;CYP2D6_results.csv:row=547;CYP1A2_results.csv:row=547;CYP2C9_results.csv:row=547;hERG_results.csv:row=547;AMES_results.csv:row=547;PGP_results.csv:row=547;PAMPA_results.csv:row=547;BBB_results.csv:row=547;Solubility_results.csv:row=547;Lipophilicity_results.csv:row=548
CHEMBL1779710,EVOGLIPTIN,CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -0.73; logP 1.51,repurposing_candidates.csv:rc_row=569;protein_drug_candidates.csv:rows=665;CYP3A4_results.csv:row=515;CYP2C19_results.csv:row=515;CYP2D6_results.csv:row=515;CYP1A2_results.csv:row=515;CYP2C9_results.csv:row=515;hERG_results.csv:row=515;AMES_results.csv:row=515;PGP_results.csv:row=515;PAMPA_results.csv:row=515;BBB_results.csv:row=515;Solubility_results.csv:row=515;Lipophilicity_results.csv:row=516
CHEMBL1082462,DBPR-108,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,32.971014492753625,80,100.0,66.18840579710145,H,KG targets DPP4; clinical phase 3.0; logS -0.22; logP 0.83,repurposing_candidates.csv:rc_row=31;protein_drug_candidates.csv:rows=674;CYP3A4_results.csv:row=31;CYP2C19_results.csv:row=31;CYP2D6_results.csv:row=31;CYP1A2_results.csv:row=31;CYP2C9_results.csv:row=31;hERG_results.csv:row=31;AMES_results.csv:row=31;PGP_results.csv:row=31;PAMPA_results.csv:row=31;BBB_results.csv:row=31;Solubility_results.csv:row=31;Lipophilicity_results.csv:row=31
CHEMBL2107455,IGURATIMOD,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,32.707856598016775,80,100.0,66.08314263920671,H,KG targets PTGS2; clinical phase 3.0; logS -4.45; logP 2.53,repurposing_candidates.csv:rc_row=730;protein_drug_candidates.csv:rows=151;pathway_drug_candidates.csv:rows=374;4492;5701;6085;6159;6233;6307;6381;6455;CYP3A4_results.csv:row=675;CYP2C19_results.csv:row=675;CYP2D6_results.csv:row=675;CYP1A2_results.csv:row=675;CYP2C9_results.csv:row=675;hERG_results.csv:row=675;AMES_results.csv:row=675;PGP_results.csv:row=675;PAMPA_results.csv:row=675;BBB_results.csv:row=675;Solubility_results.csv:row=675;Lipophilicity_results.csv:row=676
CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,32.707856598016775,80,100.0,66.08314263920671,H,KG targets NR3C1; clinical phase 3.0; logS -3.83; logP 2.20,repurposing_candidates.csv:rc_row=1576;protein_drug_candidates.csv:rows=53;pathway_drug_candidates.csv:rows=745;2054;5969;7873;8010;8076;8147;8213;8279;CYP3A4_results.csv:row=1382;CYP2C19_results.csv:row=1382;CYP2D6_results.csv:row=1382;CYP1A2_results.csv:row=1382;CYP2C9_results.csv:row=1382;hERG_results.csv:row=1382;AMES_results.csv:row=1382;PGP_results.csv:row=1382;PAMPA_results.csv:row=1382;BBB_results.csv:row=1382;Solubility_results.csv:row=1382;Lipophilicity_results.csv:row=1383
CHEMBL4297886,ASUNERCEPT,,19.374523264683447,95,100.0,65.99980930587338,H,KG targets FASLG; clinical phase 3.0,repurposing_candidates.csv:rc_row=1227;pathway_drug_candidates.csv:rows=152;7312;7313;7314;7315;7316;7317;7318;7319;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL844,BRIMONIDINE,Brc1c(NC2=NCCN2)ccc2nccnc12,33.737604881769634,100,70.0,65.99504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; hERG risk; logS -1.91; logP 1.76",repurposing_candidates.csv:rc_row=1533;protein_drug_candidates.csv:rows=1330;1383;2533;pathway_drug_candidates.csv:rows=901;954;1005;1058;1109;1161;1214;1393;1446;1497;CYP3A4_results.csv:row=1339;CYP2C19_results.csv:row=1339;CYP2D6_results.csv:row=1339;CYP1A2_results.csv:row=1339;CYP2C9_results.csv:row=1339;hERG_results.csv:row=1339;AMES_results.csv:row=1339;PGP_results.csv:row=1339;PAMPA_results.csv:row=1339;BBB_results.csv:row=1339;Solubility_results.csv:row=1339;Lipophilicity_results.csv:row=1340
CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,Cl.Clc1ccc2nsnc2c1NC1=NCCN1,33.737604881769634,100,70.0,65.99504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; hERG risk; logS -2.27; logP 2.14",repurposing_candidates.csv:rc_row=85;protein_drug_candidates.csv:rows=1335;1387;2535;pathway_drug_candidates.csv:rows=906;958;1010;1062;1114;1166;1218;1398;1450;1502;CYP3A4_results.csv:row=84;CYP2C19_results.csv:row=84;CYP2D6_results.csv:row=84;CYP1A2_results.csv:row=84;CYP2C9_results.csv:row=84;hERG_results.csv:row=84;AMES_results.csv:row=84;PGP_results.csv:row=84;PAMPA_results.csv:row=84;BBB_results.csv:row=84;Solubility_results.csv:row=84;Lipophilicity_results.csv:row=84
CHEMBL4594419,BMS-813160,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O,49.713958810068654,60,100.0,65.88558352402747,M,"KG targets CCR2, CCR5; clinical phase 2.0; logS -3.31; logP 2.25",repurposing_candidates.csv:rc_row=1296;protein_drug_candidates.csv:rows=220;232;pathway_drug_candidates.csv:rows=1250;1262;4367;4379;6761;6773;6785;CYP3A4_results.csv:row=1115;CYP2C19_results.csv:row=1115;CYP2D6_results.csv:row=1115;CYP1A2_results.csv:row=1115;CYP2C9_results.csv:row=1115;hERG_results.csv:row=1115;AMES_results.csv:row=1115;PGP_results.csv:row=1115;PAMPA_results.csv:row=1115;BBB_results.csv:row=1115;Solubility_results.csv:row=1115;Lipophilicity_results.csv:row=1116
CHEMBL1200461,MIDODRINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl,32.15865751334859,80,100.0,65.86346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 3.0; logS -0.86; logP 0.23",repurposing_candidates.csv:rc_row=104;protein_drug_candidates.csv:rows=399;1501;1859;pathway_drug_candidates.csv:rows=862;6524;6724;CYP3A4_results.csv:row=103;CYP2C19_results.csv:row=103;CYP2D6_results.csv:row=103;CYP1A2_results.csv:row=103;CYP2C9_results.csv:row=103;hERG_results.csv:row=103;AMES_results.csv:row=103;PGP_results.csv:row=103;PAMPA_results.csv:row=103;BBB_results.csv:row=103;Solubility_results.csv:row=103;Lipophilicity_results.csv:row=103
CHEMBL1111,AMBRISENTAN,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets EDNRA; clinical phase 4.0; logS -2.60; logP 3.52,repurposing_candidates.csv:rc_row=52;protein_drug_candidates.csv:rows=1911;CYP3A4_results.csv:row=52;CYP2C19_results.csv:row=52;CYP2D6_results.csv:row=52;CYP1A2_results.csv:row=52;CYP2C9_results.csv:row=52;hERG_results.csv:row=52;AMES_results.csv:row=52;PGP_results.csv:row=52;PAMPA_results.csv:row=52;BBB_results.csv:row=52;Solubility_results.csv:row=52;Lipophilicity_results.csv:row=52
CHEMBL259209,MILNACIPRAN,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.79; logP 1.77,repurposing_candidates.csv:rc_row=862;protein_drug_candidates.csv:rows=1263;CYP3A4_results.csv:row=770;CYP2C19_results.csv:row=770;CYP2D6_results.csv:row=770;CYP1A2_results.csv:row=770;CYP2C9_results.csv:row=770;hERG_results.csv:row=770;AMES_results.csv:row=770;PGP_results.csv:row=770;PAMPA_results.csv:row=770;BBB_results.csv:row=770;Solubility_results.csv:row=770;Lipophilicity_results.csv:row=771
CHEMBL490,PAROXETINE,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.15; logP 3.33,repurposing_candidates.csv:rc_row=1338;protein_drug_candidates.csv:rows=1265;CYP3A4_results.csv:row=1149;CYP2C19_results.csv:row=1149;CYP2D6_results.csv:row=1149;CYP1A2_results.csv:row=1149;CYP2C9_results.csv:row=1149;hERG_results.csv:row=1149;AMES_results.csv:row=1149;PGP_results.csv:row=1149;PAMPA_results.csv:row=1149;BBB_results.csv:row=1149;Solubility_results.csv:row=1149;Lipophilicity_results.csv:row=1150
CHEMBL2105732,LEVOMILNACIPRAN HYDROCHLORIDE,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.09; logP 2.19,repurposing_candidates.csv:rc_row=703;protein_drug_candidates.csv:rows=1247;CYP3A4_results.csv:row=648;CYP2C19_results.csv:row=648;CYP2D6_results.csv:row=648;CYP1A2_results.csv:row=648;CYP2C9_results.csv:row=648;hERG_results.csv:row=648;AMES_results.csv:row=648;PGP_results.csv:row=648;PAMPA_results.csv:row=648;BBB_results.csv:row=648;Solubility_results.csv:row=648;Lipophilicity_results.csv:row=649
CHEMBL11,IMIPRAMINE,CN(C)CCCN1c2ccccc2CCc2ccccc21,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.33; logP 3.88,repurposing_candidates.csv:rc_row=49;protein_drug_candidates.csv:rows=1252;CYP3A4_results.csv:row=49;CYP2C19_results.csv:row=49;CYP2D6_results.csv:row=49;CYP1A2_results.csv:row=49;CYP2C9_results.csv:row=49;hERG_results.csv:row=49;AMES_results.csv:row=49;PGP_results.csv:row=49;PAMPA_results.csv:row=49;BBB_results.csv:row=49;Solubility_results.csv:row=49;Lipophilicity_results.csv:row=49
CHEMBL2105740,SITAXENTAN SODIUM,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+],14.63768115942029,100,100.0,65.85507246376812,H,KG targets EDNRA; clinical phase 4.0; logS -4.12; logP 1.56,repurposing_candidates.csv:rc_row=705;protein_drug_candidates.csv:rows=1915;CYP3A4_results.csv:row=650;CYP2C19_results.csv:row=650;CYP2D6_results.csv:row=650;CYP1A2_results.csv:row=650;CYP2C9_results.csv:row=650;hERG_results.csv:row=650;AMES_results.csv:row=650;PGP_results.csv:row=650;PAMPA_results.csv:row=650;BBB_results.csv:row=650;Solubility_results.csv:row=650;Lipophilicity_results.csv:row=651
CHEMBL1118,DESVENLAFAXINE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.30; logP 2.73,repurposing_candidates.csv:rc_row=56;protein_drug_candidates.csv:rows=1253;CYP3A4_results.csv:row=56;CYP2C19_results.csv:row=56;CYP2D6_results.csv:row=56;CYP1A2_results.csv:row=56;CYP2C9_results.csv:row=56;hERG_results.csv:row=56;AMES_results.csv:row=56;PGP_results.csv:row=56;PAMPA_results.csv:row=56;BBB_results.csv:row=56;Solubility_results.csv:row=56;Lipophilicity_results.csv:row=56
CHEMBL1201728,DESVENLAFAXINE SUCCINATE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS 0.07; logP 2.67,repurposing_candidates.csv:rc_row=302;protein_drug_candidates.csv:rows=1259;CYP3A4_results.csv:row=271;CYP2C19_results.csv:row=271;CYP2D6_results.csv:row=271;CYP1A2_results.csv:row=271;CYP2C9_results.csv:row=271;hERG_results.csv:row=271;AMES_results.csv:row=271;PGP_results.csv:row=271;PAMPA_results.csv:row=271;BBB_results.csv:row=271;Solubility_results.csv:row=271;Lipophilicity_results.csv:row=272
CHEMBL940,GABAPENTIN,NCC1(CC(=O)O)CCCCC1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets CACNA2D1; clinical phase 4.0; logS -0.63; logP 1.37,repurposing_candidates.csv:rc_row=1558;protein_drug_candidates.csv:rows=2490;CYP3A4_results.csv:row=1364;CYP2C19_results.csv:row=1364;CYP2D6_results.csv:row=1364;CYP1A2_results.csv:row=1364;CYP2C9_results.csv:row=1364;hERG_results.csv:row=1364;AMES_results.csv:row=1364;PGP_results.csv:row=1364;PAMPA_results.csv:row=1364;BBB_results.csv:row=1364;Solubility_results.csv:row=1364;Lipophilicity_results.csv:row=1365
CHEMBL256997,ATALUREN,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets RPS27; clinical phase 4.0; logS -4.77; logP 3.24,repurposing_candidates.csv:rc_row=860;protein_drug_candidates.csv:rows=1729;CYP3A4_results.csv:row=768;CYP2C19_results.csv:row=768;CYP2D6_results.csv:row=768;CYP1A2_results.csv:row=768;CYP2C9_results.csv:row=768;hERG_results.csv:row=768;AMES_results.csv:row=768;PGP_results.csv:row=768;PAMPA_results.csv:row=768;BBB_results.csv:row=768;Solubility_results.csv:row=768;Lipophilicity_results.csv:row=769
CHEMBL1059,PREGABALIN,CC(C)C[C@H](CN)CC(=O)O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets CACNA2D1; clinical phase 4.0; logS -0.03; logP 1.08,repurposing_candidates.csv:rc_row=18;protein_drug_candidates.csv:rows=2491;CYP3A4_results.csv:row=18;CYP2C19_results.csv:row=18;CYP2D6_results.csv:row=18;CYP1A2_results.csv:row=18;CYP2C9_results.csv:row=18;hERG_results.csv:row=18;AMES_results.csv:row=18;PGP_results.csv:row=18;PAMPA_results.csv:row=18;BBB_results.csv:row=18;Solubility_results.csv:row=18;Lipophilicity_results.csv:row=18
CHEMBL1201649,"ESTROGENS, CONJUGATED",,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=300;protein_drug_candidates.csv:rows=2284;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201468,"ESTROGENS, ESTERIFIED",,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=280;protein_drug_candidates.csv:rows=2294;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201477,POLYESTRADIOL PHOSPHATE,,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=282;protein_drug_candidates.csv:rows=2283;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL814,FLUVOXAMINE,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -2.03; logP 3.20,repurposing_candidates.csv:rc_row=1524;protein_drug_candidates.csv:rows=1274;CYP3A4_results.csv:row=1330;CYP2C19_results.csv:row=1330;CYP2D6_results.csv:row=1330;CYP1A2_results.csv:row=1330;CYP2C9_results.csv:row=1330;hERG_results.csv:row=1330;AMES_results.csv:row=1330;PGP_results.csv:row=1330;PAMPA_results.csv:row=1330;BBB_results.csv:row=1330;Solubility_results.csv:row=1330;Lipophilicity_results.csv:row=1331
CHEMBL1201467,"SYNTHETIC CONJUGATED ESTROGENS, B",,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=279;protein_drug_candidates.csv:rows=2296;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201466,"ESTROGENS, CONJUGATED SYNTHETIC A",,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=278;protein_drug_candidates.csv:rows=2293;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL277062,BROMAZEPAM,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets GABRA2; clinical phase 4.0; logS -3.02; logP 2.63,repurposing_candidates.csv:rc_row=871;protein_drug_candidates.csv:rows=1700;CYP3A4_results.csv:row=779;CYP2C19_results.csv:row=779;CYP2D6_results.csv:row=779;CYP1A2_results.csv:row=779;CYP2C9_results.csv:row=779;hERG_results.csv:row=779;AMES_results.csv:row=779;PGP_results.csv:row=779;PAMPA_results.csv:row=779;BBB_results.csv:row=779;Solubility_results.csv:row=779;Lipophilicity_results.csv:row=780
CHEMBL2107387,VORTIOXETINE HYDROBROMIDE,Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.28; logP 4.44,repurposing_candidates.csv:rc_row=729;protein_drug_candidates.csv:rows=1276;CYP3A4_results.csv:row=674;CYP2C19_results.csv:row=674;CYP2D6_results.csv:row=674;CYP1A2_results.csv:row=674;CYP2C9_results.csv:row=674;hERG_results.csv:row=674;AMES_results.csv:row=674;PGP_results.csv:row=674;PAMPA_results.csv:row=674;BBB_results.csv:row=674;Solubility_results.csv:row=674;Lipophilicity_results.csv:row=675
CHEMBL5315115,LASOFOXIFENE TARTRATE,,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0,repurposing_candidates.csv:rc_row=1393;protein_drug_candidates.csv:rows=2291;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL544665,FINGOLIMOD HYDROCHLORIDE,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl,14.63768115942029,100,100.0,65.85507246376812,H,KG targets S1PR4; clinical phase 4.0; logS -2.42; logP 3.63,repurposing_candidates.csv:rc_row=1403;protein_drug_candidates.csv:rows=1884;CYP3A4_results.csv:row=1212;CYP2C19_results.csv:row=1212;CYP2D6_results.csv:row=1212;CYP1A2_results.csv:row=1212;CYP2C9_results.csv:row=1212;hERG_results.csv:row=1212;AMES_results.csv:row=1212;PGP_results.csv:row=1212;PAMPA_results.csv:row=1212;BBB_results.csv:row=1212;Solubility_results.csv:row=1212;Lipophilicity_results.csv:row=1213
CHEMBL549,CITALOPRAM,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.04; logP 3.81,repurposing_candidates.csv:rc_row=1405;protein_drug_candidates.csv:rows=1266;CYP3A4_results.csv:row=1214;CYP2C19_results.csv:row=1214;CYP2D6_results.csv:row=1214;CYP1A2_results.csv:row=1214;CYP2C9_results.csv:row=1214;hERG_results.csv:row=1214;AMES_results.csv:row=1214;PGP_results.csv:row=1214;PAMPA_results.csv:row=1214;BBB_results.csv:row=1214;Solubility_results.csv:row=1214;Lipophilicity_results.csv:row=1215
CHEMBL1201066,VENLAFAXINE HYDROCHLORIDE,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS 0.57; logP 3.46,repurposing_candidates.csv:rc_row=228;protein_drug_candidates.csv:rows=1250;CYP3A4_results.csv:row=226;CYP2C19_results.csv:row=226;CYP2D6_results.csv:row=226;CYP1A2_results.csv:row=226;CYP2C9_results.csv:row=226;hERG_results.csv:row=226;AMES_results.csv:row=226;PGP_results.csv:row=226;PAMPA_results.csv:row=226;BBB_results.csv:row=226;Solubility_results.csv:row=226;Lipophilicity_results.csv:row=227
CHEMBL1419,SIBUTRAMINE,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.56; logP 4.74,repurposing_candidates.csv:rc_row=406;protein_drug_candidates.csv:rows=1236;CYP3A4_results.csv:row=366;CYP2C19_results.csv:row=366;CYP2D6_results.csv:row=366;CYP1A2_results.csv:row=366;CYP2C9_results.csv:row=366;hERG_results.csv:row=366;AMES_results.csv:row=366;PGP_results.csv:row=366;PAMPA_results.csv:row=366;BBB_results.csv:row=366;Solubility_results.csv:row=366;Lipophilicity_results.csv:row=367
CHEMBL1200980,ESTROPIPATE,C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets ESR1; clinical phase 4.0; logS -2.74; logP 2.47,repurposing_candidates.csv:rc_row=207;protein_drug_candidates.csv:rows=2288;CYP3A4_results.csv:row=205;CYP2C19_results.csv:row=205;CYP2D6_results.csv:row=205;CYP1A2_results.csv:row=205;CYP2C9_results.csv:row=205;hERG_results.csv:row=205;AMES_results.csv:row=205;PGP_results.csv:row=205;PAMPA_results.csv:row=205;BBB_results.csv:row=205;Solubility_results.csv:row=205;Lipophilicity_results.csv:row=206
CHEMBL637,VENLAFAXINE,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.10; logP 3.04,repurposing_candidates.csv:rc_row=1465;protein_drug_candidates.csv:rows=1272;CYP3A4_results.csv:row=1271;CYP2C19_results.csv:row=1271;CYP2D6_results.csv:row=1271;CYP1A2_results.csv:row=1271;CYP2C9_results.csv:row=1271;hERG_results.csv:row=1271;AMES_results.csv:row=1271;PGP_results.csv:row=1271;PAMPA_results.csv:row=1271;BBB_results.csv:row=1271;Solubility_results.csv:row=1271;Lipophilicity_results.csv:row=1272
CHEMBL1200609,PAROXETINE MESYLATE,CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -2.18; logP 2.83,repurposing_candidates.csv:rc_row=133;protein_drug_candidates.csv:rows=1237;CYP3A4_results.csv:row=132;CYP2C19_results.csv:row=132;CYP2D6_results.csv:row=132;CYP1A2_results.csv:row=132;CYP2C9_results.csv:row=132;hERG_results.csv:row=132;AMES_results.csv:row=132;PGP_results.csv:row=132;PAMPA_results.csv:row=132;BBB_results.csv:row=132;Solubility_results.csv:row=132;Lipophilicity_results.csv:row=132
CHEMBL282724,SITAXENTAN,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,14.63768115942029,100,100.0,65.85507246376812,H,KG targets EDNRA; clinical phase 4.0; logS -5.15; logP 3.96,repurposing_candidates.csv:rc_row=879;protein_drug_candidates.csv:rows=1913;CYP3A4_results.csv:row=787;CYP2C19_results.csv:row=787;CYP2D6_results.csv:row=787;CYP1A2_results.csv:row=787;CYP2C9_results.csv:row=787;hERG_results.csv:row=787;AMES_results.csv:row=787;PGP_results.csv:row=787;PAMPA_results.csv:row=787;BBB_results.csv:row=787;Solubility_results.csv:row=787;Lipophilicity_results.csv:row=788
CHEMBL1409,FLUVOXAMINE MALEATE,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -1.57; logP 2.91,repurposing_candidates.csv:rc_row=404;protein_drug_candidates.csv:rows=1245;CYP3A4_results.csv:row=364;CYP2C19_results.csv:row=364;CYP2D6_results.csv:row=364;CYP1A2_results.csv:row=364;CYP2C9_results.csv:row=364;hERG_results.csv:row=364;AMES_results.csv:row=364;PGP_results.csv:row=364;PAMPA_results.csv:row=364;BBB_results.csv:row=364;Solubility_results.csv:row=364;Lipophilicity_results.csv:row=365
CHEMBL99946,LEVOMILNACIPRAN,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.79; logP 1.77,repurposing_candidates.csv:rc_row=1583;protein_drug_candidates.csv:rows=1280;CYP3A4_results.csv:row=1389;CYP2C19_results.csv:row=1389;CYP2D6_results.csv:row=1389;CYP1A2_results.csv:row=1389;CYP2C9_results.csv:row=1389;hERG_results.csv:row=1389;AMES_results.csv:row=1389;PGP_results.csv:row=1389;PAMPA_results.csv:row=1389;BBB_results.csv:row=1389;Solubility_results.csv:row=1389;Lipophilicity_results.csv:row=1390
CHEMBL4297064,MILNACIPRAN HYDROCHLORIDE,CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.09; logP 2.19,repurposing_candidates.csv:rc_row=1157;protein_drug_candidates.csv:rows=1248;CYP3A4_results.csv:row=1021;CYP2C19_results.csv:row=1021;CYP2D6_results.csv:row=1021;CYP1A2_results.csv:row=1021;CYP2C9_results.csv:row=1021;hERG_results.csv:row=1021;AMES_results.csv:row=1021;PGP_results.csv:row=1021;PAMPA_results.csv:row=1021;BBB_results.csv:row=1021;Solubility_results.csv:row=1021;Lipophilicity_results.csv:row=1022
CHEMBL1692,IMIPRAMINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.65; logP 4.30,repurposing_candidates.csv:rc_row=513;protein_drug_candidates.csv:rows=1282;CYP3A4_results.csv:row=473;CYP2C19_results.csv:row=473;CYP2D6_results.csv:row=473;CYP1A2_results.csv:row=473;CYP2C9_results.csv:row=473;hERG_results.csv:row=473;AMES_results.csv:row=473;PGP_results.csv:row=473;PAMPA_results.csv:row=473;BBB_results.csv:row=473;Solubility_results.csv:row=473;Lipophilicity_results.csv:row=474
CHEMBL3989861,DESVENLAFAXINE FUMARATE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -0.79; logP 1.62,repurposing_candidates.csv:rc_row=1095;protein_drug_candidates.csv:rows=1267;CYP3A4_results.csv:row=964;CYP2C19_results.csv:row=964;CYP2D6_results.csv:row=964;CYP1A2_results.csv:row=964;CYP2C9_results.csv:row=964;hERG_results.csv:row=964;AMES_results.csv:row=964;PGP_results.csv:row=964;PAMPA_results.csv:row=964;BBB_results.csv:row=964;Solubility_results.csv:row=964;Lipophilicity_results.csv:row=965
CHEMBL1708,PAROXETINE HYDROCHLORIDE,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.49; logP 3.75,repurposing_candidates.csv:rc_row=522;protein_drug_candidates.csv:rows=1238;CYP3A4_results.csv:row=482;CYP2C19_results.csv:row=482;CYP2D6_results.csv:row=482;CYP1A2_results.csv:row=482;CYP2C9_results.csv:row=482;hERG_results.csv:row=482;AMES_results.csv:row=482;PGP_results.csv:row=482;PAMPA_results.csv:row=482;BBB_results.csv:row=482;Solubility_results.csv:row=482;Lipophilicity_results.csv:row=483
CHEMBL1508,ESCITALOPRAM,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,14.63768115942029,100,100.0,65.85507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.04; logP 3.81,repurposing_candidates.csv:rc_row=439;protein_drug_candidates.csv:rows=1254;CYP3A4_results.csv:row=399;CYP2C19_results.csv:row=399;CYP2D6_results.csv:row=399;CYP1A2_results.csv:row=399;CYP2C9_results.csv:row=399;hERG_results.csv:row=399;AMES_results.csv:row=399;PGP_results.csv:row=399;PAMPA_results.csv:row=399;BBB_results.csv:row=399;Solubility_results.csv:row=399;Lipophilicity_results.csv:row=400
CHEMBL1628502,GABAPENTIN ENACARBIL,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,14.63768115942029,100,100.0,65.85507246376812,H,KG targets CACNA2D1; clinical phase 4.0; logS -1.99; logP 2.68,repurposing_candidates.csv:rc_row=485;protein_drug_candidates.csv:rows=2492;CYP3A4_results.csv:row=445;CYP2C19_results.csv:row=445;CYP2D6_results.csv:row=445;CYP1A2_results.csv:row=445;CYP2C9_results.csv:row=445;hERG_results.csv:row=445;AMES_results.csv:row=445;PGP_results.csv:row=445;PAMPA_results.csv:row=445;BBB_results.csv:row=445;Solubility_results.csv:row=445;Lipophilicity_results.csv:row=446
CHEMBL2103829,FAXELADOL,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1,49.18764302059497,60,100.0,65.67505720823799,M,"KG targets OPRM1, SLC6A4; clinical phase 2.0; logS -2.23; logP 3.23",repurposing_candidates.csv:rc_row=666;protein_drug_candidates.csv:rows=338;1294;pathway_drug_candidates.csv:rows=308;1342;7255;CYP3A4_results.csv:row=611;CYP2C19_results.csv:row=611;CYP2D6_results.csv:row=611;CYP1A2_results.csv:row=611;CYP2C9_results.csv:row=611;hERG_results.csv:row=611;AMES_results.csv:row=611;PGP_results.csv:row=611;PAMPA_results.csv:row=611;BBB_results.csv:row=611;Solubility_results.csv:row=611;Lipophilicity_results.csv:row=612
CHEMBL96172,EPOTHILONE D,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,58.405797101449274,60,85.0,65.61231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -3.58; logP 5.27",repurposing_candidates.csv:rc_row=1568;protein_drug_candidates.csv:rows=858;1589;2026;2264;2369;2433;2739;2804;2868;pathway_drug_candidates.csv:rows=1571;1635;1699;1763;1827;1891;1955;2120;2184;2248;2312;2376;2440;2504;2568;2632;2696;2760;2824;2888;2952;3016;3086;3150;3214;3278;3342;3406;3470;3534;3598;3689;3753;3817;3881;3945;4009;4076;CYP3A4_results.csv:row=1374;CYP2C19_results.csv:row=1374;CYP2D6_results.csv:row=1374;CYP1A2_results.csv:row=1374;CYP2C9_results.csv:row=1374;hERG_results.csv:row=1374;AMES_results.csv:row=1374;PGP_results.csv:row=1374;PAMPA_results.csv:row=1374;BBB_results.csv:row=1374;Solubility_results.csv:row=1374;Lipophilicity_results.csv:row=1375
CHEMBL4297296,KOS-1584,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1,58.405797101449274,60,85.0,65.61231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -3.27; logP 5.04",repurposing_candidates.csv:rc_row=1169;protein_drug_candidates.csv:rows=851;1585;2018;2258;2363;2429;2735;2799;2864;pathway_drug_candidates.csv:rows=1564;1628;1692;1756;1820;1884;1948;2113;2177;2241;2305;2369;2433;2497;2561;2625;2689;2753;2817;2881;2945;3009;3079;3143;3207;3271;3335;3399;3463;3527;3591;3682;3746;3810;3874;3938;4002;4069;CYP3A4_results.csv:row=1032;CYP2C19_results.csv:row=1032;CYP2D6_results.csv:row=1032;CYP1A2_results.csv:row=1032;CYP2C9_results.csv:row=1032;hERG_results.csv:row=1032;AMES_results.csv:row=1032;PGP_results.csv:row=1032;PAMPA_results.csv:row=1032;BBB_results.csv:row=1032;Solubility_results.csv:row=1032;Lipophilicity_results.csv:row=1033
CHEMBL416146,ETORICOXIB,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,32.707856598016775,100,70.0,65.58314263920671,H,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -4.00; logP 4.18,repurposing_candidates.csv:rc_row=1139;protein_drug_candidates.csv:rows=134;pathway_drug_candidates.csv:rows=357;4475;5684;6068;6142;6216;6290;6364;6438;CYP3A4_results.csv:row=1003;CYP2C19_results.csv:row=1003;CYP2D6_results.csv:row=1003;CYP1A2_results.csv:row=1003;CYP2C9_results.csv:row=1003;hERG_results.csv:row=1003;AMES_results.csv:row=1003;PGP_results.csv:row=1003;PAMPA_results.csv:row=1003;BBB_results.csv:row=1003;Solubility_results.csv:row=1003;Lipophilicity_results.csv:row=1004
CHEMBL865,VALDECOXIB,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,32.707856598016775,100,70.0,65.58314263920671,H,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -2.90; logP 2.96,repurposing_candidates.csv:rc_row=1540;protein_drug_candidates.csv:rows=104;pathway_drug_candidates.csv:rows=327;4445;5654;6038;6112;6186;6260;6334;6408;CYP3A4_results.csv:row=1346;CYP2C19_results.csv:row=1346;CYP2D6_results.csv:row=1346;CYP1A2_results.csv:row=1346;CYP2C9_results.csv:row=1346;hERG_results.csv:row=1346;AMES_results.csv:row=1346;PGP_results.csv:row=1346;PAMPA_results.csv:row=1346;BBB_results.csv:row=1346;Solubility_results.csv:row=1346;Lipophilicity_results.csv:row=1347
CHEMBL599,MELOXICAM,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,32.707856598016775,100,70.0,65.58314263920671,H,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -2.23; logP 1.95,repurposing_candidates.csv:rc_row=1439;protein_drug_candidates.csv:rows=103;pathway_drug_candidates.csv:rows=326;4444;5653;6037;6111;6185;6259;6333;6407;CYP3A4_results.csv:row=1248;CYP2C19_results.csv:row=1248;CYP2D6_results.csv:row=1248;CYP1A2_results.csv:row=1248;CYP2C9_results.csv:row=1248;hERG_results.csv:row=1248;AMES_results.csv:row=1248;PGP_results.csv:row=1248;PAMPA_results.csv:row=1248;BBB_results.csv:row=1248;Solubility_results.csv:row=1248;Lipophilicity_results.csv:row=1249
CHEMBL1206690,PARECOXIB,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,32.707856598016775,100,70.0,65.58314263920671,H,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -4.19; logP 3.53,repurposing_candidates.csv:rc_row=328;protein_drug_candidates.csv:rows=142;pathway_drug_candidates.csv:rows=365;4483;5692;6076;6150;6224;6298;6372;6446;CYP3A4_results.csv:row=291;CYP2C19_results.csv:row=291;CYP2D6_results.csv:row=291;CYP1A2_results.csv:row=291;CYP2C9_results.csv:row=291;hERG_results.csv:row=291;AMES_results.csv:row=291;PGP_results.csv:row=291;PAMPA_results.csv:row=291;BBB_results.csv:row=291;Solubility_results.csv:row=291;Lipophilicity_results.csv:row=292
CHEMBL1743050,OLOKIZUMAB,,18.321891685736077,95,100.0,65.57875667429443,H,KG targets IL6; clinical phase 3.0,repurposing_candidates.csv:rc_row=549;pathway_drug_candidates.csv:rows=119;169;4405;4541;4620;4699;7589;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1200335,TESTOSTERONE ENANTHATE,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,29.549961861174673,100,75.0,65.56998474446988,H,KG targets AR; clinical phase 4.0; logS -7.46; logP 6.40,repurposing_candidates.csv:rc_row=87;protein_drug_candidates.csv:rows=547;pathway_drug_candidates.csv:rows=1970;5885;7789;CYP3A4_results.csv:row=86;CYP2C19_results.csv:row=86;CYP2D6_results.csv:row=86;CYP1A2_results.csv:row=86;CYP2C9_results.csv:row=86;hERG_results.csv:row=86;AMES_results.csv:row=86;PGP_results.csv:row=86;PAMPA_results.csv:row=86;BBB_results.csv:row=86;Solubility_results.csv:row=86;Lipophilicity_results.csv:row=86
CHEMBL4297460,DOVRAMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC,51.79633867276888,60,95.0,65.46853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -3.57; logP 3.18",repurposing_candidates.csv:rc_row=1179;protein_drug_candidates.csv:rows=432;1065;1094;2170;pathway_drug_candidates.csv:rows=4345;5754;5782;5811;5849;5878;CYP3A4_results.csv:row=1042;CYP2C19_results.csv:row=1042;CYP2D6_results.csv:row=1042;CYP1A2_results.csv:row=1042;CYP2C9_results.csv:row=1042;hERG_results.csv:row=1042;AMES_results.csv:row=1042;PGP_results.csv:row=1042;PAMPA_results.csv:row=1042;BBB_results.csv:row=1042;Solubility_results.csv:row=1042;Lipophilicity_results.csv:row=1043
CHEMBL4650406,LEVILIMAB,,17.795575896262395,95,100.0,65.36823035850496,H,KG targets IL6R; clinical phase 3.0,repurposing_candidates.csv:rc_row=1315;pathway_drug_candidates.csv:rows=178;640;4550;4629;4708;7149;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3900554,BMS-986142,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,48.40961098398169,60,100.0,65.36384439359267,M,KG targets BTK; clinical phase 2.0; logS -4.48; logP 4.40,repurposing_candidates.csv:rc_row=1057;protein_drug_candidates.csv:rows=208;pathway_drug_candidates.csv:rows=614;4109;6571;6751;CYP3A4_results.csv:row=926;CYP2C19_results.csv:row=926;CYP2D6_results.csv:row=926;CYP1A2_results.csv:row=926;CYP2C9_results.csv:row=926;hERG_results.csv:row=926;AMES_results.csv:row=926;PGP_results.csv:row=926;PAMPA_results.csv:row=926;BBB_results.csv:row=926;Solubility_results.csv:row=926;Lipophilicity_results.csv:row=927
CHEMBL1688243,INCB-9471,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,48.40961098398169,60,100.0,65.36384439359267,M,KG targets CCR5; clinical phase 2.0; logS -2.45; logP 4.82,repurposing_candidates.csv:rc_row=510;protein_drug_candidates.csv:rows=225;pathway_drug_candidates.csv:rows=1267;4384;6766;6790;CYP3A4_results.csv:row=470;CYP2C19_results.csv:row=470;CYP2D6_results.csv:row=470;CYP1A2_results.csv:row=470;CYP2C9_results.csv:row=470;hERG_results.csv:row=470;AMES_results.csv:row=470;PGP_results.csv:row=470;PAMPA_results.csv:row=470;BBB_results.csv:row=470;Solubility_results.csv:row=470;Lipophilicity_results.csv:row=471
CHEMBL4650338,EDRALBRUTINIB,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1,48.40961098398169,60,100.0,65.36384439359267,M,KG targets BTK; clinical phase 2.0; logS -5.97; logP 3.84,repurposing_candidates.csv:rc_row=1312;protein_drug_candidates.csv:rows=203;pathway_drug_candidates.csv:rows=609;4104;6566;6746;CYP3A4_results.csv:row=1126;CYP2C19_results.csv:row=1126;CYP2D6_results.csv:row=1126;CYP1A2_results.csv:row=1126;CYP2C9_results.csv:row=1126;hERG_results.csv:row=1126;AMES_results.csv:row=1126;PGP_results.csv:row=1126;PAMPA_results.csv:row=1126;BBB_results.csv:row=1126;Solubility_results.csv:row=1126;Lipophilicity_results.csv:row=1127
CHEMBL4163691,POSELTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1,48.40961098398169,60,100.0,65.36384439359267,M,KG targets BTK; clinical phase 2.0; logS -5.36; logP 4.64,repurposing_candidates.csv:rc_row=1140;protein_drug_candidates.csv:rows=207;pathway_drug_candidates.csv:rows=613;4108;6570;6750;CYP3A4_results.csv:row=1004;CYP2C19_results.csv:row=1004;CYP2D6_results.csv:row=1004;CYP1A2_results.csv:row=1004;CYP2C9_results.csv:row=1004;hERG_results.csv:row=1004;AMES_results.csv:row=1004;PGP_results.csv:row=1004;PAMPA_results.csv:row=1004;BBB_results.csv:row=1004;Solubility_results.csv:row=1004;Lipophilicity_results.csv:row=1005
CHEMBL4071161,TIRABRUTINIB,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,48.40961098398169,60,100.0,65.36384439359267,M,KG targets BTK; clinical phase 2.0; logS -5.07; logP 2.75,repurposing_candidates.csv:rc_row=1123;protein_drug_candidates.csv:rows=204;pathway_drug_candidates.csv:rows=610;4105;6567;6747;CYP3A4_results.csv:row=987;CYP2C19_results.csv:row=987;CYP2D6_results.csv:row=987;CYP1A2_results.csv:row=987;CYP2C9_results.csv:row=987;hERG_results.csv:row=987;AMES_results.csv:row=987;PGP_results.csv:row=987;PAMPA_results.csv:row=987;BBB_results.csv:row=987;Solubility_results.csv:row=987;Lipophilicity_results.csv:row=988
CHEMBL1951914,AZD5672,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,48.40961098398169,60,100.0,65.36384439359267,M,KG targets CCR5; clinical phase 2.0; logS -3.12; logP 4.07,repurposing_candidates.csv:rc_row=611;protein_drug_candidates.csv:rows=222;pathway_drug_candidates.csv:rows=1264;4381;6763;6787;CYP3A4_results.csv:row=557;CYP2C19_results.csv:row=557;CYP2D6_results.csv:row=557;CYP1A2_results.csv:row=557;CYP2C9_results.csv:row=557;hERG_results.csv:row=557;AMES_results.csv:row=557;PGP_results.csv:row=557;PAMPA_results.csv:row=557;BBB_results.csv:row=557;Solubility_results.csv:row=557;Lipophilicity_results.csv:row=558
CHEMBL723,CARVEDILOL,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -4.23; logP 3.74",repurposing_candidates.csv:rc_row=1499;protein_drug_candidates.csv:rows=370;1473;1820;pathway_drug_candidates.csv:rows=833;6495;6695;CYP3A4_results.csv:row=1305;CYP2C19_results.csv:row=1305;CYP2D6_results.csv:row=1305;CYP1A2_results.csv:row=1305;CYP2C9_results.csv:row=1305;hERG_results.csv:row=1305;AMES_results.csv:row=1305;PGP_results.csv:row=1305;PAMPA_results.csv:row=1305;BBB_results.csv:row=1305;Solubility_results.csv:row=1305;Lipophilicity_results.csv:row=1306
CHEMBL1200561,DOXAZOSIN MESYLATE,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -2.36; logP 1.22",repurposing_candidates.csv:rc_row=124;protein_drug_candidates.csv:rows=357;1450;1819;pathway_drug_candidates.csv:rows=820;6482;6682;CYP3A4_results.csv:row=123;CYP2C19_results.csv:row=123;CYP2D6_results.csv:row=123;CYP1A2_results.csv:row=123;CYP2C9_results.csv:row=123;hERG_results.csv:row=123;AMES_results.csv:row=123;PGP_results.csv:row=123;PAMPA_results.csv:row=123;BBB_results.csv:row=123;Solubility_results.csv:row=123;Lipophilicity_results.csv:row=123
CHEMBL836,TAMSULOSIN,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -1.89; logP 2.34",repurposing_candidates.csv:rc_row=1530;protein_drug_candidates.csv:rows=348;1455;1810;pathway_drug_candidates.csv:rows=811;6473;6673;CYP3A4_results.csv:row=1336;CYP2C19_results.csv:row=1336;CYP2D6_results.csv:row=1336;CYP1A2_results.csv:row=1336;CYP2C9_results.csv:row=1336;hERG_results.csv:row=1336;AMES_results.csv:row=1336;PGP_results.csv:row=1336;PAMPA_results.csv:row=1336;BBB_results.csv:row=1336;Solubility_results.csv:row=1336;Lipophilicity_results.csv:row=1337
CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -1.21; logP 2.76",repurposing_candidates.csv:rc_row=193;protein_drug_candidates.csv:rows=345;1451;1809;pathway_drug_candidates.csv:rows=808;6470;6670;CYP3A4_results.csv:row=191;CYP2C19_results.csv:row=191;CYP2D6_results.csv:row=191;CYP1A2_results.csv:row=191;CYP2C9_results.csv:row=191;hERG_results.csv:row=191;AMES_results.csv:row=191;PGP_results.csv:row=191;PAMPA_results.csv:row=191;BBB_results.csv:row=191;Solubility_results.csv:row=191;Lipophilicity_results.csv:row=192
CHEMBL1201167,CARVEDILOL PHOSPHATE,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -4.11; logP 2.81",repurposing_candidates.csv:rc_row=248;protein_drug_candidates.csv:rows=372;1477;1837;pathway_drug_candidates.csv:rows=835;6497;6697;CYP3A4_results.csv:row=245;CYP2C19_results.csv:row=245;CYP2D6_results.csv:row=245;CYP1A2_results.csv:row=245;CYP2C9_results.csv:row=245;hERG_results.csv:row=245;AMES_results.csv:row=245;PGP_results.csv:row=245;PAMPA_results.csv:row=245;BBB_results.csv:row=245;Solubility_results.csv:row=245;Lipophilicity_results.csv:row=246
CHEMBL524,METHOXAMINE,COc1ccc(OC)c(C(O)C(C)N)c1,32.15865751334859,100,70.0,65.36346300533944,H,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -1.42; logP 1.08",repurposing_candidates.csv:rc_row=1370;protein_drug_candidates.csv:rows=355;1463;1831;pathway_drug_candidates.csv:rows=818;6480;6680;CYP3A4_results.csv:row=1181;CYP2C19_results.csv:row=1181;CYP2D6_results.csv:row=1181;CYP1A2_results.csv:row=1181;CYP2C9_results.csv:row=1181;hERG_results.csv:row=1181;AMES_results.csv:row=1181;PGP_results.csv:row=1181;PAMPA_results.csv:row=1181;BBB_results.csv:row=1181;Solubility_results.csv:row=1181;Lipophilicity_results.csv:row=1182
CHEMBL572881,MOTESANIB,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -4.28; logP 4.04",repurposing_candidates.csv:rc_row=1421;protein_drug_candidates.csv:rows=1124;1166;pathway_drug_candidates.csv:rows=571;6983;7022;7517;CYP3A4_results.csv:row=1230;CYP2C19_results.csv:row=1230;CYP2D6_results.csv:row=1230;CYP1A2_results.csv:row=1230;CYP2C9_results.csv:row=1230;hERG_results.csv:row=1230;AMES_results.csv:row=1230;PGP_results.csv:row=1230;PAMPA_results.csv:row=1230;BBB_results.csv:row=1230;Solubility_results.csv:row=1230;Lipophilicity_results.csv:row=1231
CHEMBL522892,DOVITINIB,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -2.89; logP 2.54",repurposing_candidates.csv:rc_row=1369;protein_drug_candidates.csv:rows=1121;1162;pathway_drug_candidates.csv:rows=567;6979;7019;7513;CYP3A4_results.csv:row=1180;CYP2C19_results.csv:row=1180;CYP2D6_results.csv:row=1180;CYP1A2_results.csv:row=1180;CYP2C9_results.csv:row=1180;hERG_results.csv:row=1180;AMES_results.csv:row=1180;PGP_results.csv:row=1180;PAMPA_results.csv:row=1180;BBB_results.csv:row=1180;Solubility_results.csv:row=1180;Lipophilicity_results.csv:row=1181
CHEMBL1201536,NICOTINE POLACRILEX,,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets CHRNA4, CHRNB2; clinical phase 3.0",repurposing_candidates.csv:rc_row=285;protein_drug_candidates.csv:rows=440;2133;pathway_drug_candidates.csv:rows=7920;7934;7948;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545427,CM-082,,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0",repurposing_candidates.csv:rc_row=998;protein_drug_candidates.csv:rows=1122;1163;pathway_drug_candidates.csv:rows=568;6980;7020;7514;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2103881,DEXMECAMYLAMINE,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets CHRNA4, CHRNB2; clinical phase 3.0; logS -2.22; logP 2.42",repurposing_candidates.csv:rc_row=678;protein_drug_candidates.csv:rows=441;2137;pathway_drug_candidates.csv:rows=7921;7935;7949;CYP3A4_results.csv:row=623;CYP2C19_results.csv:row=623;CYP2D6_results.csv:row=623;CYP1A2_results.csv:row=623;CYP2C9_results.csv:row=623;hERG_results.csv:row=623;AMES_results.csv:row=623;PGP_results.csv:row=623;PAMPA_results.csv:row=623;BBB_results.csv:row=623;Solubility_results.csv:row=623;Lipophilicity_results.csv:row=624
CHEMBL497939,CYTISINICLINE,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets CHRNA4, CHRNB2; clinical phase 3.0; logS 0.23; logP 0.55",repurposing_candidates.csv:rc_row=1344;protein_drug_candidates.csv:rows=438;2135;pathway_drug_candidates.csv:rows=7918;7932;7946;CYP3A4_results.csv:row=1155;CYP2C19_results.csv:row=1155;CYP2D6_results.csv:row=1155;CYP1A2_results.csv:row=1155;CYP2C9_results.csv:row=1155;hERG_results.csv:row=1155;AMES_results.csv:row=1155;PGP_results.csv:row=1155;PAMPA_results.csv:row=1155;BBB_results.csv:row=1155;Solubility_results.csv:row=1155;Lipophilicity_results.csv:row=1156
CHEMBL477772,PAZOPANIB,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,30.85430968726163,80,100.0,65.34172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -2.64; logP 3.14",repurposing_candidates.csv:rc_row=1326;protein_drug_candidates.csv:rows=1116;1158;pathway_drug_candidates.csv:rows=563;6975;7014;7509;CYP3A4_results.csv:row=1137;CYP2C19_results.csv:row=1137;CYP2D6_results.csv:row=1137;CYP1A2_results.csv:row=1137;CYP2C9_results.csv:row=1137;hERG_results.csv:row=1137;AMES_results.csv:row=1137;PGP_results.csv:row=1137;PAMPA_results.csv:row=1137;BBB_results.csv:row=1137;Solubility_results.csv:row=1137;Lipophilicity_results.csv:row=1138
CHEMBL1535,HYDROXYCHLOROQUINE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,35.064836003051106,100,65.0,65.27593440122044,M,"KG targets TLR7, TLR9; clinical phase 4.0; hERG risk; logS -2.67; logP 3.78",repurposing_candidates.csv:rc_row=453;protein_drug_candidates.csv:rows=256;599;pathway_drug_candidates.csv:rows=759;770;4255;7321;7332;7343;7354;7365;7376;7387;7398;7409;7420;7431;7442;7453;CYP3A4_results.csv:row=413;CYP2C19_results.csv:row=413;CYP2D6_results.csv:row=413;CYP1A2_results.csv:row=413;CYP2C9_results.csv:row=413;hERG_results.csv:row=413;AMES_results.csv:row=413;PGP_results.csv:row=413;PAMPA_results.csv:row=413;BBB_results.csv:row=413;Solubility_results.csv:row=413;Lipophilicity_results.csv:row=414
CHEMBL4297838,TILSOTOLIMOD,,30.602593440122043,80,100.0,65.24103737604881,H,KG targets TLR9; clinical phase 3.0,repurposing_candidates.csv:rc_row=1221;protein_drug_candidates.csv:rows=259;pathway_drug_candidates.csv:rows=773;7335;7390;7412;7434;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297564,COBITOLIMOD,,30.602593440122043,80,100.0,65.24103737604881,H,KG targets TLR9; clinical phase 3.0,repurposing_candidates.csv:rc_row=1192;protein_drug_candidates.csv:rows=257;pathway_drug_candidates.csv:rows=771;7333;7388;7410;7432;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2105842,CORTIVAZOL,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,51.04118993135011,60,95.0,65.16647597254004,M,KG targets NR3C1; clinical phase 2.0; logS -5.71; logP 4.30,repurposing_candidates.csv:rc_row=713;protein_drug_candidates.csv:rows=63;pathway_drug_candidates.csv:rows=755;2064;5979;7883;8020;8086;8157;8223;8289;CYP3A4_results.csv:row=658;CYP2C19_results.csv:row=658;CYP2D6_results.csv:row=658;CYP1A2_results.csv:row=658;CYP2C9_results.csv:row=658;hERG_results.csv:row=658;AMES_results.csv:row=658;PGP_results.csv:row=658;PAMPA_results.csv:row=658;BBB_results.csv:row=658;Solubility_results.csv:row=658;Lipophilicity_results.csv:row=659
CHEMBL4298207,ZILUCOPLAN,,17.26926010678871,95,100.0,65.1577040427155,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=1247;pathway_drug_candidates.csv:rows=1239;7176;7737;7749;7761;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4210847,PF-00489791,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21,47.88329519450801,60,100.0,65.1533180778032,M,KG targets PDE5A; clinical phase 2.0; logS -2.15; logP 1.46,repurposing_candidates.csv:rc_row=1148;protein_drug_candidates.csv:rows=880;pathway_drug_candidates.csv:rows=7680;7707;7720;CYP3A4_results.csv:row=1012;CYP2C19_results.csv:row=1012;CYP2D6_results.csv:row=1012;CYP1A2_results.csv:row=1012;CYP2C9_results.csv:row=1012;hERG_results.csv:row=1012;AMES_results.csv:row=1012;PGP_results.csv:row=1012;PAMPA_results.csv:row=1012;BBB_results.csv:row=1012;Solubility_results.csv:row=1012;Lipophilicity_results.csv:row=1013
CHEMBL2105107,INECALCITOL,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C,47.88329519450801,60,100.0,65.1533180778032,M,KG targets VDR; clinical phase 2.0; logS -4.06; logP 4.76,repurposing_candidates.csv:rc_row=687;protein_drug_candidates.csv:rows=250;pathway_drug_candidates.csv:rows=6003;7780;7898;CYP3A4_results.csv:row=632;CYP2C19_results.csv:row=632;CYP2D6_results.csv:row=632;CYP1A2_results.csv:row=632;CYP2C9_results.csv:row=632;hERG_results.csv:row=632;AMES_results.csv:row=632;PGP_results.csv:row=632;PAMPA_results.csv:row=632;BBB_results.csv:row=632;Solubility_results.csv:row=632;Lipophilicity_results.csv:row=633
CHEMBL591501,PF-03049423,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,47.88329519450801,60,100.0,65.1533180778032,M,KG targets PDE5A; clinical phase 2.0; logS -2.50; logP 1.40,repurposing_candidates.csv:rc_row=1432;protein_drug_candidates.csv:rows=881;pathway_drug_candidates.csv:rows=7681;7708;7721;CYP3A4_results.csv:row=1241;CYP2C19_results.csv:row=1241;CYP2D6_results.csv:row=1241;CYP1A2_results.csv:row=1241;CYP2C9_results.csv:row=1241;hERG_results.csv:row=1241;AMES_results.csv:row=1241;PGP_results.csv:row=1241;PAMPA_results.csv:row=1241;BBB_results.csv:row=1241;Solubility_results.csv:row=1241;Lipophilicity_results.csv:row=1242
CHEMBL2204263,JNJ-41443532,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,47.88329519450801,60,100.0,65.1533180778032,M,KG targets CCR2; clinical phase 2.0; logS -3.95; logP 2.52,repurposing_candidates.csv:rc_row=802;protein_drug_candidates.csv:rows=237;pathway_drug_candidates.csv:rows=1255;4372;6778;CYP3A4_results.csv:row=711;CYP2C19_results.csv:row=711;CYP2D6_results.csv:row=711;CYP1A2_results.csv:row=711;CYP2C9_results.csv:row=711;hERG_results.csv:row=711;AMES_results.csv:row=711;PGP_results.csv:row=711;PAMPA_results.csv:row=711;BBB_results.csv:row=711;Solubility_results.csv:row=711;Lipophilicity_results.csv:row=712
CHEMBL206815,APRATASTAT,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,47.88329519450801,60,100.0,65.1533180778032,M,KG targets MMP13; clinical phase 2.0; logS -2.51; logP 0.45,repurposing_candidates.csv:rc_row=639;protein_drug_candidates.csv:rows=624;pathway_drug_candidates.csv:rows=35;59;90;CYP3A4_results.csv:row=585;CYP2C19_results.csv:row=585;CYP2D6_results.csv:row=585;CYP1A2_results.csv:row=585;CYP2C9_results.csv:row=585;hERG_results.csv:row=585;AMES_results.csv:row=585;PGP_results.csv:row=585;PAMPA_results.csv:row=585;BBB_results.csv:row=585;Solubility_results.csv:row=585;Lipophilicity_results.csv:row=586
CHEMBL3989680,AXOMADOL,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1,47.88329519450801,60,100.0,65.1533180778032,M,KG targets OPRM1; clinical phase 2.0; logS -1.98; logP 1.61,repurposing_candidates.csv:rc_row=1078;protein_drug_candidates.csv:rows=342;pathway_drug_candidates.csv:rows=312;1346;7259;CYP3A4_results.csv:row=947;CYP2C19_results.csv:row=947;CYP2D6_results.csv:row=947;CYP1A2_results.csv:row=947;CYP2C9_results.csv:row=947;hERG_results.csv:row=947;AMES_results.csv:row=947;PGP_results.csv:row=947;PAMPA_results.csv:row=947;BBB_results.csv:row=947;Solubility_results.csv:row=947;Lipophilicity_results.csv:row=948
CHEMBL1928262,GISADENAFIL,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1,47.88329519450801,60,100.0,65.1533180778032,M,KG targets PDE5A; clinical phase 2.0; logS -2.37; logP 1.12,repurposing_candidates.csv:rc_row=600;protein_drug_candidates.csv:rows=879;pathway_drug_candidates.csv:rows=7679;7706;7719;CYP3A4_results.csv:row=546;CYP2C19_results.csv:row=546;CYP2D6_results.csv:row=546;CYP1A2_results.csv:row=546;CYP2C9_results.csv:row=546;hERG_results.csv:row=546;AMES_results.csv:row=546;PGP_results.csv:row=546;PAMPA_results.csv:row=546;BBB_results.csv:row=546;Solubility_results.csv:row=546;Lipophilicity_results.csv:row=547
CHEMBL4457723,BMS-741672,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1,47.88329519450801,60,100.0,65.1533180778032,M,KG targets CCR2; clinical phase 2.0; logS -2.52; logP 2.84,repurposing_candidates.csv:rc_row=1265;protein_drug_candidates.csv:rows=236;pathway_drug_candidates.csv:rows=1254;4371;6777;CYP3A4_results.csv:row=1085;CYP2C19_results.csv:row=1085;CYP2D6_results.csv:row=1085;CYP1A2_results.csv:row=1085;CYP2C9_results.csv:row=1085;hERG_results.csv:row=1085;AMES_results.csv:row=1085;PGP_results.csv:row=1085;PAMPA_results.csv:row=1085;BBB_results.csv:row=1085;Solubility_results.csv:row=1085;Lipophilicity_results.csv:row=1086
CHEMBL3948730,UMBRALISIB,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,28.497330282227306,100,75.0,65.14893211289092,H,KG targets ABL1; clinical phase 4.0; logS -6.90; logP 6.66,repurposing_candidates.csv:rc_row=1062;protein_drug_candidates.csv:rows=1205;pathway_drug_candidates.csv:rows=4296;CYP3A4_results.csv:row=931;CYP2C19_results.csv:row=931;CYP2D6_results.csv:row=931;CYP1A2_results.csv:row=931;CYP2C9_results.csv:row=931;hERG_results.csv:row=931;AMES_results.csv:row=931;PGP_results.csv:row=931;PAMPA_results.csv:row=931;BBB_results.csv:row=931;Solubility_results.csv:row=931;Lipophilicity_results.csv:row=932
CHEMBL2108718,SEMULOPARIN SODIUM,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=753;protein_drug_candidates.csv:rows=177;pathway_drug_candidates.csv:rows=149;7555;7584;7606;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109084,DESMOTEPLASE,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets PLG; clinical phase 3.0,repurposing_candidates.csv:rc_row=761;protein_drug_candidates.csv:rows=686;pathway_drug_candidates.csv:rows=79;110;137;460;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4085457,RITLECITINIB,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,30.076277650648358,80,100.0,65.03051106025934,H,KG targets BTK; clinical phase 3.0; logS -1.60; logP 1.94,repurposing_candidates.csv:rc_row=1128;protein_drug_candidates.csv:rows=198;pathway_drug_candidates.csv:rows=604;4099;6561;6741;CYP3A4_results.csv:row=992;CYP2C19_results.csv:row=992;CYP2D6_results.csv:row=992;CYP1A2_results.csv:row=992;CYP2C9_results.csv:row=992;hERG_results.csv:row=992;AMES_results.csv:row=992;PGP_results.csv:row=992;PAMPA_results.csv:row=992;BBB_results.csv:row=992;Solubility_results.csv:row=992;Lipophilicity_results.csv:row=993
CHEMBL2108080,PARNAPARIN SODIUM,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=744;protein_drug_candidates.csv:rows=174;pathway_drug_candidates.csv:rows=146;7552;7581;7603;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297754,FITUSIRAN,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=1215;protein_drug_candidates.csv:rows=178;pathway_drug_candidates.csv:rows=150;7556;7585;7607;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2107911,ONERCEPT,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets TNF; clinical phase 3.0,repurposing_candidates.csv:rc_row=742;protein_drug_candidates.csv:rows=85;pathway_drug_candidates.csv:rows=394;4148;4163;4512;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109204,NADROPARIN CALCIUM,,30.076277650648358,80,100.0,65.03051106025934,H,KG targets SERPINC1; clinical phase 3.0,repurposing_candidates.csv:rc_row=762;protein_drug_candidates.csv:rows=176;pathway_drug_candidates.csv:rows=148;7554;7583;7605;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297865,ABIVERTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,48.40961098398169,80,70.0,64.86384439359267,H,KG targets BTK; clinical phase 3.0; hERG risk; logS -4.87; logP 4.51,repurposing_candidates.csv:rc_row=1225;protein_drug_candidates.csv:rows=197;pathway_drug_candidates.csv:rows=603;4098;6560;6740;CYP3A4_results.csv:row=1066;CYP2C19_results.csv:row=1066;CYP2D6_results.csv:row=1066;CYP1A2_results.csv:row=1066;CYP2C9_results.csv:row=1066;hERG_results.csv:row=1066;AMES_results.csv:row=1066;PGP_results.csv:row=1066;PAMPA_results.csv:row=1066;BBB_results.csv:row=1066;Solubility_results.csv:row=1066;Lipophilicity_results.csv:row=1067
CHEMBL4072833,EVOBRUTINIB,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,48.40961098398169,80,70.0,64.86384439359267,H,KG targets BTK; clinical phase 3.0; hERG risk; logS -3.89; logP 4.35,repurposing_candidates.csv:rc_row=1125;protein_drug_candidates.csv:rows=202;pathway_drug_candidates.csv:rows=608;4103;6565;6745;CYP3A4_results.csv:row=989;CYP2C19_results.csv:row=989;CYP2D6_results.csv:row=989;CYP1A2_results.csv:row=989;CYP2C9_results.csv:row=989;hERG_results.csv:row=989;AMES_results.csv:row=989;PGP_results.csv:row=989;PAMPA_results.csv:row=989;BBB_results.csv:row=989;Solubility_results.csv:row=989;Lipophilicity_results.csv:row=990
CHEMBL4650323,TOLEBRUTINIB,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,48.40961098398169,80,70.0,64.86384439359267,H,KG targets BTK; clinical phase 3.0; hERG risk; logS -3.49; logP 3.91,repurposing_candidates.csv:rc_row=1309;protein_drug_candidates.csv:rows=200;pathway_drug_candidates.csv:rows=606;4101;6563;6743;CYP3A4_results.csv:row=1123;CYP2C19_results.csv:row=1123;CYP2D6_results.csv:row=1123;CYP1A2_results.csv:row=1123;CYP2C9_results.csv:row=1123;hERG_results.csv:row=1123;AMES_results.csv:row=1123;PGP_results.csv:row=1123;PAMPA_results.csv:row=1123;BBB_results.csv:row=1123;Solubility_results.csv:row=1123;Lipophilicity_results.csv:row=1124
CHEMBL4297866,ABIVERTINIB MALEATE,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O,48.40961098398169,80,70.0,64.86384439359267,H,KG targets BTK; clinical phase 3.0; hERG risk; logS -5.16; logP 2.57,repurposing_candidates.csv:rc_row=1226;protein_drug_candidates.csv:rows=199;pathway_drug_candidates.csv:rows=605;4100;6562;6742;CYP3A4_results.csv:row=1067;CYP2C19_results.csv:row=1067;CYP2D6_results.csv:row=1067;CYP1A2_results.csv:row=1067;CYP2C9_results.csv:row=1067;hERG_results.csv:row=1067;AMES_results.csv:row=1067;PGP_results.csv:row=1067;PAMPA_results.csv:row=1067;BBB_results.csv:row=1067;Solubility_results.csv:row=1067;Lipophilicity_results.csv:row=1068
CHEMBL4068611,RELACORILANT,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,32.707856598016775,80,95.0,64.83314263920671,H,KG targets NR3C1; clinical phase 3.0; logS -3.65; logP 4.06,repurposing_candidates.csv:rc_row=1121;protein_drug_candidates.csv:rows=52;pathway_drug_candidates.csv:rows=744;2053;5968;7872;8009;8075;8146;8212;8278;CYP3A4_results.csv:row=985;CYP2C19_results.csv:row=985;CYP2D6_results.csv:row=985;CYP1A2_results.csv:row=985;CYP2C9_results.csv:row=985;hERG_results.csv:row=985;AMES_results.csv:row=985;PGP_results.csv:row=985;PAMPA_results.csv:row=985;BBB_results.csv:row=985;Solubility_results.csv:row=985;Lipophilicity_results.csv:row=986
CHEMBL166863,POLMACOXIB,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O,32.707856598016775,80,95.0,64.83314263920671,H,KG targets PTGS2; clinical phase 3.0; logS -3.95; logP 2.72,repurposing_candidates.csv:rc_row=502;protein_drug_candidates.csv:rows=158;pathway_drug_candidates.csv:rows=381;4499;5708;6092;6166;6240;6314;6388;6462;CYP3A4_results.csv:row=462;CYP2C19_results.csv:row=462;CYP2D6_results.csv:row=462;CYP1A2_results.csv:row=462;CYP2C9_results.csv:row=462;hERG_results.csv:row=462;AMES_results.csv:row=462;PGP_results.csv:row=462;PAMPA_results.csv:row=462;BBB_results.csv:row=462;Solubility_results.csv:row=462;Lipophilicity_results.csv:row=463
CHEMBL1186579,METHYLNALTREXONE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,29.549961861174673,80,100.0,64.81998474446988,H,KG targets OPRM1; clinical phase 3.0; logS -1.99; logP 1.67,repurposing_candidates.csv:rc_row=75;protein_drug_candidates.csv:rows=326;pathway_drug_candidates.csv:rows=296;1330;7243;CYP3A4_results.csv:row=74;CYP2C19_results.csv:row=74;CYP2D6_results.csv:row=74;CYP1A2_results.csv:row=74;CYP2C9_results.csv:row=74;hERG_results.csv:row=74;AMES_results.csv:row=74;PGP_results.csv:row=74;PAMPA_results.csv:row=74;BBB_results.csv:row=74;Solubility_results.csv:row=74;Lipophilicity_results.csv:row=74
CHEMBL276711,SEMAXANIB,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,29.549961861174673,80,100.0,64.81998474446988,H,KG targets KIT; clinical phase 3.0; logS -3.82; logP 3.12,repurposing_candidates.csv:rc_row=870;protein_drug_candidates.csv:rows=1167;pathway_drug_candidates.csv:rows=572;6984;7518;CYP3A4_results.csv:row=778;CYP2C19_results.csv:row=778;CYP2D6_results.csv:row=778;CYP1A2_results.csv:row=778;CYP2C9_results.csv:row=778;hERG_results.csv:row=778;AMES_results.csv:row=778;PGP_results.csv:row=778;PAMPA_results.csv:row=778;BBB_results.csv:row=778;Solubility_results.csv:row=778;Lipophilicity_results.csv:row=779
CHEMBL2062257,BRIMONIDINE TARTRATE,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,33.737604881769634,100,65.0,64.74504195270785,M,"KG targets ADRA2A, ADRA2B; clinical phase 4.0; hERG risk; logS -1.16; logP -0.36",repurposing_candidates.csv:rc_row=635;protein_drug_candidates.csv:rows=1318;1370;2517;pathway_drug_candidates.csv:rows=889;941;993;1045;1097;1149;1201;1381;1433;1485;CYP3A4_results.csv:row=581;CYP2C19_results.csv:row=581;CYP2D6_results.csv:row=581;CYP1A2_results.csv:row=581;CYP2C9_results.csv:row=581;hERG_results.csv:row=581;AMES_results.csv:row=581;PGP_results.csv:row=581;PAMPA_results.csv:row=581;BBB_results.csv:row=581;Solubility_results.csv:row=581;Lipophilicity_results.csv:row=582
CHEMBL2108723,PEGINTERFERON LAMBDA-1A,,16.21662852784134,95,100.0,64.73665141113653,H,KG targets IL10RB; clinical phase 3.0,repurposing_candidates.csv:rc_row=754;pathway_drug_candidates.csv:rows=4394;4777;4884;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3707325,LENZILUMAB,,16.21662852784134,95,100.0,64.73665141113653,H,KG targets CSF2; clinical phase 3.0,repurposing_candidates.csv:rc_row=1021;pathway_drug_candidates.csv:rows=4389;6876;8378;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3187812,ILEPATRIL,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C,46.83066361556064,60,100.0,64.73226544622426,M,KG targets ACE; clinical phase 2.0; logS -3.08; logP 2.54,repurposing_candidates.csv:rc_row=923;protein_drug_candidates.csv:rows=657;pathway_drug_candidates.csv:rows=453;CYP3A4_results.csv:row=830;CYP2C19_results.csv:row=830;CYP2D6_results.csv:row=830;CYP1A2_results.csv:row=830;CYP2C9_results.csv:row=830;hERG_results.csv:row=830;AMES_results.csv:row=830;PGP_results.csv:row=830;PAMPA_results.csv:row=830;BBB_results.csv:row=830;Solubility_results.csv:row=830;Lipophilicity_results.csv:row=831
CHEMBL459324,DIACETYLMORPHINE,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,47.88329519450801,80,70.0,64.6533180778032,H,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -2.53; logP 1.99,repurposing_candidates.csv:rc_row=1283;protein_drug_candidates.csv:rows=329;pathway_drug_candidates.csv:rows=299;1333;7246;CYP3A4_results.csv:row=1103;CYP2C19_results.csv:row=1103;CYP2D6_results.csv:row=1103;CYP1A2_results.csv:row=1103;CYP2C9_results.csv:row=1103;hERG_results.csv:row=1103;AMES_results.csv:row=1103;PGP_results.csv:row=1103;PAMPA_results.csv:row=1103;BBB_results.csv:row=1103;Solubility_results.csv:row=1103;Lipophilicity_results.csv:row=1104
CHEMBL5095029,PF-04634817,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,49.713958810068654,60,95.0,64.63558352402747,M,"KG targets CCR2, CCR5; clinical phase 2.0; logS -3.77; logP 2.87",repurposing_candidates.csv:rc_row=1352;protein_drug_candidates.csv:rows=221;233;pathway_drug_candidates.csv:rows=1251;1263;4368;4380;6762;6774;6786;CYP3A4_results.csv:row=1163;CYP2C19_results.csv:row=1163;CYP2D6_results.csv:row=1163;CYP1A2_results.csv:row=1163;CYP2C9_results.csv:row=1163;hERG_results.csv:row=1163;AMES_results.csv:row=1163;PGP_results.csv:row=1163;PAMPA_results.csv:row=1163;BBB_results.csv:row=1163;Solubility_results.csv:row=1163;Lipophilicity_results.csv:row=1164
CHEMBL4297768,IDRABIOTAPARINUX SODIUM,,29.02364607170099,80,100.0,64.6094584286804,H,KG targets F10; clinical phase 3.0,repurposing_candidates.csv:rc_row=1216;protein_drug_candidates.csv:rows=457;pathway_drug_candidates.csv:rows=7537;7566;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3707365,BEMIPARIN,,29.02364607170099,80,100.0,64.6094584286804,H,KG targets F10; clinical phase 3.0,repurposing_candidates.csv:rc_row=1026;protein_drug_candidates.csv:rows=460;pathway_drug_candidates.csv:rows=7540;7569;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL314854,FINGOLIMOD,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,14.63768115942029,100,95.0,64.60507246376812,H,KG targets S1PR4; clinical phase 4.0; logS -3.09; logP 3.20,repurposing_candidates.csv:rc_row=913;protein_drug_candidates.csv:rows=1882;CYP3A4_results.csv:row=820;CYP2C19_results.csv:row=820;CYP2D6_results.csv:row=820;CYP1A2_results.csv:row=820;CYP2C9_results.csv:row=820;hERG_results.csv:row=820;AMES_results.csv:row=820;PGP_results.csv:row=820;PAMPA_results.csv:row=820;BBB_results.csv:row=820;Solubility_results.csv:row=820;Lipophilicity_results.csv:row=821
CHEMBL1492500,DOTHIEPIN,CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.46; logP 4.68,repurposing_candidates.csv:rc_row=433;protein_drug_candidates.csv:rows=1260;CYP3A4_results.csv:row=393;CYP2C19_results.csv:row=393;CYP2D6_results.csv:row=393;CYP1A2_results.csv:row=393;CYP2C9_results.csv:row=393;hERG_results.csv:row=393;AMES_results.csv:row=393;PGP_results.csv:row=393;PAMPA_results.csv:row=393;BBB_results.csv:row=393;Solubility_results.csv:row=393;Lipophilicity_results.csv:row=394
CHEMBL439849,VILAZODONE,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -5.27; logP 4.03,repurposing_candidates.csv:rc_row=1258;protein_drug_candidates.csv:rows=1270;CYP3A4_results.csv:row=1078;CYP2C19_results.csv:row=1078;CYP2D6_results.csv:row=1078;CYP1A2_results.csv:row=1078;CYP2C9_results.csv:row=1078;hERG_results.csv:row=1078;AMES_results.csv:row=1078;PGP_results.csv:row=1078;PAMPA_results.csv:row=1078;BBB_results.csv:row=1078;Solubility_results.csv:row=1078;Lipophilicity_results.csv:row=1079
CHEMBL445,NORTRIPTYLINE,CNCCC=C1c2ccccc2CCc2ccccc21,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.88; logP 3.83,repurposing_candidates.csv:rc_row=1264;protein_drug_candidates.csv:rows=1262;CYP3A4_results.csv:row=1084;CYP2C19_results.csv:row=1084;CYP2D6_results.csv:row=1084;CYP1A2_results.csv:row=1084;CYP2C9_results.csv:row=1084;hERG_results.csv:row=1084;AMES_results.csv:row=1084;PGP_results.csv:row=1084;PAMPA_results.csv:row=1084;BBB_results.csv:row=1084;Solubility_results.csv:row=1084;Lipophilicity_results.csv:row=1085
CHEMBL629,AMITRIPTYLINE,CN(C)CCC=C1c2ccccc2CCc2ccccc21,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.54; logP 4.17,repurposing_candidates.csv:rc_row=1461;protein_drug_candidates.csv:rows=1271;CYP3A4_results.csv:row=1267;CYP2C19_results.csv:row=1267;CYP2D6_results.csv:row=1267;CYP1A2_results.csv:row=1267;CYP2C9_results.csv:row=1267;hERG_results.csv:row=1267;AMES_results.csv:row=1267;PGP_results.csv:row=1267;PAMPA_results.csv:row=1267;BBB_results.csv:row=1267;Solubility_results.csv:row=1267;Lipophilicity_results.csv:row=1268
CHEMBL1200964,AMITRIPTYLINE HYDROCHLORIDE,CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.86; logP 4.59,repurposing_candidates.csv:rc_row=203;protein_drug_candidates.csv:rows=1279;CYP3A4_results.csv:row=201;CYP2C19_results.csv:row=201;CYP2D6_results.csv:row=201;CYP1A2_results.csv:row=201;CYP2C9_results.csv:row=201;hERG_results.csv:row=201;AMES_results.csv:row=201;PGP_results.csv:row=201;PAMPA_results.csv:row=201;BBB_results.csv:row=201;Solubility_results.csv:row=201;Lipophilicity_results.csv:row=202
CHEMBL957,BOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,14.63768115942029,100,95.0,64.60507246376812,H,KG targets EDNRA; clinical phase 4.0; logS -4.40; logP 4.20,repurposing_candidates.csv:rc_row=1566;protein_drug_candidates.csv:rows=1910;CYP3A4_results.csv:row=1372;CYP2C19_results.csv:row=1372;CYP2D6_results.csv:row=1372;CYP1A2_results.csv:row=1372;CYP2C9_results.csv:row=1372;hERG_results.csv:row=1372;AMES_results.csv:row=1372;PGP_results.csv:row=1372;PAMPA_results.csv:row=1372;BBB_results.csv:row=1372;Solubility_results.csv:row=1372;Lipophilicity_results.csv:row=1373
CHEMBL1200430,ESTRADIOL ACETATE,CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,14.63768115942029,100,95.0,64.60507246376812,H,KG targets ESR1; clinical phase 4.0; logS -4.86; logP 3.83,repurposing_candidates.csv:rc_row=100;protein_drug_candidates.csv:rows=2292;CYP3A4_results.csv:row=99;CYP2C19_results.csv:row=99;CYP2D6_results.csv:row=99;CYP1A2_results.csv:row=99;CYP2C9_results.csv:row=99;hERG_results.csv:row=99;AMES_results.csv:row=99;PGP_results.csv:row=99;PAMPA_results.csv:row=99;BBB_results.csv:row=99;Solubility_results.csv:row=99;Lipophilicity_results.csv:row=99
CHEMBL1201156,NORTRIPTYLINE HYDROCHLORIDE,CNCCC=C1c2ccccc2CCc2ccccc21.Cl,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -3.18; logP 4.25,repurposing_candidates.csv:rc_row=245;protein_drug_candidates.csv:rows=1258;CYP3A4_results.csv:row=242;CYP2C19_results.csv:row=242;CYP2D6_results.csv:row=242;CYP1A2_results.csv:row=242;CYP2C9_results.csv:row=242;hERG_results.csv:row=242;AMES_results.csv:row=242;PGP_results.csv:row=242;PAMPA_results.csv:row=242;BBB_results.csv:row=242;Solubility_results.csv:row=242;Lipophilicity_results.csv:row=243
CHEMBL273575,NOMIFENSINE,CN1Cc2c(N)cccc2C(c2ccccc2)C1,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -2.14; logP 2.85,repurposing_candidates.csv:rc_row=868;protein_drug_candidates.csv:rows=1264;CYP3A4_results.csv:row=776;CYP2C19_results.csv:row=776;CYP2D6_results.csv:row=776;CYP1A2_results.csv:row=776;CYP2C9_results.csv:row=776;hERG_results.csv:row=776;AMES_results.csv:row=776;PGP_results.csv:row=776;PAMPA_results.csv:row=776;BBB_results.csv:row=776;Solubility_results.csv:row=776;Lipophilicity_results.csv:row=777
CHEMBL135,ESTRADIOL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,14.63768115942029,100,95.0,64.60507246376812,H,KG targets ESR1; clinical phase 4.0; logS -4.85; logP 3.61,repurposing_candidates.csv:rc_row=389;protein_drug_candidates.csv:rows=2286;CYP3A4_results.csv:row=350;CYP2C19_results.csv:row=350;CYP2D6_results.csv:row=350;CYP1A2_results.csv:row=350;CYP2C9_results.csv:row=350;hERG_results.csv:row=350;AMES_results.csv:row=350;PGP_results.csv:row=350;PAMPA_results.csv:row=350;BBB_results.csv:row=350;Solubility_results.csv:row=350;Lipophilicity_results.csv:row=351
CHEMBL415,CLOMIPRAMINE,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.71; logP 4.53,repurposing_candidates.csv:rc_row=1138;protein_drug_candidates.csv:rows=1269;CYP3A4_results.csv:row=1002;CYP2C19_results.csv:row=1002;CYP2D6_results.csv:row=1002;CYP1A2_results.csv:row=1002;CYP2C9_results.csv:row=1002;hERG_results.csv:row=1002;AMES_results.csv:row=1002;PGP_results.csv:row=1002;PAMPA_results.csv:row=1002;BBB_results.csv:row=1002;Solubility_results.csv:row=1002;Lipophilicity_results.csv:row=1003
CHEMBL328560,SULTHIAME,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,14.63768115942029,100,95.0,64.60507246376812,H,KG targets CA6; clinical phase 4.0; logS -2.37; logP 0.26,repurposing_candidates.csv:rc_row=933;protein_drug_candidates.csv:rows=1235;CYP3A4_results.csv:row=840;CYP2C19_results.csv:row=840;CYP2D6_results.csv:row=840;CYP1A2_results.csv:row=840;CYP2C9_results.csv:row=840;hERG_results.csv:row=840;AMES_results.csv:row=840;PGP_results.csv:row=840;PAMPA_results.csv:row=840;BBB_results.csv:row=840;Solubility_results.csv:row=840;Lipophilicity_results.csv:row=841
CHEMBL1200710,CLOMIPRAMINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl,14.63768115942029,100,95.0,64.60507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -4.07; logP 4.95,repurposing_candidates.csv:rc_row=156;protein_drug_candidates.csv:rows=1243;CYP3A4_results.csv:row=154;CYP2C19_results.csv:row=154;CYP2D6_results.csv:row=154;CYP1A2_results.csv:row=154;CYP2C9_results.csv:row=154;hERG_results.csv:row=154;AMES_results.csv:row=154;PGP_results.csv:row=154;PAMPA_results.csv:row=154;BBB_results.csv:row=154;Solubility_results.csv:row=154;Lipophilicity_results.csv:row=155
CHEMBL1200798,TRAZODONE HYDROCHLORIDE,Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,32.971014492753625,100,65.0,64.43840579710145,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -2.77; logP 2.78,repurposing_candidates.csv:rc_row=171;protein_drug_candidates.csv:rows=1257;CYP3A4_results.csv:row=169;CYP2C19_results.csv:row=169;CYP2D6_results.csv:row=169;CYP1A2_results.csv:row=169;CYP2C9_results.csv:row=169;hERG_results.csv:row=169;AMES_results.csv:row=169;PGP_results.csv:row=169;PAMPA_results.csv:row=169;BBB_results.csv:row=169;Solubility_results.csv:row=169;Lipophilicity_results.csv:row=170
CHEMBL1200492,NEFAZODONE HYDROCHLORIDE,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl,32.971014492753625,100,65.0,64.43840579710145,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.55; logP 3.97,repurposing_candidates.csv:rc_row=112;protein_drug_candidates.csv:rows=1278;CYP3A4_results.csv:row=111;CYP2C19_results.csv:row=111;CYP2D6_results.csv:row=111;CYP1A2_results.csv:row=111;CYP2C9_results.csv:row=111;hERG_results.csv:row=111;AMES_results.csv:row=111;PGP_results.csv:row=111;PAMPA_results.csv:row=111;BBB_results.csv:row=111;Solubility_results.csv:row=111;Lipophilicity_results.csv:row=111
CHEMBL3306803,LUMATEPERONE,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,32.971014492753625,100,65.0,64.43840579710145,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.55; logP 3.92,repurposing_candidates.csv:rc_row=945;protein_drug_candidates.csv:rows=1249;CYP3A4_results.csv:row=849;CYP2C19_results.csv:row=849;CYP2D6_results.csv:row=849;CYP1A2_results.csv:row=849;CYP2C9_results.csv:row=849;hERG_results.csv:row=849;AMES_results.csv:row=849;PGP_results.csv:row=849;PAMPA_results.csv:row=849;BBB_results.csv:row=849;Solubility_results.csv:row=849;Lipophilicity_results.csv:row=850
CHEMBL2104986,TEDATIOXETINE,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1,49.18764302059497,60,95.0,64.42505720823799,M,"KG targets ADRA1A, SLC6A4; clinical phase 2.0; logS -4.17; logP 4.61",repurposing_candidates.csv:rc_row=683;protein_drug_candidates.csv:rows=405;1296;pathway_drug_candidates.csv:rows=868;6530;6730;CYP3A4_results.csv:row=628;CYP2C19_results.csv:row=628;CYP2D6_results.csv:row=628;CYP1A2_results.csv:row=628;CYP2C9_results.csv:row=628;hERG_results.csv:row=628;AMES_results.csv:row=628;PGP_results.csv:row=628;PAMPA_results.csv:row=628;BBB_results.csv:row=628;Solubility_results.csv:row=628;Lipophilicity_results.csv:row=629
CHEMBL1653,PHENIRAMINE MALEATE,CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets HRH1; clinical phase 3.0; logS -0.99; logP 2.88,repurposing_candidates.csv:rc_row=497;protein_drug_candidates.csv:rows=1025;pathway_drug_candidates.csv:rows=6655;CYP3A4_results.csv:row=457;CYP2C19_results.csv:row=457;CYP2D6_results.csv:row=457;CYP1A2_results.csv:row=457;CYP2C9_results.csv:row=457;hERG_results.csv:row=457;AMES_results.csv:row=457;PGP_results.csv:row=457;PAMPA_results.csv:row=457;BBB_results.csv:row=457;Solubility_results.csv:row=457;Lipophilicity_results.csv:row=458
CHEMBL1201758,BEPOTASTINE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,28.497330282227306,80,100.0,64.39893211289092,H,KG targets HRH1; clinical phase 3.0; logS -1.86; logP 4.17,repurposing_candidates.csv:rc_row=311;protein_drug_candidates.csv:rows=1031;pathway_drug_candidates.csv:rows=6661;CYP3A4_results.csv:row=280;CYP2C19_results.csv:row=280;CYP2D6_results.csv:row=280;CYP1A2_results.csv:row=280;CYP2C9_results.csv:row=280;hERG_results.csv:row=280;AMES_results.csv:row=280;PGP_results.csv:row=280;PAMPA_results.csv:row=280;BBB_results.csv:row=280;Solubility_results.csv:row=280;Lipophilicity_results.csv:row=281
CHEMBL1004,DOXYLAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,28.497330282227306,80,100.0,64.39893211289092,H,KG targets HRH1; clinical phase 3.0; logS -2.40; logP 2.92,repurposing_candidates.csv:rc_row=1;protein_drug_candidates.csv:rows=1034;pathway_drug_candidates.csv:rows=6664;CYP3A4_results.csv:row=1;CYP2C19_results.csv:row=1;CYP2D6_results.csv:row=1;CYP1A2_results.csv:row=1;CYP2C9_results.csv:row=1;hERG_results.csv:row=1;AMES_results.csv:row=1;PGP_results.csv:row=1;PAMPA_results.csv:row=1;BBB_results.csv:row=1;Solubility_results.csv:row=1;Lipophilicity_results.csv:row=1
CHEMBL334966,CANGRELOR,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets P2RY12; clinical phase 3.0; logS -1.51; logP 2.85,repurposing_candidates.csv:rc_row=948;protein_drug_candidates.csv:rows=472;pathway_drug_candidates.csv:rows=1357;CYP3A4_results.csv:row=852;CYP2C19_results.csv:row=852;CYP2D6_results.csv:row=852;CYP1A2_results.csv:row=852;CYP2C9_results.csv:row=852;hERG_results.csv:row=852;AMES_results.csv:row=852;PGP_results.csv:row=852;PAMPA_results.csv:row=852;BBB_results.csv:row=852;Solubility_results.csv:row=852;Lipophilicity_results.csv:row=853
CHEMBL3678958,RUSERONTINIB,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,28.497330282227306,80,100.0,64.39893211289092,H,KG targets ABL1; clinical phase 3.0; logS -2.33; logP 4.04,repurposing_candidates.csv:rc_row=1012;protein_drug_candidates.csv:rows=1213;pathway_drug_candidates.csv:rows=4304;CYP3A4_results.csv:row=898;CYP2C19_results.csv:row=898;CYP2D6_results.csv:row=898;CYP1A2_results.csv:row=898;CYP2C9_results.csv:row=898;hERG_results.csv:row=898;AMES_results.csv:row=898;PGP_results.csv:row=898;PAMPA_results.csv:row=898;BBB_results.csv:row=898;Solubility_results.csv:row=898;Lipophilicity_results.csv:row=899
CHEMBL3707398,PAC-14028,,28.497330282227306,80,100.0,64.39893211289092,H,KG targets TRPV1; clinical phase 3.0,repurposing_candidates.csv:rc_row=1030;protein_drug_candidates.csv:rows=692;pathway_drug_candidates.csv:rows=5718;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL577,ENALAPRILAT ANHYDROUS,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets ACE; clinical phase 3.0; logS -1.37; logP 1.13,repurposing_candidates.csv:rc_row=1425;protein_drug_candidates.csv:rows=656;pathway_drug_candidates.csv:rows=452;CYP3A4_results.csv:row=1234;CYP2C19_results.csv:row=1234;CYP2D6_results.csv:row=1234;CYP1A2_results.csv:row=1234;CYP2C9_results.csv:row=1234;hERG_results.csv:row=1234;AMES_results.csv:row=1234;PGP_results.csv:row=1234;PAMPA_results.csv:row=1234;BBB_results.csv:row=1234;Solubility_results.csv:row=1234;Lipophilicity_results.csv:row=1235
CHEMBL3707356,TIVANISIRAN,,28.497330282227306,80,100.0,64.39893211289092,H,KG targets TRPV1; clinical phase 3.0,repurposing_candidates.csv:rc_row=1024;protein_drug_candidates.csv:rows=694;pathway_drug_candidates.csv:rows=5720;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1200392,DOXYLAMINE SUCCINATE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets HRH1; clinical phase 3.0; logS -1.54; logP 2.86,repurposing_candidates.csv:rc_row=94;protein_drug_candidates.csv:rows=1035;pathway_drug_candidates.csv:rows=6665;CYP3A4_results.csv:row=93;CYP2C19_results.csv:row=93;CYP2D6_results.csv:row=93;CYP1A2_results.csv:row=93;CYP2C9_results.csv:row=93;hERG_results.csv:row=93;AMES_results.csv:row=93;PGP_results.csv:row=93;PAMPA_results.csv:row=93;BBB_results.csv:row=93;Solubility_results.csv:row=93;Lipophilicity_results.csv:row=93
CHEMBL1633,KETOTIFEN FUMARATE,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets HRH1; clinical phase 3.0; logS -3.22; logP 3.73,repurposing_candidates.csv:rc_row=489;protein_drug_candidates.csv:rows=1027;pathway_drug_candidates.csv:rows=6657;CYP3A4_results.csv:row=449;CYP2C19_results.csv:row=449;CYP2D6_results.csv:row=449;CYP1A2_results.csv:row=449;CYP2C9_results.csv:row=449;hERG_results.csv:row=449;AMES_results.csv:row=449;PGP_results.csv:row=449;PAMPA_results.csv:row=449;BBB_results.csv:row=449;Solubility_results.csv:row=449;Lipophilicity_results.csv:row=450
CHEMBL1237,LISINOPRIL ANHYDROUS,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets ACE; clinical phase 3.0; logS -0.22; logP 1.24,repurposing_candidates.csv:rc_row=342;protein_drug_candidates.csv:rows=653;pathway_drug_candidates.csv:rows=449;CYP3A4_results.csv:row=305;CYP2C19_results.csv:row=305;CYP2D6_results.csv:row=305;CYP1A2_results.csv:row=305;CYP2C9_results.csv:row=305;hERG_results.csv:row=305;AMES_results.csv:row=305;PGP_results.csv:row=305;PAMPA_results.csv:row=305;BBB_results.csv:row=305;Solubility_results.csv:row=305;Lipophilicity_results.csv:row=306
CHEMBL274654,ORANTINIB,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets PDGFRB; clinical phase 3.0; logS -3.68; logP 3.14,repurposing_candidates.csv:rc_row=869;protein_drug_candidates.csv:rows=1110;pathway_drug_candidates.csv:rows=7008;CYP3A4_results.csv:row=777;CYP2C19_results.csv:row=777;CYP2D6_results.csv:row=777;CYP1A2_results.csv:row=777;CYP2C9_results.csv:row=777;hERG_results.csv:row=777;AMES_results.csv:row=777;PGP_results.csv:row=777;PAMPA_results.csv:row=777;BBB_results.csv:row=777;Solubility_results.csv:row=777;Lipophilicity_results.csv:row=778
CHEMBL223360,LINIFANIB,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,28.497330282227306,80,100.0,64.39893211289092,H,KG targets PDGFRB; clinical phase 3.0; logS -5.54; logP 4.90,repurposing_candidates.csv:rc_row=817;protein_drug_candidates.csv:rows=1112;pathway_drug_candidates.csv:rows=7010;CYP3A4_results.csv:row=726;CYP2C19_results.csv:row=726;CYP2D6_results.csv:row=726;CYP1A2_results.csv:row=726;CYP2C9_results.csv:row=726;hERG_results.csv:row=726;AMES_results.csv:row=726;PGP_results.csv:row=726;PAMPA_results.csv:row=726;BBB_results.csv:row=726;Solubility_results.csv:row=726;Lipophilicity_results.csv:row=727
CHEMBL313971,ZUCAPSAICIN,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O,28.497330282227306,80,100.0,64.39893211289092,H,KG targets TRPV1; clinical phase 3.0; logS -2.83; logP 3.79,repurposing_candidates.csv:rc_row=911;protein_drug_candidates.csv:rows=693;pathway_drug_candidates.csv:rows=5719;CYP3A4_results.csv:row=818;CYP2C19_results.csv:row=818;CYP2D6_results.csv:row=818;CYP1A2_results.csv:row=818;CYP2C9_results.csv:row=818;hERG_results.csv:row=818;AMES_results.csv:row=818;PGP_results.csv:row=818;PAMPA_results.csv:row=818;BBB_results.csv:row=818;Solubility_results.csv:row=818;Lipophilicity_results.csv:row=819
CHEMBL1089636,ANG1005,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,58.405797101449274,60,80.0,64.36231884057972,M,"KG targets TUBB, TUBB1; clinical phase 2.0; logS -11.50; logP 1.38",repurposing_candidates.csv:rc_row=36;protein_drug_candidates.csv:rows=838;1573;2008;2244;2349;2413;2724;2784;2848;pathway_drug_candidates.csv:rows=1551;1615;1679;1743;1807;1871;1935;2100;2164;2228;2292;2356;2420;2484;2548;2612;2676;2740;2804;2868;2932;2996;3066;3130;3194;3258;3322;3386;3450;3514;3578;3669;3733;3797;3861;3925;3989;4056;CYP3A4_results.csv:row=36;CYP2C19_results.csv:row=36;CYP2D6_results.csv:row=36;CYP1A2_results.csv:row=36;CYP2C9_results.csv:row=36;hERG_results.csv:row=36;AMES_results.csv:row=36;PGP_results.csv:row=36;PAMPA_results.csv:row=36;BBB_results.csv:row=36;Solubility_results.csv:row=36;Lipophilicity_results.csv:row=36
CHEMBL118,CELECOXIB,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,32.707856598016775,100,65.0,64.33314263920671,M,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -4.48; logP 3.51,repurposing_candidates.csv:rc_row=74;protein_drug_candidates.csv:rows=95;pathway_drug_candidates.csv:rows=318;4436;5645;6029;6103;6177;6251;6325;6399;CYP3A4_results.csv:row=73;CYP2C19_results.csv:row=73;CYP2D6_results.csv:row=73;CYP1A2_results.csv:row=73;CYP2C9_results.csv:row=73;hERG_results.csv:row=73;AMES_results.csv:row=73;PGP_results.csv:row=73;PAMPA_results.csv:row=73;BBB_results.csv:row=73;Solubility_results.csv:row=73;Lipophilicity_results.csv:row=73
CHEMBL1070,NABUMETONE,COc1ccc2cc(CCC(C)=O)ccc2c1,32.707856598016775,100,65.0,64.33314263920671,M,KG targets PTGS2; clinical phase 4.0; hERG risk; logS -2.35; logP 3.37,repurposing_candidates.csv:rc_row=22;protein_drug_candidates.csv:rows=97;pathway_drug_candidates.csv:rows=320;4438;5647;6031;6105;6179;6253;6327;6401;CYP3A4_results.csv:row=22;CYP2C19_results.csv:row=22;CYP2D6_results.csv:row=22;CYP1A2_results.csv:row=22;CYP2C9_results.csv:row=22;hERG_results.csv:row=22;AMES_results.csv:row=22;PGP_results.csv:row=22;PAMPA_results.csv:row=22;BBB_results.csv:row=22;Solubility_results.csv:row=22;Lipophilicity_results.csv:row=22
CHEMBL963,OXYMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.11; logP 0.75,repurposing_candidates.csv:rc_row=1569;protein_drug_candidates.csv:rows=306;pathway_drug_candidates.csv:rows=276;1310;7223;CYP3A4_results.csv:row=1375;CYP2C19_results.csv:row=1375;CYP2D6_results.csv:row=1375;CYP1A2_results.csv:row=1375;CYP2C9_results.csv:row=1375;hERG_results.csv:row=1375;AMES_results.csv:row=1375;PGP_results.csv:row=1375;PAMPA_results.csv:row=1375;BBB_results.csv:row=1375;Solubility_results.csv:row=1375;Lipophilicity_results.csv:row=1376
CHEMBL2105755,NALDEMEDINE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -5.22; logP 3.48,repurposing_candidates.csv:rc_row=708;protein_drug_candidates.csv:rows=319;pathway_drug_candidates.csv:rows=289;1323;7236;CYP3A4_results.csv:row=653;CYP2C19_results.csv:row=653;CYP2D6_results.csv:row=653;CYP1A2_results.csv:row=653;CYP2C9_results.csv:row=653;hERG_results.csv:row=653;AMES_results.csv:row=653;PGP_results.csv:row=653;PAMPA_results.csv:row=653;BBB_results.csv:row=653;Solubility_results.csv:row=653;Lipophilicity_results.csv:row=654
CHEMBL24778,SILODOSIN,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,29.549961861174673,100,70.0,64.31998474446988,H,KG targets ADRA1A; clinical phase 4.0; hERG risk; logS -1.58; logP 3.07,repurposing_candidates.csv:rc_row=852;protein_drug_candidates.csv:rows=346;pathway_drug_candidates.csv:rows=809;6471;6671;CYP3A4_results.csv:row=760;CYP2C19_results.csv:row=760;CYP2D6_results.csv:row=760;CYP1A2_results.csv:row=760;CYP2C9_results.csv:row=760;hERG_results.csv:row=760;AMES_results.csv:row=760;PGP_results.csv:row=760;PAMPA_results.csv:row=760;BBB_results.csv:row=760;Solubility_results.csv:row=760;Lipophilicity_results.csv:row=761
CHEMBL1201149,NALTREXONE HYDROCHLORIDE,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.02; logP 1.95,repurposing_candidates.csv:rc_row=243;protein_drug_candidates.csv:rows=278;pathway_drug_candidates.csv:rows=248;1282;7195;CYP3A4_results.csv:row=240;CYP2C19_results.csv:row=240;CYP2D6_results.csv:row=240;CYP1A2_results.csv:row=240;CYP2C9_results.csv:row=240;hERG_results.csv:row=240;AMES_results.csv:row=240;PGP_results.csv:row=240;PAMPA_results.csv:row=240;BBB_results.csv:row=240;Solubility_results.csv:row=240;Lipophilicity_results.csv:row=241
CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.32; logP 2.13,repurposing_candidates.csv:rc_row=240;protein_drug_candidates.csv:rows=277;pathway_drug_candidates.csv:rows=247;1281;7194;CYP3A4_results.csv:row=237;CYP2C19_results.csv:row=237;CYP2D6_results.csv:row=237;CYP1A2_results.csv:row=237;CYP2C9_results.csv:row=237;hERG_results.csv:row=237;AMES_results.csv:row=237;PGP_results.csv:row=237;PAMPA_results.csv:row=237;BBB_results.csv:row=237;Solubility_results.csv:row=237;Lipophilicity_results.csv:row=238
CHEMBL4204794,AVAPRITINIB,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,29.549961861174673,100,70.0,64.31998474446988,H,KG targets KIT; clinical phase 4.0; hERG risk; logS -4.08; logP 2.61,repurposing_candidates.csv:rc_row=1144;protein_drug_candidates.csv:rows=1145;pathway_drug_candidates.csv:rows=550;6962;7496;CYP3A4_results.csv:row=1008;CYP2C19_results.csv:row=1008;CYP2D6_results.csv:row=1008;CYP1A2_results.csv:row=1008;CYP2C9_results.csv:row=1008;hERG_results.csv:row=1008;AMES_results.csv:row=1008;PGP_results.csv:row=1008;PAMPA_results.csv:row=1008;BBB_results.csv:row=1008;Solubility_results.csv:row=1008;Lipophilicity_results.csv:row=1009
CHEMBL1395,METHYLTESTOSTERONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,29.549961861174673,100,70.0,64.31998474446988,H,KG targets AR; clinical phase 4.0; hERG risk; logS -4.10; logP 4.27,repurposing_candidates.csv:rc_row=401;protein_drug_candidates.csv:rows=557;pathway_drug_candidates.csv:rows=1980;5895;7799;CYP3A4_results.csv:row=361;CYP2C19_results.csv:row=361;CYP2D6_results.csv:row=361;CYP1A2_results.csv:row=361;CYP2C9_results.csv:row=361;hERG_results.csv:row=361;AMES_results.csv:row=361;PGP_results.csv:row=361;PAMPA_results.csv:row=361;BBB_results.csv:row=361;Solubility_results.csv:row=361;Lipophilicity_results.csv:row=362
CHEMBL895,NALBUPHINE,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.00; logP 1.71,repurposing_candidates.csv:rc_row=1542;protein_drug_candidates.csv:rows=273;pathway_drug_candidates.csv:rows=243;1277;7190;CYP3A4_results.csv:row=1348;CYP2C19_results.csv:row=1348;CYP2D6_results.csv:row=1348;CYP1A2_results.csv:row=1348;CYP2C9_results.csv:row=1348;hERG_results.csv:row=1348;AMES_results.csv:row=1348;PGP_results.csv:row=1348;PAMPA_results.csv:row=1348;BBB_results.csv:row=1348;Solubility_results.csv:row=1348;Lipophilicity_results.csv:row=1349
CHEMBL398707,HYDROMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.28; logP 1.63,repurposing_candidates.csv:rc_row=1066;protein_drug_candidates.csv:rows=294;pathway_drug_candidates.csv:rows=264;1298;7211;CYP3A4_results.csv:row=935;CYP2C19_results.csv:row=935;CYP2D6_results.csv:row=935;CYP1A2_results.csv:row=935;CYP2C9_results.csv:row=935;hERG_results.csv:row=935;AMES_results.csv:row=935;PGP_results.csv:row=935;PAMPA_results.csv:row=935;BBB_results.csv:row=935;Solubility_results.csv:row=935;Lipophilicity_results.csv:row=936
CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.45; logP 1.17,repurposing_candidates.csv:rc_row=169;protein_drug_candidates.csv:rows=274;pathway_drug_candidates.csv:rows=244;1278;7191;CYP3A4_results.csv:row=167;CYP2C19_results.csv:row=167;CYP2D6_results.csv:row=167;CYP1A2_results.csv:row=167;CYP2C9_results.csv:row=167;hERG_results.csv:row=167;AMES_results.csv:row=167;PGP_results.csv:row=167;PAMPA_results.csv:row=167;BBB_results.csv:row=167;Solubility_results.csv:row=167;Lipophilicity_results.csv:row=168
CHEMBL2219418,NALOXEGOL,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -0.56; logP 1.86,repurposing_candidates.csv:rc_row=812;protein_drug_candidates.csv:rows=314;pathway_drug_candidates.csv:rows=284;1318;7231;CYP3A4_results.csv:row=721;CYP2C19_results.csv:row=721;CYP2D6_results.csv:row=721;CYP1A2_results.csv:row=721;CYP2C9_results.csv:row=721;hERG_results.csv:row=721;AMES_results.csv:row=721;PGP_results.csv:row=721;PAMPA_results.csv:row=721;BBB_results.csv:row=721;Solubility_results.csv:row=721;Lipophilicity_results.csv:row=722
CHEMBL1595,DIHYDROCODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.25; logP 1.73,repurposing_candidates.csv:rc_row=472;protein_drug_candidates.csv:rows=284;pathway_drug_candidates.csv:rows=254;1288;7201;CYP3A4_results.csv:row=432;CYP2C19_results.csv:row=432;CYP2D6_results.csv:row=432;CYP1A2_results.csv:row=432;CYP2C9_results.csv:row=432;hERG_results.csv:row=432;AMES_results.csv:row=432;PGP_results.csv:row=432;PAMPA_results.csv:row=432;BBB_results.csv:row=432;Solubility_results.csv:row=432;Lipophilicity_results.csv:row=433
CHEMBL485,CODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.51; logP 1.50,repurposing_candidates.csv:rc_row=1335;protein_drug_candidates.csv:rows=297;pathway_drug_candidates.csv:rows=267;1301;7214;CYP3A4_results.csv:row=1146;CYP2C19_results.csv:row=1146;CYP2D6_results.csv:row=1146;CYP1A2_results.csv:row=1146;CYP2C9_results.csv:row=1146;hERG_results.csv:row=1146;AMES_results.csv:row=1146;PGP_results.csv:row=1146;PAMPA_results.csv:row=1146;BBB_results.csv:row=1146;Solubility_results.csv:row=1146;Lipophilicity_results.csv:row=1147
CHEMBL651,METHADONE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.13; logP 4.29,repurposing_candidates.csv:rc_row=1473;protein_drug_candidates.csv:rows=269;pathway_drug_candidates.csv:rows=239;1273;7186;CYP3A4_results.csv:row=1279;CYP2C19_results.csv:row=1279;CYP2D6_results.csv:row=1279;CYP1A2_results.csv:row=1279;CYP2C9_results.csv:row=1279;hERG_results.csv:row=1279;AMES_results.csv:row=1279;PGP_results.csv:row=1279;PAMPA_results.csv:row=1279;BBB_results.csv:row=1279;Solubility_results.csv:row=1279;Lipophilicity_results.csv:row=1280
CHEMBL1457,HYDROCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.19; logP 1.93,repurposing_candidates.csv:rc_row=423;protein_drug_candidates.csv:rows=320;pathway_drug_candidates.csv:rows=290;1324;7237;CYP3A4_results.csv:row=383;CYP2C19_results.csv:row=383;CYP2D6_results.csv:row=383;CYP1A2_results.csv:row=383;CYP2C9_results.csv:row=383;hERG_results.csv:row=383;AMES_results.csv:row=383;PGP_results.csv:row=383;PAMPA_results.csv:row=383;BBB_results.csv:row=383;Solubility_results.csv:row=383;Lipophilicity_results.csv:row=384
CHEMBL1445,FLUOXYMESTERONE,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,29.549961861174673,100,70.0,64.31998474446988,H,KG targets AR; clinical phase 4.0; hERG risk; logS -3.72; logP 3.33,repurposing_candidates.csv:rc_row=419;protein_drug_candidates.csv:rows=550;pathway_drug_candidates.csv:rows=1973;5888;7792;CYP3A4_results.csv:row=379;CYP2C19_results.csv:row=379;CYP2D6_results.csv:row=379;CYP1A2_results.csv:row=379;CYP2C9_results.csv:row=379;hERG_results.csv:row=379;AMES_results.csv:row=379;PGP_results.csv:row=379;PAMPA_results.csv:row=379;BBB_results.csv:row=379;Solubility_results.csv:row=379;Lipophilicity_results.csv:row=380
CHEMBL70,MORPHINE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.02; logP 1.20,repurposing_candidates.csv:rc_row=1491;protein_drug_candidates.csv:rows=272;pathway_drug_candidates.csv:rows=242;1276;7189;CYP3A4_results.csv:row=1297;CYP2C19_results.csv:row=1297;CYP2D6_results.csv:row=1297;CYP1A2_results.csv:row=1297;CYP2C9_results.csv:row=1297;hERG_results.csv:row=1297;AMES_results.csv:row=1297;PGP_results.csv:row=1297;PAMPA_results.csv:row=1297;BBB_results.csv:row=1297;Solubility_results.csv:row=1297;Lipophilicity_results.csv:row=1298
CHEMBL982,NALMEFENE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -4.66; logP 2.51,repurposing_candidates.csv:rc_row=1578;protein_drug_candidates.csv:rows=323;pathway_drug_candidates.csv:rows=293;1327;7240;CYP3A4_results.csv:row=1384;CYP2C19_results.csv:row=1384;CYP2D6_results.csv:row=1384;CYP1A2_results.csv:row=1384;CYP2C9_results.csv:row=1384;hERG_results.csv:row=1384;AMES_results.csv:row=1384;PGP_results.csv:row=1384;PAMPA_results.csv:row=1384;BBB_results.csv:row=1384;Solubility_results.csv:row=1384;Lipophilicity_results.csv:row=1385
CHEMBL2219416,NALOXEGOL OXALATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.42; logP 1.02,repurposing_candidates.csv:rc_row=811;protein_drug_candidates.csv:rows=290;pathway_drug_candidates.csv:rows=260;1294;7207;CYP3A4_results.csv:row=720;CYP2C19_results.csv:row=720;CYP2D6_results.csv:row=720;CYP1A2_results.csv:row=720;CYP2C9_results.csv:row=720;hERG_results.csv:row=720;AMES_results.csv:row=720;PGP_results.csv:row=720;PAMPA_results.csv:row=720;BBB_results.csv:row=720;Solubility_results.csv:row=720;Lipophilicity_results.csv:row=721
CHEMBL1479,DANAZOL,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,29.549961861174673,100,70.0,64.31998474446988,H,KG targets AR; clinical phase 4.0; hERG risk; logS -5.68; logP 4.22,repurposing_candidates.csv:rc_row=428;protein_drug_candidates.csv:rows=555;pathway_drug_candidates.csv:rows=1978;5893;7797;CYP3A4_results.csv:row=388;CYP2C19_results.csv:row=388;CYP2D6_results.csv:row=388;CYP1A2_results.csv:row=388;CYP2C9_results.csv:row=388;hERG_results.csv:row=388;AMES_results.csv:row=388;PGP_results.csv:row=388;PAMPA_results.csv:row=388;BBB_results.csv:row=388;Solubility_results.csv:row=388;Lipophilicity_results.csv:row=389
CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -4.75; logP 1.28,repurposing_candidates.csv:rc_row=1391;protein_drug_candidates.csv:rows=322;pathway_drug_candidates.csv:rows=292;1326;7239;CYP3A4_results.csv:row=1201;CYP2C19_results.csv:row=1201;CYP2D6_results.csv:row=1201;CYP1A2_results.csv:row=1201;CYP2C9_results.csv:row=1201;hERG_results.csv:row=1201;AMES_results.csv:row=1201;PGP_results.csv:row=1201;PAMPA_results.csv:row=1201;BBB_results.csv:row=1201;Solubility_results.csv:row=1201;Lipophilicity_results.csv:row=1202
CHEMBL61006,PHENYLPROPANOLAMINE,CC(N)C(O)c1ccccc1,29.549961861174673,100,70.0,64.31998474446988,H,KG targets ADRA1A; clinical phase 4.0; hERG risk; logS -0.79; logP 1.07,repurposing_candidates.csv:rc_row=1453;protein_drug_candidates.csv:rows=391;pathway_drug_candidates.csv:rows=854;6516;6716;CYP3A4_results.csv:row=1260;CYP2C19_results.csv:row=1260;CYP2D6_results.csv:row=1260;CYP1A2_results.csv:row=1260;CYP2C9_results.csv:row=1260;hERG_results.csv:row=1260;AMES_results.csv:row=1260;PGP_results.csv:row=1260;PAMPA_results.csv:row=1260;BBB_results.csv:row=1260;Solubility_results.csv:row=1260;Lipophilicity_results.csv:row=1261
CHEMBL19019,NALTREXONE,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,29.549961861174673,100,70.0,64.31998474446988,H,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -3.69; logP 1.53,repurposing_candidates.csv:rc_row=591;protein_drug_candidates.csv:rows=321;pathway_drug_candidates.csv:rows=291;1325;7238;CYP3A4_results.csv:row=537;CYP2C19_results.csv:row=537;CYP2D6_results.csv:row=537;CYP1A2_results.csv:row=537;CYP2C9_results.csv:row=537;hERG_results.csv:row=537;AMES_results.csv:row=537;PGP_results.csv:row=537;PAMPA_results.csv:row=537;BBB_results.csv:row=537;Solubility_results.csv:row=537;Lipophilicity_results.csv:row=538
CHEMBL2311030,ERGOLOID MESYLATES,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O,38.70327993897788,100,55.0,64.23131197559115,M,"KG targets ADRA1A, ADRA1B; clinical phase 4.0; hERG risk; logS -5.88; logP 7.90",repurposing_candidates.csv:rc_row=823;protein_drug_candidates.csv:rows=353;1311;1362;1461;1816;2501;pathway_drug_candidates.csv:rows=816;882;933;986;1037;1090;1142;1193;1374;1425;1478;6478;6678;CYP3A4_results.csv:row=732;CYP2C19_results.csv:row=732;CYP2D6_results.csv:row=732;CYP1A2_results.csv:row=732;CYP2C9_results.csv:row=732;hERG_results.csv:row=732;AMES_results.csv:row=732;PGP_results.csv:row=732;PAMPA_results.csv:row=732;BBB_results.csv:row=732;Solubility_results.csv:row=732;Lipophilicity_results.csv:row=733
CHEMBL2103738,LITHIUM CITRATE,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+],32.43325705568268,100,65.0,64.22330282227307,M,"KG targets GSK3A, GSK3B; clinical phase 4.0; hERG risk; logS -1.05; logP -17.54",repurposing_candidates.csv:rc_row=654;protein_drug_candidates.csv:rows=1179;1226;pathway_drug_candidates.csv:rows=5493;5496;5501;5504;5507;5512;5515;5518;8090;CYP3A4_results.csv:row=599;CYP2C19_results.csv:row=599;CYP2D6_results.csv:row=599;CYP1A2_results.csv:row=599;CYP2C9_results.csv:row=599;hERG_results.csv:row=599;AMES_results.csv:row=599;PGP_results.csv:row=599;PAMPA_results.csv:row=599;BBB_results.csv:row=599;Solubility_results.csv:row=599;Lipophilicity_results.csv:row=600
CHEMBL1200826,LITHIUM CARBONATE,O=C([O-])[O-].[Li+].[Li+],32.43325705568268,100,65.0,64.22330282227307,M,"KG targets GSK3A, GSK3B; clinical phase 4.0; hERG risk; logS -1.09; logP -8.44",repurposing_candidates.csv:rc_row=179;protein_drug_candidates.csv:rows=1178;1225;pathway_drug_candidates.csv:rows=5492;5495;5500;5503;5506;5511;5514;5517;8089;CYP3A4_results.csv:row=177;CYP2C19_results.csv:row=177;CYP2D6_results.csv:row=177;CYP1A2_results.csv:row=177;CYP2C9_results.csv:row=177;hERG_results.csv:row=177;AMES_results.csv:row=177;PGP_results.csv:row=177;PAMPA_results.csv:row=177;BBB_results.csv:row=177;Solubility_results.csv:row=177;Lipophilicity_results.csv:row=178
CHEMBL4650343,IZENCITINIB,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1,45.31655225019069,60,100.0,64.12662090007628,M,"KG targets JAK1, JAK2; clinical phase 2.0; logS -3.48; logP 3.73",repurposing_candidates.csv:rc_row=1313;protein_drug_candidates.csv:rows=772;795;1195;pathway_drug_candidates.csv:rows=197;220;413;659;682;792;4249;4277;4428;4531;4569;4592;4614;4648;4671;4693;4727;4750;4772;4796;4813;4834;4857;4879;4903;4926;4948;4969;4992;5014;5035;5058;5080;5102;5124;5145;5168;5190;5223;5240;5273;5290;5311;5334;5356;5377;5400;5422;5438;5471;5488;6924;6947;7481;8310;8338;8366;8400;8428;8456;CYP3A4_results.csv:row=1127;CYP2C19_results.csv:row=1127;CYP2D6_results.csv:row=1127;CYP1A2_results.csv:row=1127;CYP2C9_results.csv:row=1127;hERG_results.csv:row=1127;AMES_results.csv:row=1127;PGP_results.csv:row=1127;PAMPA_results.csv:row=1127;BBB_results.csv:row=1127;Solubility_results.csv:row=1127;Lipophilicity_results.csv:row=1128
CHEMBL1269025,EDOXABAN,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,29.02364607170099,100,70.0,64.1094584286804,H,KG targets F10; clinical phase 4.0; hERG risk; logS -2.89; logP 1.29,repurposing_candidates.csv:rc_row=366;protein_drug_candidates.csv:rows=453;pathway_drug_candidates.csv:rows=7533;7562;CYP3A4_results.csv:row=328;CYP2C19_results.csv:row=328;CYP2D6_results.csv:row=328;CYP1A2_results.csv:row=328;CYP2C9_results.csv:row=328;hERG_results.csv:row=328;AMES_results.csv:row=328;PGP_results.csv:row=328;PAMPA_results.csv:row=328;BBB_results.csv:row=328;Solubility_results.csv:row=328;Lipophilicity_results.csv:row=329
CHEMBL1422,SITAGLIPTIN,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,14.63768115942029,95,100.0,64.10507246376812,H,KG targets DPP4; clinical phase 3.0; logS -1.11; logP 2.02,repurposing_candidates.csv:rc_row=408;protein_drug_candidates.csv:rows=664;CYP3A4_results.csv:row=368;CYP2C19_results.csv:row=368;CYP2D6_results.csv:row=368;CYP1A2_results.csv:row=368;CYP2C9_results.csv:row=368;hERG_results.csv:row=368;AMES_results.csv:row=368;PGP_results.csv:row=368;PAMPA_results.csv:row=368;BBB_results.csv:row=368;Solubility_results.csv:row=368;Lipophilicity_results.csv:row=369
CHEMBL5303393,VARENICLINE TARTRATE,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,30.85430968726163,80,95.0,64.09172387490466,H,"KG targets CHRNA4, CHRNB2; clinical phase 3.0; logS 0.57; logP -0.32",repurposing_candidates.csv:rc_row=1377;protein_drug_candidates.csv:rows=439;2136;pathway_drug_candidates.csv:rows=7919;7933;7947;CYP3A4_results.csv:row=1188;CYP2C19_results.csv:row=1188;CYP2D6_results.csv:row=1188;CYP1A2_results.csv:row=1188;CYP2C9_results.csv:row=1188;hERG_results.csv:row=1188;AMES_results.csv:row=1188;PGP_results.csv:row=1188;PAMPA_results.csv:row=1188;BBB_results.csv:row=1188;Solubility_results.csv:row=1188;Lipophilicity_results.csv:row=1189
CHEMBL1278146,FAMITINIB,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,30.85430968726163,80,95.0,64.09172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -3.45; logP 3.30",repurposing_candidates.csv:rc_row=372;protein_drug_candidates.csv:rows=1117;1159;pathway_drug_candidates.csv:rows=564;6976;7015;7510;CYP3A4_results.csv:row=333;CYP2C19_results.csv:row=333;CYP2D6_results.csv:row=333;CYP1A2_results.csv:row=333;CYP2C9_results.csv:row=333;hERG_results.csv:row=333;AMES_results.csv:row=333;PGP_results.csv:row=333;PAMPA_results.csv:row=333;BBB_results.csv:row=333;Solubility_results.csv:row=333;Lipophilicity_results.csv:row=334
CHEMBL4303201,CATEQUENTINIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,30.85430968726163,80,95.0,64.09172387490466,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -4.05; logP 4.83",repurposing_candidates.csv:rc_row=1250;protein_drug_candidates.csv:rows=1111;1155;pathway_drug_candidates.csv:rows=560;6972;7009;7506;CYP3A4_results.csv:row=1070;CYP2C19_results.csv:row=1070;CYP2D6_results.csv:row=1070;CYP1A2_results.csv:row=1070;CYP2C9_results.csv:row=1070;hERG_results.csv:row=1070;AMES_results.csv:row=1070;PGP_results.csv:row=1070;PAMPA_results.csv:row=1070;BBB_results.csv:row=1070;Solubility_results.csv:row=1070;Lipophilicity_results.csv:row=1071
CHEMBL1762621,BARDOXOLONE METHYL,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,43.23417238749047,80,75.0,64.04366895499619,H,KG targets IKBKB; clinical phase 3.0; logS -6.03; logP 6.38,repurposing_candidates.csv:rc_row=561;protein_drug_candidates.csv:rows=1232;pathway_drug_candidates.csv:rows=4020;4087;4113;4116;4119;4122;4125;4128;4131;4134;4137;4140;4155;4170;4173;4176;4179;4182;4185;4195;4198;4201;4204;4219;4281;4284;4287;4316;4348;CYP3A4_results.csv:row=507;CYP2C19_results.csv:row=507;CYP2D6_results.csv:row=507;CYP1A2_results.csv:row=507;CYP2C9_results.csv:row=507;hERG_results.csv:row=507;AMES_results.csv:row=507;PGP_results.csv:row=507;PAMPA_results.csv:row=507;BBB_results.csv:row=507;Solubility_results.csv:row=507;Lipophilicity_results.csv:row=508
CHEMBL1549,HYDROCORTISONE CYPIONATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,51.04118993135011,60,90.0,63.91647597254004,M,KG targets NR3C1; clinical phase 2.0; logS -6.47; logP 4.30,repurposing_candidates.csv:rc_row=456;protein_drug_candidates.csv:rows=65;pathway_drug_candidates.csv:rows=757;2066;5981;7885;8022;8088;8159;8225;8291;CYP3A4_results.csv:row=416;CYP2C19_results.csv:row=416;CYP2D6_results.csv:row=416;CYP1A2_results.csv:row=416;CYP2C9_results.csv:row=416;hERG_results.csv:row=416;AMES_results.csv:row=416;PGP_results.csv:row=416;PAMPA_results.csv:row=416;BBB_results.csv:row=416;Solubility_results.csv:row=416;Lipophilicity_results.csv:row=417
CHEMBL3188034,TRIPROLIDINE HYDROCHLORIDE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -1.40; logP 3.51,repurposing_candidates.csv:rc_row=924;protein_drug_candidates.csv:rows=961;pathway_drug_candidates.csv:rows=6591;CYP3A4_results.csv:row=831;CYP2C19_results.csv:row=831;CYP2D6_results.csv:row=831;CYP1A2_results.csv:row=831;CYP2C9_results.csv:row=831;hERG_results.csv:row=831;AMES_results.csv:row=831;PGP_results.csv:row=831;PAMPA_results.csv:row=831;BBB_results.csv:row=831;Solubility_results.csv:row=831;Lipophilicity_results.csv:row=832
CHEMBL511,PYRILAMINE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.60; logP 2.66,repurposing_candidates.csv:rc_row=1354;protein_drug_candidates.csv:rows=993;pathway_drug_candidates.csv:rows=6623;CYP3A4_results.csv:row=1165;CYP2C19_results.csv:row=1165;CYP2D6_results.csv:row=1165;CYP1A2_results.csv:row=1165;CYP2C9_results.csv:row=1165;hERG_results.csv:row=1165;AMES_results.csv:row=1165;PGP_results.csv:row=1165;PAMPA_results.csv:row=1165;BBB_results.csv:row=1165;Solubility_results.csv:row=1165;Lipophilicity_results.csv:row=1166
CHEMBL855,TRIPROLIDINE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -1.53; logP 3.92,repurposing_candidates.csv:rc_row=1536;protein_drug_candidates.csv:rows=1009;pathway_drug_candidates.csv:rows=6639;CYP3A4_results.csv:row=1342;CYP2C19_results.csv:row=1342;CYP2D6_results.csv:row=1342;CYP1A2_results.csv:row=1342;CYP2C9_results.csv:row=1342;hERG_results.csv:row=1342;AMES_results.csv:row=1342;PGP_results.csv:row=1342;PAMPA_results.csv:row=1342;BBB_results.csv:row=1342;Solubility_results.csv:row=1342;Lipophilicity_results.csv:row=1343
CHEMBL505,CHLORPHENIRAMINE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.89; logP 3.82,repurposing_candidates.csv:rc_row=1349;protein_drug_candidates.csv:rows=1006;pathway_drug_candidates.csv:rows=6636;CYP3A4_results.csv:row=1160;CYP2C19_results.csv:row=1160;CYP2D6_results.csv:row=1160;CYP1A2_results.csv:row=1160;CYP2C9_results.csv:row=1160;hERG_results.csv:row=1160;AMES_results.csv:row=1160;PGP_results.csv:row=1160;PAMPA_results.csv:row=1160;BBB_results.csv:row=1160;Solubility_results.csv:row=1160;Lipophilicity_results.csv:row=1161
CHEMBL643,PROMETHAZINE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.75; logP 4.24,repurposing_candidates.csv:rc_row=1467;protein_drug_candidates.csv:rows=988;pathway_drug_candidates.csv:rows=6618;CYP3A4_results.csv:row=1273;CYP2C19_results.csv:row=1273;CYP2D6_results.csv:row=1273;CYP1A2_results.csv:row=1273;CYP2C9_results.csv:row=1273;hERG_results.csv:row=1273;AMES_results.csv:row=1273;PGP_results.csv:row=1273;PAMPA_results.csv:row=1273;BBB_results.csv:row=1273;Solubility_results.csv:row=1273;Lipophilicity_results.csv:row=1274
CHEMBL1000,CETIRIZINE,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.90; logP 3.15,repurposing_candidates.csv:rc_row=0;protein_drug_candidates.csv:rows=977;pathway_drug_candidates.csv:rows=6607;CYP3A4_results.csv:row=0;CYP2C19_results.csv:row=0;CYP2D6_results.csv:row=0;CYP1A2_results.csv:row=0;CYP2C9_results.csv:row=0;hERG_results.csv:row=0;AMES_results.csv:row=0;PGP_results.csv:row=0;PAMPA_results.csv:row=0;BBB_results.csv:row=0;Solubility_results.csv:row=0;Lipophilicity_results.csv:row=0
CHEMBL1201245,BROMODIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.42; logP 4.12,repurposing_candidates.csv:rc_row=262;protein_drug_candidates.csv:rows=997;pathway_drug_candidates.csv:rows=6627;CYP3A4_results.csv:row=259;CYP2C19_results.csv:row=259;CYP2D6_results.csv:row=259;CYP1A2_results.csv:row=259;CYP2C9_results.csv:row=259;hERG_results.csv:row=259;AMES_results.csv:row=259;PGP_results.csv:row=259;PAMPA_results.csv:row=259;BBB_results.csv:row=259;Solubility_results.csv:row=259;Lipophilicity_results.csv:row=260
CHEMBL1607273,CETIRIZINE HYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -1.86; logP 3.99,repurposing_candidates.csv:rc_row=474;protein_drug_candidates.csv:rows=965;pathway_drug_candidates.csv:rows=6595;CYP3A4_results.csv:row=434;CYP2C19_results.csv:row=434;CYP2D6_results.csv:row=434;CYP1A2_results.csv:row=434;CYP2C9_results.csv:row=434;hERG_results.csv:row=434;AMES_results.csv:row=434;PGP_results.csv:row=434;PAMPA_results.csv:row=434;BBB_results.csv:row=434;Solubility_results.csv:row=434;Lipophilicity_results.csv:row=435
CHEMBL1492,DIPHENYLPYRALINE,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.52; logP 3.89,repurposing_candidates.csv:rc_row=432;protein_drug_candidates.csv:rows=1003;pathway_drug_candidates.csv:rows=6633;CYP3A4_results.csv:row=392;CYP2C19_results.csv:row=392;CYP2D6_results.csv:row=392;CYP1A2_results.csv:row=392;CYP2C9_results.csv:row=392;hERG_results.csv:row=392;AMES_results.csv:row=392;PGP_results.csv:row=392;PAMPA_results.csv:row=392;BBB_results.csv:row=392;Solubility_results.csv:row=392;Lipophilicity_results.csv:row=393
CHEMBL1224,ACRIVASTINE,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.40; logP 4.02,repurposing_candidates.csv:rc_row=336;protein_drug_candidates.csv:rows=1000;pathway_drug_candidates.csv:rows=6630;CYP3A4_results.csv:row=299;CYP2C19_results.csv:row=299;CYP2D6_results.csv:row=299;CYP1A2_results.csv:row=299;CYP2C9_results.csv:row=299;hERG_results.csv:row=299;AMES_results.csv:row=299;PGP_results.csv:row=299;PAMPA_results.csv:row=299;BBB_results.csv:row=299;Solubility_results.csv:row=299;Lipophilicity_results.csv:row=300
CHEMBL1659,CHLORPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.43; logP 3.53,repurposing_candidates.csv:rc_row=500;protein_drug_candidates.csv:rows=954;pathway_drug_candidates.csv:rows=6584;CYP3A4_results.csv:row=460;CYP2C19_results.csv:row=460;CYP2D6_results.csv:row=460;CYP1A2_results.csv:row=460;CYP2C9_results.csv:row=460;hERG_results.csv:row=460;AMES_results.csv:row=460;PGP_results.csv:row=460;PAMPA_results.csv:row=460;BBB_results.csv:row=460;Solubility_results.csv:row=460;Lipophilicity_results.csv:row=461
CHEMBL2110774,CHLORPHENOXAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.50; logP 4.18,repurposing_candidates.csv:rc_row=781;protein_drug_candidates.csv:rows=987;pathway_drug_candidates.csv:rows=6617;CYP3A4_results.csv:row=690;CYP2C19_results.csv:row=690;CYP2D6_results.csv:row=690;CYP1A2_results.csv:row=690;CYP2C9_results.csv:row=690;hERG_results.csv:row=690;AMES_results.csv:row=690;PGP_results.csv:row=690;PAMPA_results.csv:row=690;BBB_results.csv:row=690;Solubility_results.csv:row=690;Lipophilicity_results.csv:row=691
CHEMBL1200750,PROMETHAZINE HYDROCHLORIDE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.07; logP 4.66,repurposing_candidates.csv:rc_row=161;protein_drug_candidates.csv:rows=950;pathway_drug_candidates.csv:rows=6580;CYP3A4_results.csv:row=159;CYP2C19_results.csv:row=159;CYP2D6_results.csv:row=159;CYP1A2_results.csv:row=159;CYP2C9_results.csv:row=159;hERG_results.csv:row=159;AMES_results.csv:row=159;PGP_results.csv:row=159;PAMPA_results.csv:row=159;BBB_results.csv:row=159;Solubility_results.csv:row=159;Lipophilicity_results.csv:row=160
CHEMBL2103739,EMEDASTINE DIFUMARATE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -1.17; logP 1.64,repurposing_candidates.csv:rc_row=655;protein_drug_candidates.csv:rows=983;pathway_drug_candidates.csv:rows=6613;CYP3A4_results.csv:row=600;CYP2C19_results.csv:row=600;CYP2D6_results.csv:row=600;CYP1A2_results.csv:row=600;CYP2C9_results.csv:row=600;hERG_results.csv:row=600;AMES_results.csv:row=600;PGP_results.csv:row=600;PAMPA_results.csv:row=600;BBB_results.csv:row=600;Solubility_results.csv:row=600;Lipophilicity_results.csv:row=601
CHEMBL1200927,DEXCHLORPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.43; logP 3.53,repurposing_candidates.csv:rc_row=195;protein_drug_candidates.csv:rows=966;pathway_drug_candidates.csv:rows=6596;CYP3A4_results.csv:row=193;CYP2C19_results.csv:row=193;CYP2D6_results.csv:row=193;CYP1A2_results.csv:row=193;CYP2C9_results.csv:row=193;hERG_results.csv:row=193;AMES_results.csv:row=193;PGP_results.csv:row=193;PAMPA_results.csv:row=193;BBB_results.csv:row=193;Solubility_results.csv:row=193;Lipophilicity_results.csv:row=194
CHEMBL1241,TRIPELENNAMINE,CN(C)CCN(Cc1ccccc1)c1ccccn1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.50; logP 2.65,repurposing_candidates.csv:rc_row=351;protein_drug_candidates.csv:rows=985;pathway_drug_candidates.csv:rows=6615;CYP3A4_results.csv:row=313;CYP2C19_results.csv:row=313;CYP2D6_results.csv:row=313;CYP1A2_results.csv:row=313;CYP2C9_results.csv:row=313;hERG_results.csv:row=313;AMES_results.csv:row=313;PGP_results.csv:row=313;PAMPA_results.csv:row=313;BBB_results.csv:row=313;Solubility_results.csv:row=313;Lipophilicity_results.csv:row=314
CHEMBL1615438,LEVOCABASTINE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.95; logP 4.89,repurposing_candidates.csv:rc_row=480;protein_drug_candidates.csv:rows=979;pathway_drug_candidates.csv:rows=6609;CYP3A4_results.csv:row=440;CYP2C19_results.csv:row=440;CYP2D6_results.csv:row=440;CYP1A2_results.csv:row=440;CYP2C9_results.csv:row=440;hERG_results.csv:row=440;AMES_results.csv:row=440;PGP_results.csv:row=440;PAMPA_results.csv:row=440;BBB_results.csv:row=440;Solubility_results.csv:row=440;Lipophilicity_results.csv:row=441
CHEMBL1201191,LEVOCETIRIZINE,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.90; logP 3.15,repurposing_candidates.csv:rc_row=254;protein_drug_candidates.csv:rows=996;pathway_drug_candidates.csv:rows=6626;CYP3A4_results.csv:row=251;CYP2C19_results.csv:row=251;CYP2D6_results.csv:row=251;CYP1A2_results.csv:row=251;CYP2C9_results.csv:row=251;hERG_results.csv:row=251;AMES_results.csv:row=251;PGP_results.csv:row=251;PAMPA_results.csv:row=251;BBB_results.csv:row=251;Solubility_results.csv:row=251;Lipophilicity_results.csv:row=252
CHEMBL1411979,METHAPYRILENE,CN(C)CCN(Cc1cccs1)c1ccccn1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.45; logP 2.71,repurposing_candidates.csv:rc_row=405;protein_drug_candidates.csv:rows=1002;pathway_drug_candidates.csv:rows=6632;CYP3A4_results.csv:row=365;CYP2C19_results.csv:row=365;CYP2D6_results.csv:row=365;CYP1A2_results.csv:row=365;CYP2C9_results.csv:row=365;hERG_results.csv:row=365;AMES_results.csv:row=365;PGP_results.csv:row=365;PAMPA_results.csv:row=365;BBB_results.csv:row=365;Solubility_results.csv:row=365;Lipophilicity_results.csv:row=366
CHEMBL1201190,LEVOCETIRIZINE DIHYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -1.86; logP 3.99,repurposing_candidates.csv:rc_row=253;protein_drug_candidates.csv:rows=951;pathway_drug_candidates.csv:rows=6581;CYP3A4_results.csv:row=250;CYP2C19_results.csv:row=250;CYP2D6_results.csv:row=250;CYP1A2_results.csv:row=250;CYP2C9_results.csv:row=250;hERG_results.csv:row=250;AMES_results.csv:row=250;PGP_results.csv:row=250;PAMPA_results.csv:row=250;BBB_results.csv:row=250;Solubility_results.csv:row=250;Lipophilicity_results.csv:row=251
CHEMBL1201006,PYRILAMINE MALEATE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O,28.497330282227306,100,70.0,63.898932112890925,H,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.10; logP 2.37,repurposing_candidates.csv:rc_row=214;protein_drug_candidates.csv:rows=958;pathway_drug_candidates.csv:rows=6588;CYP3A4_results.csv:row=212;CYP2C19_results.csv:row=212;CYP2D6_results.csv:row=212;CYP1A2_results.csv:row=212;CYP2C9_results.csv:row=212;hERG_results.csv:row=212;AMES_results.csv:row=212;PGP_results.csv:row=212;PAMPA_results.csv:row=212;BBB_results.csv:row=212;Solubility_results.csv:row=212;Lipophilicity_results.csv:row=213
CHEMBL3989968,DIFAMILAST,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1,51.79633867276888,80,60.0,63.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 3.0; hERG risk; logS -5.12; logP 5.06",repurposing_candidates.csv:rc_row=1108;protein_drug_candidates.csv:rows=418;1051;1079;2156;pathway_drug_candidates.csv:rows=4330;5740;5768;5796;5835;5863;CYP3A4_results.csv:row=977;CYP2C19_results.csv:row=977;CYP2D6_results.csv:row=977;CYP1A2_results.csv:row=977;CYP2C9_results.csv:row=977;hERG_results.csv:row=977;AMES_results.csv:row=977;PGP_results.csv:row=977;PAMPA_results.csv:row=977;BBB_results.csv:row=977;Solubility_results.csv:row=977;Lipophilicity_results.csv:row=978
CHEMBL1171837,PONATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,29.801678108314263,80,95.0,63.67067124332571,H,"KG targets ABL1, BCR; clinical phase 3.0; logS -3.02; logP 4.46",repurposing_candidates.csv:rc_row=71;protein_drug_candidates.csv:rows=1210;2206;pathway_drug_candidates.csv:rows=4301;CYP3A4_results.csv:row=70;CYP2C19_results.csv:row=70;CYP2D6_results.csv:row=70;CYP1A2_results.csv:row=70;CYP2C9_results.csv:row=70;hERG_results.csv:row=70;AMES_results.csv:row=70;PGP_results.csv:row=70;PAMPA_results.csv:row=70;BBB_results.csv:row=70;Solubility_results.csv:row=70;Lipophilicity_results.csv:row=70
CHEMBL2316582,OLVEREMBATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,29.801678108314263,80,95.0,63.67067124332571,H,"KG targets ABL1, BCR; clinical phase 3.0; logS -3.64; logP 4.68",repurposing_candidates.csv:rc_row=824;protein_drug_candidates.csv:rows=1211;2207;pathway_drug_candidates.csv:rows=4302;CYP3A4_results.csv:row=733;CYP2C19_results.csv:row=733;CYP2D6_results.csv:row=733;CYP1A2_results.csv:row=733;CYP2C9_results.csv:row=733;hERG_results.csv:row=733;AMES_results.csv:row=733;PGP_results.csv:row=733;PAMPA_results.csv:row=733;BBB_results.csv:row=733;Solubility_results.csv:row=733;Lipophilicity_results.csv:row=734
CHEMBL4297507,DELGOCITINIB,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,45.31655225019069,80,70.0,63.626620900076276,H,"KG targets JAK1, JAK2; clinical phase 3.0; hERG risk; logS -3.25; logP 1.30",repurposing_candidates.csv:rc_row=1183;protein_drug_candidates.csv:rows=769;793;1193;pathway_drug_candidates.csv:rows=194;218;411;656;680;790;4246;4275;4425;4529;4566;4590;4612;4645;4669;4691;4724;4748;4770;4793;4811;4831;4855;4877;4900;4924;4946;4966;4990;5012;5032;5056;5078;5100;5122;5142;5166;5188;5220;5238;5270;5288;5308;5332;5354;5374;5398;5420;5436;5468;5486;6921;6945;7479;8308;8336;8364;8398;8426;8454;CYP3A4_results.csv:row=1046;CYP2C19_results.csv:row=1046;CYP2D6_results.csv:row=1046;CYP1A2_results.csv:row=1046;CYP2C9_results.csv:row=1046;hERG_results.csv:row=1046;AMES_results.csv:row=1046;PGP_results.csv:row=1046;PAMPA_results.csv:row=1046;BBB_results.csv:row=1046;Solubility_results.csv:row=1046;Lipophilicity_results.csv:row=1047
CHEMBL3622821,UPADACITINIB,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,45.31655225019069,80,70.0,63.626620900076276,H,"KG targets JAK1, JAK2; clinical phase 3.0; hERG risk; logS -3.45; logP 2.91",repurposing_candidates.csv:rc_row=1004;protein_drug_candidates.csv:rows=763;789;1188;pathway_drug_candidates.csv:rows=188;214;406;650;676;785;4240;4270;4419;4524;4560;4586;4607;4639;4665;4686;4718;4744;4765;4787;4806;4825;4851;4872;4894;4920;4941;4960;4986;5007;5026;5052;5073;5096;5117;5136;5162;5183;5214;5233;5264;5283;5302;5328;5349;5368;5394;5415;5431;5462;5481;6915;6941;7475;8304;8332;8360;8394;8422;8450;CYP3A4_results.csv:row=890;CYP2C19_results.csv:row=890;CYP2D6_results.csv:row=890;CYP1A2_results.csv:row=890;CYP2C9_results.csv:row=890;hERG_results.csv:row=890;AMES_results.csv:row=890;PGP_results.csv:row=890;PAMPA_results.csv:row=890;BBB_results.csv:row=890;Solubility_results.csv:row=890;Lipophilicity_results.csv:row=891
CHEMBL535,SUNITINIB,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,30.85430968726163,100,65.0,63.59172387490465,M,"KG targets KIT, PDGFRB; clinical phase 4.0; hERG risk; logS -2.48; logP 3.33",repurposing_candidates.csv:rc_row=1398;protein_drug_candidates.csv:rows=1100;1144;pathway_drug_candidates.csv:rows=549;6961;6998;7495;CYP3A4_results.csv:row=1207;CYP2C19_results.csv:row=1207;CYP2D6_results.csv:row=1207;CYP1A2_results.csv:row=1207;CYP2C9_results.csv:row=1207;hERG_results.csv:row=1207;AMES_results.csv:row=1207;PGP_results.csv:row=1207;PAMPA_results.csv:row=1207;BBB_results.csv:row=1207;Solubility_results.csv:row=1207;Lipophilicity_results.csv:row=1208
CHEMBL1738889,ENOBOSARM,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,29.549961861174673,80,95.0,63.56998474446987,H,KG targets AR; clinical phase 3.0; logS -2.59; logP 3.22,repurposing_candidates.csv:rc_row=537;protein_drug_candidates.csv:rows=561;pathway_drug_candidates.csv:rows=1984;5899;7803;CYP3A4_results.csv:row=497;CYP2C19_results.csv:row=497;CYP2D6_results.csv:row=497;CYP1A2_results.csv:row=497;CYP2C9_results.csv:row=497;hERG_results.csv:row=497;AMES_results.csv:row=497;PGP_results.csv:row=497;PAMPA_results.csv:row=497;BBB_results.csv:row=497;Solubility_results.csv:row=497;Lipophilicity_results.csv:row=498
CHEMBL4297214,PRALICIGUAT,OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F,46.83066361556064,60,95.0,63.48226544622426,M,KG targets GUCY1B1; clinical phase 2.0; logS -3.77; logP 4.59,repurposing_candidates.csv:rc_row=1162;protein_drug_candidates.csv:rows=77;pathway_drug_candidates.csv:rows=7693;CYP3A4_results.csv:row=1025;CYP2C19_results.csv:row=1025;CYP2D6_results.csv:row=1025;CYP1A2_results.csv:row=1025;CYP2C9_results.csv:row=1025;hERG_results.csv:row=1025;AMES_results.csv:row=1025;PGP_results.csv:row=1025;PAMPA_results.csv:row=1025;BBB_results.csv:row=1025;Solubility_results.csv:row=1025;Lipophilicity_results.csv:row=1026
CHEMBL4297632,OXYCODEGOL,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5,47.88329519450801,80,65.0,63.403318077803206,M,KG targets OPRM1; clinical phase 3.0; hERG risk; logS 0.63; logP 1.59,repurposing_candidates.csv:rc_row=1201;protein_drug_candidates.csv:rows=332;pathway_drug_candidates.csv:rows=302;1336;7249;CYP3A4_results.csv:row=1061;CYP2C19_results.csv:row=1061;CYP2D6_results.csv:row=1061;CYP1A2_results.csv:row=1061;CYP2C9_results.csv:row=1061;hERG_results.csv:row=1061;AMES_results.csv:row=1061;PGP_results.csv:row=1061;PAMPA_results.csv:row=1061;BBB_results.csv:row=1061;Solubility_results.csv:row=1061;Lipophilicity_results.csv:row=1062
CHEMBL1201159,FENTANYL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl,47.88329519450801,80,65.0,63.403318077803206,M,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -3.34; logP 4.56,repurposing_candidates.csv:rc_row=246;protein_drug_candidates.csv:rows=330;pathway_drug_candidates.csv:rows=300;1334;7247;CYP3A4_results.csv:row=243;CYP2C19_results.csv:row=243;CYP2D6_results.csv:row=243;CYP1A2_results.csv:row=243;CYP2C9_results.csv:row=243;hERG_results.csv:row=243;AMES_results.csv:row=243;PGP_results.csv:row=243;PAMPA_results.csv:row=243;BBB_results.csv:row=243;Solubility_results.csv:row=243;Lipophilicity_results.csv:row=244
CHEMBL5314374,IDRAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],29.02364607170099,80,95.0,63.3594584286804,H,KG targets F10; clinical phase 3.0; logS 7.73; logP -39.75,repurposing_candidates.csv:rc_row=1378;protein_drug_candidates.csv:rows=458;pathway_drug_candidates.csv:rows=7538;7567;CYP3A4_results.csv:row=1189;CYP2C19_results.csv:row=1189;CYP2D6_results.csv:row=1189;CYP1A2_results.csv:row=1189;CYP2C9_results.csv:row=1189;hERG_results.csv:row=1189;AMES_results.csv:row=1189;PGP_results.csv:row=1189;PAMPA_results.csv:row=1189;BBB_results.csv:row=1189;Solubility_results.csv:row=1189;Lipophilicity_results.csv:row=1190
CHEMBL5314801,IDRAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O,29.02364607170099,80,95.0,63.3594584286804,H,KG targets F10; clinical phase 3.0; logS 2.59; logP -7.72,repurposing_candidates.csv:rc_row=1387;protein_drug_candidates.csv:rows=459;pathway_drug_candidates.csv:rows=7539;7568;CYP3A4_results.csv:row=1198;CYP2C19_results.csv:row=1198;CYP2D6_results.csv:row=1198;CYP1A2_results.csv:row=1198;CYP2C9_results.csv:row=1198;hERG_results.csv:row=1198;AMES_results.csv:row=1198;PGP_results.csv:row=1198;PAMPA_results.csv:row=1198;BBB_results.csv:row=1198;Solubility_results.csv:row=1198;Lipophilicity_results.csv:row=1199
CHEMBL691,ETHINYL ESTRADIOL,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,14.63768115942029,100,90.0,63.35507246376812,H,KG targets ESR1; clinical phase 4.0; logS -6.45; logP 3.61,repurposing_candidates.csv:rc_row=1490;protein_drug_candidates.csv:rows=2280;CYP3A4_results.csv:row=1296;CYP2C19_results.csv:row=1296;CYP2D6_results.csv:row=1296;CYP1A2_results.csv:row=1296;CYP2C9_results.csv:row=1296;hERG_results.csv:row=1296;AMES_results.csv:row=1296;PGP_results.csv:row=1296;PAMPA_results.csv:row=1296;BBB_results.csv:row=1296;Solubility_results.csv:row=1296;Lipophilicity_results.csv:row=1297
CHEMBL809,SERTRALINE,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,14.63768115942029,100,90.0,63.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -5.27; logP 5.18,repurposing_candidates.csv:rc_row=1521;protein_drug_candidates.csv:rows=1273;CYP3A4_results.csv:row=1327;CYP2C19_results.csv:row=1327;CYP2D6_results.csv:row=1327;CYP1A2_results.csv:row=1327;CYP2C9_results.csv:row=1327;hERG_results.csv:row=1327;AMES_results.csv:row=1327;PGP_results.csv:row=1327;PAMPA_results.csv:row=1327;BBB_results.csv:row=1327;Solubility_results.csv:row=1327;Lipophilicity_results.csv:row=1328
CHEMBL1200328,DULOXETINE HYDROCHLORIDE,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,14.63768115942029,100,90.0,63.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; logS -2.74; logP 5.05,repurposing_candidates.csv:rc_row=84;protein_drug_candidates.csv:rows=1246;CYP3A4_results.csv:row=83;CYP2C19_results.csv:row=83;CYP2D6_results.csv:row=83;CYP1A2_results.csv:row=83;CYP2C9_results.csv:row=83;hERG_results.csv:row=83;AMES_results.csv:row=83;PGP_results.csv:row=83;PAMPA_results.csv:row=83;BBB_results.csv:row=83;Solubility_results.csv:row=83;Lipophilicity_results.csv:row=83
CHEMBL3989933,ETRASIMOD ARGININE,N=C(N)NCCC[C@@H](N)C(=O)O.O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,14.63768115942029,100,90.0,63.35507246376812,H,KG targets S1PR4; clinical phase 4.0; logS -5.73; logP 5.59,repurposing_candidates.csv:rc_row=1104;protein_drug_candidates.csv:rows=1883;CYP3A4_results.csv:row=973;CYP2C19_results.csv:row=973;CYP2D6_results.csv:row=973;CYP1A2_results.csv:row=973;CYP2C9_results.csv:row=973;hERG_results.csv:row=973;AMES_results.csv:row=973;PGP_results.csv:row=973;PAMPA_results.csv:row=973;BBB_results.csv:row=973;Solubility_results.csv:row=973;Lipophilicity_results.csv:row=974
CHEMBL2103873,MACITENTAN,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,14.63768115942029,100,90.0,63.35507246376812,H,KG targets EDNRA; clinical phase 4.0; logS -6.27; logP 3.57,repurposing_candidates.csv:rc_row=674;protein_drug_candidates.csv:rows=1912;CYP3A4_results.csv:row=619;CYP2C19_results.csv:row=619;CYP2D6_results.csv:row=619;CYP1A2_results.csv:row=619;CYP2C9_results.csv:row=619;hERG_results.csv:row=619;AMES_results.csv:row=619;PGP_results.csv:row=619;PAMPA_results.csv:row=619;BBB_results.csv:row=619;Solubility_results.csv:row=619;Lipophilicity_results.csv:row=620
CHEMBL3544945,SAR-113945,,43.23417238749047,60,100.0,63.29366895499619,M,KG targets IKBKB; clinical phase 2.0,repurposing_candidates.csv:rc_row=957;protein_drug_candidates.csv:rows=1234;pathway_drug_candidates.csv:rows=4022;4089;4115;4118;4121;4124;4127;4130;4133;4136;4139;4142;4157;4172;4175;4178;4181;4184;4187;4197;4200;4203;4206;4221;4283;4286;4289;4318;4350;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545168,IMD-1041,,43.23417238749047,60,100.0,63.29366895499619,M,KG targets IKBKB; clinical phase 2.0,repurposing_candidates.csv:rc_row=975;protein_drug_candidates.csv:rows=1233;pathway_drug_candidates.csv:rows=4021;4088;4114;4117;4120;4123;4126;4129;4132;4135;4138;4141;4156;4171;4174;4177;4180;4183;4186;4196;4199;4202;4205;4220;4282;4285;4288;4317;4349;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201202,FONDAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,30.076277650648358,100,65.0,63.28051106025934,M,KG targets SERPINC1; clinical phase 4.0; hERG risk; logS 3.59; logP -13.75,repurposing_candidates.csv:rc_row=256;protein_drug_candidates.csv:rows=171;pathway_drug_candidates.csv:rows=143;7549;7578;7600;CYP3A4_results.csv:row=253;CYP2C19_results.csv:row=253;CYP2D6_results.csv:row=253;CYP1A2_results.csv:row=253;CYP2C9_results.csv:row=253;hERG_results.csv:row=253;AMES_results.csv:row=253;PGP_results.csv:row=253;PAMPA_results.csv:row=253;BBB_results.csv:row=253;Solubility_results.csv:row=253;Lipophilicity_results.csv:row=254
CHEMBL2095206,BOSUTINIB MONOHYDRATE,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O,29.801678108314263,100,65.0,63.17067124332571,M,"KG targets ABL1, BCR; clinical phase 4.0; hERG risk; logS -5.31; logP 4.37",repurposing_candidates.csv:rc_row=649;protein_drug_candidates.csv:rows=1203;2201;pathway_drug_candidates.csv:rows=4294;CYP3A4_results.csv:row=595;CYP2C19_results.csv:row=595;CYP2D6_results.csv:row=595;CYP1A2_results.csv:row=595;CYP2C9_results.csv:row=595;hERG_results.csv:row=595;AMES_results.csv:row=595;PGP_results.csv:row=595;PAMPA_results.csv:row=595;BBB_results.csv:row=595;Solubility_results.csv:row=595;Lipophilicity_results.csv:row=596
CHEMBL1305,ANTAZOLINE,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,28.497330282227306,80,95.0,63.148932112890925,H,KG targets HRH1; clinical phase 3.0; logS -2.83; logP 2.69,repurposing_candidates.csv:rc_row=379;protein_drug_candidates.csv:rows=1026;pathway_drug_candidates.csv:rows=6656;CYP3A4_results.csv:row=340;CYP2C19_results.csv:row=340;CYP2D6_results.csv:row=340;CYP1A2_results.csv:row=340;CYP2C9_results.csv:row=340;hERG_results.csv:row=340;AMES_results.csv:row=340;PGP_results.csv:row=340;PAMPA_results.csv:row=340;BBB_results.csv:row=340;Solubility_results.csv:row=340;Lipophilicity_results.csv:row=341
CHEMBL90,HISTAMINE,NCCc1c[nH]cn1,28.497330282227306,80,95.0,63.148932112890925,H,KG targets HRH1; clinical phase 3.0; logS 0.82; logP -0.09,repurposing_candidates.csv:rc_row=1545;protein_drug_candidates.csv:rows=1022;pathway_drug_candidates.csv:rows=6652;CYP3A4_results.csv:row=1351;CYP2C19_results.csv:row=1351;CYP2D6_results.csv:row=1351;CYP1A2_results.csv:row=1351;CYP2C9_results.csv:row=1351;hERG_results.csv:row=1351;AMES_results.csv:row=1351;PGP_results.csv:row=1351;PAMPA_results.csv:row=1351;BBB_results.csv:row=1351;Solubility_results.csv:row=1351;Lipophilicity_results.csv:row=1352
CHEMBL4297589,SELATOGREL,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1,28.497330282227306,80,95.0,63.148932112890925,H,KG targets P2RY12; clinical phase 3.0; logS -3.22; logP 1.73,repurposing_candidates.csv:rc_row=1194;protein_drug_candidates.csv:rows=473;pathway_drug_candidates.csv:rows=1358;CYP3A4_results.csv:row=1054;CYP2C19_results.csv:row=1054;CYP2D6_results.csv:row=1054;CYP1A2_results.csv:row=1054;CYP2C9_results.csv:row=1054;hERG_results.csv:row=1054;AMES_results.csv:row=1054;PGP_results.csv:row=1054;PAMPA_results.csv:row=1054;BBB_results.csv:row=1054;Solubility_results.csv:row=1054;Lipophilicity_results.csv:row=1055
CHEMBL3989677,HYDROCODONE BITARTRATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O,29.549961861174673,100,65.0,63.06998474446987,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -2.15; logP -1.84,repurposing_candidates.csv:rc_row=1077;protein_drug_candidates.csv:rows=295;pathway_drug_candidates.csv:rows=265;1299;7212;CYP3A4_results.csv:row=946;CYP2C19_results.csv:row=946;CYP2D6_results.csv:row=946;CYP1A2_results.csv:row=946;CYP2C9_results.csv:row=946;hERG_results.csv:row=946;AMES_results.csv:row=946;PGP_results.csv:row=946;PAMPA_results.csv:row=946;BBB_results.csv:row=946;Solubility_results.csv:row=946;Lipophilicity_results.csv:row=947
CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl,29.549961861174673,100,65.0,63.06998474446987,M,KG targets ADRA1A; clinical phase 4.0; hERG risk; logS -1.99; logP 2.71,repurposing_candidates.csv:rc_row=221;protein_drug_candidates.csv:rows=378;pathway_drug_candidates.csv:rows=841;6503;6703;CYP3A4_results.csv:row=219;CYP2C19_results.csv:row=219;CYP2D6_results.csv:row=219;CYP1A2_results.csv:row=219;CYP2C9_results.csv:row=219;hERG_results.csv:row=219;AMES_results.csv:row=219;PGP_results.csv:row=219;PAMPA_results.csv:row=219;BBB_results.csv:row=219;Solubility_results.csv:row=219;Lipophilicity_results.csv:row=220
CHEMBL386630,TESTOSTERONE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,29.549961861174673,100,65.0,63.06998474446987,M,KG targets AR; clinical phase 4.0; hERG risk; logS -3.67; logP 3.88,repurposing_candidates.csv:rc_row=1053;protein_drug_candidates.csv:rows=551;pathway_drug_candidates.csv:rows=1974;5889;7793;CYP3A4_results.csv:row=922;CYP2C19_results.csv:row=922;CYP2D6_results.csv:row=922;CYP1A2_results.csv:row=922;CYP2C9_results.csv:row=922;hERG_results.csv:row=922;AMES_results.csv:row=922;PGP_results.csv:row=922;PAMPA_results.csv:row=922;BBB_results.csv:row=922;Solubility_results.csv:row=922;Lipophilicity_results.csv:row=923
CHEMBL1201216,DAPIPRAZOLE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,29.549961861174673,100,65.0,63.06998474446987,M,KG targets ADRA1A; clinical phase 4.0; hERG risk; logS -2.68; logP 2.29,repurposing_candidates.csv:rc_row=259;protein_drug_candidates.csv:rows=393;pathway_drug_candidates.csv:rows=856;6518;6718;CYP3A4_results.csv:row=256;CYP2C19_results.csv:row=256;CYP2D6_results.csv:row=256;CYP1A2_results.csv:row=256;CYP2C9_results.csv:row=256;hERG_results.csv:row=256;AMES_results.csv:row=256;PGP_results.csv:row=256;PAMPA_results.csv:row=256;BBB_results.csv:row=256;Solubility_results.csv:row=256;Lipophilicity_results.csv:row=257
CHEMBL2107067,TESTOSTERONE UNDECANOATE,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,29.549961861174673,100,65.0,63.06998474446987,M,KG targets AR; clinical phase 4.0; logS -8.05; logP 7.96,repurposing_candidates.csv:rc_row=722;protein_drug_candidates.csv:rows=546;pathway_drug_candidates.csv:rows=1969;5884;7788;CYP3A4_results.csv:row=667;CYP2C19_results.csv:row=667;CYP2D6_results.csv:row=667;CYP1A2_results.csv:row=667;CYP2C9_results.csv:row=667;hERG_results.csv:row=667;AMES_results.csv:row=667;PGP_results.csv:row=667;PAMPA_results.csv:row=667;BBB_results.csv:row=667;Solubility_results.csv:row=667;Lipophilicity_results.csv:row=668
CHEMBL4297091,CODEINE SULFATE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O,29.549961861174673,100,65.0,63.06998474446987,M,KG targets OPRM1; clinical phase 4.0; hERG risk; logS -1.97; logP -0.12,repurposing_candidates.csv:rc_row=1158;protein_drug_candidates.csv:rows=296;pathway_drug_candidates.csv:rows=266;1300;7213;CYP3A4_results.csv:row=1022;CYP2C19_results.csv:row=1022;CYP2D6_results.csv:row=1022;CYP1A2_results.csv:row=1022;CYP2C9_results.csv:row=1022;hERG_results.csv:row=1022;AMES_results.csv:row=1022;PGP_results.csv:row=1022;PAMPA_results.csv:row=1022;BBB_results.csv:row=1022;Solubility_results.csv:row=1022;Lipophilicity_results.csv:row=1023
CHEMBL135400,ZOPICLONE,CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,25.072463768115938,80,100.0,63.028985507246375,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; logS -1.39; logP 1.57",repurposing_candidates.csv:rc_row=390;protein_drug_candidates.csv:rows=510;1524;1709;1750;1783;1938;2070;2116;2586;CYP3A4_results.csv:row=351;CYP2C19_results.csv:row=351;CYP2D6_results.csv:row=351;CYP1A2_results.csv:row=351;CYP2C9_results.csv:row=351;hERG_results.csv:row=351;AMES_results.csv:row=351;PGP_results.csv:row=351;PAMPA_results.csv:row=351;BBB_results.csv:row=351;Solubility_results.csv:row=351;Lipophilicity_results.csv:row=352
CHEMBL3989967,LOTAMILAST,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1,51.79633867276888,60,85.0,62.96853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -6.54; logP 4.39",repurposing_candidates.csv:rc_row=1107;protein_drug_candidates.csv:rows=427;1059;1090;2163;pathway_drug_candidates.csv:rows=4341;5749;5776;5807;5844;5874;CYP3A4_results.csv:row=976;CYP2C19_results.csv:row=976;CYP2D6_results.csv:row=976;CYP1A2_results.csv:row=976;CYP2C9_results.csv:row=976;hERG_results.csv:row=976;AMES_results.csv:row=976;PGP_results.csv:row=976;PAMPA_results.csv:row=976;BBB_results.csv:row=976;Solubility_results.csv:row=976;Lipophilicity_results.csv:row=977
CHEMBL576982,QUIZARTINIB,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,30.85430968726163,80,90.0,62.84172387490465,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -5.83; logP 5.86",repurposing_candidates.csv:rc_row=1424;protein_drug_candidates.csv:rows=1114;1157;pathway_drug_candidates.csv:rows=562;6974;7012;7508;CYP3A4_results.csv:row=1233;CYP2C19_results.csv:row=1233;CYP2D6_results.csv:row=1233;CYP1A2_results.csv:row=1233;CYP2C9_results.csv:row=1233;hERG_results.csv:row=1233;AMES_results.csv:row=1233;PGP_results.csv:row=1233;PAMPA_results.csv:row=1233;BBB_results.csv:row=1233;Solubility_results.csv:row=1233;Lipophilicity_results.csv:row=1234
CHEMBL2105705,LUNACALCIPOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,60,90.0,62.653318077803206,M,KG targets VDR; clinical phase 2.0; logS -3.75; logP 5.80,repurposing_candidates.csv:rc_row=699;protein_drug_candidates.csv:rows=252;pathway_drug_candidates.csv:rows=6005;7782;7900;CYP3A4_results.csv:row=644;CYP2C19_results.csv:row=644;CYP2D6_results.csv:row=644;CYP1A2_results.csv:row=644;CYP2C9_results.csv:row=644;hERG_results.csv:row=644;AMES_results.csv:row=644;PGP_results.csv:row=644;PAMPA_results.csv:row=644;BBB_results.csv:row=644;Solubility_results.csv:row=644;Lipophilicity_results.csv:row=645
CHEMBL1200795,CLEMASTINE FUMARATE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.90; logP 4.82,repurposing_candidates.csv:rc_row=170;protein_drug_candidates.csv:rows=956;pathway_drug_candidates.csv:rows=6586;CYP3A4_results.csv:row=168;CYP2C19_results.csv:row=168;CYP2D6_results.csv:row=168;CYP1A2_results.csv:row=168;CYP2C9_results.csv:row=168;hERG_results.csv:row=168;AMES_results.csv:row=168;PGP_results.csv:row=168;PAMPA_results.csv:row=168;BBB_results.csv:row=168;Solubility_results.csv:row=168;Lipophilicity_results.csv:row=169
CHEMBL1200809,AZELASTINE HYDROCHLORIDE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.20; logP 4.72,repurposing_candidates.csv:rc_row=175;protein_drug_candidates.csv:rows=972;pathway_drug_candidates.csv:rows=6602;CYP3A4_results.csv:row=173;CYP2C19_results.csv:row=173;CYP2D6_results.csv:row=173;CYP1A2_results.csv:row=173;CYP2C9_results.csv:row=173;hERG_results.csv:row=173;AMES_results.csv:row=173;PGP_results.csv:row=173;PAMPA_results.csv:row=173;BBB_results.csv:row=173;Solubility_results.csv:row=173;Lipophilicity_results.csv:row=174
CHEMBL639,AZELASTINE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.88; logP 4.30,repurposing_candidates.csv:rc_row=1466;protein_drug_candidates.csv:rows=971;pathway_drug_candidates.csv:rows=6601;CYP3A4_results.csv:row=1272;CYP2C19_results.csv:row=1272;CYP2D6_results.csv:row=1272;CYP1A2_results.csv:row=1272;CYP2C9_results.csv:row=1272;hERG_results.csv:row=1272;AMES_results.csv:row=1272;PGP_results.csv:row=1272;PAMPA_results.csv:row=1272;BBB_results.csv:row=1272;Solubility_results.csv:row=1272;Lipophilicity_results.csv:row=1273
CHEMBL278398,PHENINDAMINE,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.91; logP 3.92,repurposing_candidates.csv:rc_row=875;protein_drug_candidates.csv:rows=1016;pathway_drug_candidates.csv:rows=6646;CYP3A4_results.csv:row=783;CYP2C19_results.csv:row=783;CYP2D6_results.csv:row=783;CYP1A2_results.csv:row=783;CYP2C9_results.csv:row=783;hERG_results.csv:row=783;AMES_results.csv:row=783;PGP_results.csv:row=783;PAMPA_results.csv:row=783;BBB_results.csv:row=783;Solubility_results.csv:row=783;Lipophilicity_results.csv:row=784
CHEMBL594,EMEDASTINE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.04; logP 2.21,repurposing_candidates.csv:rc_row=1436;protein_drug_candidates.csv:rows=980;pathway_drug_candidates.csv:rows=6610;CYP3A4_results.csv:row=1245;CYP2C19_results.csv:row=1245;CYP2D6_results.csv:row=1245;CYP1A2_results.csv:row=1245;CYP2C9_results.csv:row=1245;hERG_results.csv:row=1245;AMES_results.csv:row=1245;PGP_results.csv:row=1245;PAMPA_results.csv:row=1245;BBB_results.csv:row=1245;Solubility_results.csv:row=1245;Lipophilicity_results.csv:row=1246
CHEMBL73451,MEQUITAZINE,c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.83; logP 4.63,repurposing_candidates.csv:rc_row=1502;protein_drug_candidates.csv:rows=1018;pathway_drug_candidates.csv:rows=6648;CYP3A4_results.csv:row=1308;CYP2C19_results.csv:row=1308;CYP2D6_results.csv:row=1308;CYP1A2_results.csv:row=1308;CYP2C9_results.csv:row=1308;hERG_results.csv:row=1308;AMES_results.csv:row=1308;PGP_results.csv:row=1308;PAMPA_results.csv:row=1308;BBB_results.csv:row=1308;Solubility_results.csv:row=1308;Lipophilicity_results.csv:row=1309
CHEMBL896,HYDROXYZINE,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -2.52; logP 3.06,repurposing_candidates.csv:rc_row=1543;protein_drug_candidates.csv:rows=976;pathway_drug_candidates.csv:rows=6606;CYP3A4_results.csv:row=1349;CYP2C19_results.csv:row=1349;CYP2D6_results.csv:row=1349;CYP1A2_results.csv:row=1349;CYP2C9_results.csv:row=1349;hERG_results.csv:row=1349;AMES_results.csv:row=1349;PGP_results.csv:row=1349;PAMPA_results.csv:row=1349;BBB_results.csv:row=1349;Solubility_results.csv:row=1349;Lipophilicity_results.csv:row=1350
CHEMBL94454,MIZOLASTINE,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.43; logP 3.41,repurposing_candidates.csv:rc_row=1561;protein_drug_candidates.csv:rows=1020;pathway_drug_candidates.csv:rows=6650;CYP3A4_results.csv:row=1367;CYP2C19_results.csv:row=1367;CYP2D6_results.csv:row=1367;CYP1A2_results.csv:row=1367;CYP2C9_results.csv:row=1367;hERG_results.csv:row=1367;AMES_results.csv:row=1367;PGP_results.csv:row=1367;PAMPA_results.csv:row=1367;BBB_results.csv:row=1367;Solubility_results.csv:row=1367;Lipophilicity_results.csv:row=1368
CHEMBL1200959,METHDILAZINE,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1,28.497330282227306,100,65.0,62.648932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.90; logP 4.24,repurposing_candidates.csv:rc_row=201;protein_drug_candidates.csv:rows=995;pathway_drug_candidates.csv:rows=6625;CYP3A4_results.csv:row=199;CYP2C19_results.csv:row=199;CYP2D6_results.csv:row=199;CYP1A2_results.csv:row=199;CYP2C9_results.csv:row=199;hERG_results.csv:row=199;AMES_results.csv:row=199;PGP_results.csv:row=199;PAMPA_results.csv:row=199;BBB_results.csv:row=199;Solubility_results.csv:row=199;Lipophilicity_results.csv:row=200
CHEMBL1668019,APLAVIROC HYDROCHLORIDE,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,48.40961098398169,80,60.0,62.36384439359268,M,KG targets CCR5; clinical phase 3.0; hERG risk; logS -5.54; logP 5.00,repurposing_candidates.csv:rc_row=501;protein_drug_candidates.csv:rows=216;pathway_drug_candidates.csv:rows=1258;4375;6757;6781;CYP3A4_results.csv:row=461;CYP2C19_results.csv:row=461;CYP2D6_results.csv:row=461;CYP1A2_results.csv:row=461;CYP2C9_results.csv:row=461;hERG_results.csv:row=461;AMES_results.csv:row=461;PGP_results.csv:row=461;PAMPA_results.csv:row=461;BBB_results.csv:row=461;Solubility_results.csv:row=461;Lipophilicity_results.csv:row=462
CHEMBL4650293,APRUTUMAB IXADOTIN,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=1304;protein_drug_candidates.csv:rows=866;1600;2035;2273;2379;2442;2750;2814;2878;pathway_drug_candidates.csv:rows=1579;1643;1707;1771;1835;1899;1963;2128;2192;2256;2320;2384;2448;2512;2576;2640;2704;2768;2832;2896;2960;3024;3094;3158;3222;3286;3350;3414;3478;3542;3606;3697;3761;3825;3889;3953;4017;4084;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3833306,VANDORTUZUMAB VEDOTIN,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=1041;protein_drug_candidates.csv:rows=868;1601;2036;2275;2380;2444;2751;2815;2879;pathway_drug_candidates.csv:rows=1581;1645;1709;1773;1837;1901;1965;2130;2194;2258;2322;2386;2450;2514;2578;2642;2706;2770;2834;2898;2962;3026;3096;3160;3224;3288;3352;3416;3480;3544;3608;3699;3763;3827;3891;3955;4019;4086;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3301585,PINATUZUMAB VEDOTIN,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=936;protein_drug_candidates.csv:rows=860;1593;2028;2267;2372;2436;2743;2807;2871;pathway_drug_candidates.csv:rows=1573;1637;1701;1765;1829;1893;1957;2122;2186;2250;2314;2378;2442;2506;2570;2634;2698;2762;2826;2890;2954;3018;3088;3152;3216;3280;3344;3408;3472;3536;3600;3691;3755;3819;3883;3947;4011;4078;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109574,ASG-5ME,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=771;protein_drug_candidates.csv:rows=864;1597;2032;2270;2375;2439;2748;2811;2874;pathway_drug_candidates.csv:rows=1577;1641;1705;1769;1833;1897;1961;2126;2190;2254;2318;2382;2446;2510;2574;2638;2702;2766;2830;2894;2958;3022;3092;3156;3220;3284;3348;3412;3476;3540;3604;3695;3759;3823;3887;3951;4015;4082;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545372,SOFITUZUMAB VEDOTIN,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=993;protein_drug_candidates.csv:rows=865;1598;2033;2272;2376;2441;2747;2812;2876;pathway_drug_candidates.csv:rows=1578;1642;1706;1770;1834;1898;1962;2127;2191;2255;2319;2383;2447;2511;2575;2639;2703;2767;2831;2895;2959;3023;3093;3157;3221;3285;3349;3413;3477;3541;3605;3696;3760;3824;3888;3952;4016;4083;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=1223;protein_drug_candidates.csv:rows=863;1596;2031;2271;2377;2440;2746;2810;2875;pathway_drug_candidates.csv:rows=1576;1640;1704;1768;1832;1896;1960;2125;2189;2253;2317;2381;2445;2509;2573;2637;2701;2765;2829;2893;2957;3021;3091;3155;3219;3283;3347;3411;3475;3539;3603;3694;3758;3822;3886;3950;4014;4081;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297935,RG-7841,,58.405797101449274,40,100.0,62.36231884057971,L,"KG targets TUBB, TUBB1; clinical phase 1.0",repurposing_candidates.csv:rc_row=1232;protein_drug_candidates.csv:rows=862;1595;2030;2269;2374;2438;2744;2808;2873;pathway_drug_candidates.csv:rows=1575;1639;1703;1767;1831;1895;1959;2124;2188;2252;2316;2380;2444;2508;2572;2636;2700;2764;2828;2892;2956;3020;3090;3154;3218;3282;3346;3410;3474;3538;3602;3693;3757;3821;3885;3949;4013;4080;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4541964,ZATOLMILAST,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,29.549961861174673,80,90.0,62.31998474446987,H,KG targets PDE4D; clinical phase 3.0; logS -4.63; logP 5.64,repurposing_candidates.csv:rc_row=1278;protein_drug_candidates.csv:rows=1086;pathway_drug_candidates.csv:rows=4337;5803;5870;CYP3A4_results.csv:row=1098;CYP2C19_results.csv:row=1098;CYP2D6_results.csv:row=1098;CYP1A2_results.csv:row=1098;CYP2C9_results.csv:row=1098;hERG_results.csv:row=1098;AMES_results.csv:row=1098;PGP_results.csv:row=1098;PAMPA_results.csv:row=1098;BBB_results.csv:row=1098;Solubility_results.csv:row=1098;Lipophilicity_results.csv:row=1099
CHEMBL2364605,CEBRANOPADOL,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12,29.549961861174673,80,90.0,62.31998474446987,H,KG targets OPRM1; clinical phase 3.0; logS -5.53; logP 5.11,repurposing_candidates.csv:rc_row=834;protein_drug_candidates.csv:rows=328;pathway_drug_candidates.csv:rows=298;1332;7245;CYP3A4_results.csv:row=743;CYP2C19_results.csv:row=743;CYP2D6_results.csv:row=743;CYP1A2_results.csv:row=743;CYP2C9_results.csv:row=743;hERG_results.csv:row=743;AMES_results.csv:row=743;PGP_results.csv:row=743;PAMPA_results.csv:row=743;BBB_results.csv:row=743;Solubility_results.csv:row=743;Lipophilicity_results.csv:row=744
CHEMBL2107729,ATACIGUAT,O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1,46.83066361556064,60,90.0,62.23226544622426,M,KG targets GUCY1B1; clinical phase 2.0; logS -7.52; logP 4.13,repurposing_candidates.csv:rc_row=732;protein_drug_candidates.csv:rows=75;pathway_drug_candidates.csv:rows=7691;CYP3A4_results.csv:row=677;CYP2C19_results.csv:row=677;CYP2D6_results.csv:row=677;CYP1A2_results.csv:row=677;CYP2C9_results.csv:row=677;hERG_results.csv:row=677;AMES_results.csv:row=677;PGP_results.csv:row=677;PAMPA_results.csv:row=677;BBB_results.csv:row=677;Solubility_results.csv:row=677;Lipophilicity_results.csv:row=678
CHEMBL4650322,RUNCACIGUAT,C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F,46.83066361556064,60,90.0,62.23226544622426,M,KG targets GUCY1B1; clinical phase 2.0; logS -4.95; logP 6.88,repurposing_candidates.csv:rc_row=1308;protein_drug_candidates.csv:rows=78;pathway_drug_candidates.csv:rows=7694;CYP3A4_results.csv:row=1122;CYP2C19_results.csv:row=1122;CYP2D6_results.csv:row=1122;CYP1A2_results.csv:row=1122;CYP2C9_results.csv:row=1122;hERG_results.csv:row=1122;AMES_results.csv:row=1122;PGP_results.csv:row=1122;PAMPA_results.csv:row=1122;BBB_results.csv:row=1122;Solubility_results.csv:row=1122;Lipophilicity_results.csv:row=1123
CHEMBL1236936,CINACIGUAT,O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,46.83066361556064,60,90.0,62.23226544622426,M,KG targets GUCY1B1; clinical phase 2.0; logS -4.56; logP 7.05,repurposing_candidates.csv:rc_row=341;protein_drug_candidates.csv:rows=76;pathway_drug_candidates.csv:rows=7692;CYP3A4_results.csv:row=304;CYP2C19_results.csv:row=304;CYP2D6_results.csv:row=304;CYP1A2_results.csv:row=304;CYP2C9_results.csv:row=304;hERG_results.csv:row=304;AMES_results.csv:row=304;PGP_results.csv:row=304;PAMPA_results.csv:row=304;BBB_results.csv:row=304;Solubility_results.csv:row=304;Lipophilicity_results.csv:row=305
CHEMBL467084,LANICEMINE,N[C@@H](Cc1ccccn1)c1ccccc1,40.53394355453852,60,100.0,62.21357742181541,M,"KG targets GRIN1, GRIN2A; clinical phase 2.0; logS -0.46; logP 2.32",repurposing_candidates.csv:rc_row=1321;protein_drug_candidates.csv:rows=728;1623;1969;2197;2621;2664;2686;pathway_drug_candidates.csv:rows=3634;6818;6845;6872;6905;7063;7090;7117;7144;CYP3A4_results.csv:row=1132;CYP2C19_results.csv:row=1132;CYP2D6_results.csv:row=1132;CYP1A2_results.csv:row=1132;CYP2C9_results.csv:row=1132;hERG_results.csv:row=1132;AMES_results.csv:row=1132;PGP_results.csv:row=1132;PAMPA_results.csv:row=1132;BBB_results.csv:row=1132;Solubility_results.csv:row=1132;Lipophilicity_results.csv:row=1133
CHEMBL3707400,INDANTADOL,,40.53394355453852,60,100.0,62.21357742181541,M,"KG targets GRIN1, GRIN2A; clinical phase 2.0",repurposing_candidates.csv:rc_row=1031;protein_drug_candidates.csv:rows=725;1622;1968;2194;2617;2661;2685;pathway_drug_candidates.csv:rows=3631;6815;6842;6869;6902;7060;7087;7114;7141;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2105395,OSPEMIFENE,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,14.63768115942029,100,85.0,62.10507246376812,H,KG targets ESR1; clinical phase 4.0; logS -5.90; logP 5.65,repurposing_candidates.csv:rc_row=688;protein_drug_candidates.csv:rows=2295;CYP3A4_results.csv:row=633;CYP2C19_results.csv:row=633;CYP2D6_results.csv:row=633;CYP1A2_results.csv:row=633;CYP2C9_results.csv:row=633;hERG_results.csv:row=633;AMES_results.csv:row=633;PGP_results.csv:row=633;PAMPA_results.csv:row=633;BBB_results.csv:row=633;Solubility_results.csv:row=633;Lipophilicity_results.csv:row=634
CHEMBL968,FLURAZEPAM,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,22.46376811594203,80,100.0,61.98550724637681,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; logS -4.44; logP 4.00",repurposing_candidates.csv:rc_row=1571;protein_drug_candidates.csv:rows=514;1440;1666;1713;2073;2119;2477;CYP3A4_results.csv:row=1377;CYP2C19_results.csv:row=1377;CYP2D6_results.csv:row=1377;CYP1A2_results.csv:row=1377;CYP2C9_results.csv:row=1377;hERG_results.csv:row=1377;AMES_results.csv:row=1377;PGP_results.csv:row=1377;PAMPA_results.csv:row=1377;BBB_results.csv:row=1377;Solubility_results.csv:row=1377;Lipophilicity_results.csv:row=1378
CHEMBL4297526,REMIMAZOLAM,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,22.46376811594203,80,100.0,61.98550724637681,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; logS -3.54; logP 4.18",repurposing_candidates.csv:rc_row=1189;protein_drug_candidates.csv:rows=506;1435;1659;1705;2067;2113;2473;CYP3A4_results.csv:row=1052;CYP2C19_results.csv:row=1052;CYP2D6_results.csv:row=1052;CYP1A2_results.csv:row=1052;CYP2C9_results.csv:row=1052;hERG_results.csv:row=1052;AMES_results.csv:row=1052;PGP_results.csv:row=1052;PAMPA_results.csv:row=1052;BBB_results.csv:row=1052;Solubility_results.csv:row=1052;Lipophilicity_results.csv:row=1053
CHEMBL1944698,ZOTIRACICLIB,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,57.35697940503432,40,100.0,61.94279176201373,L,KG targets JAK2; clinical phase 1.0; logS -3.14; logP 4.66,repurposing_candidates.csv:rc_row=606;protein_drug_candidates.csv:rows=798;pathway_drug_candidates.csv:rows=223;685;4595;4674;4753;4860;4929;4995;5061;5105;5171;5337;5403;6950;7484;8313;8341;8369;8403;8431;8459;CYP3A4_results.csv:row=552;CYP2C19_results.csv:row=552;CYP2D6_results.csv:row=552;CYP1A2_results.csv:row=552;CYP2C9_results.csv:row=552;hERG_results.csv:row=552;AMES_results.csv:row=552;PGP_results.csv:row=552;PAMPA_results.csv:row=552;BBB_results.csv:row=552;Solubility_results.csv:row=552;Lipophilicity_results.csv:row=553
CHEMBL3545215,BMS-911543,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,57.35697940503432,40,100.0,61.94279176201373,L,KG targets JAK2; clinical phase 1.0; logS -1.90; logP 3.50,repurposing_candidates.csv:rc_row=980;protein_drug_candidates.csv:rows=804;pathway_drug_candidates.csv:rows=229;691;4601;4680;4759;4866;4935;5001;5067;5111;5177;5343;5409;6956;7490;8319;8347;8375;8409;8437;8465;CYP3A4_results.csv:row=876;CYP2C19_results.csv:row=876;CYP2D6_results.csv:row=876;CYP1A2_results.csv:row=876;CYP2C9_results.csv:row=876;hERG_results.csv:row=876;AMES_results.csv:row=876;PGP_results.csv:row=876;PAMPA_results.csv:row=876;BBB_results.csv:row=876;Solubility_results.csv:row=876;Lipophilicity_results.csv:row=877
CHEMBL1231124,AZD-1480,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,57.35697940503432,40,100.0,61.94279176201373,L,KG targets JAK2; clinical phase 1.0; logS -3.48; logP 3.01,repurposing_candidates.csv:rc_row=340;protein_drug_candidates.csv:rows=799;pathway_drug_candidates.csv:rows=224;686;4596;4675;4754;4861;4930;4996;5062;5106;5172;5338;5404;6951;7485;8314;8342;8370;8404;8432;8460;CYP3A4_results.csv:row=303;CYP2C19_results.csv:row=303;CYP2D6_results.csv:row=303;CYP1A2_results.csv:row=303;CYP2C9_results.csv:row=303;hERG_results.csv:row=303;AMES_results.csv:row=303;PGP_results.csv:row=303;PAMPA_results.csv:row=303;BBB_results.csv:row=303;Solubility_results.csv:row=303;Lipophilicity_results.csv:row=304
CHEMBL3545328,XL-019,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,57.35697940503432,40,100.0,61.94279176201373,L,KG targets JAK2; clinical phase 1.0; logS -3.67; logP 3.41,repurposing_candidates.csv:rc_row=989;protein_drug_candidates.csv:rows=800;pathway_drug_candidates.csv:rows=225;687;4597;4676;4755;4862;4931;4997;5063;5107;5173;5339;5405;6952;7486;8315;8343;8371;8405;8433;8461;CYP3A4_results.csv:row=881;CYP2C19_results.csv:row=881;CYP2D6_results.csv:row=881;CYP1A2_results.csv:row=881;CYP2C9_results.csv:row=881;hERG_results.csv:row=881;AMES_results.csv:row=881;PGP_results.csv:row=881;PAMPA_results.csv:row=881;BBB_results.csv:row=881;Solubility_results.csv:row=881;Lipophilicity_results.csv:row=882
CHEMBL2110727,CENICRIVIROC,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,49.713958810068654,95,35.0,61.88558352402747,L,"KG targets CCR2, CCR5; clinical phase 3.0; hERG risk; logS -8.03; logP 8.74",repurposing_candidates.csv:rc_row=780;protein_drug_candidates.csv:rows=218;228;pathway_drug_candidates.csv:rows=1246;1260;4363;4377;6759;6769;6783;CYP3A4_results.csv:row=689;CYP2C19_results.csv:row=689;CYP2D6_results.csv:row=689;CYP1A2_results.csv:row=689;CYP2C9_results.csv:row=689;hERG_results.csv:row=689;AMES_results.csv:row=689;PGP_results.csv:row=689;PAMPA_results.csv:row=689;BBB_results.csv:row=689;Solubility_results.csv:row=689;Lipophilicity_results.csv:row=690
CHEMBL4297520,OGLEMILAST,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,51.79633867276888,60,80.0,61.71853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; logS -6.13; logP 5.51",repurposing_candidates.csv:rc_row=1186;protein_drug_candidates.csv:rows=428;1060;1088;2164;pathway_drug_candidates.csv:rows=4339;5750;5777;5805;5845;5872;CYP3A4_results.csv:row=1049;CYP2C19_results.csv:row=1049;CYP2D6_results.csv:row=1049;CYP1A2_results.csv:row=1049;CYP2C9_results.csv:row=1049;hERG_results.csv:row=1049;AMES_results.csv:row=1049;PGP_results.csv:row=1049;PAMPA_results.csv:row=1049;BBB_results.csv:row=1049;Solubility_results.csv:row=1049;Lipophilicity_results.csv:row=1050
CHEMBL3301600,SPEBRUTINIB BESYLATE,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1,48.40961098398169,60,85.0,61.61384439359268,M,KG targets BTK; clinical phase 2.0; logS -1.87; logP 5.19,repurposing_candidates.csv:rc_row=939;protein_drug_candidates.csv:rows=205;pathway_drug_candidates.csv:rows=611;4106;6568;6748;CYP3A4_results.csv:row=843;CYP2C19_results.csv:row=843;CYP2D6_results.csv:row=843;CYP1A2_results.csv:row=843;CYP2C9_results.csv:row=843;hERG_results.csv:row=843;AMES_results.csv:row=843;PGP_results.csv:row=843;PAMPA_results.csv:row=843;BBB_results.csv:row=843;Solubility_results.csv:row=843;Lipophilicity_results.csv:row=844
CHEMBL4650333,SERALUTINIB,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC,30.85430968726163,80,85.0,61.59172387490465,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -3.85; logP 5.29",repurposing_candidates.csv:rc_row=1310;protein_drug_candidates.csv:rows=1123;1164;pathway_drug_candidates.csv:rows=569;6981;7021;7515;CYP3A4_results.csv:row=1124;CYP2C19_results.csv:row=1124;CYP2D6_results.csv:row=1124;CYP1A2_results.csv:row=1124;CYP2C9_results.csv:row=1124;hERG_results.csv:row=1124;AMES_results.csv:row=1124;PGP_results.csv:row=1124;PAMPA_results.csv:row=1124;BBB_results.csv:row=1124;Solubility_results.csv:row=1124;Lipophilicity_results.csv:row=1125
CHEMBL605525,DP001,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O,47.88329519450801,60,85.0,61.403318077803206,M,KG targets VDR; clinical phase 2.0; logS -3.71; logP 5.70,repurposing_candidates.csv:rc_row=1443;protein_drug_candidates.csv:rows=253;pathway_drug_candidates.csv:rows=6006;7783;7901;CYP3A4_results.csv:row=1252;CYP2C19_results.csv:row=1252;CYP2D6_results.csv:row=1252;CYP1A2_results.csv:row=1252;CYP2C9_results.csv:row=1252;hERG_results.csv:row=1252;AMES_results.csv:row=1252;PGP_results.csv:row=1252;PAMPA_results.csv:row=1252;BBB_results.csv:row=1252;Solubility_results.csv:row=1252;Lipophilicity_results.csv:row=1253
CHEMBL914,FEXOFENADINE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -5.13; logP 5.51,repurposing_candidates.csv:rc_row=1552;protein_drug_candidates.csv:rows=1011;pathway_drug_candidates.csv:rows=6641;CYP3A4_results.csv:row=1358;CYP2C19_results.csv:row=1358;CYP2D6_results.csv:row=1358;CYP1A2_results.csv:row=1358;CYP2C9_results.csv:row=1358;hERG_results.csv:row=1358;AMES_results.csv:row=1358;PGP_results.csv:row=1358;PAMPA_results.csv:row=1358;BBB_results.csv:row=1358;Solubility_results.csv:row=1358;Lipophilicity_results.csv:row=1359
CHEMBL4459585,ROPSACITINIB,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1,38.49733028222731,60,100.0,61.398932112890925,M,KG targets TYK2; clinical phase 2.0; logS -1.61; logP 2.54,repurposing_candidates.csv:rc_row=1266;protein_drug_candidates.csv:rows=1196;pathway_drug_candidates.csv:rows=414;793;4278;4532;4615;4694;4773;4814;4880;4949;5015;5081;5125;5191;5241;5291;5357;5423;5439;5489;CYP3A4_results.csv:row=1086;CYP2C19_results.csv:row=1086;CYP2D6_results.csv:row=1086;CYP1A2_results.csv:row=1086;CYP2C9_results.csv:row=1086;hERG_results.csv:row=1086;AMES_results.csv:row=1086;PGP_results.csv:row=1086;PAMPA_results.csv:row=1086;BBB_results.csv:row=1086;Solubility_results.csv:row=1086;Lipophilicity_results.csv:row=1087
CHEMBL3989555,MECLIZINE HYDROCHLORIDE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.91; logP 5.57,repurposing_candidates.csv:rc_row=1072;protein_drug_candidates.csv:rows=981;pathway_drug_candidates.csv:rows=6611;CYP3A4_results.csv:row=941;CYP2C19_results.csv:row=941;CYP2D6_results.csv:row=941;CYP1A2_results.csv:row=941;CYP2C9_results.csv:row=941;hERG_results.csv:row=941;AMES_results.csv:row=941;PGP_results.csv:row=941;PAMPA_results.csv:row=941;BBB_results.csv:row=941;Solubility_results.csv:row=941;Lipophilicity_results.csv:row=942
CHEMBL1623,MECLIZINE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.43; logP 5.56,repurposing_candidates.csv:rc_row=483;protein_drug_candidates.csv:rows=1004;pathway_drug_candidates.csv:rows=6634;CYP3A4_results.csv:row=443;CYP2C19_results.csv:row=443;CYP2D6_results.csv:row=443;CYP1A2_results.csv:row=443;CYP2C9_results.csv:row=443;hERG_results.csv:row=443;AMES_results.csv:row=443;PGP_results.csv:row=443;PAMPA_results.csv:row=443;BBB_results.csv:row=443;Solubility_results.csv:row=443;Lipophilicity_results.csv:row=444
CHEMBL1200618,FEXOFENADINE HYDROCHLORIDE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.43; logP 5.93,repurposing_candidates.csv:rc_row=136;protein_drug_candidates.csv:rows=955;pathway_drug_candidates.csv:rows=6585;CYP3A4_results.csv:row=135;CYP2C19_results.csv:row=135;CYP2D6_results.csv:row=135;CYP1A2_results.csv:row=135;CYP2C9_results.csv:row=135;hERG_results.csv:row=135;AMES_results.csv:row=135;PGP_results.csv:row=135;PAMPA_results.csv:row=135;BBB_results.csv:row=135;Solubility_results.csv:row=135;Lipophilicity_results.csv:row=135
CHEMBL1200467,HYDROXYZINE PAMOATE,O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.37; logP 7.45,repurposing_candidates.csv:rc_row=106;protein_drug_candidates.csv:rows=952;pathway_drug_candidates.csv:rows=6582;CYP3A4_results.csv:row=105;CYP2C19_results.csv:row=105;CYP2D6_results.csv:row=105;CYP1A2_results.csv:row=105;CYP2C9_results.csv:row=105;hERG_results.csv:row=105;AMES_results.csv:row=105;PGP_results.csv:row=105;PAMPA_results.csv:row=105;BBB_results.csv:row=105;Solubility_results.csv:row=105;Lipophilicity_results.csv:row=105
CHEMBL1201759,BEPOTASTINE BESYLATE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1,28.497330282227306,100,60.0,61.398932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -0.11; logP 5.10,repurposing_candidates.csv:rc_row=312;protein_drug_candidates.csv:rows=973;pathway_drug_candidates.csv:rows=6603;CYP3A4_results.csv:row=281;CYP2C19_results.csv:row=281;CYP2D6_results.csv:row=281;CYP1A2_results.csv:row=281;CYP2C9_results.csv:row=281;hERG_results.csv:row=281;AMES_results.csv:row=281;PGP_results.csv:row=281;PAMPA_results.csv:row=281;BBB_results.csv:row=281;Solubility_results.csv:row=281;Lipophilicity_results.csv:row=282
CHEMBL3113974,TRANIMILAST,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1,51.79633867276888,80,50.0,61.21853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 3.0; hERG risk; logS -6.80; logP 6.32",repurposing_candidates.csv:rc_row=902;protein_drug_candidates.csv:rows=421;1052;1081;2157;pathway_drug_candidates.csv:rows=4332;5743;5769;5798;5838;5865;CYP3A4_results.csv:row=809;CYP2C19_results.csv:row=809;CYP2D6_results.csv:row=809;CYP1A2_results.csv:row=809;CYP2C9_results.csv:row=809;hERG_results.csv:row=809;AMES_results.csv:row=809;PGP_results.csv:row=809;PAMPA_results.csv:row=809;BBB_results.csv:row=809;Solubility_results.csv:row=809;Lipophilicity_results.csv:row=810
CHEMBL3545225,INCB-047986,,37.971014492753625,60,100.0,61.18840579710145,M,KG targets JAK1; clinical phase 2.0,repurposing_candidates.csv:rc_row=982;protein_drug_candidates.csv:rows=774;pathway_drug_candidates.csv:rows=199;661;4251;4430;4571;4650;4729;4798;4836;4905;4971;5037;5147;5225;5275;5313;5379;5473;6926;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297524,RADOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,29.801678108314263,80,85.0,61.17067124332571,H,"KG targets ABL1, BCR; clinical phase 3.0; logS -3.31; logP 5.75",repurposing_candidates.csv:rc_row=1188;protein_drug_candidates.csv:rows=1216;2210;pathway_drug_candidates.csv:rows=4307;CYP3A4_results.csv:row=1051;CYP2C19_results.csv:row=1051;CYP2D6_results.csv:row=1051;CYP1A2_results.csv:row=1051;CYP2C9_results.csv:row=1051;hERG_results.csv:row=1051;AMES_results.csv:row=1051;PGP_results.csv:row=1051;PAMPA_results.csv:row=1051;BBB_results.csv:row=1051;Solubility_results.csv:row=1051;Lipophilicity_results.csv:row=1052
CHEMBL255863,NILOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,29.801678108314263,80,85.0,61.17067124332571,H,"KG targets ABL1, BCR; clinical phase 3.0; logS -3.52; logP 6.36",repurposing_candidates.csv:rc_row=858;protein_drug_candidates.csv:rows=1214;2208;pathway_drug_candidates.csv:rows=4305;CYP3A4_results.csv:row=766;CYP2C19_results.csv:row=766;CYP2D6_results.csv:row=766;CYP1A2_results.csv:row=766;CYP2C9_results.csv:row=766;hERG_results.csv:row=766;AMES_results.csv:row=766;PGP_results.csv:row=766;PAMPA_results.csv:row=766;BBB_results.csv:row=766;Solubility_results.csv:row=766;Lipophilicity_results.csv:row=767
CHEMBL1040,CALCIFEDIOL ANHYDROUS,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12,29.549961861174673,80,85.0,61.06998474446987,H,KG targets VDR; clinical phase 3.0; logS -4.52; logP 6.73,repurposing_candidates.csv:rc_row=14;protein_drug_candidates.csv:rows=246;pathway_drug_candidates.csv:rows=5999;7776;7894;CYP3A4_results.csv:row=14;CYP2C19_results.csv:row=14;CYP2D6_results.csv:row=14;CYP1A2_results.csv:row=14;CYP2C9_results.csv:row=14;hERG_results.csv:row=14;AMES_results.csv:row=14;PGP_results.csv:row=14;PAMPA_results.csv:row=14;BBB_results.csv:row=14;Solubility_results.csv:row=14;Lipophilicity_results.csv:row=14
CHEMBL3989872,APIMOSTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O,40.53394355453852,60,95.0,60.96357742181541,M,"KG targets GRIN1, GRIN2A; clinical phase 2.0; logS -0.94; logP -1.36",repurposing_candidates.csv:rc_row=1098;protein_drug_candidates.csv:rows=727;1624;1970;2196;2620;2663;2687;pathway_drug_candidates.csv:rows=3633;6817;6844;6871;6904;7062;7089;7116;7143;CYP3A4_results.csv:row=967;CYP2C19_results.csv:row=967;CYP2D6_results.csv:row=967;CYP1A2_results.csv:row=967;CYP2C9_results.csv:row=967;hERG_results.csv:row=967;AMES_results.csv:row=967;PGP_results.csv:row=967;PAMPA_results.csv:row=967;BBB_results.csv:row=967;Solubility_results.csv:row=967;Lipophilicity_results.csv:row=968
CHEMBL2108752,PEGAPTANIB OCTASODIUM,,19.90083905415713,80,100.0,60.96033562166285,H,KG targets VEGFA; clinical phase 3.0,repurposing_candidates.csv:rc_row=757;pathway_drug_candidates.csv:rows=427;471;483;495;507;519;531;543;593;806;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108313,CONBERCEPT,,19.90083905415713,80,100.0,60.96033562166285,H,KG targets VEGFA; clinical phase 3.0,repurposing_candidates.csv:rc_row=748;pathway_drug_candidates.csv:rows=424;468;480;492;504;516;528;540;590;803;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297163,MUPARFOSTAT,,19.90083905415713,80,100.0,60.96033562166285,H,KG targets VEGFA; clinical phase 3.0,repurposing_candidates.csv:rc_row=1160;pathway_drug_candidates.csv:rows=423;467;479;491;503;515;527;539;589;802;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297684,ABICIPAR PEGOL,,19.90083905415713,80,100.0,60.96033562166285,H,KG targets VEGFA; clinical phase 3.0,repurposing_candidates.csv:rc_row=1207;pathway_drug_candidates.csv:rows=426;470;482;494;506;518;530;542;592;805;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL49642,INDIBULIN,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,76.73913043478261,40,65.0,60.94565217391305,L,"KG targets TUBB, TUBB1; clinical phase 1.0; hERG risk; logS -4.40; logP 4.56",repurposing_candidates.csv:rc_row=1343;protein_drug_candidates.csv:rows=861;1594;2029;2268;2373;2437;2745;2809;2872;pathway_drug_candidates.csv:rows=1574;1638;1702;1766;1830;1894;1958;2123;2187;2251;2315;2379;2443;2507;2571;2635;2699;2763;2827;2891;2955;3019;3089;3153;3217;3281;3345;3409;3473;3537;3601;3692;3756;3820;3884;3948;4012;4079;CYP3A4_results.csv:row=1154;CYP2C19_results.csv:row=1154;CYP2D6_results.csv:row=1154;CYP1A2_results.csv:row=1154;CYP2C9_results.csv:row=1154;hERG_results.csv:row=1154;AMES_results.csv:row=1154;PGP_results.csv:row=1154;PAMPA_results.csv:row=1154;BBB_results.csv:row=1154;Solubility_results.csv:row=1154;Lipophilicity_results.csv:row=1155
CHEMBL21333,PRANLUKAST,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1,29.02364607170099,80,85.0,60.8594584286804,H,KG targets CYSLTR1; clinical phase 3.0; logS -6.05; logP 4.63,repurposing_candidates.csv:rc_row=787;protein_drug_candidates.csv:rows=1231;pathway_drug_candidates.csv:rows=621;6578;CYP3A4_results.csv:row=696;CYP2C19_results.csv:row=696;CYP2D6_results.csv:row=696;CYP1A2_results.csv:row=696;CYP2C9_results.csv:row=696;hERG_results.csv:row=696;AMES_results.csv:row=696;PGP_results.csv:row=696;PAMPA_results.csv:row=696;BBB_results.csv:row=696;Solubility_results.csv:row=696;Lipophilicity_results.csv:row=697
CHEMBL3545241,AC-430,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,57.35697940503432,40,95.0,60.69279176201373,L,KG targets JAK2; clinical phase 1.0; logS -3.65; logP 3.63,repurposing_candidates.csv:rc_row=984;protein_drug_candidates.csv:rows=801;pathway_drug_candidates.csv:rows=226;688;4598;4677;4756;4863;4932;4998;5064;5108;5174;5340;5406;6953;7487;8316;8344;8372;8406;8434;8462;CYP3A4_results.csv:row=878;CYP2C19_results.csv:row=878;CYP2D6_results.csv:row=878;CYP1A2_results.csv:row=878;CYP2C9_results.csv:row=878;hERG_results.csv:row=878;AMES_results.csv:row=878;PGP_results.csv:row=878;PAMPA_results.csv:row=878;BBB_results.csv:row=878;Solubility_results.csv:row=878;Lipophilicity_results.csv:row=879
CHEMBL4303389,NS-018,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,57.35697940503432,40,95.0,60.69279176201373,L,KG targets JAK2; clinical phase 1.0; logS -2.84; logP 4.33,repurposing_candidates.csv:rc_row=1251;protein_drug_candidates.csv:rows=802;pathway_drug_candidates.csv:rows=227;689;4599;4678;4757;4864;4933;4999;5065;5109;5175;5341;5407;6954;7488;8317;8345;8373;8407;8435;8463;CYP3A4_results.csv:row=1071;CYP2C19_results.csv:row=1071;CYP2D6_results.csv:row=1071;CYP1A2_results.csv:row=1071;CYP2C9_results.csv:row=1071;hERG_results.csv:row=1071;AMES_results.csv:row=1071;PGP_results.csv:row=1071;PAMPA_results.csv:row=1071;BBB_results.csv:row=1071;Solubility_results.csv:row=1071;Lipophilicity_results.csv:row=1072
CHEMBL3545413,FLUMATINIB,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,28.497330282227306,80,85.0,60.648932112890925,H,KG targets ABL1; clinical phase 3.0; logS -0.79; logP 5.00,repurposing_candidates.csv:rc_row=997;protein_drug_candidates.csv:rows=1212;pathway_drug_candidates.csv:rows=4303;CYP3A4_results.csv:row=885;CYP2C19_results.csv:row=885;CYP2D6_results.csv:row=885;CYP1A2_results.csv:row=885;CYP2C9_results.csv:row=885;hERG_results.csv:row=885;AMES_results.csv:row=885;PGP_results.csv:row=885;PAMPA_results.csv:row=885;BBB_results.csv:row=885;Solubility_results.csv:row=885;Lipophilicity_results.csv:row=886
CHEMBL91397,RUPATADINE,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,28.497330282227306,80,85.0,60.648932112890925,H,KG targets HRH1; clinical phase 3.0; logS -3.62; logP 5.63,repurposing_candidates.csv:rc_row=1551;protein_drug_candidates.csv:rows=1024;pathway_drug_candidates.csv:rows=6654;CYP3A4_results.csv:row=1357;CYP2C19_results.csv:row=1357;CYP2D6_results.csv:row=1357;CYP1A2_results.csv:row=1357;CYP2C9_results.csv:row=1357;hERG_results.csv:row=1357;AMES_results.csv:row=1357;PGP_results.csv:row=1357;PAMPA_results.csv:row=1357;BBB_results.csv:row=1357;Solubility_results.csv:row=1357;Lipophilicity_results.csv:row=1358
CHEMBL4297572,ABBV-3373,,36.117467581998476,60,100.0,60.44698703279939,M,"KG targets NR3C1, TNF; clinical phase 2.0",repurposing_candidates.csv:rc_row=1193;protein_drug_candidates.csv:rows=60;88;pathway_drug_candidates.csv:rows=397;752;2061;4151;4166;4515;5976;7880;8017;8083;8154;8220;8286;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1289494,TIVOZANIB,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,30.85430968726163,80,80.0,60.34172387490465,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -6.16; logP 5.64",repurposing_candidates.csv:rc_row=376;protein_drug_candidates.csv:rows=1119;1161;pathway_drug_candidates.csv:rows=566;6978;7017;7512;CYP3A4_results.csv:row=337;CYP2C19_results.csv:row=337;CYP2D6_results.csv:row=337;CYP1A2_results.csv:row=337;CYP2C9_results.csv:row=337;hERG_results.csv:row=337;AMES_results.csv:row=337;PGP_results.csv:row=337;PAMPA_results.csv:row=337;BBB_results.csv:row=337;Solubility_results.csv:row=337;Lipophilicity_results.csv:row=338
CHEMBL1336,SORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,30.85430968726163,80,80.0,60.34172387490465,H,"KG targets KIT, PDGFRB; clinical phase 3.0; logS -6.43; logP 5.55",repurposing_candidates.csv:rc_row=384;protein_drug_candidates.csv:rows=1109;1154;pathway_drug_candidates.csv:rows=559;6971;7007;7505;CYP3A4_results.csv:row=345;CYP2C19_results.csv:row=345;CYP2D6_results.csv:row=345;CYP1A2_results.csv:row=345;CYP2C9_results.csv:row=345;hERG_results.csv:row=345;AMES_results.csv:row=345;PGP_results.csv:row=345;PAMPA_results.csv:row=345;BBB_results.csv:row=345;Solubility_results.csv:row=345;Lipophilicity_results.csv:row=346
CHEMBL1743071,SIRUKUMAB,,18.321891685736077,80,100.0,60.32875667429443,H,KG targets IL6; clinical phase 3.0,repurposing_candidates.csv:rc_row=554;pathway_drug_candidates.csv:rows=118;168;4404;4540;4619;4698;7588;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743026,GEVOKIZUMAB,,18.321891685736077,80,100.0,60.32875667429443,H,KG targets IL1B; clinical phase 3.0,repurposing_candidates.csv:rc_row=544;pathway_drug_candidates.csv:rows=165;4190;4353;4357;4361;4398;4537;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4594518,LUTIKIZUMAB,,18.321891685736077,80,100.0,60.32875667429443,H,KG targets IL1B; clinical phase 3.0,repurposing_candidates.csv:rc_row=1298;pathway_drug_candidates.csv:rows=166;4191;4354;4358;4362;4399;4538;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2179529,AZD1446,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,54.18764302059497,60,70.0,60.17505720823799,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0; hERG risk; logS -2.02; logP 1.22",repurposing_candidates.csv:rc_row=800;protein_drug_candidates.csv:rows=446;2142;pathway_drug_candidates.csv:rows=7926;7940;7954;CYP3A4_results.csv:row=709;CYP2C19_results.csv:row=709;CYP2D6_results.csv:row=709;CYP1A2_results.csv:row=709;CYP2C9_results.csv:row=709;hERG_results.csv:row=709;AMES_results.csv:row=709;PGP_results.csv:row=709;PAMPA_results.csv:row=709;BBB_results.csv:row=709;Solubility_results.csv:row=709;Lipophilicity_results.csv:row=710
CHEMBL238465,SOFINICLINE,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl,54.18764302059497,60,70.0,60.17505720823799,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0; hERG risk; logS -4.01; logP 1.80",repurposing_candidates.csv:rc_row=846;protein_drug_candidates.csv:rows=442;2138;pathway_drug_candidates.csv:rows=7922;7936;7950;CYP3A4_results.csv:row=754;CYP2C19_results.csv:row=754;CYP2D6_results.csv:row=754;CYP1A2_results.csv:row=754;CYP2C9_results.csv:row=754;hERG_results.csv:row=754;AMES_results.csv:row=754;PGP_results.csv:row=754;PAMPA_results.csv:row=754;BBB_results.csv:row=754;Solubility_results.csv:row=754;Lipophilicity_results.csv:row=755
CHEMBL296419,ASTEMIZOLE,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,28.497330282227306,100,55.0,60.148932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -5.72; logP 5.35,repurposing_candidates.csv:rc_row=885;protein_drug_candidates.csv:rows=1005;pathway_drug_candidates.csv:rows=6635;CYP3A4_results.csv:row=793;CYP2C19_results.csv:row=793;CYP2D6_results.csv:row=793;CYP1A2_results.csv:row=793;CYP2C9_results.csv:row=793;hERG_results.csv:row=793;AMES_results.csv:row=793;PGP_results.csv:row=793;PAMPA_results.csv:row=793;BBB_results.csv:row=793;Solubility_results.csv:row=793;Lipophilicity_results.csv:row=794
CHEMBL1626,CLEMASTINE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,28.497330282227306,100,55.0,60.148932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -3.38; logP 5.10,repurposing_candidates.csv:rc_row=484;protein_drug_candidates.csv:rows=992;pathway_drug_candidates.csv:rows=6622;CYP3A4_results.csv:row=444;CYP2C19_results.csv:row=444;CYP2D6_results.csv:row=444;CYP1A2_results.csv:row=444;CYP2C9_results.csv:row=444;hERG_results.csv:row=444;AMES_results.csv:row=444;PGP_results.csv:row=444;PAMPA_results.csv:row=444;BBB_results.csv:row=444;Solubility_results.csv:row=444;Lipophilicity_results.csv:row=445
CHEMBL43064,CINNARIZINE,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,28.497330282227306,100,55.0,60.148932112890925,M,KG targets HRH1; clinical phase 4.0; hERG risk; logS -4.55; logP 5.11,repurposing_candidates.csv:rc_row=1253;protein_drug_candidates.csv:rows=994;pathway_drug_candidates.csv:rows=6624;CYP3A4_results.csv:row=1073;CYP2C19_results.csv:row=1073;CYP2D6_results.csv:row=1073;CYP1A2_results.csv:row=1073;CYP2C9_results.csv:row=1073;hERG_results.csv:row=1073;AMES_results.csv:row=1073;PGP_results.csv:row=1073;PAMPA_results.csv:row=1073;BBB_results.csv:row=1073;Solubility_results.csv:row=1073;Lipophilicity_results.csv:row=1074
CHEMBL4297995,BAZLITORAN,,35.064836003051106,60,100.0,60.02593440122044,M,"KG targets TLR7, TLR9; clinical phase 2.0",repurposing_candidates.csv:rc_row=1237;protein_drug_candidates.csv:rows=263;604;pathway_drug_candidates.csv:rows=764;777;4260;7326;7339;7348;7359;7370;7381;7394;7403;7416;7425;7438;7447;7458;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297928,NOMACOPAN,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=1231;pathway_drug_candidates.csv:rows=1242;7179;7740;7752;7764;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109636,VILOBELIMAB,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=776;pathway_drug_candidates.csv:rows=1243;7180;7741;7753;7765;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297722,CEMDISIRAN,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=1210;pathway_drug_candidates.csv:rows=1241;7178;7739;7751;7763;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2107842,ALBINTERFERON ALFA-2B,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets IFNAR1; clinical phase 3.0,repurposing_candidates.csv:rc_row=741;pathway_drug_candidates.csv:rows=632;4217;5204;5254;5452;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2107979,PEXELIZUMAB,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=743;pathway_drug_candidates.csv:rows=1238;7175;7736;7748;7760;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4594316,CROVALIMAB,,17.26926010678871,80,100.0,59.90770404271549,H,KG targets C5; clinical phase 3.0,repurposing_candidates.csv:rc_row=1291;pathway_drug_candidates.csv:rows=1240;7177;7738;7750;7762;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL441,THIOPENTAL,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,17.246376811594203,80,100.0,59.89855072463768,H,"KG targets GABRB1, GABRB2; clinical phase 3.0; logS -3.73; logP 1.35",repurposing_candidates.csv:rc_row=1260;protein_drug_candidates.csv:rows=1527;1754;2588;CYP3A4_results.csv:row=1080;CYP2C19_results.csv:row=1080;CYP2D6_results.csv:row=1080;CYP1A2_results.csv:row=1080;CYP2C9_results.csv:row=1080;hERG_results.csv:row=1080;AMES_results.csv:row=1080;PGP_results.csv:row=1080;PAMPA_results.csv:row=1080;BBB_results.csv:row=1080;Solubility_results.csv:row=1080;Lipophilicity_results.csv:row=1081
CHEMBL425,OLSALAZINE,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,34.53852021357742,60,100.0,59.81540808543097,M,"KG targets PTGS1, PTGS2; clinical phase 2.0; logS -4.17; logP 2.91",repurposing_candidates.csv:rc_row=1151;protein_drug_candidates.csv:rows=162;939;pathway_drug_candidates.csv:rows=385;4503;5579;5639;5712;6096;6170;6244;6318;6392;6466;CYP3A4_results.csv:row=1015;CYP2C19_results.csv:row=1015;CYP2D6_results.csv:row=1015;CYP1A2_results.csv:row=1015;CYP2C9_results.csv:row=1015;hERG_results.csv:row=1015;AMES_results.csv:row=1015;PGP_results.csv:row=1015;PAMPA_results.csv:row=1015;BBB_results.csv:row=1015;Solubility_results.csv:row=1015;Lipophilicity_results.csv:row=1016
CHEMBL2110581,BEVASIRANIB,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O,19.90083905415713,80,95.0,59.71033562166285,H,KG targets VEGFA; clinical phase 3.0; logS -0.83; logP -25.64,repurposing_candidates.csv:rc_row=778;pathway_drug_candidates.csv:rows=425;469;481;493;505;517;529;541;591;804;CYP3A4_results.csv:row=687;CYP2C19_results.csv:row=687;CYP2D6_results.csv:row=687;CYP1A2_results.csv:row=687;CYP2C9_results.csv:row=687;hERG_results.csv:row=687;AMES_results.csv:row=687;PGP_results.csv:row=687;PAMPA_results.csv:row=687;BBB_results.csv:row=687;Solubility_results.csv:row=687;Lipophilicity_results.csv:row=688
CHEMBL3647536,DARIGABAT,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,34.20289855072463,60,100.0,59.68115942028985,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; logS -4.94; logP 4.12",repurposing_candidates.csv:rc_row=1008;protein_drug_candidates.csv:rows=520;1443;1530;1668;1718;1757;1787;1806;1879;1942;2075;2122;2483;2565;2592;2636;CYP3A4_results.csv:row=894;CYP2C19_results.csv:row=894;CYP2D6_results.csv:row=894;CYP1A2_results.csv:row=894;CYP2C9_results.csv:row=894;hERG_results.csv:row=894;AMES_results.csv:row=894;PGP_results.csv:row=894;PAMPA_results.csv:row=894;BBB_results.csv:row=894;Solubility_results.csv:row=894;Lipophilicity_results.csv:row=895
CHEMBL1511,ESTRADIOL VALERATE,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,14.63768115942029,100,75.0,59.60507246376812,H,KG targets ESR1; clinical phase 4.0; logS -6.42; logP 5.35,repurposing_candidates.csv:rc_row=440;protein_drug_candidates.csv:rows=2289;CYP3A4_results.csv:row=400;CYP2C19_results.csv:row=400;CYP2D6_results.csv:row=400;CYP1A2_results.csv:row=400;CYP2C9_results.csv:row=400;hERG_results.csv:row=400;AMES_results.csv:row=400;PGP_results.csv:row=400;PAMPA_results.csv:row=400;BBB_results.csv:row=400;Solubility_results.csv:row=400;Lipophilicity_results.csv:row=401
CHEMBL83,TAMOXIFEN,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,14.63768115942029,100,75.0,59.60507246376812,H,KG targets ESR1; clinical phase 4.0; logS -7.82; logP 6.00,repurposing_candidates.csv:rc_row=1527;protein_drug_candidates.csv:rows=2281;CYP3A4_results.csv:row=1333;CYP2C19_results.csv:row=1333;CYP2D6_results.csv:row=1333;CYP1A2_results.csv:row=1333;CYP2C9_results.csv:row=1333;hERG_results.csv:row=1333;AMES_results.csv:row=1333;PGP_results.csv:row=1333;PAMPA_results.csv:row=1333;BBB_results.csv:row=1333;Solubility_results.csv:row=1333;Lipophilicity_results.csv:row=1334
CHEMBL3545350,EVT-101,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1,34.012204424103736,60,100.0,59.604881769641494,M,"KG targets GRIN1, GRIN2B; clinical phase 2.0; logS -3.08; logP 3.77",repurposing_candidates.csv:rc_row=991;protein_drug_candidates.csv:rows=729;2622;pathway_drug_candidates.csv:rows=3635;6819;6846;6873;6906;7064;7091;7118;7145;CYP3A4_results.csv:row=882;CYP2C19_results.csv:row=882;CYP2D6_results.csv:row=882;CYP1A2_results.csv:row=882;CYP2C9_results.csv:row=882;hERG_results.csv:row=882;AMES_results.csv:row=882;PGP_results.csv:row=882;PAMPA_results.csv:row=882;BBB_results.csv:row=882;Solubility_results.csv:row=882;Lipophilicity_results.csv:row=883
CHEMBL2424780,VESATOLIMOD,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,33.760488176964145,60,100.0,59.50419527078566,M,KG targets TLR7; clinical phase 2.0; logS -3.17; logP 2.79,repurposing_candidates.csv:rc_row=848;protein_drug_candidates.csv:rows=601;pathway_drug_candidates.csv:rows=761;4257;7323;7345;7356;7367;7378;7400;7422;7444;7455;CYP3A4_results.csv:row=756;CYP2C19_results.csv:row=756;CYP2D6_results.csv:row=756;CYP1A2_results.csv:row=756;CYP2C9_results.csv:row=756;hERG_results.csv:row=756;AMES_results.csv:row=756;PGP_results.csv:row=756;PAMPA_results.csv:row=756;BBB_results.csv:row=756;Solubility_results.csv:row=756;Lipophilicity_results.csv:row=757
CHEMBL4297356,AZD-8848,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1,33.760488176964145,60,100.0,59.50419527078566,M,KG targets TLR7; clinical phase 2.0; logS -1.79; logP 2.21,repurposing_candidates.csv:rc_row=1171;protein_drug_candidates.csv:rows=607;pathway_drug_candidates.csv:rows=767;4263;7329;7351;7362;7373;7384;7406;7428;7450;7461;CYP3A4_results.csv:row=1034;CYP2C19_results.csv:row=1034;CYP2D6_results.csv:row=1034;CYP1A2_results.csv:row=1034;CYP2C9_results.csv:row=1034;hERG_results.csv:row=1034;AMES_results.csv:row=1034;PGP_results.csv:row=1034;PAMPA_results.csv:row=1034;BBB_results.csv:row=1034;Solubility_results.csv:row=1034;Lipophilicity_results.csv:row=1035
CHEMBL4297492,GSK-2245035,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1,33.760488176964145,60,100.0,59.50419527078566,M,KG targets TLR7; clinical phase 2.0; logS -1.66; logP 2.93,repurposing_candidates.csv:rc_row=1181;protein_drug_candidates.csv:rows=606;pathway_drug_candidates.csv:rows=766;4262;7328;7350;7361;7372;7383;7405;7427;7449;7460;CYP3A4_results.csv:row=1044;CYP2C19_results.csv:row=1044;CYP2D6_results.csv:row=1044;CYP1A2_results.csv:row=1044;CYP2C9_results.csv:row=1044;hERG_results.csv:row=1044;AMES_results.csv:row=1044;PGP_results.csv:row=1044;PAMPA_results.csv:row=1044;BBB_results.csv:row=1044;Solubility_results.csv:row=1044;Lipophilicity_results.csv:row=1045
CHEMBL4298023,M-1095,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets IL17A; clinical phase 3.0,repurposing_candidates.csv:rc_row=1239;pathway_drug_candidates.csv:rows=157;4226;7306;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297686,IZOKIBEP,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets IL17A; clinical phase 3.0,repurposing_candidates.csv:rc_row=1208;pathway_drug_candidates.csv:rows=158;4227;7307;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109433,OTILIMAB,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets CSF2; clinical phase 3.0,repurposing_candidates.csv:rc_row=768;pathway_drug_candidates.csv:rows=4388;6875;8377;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3989992,PEGILODECAKIN,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets IL10RB; clinical phase 3.0,repurposing_candidates.csv:rc_row=1111;pathway_drug_candidates.csv:rows=4393;4776;4883;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298102,VUNAKIZUMAB,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets IL17A; clinical phase 3.0,repurposing_candidates.csv:rc_row=1245;pathway_drug_candidates.csv:rows=156;4225;7305;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,,16.21662852784134,80,100.0,59.486651411136535,H,KG targets CSF2; clinical phase 3.0,repurposing_candidates.csv:rc_row=897;pathway_drug_candidates.csv:rows=4387;6874;8376;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL911,ZOLPIDEM,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,15.942028985507244,80,100.0,59.3768115942029,H,"KG targets GABRB1, GABRG2; clinical phase 3.0; logS -1.42; logP 3.25",repurposing_candidates.csv:rc_row=1550;protein_drug_candidates.csv:rows=1663;1751;CYP3A4_results.csv:row=1356;CYP2C19_results.csv:row=1356;CYP2D6_results.csv:row=1356;CYP1A2_results.csv:row=1356;CYP2C9_results.csv:row=1356;hERG_results.csv:row=1356;AMES_results.csv:row=1356;PGP_results.csv:row=1356;PAMPA_results.csv:row=1356;BBB_results.csv:row=1356;Solubility_results.csv:row=1356;Lipophilicity_results.csv:row=1357
CHEMBL2103836,IMAGABALIN,CCC[C@@H](C)C[C@H](N)CC(=O)O,15.942028985507244,80,100.0,59.3768115942029,H,"KG targets CACNA1A, CACNA2D1; clinical phase 3.0; logS -1.37; logP 1.61",repurposing_candidates.csv:rc_row=668;protein_drug_candidates.csv:rows=1908;2495;CYP3A4_results.csv:row=613;CYP2C19_results.csv:row=613;CYP2D6_results.csv:row=613;CYP1A2_results.csv:row=613;CYP2C9_results.csv:row=613;hERG_results.csv:row=613;AMES_results.csv:row=613;PGP_results.csv:row=613;PAMPA_results.csv:row=613;BBB_results.csv:row=613;Solubility_results.csv:row=613;Lipophilicity_results.csv:row=614
CHEMBL2104745,PAGOCLONE,CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,45.79710144927536,60,80.0,59.31884057971014,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; logS -6.48; logP 5.38",repurposing_candidates.csv:rc_row=679;protein_drug_candidates.csv:rows=519;1447;1672;1720;2077;2127;2482;CYP3A4_results.csv:row=624;CYP2C19_results.csv:row=624;CYP2D6_results.csv:row=624;CYP1A2_results.csv:row=624;CYP2C9_results.csv:row=624;hERG_results.csv:row=624;AMES_results.csv:row=624;PGP_results.csv:row=624;PAMPA_results.csv:row=624;BBB_results.csv:row=624;Solubility_results.csv:row=624;Lipophilicity_results.csv:row=625
CHEMBL461522,METAMIZOLE,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,34.53852021357742,80,70.0,59.31540808543097,H,"KG targets PTGS1, PTGS2; clinical phase 3.0; hERG risk; logS 0.48; logP 0.77",repurposing_candidates.csv:rc_row=1301;protein_drug_candidates.csv:rows=155;935;pathway_drug_candidates.csv:rows=378;4496;5575;5635;5705;6089;6163;6237;6311;6385;6459;CYP3A4_results.csv:row=1117;CYP2C19_results.csv:row=1117;CYP2D6_results.csv:row=1117;CYP1A2_results.csv:row=1117;CYP2C9_results.csv:row=1117;hERG_results.csv:row=1117;AMES_results.csv:row=1117;PGP_results.csv:row=1117;PAMPA_results.csv:row=1117;BBB_results.csv:row=1117;Solubility_results.csv:row=1117;Lipophilicity_results.csv:row=1118
CHEMBL4297287,HT-0712,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1,51.79633867276888,60,70.0,59.21853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; hERG risk; logS -3.80; logP 4.79",repurposing_candidates.csv:rc_row=1167;protein_drug_candidates.csv:rows=431;1064;1093;2169;pathway_drug_candidates.csv:rows=4344;5753;5781;5810;5848;5877;CYP3A4_results.csv:row=1030;CYP2C19_results.csv:row=1030;CYP2D6_results.csv:row=1030;CYP1A2_results.csv:row=1030;CYP2C9_results.csv:row=1030;hERG_results.csv:row=1030;AMES_results.csv:row=1030;PGP_results.csv:row=1030;PAMPA_results.csv:row=1030;BBB_results.csv:row=1030;Solubility_results.csv:row=1030;Lipophilicity_results.csv:row=1031
CHEMBL63,ROLIPRAM,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,51.79633867276888,60,70.0,59.21853546910755,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; hERG risk; logS -2.45; logP 2.62",repurposing_candidates.csv:rc_row=1462;protein_drug_candidates.csv:rows=434;1067;1096;2172;pathway_drug_candidates.csv:rows=4347;5756;5784;5813;5851;5880;CYP3A4_results.csv:row=1268;CYP2C19_results.csv:row=1268;CYP2D6_results.csv:row=1268;CYP1A2_results.csv:row=1268;CYP2C9_results.csv:row=1268;hERG_results.csv:row=1268;AMES_results.csv:row=1268;PGP_results.csv:row=1268;PAMPA_results.csv:row=1268;BBB_results.csv:row=1268;Solubility_results.csv:row=1268;Lipophilicity_results.csv:row=1269
CHEMBL4297624,BISEGLIPTIN,CCOC(=O)C12CCC(NCC(=O)N3C[C@@H](F)C[C@H]3C#N)(CC1)CC2,32.971014492753625,60,100.0,59.18840579710145,M,KG targets DPP4; clinical phase 2.0; logS -2.53; logP 1.69,repurposing_candidates.csv:rc_row=1198;protein_drug_candidates.csv:rows=679;CYP3A4_results.csv:row=1058;CYP2C19_results.csv:row=1058;CYP2D6_results.csv:row=1058;CYP1A2_results.csv:row=1058;CYP2C9_results.csv:row=1058;hERG_results.csv:row=1058;AMES_results.csv:row=1058;PGP_results.csv:row=1058;PAMPA_results.csv:row=1058;BBB_results.csv:row=1058;Solubility_results.csv:row=1058;Lipophilicity_results.csv:row=1059
CHEMBL681,ETOMIDATE,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,34.20289855072463,80,70.0,59.18115942028985,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; hERG risk; logS -4.37; logP 2.67",repurposing_candidates.csv:rc_row=1485;protein_drug_candidates.csv:rows=508;1437;1522;1661;1707;1748;1781;1802;1875;1936;2068;2114;2475;2561;2584;2632;CYP3A4_results.csv:row=1291;CYP2C19_results.csv:row=1291;CYP2D6_results.csv:row=1291;CYP1A2_results.csv:row=1291;CYP2C9_results.csv:row=1291;hERG_results.csv:row=1291;AMES_results.csv:row=1291;PGP_results.csv:row=1291;PAMPA_results.csv:row=1291;BBB_results.csv:row=1291;Solubility_results.csv:row=1291;Lipophilicity_results.csv:row=1292
CHEMBL2106227,ETIFOXINE,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,34.20289855072463,80,70.0,59.18115942028985,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; hERG risk; logS -4.36; logP 4.23",repurposing_candidates.csv:rc_row=716;protein_drug_candidates.csv:rows=511;1439;1529;1664;1710;1752;1784;1804;1877;1939;2074;2117;2478;2563;2591;2635;CYP3A4_results.csv:row=661;CYP2C19_results.csv:row=661;CYP2D6_results.csv:row=661;CYP1A2_results.csv:row=661;CYP2C9_results.csv:row=661;hERG_results.csv:row=661;AMES_results.csv:row=661;PGP_results.csv:row=661;PAMPA_results.csv:row=661;BBB_results.csv:row=661;Solubility_results.csv:row=661;Lipophilicity_results.csv:row=662
CHEMBL1835207,APRICOXIB,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1,32.707856598016775,60,100.0,59.08314263920671,M,KG targets PTGS2; clinical phase 2.0; logS -3.79; logP 3.50,repurposing_candidates.csv:rc_row=582;protein_drug_candidates.csv:rows=161;pathway_drug_candidates.csv:rows=384;4502;5711;6095;6169;6243;6317;6391;6465;CYP3A4_results.csv:row=528;CYP2C19_results.csv:row=528;CYP2D6_results.csv:row=528;CYP1A2_results.csv:row=528;CYP2C9_results.csv:row=528;hERG_results.csv:row=528;AMES_results.csv:row=528;PGP_results.csv:row=528;PAMPA_results.csv:row=528;BBB_results.csv:row=528;Solubility_results.csv:row=528;Lipophilicity_results.csv:row=529
CHEMBL1079,TIZANIDINE,Clc1ccc2nsnc2c1NC1=NCCN1,33.737604881769634,80,70.0,58.99504195270785,H,"KG targets ADRA2A, ADRA2B; clinical phase 3.0; hERG risk; logS -2.98; logP 1.72",repurposing_candidates.csv:rc_row=29;protein_drug_candidates.csv:rows=1347;1398;2545;pathway_drug_candidates.csv:rows=918;969;1022;1073;1126;1178;1229;1410;1461;1514;CYP3A4_results.csv:row=29;CYP2C19_results.csv:row=29;CYP2D6_results.csv:row=29;CYP1A2_results.csv:row=29;CYP2C9_results.csv:row=29;hERG_results.csv:row=29;AMES_results.csv:row=29;PGP_results.csv:row=29;PAMPA_results.csv:row=29;BBB_results.csv:row=29;Solubility_results.csv:row=29;Lipophilicity_results.csv:row=29
CHEMBL2103793,AGATOLIMOD SODIUM,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],30.602593440122043,80,75.0,58.991037376048816,H,KG targets TLR9; clinical phase 3.0; logS -16.10; logP -91.31,repurposing_candidates.csv:rc_row=660;protein_drug_candidates.csv:rows=260;pathway_drug_candidates.csv:rows=774;7336;7391;7413;7435;CYP3A4_results.csv:row=605;CYP2C19_results.csv:row=605;CYP2D6_results.csv:row=605;CYP1A2_results.csv:row=605;CYP2C9_results.csv:row=605;hERG_results.csv:row=605;AMES_results.csv:row=605;PGP_results.csv:row=605;PAMPA_results.csv:row=605;BBB_results.csv:row=605;Solubility_results.csv:row=605;Lipophilicity_results.csv:row=606
CHEMBL2103792,AGATOLIMOD,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O,30.602593440122043,80,75.0,58.991037376048816,H,KG targets TLR9; clinical phase 3.0; logS -28.60; logP -7.86,repurposing_candidates.csv:rc_row=659;protein_drug_candidates.csv:rows=258;pathway_drug_candidates.csv:rows=772;7334;7389;7411;7433;CYP3A4_results.csv:row=604;CYP2C19_results.csv:row=604;CYP2D6_results.csv:row=604;CYP1A2_results.csv:row=604;CYP2C9_results.csv:row=604;hERG_results.csv:row=604;AMES_results.csv:row=604;PGP_results.csv:row=604;PAMPA_results.csv:row=604;BBB_results.csv:row=604;Solubility_results.csv:row=604;Lipophilicity_results.csv:row=605
CHEMBL4297863,REMTOLUMAB,,32.43325705568268,60,100.0,58.97330282227307,M,"KG targets IL17A, TNF; clinical phase 2.0",repurposing_candidates.csv:rc_row=1224;protein_drug_candidates.csv:rows=91;pathway_drug_candidates.csv:rows=159;400;4154;4169;4228;4518;7308;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL362558,LY-2090314,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,32.43325705568268,60,100.0,58.97330282227307,M,"KG targets GSK3A, GSK3B; clinical phase 2.0; logS -3.96; logP 3.42",repurposing_candidates.csv:rc_row=1005;protein_drug_candidates.csv:rows=1180;1227;pathway_drug_candidates.csv:rows=5494;5497;5502;5505;5508;5513;5516;5519;8091;CYP3A4_results.csv:row=891;CYP2C19_results.csv:row=891;CYP2D6_results.csv:row=891;CYP1A2_results.csv:row=891;CYP2C9_results.csv:row=891;hERG_results.csv:row=891;AMES_results.csv:row=891;PGP_results.csv:row=891;PAMPA_results.csv:row=891;BBB_results.csv:row=891;Solubility_results.csv:row=891;Lipophilicity_results.csv:row=892
CHEMBL3989410,INDOMETHACIN SODIUM,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+],52.87185354691076,40,95.0,58.8987414187643,L,"KG targets PTGS1, PTGS2; clinical phase 1.0; logS -4.78; logP -2.88",repurposing_candidates.csv:rc_row=1069;protein_drug_candidates.csv:rows=165;941;pathway_drug_candidates.csv:rows=388;4506;5581;5641;5715;6099;6173;6247;6321;6395;6469;CYP3A4_results.csv:row=938;CYP2C19_results.csv:row=938;CYP2D6_results.csv:row=938;CYP1A2_results.csv:row=938;CYP2C9_results.csv:row=938;hERG_results.csv:row=938;AMES_results.csv:row=938;PGP_results.csv:row=938;PAMPA_results.csv:row=938;BBB_results.csv:row=938;Solubility_results.csv:row=938;Lipophilicity_results.csv:row=939
CHEMBL363295,TERODILINE,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,15.942028985507244,100,70.0,58.8768115942029,H,"KG targets CACNA1A, CACNA2D1; clinical phase 4.0; hERG risk; logS -2.76; logP 4.99",repurposing_candidates.csv:rc_row=1006;protein_drug_candidates.csv:rows=1906;2494;CYP3A4_results.csv:row=892;CYP2C19_results.csv:row=892;CYP2D6_results.csv:row=892;CYP1A2_results.csv:row=892;CYP2C9_results.csv:row=892;hERG_results.csv:row=892;AMES_results.csv:row=892;PGP_results.csv:row=892;PAMPA_results.csv:row=892;BBB_results.csv:row=892;Solubility_results.csv:row=892;Lipophilicity_results.csv:row=893
CHEMBL1197051,ISOXSUPRINE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1,32.15865751334859,60,100.0,58.86346300533943,M,"KG targets ADRA1A, ADRA1B; clinical phase 2.0; logS -1.68; logP 2.87",repurposing_candidates.csv:rc_row=80;protein_drug_candidates.csv:rows=402;1502;1862;pathway_drug_candidates.csv:rows=865;6527;6727;CYP3A4_results.csv:row=79;CYP2C19_results.csv:row=79;CYP2D6_results.csv:row=79;CYP1A2_results.csv:row=79;CYP2C9_results.csv:row=79;hERG_results.csv:row=79;AMES_results.csv:row=79;PGP_results.csv:row=79;PAMPA_results.csv:row=79;BBB_results.csv:row=79;Solubility_results.csv:row=79;Lipophilicity_results.csv:row=79
CHEMBL3989830,SIBUTRAMINE HYDROCHLORIDE,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -3.34; logP 4.34,repurposing_candidates.csv:rc_row=1092;protein_drug_candidates.csv:rows=1284;CYP3A4_results.csv:row=961;CYP2C19_results.csv:row=961;CYP2D6_results.csv:row=961;CYP1A2_results.csv:row=961;CYP2C9_results.csv:row=961;hERG_results.csv:row=961;AMES_results.csv:row=961;PGP_results.csv:row=961;PAMPA_results.csv:row=961;BBB_results.csv:row=961;Solubility_results.csv:row=961;Lipophilicity_results.csv:row=962
CHEMBL376359,ALOGLIPTIN,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,14.63768115942029,80,100.0,58.85507246376812,H,KG targets DPP4; clinical phase 3.0; logS -2.46; logP 0.39,repurposing_candidates.csv:rc_row=1033;protein_drug_candidates.csv:rows=671;CYP3A4_results.csv:row=908;CYP2C19_results.csv:row=908;CYP2D6_results.csv:row=908;CYP1A2_results.csv:row=908;CYP2C9_results.csv:row=908;hERG_results.csv:row=908;AMES_results.csv:row=908;PGP_results.csv:row=908;PAMPA_results.csv:row=908;BBB_results.csv:row=908;Solubility_results.csv:row=908;Lipophilicity_results.csv:row=909
CHEMBL109648,CLAZOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,14.63768115942029,80,100.0,58.85507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.61; logP 2.39,repurposing_candidates.csv:rc_row=47;protein_drug_candidates.csv:rows=1920;CYP3A4_results.csv:row=47;CYP2C19_results.csv:row=47;CYP2D6_results.csv:row=47;CYP1A2_results.csv:row=47;CYP2C9_results.csv:row=47;hERG_results.csv:row=47;AMES_results.csv:row=47;PGP_results.csv:row=47;PAMPA_results.csv:row=47;BBB_results.csv:row=47;Solubility_results.csv:row=47;Lipophilicity_results.csv:row=47
CHEMBL1628688,ZIBOTENTAN,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.44; logP 2.71,repurposing_candidates.csv:rc_row=486;protein_drug_candidates.csv:rows=1923;CYP3A4_results.csv:row=446;CYP2C19_results.csv:row=446;CYP2D6_results.csv:row=446;CYP1A2_results.csv:row=446;CYP2C9_results.csv:row=446;hERG_results.csv:row=446;AMES_results.csv:row=446;PGP_results.csv:row=446;PAMPA_results.csv:row=446;BBB_results.csv:row=446;Solubility_results.csv:row=446;Lipophilicity_results.csv:row=447
CHEMBL2110900,DAPOXETINE,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -4.24; logP 4.91,repurposing_candidates.csv:rc_row=783;protein_drug_candidates.csv:rows=1287;CYP3A4_results.csv:row=692;CYP2C19_results.csv:row=692;CYP2D6_results.csv:row=692;CYP1A2_results.csv:row=692;CYP2C9_results.csv:row=692;hERG_results.csv:row=692;AMES_results.csv:row=692;PGP_results.csv:row=692;PAMPA_results.csv:row=692;BBB_results.csv:row=692;Solubility_results.csv:row=692;Lipophilicity_results.csv:row=693
CHEMBL1650443,TRELAGLIPTIN,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,14.63768115942029,80,100.0,58.85507246376812,H,KG targets DPP4; clinical phase 3.0; logS -2.61; logP 0.53,repurposing_candidates.csv:rc_row=494;protein_drug_candidates.csv:rows=668;CYP3A4_results.csv:row=454;CYP2C19_results.csv:row=454;CYP2D6_results.csv:row=454;CYP1A2_results.csv:row=454;CYP2C9_results.csv:row=454;hERG_results.csv:row=454;AMES_results.csv:row=454;PGP_results.csv:row=454;PAMPA_results.csv:row=454;BBB_results.csv:row=454;Solubility_results.csv:row=454;Lipophilicity_results.csv:row=455
CHEMBL1175,DULOXETINE,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -3.42; logP 4.63,repurposing_candidates.csv:rc_row=73;protein_drug_candidates.csv:rows=1285;CYP3A4_results.csv:row=72;CYP2C19_results.csv:row=72;CYP2D6_results.csv:row=72;CYP1A2_results.csv:row=72;CYP2C9_results.csv:row=72;hERG_results.csv:row=72;AMES_results.csv:row=72;PGP_results.csv:row=72;PAMPA_results.csv:row=72;BBB_results.csv:row=72;Solubility_results.csv:row=72;Lipophilicity_results.csv:row=72
CHEMBL3301621,CENTANAFADINE,c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -3.70; logP 2.70,repurposing_candidates.csv:rc_row=942;protein_drug_candidates.csv:rows=1288;CYP3A4_results.csv:row=846;CYP2C19_results.csv:row=846;CYP2D6_results.csv:row=846;CYP1A2_results.csv:row=846;CYP2C9_results.csv:row=846;hERG_results.csv:row=846;AMES_results.csv:row=846;PGP_results.csv:row=846;PAMPA_results.csv:row=846;BBB_results.csv:row=846;Solubility_results.csv:row=846;Lipophilicity_results.csv:row=847
CHEMBL9194,ATRASENTAN,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.55; logP 4.69,repurposing_candidates.csv:rc_row=1553;protein_drug_candidates.csv:rows=1917;CYP3A4_results.csv:row=1359;CYP2C19_results.csv:row=1359;CYP2D6_results.csv:row=1359;CYP1A2_results.csv:row=1359;CYP2C9_results.csv:row=1359;hERG_results.csv:row=1359;AMES_results.csv:row=1359;PGP_results.csv:row=1359;PAMPA_results.csv:row=1359;BBB_results.csv:row=1359;Solubility_results.csv:row=1359;Lipophilicity_results.csv:row=1360
CHEMBL3833357,BEGELOMAB,,14.63768115942029,80,100.0,58.85507246376812,H,KG targets DPP4; clinical phase 3.0,repurposing_candidates.csv:rc_row=1045;protein_drug_candidates.csv:rows=672;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3989834,AVOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC,14.63768115942029,80,100.0,58.85507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.83; logP 3.85,repurposing_candidates.csv:rc_row=1094;protein_drug_candidates.csv:rows=1916;CYP3A4_results.csv:row=963;CYP2C19_results.csv:row=963;CYP2D6_results.csv:row=963;CYP1A2_results.csv:row=963;CYP2C9_results.csv:row=963;hERG_results.csv:row=963;AMES_results.csv:row=963;PGP_results.csv:row=963;PAMPA_results.csv:row=963;BBB_results.csv:row=963;Solubility_results.csv:row=963;Lipophilicity_results.csv:row=964
CHEMBL4650316,GIREDESTRANT,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,14.63768115942029,80,100.0,58.85507246376812,H,KG targets ESR1; clinical phase 3.0; logS -4.60; logP 4.87,repurposing_candidates.csv:rc_row=1306;protein_drug_candidates.csv:rows=2307;CYP3A4_results.csv:row=1120;CYP2C19_results.csv:row=1120;CYP2D6_results.csv:row=1120;CYP1A2_results.csv:row=1120;CYP2C9_results.csv:row=1120;hERG_results.csv:row=1120;AMES_results.csv:row=1120;PGP_results.csv:row=1120;PAMPA_results.csv:row=1120;BBB_results.csv:row=1120;Solubility_results.csv:row=1120;Lipophilicity_results.csv:row=1121
CHEMBL2104993,VORTIOXETINE,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -3.98; logP 3.86,repurposing_candidates.csv:rc_row=686;protein_drug_candidates.csv:rows=1291;CYP3A4_results.csv:row=631;CYP2C19_results.csv:row=631;CYP2D6_results.csv:row=631;CYP1A2_results.csv:row=631;CYP2C9_results.csv:row=631;hERG_results.csv:row=631;AMES_results.csv:row=631;PGP_results.csv:row=631;PAMPA_results.csv:row=631;BBB_results.csv:row=631;Solubility_results.csv:row=631;Lipophilicity_results.csv:row=632
CHEMBL4297919,PAROXETINE HYDROCHLORIDE HEMIHYDRATE,,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0,repurposing_candidates.csv:rc_row=1229;protein_drug_candidates.csv:rows=1289;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL23261,DARUSENTAN,COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.15; logP 2.92,repurposing_candidates.csv:rc_row=826;protein_drug_candidates.csv:rows=1919;CYP3A4_results.csv:row=735;CYP2C19_results.csv:row=735;CYP2D6_results.csv:row=735;CYP1A2_results.csv:row=735;CYP2C9_results.csv:row=735;hERG_results.csv:row=735;AMES_results.csv:row=735;PGP_results.csv:row=735;PAMPA_results.csv:row=735;BBB_results.csv:row=735;Solubility_results.csv:row=735;Lipophilicity_results.csv:row=736
CHEMBL3545125,MIROGABALIN,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O,14.63768115942029,80,100.0,58.85507246376812,H,KG targets CACNA2D1; clinical phase 3.0; logS -1.95; logP 1.78,repurposing_candidates.csv:rc_row=971;protein_drug_candidates.csv:rows=2496;CYP3A4_results.csv:row=871;CYP2C19_results.csv:row=871;CYP2D6_results.csv:row=871;CYP1A2_results.csv:row=871;CYP2C9_results.csv:row=871;hERG_results.csv:row=871;AMES_results.csv:row=871;PGP_results.csv:row=871;PAMPA_results.csv:row=871;BBB_results.csv:row=871;Solubility_results.csv:row=871;Lipophilicity_results.csv:row=872
CHEMBL511099,BICIFADINE,Cc1ccc(C23CNCC2C3)cc1,14.63768115942029,80,100.0,58.85507246376812,H,KG targets SLC6A4; clinical phase 3.0; logS -3.22; logP 1.86,repurposing_candidates.csv:rc_row=1355;protein_drug_candidates.csv:rows=1290;CYP3A4_results.csv:row=1166;CYP2C19_results.csv:row=1166;CYP2D6_results.csv:row=1166;CYP1A2_results.csv:row=1166;CYP2C9_results.csv:row=1166;hERG_results.csv:row=1166;AMES_results.csv:row=1166;PGP_results.csv:row=1166;PAMPA_results.csv:row=1166;BBB_results.csv:row=1166;Solubility_results.csv:row=1166;Lipophilicity_results.csv:row=1167
CHEMBL385517,SAXAGLIPTIN ANHYDROUS,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,14.63768115942029,80,100.0,58.85507246376812,H,KG targets DPP4; clinical phase 3.0; logS -1.63; logP 1.16,repurposing_candidates.csv:rc_row=1052;protein_drug_candidates.csv:rows=667;CYP3A4_results.csv:row=921;CYP2C19_results.csv:row=921;CYP2D6_results.csv:row=921;CYP1A2_results.csv:row=921;CYP2C9_results.csv:row=921;hERG_results.csv:row=921;AMES_results.csv:row=921;PGP_results.csv:row=921;PAMPA_results.csv:row=921;BBB_results.csv:row=921;Solubility_results.csv:row=921;Lipophilicity_results.csv:row=922
CHEMBL2147777,TENELIGLIPTIN,Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,32.971014492753625,80,70.0,58.68840579710145,H,KG targets DPP4; clinical phase 3.0; hERG risk; logS -3.42; logP 1.57,repurposing_candidates.csv:rc_row=791;protein_drug_candidates.csv:rows=676;CYP3A4_results.csv:row=700;CYP2C19_results.csv:row=700;CYP2D6_results.csv:row=700;CYP1A2_results.csv:row=700;CYP2C9_results.csv:row=700;hERG_results.csv:row=700;AMES_results.csv:row=700;PGP_results.csv:row=700;PAMPA_results.csv:row=700;BBB_results.csv:row=700;Solubility_results.csv:row=700;Lipophilicity_results.csv:row=701
CHEMBL364804,GW-406381,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1,32.707856598016775,80,70.0,58.58314263920671,H,KG targets PTGS2; clinical phase 3.0; hERG risk; logS -4.14; logP 3.87,repurposing_candidates.csv:rc_row=1009;protein_drug_candidates.csv:rows=152;pathway_drug_candidates.csv:rows=375;4493;5702;6086;6160;6234;6308;6382;6456;CYP3A4_results.csv:row=895;CYP2C19_results.csv:row=895;CYP2D6_results.csv:row=895;CYP1A2_results.csv:row=895;CYP2C9_results.csv:row=895;hERG_results.csv:row=895;AMES_results.csv:row=895;PGP_results.csv:row=895;PAMPA_results.csv:row=895;BBB_results.csv:row=895;Solubility_results.csv:row=895;Lipophilicity_results.csv:row=896
CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,32.707856598016775,80,70.0,58.58314263920671,H,KG targets NR3C1; clinical phase 3.0; hERG risk; logS -3.46; logP 1.67,repurposing_candidates.csv:rc_row=260;protein_drug_candidates.csv:rows=55;pathway_drug_candidates.csv:rows=747;2056;5971;7875;8012;8078;8149;8215;8281;CYP3A4_results.csv:row=257;CYP2C19_results.csv:row=257;CYP2D6_results.csv:row=257;CYP1A2_results.csv:row=257;CYP2C9_results.csv:row=257;hERG_results.csv:row=257;AMES_results.csv:row=257;PGP_results.csv:row=257;PAMPA_results.csv:row=257;BBB_results.csv:row=257;Solubility_results.csv:row=257;Lipophilicity_results.csv:row=258
CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,32.707856598016775,80,70.0,58.58314263920671,H,KG targets NR3C1; clinical phase 3.0; hERG risk; logS -4.05; logP 2.01,repurposing_candidates.csv:rc_row=257;protein_drug_candidates.csv:rows=56;pathway_drug_candidates.csv:rows=748;2057;5972;7876;8013;8079;8150;8216;8282;CYP3A4_results.csv:row=254;CYP2C19_results.csv:row=254;CYP2D6_results.csv:row=254;CYP1A2_results.csv:row=254;CYP2C9_results.csv:row=254;hERG_results.csv:row=254;AMES_results.csv:row=254;PGP_results.csv:row=254;PAMPA_results.csv:row=254;BBB_results.csv:row=254;Solubility_results.csv:row=254;Lipophilicity_results.csv:row=255
CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,32.707856598016775,80,70.0,58.58314263920671,H,KG targets NR3C1; clinical phase 3.0; hERG risk; logS -4.05; logP 2.01,repurposing_candidates.csv:rc_row=270;protein_drug_candidates.csv:rows=54;pathway_drug_candidates.csv:rows=746;2055;5970;7874;8011;8077;8148;8214;8280;CYP3A4_results.csv:row=267;CYP2C19_results.csv:row=267;CYP2D6_results.csv:row=267;CYP1A2_results.csv:row=267;CYP2C9_results.csv:row=267;hERG_results.csv:row=267;AMES_results.csv:row=267;PGP_results.csv:row=267;PAMPA_results.csv:row=267;BBB_results.csv:row=267;Solubility_results.csv:row=267;Lipophilicity_results.csv:row=268
CHEMBL4297674,BRANEBRUTINIB,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,48.40961098398169,40,100.0,58.36384439359268,L,KG targets BTK; clinical phase 1.0; logS -2.76; logP 2.13,repurposing_candidates.csv:rc_row=1205;protein_drug_candidates.csv:rows=210;pathway_drug_candidates.csv:rows=616;4111;6573;6753;CYP3A4_results.csv:row=1065;CYP2C19_results.csv:row=1065;CYP2D6_results.csv:row=1065;CYP1A2_results.csv:row=1065;CYP2C9_results.csv:row=1065;hERG_results.csv:row=1065;AMES_results.csv:row=1065;PGP_results.csv:row=1065;PAMPA_results.csv:row=1065;BBB_results.csv:row=1065;Solubility_results.csv:row=1065;Lipophilicity_results.csv:row=1066
CHEMBL1200332,PROTRIPTYLINE HYDROCHLORIDE,CNCCCC1c2ccccc2C=Cc2ccccc21.Cl,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -1.97; logP 4.72,repurposing_candidates.csv:rc_row=86;protein_drug_candidates.csv:rows=1281;CYP3A4_results.csv:row=85;CYP2C19_results.csv:row=85;CYP2D6_results.csv:row=85;CYP1A2_results.csv:row=85;CYP2C9_results.csv:row=85;hERG_results.csv:row=85;AMES_results.csv:row=85;PGP_results.csv:row=85;PAMPA_results.csv:row=85;BBB_results.csv:row=85;Solubility_results.csv:row=85;Lipophilicity_results.csv:row=85
CHEMBL1201082,FLUOXETINE HYDROCHLORIDE,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -1.20; logP 4.86,repurposing_candidates.csv:rc_row=231;protein_drug_candidates.csv:rows=1244;CYP3A4_results.csv:row=229;CYP2C19_results.csv:row=229;CYP2D6_results.csv:row=229;CYP1A2_results.csv:row=229;CYP2C9_results.csv:row=229;hERG_results.csv:row=229;AMES_results.csv:row=229;PGP_results.csv:row=229;PAMPA_results.csv:row=229;BBB_results.csv:row=229;Solubility_results.csv:row=229;Lipophilicity_results.csv:row=230
CHEMBL411,DIETHYLSTILBESTROL,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,14.63768115942029,100,70.0,58.35507246376812,H,KG targets ESR1; clinical phase 4.0; hERG risk; logS -4.56; logP 4.83,repurposing_candidates.csv:rc_row=1133;protein_drug_candidates.csv:rows=2279;CYP3A4_results.csv:row=997;CYP2C19_results.csv:row=997;CYP2D6_results.csv:row=997;CYP1A2_results.csv:row=997;CYP2C9_results.csv:row=997;hERG_results.csv:row=997;AMES_results.csv:row=997;PGP_results.csv:row=997;PAMPA_results.csv:row=997;BBB_results.csv:row=997;Solubility_results.csv:row=997;Lipophilicity_results.csv:row=998
CHEMBL668,PROTRIPTYLINE,CNCCCC1c2ccccc2C=Cc2ccccc21,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -2.65; logP 4.30,repurposing_candidates.csv:rc_row=1482;protein_drug_candidates.csv:rows=1277;CYP3A4_results.csv:row=1288;CYP2C19_results.csv:row=1288;CYP2D6_results.csv:row=1288;CYP1A2_results.csv:row=1288;CYP2C9_results.csv:row=1288;hERG_results.csv:row=1288;AMES_results.csv:row=1288;PGP_results.csv:row=1288;PAMPA_results.csv:row=1288;BBB_results.csv:row=1288;Solubility_results.csv:row=1288;Lipophilicity_results.csv:row=1289
CHEMBL1201201,METHAMPHETAMINE,CN[C@@H](C)Cc1ccccc1,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -1.69; logP 1.84,repurposing_candidates.csv:rc_row=255;protein_drug_candidates.csv:rows=1242;CYP3A4_results.csv:row=252;CYP2C19_results.csv:row=252;CYP2D6_results.csv:row=252;CYP1A2_results.csv:row=252;CYP2C9_results.csv:row=252;hERG_results.csv:row=252;AMES_results.csv:row=252;PGP_results.csv:row=252;PAMPA_results.csv:row=252;BBB_results.csv:row=252;Solubility_results.csv:row=252;Lipophilicity_results.csv:row=253
CHEMBL1200322,ESCITALOPRAM OXALATE,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.58; logP 2.97,repurposing_candidates.csv:rc_row=82;protein_drug_candidates.csv:rows=1251;CYP3A4_results.csv:row=81;CYP2C19_results.csv:row=81;CYP2D6_results.csv:row=81;CYP1A2_results.csv:row=81;CYP2C9_results.csv:row=81;hERG_results.csv:row=81;AMES_results.csv:row=81;PGP_results.csv:row=81;PAMPA_results.csv:row=81;BBB_results.csv:row=81;Solubility_results.csv:row=81;Lipophilicity_results.csv:row=81
CHEMBL1200952,METHAMPHETAMINE HYDROCHLORIDE,CN[C@@H](C)Cc1ccccc1.Cl,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -1.02; logP 2.26,repurposing_candidates.csv:rc_row=199;protein_drug_candidates.csv:rows=1240;CYP3A4_results.csv:row=197;CYP2C19_results.csv:row=197;CYP2D6_results.csv:row=197;CYP1A2_results.csv:row=197;CYP2C9_results.csv:row=197;hERG_results.csv:row=197;AMES_results.csv:row=197;PGP_results.csv:row=197;PAMPA_results.csv:row=197;BBB_results.csv:row=197;Solubility_results.csv:row=197;Lipophilicity_results.csv:row=198
CHEMBL52440,DEXTROMETHORPHAN,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,14.63768115942029,100,70.0,58.35507246376812,H,KG targets GRIN2A; clinical phase 4.0; hERG risk; logS -3.67; logP 3.38,repurposing_candidates.csv:rc_row=1371;protein_drug_candidates.csv:rows=2645;CYP3A4_results.csv:row=1182;CYP2C19_results.csv:row=1182;CYP2D6_results.csv:row=1182;CYP1A2_results.csv:row=1182;CYP2C9_results.csv:row=1182;hERG_results.csv:row=1182;AMES_results.csv:row=1182;PGP_results.csv:row=1182;PAMPA_results.csv:row=1182;BBB_results.csv:row=1182;Solubility_results.csv:row=1182;Lipophilicity_results.csv:row=1183
CHEMBL1200781,CITALOPRAM HYDROBROMIDE,Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -3.24; logP 4.39,repurposing_candidates.csv:rc_row=165;protein_drug_candidates.csv:rows=1256;CYP3A4_results.csv:row=163;CYP2C19_results.csv:row=163;CYP2D6_results.csv:row=163;CYP1A2_results.csv:row=163;CYP2C9_results.csv:row=163;hERG_results.csv:row=163;AMES_results.csv:row=163;PGP_results.csv:row=163;PAMPA_results.csv:row=163;BBB_results.csv:row=163;Solubility_results.csv:row=163;Lipophilicity_results.csv:row=164
CHEMBL1256818,DEXTROMETHORPHAN HYDROBROMIDE,Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,14.63768115942029,100,70.0,58.35507246376812,H,KG targets GRIN2A; clinical phase 4.0; hERG risk; logS -3.40; logP 3.14,repurposing_candidates.csv:rc_row=356;protein_drug_candidates.csv:rows=2642;CYP3A4_results.csv:row=318;CYP2C19_results.csv:row=318;CYP2D6_results.csv:row=318;CYP1A2_results.csv:row=318;CYP2C9_results.csv:row=318;hERG_results.csv:row=318;AMES_results.csv:row=318;PGP_results.csv:row=318;PAMPA_results.csv:row=318;BBB_results.csv:row=318;Solubility_results.csv:row=318;Lipophilicity_results.csv:row=319
CHEMBL1200598,DIETHYLSTILBESTROL DIPHOSPHATE,CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1,14.63768115942029,100,70.0,58.35507246376812,H,KG targets ESR1; clinical phase 4.0; hERG risk; logS -3.55; logP 4.36,repurposing_candidates.csv:rc_row=130;protein_drug_candidates.csv:rows=2282;CYP3A4_results.csv:row=129;CYP2C19_results.csv:row=129;CYP2D6_results.csv:row=129;CYP1A2_results.csv:row=129;CYP2C9_results.csv:row=129;hERG_results.csv:row=129;AMES_results.csv:row=129;PGP_results.csv:row=129;PAMPA_results.csv:row=129;BBB_results.csv:row=129;Solubility_results.csv:row=129;Lipophilicity_results.csv:row=129
CHEMBL1230314,ESTETROL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,14.63768115942029,100,70.0,58.35507246376812,H,KG targets ESR1; clinical phase 4.0; hERG risk; logS -4.63; logP 1.55,repurposing_candidates.csv:rc_row=338;protein_drug_candidates.csv:rows=2290;CYP3A4_results.csv:row=301;CYP2C19_results.csv:row=301;CYP2D6_results.csv:row=301;CYP1A2_results.csv:row=301;CYP2C9_results.csv:row=301;hERG_results.csv:row=301;AMES_results.csv:row=301;PGP_results.csv:row=301;PAMPA_results.csv:row=301;BBB_results.csv:row=301;Solubility_results.csv:row=301;Lipophilicity_results.csv:row=302
CHEMBL781,MAZINDOL,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21,14.63768115942029,100,70.0,58.35507246376812,H,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.65; logP 2.61,repurposing_candidates.csv:rc_row=1514;protein_drug_candidates.csv:rows=1239;CYP3A4_results.csv:row=1320;CYP2C19_results.csv:row=1320;CYP2D6_results.csv:row=1320;CYP1A2_results.csv:row=1320;CYP2C9_results.csv:row=1320;hERG_results.csv:row=1320;AMES_results.csv:row=1320;PGP_results.csv:row=1320;PAMPA_results.csv:row=1320;BBB_results.csv:row=1320;Solubility_results.csv:row=1320;Lipophilicity_results.csv:row=1321
CHEMBL2068839,RISLENEMDAZ,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,34.012204424103736,60,95.0,58.354881769641494,M,"KG targets GRIN1, GRIN2B; clinical phase 2.0; logS -3.81; logP 3.19",repurposing_candidates.csv:rc_row=643;protein_drug_candidates.csv:rows=726;2619;pathway_drug_candidates.csv:rows=3632;6816;6843;6870;6903;7061;7088;7115;7142;CYP3A4_results.csv:row=589;CYP2C19_results.csv:row=589;CYP2D6_results.csv:row=589;CYP1A2_results.csv:row=589;CYP2C9_results.csv:row=589;hERG_results.csv:row=589;AMES_results.csv:row=589;PGP_results.csv:row=589;PAMPA_results.csv:row=589;BBB_results.csv:row=589;Solubility_results.csv:row=589;Lipophilicity_results.csv:row=590
CHEMBL182066,RADIPRODIL,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,34.012204424103736,60,95.0,58.354881769641494,M,"KG targets GRIN1, GRIN2B; clinical phase 2.0; logS -3.91; logP 3.09",repurposing_candidates.csv:rc_row=581;protein_drug_candidates.csv:rows=724;2616;pathway_drug_candidates.csv:rows=3630;6814;6841;6868;6901;7059;7086;7113;7140;CYP3A4_results.csv:row=527;CYP2C19_results.csv:row=527;CYP2D6_results.csv:row=527;CYP1A2_results.csv:row=527;CYP2C9_results.csv:row=527;hERG_results.csv:row=527;AMES_results.csv:row=527;PGP_results.csv:row=527;PAMPA_results.csv:row=527;BBB_results.csv:row=527;Solubility_results.csv:row=527;Lipophilicity_results.csv:row=528
CHEMBL1721885,SU-014813,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0; logS -1.94; logP 1.69",repurposing_candidates.csv:rc_row=531;protein_drug_candidates.csv:rows=1130;1173;pathway_drug_candidates.csv:rows=578;6990;7028;7524;CYP3A4_results.csv:row=491;CYP2C19_results.csv:row=491;CYP2D6_results.csv:row=491;CYP1A2_results.csv:row=491;CYP2C9_results.csv:row=491;hERG_results.csv:row=491;AMES_results.csv:row=491;PGP_results.csv:row=491;PAMPA_results.csv:row=491;BBB_results.csv:row=491;Solubility_results.csv:row=491;Lipophilicity_results.csv:row=492
CHEMBL188462,ISPRONICLINE,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0; logS -1.25; logP 2.88",repurposing_candidates.csv:rc_row=586;protein_drug_candidates.csv:rows=444;2140;pathway_drug_candidates.csv:rows=7924;7938;7952;CYP3A4_results.csv:row=532;CYP2C19_results.csv:row=532;CYP2D6_results.csv:row=532;CYP1A2_results.csv:row=532;CYP2C9_results.csv:row=532;hERG_results.csv:row=532;AMES_results.csv:row=532;PGP_results.csv:row=532;PAMPA_results.csv:row=532;BBB_results.csv:row=532;Solubility_results.csv:row=532;Lipophilicity_results.csv:row=533
CHEMBL3707250,CP-601927,,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0",repurposing_candidates.csv:rc_row=1017;protein_drug_candidates.csv:rows=447;2143;pathway_drug_candidates.csv:rows=7927;7941;7955;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL127071,POZANICLINE,Cc1ncccc1OC[C@@H]1CCCN1,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets CHRNA4, CHRNB2; clinical phase 2.0; logS -0.41; logP 1.52",repurposing_candidates.csv:rc_row=368;protein_drug_candidates.csv:rows=445;2141;pathway_drug_candidates.csv:rows=7925;7939;7953;CYP3A4_results.csv:row=329;CYP2C19_results.csv:row=329;CYP2D6_results.csv:row=329;CYP1A2_results.csv:row=329;CYP2C9_results.csv:row=329;hERG_results.csv:row=329;AMES_results.csv:row=329;PGP_results.csv:row=329;PAMPA_results.csv:row=329;BBB_results.csv:row=329;Solubility_results.csv:row=329;Lipophilicity_results.csv:row=330
CHEMBL2079588,TELATINIB,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0; logS -4.03; logP 3.95",repurposing_candidates.csv:rc_row=647;protein_drug_candidates.csv:rows=1134;1174;pathway_drug_candidates.csv:rows=579;6991;7032;7525;CYP3A4_results.csv:row=593;CYP2C19_results.csv:row=593;CYP2D6_results.csv:row=593;CYP1A2_results.csv:row=593;CYP2C9_results.csv:row=593;hERG_results.csv:row=593;AMES_results.csv:row=593;PGP_results.csv:row=593;PAMPA_results.csv:row=593;BBB_results.csv:row=593;Solubility_results.csv:row=593;Lipophilicity_results.csv:row=594
CHEMBL3545402,XL-820,,30.85430968726163,60,100.0,58.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0",repurposing_candidates.csv:rc_row=996;protein_drug_candidates.csv:rows=1136;1175;pathway_drug_candidates.csv:rows=580;6992;7034;7526;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1255582,FIPAMEZOLE,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1,33.737604881769634,60,95.0,58.24504195270785,M,"KG targets ADRA2A, ADRA2B; clinical phase 2.0; logS -2.97; logP 3.00",repurposing_candidates.csv:rc_row=353;protein_drug_candidates.csv:rows=1349;1401;2549;pathway_drug_candidates.csv:rows=920;972;1024;1076;1128;1180;1232;1412;1464;1516;CYP3A4_results.csv:row=315;CYP2C19_results.csv:row=315;CYP2D6_results.csv:row=315;CYP1A2_results.csv:row=315;CYP2C9_results.csv:row=315;hERG_results.csv:row=315;AMES_results.csv:row=315;PGP_results.csv:row=315;PAMPA_results.csv:row=315;BBB_results.csv:row=315;Solubility_results.csv:row=315;Lipophilicity_results.csv:row=316
CHEMBL4297994,TILSOTOLIMOD SODIUM,,30.602593440122043,60,100.0,58.241037376048816,M,KG targets TLR9; clinical phase 2.0,repurposing_candidates.csv:rc_row=1236;protein_drug_candidates.csv:rows=265;pathway_drug_candidates.csv:rows=779;7341;7396;7418;7440;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297776,LEFITOLIMOD,,30.602593440122043,60,100.0,58.241037376048816,M,KG targets TLR9; clinical phase 2.0,repurposing_candidates.csv:rc_row=1217;protein_drug_candidates.csv:rows=262;pathway_drug_candidates.csv:rows=776;7338;7393;7415;7437;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297993,EMD-1201081,,30.602593440122043,60,100.0,58.241037376048816,M,KG targets TLR9; clinical phase 2.0,repurposing_candidates.csv:rc_row=1235;protein_drug_candidates.csv:rows=264;pathway_drug_candidates.csv:rows=778;7340;7395;7417;7439;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL37676,APC-100,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,47.88329519450801,40,100.0,58.153318077803206,L,KG targets AR; clinical phase 1.0; logS -4.23; logP 3.42,repurposing_candidates.csv:rc_row=1034;protein_drug_candidates.csv:rows=576;pathway_drug_candidates.csv:rows=1999;5914;7818;CYP3A4_results.csv:row=909;CYP2C19_results.csv:row=909;CYP2D6_results.csv:row=909;CYP1A2_results.csv:row=909;CYP2C9_results.csv:row=909;hERG_results.csv:row=909;AMES_results.csv:row=909;PGP_results.csv:row=909;PAMPA_results.csv:row=909;BBB_results.csv:row=909;Solubility_results.csv:row=909;Lipophilicity_results.csv:row=910
CHEMBL284121,ILX23-7553,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,47.88329519450801,40,100.0,58.153318077803206,L,KG targets VDR; clinical phase 1.0; logS -3.40; logP 4.85,repurposing_candidates.csv:rc_row=880;protein_drug_candidates.csv:rows=254;pathway_drug_candidates.csv:rows=6007;7784;7902;CYP3A4_results.csv:row=788;CYP2C19_results.csv:row=788;CYP2D6_results.csv:row=788;CYP1A2_results.csv:row=788;CYP2C9_results.csv:row=788;hERG_results.csv:row=788;AMES_results.csv:row=788;PGP_results.csv:row=788;PAMPA_results.csv:row=788;BBB_results.csv:row=788;Solubility_results.csv:row=788;Lipophilicity_results.csv:row=789
CHEMBL1431,METFORMIN,CN(C)C(=N)NC(=N)N,17.246376811594203,100,65.0,58.14855072463768,M,"KG targets GPD2, MT-ND4; clinical phase 4.0; hERG risk; logS -0.24; logP -1.03",repurposing_candidates.csv:rc_row=412;protein_drug_candidates.csv:rows=1535;1945;2173;CYP3A4_results.csv:row=372;CYP2C19_results.csv:row=372;CYP2D6_results.csv:row=372;CYP1A2_results.csv:row=372;CYP2C9_results.csv:row=372;hERG_results.csv:row=372;AMES_results.csv:row=372;PGP_results.csv:row=372;PAMPA_results.csv:row=372;BBB_results.csv:row=372;Solubility_results.csv:row=372;Lipophilicity_results.csv:row=373
CHEMBL1703,METFORMIN HYDROCHLORIDE,CN(C)C(=N)NC(=N)N.Cl,17.246376811594203,100,65.0,58.14855072463768,M,"KG targets GPD2, MT-ND4; clinical phase 4.0; hERG risk; logS 0.45; logP -0.61",repurposing_candidates.csv:rc_row=518;protein_drug_candidates.csv:rows=1536;1946;2174;CYP3A4_results.csv:row=478;CYP2C19_results.csv:row=478;CYP2D6_results.csv:row=478;CYP1A2_results.csv:row=478;CYP2C9_results.csv:row=478;hERG_results.csv:row=478;AMES_results.csv:row=478;PGP_results.csv:row=478;PAMPA_results.csv:row=478;BBB_results.csv:row=478;Solubility_results.csv:row=478;Lipophilicity_results.csv:row=479
CHEMBL4802159,ENPATORAN,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12,52.09382151029748,60,65.0,58.087528604118994,M,KG targets TLR7; clinical phase 2.0; hERG risk; logS -3.79; logP 2.82,repurposing_candidates.csv:rc_row=1330;protein_drug_candidates.csv:rows=602;pathway_drug_candidates.csv:rows=762;4258;7324;7346;7357;7368;7379;7401;7423;7445;7456;CYP3A4_results.csv:row=1141;CYP2C19_results.csv:row=1141;CYP2D6_results.csv:row=1141;CYP1A2_results.csv:row=1141;CYP2C9_results.csv:row=1141;hERG_results.csv:row=1141;AMES_results.csv:row=1141;PGP_results.csv:row=1141;PAMPA_results.csv:row=1141;BBB_results.csv:row=1141;Solubility_results.csv:row=1141;Lipophilicity_results.csv:row=1142
CHEMBL1201101,TESTOSTERONE CYPIONATE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,29.549961861174673,100,45.0,58.06998474446987,L,KG targets AR; clinical phase 4.0; hERG risk; logS -7.16; logP 6.40,repurposing_candidates.csv:rc_row=234;protein_drug_candidates.csv:rows=548;pathway_drug_candidates.csv:rows=1971;5886;7790;CYP3A4_results.csv:row=231;CYP2C19_results.csv:row=231;CYP2D6_results.csv:row=231;CYP1A2_results.csv:row=231;CYP2C9_results.csv:row=231;hERG_results.csv:row=231;AMES_results.csv:row=231;PGP_results.csv:row=231;PAMPA_results.csv:row=231;BBB_results.csv:row=231;Solubility_results.csv:row=231;Lipophilicity_results.csv:row=232
CHEMBL1743057,PEGSUNERCEPT,,30.076277650648358,60,100.0,58.03051106025934,M,KG targets TNF; clinical phase 2.0,repurposing_candidates.csv:rc_row=551;protein_drug_candidates.csv:rows=87;pathway_drug_candidates.csv:rows=396;4150;4165;4514;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743054,OZORALIZUMAB,,30.076277650648358,60,100.0,58.03051106025934,M,KG targets TNF; clinical phase 2.0,repurposing_candidates.csv:rc_row=550;protein_drug_candidates.csv:rows=89;pathway_drug_candidates.csv:rows=398;4152;4167;4516;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108887,AFELIMOMAB,,30.076277650648358,60,100.0,58.03051106025934,M,KG targets TNF; clinical phase 2.0,repurposing_candidates.csv:rc_row=759;protein_drug_candidates.csv:rows=86;pathway_drug_candidates.csv:rows=395;4149;4164;4513;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1201513,HEPARIN CALCIUM,,30.076277650648358,60,100.0,58.03051106025934,M,KG targets SERPINC1; clinical phase 2.0,repurposing_candidates.csv:rc_row=283;protein_drug_candidates.csv:rows=179;pathway_drug_candidates.csv:rows=151;7557;7586;7608;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108739,PLACULUMAB,,30.076277650648358,60,100.0,58.03051106025934,M,KG targets TNF; clinical phase 2.0,repurposing_candidates.csv:rc_row=756;protein_drug_candidates.csv:rows=90;pathway_drug_candidates.csv:rows=399;4153;4168;4517;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545157,TIDEGLUSIB,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,30.076277650648358,60,100.0,58.03051106025934,M,KG targets GSK3B; clinical phase 2.0; logS -4.79; logP 3.26,repurposing_candidates.csv:rc_row=974;protein_drug_candidates.csv:rows=1182;pathway_drug_candidates.csv:rows=5499;5510;5521;8093;CYP3A4_results.csv:row=873;CYP2C19_results.csv:row=873;CYP2D6_results.csv:row=873;CYP1A2_results.csv:row=873;CYP2C9_results.csv:row=873;hERG_results.csv:row=873;AMES_results.csv:row=873;PGP_results.csv:row=873;PAMPA_results.csv:row=873;BBB_results.csv:row=873;Solubility_results.csv:row=873;Lipophilicity_results.csv:row=874
CHEMBL1649931,PF-232798,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1,30.076277650648358,60,100.0,58.03051106025934,M,KG targets CCR5; clinical phase 2.0; logS -3.13; logP 4.31,repurposing_candidates.csv:rc_row=492;protein_drug_candidates.csv:rows=223;pathway_drug_candidates.csv:rows=1265;4382;6764;6788;CYP3A4_results.csv:row=452;CYP2C19_results.csv:row=452;CYP2D6_results.csv:row=452;CYP1A2_results.csv:row=452;CYP2C9_results.csv:row=452;hERG_results.csv:row=452;AMES_results.csv:row=452;PGP_results.csv:row=452;PAMPA_results.csv:row=452;BBB_results.csv:row=452;Solubility_results.csv:row=452;Lipophilicity_results.csv:row=453
CHEMBL432162,TASOSARTAN,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,48.40961098398169,60,70.0,57.86384439359268,M,KG targets AGTR1; clinical phase 2.0; hERG risk; logS -3.92; logP 3.42,repurposing_candidates.csv:rc_row=1255;protein_drug_candidates.csv:rows=596;pathway_drug_candidates.csv:rows=6550;7169;7280;7300;CYP3A4_results.csv:row=1075;CYP2C19_results.csv:row=1075;CYP2D6_results.csv:row=1075;CYP1A2_results.csv:row=1075;CYP2C9_results.csv:row=1075;hERG_results.csv:row=1075;AMES_results.csv:row=1075;PGP_results.csv:row=1075;PAMPA_results.csv:row=1075;BBB_results.csv:row=1075;Solubility_results.csv:row=1075;Lipophilicity_results.csv:row=1076
CHEMBL2107384,VICRIVIROC MALEATE,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O,48.40961098398169,60,70.0,57.86384439359268,M,KG targets CCR5; clinical phase 2.0; hERG risk; logS -2.02; logP 4.21,repurposing_candidates.csv:rc_row=728;protein_drug_candidates.csv:rows=224;pathway_drug_candidates.csv:rows=1266;4383;6765;6789;CYP3A4_results.csv:row=673;CYP2C19_results.csv:row=673;CYP2D6_results.csv:row=673;CYP1A2_results.csv:row=673;CYP2C9_results.csv:row=673;hERG_results.csv:row=673;AMES_results.csv:row=673;PGP_results.csv:row=673;PAMPA_results.csv:row=673;BBB_results.csv:row=673;Solubility_results.csv:row=673;Lipophilicity_results.csv:row=674
CHEMBL4594348,ELSUBRUTINIB,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1,48.40961098398169,60,70.0,57.86384439359268,M,KG targets BTK; clinical phase 2.0; hERG risk; logS -2.13; logP 2.16,repurposing_candidates.csv:rc_row=1292;protein_drug_candidates.csv:rows=209;pathway_drug_candidates.csv:rows=615;4110;6572;6752;CYP3A4_results.csv:row=1111;CYP2C19_results.csv:row=1111;CYP2D6_results.csv:row=1111;CYP1A2_results.csv:row=1111;CYP2C9_results.csv:row=1111;hERG_results.csv:row=1111;AMES_results.csv:row=1111;PGP_results.csv:row=1111;PAMPA_results.csv:row=1111;BBB_results.csv:row=1111;Solubility_results.csv:row=1111;Lipophilicity_results.csv:row=1112
CHEMBL187927,DIANICLINE,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3,30.85430968726163,80,70.0,57.84172387490465,H,"KG targets CHRNA4, CHRNB2; clinical phase 3.0; hERG risk; logS -2.39; logP 1.48",repurposing_candidates.csv:rc_row=585;protein_drug_candidates.csv:rows=437;2134;pathway_drug_candidates.csv:rows=7917;7931;7945;CYP3A4_results.csv:row=531;CYP2C19_results.csv:row=531;CYP2D6_results.csv:row=531;CYP1A2_results.csv:row=531;CYP2C9_results.csv:row=531;hERG_results.csv:row=531;AMES_results.csv:row=531;PGP_results.csv:row=531;PAMPA_results.csv:row=531;BBB_results.csv:row=531;Solubility_results.csv:row=531;Lipophilicity_results.csv:row=532
CHEMBL435381,CIMICOXIB,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F,32.707856598016775,60,95.0,57.83314263920671,M,KG targets PTGS2; clinical phase 2.0; logS -3.15; logP 2.99,repurposing_candidates.csv:rc_row=1257;protein_drug_candidates.csv:rows=163;pathway_drug_candidates.csv:rows=386;4504;5713;6097;6171;6245;6319;6393;6467;CYP3A4_results.csv:row=1077;CYP2C19_results.csv:row=1077;CYP2D6_results.csv:row=1077;CYP1A2_results.csv:row=1077;CYP2C9_results.csv:row=1077;hERG_results.csv:row=1077;AMES_results.csv:row=1077;PGP_results.csv:row=1077;PAMPA_results.csv:row=1077;BBB_results.csv:row=1077;Solubility_results.csv:row=1077;Lipophilicity_results.csv:row=1078
CHEMBL3545092,CR 1447,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets AR; clinical phase 2.0,repurposing_candidates.csv:rc_row=969;protein_drug_candidates.csv:rows=565;pathway_drug_candidates.csv:rows=1988;5903;7807;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2364619,METHYLSAMIDORPHAN,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13,29.549961861174673,60,100.0,57.81998474446987,M,KG targets OPRM1; clinical phase 2.0; logS -1.13; logP 1.40,repurposing_candidates.csv:rc_row=839;protein_drug_candidates.csv:rows=340;pathway_drug_candidates.csv:rows=310;1344;7257;CYP3A4_results.csv:row=748;CYP2C19_results.csv:row=748;CYP2D6_results.csv:row=748;CYP1A2_results.csv:row=748;CYP2C9_results.csv:row=748;hERG_results.csv:row=748;AMES_results.csv:row=748;PGP_results.csv:row=748;PAMPA_results.csv:row=748;BBB_results.csv:row=748;Solubility_results.csv:row=748;Lipophilicity_results.csv:row=749
CHEMBL4297538,MK-0812,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets CCR2; clinical phase 2.0,repurposing_candidates.csv:rc_row=1191;protein_drug_candidates.csv:rows=234;pathway_drug_candidates.csv:rows=1252;4369;6775;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3137313,AXELOPRAN,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1,29.549961861174673,60,100.0,57.81998474446987,M,KG targets OPRM1; clinical phase 2.0; logS -2.80; logP 2.26,repurposing_candidates.csv:rc_row=909;protein_drug_candidates.csv:rows=341;pathway_drug_candidates.csv:rows=311;1345;7258;CYP3A4_results.csv:row=816;CYP2C19_results.csv:row=816;CYP2D6_results.csv:row=816;CYP1A2_results.csv:row=816;CYP2C9_results.csv:row=816;hERG_results.csv:row=816;AMES_results.csv:row=816;PGP_results.csv:row=816;PAMPA_results.csv:row=816;BBB_results.csv:row=816;Solubility_results.csv:row=816;Lipophilicity_results.csv:row=817
CHEMBL3707228,PLOZALIZUMAB,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets CCR2; clinical phase 2.0,repurposing_candidates.csv:rc_row=1015;protein_drug_candidates.csv:rows=230;pathway_drug_candidates.csv:rows=1248;4365;6771;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3542265,LY2452473,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,29.549961861174673,60,100.0,57.81998474446987,M,KG targets AR; clinical phase 2.0; logS -4.09; logP 3.56,repurposing_candidates.csv:rc_row=954;protein_drug_candidates.csv:rows=566;pathway_drug_candidates.csv:rows=1989;5904;7808;CYP3A4_results.csv:row=858;CYP2C19_results.csv:row=858;CYP2D6_results.csv:row=858;CYP1A2_results.csv:row=858;CYP2C9_results.csv:row=858;hERG_results.csv:row=858;AMES_results.csv:row=858;PGP_results.csv:row=858;PAMPA_results.csv:row=858;BBB_results.csv:row=858;Solubility_results.csv:row=858;Lipophilicity_results.csv:row=859
CHEMBL3545174,GSK2881078,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets AR; clinical phase 2.0,repurposing_candidates.csv:rc_row=976;protein_drug_candidates.csv:rows=572;pathway_drug_candidates.csv:rows=1995;5910;7814;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545221,AZD2423,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets CCR2; clinical phase 2.0,repurposing_candidates.csv:rc_row=981;protein_drug_candidates.csv:rows=229;pathway_drug_candidates.csv:rows=1247;4364;6770;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545333,MK-0773,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets AR; clinical phase 2.0,repurposing_candidates.csv:rc_row=990;protein_drug_candidates.csv:rows=571;pathway_drug_candidates.csv:rows=1994;5909;7813;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL482968,ENMD-2076,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,29.549961861174673,60,100.0,57.81998474446987,M,KG targets KIT; clinical phase 2.0; logS -4.60; logP 3.17,repurposing_candidates.csv:rc_row=1332;protein_drug_candidates.csv:rows=1168;pathway_drug_candidates.csv:rows=573;6985;7519;CYP3A4_results.csv:row=1143;CYP2C19_results.csv:row=1143;CYP2D6_results.csv:row=1143;CYP1A2_results.csv:row=1143;CYP2C9_results.csv:row=1143;hERG_results.csv:row=1143;AMES_results.csv:row=1143;PGP_results.csv:row=1143;PAMPA_results.csv:row=1143;BBB_results.csv:row=1143;Solubility_results.csv:row=1143;Lipophilicity_results.csv:row=1144
CHEMBL128748,DIMETHYLCURCUMIN,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,29.549961861174673,60,100.0,57.81998474446987,M,KG targets AR; clinical phase 2.0; logS -3.83; logP 4.46,repurposing_candidates.csv:rc_row=374;protein_drug_candidates.csv:rows=570;pathway_drug_candidates.csv:rows=1993;5908;7812;CYP3A4_results.csv:row=335;CYP2C19_results.csv:row=335;CYP2D6_results.csv:row=335;CYP1A2_results.csv:row=335;CYP2C9_results.csv:row=335;hERG_results.csv:row=335;AMES_results.csv:row=335;PGP_results.csv:row=335;PAMPA_results.csv:row=335;BBB_results.csv:row=335;Solubility_results.csv:row=335;Lipophilicity_results.csv:row=336
CHEMBL4650501,PF-4136309,,29.549961861174673,60,100.0,57.81998474446987,M,KG targets CCR2; clinical phase 2.0,repurposing_candidates.csv:rc_row=1317;protein_drug_candidates.csv:rows=235;pathway_drug_candidates.csv:rows=1253;4370;6776;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL426084,SAMIDORPHAN,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3,29.549961861174673,60,100.0,57.81998474446987,M,KG targets OPRM1; clinical phase 2.0; logS -2.88; logP 1.25,repurposing_candidates.csv:rc_row=1152;protein_drug_candidates.csv:rows=339;pathway_drug_candidates.csv:rows=309;1343;7256;CYP3A4_results.csv:row=1016;CYP2C19_results.csv:row=1016;CYP2D6_results.csv:row=1016;CYP1A2_results.csv:row=1016;CYP2C9_results.csv:row=1016;hERG_results.csv:row=1016;AMES_results.csv:row=1016;PGP_results.csv:row=1016;PAMPA_results.csv:row=1016;BBB_results.csv:row=1016;Solubility_results.csv:row=1016;Lipophilicity_results.csv:row=1017
CHEMBL1200988,METHANTHELINE BROMIDE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-],46.83066361556064,40,100.0,57.73226544622426,L,KG targets HRH2; clinical phase 1.0; logS -0.77; logP 0.96,repurposing_candidates.csv:rc_row=211;protein_drug_candidates.csv:rows=754;pathway_drug_candidates.csv:rows=5823;CYP3A4_results.csv:row=209;CYP2C19_results.csv:row=209;CYP2D6_results.csv:row=209;CYP1A2_results.csv:row=209;CYP2C9_results.csv:row=209;hERG_results.csv:row=209;AMES_results.csv:row=209;PGP_results.csv:row=209;PAMPA_results.csv:row=209;BBB_results.csv:row=209;Solubility_results.csv:row=209;Lipophilicity_results.csv:row=210
CHEMBL3264610,SEVITERONEL,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,47.88329519450801,60,70.0,57.653318077803206,M,KG targets AR; clinical phase 2.0; hERG risk; logS -4.62; logP 4.05,repurposing_candidates.csv:rc_row=931;protein_drug_candidates.csv:rows=567;pathway_drug_candidates.csv:rows=1990;5905;7809;CYP3A4_results.csv:row=838;CYP2C19_results.csv:row=838;CYP2D6_results.csv:row=838;CYP1A2_results.csv:row=838;CYP2C9_results.csv:row=838;hERG_results.csv:row=838;AMES_results.csv:row=838;PGP_results.csv:row=838;PAMPA_results.csv:row=838;BBB_results.csv:row=838;Solubility_results.csv:row=838;Lipophilicity_results.csv:row=839
CHEMBL2178573,ILACIRNON,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,47.88329519450801,60,70.0,57.653318077803206,M,KG targets CCR2; clinical phase 2.0; hERG risk; logS -4.32; logP 4.37,repurposing_candidates.csv:rc_row=798;protein_drug_candidates.csv:rows=231;pathway_drug_candidates.csv:rows=1249;4366;6772;CYP3A4_results.csv:row=707;CYP2C19_results.csv:row=707;CYP2D6_results.csv:row=707;CYP1A2_results.csv:row=707;CYP2C9_results.csv:row=707;hERG_results.csv:row=707;AMES_results.csv:row=707;PGP_results.csv:row=707;PAMPA_results.csv:row=707;BBB_results.csv:row=707;Solubility_results.csv:row=707;Lipophilicity_results.csv:row=708
CHEMBL17157,TERFENADINE,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,28.497330282227306,100,45.0,57.648932112890925,L,KG targets HRH1; clinical phase 4.0; hERG risk; logS -6.11; logP 6.45,repurposing_candidates.csv:rc_row=526;protein_drug_candidates.csv:rows=1015;pathway_drug_candidates.csv:rows=6645;CYP3A4_results.csv:row=486;CYP2C19_results.csv:row=486;CYP2D6_results.csv:row=486;CYP1A2_results.csv:row=486;CYP2C9_results.csv:row=486;hERG_results.csv:row=486;AMES_results.csv:row=486;PGP_results.csv:row=486;PAMPA_results.csv:row=486;BBB_results.csv:row=486;Solubility_results.csv:row=486;Lipophilicity_results.csv:row=487
CHEMBL1201271,BUCLIZINE,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,28.497330282227306,100,45.0,57.648932112890925,L,KG targets HRH1; clinical phase 4.0; hERG risk; logS -6.06; logP 6.54,repurposing_candidates.csv:rc_row=266;protein_drug_candidates.csv:rows=998;pathway_drug_candidates.csv:rows=6628;CYP3A4_results.csv:row=263;CYP2C19_results.csv:row=263;CYP2D6_results.csv:row=263;CYP1A2_results.csv:row=263;CYP2C9_results.csv:row=263;hERG_results.csv:row=263;AMES_results.csv:row=263;PGP_results.csv:row=263;PAMPA_results.csv:row=263;BBB_results.csv:row=263;Solubility_results.csv:row=263;Lipophilicity_results.csv:row=264
CHEMBL1521,ZALEPLON,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,15.942028985507244,100,65.0,57.6268115942029,M,"KG targets GABRB1, GABRG2; clinical phase 4.0; hERG risk; logS -2.47; logP 2.64",repurposing_candidates.csv:rc_row=448;protein_drug_candidates.csv:rows=1639;1743;CYP3A4_results.csv:row=408;CYP2C19_results.csv:row=408;CYP2D6_results.csv:row=408;CYP1A2_results.csv:row=408;CYP2C9_results.csv:row=408;hERG_results.csv:row=408;AMES_results.csv:row=408;PGP_results.csv:row=408;PAMPA_results.csv:row=408;BBB_results.csv:row=408;Solubility_results.csv:row=408;Lipophilicity_results.csv:row=409
CHEMBL1008,BEPRIDIL,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,15.942028985507244,100,65.0,57.6268115942029,M,"KG targets CACNA1A, CACNA2D1; clinical phase 4.0; hERG risk; logS -3.93; logP 4.83",repurposing_candidates.csv:rc_row=3;protein_drug_candidates.csv:rows=1905;2489;CYP3A4_results.csv:row=3;CYP2C19_results.csv:row=3;CYP2D6_results.csv:row=3;CYP1A2_results.csv:row=3;CYP2C9_results.csv:row=3;hERG_results.csv:row=3;AMES_results.csv:row=3;PGP_results.csv:row=3;PAMPA_results.csv:row=3;BBB_results.csv:row=3;Solubility_results.csv:row=3;Lipophilicity_results.csv:row=3
CHEMBL321582,BUCINDOLOL,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N,32.15865751334859,60,95.0,57.61346300533943,M,"KG targets ADRA1A, ADRA1B; clinical phase 2.0; logS -3.25; logP 3.39",repurposing_candidates.csv:rc_row=927;protein_drug_candidates.csv:rows=401;1504;1861;pathway_drug_candidates.csv:rows=864;6526;6726;CYP3A4_results.csv:row=834;CYP2C19_results.csv:row=834;CYP2D6_results.csv:row=834;CYP1A2_results.csv:row=834;CYP2C9_results.csv:row=834;hERG_results.csv:row=834;AMES_results.csv:row=834;PGP_results.csv:row=834;PAMPA_results.csv:row=834;BBB_results.csv:row=834;Solubility_results.csv:row=834;Lipophilicity_results.csv:row=835
CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl,32.15865751334859,60,95.0,57.61346300533943,M,"KG targets ADRA1A, ADRA1B; clinical phase 2.0; logS -2.60; logP 3.81",repurposing_candidates.csv:rc_row=731;protein_drug_candidates.csv:rows=400;1503;1860;pathway_drug_candidates.csv:rows=863;6525;6725;CYP3A4_results.csv:row=676;CYP2C19_results.csv:row=676;CYP2D6_results.csv:row=676;CYP1A2_results.csv:row=676;CYP2C9_results.csv:row=676;hERG_results.csv:row=676;AMES_results.csv:row=676;PGP_results.csv:row=676;PAMPA_results.csv:row=676;BBB_results.csv:row=676;Solubility_results.csv:row=676;Lipophilicity_results.csv:row=677
CHEMBL1405,ESTRONE,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,14.63768115942029,80,95.0,57.60507246376812,H,KG targets ESR1; clinical phase 3.0; logS -4.84; logP 3.82,repurposing_candidates.csv:rc_row=403;protein_drug_candidates.csv:rows=2309;CYP3A4_results.csv:row=363;CYP2C19_results.csv:row=363;CYP2D6_results.csv:row=363;CYP1A2_results.csv:row=363;CYP2C9_results.csv:row=363;hERG_results.csv:row=363;AMES_results.csv:row=363;PGP_results.csv:row=363;PAMPA_results.csv:row=363;BBB_results.csv:row=363;Solubility_results.csv:row=363;Lipophilicity_results.csv:row=364
CHEMBL193482,ESTRIOL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,14.63768115942029,80,95.0,57.60507246376812,H,KG targets ESR1; clinical phase 3.0; logS -4.24; logP 2.58,repurposing_candidates.csv:rc_row=604;protein_drug_candidates.csv:rows=2304;CYP3A4_results.csv:row=550;CYP2C19_results.csv:row=550;CYP2D6_results.csv:row=550;CYP1A2_results.csv:row=550;CYP2C9_results.csv:row=550;hERG_results.csv:row=550;AMES_results.csv:row=550;PGP_results.csv:row=550;PAMPA_results.csv:row=550;BBB_results.csv:row=550;Solubility_results.csv:row=550;Lipophilicity_results.csv:row=551
CHEMBL61780,TEZOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,14.63768115942029,80,95.0,57.60507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -5.21; logP 3.21,repurposing_candidates.csv:rc_row=1455;protein_drug_candidates.csv:rows=1921;CYP3A4_results.csv:row=1262;CYP2C19_results.csv:row=1262;CYP2D6_results.csv:row=1262;CYP1A2_results.csv:row=1262;CYP2C9_results.csv:row=1262;hERG_results.csv:row=1262;AMES_results.csv:row=1262;PGP_results.csv:row=1262;PAMPA_results.csv:row=1262;BBB_results.csv:row=1262;Solubility_results.csv:row=1262;Lipophilicity_results.csv:row=1263
CHEMBL82301,VICRIVIROC,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,30.076277650648358,80,70.0,57.53051106025934,H,KG targets CCR5; clinical phase 3.0; hERG risk; logS -2.39; logP 4.50,repurposing_candidates.csv:rc_row=1525;protein_drug_candidates.csv:rows=217;pathway_drug_candidates.csv:rows=1259;4376;6758;6782;CYP3A4_results.csv:row=1331;CYP2C19_results.csv:row=1331;CYP2D6_results.csv:row=1331;CYP1A2_results.csv:row=1331;CYP2C9_results.csv:row=1331;hERG_results.csv:row=1331;AMES_results.csv:row=1331;PGP_results.csv:row=1331;PAMPA_results.csv:row=1331;BBB_results.csv:row=1331;Solubility_results.csv:row=1331;Lipophilicity_results.csv:row=1332
CHEMBL515387,GOSOGLIPTIN,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,32.971014492753625,80,65.0,57.43840579710145,M,KG targets DPP4; clinical phase 3.0; hERG risk; logS -2.84; logP 0.20,repurposing_candidates.csv:rc_row=1362;protein_drug_candidates.csv:rows=677;CYP3A4_results.csv:row=1173;CYP2C19_results.csv:row=1173;CYP2D6_results.csv:row=1173;CYP1A2_results.csv:row=1173;CYP2C9_results.csv:row=1173;hERG_results.csv:row=1173;AMES_results.csv:row=1173;PGP_results.csv:row=1173;PAMPA_results.csv:row=1173;BBB_results.csv:row=1173;Solubility_results.csv:row=1173;Lipophilicity_results.csv:row=1174
CHEMBL4296719,DUTOGLIPTIN,O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,32.971014492753625,80,65.0,57.43840579710145,M,KG targets DPP4; clinical phase 3.0; hERG risk; logS -0.73; logP -2.06,repurposing_candidates.csv:rc_row=1156;protein_drug_candidates.csv:rows=673;CYP3A4_results.csv:row=1020;CYP2C19_results.csv:row=1020;CYP2D6_results.csv:row=1020;CYP1A2_results.csv:row=1020;CYP2C9_results.csv:row=1020;hERG_results.csv:row=1020;AMES_results.csv:row=1020;PGP_results.csv:row=1020;PAMPA_results.csv:row=1020;BBB_results.csv:row=1020;Solubility_results.csv:row=1020;Lipophilicity_results.csv:row=1021
CHEMBL1162175,REGRELOR,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21,28.497330282227306,60,100.0,57.398932112890925,M,KG targets P2RY12; clinical phase 2.0; logS -4.33; logP 1.80,repurposing_candidates.csv:rc_row=67;protein_drug_candidates.csv:rows=475;pathway_drug_candidates.csv:rows=1360;CYP3A4_results.csv:row=66;CYP2C19_results.csv:row=66;CYP2D6_results.csv:row=66;CYP1A2_results.csv:row=66;CYP2C9_results.csv:row=66;hERG_results.csv:row=66;AMES_results.csv:row=66;PGP_results.csv:row=66;PAMPA_results.csv:row=66;BBB_results.csv:row=66;Solubility_results.csv:row=66;Lipophilicity_results.csv:row=66
CHEMBL3544953,SAF312,,28.497330282227306,60,100.0,57.398932112890925,M,KG targets TRPV1; clinical phase 2.0,repurposing_candidates.csv:rc_row=959;protein_drug_candidates.csv:rows=697;pathway_drug_candidates.csv:rows=5723;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297616,OLINCIGUAT,NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F,28.497330282227306,60,100.0,57.398932112890925,M,KG targets GUCY1B1; clinical phase 2.0; logS -2.42; logP 2.51,repurposing_candidates.csv:rc_row=1197;protein_drug_candidates.csv:rows=79;pathway_drug_candidates.csv:rows=7695;CYP3A4_results.csv:row=1057;CYP2C19_results.csv:row=1057;CYP2D6_results.csv:row=1057;CYP1A2_results.csv:row=1057;CYP2C9_results.csv:row=1057;hERG_results.csv:row=1057;AMES_results.csv:row=1057;PGP_results.csv:row=1057;PAMPA_results.csv:row=1057;BBB_results.csv:row=1057;Solubility_results.csv:row=1057;Lipophilicity_results.csv:row=1058
CHEMBL3545039,AZD1386,Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O,28.497330282227306,60,100.0,57.398932112890925,M,KG targets TRPV1; clinical phase 2.0; logS -4.56; logP 3.25,repurposing_candidates.csv:rc_row=965;protein_drug_candidates.csv:rows=698;pathway_drug_candidates.csv:rows=5724;CYP3A4_results.csv:row=867;CYP2C19_results.csv:row=867;CYP2D6_results.csv:row=867;CYP1A2_results.csv:row=867;CYP2C9_results.csv:row=867;hERG_results.csv:row=867;AMES_results.csv:row=867;PGP_results.csv:row=867;PAMPA_results.csv:row=867;BBB_results.csv:row=867;Solubility_results.csv:row=867;Lipophilicity_results.csv:row=868
CHEMBL3545316,RINUCUMAB,,28.497330282227306,60,100.0,57.398932112890925,M,KG targets PDGFRB; clinical phase 2.0,repurposing_candidates.csv:rc_row=988;protein_drug_candidates.csv:rows=1131;pathway_drug_candidates.csv:rows=7029;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3707293,XEN-D0501,,28.497330282227306,60,100.0,57.398932112890925,M,KG targets TRPV1; clinical phase 2.0,repurposing_candidates.csv:rc_row=1018;protein_drug_candidates.csv:rows=695;pathway_drug_candidates.csv:rows=5721;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545401,X-82,,28.497330282227306,60,100.0,57.398932112890925,M,KG targets PDGFRB; clinical phase 2.0,repurposing_candidates.csv:rc_row=995;protein_drug_candidates.csv:rows=1129;pathway_drug_candidates.csv:rows=7027;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL22108,DIMETHINDENE,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,28.497330282227306,60,100.0,57.398932112890925,M,KG targets HRH1; clinical phase 2.0; logS -3.61; logP 4.15,repurposing_candidates.csv:rc_row=805;protein_drug_candidates.csv:rows=1039;pathway_drug_candidates.csv:rows=6669;CYP3A4_results.csv:row=714;CYP2C19_results.csv:row=714;CYP2D6_results.csv:row=714;CYP1A2_results.csv:row=714;CYP2C9_results.csv:row=714;hERG_results.csv:row=714;AMES_results.csv:row=714;PGP_results.csv:row=714;PAMPA_results.csv:row=714;BBB_results.csv:row=714;Solubility_results.csv:row=714;Lipophilicity_results.csv:row=715
CHEMBL3039511,BEVENOPRAN,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,29.549961861174673,80,70.0,57.31998474446987,H,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -2.48; logP 2.28,repurposing_candidates.csv:rc_row=896;protein_drug_candidates.csv:rows=331;pathway_drug_candidates.csv:rows=301;1335;7248;CYP3A4_results.csv:row=804;CYP2C19_results.csv:row=804;CYP2D6_results.csv:row=804;CYP1A2_results.csv:row=804;CYP2C9_results.csv:row=804;hERG_results.csv:row=804;AMES_results.csv:row=804;PGP_results.csv:row=804;PAMPA_results.csv:row=804;BBB_results.csv:row=804;Solubility_results.csv:row=804;Lipophilicity_results.csv:row=805
CHEMBL1200436,OXANDROLONE,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,29.549961861174673,80,70.0,57.31998474446987,H,KG targets AR; clinical phase 3.0; hERG risk; logS -4.60; logP 3.54,repurposing_candidates.csv:rc_row=102;protein_drug_candidates.csv:rows=558;pathway_drug_candidates.csv:rows=1981;5896;7800;CYP3A4_results.csv:row=101;CYP2C19_results.csv:row=101;CYP2D6_results.csv:row=101;CYP1A2_results.csv:row=101;CYP2C9_results.csv:row=101;hERG_results.csv:row=101;AMES_results.csv:row=101;PGP_results.csv:row=101;PAMPA_results.csv:row=101;BBB_results.csv:row=101;Solubility_results.csv:row=101;Lipophilicity_results.csv:row=101
CHEMBL440498,CTS-1027,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,49.713958810068654,60,65.0,57.13558352402747,M,"KG targets MMP13, MMP8; clinical phase 2.0; hERG risk; logS -4.06; logP 3.21",repurposing_candidates.csv:rc_row=1259;protein_drug_candidates.csv:rows=618;625;pathway_drug_candidates.csv:rows=36;47;60;71;91;102;3031;CYP3A4_results.csv:row=1079;CYP2C19_results.csv:row=1079;CYP2D6_results.csv:row=1079;CYP1A2_results.csv:row=1079;CYP2C9_results.csv:row=1079;hERG_results.csv:row=1079;AMES_results.csv:row=1079;PGP_results.csv:row=1079;PAMPA_results.csv:row=1079;BBB_results.csv:row=1079;Solubility_results.csv:row=1079;Lipophilicity_results.csv:row=1080
CHEMBL4802163,NEZULCITINIB,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1,45.31655225019069,40,100.0,57.126620900076276,L,"KG targets JAK1, JAK2; clinical phase 1.0; logS -3.49; logP 3.80",repurposing_candidates.csv:rc_row=1331;protein_drug_candidates.csv:rows=776;803;1198;pathway_drug_candidates.csv:rows=201;228;416;663;690;795;4253;4280;4432;4534;4573;4600;4617;4652;4679;4696;4731;4758;4775;4800;4816;4838;4865;4882;4907;4934;4951;4973;5000;5017;5039;5066;5083;5110;5127;5149;5176;5193;5227;5243;5277;5293;5315;5342;5359;5381;5408;5425;5441;5475;5491;6928;6955;7489;8318;8346;8374;8408;8436;8464;CYP3A4_results.csv:row=1142;CYP2C19_results.csv:row=1142;CYP2D6_results.csv:row=1142;CYP1A2_results.csv:row=1142;CYP2C9_results.csv:row=1142;hERG_results.csv:row=1142;AMES_results.csv:row=1142;PGP_results.csv:row=1142;PAMPA_results.csv:row=1142;BBB_results.csv:row=1142;Solubility_results.csv:row=1142;Lipophilicity_results.csv:row=1143
CHEMBL1615374,VILAZODONE HYDROCHLORIDE,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,14.63768115942029,100,65.0,57.10507246376812,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.63; logP 4.45,repurposing_candidates.csv:rc_row=479;protein_drug_candidates.csv:rows=1261;CYP3A4_results.csv:row=439;CYP2C19_results.csv:row=439;CYP2D6_results.csv:row=439;CYP1A2_results.csv:row=439;CYP2C9_results.csv:row=439;hERG_results.csv:row=439;AMES_results.csv:row=439;PGP_results.csv:row=439;PAMPA_results.csv:row=439;BBB_results.csv:row=439;Solubility_results.csv:row=439;Lipophilicity_results.csv:row=440
CHEMBL1113,AMOXAPINE,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,14.63768115942029,100,65.0,57.10507246376812,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.94; logP 3.43,repurposing_candidates.csv:rc_row=54;protein_drug_candidates.csv:rows=1255;CYP3A4_results.csv:row=54;CYP2C19_results.csv:row=54;CYP2D6_results.csv:row=54;CYP1A2_results.csv:row=54;CYP2C9_results.csv:row=54;hERG_results.csv:row=54;AMES_results.csv:row=54;PGP_results.csv:row=54;PAMPA_results.csv:row=54;BBB_results.csv:row=54;Solubility_results.csv:row=54;Lipophilicity_results.csv:row=54
CHEMBL24828,VANDETANIB,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,14.63768115942029,100,65.0,57.10507246376812,M,KG targets EPHA7; clinical phase 4.0; hERG risk; logS -4.32; logP 4.43,repurposing_candidates.csv:rc_row=853;protein_drug_candidates.csv:rows=1770;CYP3A4_results.csv:row=761;CYP2C19_results.csv:row=761;CYP2D6_results.csv:row=761;CYP1A2_results.csv:row=761;CYP2C9_results.csv:row=761;hERG_results.csv:row=761;AMES_results.csv:row=761;PGP_results.csv:row=761;PAMPA_results.csv:row=761;BBB_results.csv:row=761;Solubility_results.csv:row=761;Lipophilicity_results.csv:row=762
CHEMBL621,TRAZODONE,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,14.63768115942029,100,65.0,57.10507246376812,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -3.39; logP 2.36,repurposing_candidates.csv:rc_row=1456;protein_drug_candidates.csv:rows=1268;CYP3A4_results.csv:row=1263;CYP2C19_results.csv:row=1263;CYP2D6_results.csv:row=1263;CYP1A2_results.csv:row=1263;CYP2C9_results.csv:row=1263;hERG_results.csv:row=1263;AMES_results.csv:row=1263;PGP_results.csv:row=1263;PAMPA_results.csv:row=1263;BBB_results.csv:row=1263;Solubility_results.csv:row=1263;Lipophilicity_results.csv:row=1264
CHEMBL623,NEFAZODONE,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,14.63768115942029,100,65.0,57.10507246376812,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -5.21; logP 3.55,repurposing_candidates.csv:rc_row=1458;protein_drug_candidates.csv:rows=1275;CYP3A4_results.csv:row=1265;CYP2C19_results.csv:row=1265;CYP2D6_results.csv:row=1265;CYP1A2_results.csv:row=1265;CYP2C9_results.csv:row=1265;hERG_results.csv:row=1265;AMES_results.csv:row=1265;PGP_results.csv:row=1265;PAMPA_results.csv:row=1265;BBB_results.csv:row=1265;Solubility_results.csv:row=1265;Lipophilicity_results.csv:row=1266
CHEMBL5314391,XL-999,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,30.85430968726163,60,95.0,57.09172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0; logS -5.07; logP 4.66",repurposing_candidates.csv:rc_row=1380;protein_drug_candidates.csv:rows=1126;1169;pathway_drug_candidates.csv:rows=574;6986;7024;7520;CYP3A4_results.csv:row=1191;CYP2C19_results.csv:row=1191;CYP2D6_results.csv:row=1191;CYP1A2_results.csv:row=1191;CYP2C9_results.csv:row=1191;hERG_results.csv:row=1191;AMES_results.csv:row=1191;PGP_results.csv:row=1191;PAMPA_results.csv:row=1191;BBB_results.csv:row=1191;Solubility_results.csv:row=1191;Lipophilicity_results.csv:row=1192
CHEMBL1201353,DEXCHLORPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,28.497330282227306,80,70.0,56.898932112890925,H,KG targets HRH1; clinical phase 3.0; hERG risk; logS -2.89; logP 3.82,repurposing_candidates.csv:rc_row=273;protein_drug_candidates.csv:rows=1029;pathway_drug_candidates.csv:rows=6659;CYP3A4_results.csv:row=270;CYP2C19_results.csv:row=270;CYP2D6_results.csv:row=270;CYP1A2_results.csv:row=270;CYP2C9_results.csv:row=270;hERG_results.csv:row=270;AMES_results.csv:row=270;PGP_results.csv:row=270;PAMPA_results.csv:row=270;BBB_results.csv:row=270;Solubility_results.csv:row=270;Lipophilicity_results.csv:row=271
CHEMBL2105728,CRENOLANIB,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,28.497330282227306,80,70.0,56.898932112890925,H,KG targets PDGFRB; clinical phase 3.0; hERG risk; logS -5.19; logP 3.92,repurposing_candidates.csv:rc_row=702;protein_drug_candidates.csv:rows=1115;pathway_drug_candidates.csv:rows=7013;CYP3A4_results.csv:row=647;CYP2C19_results.csv:row=647;CYP2D6_results.csv:row=647;CYP1A2_results.csv:row=647;CYP2C9_results.csv:row=647;hERG_results.csv:row=647;AMES_results.csv:row=647;PGP_results.csv:row=647;PAMPA_results.csv:row=647;BBB_results.csv:row=647;Solubility_results.csv:row=647;Lipophilicity_results.csv:row=648
CHEMBL1201089,DIPHENHYDRAMINE CITRATE,CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,28.497330282227306,80,70.0,56.898932112890925,H,KG targets HRH1; clinical phase 3.0; hERG risk; logS -2.18; logP 2.11,repurposing_candidates.csv:rc_row=232;protein_drug_candidates.csv:rows=1036;pathway_drug_candidates.csv:rows=6666;CYP3A4_results.csv:row=230;CYP2C19_results.csv:row=230;CYP2D6_results.csv:row=230;CYP1A2_results.csv:row=230;CYP2C9_results.csv:row=230;hERG_results.csv:row=230;AMES_results.csv:row=230;PGP_results.csv:row=230;PAMPA_results.csv:row=230;BBB_results.csv:row=230;Solubility_results.csv:row=230;Lipophilicity_results.csv:row=231
CHEMBL4297447,TRV-120027,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O,30.076277650648358,60,95.0,56.78051106025934,M,KG targets AGTR1; clinical phase 2.0; logS 0.01; logP -1.91,repurposing_candidates.csv:rc_row=1177;protein_drug_candidates.csv:rows=597;pathway_drug_candidates.csv:rows=6551;7170;7281;7301;CYP3A4_results.csv:row=1040;CYP2C19_results.csv:row=1040;CYP2D6_results.csv:row=1040;CYP1A2_results.csv:row=1040;CYP2C9_results.csv:row=1040;hERG_results.csv:row=1040;AMES_results.csv:row=1040;PGP_results.csv:row=1040;PAMPA_results.csv:row=1040;BBB_results.csv:row=1040;Solubility_results.csv:row=1040;Lipophilicity_results.csv:row=1041
CHEMBL3301625,SPEBRUTINIB,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,30.076277650648358,60,95.0,56.78051106025934,M,KG targets BTK; clinical phase 2.0; logS -3.45; logP 4.25,repurposing_candidates.csv:rc_row=943;protein_drug_candidates.csv:rows=206;pathway_drug_candidates.csv:rows=612;4107;6569;6749;CYP3A4_results.csv:row=847;CYP2C19_results.csv:row=847;CYP2D6_results.csv:row=847;CYP1A2_results.csv:row=847;CYP2C9_results.csv:row=847;hERG_results.csv:row=847;AMES_results.csv:row=847;PGP_results.csv:row=847;PAMPA_results.csv:row=847;BBB_results.csv:row=847;Solubility_results.csv:row=847;Lipophilicity_results.csv:row=848
CHEMBL483465,ELRAGLUSIB,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3,30.076277650648358,60,95.0,56.78051106025934,M,KG targets GSK3B; clinical phase 2.0; logS -5.41; logP 3.36,repurposing_candidates.csv:rc_row=1333;protein_drug_candidates.csv:rows=1181;pathway_drug_candidates.csv:rows=5498;5509;5520;8092;CYP3A4_results.csv:row=1144;CYP2C19_results.csv:row=1144;CYP2D6_results.csv:row=1144;CYP1A2_results.csv:row=1144;CYP2C9_results.csv:row=1144;hERG_results.csv:row=1144;AMES_results.csv:row=1144;PGP_results.csv:row=1144;PAMPA_results.csv:row=1144;BBB_results.csv:row=1144;Solubility_results.csv:row=1144;Lipophilicity_results.csv:row=1145
CHEMBL1651534,REDAFAMDASTAT,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,32.971014492753625,60,90.0,56.68840579710145,M,KG targets FAAH; clinical phase 2.0; logS -5.18; logP 5.39,repurposing_candidates.csv:rc_row=496;protein_drug_candidates.csv:rows=688;CYP3A4_results.csv:row=456;CYP2C19_results.csv:row=456;CYP2D6_results.csv:row=456;CYP1A2_results.csv:row=456;CYP2C9_results.csv:row=456;hERG_results.csv:row=456;AMES_results.csv:row=456;PGP_results.csv:row=456;PAMPA_results.csv:row=456;BBB_results.csv:row=456;Solubility_results.csv:row=456;Lipophilicity_results.csv:row=457
CHEMBL52885,ENMD-981693,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21,29.801678108314263,60,95.0,56.67067124332571,M,"KG targets BLK, PDGFRB; clinical phase 2.0; logS -3.81; logP 3.15",repurposing_candidates.csv:rc_row=1374;protein_drug_candidates.csv:rows=943;1132;pathway_drug_candidates.csv:rows=7030;CYP3A4_results.csv:row=1185;CYP2C19_results.csv:row=1185;CYP2D6_results.csv:row=1185;CYP1A2_results.csv:row=1185;CYP2C9_results.csv:row=1185;hERG_results.csv:row=1185;AMES_results.csv:row=1185;PGP_results.csv:row=1185;PAMPA_results.csv:row=1185;BBB_results.csv:row=1185;Solubility_results.csv:row=1185;Lipophilicity_results.csv:row=1186
CHEMBL4594275,GUSACITINIB,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,45.31655225019069,60,70.0,56.626620900076276,M,"KG targets JAK1, JAK2; clinical phase 2.0; hERG risk; logS -3.69; logP 2.55",repurposing_candidates.csv:rc_row=1287;protein_drug_candidates.csv:rows=771;794;1194;pathway_drug_candidates.csv:rows=196;219;412;658;681;791;4248;4276;4427;4530;4568;4591;4613;4647;4670;4692;4726;4749;4771;4795;4812;4833;4856;4878;4902;4925;4947;4968;4991;5013;5034;5057;5079;5101;5123;5144;5167;5189;5222;5239;5272;5289;5310;5333;5355;5376;5399;5421;5437;5470;5487;6923;6946;7480;8309;8337;8365;8399;8427;8455;CYP3A4_results.csv:row=1107;CYP2C19_results.csv:row=1107;CYP2D6_results.csv:row=1107;CYP1A2_results.csv:row=1107;CYP2C9_results.csv:row=1107;hERG_results.csv:row=1107;AMES_results.csv:row=1107;PGP_results.csv:row=1107;PAMPA_results.csv:row=1107;BBB_results.csv:row=1107;Solubility_results.csv:row=1107;Lipophilicity_results.csv:row=1108
CHEMBL41,FLUOXETINE,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,14.63768115942029,95,70.0,56.60507246376812,H,KG targets SLC6A4; clinical phase 3.0; hERG risk; logS -1.87; logP 4.44,repurposing_candidates.csv:rc_row=1131;protein_drug_candidates.csv:rows=1283;CYP3A4_results.csv:row=995;CYP2C19_results.csv:row=995;CYP2D6_results.csv:row=995;CYP1A2_results.csv:row=995;CYP2C9_results.csv:row=995;hERG_results.csv:row=995;AMES_results.csv:row=995;PGP_results.csv:row=995;PAMPA_results.csv:row=995;BBB_results.csv:row=995;Solubility_results.csv:row=995;Lipophilicity_results.csv:row=996
CHEMBL5170587,VK5211,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F,29.549961861174673,60,95.0,56.56998474446987,M,KG targets AR; clinical phase 2.0; logS -2.34; logP 3.47,repurposing_candidates.csv:rc_row=1366;protein_drug_candidates.csv:rows=569;pathway_drug_candidates.csv:rows=1992;5907;7811;CYP3A4_results.csv:row=1177;CYP2C19_results.csv:row=1177;CYP2D6_results.csv:row=1177;CYP1A2_results.csv:row=1177;CYP2C9_results.csv:row=1177;hERG_results.csv:row=1177;AMES_results.csv:row=1177;PGP_results.csv:row=1177;PAMPA_results.csv:row=1177;BBB_results.csv:row=1177;Solubility_results.csv:row=1177;Lipophilicity_results.csv:row=1178
CHEMBL404849,SULOCTIDIL,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,15.942028985507244,100,60.0,56.3768115942029,M,"KG targets CACNA1A, CACNA2D1; clinical phase 4.0; hERG risk; logS -5.93; logP 5.56",repurposing_candidates.csv:rc_row=1118;protein_drug_candidates.csv:rows=1904;2488;CYP3A4_results.csv:row=982;CYP2C19_results.csv:row=982;CYP2D6_results.csv:row=982;CYP1A2_results.csv:row=982;CYP2C9_results.csv:row=982;hERG_results.csv:row=982;AMES_results.csv:row=982;PGP_results.csv:row=982;PAMPA_results.csv:row=982;BBB_results.csv:row=982;Solubility_results.csv:row=982;Lipophilicity_results.csv:row=983
CHEMBL2017179,EVACETRAPIB,Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1,14.63768115942029,80,90.0,56.35507246376812,H,KG targets CETP; clinical phase 3.0; logS -3.68; logP 7.10,repurposing_candidates.csv:rc_row=621;protein_drug_candidates.csv:rows=1897;CYP3A4_results.csv:row=567;CYP2C19_results.csv:row=567;CYP2D6_results.csv:row=567;CYP1A2_results.csv:row=567;CYP2C9_results.csv:row=567;hERG_results.csv:row=567;AMES_results.csv:row=567;PGP_results.csv:row=567;PAMPA_results.csv:row=567;BBB_results.csv:row=567;Solubility_results.csv:row=567;Lipophilicity_results.csv:row=568
CHEMBL328190,LASOFOXIFENE,Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,14.63768115942029,80,90.0,56.35507246376812,H,KG targets ESR1; clinical phase 3.0; logS -5.52; logP 5.73,repurposing_candidates.csv:rc_row=932;protein_drug_candidates.csv:rows=2303;CYP3A4_results.csv:row=839;CYP2C19_results.csv:row=839;CYP2D6_results.csv:row=839;CYP1A2_results.csv:row=839;CYP2C9_results.csv:row=839;hERG_results.csv:row=839;AMES_results.csv:row=839;PGP_results.csv:row=839;PAMPA_results.csv:row=839;BBB_results.csv:row=839;Solubility_results.csv:row=839;Lipophilicity_results.csv:row=840
CHEMBL3785197,OBICETRAPIB,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC,14.63768115942029,80,90.0,56.35507246376812,H,KG targets CETP; clinical phase 3.0; logS -5.17; logP 8.67,repurposing_candidates.csv:rc_row=1036;protein_drug_candidates.csv:rows=1899;CYP3A4_results.csv:row=911;CYP2C19_results.csv:row=911;CYP2D6_results.csv:row=911;CYP1A2_results.csv:row=911;CYP2C9_results.csv:row=911;hERG_results.csv:row=911;AMES_results.csv:row=911;PGP_results.csv:row=911;PAMPA_results.csv:row=911;BBB_results.csv:row=911;Solubility_results.csv:row=911;Lipophilicity_results.csv:row=912
CHEMBL2106068,ATRASENTAN HYDROCHLORIDE,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl,14.63768115942029,80,90.0,56.35507246376812,H,KG targets EDNRA; clinical phase 3.0; logS -3.01; logP 5.12,repurposing_candidates.csv:rc_row=714;protein_drug_candidates.csv:rows=1922;CYP3A4_results.csv:row=659;CYP2C19_results.csv:row=659;CYP2D6_results.csv:row=659;CYP1A2_results.csv:row=659;CYP2C9_results.csv:row=659;hERG_results.csv:row=659;AMES_results.csv:row=659;PGP_results.csv:row=659;PAMPA_results.csv:row=659;BBB_results.csv:row=659;Solubility_results.csv:row=659;Lipophilicity_results.csv:row=660
CHEMBL1095032,LETAXABAN,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1,47.35697940503432,60,65.0,56.19279176201373,M,KG targets F10; clinical phase 2.0; hERG risk; logS -5.57; logP 2.03,repurposing_candidates.csv:rc_row=44;protein_drug_candidates.csv:rows=463;pathway_drug_candidates.csv:rows=7543;7572;CYP3A4_results.csv:row=44;CYP2C19_results.csv:row=44;CYP2D6_results.csv:row=44;CYP1A2_results.csv:row=44;CYP2C9_results.csv:row=44;hERG_results.csv:row=44;AMES_results.csv:row=44;PGP_results.csv:row=44;PAMPA_results.csv:row=44;BBB_results.csv:row=44;Solubility_results.csv:row=44;Lipophilicity_results.csv:row=44
CHEMBL261244,REGRELOR DISODIUM,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+],28.497330282227306,60,95.0,56.148932112890925,M,KG targets P2RY12; clinical phase 2.0; logS -2.77; logP -5.46,repurposing_candidates.csv:rc_row=863;protein_drug_candidates.csv:rows=476;pathway_drug_candidates.csv:rows=1361;CYP3A4_results.csv:row=771;CYP2C19_results.csv:row=771;CYP2D6_results.csv:row=771;CYP1A2_results.csv:row=771;CYP2C9_results.csv:row=771;hERG_results.csv:row=771;AMES_results.csv:row=771;PGP_results.csv:row=771;PAMPA_results.csv:row=771;BBB_results.csv:row=771;Solubility_results.csv:row=771;Lipophilicity_results.csv:row=772
CHEMBL217092,SARACATINIB,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,28.497330282227306,60,95.0,56.148932112890925,M,KG targets ABL1; clinical phase 2.0; logS -3.95; logP 3.94,repurposing_candidates.csv:rc_row=796;protein_drug_candidates.csv:rows=1218;pathway_drug_candidates.csv:rows=4309;CYP3A4_results.csv:row=705;CYP2C19_results.csv:row=705;CYP2D6_results.csv:row=705;CYP1A2_results.csv:row=705;CYP2C9_results.csv:row=705;hERG_results.csv:row=705;AMES_results.csv:row=705;PGP_results.csv:row=705;PAMPA_results.csv:row=705;BBB_results.csv:row=705;Solubility_results.csv:row=705;Lipophilicity_results.csv:row=706
CHEMBL658,SUFENTANIL,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,29.549961861174673,80,65.0,56.06998474446987,M,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -3.51; logP 4.21,repurposing_candidates.csv:rc_row=1478;protein_drug_candidates.csv:rows=324;pathway_drug_candidates.csv:rows=294;1328;7241;CYP3A4_results.csv:row=1284;CYP2C19_results.csv:row=1284;CYP2D6_results.csv:row=1284;CYP1A2_results.csv:row=1284;CYP2C9_results.csv:row=1284;hERG_results.csv:row=1284;AMES_results.csv:row=1284;PGP_results.csv:row=1284;PAMPA_results.csv:row=1284;BBB_results.csv:row=1284;Solubility_results.csv:row=1284;Lipophilicity_results.csv:row=1285
CHEMBL1005,REMIFENTANIL,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,29.549961861174673,80,65.0,56.06998474446987,M,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -2.30; logP 2.00,repurposing_candidates.csv:rc_row=2;protein_drug_candidates.csv:rows=325;pathway_drug_candidates.csv:rows=295;1329;7242;CYP3A4_results.csv:row=2;CYP2C19_results.csv:row=2;CYP2D6_results.csv:row=2;CYP1A2_results.csv:row=2;CYP2C9_results.csv:row=2;hERG_results.csv:row=2;AMES_results.csv:row=2;PGP_results.csv:row=2;PAMPA_results.csv:row=2;BBB_results.csv:row=2;Solubility_results.csv:row=2;Lipophilicity_results.csv:row=2
CHEMBL2106615,BAZEDOXIFENE ACETATE,CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,14.63768115942029,100,60.0,55.85507246376812,M,KG targets ESR1; clinical phase 4.0; hERG risk; logS -4.82; logP 6.42,repurposing_candidates.csv:rc_row=719;protein_drug_candidates.csv:rows=2285;CYP3A4_results.csv:row=664;CYP2C19_results.csv:row=664;CYP2D6_results.csv:row=664;CYP1A2_results.csv:row=664;CYP2C9_results.csv:row=664;hERG_results.csv:row=664;AMES_results.csv:row=664;PGP_results.csv:row=664;PAMPA_results.csv:row=664;BBB_results.csv:row=664;Solubility_results.csv:row=664;Lipophilicity_results.csv:row=665
CHEMBL3185958,CLOMIPHENE CITRATE,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,14.63768115942029,100,60.0,55.85507246376812,M,KG targets ESR1; clinical phase 4.0; hERG risk; logS -5.70; logP 5.31,repurposing_candidates.csv:rc_row=922;protein_drug_candidates.csv:rows=2278;CYP3A4_results.csv:row=829;CYP2C19_results.csv:row=829;CYP2D6_results.csv:row=829;CYP1A2_results.csv:row=829;CYP2C9_results.csv:row=829;hERG_results.csv:row=829;AMES_results.csv:row=829;PGP_results.csv:row=829;PAMPA_results.csv:row=829;BBB_results.csv:row=829;Solubility_results.csv:row=829;Lipophilicity_results.csv:row=830
CHEMBL1200675,TOREMIFENE CITRATE,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,14.63768115942029,100,60.0,55.85507246376812,M,KG targets ESR1; clinical phase 4.0; hERG risk; logS -6.27; logP 4.97,repurposing_candidates.csv:rc_row=147;protein_drug_candidates.csv:rows=2276;CYP3A4_results.csv:row=146;CYP2C19_results.csv:row=146;CYP2D6_results.csv:row=146;CYP1A2_results.csv:row=146;CYP2C9_results.csv:row=146;hERG_results.csv:row=146;AMES_results.csv:row=146;PGP_results.csv:row=146;PAMPA_results.csv:row=146;BBB_results.csv:row=146;Solubility_results.csv:row=146;Lipophilicity_results.csv:row=146
CHEMBL1709,SERTRALINE HYDROCHLORIDE,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl,14.63768115942029,100,60.0,55.85507246376812,M,KG targets SLC6A4; clinical phase 4.0; hERG risk; logS -4.61; logP 5.60,repurposing_candidates.csv:rc_row=523;protein_drug_candidates.csv:rows=1241;CYP3A4_results.csv:row=483;CYP2C19_results.csv:row=483;CYP2D6_results.csv:row=483;CYP1A2_results.csv:row=483;CYP2C9_results.csv:row=483;hERG_results.csv:row=483;AMES_results.csv:row=483;PGP_results.csv:row=483;PAMPA_results.csv:row=483;BBB_results.csv:row=483;Solubility_results.csv:row=483;Lipophilicity_results.csv:row=484
CHEMBL786,TAMOXIFEN CITRATE,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,14.63768115942029,100,60.0,55.85507246376812,M,KG targets ESR1; clinical phase 4.0; hERG risk; logS -7.33; logP 4.75,repurposing_candidates.csv:rc_row=1515;protein_drug_candidates.csv:rows=2297;CYP3A4_results.csv:row=1321;CYP2C19_results.csv:row=1321;CYP2D6_results.csv:row=1321;CYP1A2_results.csv:row=1321;CYP2C9_results.csv:row=1321;hERG_results.csv:row=1321;AMES_results.csv:row=1321;PGP_results.csv:row=1321;PAMPA_results.csv:row=1321;BBB_results.csv:row=1321;Solubility_results.csv:row=1321;Lipophilicity_results.csv:row=1322
CHEMBL25202,TAMIBAROTENE,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,15.942028985507244,80,85.0,55.6268115942029,H,"KG targets RARA, RARB; clinical phase 3.0; logS -6.26; logP 4.99",repurposing_candidates.csv:rc_row=855;protein_drug_candidates.csv:rows=1768;1895;CYP3A4_results.csv:row=763;CYP2C19_results.csv:row=763;CYP2D6_results.csv:row=763;CYP1A2_results.csv:row=763;CYP2C9_results.csv:row=763;hERG_results.csv:row=763;AMES_results.csv:row=763;PGP_results.csv:row=763;PAMPA_results.csv:row=763;BBB_results.csv:row=763;Solubility_results.csv:row=763;Lipophilicity_results.csv:row=764
CHEMBL312443,GABOXADOL,Oc1noc2c1CCNC2,25.072463768115938,80,70.0,55.528985507246375,H,"KG targets GABRA1, GABRA2; clinical phase 3.0; hERG risk; logS -0.76; logP 0.03",repurposing_candidates.csv:rc_row=904;protein_drug_candidates.csv:rows=513;1526;1711;1753;1785;1940;2071;2118;2590;CYP3A4_results.csv:row=811;CYP2C19_results.csv:row=811;CYP2D6_results.csv:row=811;CYP1A2_results.csv:row=811;CYP2C9_results.csv:row=811;hERG_results.csv:row=811;AMES_results.csv:row=811;PGP_results.csv:row=811;PAMPA_results.csv:row=811;BBB_results.csv:row=811;Solubility_results.csv:row=811;Lipophilicity_results.csv:row=812
CHEMBL403989,TG100-801,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,29.801678108314263,60,90.0,55.42067124332571,M,"KG targets BLK, PDGFRB; clinical phase 2.0; logS -5.96; logP 7.09",repurposing_candidates.csv:rc_row=1116;protein_drug_candidates.csv:rows=944;1133;pathway_drug_candidates.csv:rows=7031;CYP3A4_results.csv:row=980;CYP2C19_results.csv:row=980;CYP2D6_results.csv:row=980;CYP1A2_results.csv:row=980;CYP2C9_results.csv:row=980;hERG_results.csv:row=980;AMES_results.csv:row=980;PGP_results.csv:row=980;PAMPA_results.csv:row=980;BBB_results.csv:row=980;Solubility_results.csv:row=980;Lipophilicity_results.csv:row=981
CHEMBL1980297,ILORASERTIB,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,29.801678108314263,60,90.0,55.42067124332571,M,"KG targets BLK, PDGFRB; clinical phase 2.0; logS -4.64; logP 5.18",repurposing_candidates.csv:rc_row=616;protein_drug_candidates.csv:rows=945;1135;pathway_drug_candidates.csv:rows=7033;CYP3A4_results.csv:row=562;CYP2C19_results.csv:row=562;CYP2D6_results.csv:row=562;CYP1A2_results.csv:row=562;CYP2C9_results.csv:row=562;hERG_results.csv:row=562;AMES_results.csv:row=562;PGP_results.csv:row=562;PAMPA_results.csv:row=562;BBB_results.csv:row=562;Solubility_results.csv:row=562;Lipophilicity_results.csv:row=563
CHEMBL491473,CEDIRANIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,30.85430968726163,80,60.0,55.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 3.0; hERG risk; logS -3.60; logP 5.22",repurposing_candidates.csv:rc_row=1340;protein_drug_candidates.csv:rows=1118;1160;pathway_drug_candidates.csv:rows=565;6977;7016;7511;CYP3A4_results.csv:row=1151;CYP2C19_results.csv:row=1151;CYP2D6_results.csv:row=1151;CYP1A2_results.csv:row=1151;CYP2C9_results.csv:row=1151;hERG_results.csv:row=1151;AMES_results.csv:row=1151;PGP_results.csv:row=1151;PAMPA_results.csv:row=1151;BBB_results.csv:row=1151;Solubility_results.csv:row=1151;Lipophilicity_results.csv:row=1152
CHEMBL4072756,AZD-5423,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1,32.707856598016775,60,85.0,55.33314263920671,M,KG targets NR3C1; clinical phase 2.0; logS -5.79; logP 5.36,repurposing_candidates.csv:rc_row=1124;protein_drug_candidates.csv:rows=58;pathway_drug_candidates.csv:rows=750;2059;5974;7878;8015;8081;8152;8218;8284;CYP3A4_results.csv:row=988;CYP2C19_results.csv:row=988;CYP2D6_results.csv:row=988;CYP1A2_results.csv:row=988;CYP2C9_results.csv:row=988;hERG_results.csv:row=988;AMES_results.csv:row=988;PGP_results.csv:row=988;PAMPA_results.csv:row=988;BBB_results.csv:row=988;Solubility_results.csv:row=988;Lipophilicity_results.csv:row=989
CHEMBL3666807,VELSECORAT,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,32.707856598016775,60,85.0,55.33314263920671,M,KG targets NR3C1; clinical phase 2.0; logS -6.25; logP 4.60,repurposing_candidates.csv:rc_row=1011;protein_drug_candidates.csv:rows=64;pathway_drug_candidates.csv:rows=756;2065;5980;7884;8021;8087;8158;8224;8290;CYP3A4_results.csv:row=897;CYP2C19_results.csv:row=897;CYP2D6_results.csv:row=897;CYP1A2_results.csv:row=897;CYP2C9_results.csv:row=897;hERG_results.csv:row=897;AMES_results.csv:row=897;PGP_results.csv:row=897;PAMPA_results.csv:row=897;BBB_results.csv:row=897;Solubility_results.csv:row=897;Lipophilicity_results.csv:row=898
CHEMBL4297383,GSK-1521498,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1,29.549961861174673,60,90.0,55.31998474446987,M,KG targets OPRM1; clinical phase 2.0; logS -6.13; logP 4.67,repurposing_candidates.csv:rc_row=1172;protein_drug_candidates.csv:rows=336;pathway_drug_candidates.csv:rows=306;1340;7253;CYP3A4_results.csv:row=1035;CYP2C19_results.csv:row=1035;CYP2D6_results.csv:row=1035;CYP1A2_results.csv:row=1035;CYP2C9_results.csv:row=1035;hERG_results.csv:row=1035;AMES_results.csv:row=1035;PGP_results.csv:row=1035;PAMPA_results.csv:row=1035;BBB_results.csv:row=1035;Solubility_results.csv:row=1035;Lipophilicity_results.csv:row=1036
CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl,47.88329519450801,60,60.0,55.153318077803206,M,KG targets OPRM1; clinical phase 2.0; hERG risk; logS -3.32; logP 5.91,repurposing_candidates.csv:rc_row=145;protein_drug_candidates.csv:rows=333;pathway_drug_candidates.csv:rows=303;1337;7250;CYP3A4_results.csv:row=144;CYP2C19_results.csv:row=144;CYP2D6_results.csv:row=144;CYP1A2_results.csv:row=144;CYP2C9_results.csv:row=144;hERG_results.csv:row=144;AMES_results.csv:row=144;PGP_results.csv:row=144;PAMPA_results.csv:row=144;BBB_results.csv:row=144;Solubility_results.csv:row=144;Lipophilicity_results.csv:row=144
CHEMBL2104955,BECOCALCIDIOL,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O,47.88329519450801,60,60.0,55.153318077803206,M,KG targets VDR; clinical phase 2.0; hERG risk; logS -4.80; logP 5.17,repurposing_candidates.csv:rc_row=681;protein_drug_candidates.csv:rows=251;pathway_drug_candidates.csv:rows=6004;7781;7899;CYP3A4_results.csv:row=626;CYP2C19_results.csv:row=626;CYP2D6_results.csv:row=626;CYP1A2_results.csv:row=626;CYP2C9_results.csv:row=626;hERG_results.csv:row=626;AMES_results.csv:row=626;PGP_results.csv:row=626;PAMPA_results.csv:row=626;BBB_results.csv:row=626;Solubility_results.csv:row=626;Lipophilicity_results.csv:row=627
CHEMBL479527,TORCETRAPIB,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,14.63768115942029,80,85.0,55.10507246376812,H,KG targets CETP; clinical phase 3.0; logS -3.69; logP 8.20,repurposing_candidates.csv:rc_row=1328;protein_drug_candidates.csv:rows=1898;CYP3A4_results.csv:row=1139;CYP2C19_results.csv:row=1139;CYP2D6_results.csv:row=1139;CYP1A2_results.csv:row=1139;CYP2C9_results.csv:row=1139;hERG_results.csv:row=1139;AMES_results.csv:row=1139;PGP_results.csv:row=1139;PAMPA_results.csv:row=1139;BBB_results.csv:row=1139;Solubility_results.csv:row=1139;Lipophilicity_results.csv:row=1140
CHEMBL1255794,APLAVIROC,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,30.076277650648358,80,60.0,55.03051106025934,M,KG targets CCR5; clinical phase 3.0; hERG risk; logS -6.15; logP 4.58,repurposing_candidates.csv:rc_row=354;protein_drug_candidates.csv:rows=215;pathway_drug_candidates.csv:rows=1257;4374;6756;6780;CYP3A4_results.csv:row=316;CYP2C19_results.csv:row=316;CYP2D6_results.csv:row=316;CYP1A2_results.csv:row=316;CYP2C9_results.csv:row=316;hERG_results.csv:row=316;AMES_results.csv:row=316;PGP_results.csv:row=316;PAMPA_results.csv:row=316;BBB_results.csv:row=316;Solubility_results.csv:row=316;Lipophilicity_results.csv:row=317
CHEMBL2028661,AZILSARTAN MEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,30.076277650648358,80,60.0,55.03051106025934,M,KG targets AGTR1; clinical phase 3.0; hERG risk; logS -6.95; logP 4.71,repurposing_candidates.csv:rc_row=625;protein_drug_candidates.csv:rows=592;pathway_drug_candidates.csv:rows=6546;7165;7276;7296;CYP3A4_results.csv:row=571;CYP2C19_results.csv:row=571;CYP2D6_results.csv:row=571;CYP1A2_results.csv:row=571;CYP2C9_results.csv:row=571;hERG_results.csv:row=571;AMES_results.csv:row=571;PGP_results.csv:row=571;PAMPA_results.csv:row=571;BBB_results.csv:row=571;Solubility_results.csv:row=571;Lipophilicity_results.csv:row=572
CHEMBL407,FLUMAZENIL,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,22.46376811594203,60,100.0,54.98550724637681,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; logS -2.77; logP 1.77",repurposing_candidates.csv:rc_row=1122;protein_drug_candidates.csv:rows=516;1442;1667;1714;2076;2121;2480;CYP3A4_results.csv:row=986;CYP2C19_results.csv:row=986;CYP2D6_results.csv:row=986;CYP1A2_results.csv:row=986;CYP2C9_results.csv:row=986;hERG_results.csv:row=986;AMES_results.csv:row=986;PGP_results.csv:row=986;PAMPA_results.csv:row=986;BBB_results.csv:row=986;Solubility_results.csv:row=986;Lipophilicity_results.csv:row=987
CHEMBL2103791,ADIPIPLON,CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12,22.46376811594203,60,100.0,54.98550724637681,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; logS -2.24; logP 2.83",repurposing_candidates.csv:rc_row=658;protein_drug_candidates.csv:rows=518;1445;1669;1717;2079;2125;2484;CYP3A4_results.csv:row=603;CYP2C19_results.csv:row=603;CYP2D6_results.csv:row=603;CYP1A2_results.csv:row=603;CYP2C9_results.csv:row=603;hERG_results.csv:row=603;AMES_results.csv:row=603;PGP_results.csv:row=603;PAMPA_results.csv:row=603;BBB_results.csv:row=603;Solubility_results.csv:row=603;Lipophilicity_results.csv:row=604
CHEMBL2103828,ELINOGREL,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,28.497330282227306,60,90.0,54.898932112890925,M,KG targets P2RY12; clinical phase 2.0; logS -6.77; logP 3.09,repurposing_candidates.csv:rc_row=665;protein_drug_candidates.csv:rows=474;pathway_drug_candidates.csv:rows=1359;CYP3A4_results.csv:row=610;CYP2C19_results.csv:row=610;CYP2D6_results.csv:row=610;CYP1A2_results.csv:row=610;CYP2C9_results.csv:row=610;hERG_results.csv:row=610;AMES_results.csv:row=610;PGP_results.csv:row=610;PAMPA_results.csv:row=610;BBB_results.csv:row=610;Solubility_results.csv:row=610;Lipophilicity_results.csv:row=611
CHEMBL5314400,DWP05195,FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1,28.497330282227306,60,90.0,54.898932112890925,M,KG targets TRPV1; clinical phase 2.0; logS -4.13; logP 5.47,repurposing_candidates.csv:rc_row=1384;protein_drug_candidates.csv:rows=700;pathway_drug_candidates.csv:rows=5726;CYP3A4_results.csv:row=1195;CYP2C19_results.csv:row=1195;CYP2D6_results.csv:row=1195;CYP1A2_results.csv:row=1195;CYP2C9_results.csv:row=1195;hERG_results.csv:row=1195;AMES_results.csv:row=1195;PGP_results.csv:row=1195;PAMPA_results.csv:row=1195;BBB_results.csv:row=1195;Solubility_results.csv:row=1195;Lipophilicity_results.csv:row=1196
CHEMBL4594273,ELACESTRANT HYDROCHLORIDE,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1.Cl.Cl,14.63768115942029,100,55.0,54.60507246376812,M,KG targets ESR1; clinical phase 4.0; hERG risk; logS -2.47; logP 6.70,repurposing_candidates.csv:rc_row=1286;protein_drug_candidates.csv:rows=2287;CYP3A4_results.csv:row=1106;CYP2C19_results.csv:row=1106;CYP2D6_results.csv:row=1106;CYP1A2_results.csv:row=1106;CYP2C9_results.csv:row=1106;hERG_results.csv:row=1106;AMES_results.csv:row=1106;PGP_results.csv:row=1106;PAMPA_results.csv:row=1106;BBB_results.csv:row=1106;Solubility_results.csv:row=1106;Lipophilicity_results.csv:row=1107
CHEMBL305660,EBASTINE,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,28.497330282227306,80,60.0,54.398932112890925,M,KG targets HRH1; clinical phase 3.0; hERG risk; logS -5.99; logP 7.22,repurposing_candidates.csv:rc_row=901;protein_drug_candidates.csv:rows=1023;pathway_drug_candidates.csv:rows=6653;CYP3A4_results.csv:row=808;CYP2C19_results.csv:row=808;CYP2D6_results.csv:row=808;CYP1A2_results.csv:row=808;CYP2C9_results.csv:row=808;hERG_results.csv:row=808;AMES_results.csv:row=808;PGP_results.csv:row=808;PAMPA_results.csv:row=808;BBB_results.csv:row=808;Solubility_results.csv:row=808;Lipophilicity_results.csv:row=809
CHEMBL1237102,LEVOCABASTINE HYDROCHLORIDE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl,28.497330282227306,80,60.0,54.398932112890925,M,KG targets HRH1; clinical phase 3.0; hERG risk; logS -3.27; logP 5.32,repurposing_candidates.csv:rc_row=349;protein_drug_candidates.csv:rows=1032;pathway_drug_candidates.csv:rows=6662;CYP3A4_results.csv:row=311;CYP2C19_results.csv:row=311;CYP2D6_results.csv:row=311;CYP1A2_results.csv:row=311;CYP2C9_results.csv:row=311;hERG_results.csv:row=311;AMES_results.csv:row=311;PGP_results.csv:row=311;PAMPA_results.csv:row=311;BBB_results.csv:row=311;Solubility_results.csv:row=311;Lipophilicity_results.csv:row=312
CHEMBL101253,VATALANIB,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,30.85430968726163,80,55.0,54.09172387490465,M,"KG targets KIT, PDGFRB; clinical phase 3.0; hERG risk; logS -4.27; logP 5.01",repurposing_candidates.csv:rc_row=5;protein_drug_candidates.csv:rows=1125;1165;pathway_drug_candidates.csv:rows=570;6982;7023;7516;CYP3A4_results.csv:row=5;CYP2C19_results.csv:row=5;CYP2D6_results.csv:row=5;CYP1A2_results.csv:row=5;CYP2C9_results.csv:row=5;hERG_results.csv:row=5;AMES_results.csv:row=5;PGP_results.csv:row=5;PAMPA_results.csv:row=5;BBB_results.csv:row=5;Solubility_results.csv:row=5;Lipophilicity_results.csv:row=5
CHEMBL738,THIOPENTAL SODIUM,CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+],40.57971014492753,40,95.0,53.981884057971016,L,"KG targets GABRB1, GABRB2; clinical phase 1.0; logS -2.70; logP -0.86",repurposing_candidates.csv:rc_row=1503;protein_drug_candidates.csv:rows=1534;1760;2595;CYP3A4_results.csv:row=1309;CYP2C19_results.csv:row=1309;CYP2D6_results.csv:row=1309;CYP1A2_results.csv:row=1309;CYP2C9_results.csv:row=1309;hERG_results.csv:row=1309;AMES_results.csv:row=1309;PGP_results.csv:row=1309;PAMPA_results.csv:row=1309;BBB_results.csv:row=1309;Solubility_results.csv:row=1309;Lipophilicity_results.csv:row=1310
CHEMBL3545259,VANUCIZUMAB,,19.90083905415713,60,100.0,53.96033562166285,M,KG targets VEGFA; clinical phase 2.0,repurposing_candidates.csv:rc_row=986;pathway_drug_candidates.csv:rows=428;472;484;496;508;520;532;544;594;807;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL313006,DALCETRAPIB,CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1,14.63768115942029,80,80.0,53.85507246376812,H,KG targets CETP; clinical phase 3.0; logS -6.66; logP 6.68,repurposing_candidates.csv:rc_row=906;protein_drug_candidates.csv:rows=1896;CYP3A4_results.csv:row=813;CYP2C19_results.csv:row=813;CYP2D6_results.csv:row=813;CYP1A2_results.csv:row=813;CYP2C9_results.csv:row=813;hERG_results.csv:row=813;AMES_results.csv:row=813;PGP_results.csv:row=813;PAMPA_results.csv:row=813;BBB_results.csv:row=813;Solubility_results.csv:row=813;Lipophilicity_results.csv:row=814
CHEMBL3358920,ETRASIMOD,O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,14.63768115942029,80,80.0,53.85507246376812,H,KG targets S1PR4; clinical phase 3.0; logS -6.79; logP 6.93,repurposing_candidates.csv:rc_row=949;protein_drug_candidates.csv:rows=1885;CYP3A4_results.csv:row=853;CYP2C19_results.csv:row=853;CYP2D6_results.csv:row=853;CYP1A2_results.csv:row=853;CYP2C9_results.csv:row=853;hERG_results.csv:row=853;AMES_results.csv:row=853;PGP_results.csv:row=853;PAMPA_results.csv:row=853;BBB_results.csv:row=853;Solubility_results.csv:row=853;Lipophilicity_results.csv:row=854
CHEMBL954,ENCLOMIPHENE,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1,14.63768115942029,80,80.0,53.85507246376812,H,KG targets ESR1; clinical phase 3.0; logS -6.31; logP 6.56,repurposing_candidates.csv:rc_row=1564;protein_drug_candidates.csv:rows=2300;CYP3A4_results.csv:row=1370;CYP2C19_results.csv:row=1370;CYP2D6_results.csv:row=1370;CYP1A2_results.csv:row=1370;CYP2C9_results.csv:row=1370;hERG_results.csv:row=1370;AMES_results.csv:row=1370;PGP_results.csv:row=1370;PAMPA_results.csv:row=1370;BBB_results.csv:row=1370;Solubility_results.csv:row=1370;Lipophilicity_results.csv:row=1371
CHEMBL2355051,CLOMIPHENE,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,14.63768115942029,80,80.0,53.85507246376812,H,KG targets ESR1; clinical phase 3.0; logS -6.31; logP 6.56,repurposing_candidates.csv:rc_row=829;protein_drug_candidates.csv:rows=2298;CYP3A4_results.csv:row=738;CYP2C19_results.csv:row=738;CYP2D6_results.csv:row=738;CYP1A2_results.csv:row=738;CYP2C9_results.csv:row=738;hERG_results.csv:row=738;AMES_results.csv:row=738;PGP_results.csv:row=738;PAMPA_results.csv:row=738;BBB_results.csv:row=738;Solubility_results.csv:row=738;Lipophilicity_results.csv:row=739
CHEMBL288441,BOSUTINIB,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,29.801678108314263,80,55.0,53.67067124332571,M,"KG targets ABL1, BCR; clinical phase 3.0; hERG risk; logS -4.77; logP 5.19",repurposing_candidates.csv:rc_row=882;protein_drug_candidates.csv:rows=1215;2209;pathway_drug_candidates.csv:rows=4306;CYP3A4_results.csv:row=790;CYP2C19_results.csv:row=790;CYP2D6_results.csv:row=790;CYP1A2_results.csv:row=790;CYP2C9_results.csv:row=790;hERG_results.csv:row=790;AMES_results.csv:row=790;PGP_results.csv:row=790;PAMPA_results.csv:row=790;BBB_results.csv:row=790;Solubility_results.csv:row=790;Lipophilicity_results.csv:row=791
CHEMBL214796,NGD-8243,FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,28.497330282227306,60,85.0,53.648932112890925,M,KG targets TRPV1; clinical phase 2.0; logS -3.66; logP 6.47,repurposing_candidates.csv:rc_row=792;protein_drug_candidates.csv:rows=699;pathway_drug_candidates.csv:rows=5725;CYP3A4_results.csv:row=701;CYP2C19_results.csv:row=701;CYP2D6_results.csv:row=701;CYP1A2_results.csv:row=701;CYP2C9_results.csv:row=701;hERG_results.csv:row=701;AMES_results.csv:row=701;PGP_results.csv:row=701;PAMPA_results.csv:row=701;BBB_results.csv:row=701;Solubility_results.csv:row=701;Lipophilicity_results.csv:row=702
CHEMBL206834,BAFETINIB,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,28.497330282227306,60,85.0,53.648932112890925,M,KG targets ABL1; clinical phase 2.0; logS -3.09; logP 5.39,repurposing_candidates.csv:rc_row=640;protein_drug_candidates.csv:rows=1217;pathway_drug_candidates.csv:rows=4308;CYP3A4_results.csv:row=586;CYP2C19_results.csv:row=586;CYP2D6_results.csv:row=586;CYP1A2_results.csv:row=586;CYP2C9_results.csv:row=586;hERG_results.csv:row=586;AMES_results.csv:row=586;PGP_results.csv:row=586;PAMPA_results.csv:row=586;BBB_results.csv:row=586;Solubility_results.csv:row=586;Lipophilicity_results.csv:row=587
CHEMBL841,LOPERAMIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,29.549961861174673,80,55.0,53.56998474446987,M,KG targets OPRM1; clinical phase 3.0; hERG risk; logS -3.04; logP 5.09,repurposing_candidates.csv:rc_row=1532;protein_drug_candidates.csv:rows=327;pathway_drug_candidates.csv:rows=297;1331;7244;CYP3A4_results.csv:row=1338;CYP2C19_results.csv:row=1338;CYP2D6_results.csv:row=1338;CYP1A2_results.csv:row=1338;CYP2C9_results.csv:row=1338;hERG_results.csv:row=1338;AMES_results.csv:row=1338;PGP_results.csv:row=1338;PAMPA_results.csv:row=1338;BBB_results.csv:row=1338;Solubility_results.csv:row=1338;Lipophilicity_results.csv:row=1339
CHEMBL2109613,PF-04236921,,18.321891685736077,60,100.0,53.32875667429443,M,KG targets IL6; clinical phase 2.0,repurposing_candidates.csv:rc_row=773;pathway_drug_candidates.csv:rows=120;170;4406;4542;4621;4700;7590;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2108589,CLAZAKIZUMAB,,18.321891685736077,60,100.0,53.32875667429443,M,KG targets IL6; clinical phase 2.0,repurposing_candidates.csv:rc_row=750;pathway_drug_candidates.csv:rows=121;171;4407;4543;4622;4701;7591;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3833343,VOBARILIZUMAB,,17.795575896262395,60,100.0,53.11823035850496,M,KG targets IL6R; clinical phase 2.0,repurposing_candidates.csv:rc_row=1044;pathway_drug_candidates.csv:rows=179;641;4551;4630;4709;7150;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3990025,OLENDALIZUMAB,,17.26926010678871,60,100.0,52.90770404271548,M,KG targets C5; clinical phase 2.0,repurposing_candidates.csv:rc_row=1113;pathway_drug_candidates.csv:rows=1245;7182;7743;7755;7767;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298012,TESIDOLUMAB,,17.26926010678871,60,100.0,52.90770404271548,M,KG targets C5; clinical phase 2.0,repurposing_candidates.csv:rc_row=1238;pathway_drug_candidates.csv:rows=1244;7181;7742;7754;7766;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109047,INTERFERON ALFA-N3,,17.26926010678871,60,100.0,52.90770404271548,M,KG targets IFNAR1; clinical phase 2.0,repurposing_candidates.csv:rc_row=760;pathway_drug_candidates.csv:rows=633;4218;5205;5255;5453;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545391,ORG-34517,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C,32.707856598016775,60,75.0,52.83314263920671,M,KG targets NR3C1; clinical phase 2.0; logS -6.42; logP 5.07,repurposing_candidates.csv:rc_row=994;protein_drug_candidates.csv:rows=59;pathway_drug_candidates.csv:rows=751;2060;5975;7879;8016;8082;8153;8219;8285;CYP3A4_results.csv:row=884;CYP2C19_results.csv:row=884;CYP2D6_results.csv:row=884;CYP1A2_results.csv:row=884;CYP2C9_results.csv:row=884;hERG_results.csv:row=884;AMES_results.csv:row=884;PGP_results.csv:row=884;PAMPA_results.csv:row=884;BBB_results.csv:row=884;Solubility_results.csv:row=884;Lipophilicity_results.csv:row=885
CHEMBL2364968,ERGOLOID,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,38.70327993897788,60,65.0,52.731311975591154,M,"KG targets ADRA1A, ADRA1B; clinical phase 2.0; logS -11.10; logP 9.89",repurposing_candidates.csv:rc_row=843;protein_drug_candidates.csv:rows=403;1348;1400;1506;1864;2547;pathway_drug_candidates.csv:rows=866;919;971;1023;1075;1127;1179;1231;1411;1463;1515;6528;6728;CYP3A4_results.csv:row=751;CYP2C19_results.csv:row=751;CYP2D6_results.csv:row=751;CYP1A2_results.csv:row=751;CYP2C9_results.csv:row=751;hERG_results.csv:row=751;AMES_results.csv:row=751;PGP_results.csv:row=751;PAMPA_results.csv:row=751;BBB_results.csv:row=751;Solubility_results.csv:row=751;Lipophilicity_results.csv:row=752
CHEMBL1655,TOREMIFENE,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,14.63768115942029,80,75.0,52.60507246376812,H,KG targets ESR1; clinical phase 3.0; logS -6.72; logP 6.22,repurposing_candidates.csv:rc_row=498;protein_drug_candidates.csv:rows=2299;CYP3A4_results.csv:row=458;CYP2C19_results.csv:row=458;CYP2D6_results.csv:row=458;CYP1A2_results.csv:row=458;CYP2C9_results.csv:row=458;hERG_results.csv:row=458;AMES_results.csv:row=458;PGP_results.csv:row=458;PAMPA_results.csv:row=458;BBB_results.csv:row=458;Solubility_results.csv:row=458;Lipophilicity_results.csv:row=459
CHEMBL420,GUANABENZ,N=C(N)N/N=C/c1c(Cl)cccc1Cl,33.737604881769634,40,100.0,52.49504195270785,L,"KG targets ADRA2A, ADRA2B; clinical phase 1.0; logS -2.79; logP 1.81",repurposing_candidates.csv:rc_row=1143;protein_drug_candidates.csv:rows=1350;1402;2550;pathway_drug_candidates.csv:rows=921;973;1025;1077;1129;1181;1233;1413;1465;1517;CYP3A4_results.csv:row=1007;CYP2C19_results.csv:row=1007;CYP2D6_results.csv:row=1007;CYP1A2_results.csv:row=1007;CYP2C9_results.csv:row=1007;hERG_results.csv:row=1007;AMES_results.csv:row=1007;PGP_results.csv:row=1007;PAMPA_results.csv:row=1007;BBB_results.csv:row=1007;Solubility_results.csv:row=1007;Lipophilicity_results.csv:row=1008
CHEMBL4650518,PLONMARLIMAB,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets CSF2; clinical phase 2.0,repurposing_candidates.csv:rc_row=1318;pathway_drug_candidates.csv:rows=4391;6878;8380;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3990000,TIBULIZUMAB,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets IL17A; clinical phase 2.0,repurposing_candidates.csv:rc_row=1112;pathway_drug_candidates.csv:rows=160;4229;7309;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297926,CJM-112,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets IL17A; clinical phase 2.0,repurposing_candidates.csv:rc_row=1230;pathway_drug_candidates.csv:rows=161;4230;7310;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4594542,EFLEPEDOCOKIN ALFA,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets IL10RB; clinical phase 2.0,repurposing_candidates.csv:rc_row=1299;pathway_drug_candidates.csv:rows=4395;4778;4885;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1743044,NAMILUMAB,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets CSF2; clinical phase 2.0,repurposing_candidates.csv:rc_row=548;pathway_drug_candidates.csv:rows=4390;6877;8379;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109430,GIMSILUMAB,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets CSF2; clinical phase 2.0,repurposing_candidates.csv:rc_row=767;pathway_drug_candidates.csv:rows=4392;6879;8381;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109458,AMG-108,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets IL1R1; clinical phase 2.0,repurposing_candidates.csv:rc_row=769;pathway_drug_candidates.csv:rows=635;4193;4401;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109607,MEDI-8968,,16.21662852784134,60,100.0,52.486651411136535,M,KG targets IL1R1; clinical phase 2.0,repurposing_candidates.csv:rc_row=772;pathway_drug_candidates.csv:rows=636;4194;4402;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL593430,ATAGABALIN,C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C,15.942028985507244,60,100.0,52.3768115942029,M,"KG targets CACNA1A, CACNA2D1; clinical phase 2.0; logS -0.04; logP 1.47",repurposing_candidates.csv:rc_row=1435;protein_drug_candidates.csv:rows=1909;2497;CYP3A4_results.csv:row=1244;CYP2C19_results.csv:row=1244;CYP2D6_results.csv:row=1244;CYP1A2_results.csv:row=1244;CYP2C9_results.csv:row=1244;hERG_results.csv:row=1244;AMES_results.csv:row=1244;PGP_results.csv:row=1244;PAMPA_results.csv:row=1244;BBB_results.csv:row=1244;Solubility_results.csv:row=1244;Lipophilicity_results.csv:row=1245
CHEMBL1783282,AZD7325,CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,15.942028985507244,60,100.0,52.3768115942029,M,"KG targets GABRA2, GABRA3; clinical phase 2.0; logS -4.31; logP 3.17",repurposing_candidates.csv:rc_row=571;protein_drug_candidates.csv:rows=1716;2124;CYP3A4_results.csv:row=517;CYP2C19_results.csv:row=517;CYP2D6_results.csv:row=517;CYP1A2_results.csv:row=517;CYP2C9_results.csv:row=517;hERG_results.csv:row=517;AMES_results.csv:row=517;PGP_results.csv:row=517;PAMPA_results.csv:row=517;BBB_results.csv:row=517;Solubility_results.csv:row=517;Lipophilicity_results.csv:row=518
CHEMBL1358,FULVESTRANT,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,14.63768115942029,100,45.0,52.10507246376812,L,KG targets ESR1; clinical phase 4.0; hERG risk; logS -6.42; logP 8.68,repurposing_candidates.csv:rc_row=392;protein_drug_candidates.csv:rows=2277;CYP3A4_results.csv:row=353;CYP2C19_results.csv:row=353;CYP2D6_results.csv:row=353;CYP1A2_results.csv:row=353;CYP2C9_results.csv:row=353;hERG_results.csv:row=353;AMES_results.csv:row=353;PGP_results.csv:row=353;PAMPA_results.csv:row=353;BBB_results.csv:row=353;Solubility_results.csv:row=353;Lipophilicity_results.csv:row=354
CHEMBL17350,TRAXOPRODIL,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,34.012204424103736,60,70.0,52.104881769641494,M,"KG targets GRIN1, GRIN2B; clinical phase 2.0; hERG risk; logS -2.59; logP 2.80",repurposing_candidates.csv:rc_row=534;protein_drug_candidates.csv:rows=722;2615;pathway_drug_candidates.csv:rows=3628;6812;6839;6866;6899;7057;7084;7111;7138;CYP3A4_results.csv:row=494;CYP2C19_results.csv:row=494;CYP2D6_results.csv:row=494;CYP1A2_results.csv:row=494;CYP2C9_results.csv:row=494;hERG_results.csv:row=494;AMES_results.csv:row=494;PGP_results.csv:row=494;PAMPA_results.csv:row=494;BBB_results.csv:row=494;Solubility_results.csv:row=494;Lipophilicity_results.csv:row=495
CHEMBL549344,CPG-52852,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O,33.760488176964145,60,70.0,52.00419527078566,M,KG targets TLR7; clinical phase 2.0; hERG risk; logS -3.19; logP 2.06,repurposing_candidates.csv:rc_row=1406;protein_drug_candidates.csv:rows=603;pathway_drug_candidates.csv:rows=763;4259;7325;7347;7358;7369;7380;7402;7424;7446;7457;CYP3A4_results.csv:row=1215;CYP2C19_results.csv:row=1215;CYP2D6_results.csv:row=1215;CYP1A2_results.csv:row=1215;CYP2C9_results.csv:row=1215;hERG_results.csv:row=1215;AMES_results.csv:row=1215;PGP_results.csv:row=1215;PAMPA_results.csv:row=1215;BBB_results.csv:row=1215;Solubility_results.csv:row=1215;Lipophilicity_results.csv:row=1216
CHEMBL383322,RESIQUIMOD,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,33.760488176964145,60,70.0,52.00419527078566,M,KG targets TLR7; clinical phase 2.0; hERG risk; logS -1.89; logP 2.47,repurposing_candidates.csv:rc_row=1040;protein_drug_candidates.csv:rows=605;pathway_drug_candidates.csv:rows=765;4261;7327;7349;7360;7371;7382;7404;7426;7448;7459;CYP3A4_results.csv:row=915;CYP2C19_results.csv:row=915;CYP2D6_results.csv:row=915;CYP1A2_results.csv:row=915;CYP2C9_results.csv:row=915;hERG_results.csv:row=915;AMES_results.csv:row=915;PGP_results.csv:row=915;PAMPA_results.csv:row=915;BBB_results.csv:row=915;Solubility_results.csv:row=915;Lipophilicity_results.csv:row=916
CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl,32.15865751334859,40,100.0,51.86346300533943,L,"KG targets ADRA1A, ADRA1B; clinical phase 1.0; logS -1.02; logP 3.29",repurposing_candidates.csv:rc_row=1411;protein_drug_candidates.csv:rows=406;1507;1865;pathway_drug_candidates.csv:rows=869;6531;6731;CYP3A4_results.csv:row=1220;CYP2C19_results.csv:row=1220;CYP2D6_results.csv:row=1220;CYP1A2_results.csv:row=1220;CYP2C9_results.csv:row=1220;hERG_results.csv:row=1220;AMES_results.csv:row=1220;PGP_results.csv:row=1220;PAMPA_results.csv:row=1220;BBB_results.csv:row=1220;Solubility_results.csv:row=1220;Lipophilicity_results.csv:row=1221
CHEMBL1201461,DEXTROMETHORPHAN POLISTIREX,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets GRIN2A; clinical phase 2.0,repurposing_candidates.csv:rc_row=277;protein_drug_candidates.csv:rows=2662;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3260567,VACTOSERTIB,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets TGFBR1; clinical phase 2.0; logS -2.98; logP 4.24,repurposing_candidates.csv:rc_row=930;protein_drug_candidates.csv:rows=1972;CYP3A4_results.csv:row=837;CYP2C19_results.csv:row=837;CYP2D6_results.csv:row=837;CYP1A2_results.csv:row=837;CYP2C9_results.csv:row=837;hERG_results.csv:row=837;AMES_results.csv:row=837;PGP_results.csv:row=837;PAMPA_results.csv:row=837;BBB_results.csv:row=837;Solubility_results.csv:row=837;Lipophilicity_results.csv:row=838
CHEMBL4297744,ELX-02,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets RPS27; clinical phase 2.0,repurposing_candidates.csv:rc_row=1213;protein_drug_candidates.csv:rows=1731;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297789,MT-3724,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets RPS27; clinical phase 2.0,repurposing_candidates.csv:rc_row=1218;protein_drug_candidates.csv:rows=1730;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL356388,ETAZOLATE,CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C,14.63768115942029,60,100.0,51.85507246376812,M,KG targets GABRB3; clinical phase 2.0; logS -3.28; logP 2.44,repurposing_candidates.csv:rc_row=1000;protein_drug_candidates.csv:rows=1532;CYP3A4_results.csv:row=886;CYP2C19_results.csv:row=886;CYP2D6_results.csv:row=886;CYP1A2_results.csv:row=886;CYP2C9_results.csv:row=886;hERG_results.csv:row=886;AMES_results.csv:row=886;PGP_results.csv:row=886;PAMPA_results.csv:row=886;BBB_results.csv:row=886;Solubility_results.csv:row=886;Lipophilicity_results.csv:row=887
CHEMBL4444976,CCX354,COc1cc(N2CCN(C(=O)Cn3nc(-c4ncc[nH]4)c4cccnc43)CC2)ccc1Cl,14.63768115942029,60,100.0,51.85507246376812,M,KG targets CCR1; clinical phase 2.0; logS -4.58; logP 2.83,repurposing_candidates.csv:rc_row=1263;protein_drug_candidates.csv:rows=1792;CYP3A4_results.csv:row=1083;CYP2C19_results.csv:row=1083;CYP2D6_results.csv:row=1083;CYP1A2_results.csv:row=1083;CYP2C9_results.csv:row=1083;hERG_results.csv:row=1083;AMES_results.csv:row=1083;PGP_results.csv:row=1083;PAMPA_results.csv:row=1083;BBB_results.csv:row=1083;Solubility_results.csv:row=1083;Lipophilicity_results.csv:row=1084
CHEMBL574737,UCN-01,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,14.63768115942029,60,100.0,51.85507246376812,M,KG targets PDPK1; clinical phase 2.0; logS -4.85; logP 3.84,repurposing_candidates.csv:rc_row=1423;protein_drug_candidates.csv:rows=1627;CYP3A4_results.csv:row=1232;CYP2C19_results.csv:row=1232;CYP2D6_results.csv:row=1232;CYP1A2_results.csv:row=1232;CYP2C9_results.csv:row=1232;hERG_results.csv:row=1232;AMES_results.csv:row=1232;PGP_results.csv:row=1232;PAMPA_results.csv:row=1232;BBB_results.csv:row=1232;Solubility_results.csv:row=1232;Lipophilicity_results.csv:row=1233
CHEMBL3833330,CINPANEMAB,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets SNCA; clinical phase 2.0,repurposing_candidates.csv:rc_row=1043;protein_drug_candidates.csv:rows=2568;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1269102,BQ-123,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets EDNRA; clinical phase 2.0,repurposing_candidates.csv:rc_row=367;protein_drug_candidates.csv:rows=1925;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4298077,PRASINEZUMAB,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets SNCA; clinical phase 2.0,repurposing_candidates.csv:rc_row=1241;protein_drug_candidates.csv:rows=2569;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1631540,GSK163090,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets SLC6A4; clinical phase 2.0; logS -4.19; logP 3.44,repurposing_candidates.csv:rc_row=488;protein_drug_candidates.csv:rows=1298;CYP3A4_results.csv:row=448;CYP2C19_results.csv:row=448;CYP2D6_results.csv:row=448;CYP1A2_results.csv:row=448;CYP2C9_results.csv:row=448;hERG_results.csv:row=448;AMES_results.csv:row=448;PGP_results.csv:row=448;PAMPA_results.csv:row=448;BBB_results.csv:row=448;Solubility_results.csv:row=448;Lipophilicity_results.csv:row=449
CHEMBL4297813,PRI-724,,14.63768115942029,60,100.0,51.85507246376812,M,KG targets CREBBP; clinical phase 2.0,repurposing_candidates.csv:rc_row=1219;protein_drug_candidates.csv:rows=2551;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297218,ROVAZOLAC,CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets NR1H2; clinical phase 2.0; logS -4.80; logP 4.20,repurposing_candidates.csv:rc_row=1164;protein_drug_candidates.csv:rows=1724;CYP3A4_results.csv:row=1027;CYP2C19_results.csv:row=1027;CYP2D6_results.csv:row=1027;CYP1A2_results.csv:row=1027;CYP2C9_results.csv:row=1027;hERG_results.csv:row=1027;AMES_results.csv:row=1027;PGP_results.csv:row=1027;PAMPA_results.csv:row=1027;BBB_results.csv:row=1027;Solubility_results.csv:row=1027;Lipophilicity_results.csv:row=1028
CHEMBL2364614,LIAFENSINE,CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets SLC6A4; clinical phase 2.0; logS -4.37; logP 4.46,repurposing_candidates.csv:rc_row=837;protein_drug_candidates.csv:rows=1295;CYP3A4_results.csv:row=746;CYP2C19_results.csv:row=746;CYP2D6_results.csv:row=746;CYP1A2_results.csv:row=746;CYP2C9_results.csv:row=746;hERG_results.csv:row=746;AMES_results.csv:row=746;PGP_results.csv:row=746;PAMPA_results.csv:row=746;BBB_results.csv:row=746;Solubility_results.csv:row=746;Lipophilicity_results.csv:row=747
CHEMBL2107760,NEBENTAN,COc1ccccc1Oc1c(NS(=O)(=O)/C=C/c2ccccc2)nc(-c2ncccn2)nc1OC,14.63768115942029,60,100.0,51.85507246376812,M,KG targets EDNRA; clinical phase 2.0; logS -4.75; logP 4.16,repurposing_candidates.csv:rc_row=734;protein_drug_candidates.csv:rows=1924;CYP3A4_results.csv:row=679;CYP2C19_results.csv:row=679;CYP2D6_results.csv:row=679;CYP1A2_results.csv:row=679;CYP2C9_results.csv:row=679;hERG_results.csv:row=679;AMES_results.csv:row=679;PGP_results.csv:row=679;PAMPA_results.csv:row=679;BBB_results.csv:row=679;Solubility_results.csv:row=679;Lipophilicity_results.csv:row=680
CHEMBL2364611,GALUNISERTIB,Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets TGFBR1; clinical phase 2.0; logS -1.81; logP 3.51,repurposing_candidates.csv:rc_row=836;protein_drug_candidates.csv:rows=1971;CYP3A4_results.csv:row=745;CYP2C19_results.csv:row=745;CYP2D6_results.csv:row=745;CYP1A2_results.csv:row=745;CYP2C9_results.csv:row=745;hERG_results.csv:row=745;AMES_results.csv:row=745;PGP_results.csv:row=745;PAMPA_results.csv:row=745;BBB_results.csv:row=745;Solubility_results.csv:row=745;Lipophilicity_results.csv:row=746
CHEMBL3334824,BMS-817399,CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1,14.63768115942029,60,100.0,51.85507246376812,M,KG targets CCR1; clinical phase 2.0; logS -3.08; logP 2.88,repurposing_candidates.csv:rc_row=947;protein_drug_candidates.csv:rows=1791;CYP3A4_results.csv:row=851;CYP2C19_results.csv:row=851;CYP2D6_results.csv:row=851;CYP1A2_results.csv:row=851;CYP2C9_results.csv:row=851;hERG_results.csv:row=851;AMES_results.csv:row=851;PGP_results.csv:row=851;PAMPA_results.csv:row=851;BBB_results.csv:row=851;Solubility_results.csv:row=851;Lipophilicity_results.csv:row=852
CHEMBL4297294,JNJ-42165279,O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,32.971014492753625,60,70.0,51.68840579710145,M,KG targets FAAH; clinical phase 2.0; hERG risk; logS -3.78; logP 3.41,repurposing_candidates.csv:rc_row=1168;protein_drug_candidates.csv:rows=689;CYP3A4_results.csv:row=1031;CYP2C19_results.csv:row=1031;CYP2D6_results.csv:row=1031;CYP1A2_results.csv:row=1031;CYP2C9_results.csv:row=1031;hERG_results.csv:row=1031;AMES_results.csv:row=1031;PGP_results.csv:row=1031;PAMPA_results.csv:row=1031;BBB_results.csv:row=1031;Solubility_results.csv:row=1031;Lipophilicity_results.csv:row=1032
CHEMBL591118,CARMEGLIPTIN,COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2,32.971014492753625,60,70.0,51.68840579710145,M,KG targets DPP4; clinical phase 2.0; hERG risk; logS -1.52; logP 1.52,repurposing_candidates.csv:rc_row=1431;protein_drug_candidates.csv:rows=678;CYP3A4_results.csv:row=1240;CYP2C19_results.csv:row=1240;CYP2D6_results.csv:row=1240;CYP1A2_results.csv:row=1240;CYP2C9_results.csv:row=1240;hERG_results.csv:row=1240;AMES_results.csv:row=1240;PGP_results.csv:row=1240;PAMPA_results.csv:row=1240;BBB_results.csv:row=1240;Solubility_results.csv:row=1240;Lipophilicity_results.csv:row=1241
CHEMBL1200946,NANDROLONE DECANOATE,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,29.549961861174673,60,75.0,51.56998474446987,M,KG targets AR; clinical phase 2.0; logS -7.08; logP 7.18,repurposing_candidates.csv:rc_row=197;protein_drug_candidates.csv:rows=568;pathway_drug_candidates.csv:rows=1991;5906;7810;CYP3A4_results.csv:row=195;CYP2C19_results.csv:row=195;CYP2D6_results.csv:row=195;CYP1A2_results.csv:row=195;CYP2C9_results.csv:row=195;hERG_results.csv:row=195;AMES_results.csv:row=195;PGP_results.csv:row=195;PAMPA_results.csv:row=195;BBB_results.csv:row=195;Solubility_results.csv:row=195;Lipophilicity_results.csv:row=196
CHEMBL4094894,CIPEPOFOL,CC(C)c1cccc([C@H](C)C2CC2)c1O,34.20289855072463,40,95.0,51.43115942028985,L,"KG targets GABRA1, GABRA2; clinical phase 1.0; logS -3.77; logP 4.03",repurposing_candidates.csv:rc_row=1130;protein_drug_candidates.csv:rows=523;1449;1533;1674;1722;1759;1789;1808;1881;1944;2082;2129;2487;2567;2594;2638;CYP3A4_results.csv:row=994;CYP2C19_results.csv:row=994;CYP2D6_results.csv:row=994;CYP1A2_results.csv:row=994;CYP2C9_results.csv:row=994;hERG_results.csv:row=994;AMES_results.csv:row=994;PGP_results.csv:row=994;PAMPA_results.csv:row=994;BBB_results.csv:row=994;Solubility_results.csv:row=994;Lipophilicity_results.csv:row=995
CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)C(C)N)c1.Cl,32.15865751334859,60,70.0,51.36346300533943,M,"KG targets ADRA1A, ADRA1B; clinical phase 2.0; hERG risk; logS -0.72; logP 1.51",repurposing_candidates.csv:rc_row=235;protein_drug_candidates.csv:rows=404;1505;1863;pathway_drug_candidates.csv:rows=867;6529;6729;CYP3A4_results.csv:row=232;CYP2C19_results.csv:row=232;CYP2D6_results.csv:row=232;CYP1A2_results.csv:row=232;CYP2C9_results.csv:row=232;hERG_results.csv:row=232;AMES_results.csv:row=232;PGP_results.csv:row=232;PAMPA_results.csv:row=232;BBB_results.csv:row=232;Solubility_results.csv:row=232;Lipophilicity_results.csv:row=233
CHEMBL142635,NAFTOPIDIL,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,14.63768115942029,80,70.0,51.35507246376812,H,KG targets ADRA1D; clinical phase 3.0; hERG risk; logS -5.19; logP 3.41,repurposing_candidates.csv:rc_row=410;protein_drug_candidates.csv:rows=1498;CYP3A4_results.csv:row=370;CYP2C19_results.csv:row=370;CYP2D6_results.csv:row=370;CYP1A2_results.csv:row=370;CYP2C9_results.csv:row=370;hERG_results.csv:row=370;AMES_results.csv:row=370;PGP_results.csv:row=370;PAMPA_results.csv:row=370;BBB_results.csv:row=370;Solubility_results.csv:row=370;Lipophilicity_results.csv:row=371
CHEMBL4650365,CAMIZESTRANT,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,14.63768115942029,80,70.0,51.35507246376812,H,KG targets ESR1; clinical phase 3.0; hERG risk; logS -4.09; logP 4.31,repurposing_candidates.csv:rc_row=1314;protein_drug_candidates.csv:rows=2308;CYP3A4_results.csv:row=1128;CYP2C19_results.csv:row=1128;CYP2D6_results.csv:row=1128;CYP1A2_results.csv:row=1128;CYP2C9_results.csv:row=1128;hERG_results.csv:row=1128;AMES_results.csv:row=1128;PGP_results.csv:row=1128;PAMPA_results.csv:row=1128;BBB_results.csv:row=1128;Solubility_results.csv:row=1128;Lipophilicity_results.csv:row=1129
CHEMBL262075,INDIPLON,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,14.63768115942029,80,70.0,51.35507246376812,H,KG targets GABRA1; clinical phase 3.0; hERG risk; logS -1.36; logP 3.67,repurposing_candidates.csv:rc_row=865;protein_drug_candidates.csv:rows=512;CYP3A4_results.csv:row=773;CYP2C19_results.csv:row=773;CYP2D6_results.csv:row=773;CYP1A2_results.csv:row=773;CYP2C9_results.csv:row=773;hERG_results.csv:row=773;AMES_results.csv:row=773;PGP_results.csv:row=773;PAMPA_results.csv:row=773;BBB_results.csv:row=773;Solubility_results.csv:row=773;Lipophilicity_results.csv:row=774
CHEMBL3301595,DASOTRALINE,N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,14.63768115942029,80,70.0,51.35507246376812,H,KG targets SLC6A4; clinical phase 3.0; hERG risk; logS -5.31; logP 4.92,repurposing_candidates.csv:rc_row=938;protein_drug_candidates.csv:rows=1286;CYP3A4_results.csv:row=842;CYP2C19_results.csv:row=842;CYP2D6_results.csv:row=842;CYP1A2_results.csv:row=842;CYP2C9_results.csv:row=842;hERG_results.csv:row=842;AMES_results.csv:row=842;PGP_results.csv:row=842;PAMPA_results.csv:row=842;BBB_results.csv:row=842;Solubility_results.csv:row=842;Lipophilicity_results.csv:row=843
CHEMBL2109342,HGS-1025,,30.076277650648358,40,100.0,51.03051106025934,L,KG targets CCR5; clinical phase 1.0,repurposing_candidates.csv:rc_row=765;protein_drug_candidates.csv:rows=226;pathway_drug_candidates.csv:rows=1268;4385;6767;6791;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545193,MSC-2364447,,30.076277650648358,40,100.0,51.03051106025934,L,KG targets BTK; clinical phase 1.0,repurposing_candidates.csv:rc_row=977;protein_drug_candidates.csv:rows=211;pathway_drug_candidates.csv:rows=617;4112;6574;6754;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109341,CCR5MAB004,,30.076277650648358,40,100.0,51.03051106025934,L,KG targets CCR5; clinical phase 1.0,repurposing_candidates.csv:rc_row=764;protein_drug_candidates.csv:rows=227;pathway_drug_candidates.csv:rows=1269;4386;6768;6792;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109325,AMG-191,,29.549961861174673,40,100.0,50.81998474446987,L,KG targets KIT; clinical phase 1.0,repurposing_candidates.csv:rc_row=763;protein_drug_candidates.csv:rows=1177;pathway_drug_candidates.csv:rows=582;6994;7528;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL3545046,GSK2849466,,29.549961861174673,40,100.0,50.81998474446987,L,KG targets AR; clinical phase 1.0,repurposing_candidates.csv:rc_row=966;protein_drug_candidates.csv:rows=573;pathway_drug_candidates.csv:rows=1996;5911;7815;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1493,FLAVOXATE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,33.46300533943554,60,65.0,50.635202135774215,M,"KG targets PDE4A, PDE4B; clinical phase 2.0; hERG risk; logS -3.88; logP 4.41",repurposing_candidates.csv:rc_row=434;protein_drug_candidates.csv:rows=433;1066;1095;2171;pathway_drug_candidates.csv:rows=4346;5755;5783;5812;5850;5879;CYP3A4_results.csv:row=394;CYP2C19_results.csv:row=394;CYP2D6_results.csv:row=394;CYP1A2_results.csv:row=394;CYP2C9_results.csv:row=394;hERG_results.csv:row=394;AMES_results.csv:row=394;PGP_results.csv:row=394;PAMPA_results.csv:row=394;BBB_results.csv:row=394;Solubility_results.csv:row=394;Lipophilicity_results.csv:row=395
CHEMBL3545017,GTX-758,O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,14.63768115942029,60,95.0,50.60507246376812,M,KG targets ESR1; clinical phase 2.0; logS -4.10; logP 4.35,repurposing_candidates.csv:rc_row=964;protein_drug_candidates.csv:rows=2313;CYP3A4_results.csv:row=866;CYP2C19_results.csv:row=866;CYP2D6_results.csv:row=866;CYP1A2_results.csv:row=866;CYP2C9_results.csv:row=866;hERG_results.csv:row=866;AMES_results.csv:row=866;PGP_results.csv:row=866;PAMPA_results.csv:row=866;BBB_results.csv:row=866;Solubility_results.csv:row=866;Lipophilicity_results.csv:row=867
CHEMBL4130229,VODOBATINIB,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1,29.801678108314263,60,70.0,50.42067124332571,M,"KG targets ABL1, BCR; clinical phase 2.0; hERG risk; logS -4.85; logP 4.98",repurposing_candidates.csv:rc_row=1137;protein_drug_candidates.csv:rows=1220;2211;pathway_drug_candidates.csv:rows=4311;CYP3A4_results.csv:row=1001;CYP2C19_results.csv:row=1001;CYP2D6_results.csv:row=1001;CYP1A2_results.csv:row=1001;CYP2C9_results.csv:row=1001;hERG_results.csv:row=1001;AMES_results.csv:row=1001;PGP_results.csv:row=1001;PAMPA_results.csv:row=1001;BBB_results.csv:row=1001;Solubility_results.csv:row=1001;Lipophilicity_results.csv:row=1002
CHEMBL1908397,KW-2449,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,28.497330282227306,40,100.0,50.398932112890925,L,KG targets ABL1; clinical phase 1.0; logS -3.04; logP 2.78,repurposing_candidates.csv:rc_row=595;protein_drug_candidates.csv:rows=1222;pathway_drug_candidates.csv:rows=4313;CYP3A4_results.csv:row=541;CYP2C19_results.csv:row=541;CYP2D6_results.csv:row=541;CYP1A2_results.csv:row=541;CYP2C9_results.csv:row=541;hERG_results.csv:row=541;AMES_results.csv:row=541;PGP_results.csv:row=541;PAMPA_results.csv:row=541;BBB_results.csv:row=541;Solubility_results.csv:row=541;Lipophilicity_results.csv:row=542
CHEMBL1980391,RG-1530,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,28.497330282227306,40,100.0,50.398932112890925,L,KG targets PDGFRB; clinical phase 1.0; logS -4.69; logP 4.75,repurposing_candidates.csv:rc_row=617;protein_drug_candidates.csv:rows=1137;pathway_drug_candidates.csv:rows=7035;CYP3A4_results.csv:row=563;CYP2C19_results.csv:row=563;CYP2D6_results.csv:row=563;CYP1A2_results.csv:row=563;CYP2C9_results.csv:row=563;hERG_results.csv:row=563;AMES_results.csv:row=563;PGP_results.csv:row=563;PAMPA_results.csv:row=563;BBB_results.csv:row=563;Solubility_results.csv:row=563;Lipophilicity_results.csv:row=564
CHEMBL17976,RESINIFERATOXIN,C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2,28.497330282227306,40,100.0,50.398932112890925,L,KG targets TRPV1; clinical phase 1.0; logS -5.43; logP 4.74,repurposing_candidates.csv:rc_row=578;protein_drug_candidates.csv:rows=701;pathway_drug_candidates.csv:rows=5727;CYP3A4_results.csv:row=524;CYP2C19_results.csv:row=524;CYP2D6_results.csv:row=524;CYP1A2_results.csv:row=524;CYP2C9_results.csv:row=524;hERG_results.csv:row=524;AMES_results.csv:row=524;PGP_results.csv:row=524;PAMPA_results.csv:row=524;BBB_results.csv:row=524;Solubility_results.csv:row=524;Lipophilicity_results.csv:row=525
CHEMBL2180604,TAK-593,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,28.497330282227306,40,100.0,50.398932112890925,L,KG targets PDGFRB; clinical phase 1.0; logS -5.08; logP 3.47,repurposing_candidates.csv:rc_row=801;protein_drug_candidates.csv:rows=1139;pathway_drug_candidates.csv:rows=7037;CYP3A4_results.csv:row=710;CYP2C19_results.csv:row=710;CYP2D6_results.csv:row=710;CYP1A2_results.csv:row=710;CYP2C9_results.csv:row=710;hERG_results.csv:row=710;AMES_results.csv:row=710;PGP_results.csv:row=710;PAMPA_results.csv:row=710;BBB_results.csv:row=710;Solubility_results.csv:row=710;Lipophilicity_results.csv:row=711
CHEMBL2103851,AMUVATINIB,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,29.549961861174673,60,70.0,50.31998474446987,M,KG targets KIT; clinical phase 2.0; hERG risk; logS -5.99; logP 3.30,repurposing_candidates.csv:rc_row=671;protein_drug_candidates.csv:rows=1172;pathway_drug_candidates.csv:rows=577;6989;7523;CYP3A4_results.csv:row=616;CYP2C19_results.csv:row=616;CYP2D6_results.csv:row=616;CYP1A2_results.csv:row=616;CYP2C9_results.csv:row=616;hERG_results.csv:row=616;AMES_results.csv:row=616;PGP_results.csv:row=616;PAMPA_results.csv:row=616;BBB_results.csv:row=616;Solubility_results.csv:row=616;Lipophilicity_results.csv:row=617
CHEMBL3219616,CP-866087,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,29.549961861174673,60,70.0,50.31998474446987,M,KG targets OPRM1; clinical phase 2.0; hERG risk; logS -4.91; logP 2.80,repurposing_candidates.csv:rc_row=928;protein_drug_candidates.csv:rows=337;pathway_drug_candidates.csv:rows=307;1341;7254;CYP3A4_results.csv:row=835;CYP2C19_results.csv:row=835;CYP2D6_results.csv:row=835;CYP1A2_results.csv:row=835;CYP2C9_results.csv:row=835;hERG_results.csv:row=835;AMES_results.csv:row=835;PGP_results.csv:row=835;PAMPA_results.csv:row=835;BBB_results.csv:row=835;Solubility_results.csv:row=835;Lipophilicity_results.csv:row=836
CHEMBL2103878,ODELEPRAN,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1,29.549961861174673,60,70.0,50.31998474446987,M,KG targets OPRM1; clinical phase 2.0; hERG risk; logS -1.53; logP 3.02,repurposing_candidates.csv:rc_row=676;protein_drug_candidates.csv:rows=343;pathway_drug_candidates.csv:rows=313;1347;7260;CYP3A4_results.csv:row=621;CYP2C19_results.csv:row=621;CYP2D6_results.csv:row=621;CYP1A2_results.csv:row=621;CYP2C9_results.csv:row=621;hERG_results.csv:row=621;AMES_results.csv:row=621;PGP_results.csv:row=621;PAMPA_results.csv:row=621;BBB_results.csv:row=621;Solubility_results.csv:row=621;Lipophilicity_results.csv:row=622
CHEMBL2165326,APROCITENTAN,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,14.63768115942029,80,65.0,50.10507246376812,M,KG targets EDNRA; clinical phase 3.0; hERG risk; logS -5.78; logP 2.53,repurposing_candidates.csv:rc_row=795;protein_drug_candidates.csv:rows=1918;CYP3A4_results.csv:row=704;CYP2C19_results.csv:row=704;CYP2D6_results.csv:row=704;CYP1A2_results.csv:row=704;CYP2C9_results.csv:row=704;hERG_results.csv:row=704;AMES_results.csv:row=704;PGP_results.csv:row=704;PAMPA_results.csv:row=704;BBB_results.csv:row=704;Solubility_results.csv:row=704;Lipophilicity_results.csv:row=705
CHEMBL1800807,ANACETRAPIB,COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,14.63768115942029,80,65.0,50.10507246376812,M,KG targets CETP; clinical phase 3.0; logS -8.31; logP 9.76,repurposing_candidates.csv:rc_row=579;protein_drug_candidates.csv:rows=1900;CYP3A4_results.csv:row=525;CYP2C19_results.csv:row=525;CYP2D6_results.csv:row=525;CYP1A2_results.csv:row=525;CYP2C9_results.csv:row=525;hERG_results.csv:row=525;AMES_results.csv:row=525;PGP_results.csv:row=525;PAMPA_results.csv:row=525;BBB_results.csv:row=525;Solubility_results.csv:row=525;Lipophilicity_results.csv:row=526
CHEMBL207433,SB-705498,O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,28.497330282227306,60,70.0,49.898932112890925,M,KG targets TRPV1; clinical phase 2.0; hERG risk; logS -5.57; logP 4.26,repurposing_candidates.csv:rc_row=644;protein_drug_candidates.csv:rows=696;pathway_drug_candidates.csv:rows=5722;CYP3A4_results.csv:row=590;CYP2C19_results.csv:row=590;CYP2D6_results.csv:row=590;CYP1A2_results.csv:row=590;CYP2C9_results.csv:row=590;hERG_results.csv:row=590;AMES_results.csv:row=590;PGP_results.csv:row=590;PAMPA_results.csv:row=590;BBB_results.csv:row=590;Solubility_results.csv:row=590;Lipophilicity_results.csv:row=591
CHEMBL1170,TESTOSTERONE PROPIONATE,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,29.549961861174673,40,95.0,49.56998474446987,L,KG targets AR; clinical phase 1.0; logS -5.04; logP 4.84,repurposing_candidates.csv:rc_row=70;protein_drug_candidates.csv:rows=574;pathway_drug_candidates.csv:rows=1997;5912;7816;CYP3A4_results.csv:row=69;CYP2C19_results.csv:row=69;CYP2D6_results.csv:row=69;CYP1A2_results.csv:row=69;CYP2C9_results.csv:row=69;hERG_results.csv:row=69;AMES_results.csv:row=69;PGP_results.csv:row=69;PAMPA_results.csv:row=69;BBB_results.csv:row=69;Solubility_results.csv:row=69;Lipophilicity_results.csv:row=69
CHEMBL5314408,AZD-0424,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1,28.497330282227306,40,95.0,49.148932112890925,L,KG targets ABL1; clinical phase 1.0; logS -4.15; logP 3.48,repurposing_candidates.csv:rc_row=1385;protein_drug_candidates.csv:rows=1224;pathway_drug_candidates.csv:rows=4315;CYP3A4_results.csv:row=1196;CYP2C19_results.csv:row=1196;CYP2D6_results.csv:row=1196;CYP1A2_results.csv:row=1196;CYP2C9_results.csv:row=1196;hERG_results.csv:row=1196;AMES_results.csv:row=1196;PGP_results.csv:row=1196;PAMPA_results.csv:row=1196;BBB_results.csv:row=1196;Solubility_results.csv:row=1196;Lipophilicity_results.csv:row=1197
CHEMBL3137316,FOSDAGROCORAT,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1,32.707856598016775,60,60.0,49.08314263920671,M,KG targets NR3C1; clinical phase 2.0; hERG risk; logS -5.31; logP 6.28,repurposing_candidates.csv:rc_row=910;protein_drug_candidates.csv:rows=61;pathway_drug_candidates.csv:rows=753;2062;5977;7881;8018;8084;8155;8221;8287;CYP3A4_results.csv:row=817;CYP2C19_results.csv:row=817;CYP2D6_results.csv:row=817;CYP1A2_results.csv:row=817;CYP2C9_results.csv:row=817;hERG_results.csv:row=817;AMES_results.csv:row=817;PGP_results.csv:row=817;PAMPA_results.csv:row=817;BBB_results.csv:row=817;Solubility_results.csv:row=817;Lipophilicity_results.csv:row=818
CHEMBL2079587,STANOZOLOL,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,29.549961861174673,60,65.0,49.06998474446987,M,KG targets AR; clinical phase 2.0; hERG risk; logS -5.27; logP 4.12,repurposing_candidates.csv:rc_row=646;protein_drug_candidates.csv:rows=564;pathway_drug_candidates.csv:rows=1987;5902;7806;CYP3A4_results.csv:row=592;CYP2C19_results.csv:row=592;CYP2D6_results.csv:row=592;CYP1A2_results.csv:row=592;CYP2C9_results.csv:row=592;hERG_results.csv:row=592;AMES_results.csv:row=592;PGP_results.csv:row=592;PAMPA_results.csv:row=592;BBB_results.csv:row=592;Solubility_results.csv:row=592;Lipophilicity_results.csv:row=593
CHEMBL2364574,DOXYCYCLINE CALCIUM,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2],53.901601830663616,10,95.0,48.81064073226545,L,"KG targets MMP1, MMP13; clinical phase 0.5; logS -3.75; logP -2.34",repurposing_candidates.csv:rc_row=833;protein_drug_candidates.csv:rows=613;619;626;632;pathway_drug_candidates.csv:rows=30;37;42;48;54;61;66;72;85;92;97;103;116;130;235;3032;CYP3A4_results.csv:row=742;CYP2C19_results.csv:row=742;CYP2D6_results.csv:row=742;CYP1A2_results.csv:row=742;CYP2C9_results.csv:row=742;hERG_results.csv:row=742;AMES_results.csv:row=742;PGP_results.csv:row=742;PAMPA_results.csv:row=742;BBB_results.csv:row=742;Solubility_results.csv:row=742;Lipophilicity_results.csv:row=743
CHEMBL5314393,LY2624803,CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O,28.497330282227306,60,65.0,48.648932112890925,M,KG targets HRH1; clinical phase 2.0; hERG risk; logS -4.64; logP 3.60,repurposing_candidates.csv:rc_row=1381;protein_drug_candidates.csv:rows=1037;pathway_drug_candidates.csv:rows=6667;CYP3A4_results.csv:row=1192;CYP2C19_results.csv:row=1192;CYP2D6_results.csv:row=1192;CYP1A2_results.csv:row=1192;CYP2C9_results.csv:row=1192;hERG_results.csv:row=1192;AMES_results.csv:row=1192;PGP_results.csv:row=1192;PAMPA_results.csv:row=1192;BBB_results.csv:row=1192;Solubility_results.csv:row=1192;Lipophilicity_results.csv:row=1193
CHEMBL1230609,FORETINIB,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,30.85430968726163,60,60.0,48.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0; hERG risk; logS -5.35; logP 5.77",repurposing_candidates.csv:rc_row=339;protein_drug_candidates.csv:rows=1128;1171;pathway_drug_candidates.csv:rows=576;6988;7026;7522;CYP3A4_results.csv:row=302;CYP2C19_results.csv:row=302;CYP2D6_results.csv:row=302;CYP1A2_results.csv:row=302;CYP2C9_results.csv:row=302;hERG_results.csv:row=302;AMES_results.csv:row=302;PGP_results.csv:row=302;PAMPA_results.csv:row=302;BBB_results.csv:row=302;Solubility_results.csv:row=302;Lipophilicity_results.csv:row=303
CHEMBL124660,TANDUTINIB,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,30.85430968726163,60,60.0,48.34172387490465,M,"KG targets KIT, PDGFRB; clinical phase 2.0; hERG risk; logS -4.54; logP 5.03",repurposing_candidates.csv:rc_row=352;protein_drug_candidates.csv:rows=1127;1170;pathway_drug_candidates.csv:rows=575;6987;7025;7521;CYP3A4_results.csv:row=314;CYP2C19_results.csv:row=314;CYP2D6_results.csv:row=314;CYP1A2_results.csv:row=314;CYP2C9_results.csv:row=314;hERG_results.csv:row=314;AMES_results.csv:row=314;PGP_results.csv:row=314;PAMPA_results.csv:row=314;BBB_results.csv:row=314;Solubility_results.csv:row=314;Lipophilicity_results.csv:row=315
CHEMBL3545237,HE3235,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C,29.549961861174673,40,90.0,48.31998474446987,L,KG targets AR; clinical phase 1.0; logS -6.10; logP 3.75,repurposing_candidates.csv:rc_row=983;protein_drug_candidates.csv:rows=575;pathway_drug_candidates.csv:rows=1998;5913;7817;CYP3A4_results.csv:row=877;CYP2C19_results.csv:row=877;CYP2D6_results.csv:row=877;CYP1A2_results.csv:row=877;CYP2C9_results.csv:row=877;hERG_results.csv:row=877;AMES_results.csv:row=877;PGP_results.csv:row=877;PAMPA_results.csv:row=877;BBB_results.csv:row=877;Solubility_results.csv:row=877;Lipophilicity_results.csv:row=878
CHEMBL2107341,FISPEMIFENE,OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,14.63768115942029,60,85.0,48.10507246376812,M,KG targets ESR1; clinical phase 2.0; logS -5.96; logP 5.66,repurposing_candidates.csv:rc_row=725;protein_drug_candidates.csv:rows=2311;CYP3A4_results.csv:row=670;CYP2C19_results.csv:row=670;CYP2D6_results.csv:row=670;CYP1A2_results.csv:row=670;CYP2C9_results.csv:row=670;hERG_results.csv:row=670;AMES_results.csv:row=670;PGP_results.csv:row=670;PAMPA_results.csv:row=670;BBB_results.csv:row=670;Solubility_results.csv:row=670;Lipophilicity_results.csv:row=671
CHEMBL3545155,JI-101,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,28.497330282227306,40,90.0,47.898932112890925,L,KG targets PDGFRB; clinical phase 1.0; logS -5.17; logP 5.08,repurposing_candidates.csv:rc_row=973;protein_drug_candidates.csv:rows=1138;pathway_drug_candidates.csv:rows=7036;CYP3A4_results.csv:row=872;CYP2C19_results.csv:row=872;CYP2D6_results.csv:row=872;CYP1A2_results.csv:row=872;CYP2C9_results.csv:row=872;hERG_results.csv:row=872;AMES_results.csv:row=872;PGP_results.csv:row=872;PAMPA_results.csv:row=872;BBB_results.csv:row=872;Solubility_results.csv:row=872;Lipophilicity_results.csv:row=873
CHEMBL2364618,MAVATREP,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1,28.497330282227306,40,90.0,47.898932112890925,L,KG targets TRPV1; clinical phase 1.0; logS -5.98; logP 6.65,repurposing_candidates.csv:rc_row=838;protein_drug_candidates.csv:rows=702;pathway_drug_candidates.csv:rows=5728;CYP3A4_results.csv:row=747;CYP2C19_results.csv:row=747;CYP2D6_results.csv:row=747;CYP1A2_results.csv:row=747;CYP2C9_results.csv:row=747;hERG_results.csv:row=747;AMES_results.csv:row=747;PGP_results.csv:row=747;PAMPA_results.csv:row=747;BBB_results.csv:row=747;Solubility_results.csv:row=747;Lipophilicity_results.csv:row=748
CHEMBL1201294,DIPHENOXYLATE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1,29.549961861174673,60,60.0,47.81998474446987,M,KG targets OPRM1; clinical phase 2.0; hERG risk; logS -4.00; logP 5.48,repurposing_candidates.csv:rc_row=269;protein_drug_candidates.csv:rows=334;pathway_drug_candidates.csv:rows=304;1338;7251;CYP3A4_results.csv:row=266;CYP2C19_results.csv:row=266;CYP2D6_results.csv:row=266;CYP1A2_results.csv:row=266;CYP2C9_results.csv:row=266;hERG_results.csv:row=266;AMES_results.csv:row=266;PGP_results.csv:row=266;PAMPA_results.csv:row=266;BBB_results.csv:row=266;Solubility_results.csv:row=266;Lipophilicity_results.csv:row=267
CHEMBL46740,BAZEDOXIFENE,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,14.63768115942029,80,55.0,47.60507246376812,M,KG targets ESR1; clinical phase 3.0; hERG risk; logS -5.47; logP 6.33,repurposing_candidates.csv:rc_row=1323;protein_drug_candidates.csv:rows=2301;CYP3A4_results.csv:row=1134;CYP2C19_results.csv:row=1134;CYP2D6_results.csv:row=1134;CYP1A2_results.csv:row=1134;CYP2C9_results.csv:row=1134;hERG_results.csv:row=1134;AMES_results.csv:row=1134;PGP_results.csv:row=1134;PAMPA_results.csv:row=1134;BBB_results.csv:row=1134;Solubility_results.csv:row=1134;Lipophilicity_results.csv:row=1135
CHEMBL226267,ARZOXIFENE,COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1,14.63768115942029,80,55.0,47.60507246376812,M,KG targets ESR1; clinical phase 3.0; hERG risk; logS -5.02; logP 6.94,repurposing_candidates.csv:rc_row=819;protein_drug_candidates.csv:rows=2302;CYP3A4_results.csv:row=728;CYP2C19_results.csv:row=728;CYP2D6_results.csv:row=728;CYP1A2_results.csv:row=728;CYP2C9_results.csv:row=728;hERG_results.csv:row=728;AMES_results.csv:row=728;PGP_results.csv:row=728;PAMPA_results.csv:row=728;BBB_results.csv:row=728;Solubility_results.csv:row=728;Lipophilicity_results.csv:row=729
CHEMBL4297509,ELACESTRANT,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1,14.63768115942029,80,55.0,47.60507246376812,M,KG targets ESR1; clinical phase 3.0; hERG risk; logS -3.40; logP 5.85,repurposing_candidates.csv:rc_row=1184;protein_drug_candidates.csv:rows=2305;CYP3A4_results.csv:row=1047;CYP2C19_results.csv:row=1047;CYP2D6_results.csv:row=1047;CYP1A2_results.csv:row=1047;CYP2C9_results.csv:row=1047;hERG_results.csv:row=1047;AMES_results.csv:row=1047;PGP_results.csv:row=1047;PAMPA_results.csv:row=1047;BBB_results.csv:row=1047;Solubility_results.csv:row=1047;Lipophilicity_results.csv:row=1048
CHEMBL4297631,TELRATOLIMOD,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21,33.760488176964145,40,80.0,47.50419527078566,L,KG targets TLR7; clinical phase 1.0; logS -6.36; logP 9.10,repurposing_candidates.csv:rc_row=1200;protein_drug_candidates.csv:rows=608;pathway_drug_candidates.csv:rows=768;4264;7330;7352;7363;7374;7385;7407;7429;7451;7462;CYP3A4_results.csv:row=1060;CYP2C19_results.csv:row=1060;CYP2D6_results.csv:row=1060;CYP1A2_results.csv:row=1060;CYP2C9_results.csv:row=1060;hERG_results.csv:row=1060;AMES_results.csv:row=1060;PGP_results.csv:row=1060;PAMPA_results.csv:row=1060;BBB_results.csv:row=1060;Solubility_results.csv:row=1060;Lipophilicity_results.csv:row=1061
CHEMBL1614710,OSI-930,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,29.549961861174673,40,85.0,47.06998474446987,L,KG targets KIT; clinical phase 1.0; logS -4.78; logP 6.06,repurposing_candidates.csv:rc_row=477;protein_drug_candidates.csv:rows=1176;pathway_drug_candidates.csv:rows=581;6993;7527;CYP3A4_results.csv:row=437;CYP2C19_results.csv:row=437;CYP2D6_results.csv:row=437;CYP1A2_results.csv:row=437;CYP2C9_results.csv:row=437;hERG_results.csv:row=437;AMES_results.csv:row=437;PGP_results.csv:row=437;PAMPA_results.csv:row=437;BBB_results.csv:row=437;Solubility_results.csv:row=437;Lipophilicity_results.csv:row=438
CHEMBL107430,NRX195183,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,14.63768115942029,60,80.0,46.85507246376812,M,KG targets RARA; clinical phase 2.0; logS -7.35; logP 5.62,repurposing_candidates.csv:rc_row=24;protein_drug_candidates.csv:rows=1769;CYP3A4_results.csv:row=24;CYP2C19_results.csv:row=24;CYP2D6_results.csv:row=24;CYP1A2_results.csv:row=24;CYP2C9_results.csv:row=24;hERG_results.csv:row=24;AMES_results.csv:row=24;PGP_results.csv:row=24;PAMPA_results.csv:row=24;BBB_results.csv:row=24;Solubility_results.csv:row=24;Lipophilicity_results.csv:row=24
CHEMBL4475463,AMCENESTRANT,O=C(O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1,14.63768115942029,80,50.0,46.35507246376812,M,KG targets ESR1; clinical phase 3.0; hERG risk; logS -6.81; logP 7.80,repurposing_candidates.csv:rc_row=1267;protein_drug_candidates.csv:rows=2306;CYP3A4_results.csv:row=1087;CYP2C19_results.csv:row=1087;CYP2D6_results.csv:row=1087;CYP1A2_results.csv:row=1087;CYP2C9_results.csv:row=1087;hERG_results.csv:row=1087;AMES_results.csv:row=1087;PGP_results.csv:row=1087;PAMPA_results.csv:row=1087;BBB_results.csv:row=1087;Solubility_results.csv:row=1087;Lipophilicity_results.csv:row=1088
CHEMBL4297732,ZILTIVEKIMAB,,18.321891685736077,40,100.0,46.32875667429443,L,KG targets IL6; clinical phase 1.0,repurposing_candidates.csv:rc_row=1211;pathway_drug_candidates.csv:rows=123;173;4409;4545;4624;4703;7593;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109614,MEDI-5117,,18.321891685736077,40,100.0,46.32875667429443,L,KG targets IL6; clinical phase 1.0,repurposing_candidates.csv:rc_row=774;pathway_drug_candidates.csv:rows=122;172;4408;4544;4623;4702;7592;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL2109615,MRA 003 US,,18.321891685736077,40,100.0,46.32875667429443,L,KG targets IL6; clinical phase 1.0,repurposing_candidates.csv:rc_row=775;pathway_drug_candidates.csv:rows=124;174;4410;4546;4625;4704;7594;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL4297521,PADSEVONIL,COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,22.46376811594203,60,65.0,46.23550724637681,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; hERG risk; logS -2.06; logP 3.53",repurposing_candidates.csv:rc_row=1187;protein_drug_candidates.csv:rows=517;1444;1670;1715;2078;2123;2481;CYP3A4_results.csv:row=1050;CYP2C19_results.csv:row=1050;CYP2D6_results.csv:row=1050;CYP1A2_results.csv:row=1050;CYP2C9_results.csv:row=1050;hERG_results.csv:row=1050;AMES_results.csv:row=1050;PGP_results.csv:row=1050;PAMPA_results.csv:row=1050;BBB_results.csv:row=1050;Solubility_results.csv:row=1050;Lipophilicity_results.csv:row=1051
CHEMBL2107801,RESEQUINIL,COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1,22.46376811594203,60,65.0,46.23550724637681,M,"KG targets GABRA1, GABRA2; clinical phase 2.0; hERG risk; logS -4.13; logP 2.96",repurposing_candidates.csv:rc_row=737;protein_drug_candidates.csv:rows=522;1448;1673;1721;2081;2128;2486;CYP3A4_results.csv:row=682;CYP2C19_results.csv:row=682;CYP2D6_results.csv:row=682;CYP1A2_results.csv:row=682;CYP2C9_results.csv:row=682;hERG_results.csv:row=682;AMES_results.csv:row=682;PGP_results.csv:row=682;PAMPA_results.csv:row=682;BBB_results.csv:row=682;Solubility_results.csv:row=682;Lipophilicity_results.csv:row=683
CHEMBL489,AFIMOXIFENE,CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,14.63768115942029,60,75.0,45.60507246376812,M,KG targets ESR1; clinical phase 2.0; logS -6.75; logP 5.70,repurposing_candidates.csv:rc_row=1337;protein_drug_candidates.csv:rows=2310;CYP3A4_results.csv:row=1148;CYP2C19_results.csv:row=1148;CYP2D6_results.csv:row=1148;CYP1A2_results.csv:row=1148;CYP2C9_results.csv:row=1148;hERG_results.csv:row=1148;AMES_results.csv:row=1148;PGP_results.csv:row=1148;PAMPA_results.csv:row=1148;BBB_results.csv:row=1148;Solubility_results.csv:row=1148;Lipophilicity_results.csv:row=1149
CHEMBL2109470,PERAKIZUMAB,,16.21662852784134,40,100.0,45.486651411136535,L,KG targets IL17A; clinical phase 1.0,repurposing_candidates.csv:rc_row=770;pathway_drug_candidates.csv:rows=162;4231;7311;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1783256,AZD6280,CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N,15.942028985507244,40,100.0,45.3768115942029,L,"KG targets GABRA2, GABRA3; clinical phase 1.0; logS -4.82; logP 3.04",repurposing_candidates.csv:rc_row=570;protein_drug_candidates.csv:rows=1723;2130;CYP3A4_results.csv:row=516;CYP2C19_results.csv:row=516;CYP2D6_results.csv:row=516;CYP1A2_results.csv:row=516;CYP2C9_results.csv:row=516;hERG_results.csv:row=516;AMES_results.csv:row=516;PGP_results.csv:row=516;PAMPA_results.csv:row=516;BBB_results.csv:row=516;Solubility_results.csv:row=516;Lipophilicity_results.csv:row=517
CHEMBL5314386,ME-344,Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,15.942028985507244,40,100.0,45.3768115942029,L,"KG targets MT-ND4, NDUFA4; clinical phase 1.0; logS -4.50; logP 4.42",repurposing_candidates.csv:rc_row=1379;protein_drug_candidates.csv:rows=1537;1947;CYP3A4_results.csv:row=1190;CYP2C19_results.csv:row=1190;CYP2D6_results.csv:row=1190;CYP1A2_results.csv:row=1190;CYP2C9_results.csv:row=1190;hERG_results.csv:row=1190;AMES_results.csv:row=1190;PGP_results.csv:row=1190;PAMPA_results.csv:row=1190;BBB_results.csv:row=1190;Solubility_results.csv:row=1190;Lipophilicity_results.csv:row=1191
CHEMBL4594402,ORP-101,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,29.549961861174673,60,50.0,45.31998474446987,M,KG targets OPRM1; clinical phase 2.0; hERG risk; logS -6.82; logP 9.19,repurposing_candidates.csv:rc_row=1294;protein_drug_candidates.csv:rows=335;pathway_drug_candidates.csv:rows=305;1339;7252;CYP3A4_results.csv:row=1113;CYP2C19_results.csv:row=1113;CYP2D6_results.csv:row=1113;CYP1A2_results.csv:row=1113;CYP2C9_results.csv:row=1113;hERG_results.csv:row=1113;AMES_results.csv:row=1113;PGP_results.csv:row=1113;PAMPA_results.csv:row=1113;BBB_results.csv:row=1113;Solubility_results.csv:row=1113;Lipophilicity_results.csv:row=1114
CHEMBL4297385,NS-2359,COC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,14.63768115942029,60,70.0,44.35507246376812,M,KG targets SLC6A4; clinical phase 2.0; hERG risk; logS -3.73; logP 4.21,repurposing_candidates.csv:rc_row=1173;protein_drug_candidates.csv:rows=1293;CYP3A4_results.csv:row=1036;CYP2C19_results.csv:row=1036;CYP2D6_results.csv:row=1036;CYP1A2_results.csv:row=1036;CYP2C9_results.csv:row=1036;hERG_results.csv:row=1036;AMES_results.csv:row=1036;PGP_results.csv:row=1036;PAMPA_results.csv:row=1036;BBB_results.csv:row=1036;Solubility_results.csv:row=1036;Lipophilicity_results.csv:row=1037
CHEMBL3989690,TESOFENSINE,CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,14.63768115942029,60,70.0,44.35507246376812,M,KG targets SLC6A4; clinical phase 2.0; hERG risk; logS -4.22; logP 4.60,repurposing_candidates.csv:rc_row=1080;protein_drug_candidates.csv:rows=1292;CYP3A4_results.csv:row=949;CYP2C19_results.csv:row=949;CYP2D6_results.csv:row=949;CYP1A2_results.csv:row=949;CYP2C9_results.csv:row=949;hERG_results.csv:row=949;AMES_results.csv:row=949;PGP_results.csv:row=949;PAMPA_results.csv:row=949;BBB_results.csv:row=949;Solubility_results.csv:row=949;Lipophilicity_results.csv:row=950
CHEMBL2178570,AZD4818,CC(=O)Nc1ccc(O)cc1OC[C@@](C)(O)CNC1CCN(Cc2ccc(Cl)cc2)CC1,14.63768115942029,60,70.0,44.35507246376812,M,KG targets CCR1; clinical phase 2.0; hERG risk; logS -2.23; logP 3.39,repurposing_candidates.csv:rc_row=797;protein_drug_candidates.csv:rows=1790;CYP3A4_results.csv:row=706;CYP2C19_results.csv:row=706;CYP2D6_results.csv:row=706;CYP1A2_results.csv:row=706;CYP2C9_results.csv:row=706;hERG_results.csv:row=706;AMES_results.csv:row=706;PGP_results.csv:row=706;PAMPA_results.csv:row=706;BBB_results.csv:row=706;Solubility_results.csv:row=706;Lipophilicity_results.csv:row=707
CHEMBL1738757,REBASTINIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,28.497330282227306,40,75.0,44.148932112890925,L,KG targets ABL1; clinical phase 1.0; logS -6.37; logP 6.05,repurposing_candidates.csv:rc_row=536;protein_drug_candidates.csv:rows=1223;pathway_drug_candidates.csv:rows=4314;CYP3A4_results.csv:row=496;CYP2C19_results.csv:row=496;CYP2D6_results.csv:row=496;CYP1A2_results.csv:row=496;CYP2C9_results.csv:row=496;hERG_results.csv:row=496;AMES_results.csv:row=496;PGP_results.csv:row=496;PAMPA_results.csv:row=496;BBB_results.csv:row=496;Solubility_results.csv:row=496;Lipophilicity_results.csv:row=497
CHEMBL504652,TC-2216,c1cncc(N2CCC3(CCCN3)C2)c1,30.85430968726163,40,70.0,43.84172387490465,L,"KG targets CHRNA4, CHRNB2; clinical phase 1.0; hERG risk; logS -1.29; logP 1.41",repurposing_candidates.csv:rc_row=1348;protein_drug_candidates.csv:rows=448;2144;pathway_drug_candidates.csv:rows=7928;7942;7956;CYP3A4_results.csv:row=1159;CYP2C19_results.csv:row=1159;CYP2D6_results.csv:row=1159;CYP1A2_results.csv:row=1159;CYP2C9_results.csv:row=1159;hERG_results.csv:row=1159;AMES_results.csv:row=1159;PGP_results.csv:row=1159;PAMPA_results.csv:row=1159;BBB_results.csv:row=1159;Solubility_results.csv:row=1159;Lipophilicity_results.csv:row=1160
CHEMBL1767164,GSK-1004723,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,28.497330282227306,60,45.0,43.648932112890925,L,KG targets HRH1; clinical phase 2.0; hERG risk; logS -7.89; logP 7.77,repurposing_candidates.csv:rc_row=565;protein_drug_candidates.csv:rows=1038;pathway_drug_candidates.csv:rows=6668;CYP3A4_results.csv:row=511;CYP2C19_results.csv:row=511;CYP2D6_results.csv:row=511;CYP1A2_results.csv:row=511;CYP2C9_results.csv:row=511;hERG_results.csv:row=511;AMES_results.csv:row=511;PGP_results.csv:row=511;PAMPA_results.csv:row=511;BBB_results.csv:row=511;Solubility_results.csv:row=511;Lipophilicity_results.csv:row=512
CHEMBL272621,HYODEOXYCHOLIC_ACID,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,14.63768115942029,40,95.0,43.60507246376812,L,KG targets NR1H2; clinical phase 1.0; logS -4.94; logP 4.48,repurposing_candidates.csv:rc_row=867;protein_drug_candidates.csv:rows=1728;CYP3A4_results.csv:row=775;CYP2C19_results.csv:row=775;CYP2D6_results.csv:row=775;CYP1A2_results.csv:row=775;CYP2C9_results.csv:row=775;hERG_results.csv:row=775;AMES_results.csv:row=775;PGP_results.csv:row=775;PAMPA_results.csv:row=775;BBB_results.csv:row=775;Solubility_results.csv:row=775;Lipophilicity_results.csv:row=776
CHEMBL3545085,XL-228,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,29.801678108314263,40,70.0,43.42067124332571,L,"KG targets ABL1, BLK; clinical phase 1.0; hERG risk; logS -3.89; logP 3.30",repurposing_candidates.csv:rc_row=968;protein_drug_candidates.csv:rows=946;1221;pathway_drug_candidates.csv:rows=4312;CYP3A4_results.csv:row=869;CYP2C19_results.csv:row=869;CYP2D6_results.csv:row=869;CYP1A2_results.csv:row=869;CYP2C9_results.csv:row=869;hERG_results.csv:row=869;AMES_results.csv:row=869;PGP_results.csv:row=869;PAMPA_results.csv:row=869;BBB_results.csv:row=869;Solubility_results.csv:row=869;Lipophilicity_results.csv:row=870
CHEMBL2346976,AZD3514,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,29.549961861174673,40,70.0,43.31998474446987,L,KG targets AR; clinical phase 1.0; hERG risk; logS -1.96; logP 2.83,repurposing_candidates.csv:rc_row=827;protein_drug_candidates.csv:rows=577;pathway_drug_candidates.csv:rows=2000;5915;7819;CYP3A4_results.csv:row=736;CYP2C19_results.csv:row=736;CYP2D6_results.csv:row=736;CYP1A2_results.csv:row=736;CYP2C9_results.csv:row=736;hERG_results.csv:row=736;AMES_results.csv:row=736;PGP_results.csv:row=736;PAMPA_results.csv:row=736;BBB_results.csv:row=736;Solubility_results.csv:row=736;Lipophilicity_results.csv:row=737
CHEMBL592374,AMITIFADINE,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl,14.63768115942029,60,65.0,43.10507246376812,M,KG targets SLC6A4; clinical phase 2.0; hERG risk; logS -3.64; logP 2.85,repurposing_candidates.csv:rc_row=1434;protein_drug_candidates.csv:rows=1297;CYP3A4_results.csv:row=1243;CYP2C19_results.csv:row=1243;CYP2D6_results.csv:row=1243;CYP1A2_results.csv:row=1243;CYP2C9_results.csv:row=1243;hERG_results.csv:row=1243;AMES_results.csv:row=1243;PGP_results.csv:row=1243;PAMPA_results.csv:row=1243;BBB_results.csv:row=1243;Solubility_results.csv:row=1243;Lipophilicity_results.csv:row=1244
CHEMBL3707374,AMISELIMOD HYDROCHLORIDE,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl,14.63768115942029,60,65.0,43.10507246376812,M,KG targets S1PR4; clinical phase 2.0; hERG risk; logS -4.12; logP 4.09,repurposing_candidates.csv:rc_row=1027;protein_drug_candidates.csv:rows=1886;CYP3A4_results.csv:row=904;CYP2C19_results.csv:row=904;CYP2D6_results.csv:row=904;CYP1A2_results.csv:row=904;CYP2C9_results.csv:row=904;hERG_results.csv:row=904;AMES_results.csv:row=904;PGP_results.csv:row=904;PAMPA_results.csv:row=904;BBB_results.csv:row=904;Solubility_results.csv:row=904;Lipophilicity_results.csv:row=905
CHEMBL3707375,AMISELIMOD,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,14.63768115942029,60,65.0,43.10507246376812,M,KG targets S1PR4; clinical phase 2.0; hERG risk; logS -4.69; logP 3.67,repurposing_candidates.csv:rc_row=1028;protein_drug_candidates.csv:rows=1887;CYP3A4_results.csv:row=905;CYP2C19_results.csv:row=905;CYP2D6_results.csv:row=905;CYP1A2_results.csv:row=905;CYP2C9_results.csv:row=905;hERG_results.csv:row=905;AMES_results.csv:row=905;PGP_results.csv:row=905;PAMPA_results.csv:row=905;BBB_results.csv:row=905;Solubility_results.csv:row=905;Lipophilicity_results.csv:row=906
CHEMBL4297312,ORM-12741,COC[C@@]1(C)CCCN2CCc3c(oc4ccccc34)[C@@H]21,14.63768115942029,60,65.0,43.10507246376812,M,KG targets ADRA2C; clinical phase 2.0; hERG risk; logS -3.22; logP 3.78,repurposing_candidates.csv:rc_row=1170;protein_drug_candidates.csv:rows=2548;CYP3A4_results.csv:row=1033;CYP2C19_results.csv:row=1033;CYP2D6_results.csv:row=1033;CYP1A2_results.csv:row=1033;CYP2C9_results.csv:row=1033;hERG_results.csv:row=1033;AMES_results.csv:row=1033;PGP_results.csv:row=1033;PAMPA_results.csv:row=1033;BBB_results.csv:row=1033;Solubility_results.csv:row=1033;Lipophilicity_results.csv:row=1034
CHEMBL3360975,BMS-779788,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,14.63768115942029,40,90.0,42.35507246376812,L,KG targets NR1H2; clinical phase 1.0; logS -5.80; logP 6.15,repurposing_candidates.csv:rc_row=950;protein_drug_candidates.csv:rows=1726;CYP3A4_results.csv:row=854;CYP2C19_results.csv:row=854;CYP2D6_results.csv:row=854;CYP1A2_results.csv:row=854;CYP2C9_results.csv:row=854;hERG_results.csv:row=854;AMES_results.csv:row=854;PGP_results.csv:row=854;PAMPA_results.csv:row=854;BBB_results.csv:row=854;Solubility_results.csv:row=854;Lipophilicity_results.csv:row=855
CHEMBL3945199,BMS-852927,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,14.63768115942029,40,90.0,42.35507246376812,L,KG targets NR1H2; clinical phase 1.0; logS -5.35; logP 6.57,repurposing_candidates.csv:rc_row=1061;protein_drug_candidates.csv:rows=1727;CYP3A4_results.csv:row=930;CYP2C19_results.csv:row=930;CYP2D6_results.csv:row=930;CYP1A2_results.csv:row=930;CYP2C9_results.csv:row=930;hERG_results.csv:row=930;AMES_results.csv:row=930;PGP_results.csv:row=930;PAMPA_results.csv:row=930;BBB_results.csv:row=930;Solubility_results.csv:row=930;Lipophilicity_results.csv:row=931
CHEMBL68055,ACOLBIFENE,CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21,14.63768115942029,60,60.0,41.85507246376812,M,KG targets ESR1; clinical phase 2.0; hERG risk; logS -4.66; logP 6.03,repurposing_candidates.csv:rc_row=1484;protein_drug_candidates.csv:rows=2316;CYP3A4_results.csv:row=1290;CYP2C19_results.csv:row=1290;CYP2D6_results.csv:row=1290;CYP1A2_results.csv:row=1290;CYP2C9_results.csv:row=1290;hERG_results.csv:row=1290;AMES_results.csv:row=1290;PGP_results.csv:row=1290;PAMPA_results.csv:row=1290;BBB_results.csv:row=1290;Solubility_results.csv:row=1290;Lipophilicity_results.csv:row=1291
CHEMBL3545210,SR16234,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1.O=C(O)CC(O)(CC(=O)O)C(=O)O,14.63768115942029,60,60.0,41.85507246376812,M,KG targets ESR1; clinical phase 2.0; hERG risk; logS -5.43; logP 6.18,repurposing_candidates.csv:rc_row=978;protein_drug_candidates.csv:rows=2314;CYP3A4_results.csv:row=874;CYP2C19_results.csv:row=874;CYP2D6_results.csv:row=874;CYP1A2_results.csv:row=874;CYP2C9_results.csv:row=874;hERG_results.csv:row=874;AMES_results.csv:row=874;PGP_results.csv:row=874;PAMPA_results.csv:row=874;BBB_results.csv:row=874;Solubility_results.csv:row=874;Lipophilicity_results.csv:row=875
CHEMBL3545211,SR16234,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1,14.63768115942029,60,60.0,41.85507246376812,M,KG targets ESR1; clinical phase 2.0; hERG risk; logS -5.52; logP 7.43,repurposing_candidates.csv:rc_row=979;protein_drug_candidates.csv:rows=2312;CYP3A4_results.csv:row=875;CYP2C19_results.csv:row=875;CYP2D6_results.csv:row=875;CYP1A2_results.csv:row=875;CYP2C9_results.csv:row=875;hERG_results.csv:row=875;AMES_results.csv:row=875;PGP_results.csv:row=875;PAMPA_results.csv:row=875;BBB_results.csv:row=875;Solubility_results.csv:row=875;Lipophilicity_results.csv:row=876
CHEMBL1201010,FLUDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,18.333333333333332,25,100.0,41.08333333333333,L,KG-supported from 1 sources; logS -4.30; logP 2.44,repurposing_candidates.csv:rc_row=215;CYP3A4_results.csv:row=213;CYP2C19_results.csv:row=213;CYP2D6_results.csv:row=213;CYP1A2_results.csv:row=213;CYP2C9_results.csv:row=213;hERG_results.csv:row=213;AMES_results.csv:row=213;PGP_results.csv:row=213;PAMPA_results.csv:row=213;BBB_results.csv:row=213;Solubility_results.csv:row=213;Lipophilicity_results.csv:row=214
CHEMBL429910,DAPAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,18.333333333333332,25,100.0,41.08333333333333,L,KG-supported from 1 sources; logS -4.91; logP 1.84,repurposing_candidates.csv:rc_row=1249;CYP3A4_results.csv:row=1069;CYP2C19_results.csv:row=1069;CYP2D6_results.csv:row=1069;CYP1A2_results.csv:row=1069;CYP2C9_results.csv:row=1069;hERG_results.csv:row=1069;AMES_results.csv:row=1069;PGP_results.csv:row=1069;PAMPA_results.csv:row=1069;BBB_results.csv:row=1069;Solubility_results.csv:row=1069;Lipophilicity_results.csv:row=1070
CHEMBL3900409,BRENSOCATIB,Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,18.333333333333332,25,100.0,41.08333333333333,L,KG-supported from 1 sources; logS -3.33; logP 1.73,repurposing_candidates.csv:rc_row=1056;CYP3A4_results.csv:row=925;CYP2C19_results.csv:row=925;CYP2D6_results.csv:row=925;CYP1A2_results.csv:row=925;CYP2C9_results.csv:row=925;hERG_results.csv:row=925;AMES_results.csv:row=925;PGP_results.csv:row=925;PAMPA_results.csv:row=925;BBB_results.csv:row=925;Solubility_results.csv:row=925;Lipophilicity_results.csv:row=926
CHEMBL1088752,LOSMAPIMOD,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,18.333333333333332,25,100.0,41.08333333333333,L,KG-supported from 1 sources; logS -4.63; logP 3.86,repurposing_candidates.csv:rc_row=35;CYP3A4_results.csv:row=35;CYP2C19_results.csv:row=35;CYP2D6_results.csv:row=35;CYP1A2_results.csv:row=35;CYP2C9_results.csv:row=35;hERG_results.csv:row=35;AMES_results.csv:row=35;PGP_results.csv:row=35;PAMPA_results.csv:row=35;BBB_results.csv:row=35;Solubility_results.csv:row=35;Lipophilicity_results.csv:row=35
CHEMBL592,LEVORPHANOL,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,29.549961861174673,10,100.0,40.31998474446987,L,KG targets OPRM1; clinical phase 0.5; logS -2.80; logP 3.08,repurposing_candidates.csv:rc_row=1433;protein_drug_candidates.csv:rows=344;pathway_drug_candidates.csv:rows=314;1348;7261;CYP3A4_results.csv:row=1242;CYP2C19_results.csv:row=1242;CYP2D6_results.csv:row=1242;CYP1A2_results.csv:row=1242;CYP2C9_results.csv:row=1242;hERG_results.csv:row=1242;AMES_results.csv:row=1242;PGP_results.csv:row=1242;PAMPA_results.csv:row=1242;BBB_results.csv:row=1242;Solubility_results.csv:row=1242;Lipophilicity_results.csv:row=1243
CHEMBL451930,PLITIDEPSIN,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,18.333333333333332,25,95.0,39.83333333333333,L,KG-supported from 1 sources; logS -2.14; logP 2.52,repurposing_candidates.csv:rc_row=1273;CYP3A4_results.csv:row=1093;CYP2C19_results.csv:row=1093;CYP2D6_results.csv:row=1093;CYP1A2_results.csv:row=1093;CYP2C9_results.csv:row=1093;hERG_results.csv:row=1093;AMES_results.csv:row=1093;PGP_results.csv:row=1093;PAMPA_results.csv:row=1093;BBB_results.csv:row=1093;Solubility_results.csv:row=1093;Lipophilicity_results.csv:row=1094
CHEMBL1643,RIBAVIRIN,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,18.333333333333332,25,95.0,39.83333333333333,L,KG-supported from 1 sources; logS -0.16; logP -3.01,repurposing_candidates.csv:rc_row=491;CYP3A4_results.csv:row=451;CYP2C19_results.csv:row=451;CYP2D6_results.csv:row=451;CYP1A2_results.csv:row=451;CYP2C9_results.csv:row=451;hERG_results.csv:row=451;AMES_results.csv:row=451;PGP_results.csv:row=451;PAMPA_results.csv:row=451;BBB_results.csv:row=451;Solubility_results.csv:row=451;Lipophilicity_results.csv:row=452
CHEMBL3581693,BRILANESTRANT,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,14.63768115942029,60,45.0,38.10507246376812,L,KG targets ESR1; clinical phase 2.0; hERG risk; logS -6.44; logP 6.82,repurposing_candidates.csv:rc_row=1001;protein_drug_candidates.csv:rows=2315;CYP3A4_results.csv:row=887;CYP2C19_results.csv:row=887;CYP2D6_results.csv:row=887;CYP1A2_results.csv:row=887;CYP2C9_results.csv:row=887;hERG_results.csv:row=887;AMES_results.csv:row=887;PGP_results.csv:row=887;PAMPA_results.csv:row=887;BBB_results.csv:row=887;Solubility_results.csv:row=887;Lipophilicity_results.csv:row=888
CHEMBL111659,ALTINICLINE,C#Cc1cncc([C@@H]2CCCN2C)c1,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -1.16; logP 1.83,repurposing_candidates.csv:rc_row=55;CYP3A4_results.csv:row=55;CYP2C19_results.csv:row=55;CYP2D6_results.csv:row=55;CYP1A2_results.csv:row=55;CYP2C9_results.csv:row=55;hERG_results.csv:row=55;AMES_results.csv:row=55;PGP_results.csv:row=55;PAMPA_results.csv:row=55;BBB_results.csv:row=55;Solubility_results.csv:row=55;Lipophilicity_results.csv:row=55
CHEMBL1200790,METHYPRYLON,CCC1(CC)C(=O)NCC(C)C1=O,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -0.65; logP 1.13,repurposing_candidates.csv:rc_row=167;CYP3A4_results.csv:row=165;CYP2C19_results.csv:row=165;CYP2D6_results.csv:row=165;CYP1A2_results.csv:row=165;CYP2C9_results.csv:row=165;hERG_results.csv:row=165;AMES_results.csv:row=165;PGP_results.csv:row=165;PAMPA_results.csv:row=165;BBB_results.csv:row=165;Solubility_results.csv:row=165;Lipophilicity_results.csv:row=166
CHEMBL282052,METHAQUALONE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -3.13; logP 3.00,repurposing_candidates.csv:rc_row=878;CYP3A4_results.csv:row=786;CYP2C19_results.csv:row=786;CYP2D6_results.csv:row=786;CYP1A2_results.csv:row=786;CYP2C9_results.csv:row=786;hERG_results.csv:row=786;AMES_results.csv:row=786;PGP_results.csv:row=786;PAMPA_results.csv:row=786;BBB_results.csv:row=786;Solubility_results.csv:row=786;Lipophilicity_results.csv:row=787
CHEMBL2106829,METHAQUALONE HYDROCHLORIDE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -2.45; logP 3.42,repurposing_candidates.csv:rc_row=721;CYP3A4_results.csv:row=666;CYP2C19_results.csv:row=666;CYP2D6_results.csv:row=666;CYP1A2_results.csv:row=666;CYP2C9_results.csv:row=666;hERG_results.csv:row=666;AMES_results.csv:row=666;PGP_results.csv:row=666;PAMPA_results.csv:row=666;BBB_results.csv:row=666;Solubility_results.csv:row=666;Lipophilicity_results.csv:row=667
CHEMBL13280,FLUNITRAZEPAM,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -3.95; logP 2.55,repurposing_candidates.csv:rc_row=383;CYP3A4_results.csv:row=344;CYP2C19_results.csv:row=344;CYP2D6_results.csv:row=344;CYP1A2_results.csv:row=344;CYP2C9_results.csv:row=344;hERG_results.csv:row=344;AMES_results.csv:row=344;PGP_results.csv:row=344;PAMPA_results.csv:row=344;BBB_results.csv:row=344;Solubility_results.csv:row=344;Lipophilicity_results.csv:row=345
CHEMBL2104964,TEBANICLINE TOSYLATE,Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(OC[C@H]2CCN2)cn1,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -1.27; logP 2.72,repurposing_candidates.csv:rc_row=682;CYP3A4_results.csv:row=627;CYP2C19_results.csv:row=627;CYP2D6_results.csv:row=627;CYP1A2_results.csv:row=627;CYP2C9_results.csv:row=627;hERG_results.csv:row=627;AMES_results.csv:row=627;PGP_results.csv:row=627;PAMPA_results.csv:row=627;BBB_results.csv:row=627;Solubility_results.csv:row=627;Lipophilicity_results.csv:row=628
CHEMBL1200703,CHLORDIAZEPOXIDE HYDROCHLORIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -3.59; logP 3.37,repurposing_candidates.csv:rc_row=155;CYP3A4_results.csv:row=153;CYP2C19_results.csv:row=153;CYP2D6_results.csv:row=153;CYP1A2_results.csv:row=153;CYP2C9_results.csv:row=153;hERG_results.csv:row=153;AMES_results.csv:row=153;PGP_results.csv:row=153;PAMPA_results.csv:row=153;BBB_results.csv:row=153;Solubility_results.csv:row=153;Lipophilicity_results.csv:row=154
CHEMBL1200802,TALBUTAL,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O,23.333333333333332,10,100.0,37.833333333333336,L,KG-supported from 1 sources; logS -2.21; logP 0.96,repurposing_candidates.csv:rc_row=172;CYP3A4_results.csv:row=170;CYP2C19_results.csv:row=170;CYP2D6_results.csv:row=170;CYP1A2_results.csv:row=170;CYP2C9_results.csv:row=170;hERG_results.csv:row=170;AMES_results.csv:row=170;PGP_results.csv:row=170;PAMPA_results.csv:row=170;BBB_results.csv:row=170;Solubility_results.csv:row=170;Lipophilicity_results.csv:row=171
CHEMBL3544984,TRADIPITANT,O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1,18.333333333333332,25,85.0,37.33333333333333,L,KG-supported from 1 sources; logS -4.81; logP 7.37,repurposing_candidates.csv:rc_row=961;CYP3A4_results.csv:row=863;CYP2C19_results.csv:row=863;CYP2D6_results.csv:row=863;CYP1A2_results.csv:row=863;CYP2C9_results.csv:row=863;hERG_results.csv:row=863;AMES_results.csv:row=863;PGP_results.csv:row=863;PAMPA_results.csv:row=863;BBB_results.csv:row=863;Solubility_results.csv:row=863;Lipophilicity_results.csv:row=864
CHEMBL1201065,THIAMYLAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+],23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS -2.68; logP -0.70,repurposing_candidates.csv:rc_row=227;CYP3A4_results.csv:row=225;CYP2C19_results.csv:row=225;CYP2D6_results.csv:row=225;CYP1A2_results.csv:row=225;CYP2C9_results.csv:row=225;hERG_results.csv:row=225;AMES_results.csv:row=225;PGP_results.csv:row=225;PAMPA_results.csv:row=225;BBB_results.csv:row=225;Solubility_results.csv:row=225;Lipophilicity_results.csv:row=226
CHEMBL30219,METHOHEXITAL SODIUM,C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+],23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS -0.77; logP -2.68,repurposing_candidates.csv:rc_row=890;CYP3A4_results.csv:row=798;CYP2C19_results.csv:row=798;CYP2D6_results.csv:row=798;CYP1A2_results.csv:row=798;CYP2C9_results.csv:row=798;hERG_results.csv:row=798;AMES_results.csv:row=798;PGP_results.csv:row=798;PAMPA_results.csv:row=798;BBB_results.csv:row=798;Solubility_results.csv:row=798;Lipophilicity_results.csv:row=799
CHEMBL971,PENTOBARBITAL SODIUM,CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+],23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS -0.78; logP -2.80,repurposing_candidates.csv:rc_row=1574;CYP3A4_results.csv:row=1380;CYP2C19_results.csv:row=1380;CYP2D6_results.csv:row=1380;CYP1A2_results.csv:row=1380;CYP2C9_results.csv:row=1380;hERG_results.csv:row=1380;AMES_results.csv:row=1380;PGP_results.csv:row=1380;PAMPA_results.csv:row=1380;BBB_results.csv:row=1380;Solubility_results.csv:row=1380;Lipophilicity_results.csv:row=1381
CHEMBL6067972,VARENICLINE TARTRATE,O=C(O)[C@H](O)[C@@H](O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS 0.57; logP -0.32,repurposing_candidates.csv:rc_row=1445;CYP3A4_results.csv:row=1253;CYP2C19_results.csv:row=1253;CYP2D6_results.csv:row=1253;CYP1A2_results.csv:row=1253;CYP2C9_results.csv:row=1253;hERG_results.csv:row=1253;AMES_results.csv:row=1253;PGP_results.csv:row=1253;PAMPA_results.csv:row=1253;BBB_results.csv:row=1253;Solubility_results.csv:row=1253;Lipophilicity_results.csv:row=1254
CHEMBL1200982,BUTABARBITAL SODIUM,CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+],23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS -1.29; logP -1.42,repurposing_candidates.csv:rc_row=208;CYP3A4_results.csv:row=206;CYP2C19_results.csv:row=206;CYP2D6_results.csv:row=206;CYP1A2_results.csv:row=206;CYP2C9_results.csv:row=206;hERG_results.csv:row=206;AMES_results.csv:row=206;PGP_results.csv:row=206;PAMPA_results.csv:row=206;BBB_results.csv:row=206;Solubility_results.csv:row=206;Lipophilicity_results.csv:row=207
CHEMBL1200903,SECOBARBITAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+],23.333333333333332,10,95.0,36.583333333333336,L,KG-supported from 1 sources; logS -1.51; logP -0.86,repurposing_candidates.csv:rc_row=190;CYP3A4_results.csv:row=188;CYP2C19_results.csv:row=188;CYP2D6_results.csv:row=188;CYP1A2_results.csv:row=188;CYP2C9_results.csv:row=188;hERG_results.csv:row=188;AMES_results.csv:row=188;PGP_results.csv:row=188;PAMPA_results.csv:row=188;BBB_results.csv:row=188;Solubility_results.csv:row=188;Lipophilicity_results.csv:row=189
CHEMBL4297601,ROCACETRAPIB,COc1cc(F)c(C(C)C)cc1C1=C(CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)CC(C)(C)CC1,14.63768115942029,40,65.0,36.10507246376812,L,KG targets CETP; clinical phase 1.0; logS -9.17; logP 9.54,repurposing_candidates.csv:rc_row=1195;protein_drug_candidates.csv:rows=1901;CYP3A4_results.csv:row=1055;CYP2C19_results.csv:row=1055;CYP2D6_results.csv:row=1055;CYP1A2_results.csv:row=1055;CYP2C9_results.csv:row=1055;hERG_results.csv:row=1055;AMES_results.csv:row=1055;PGP_results.csv:row=1055;PAMPA_results.csv:row=1055;BBB_results.csv:row=1055;Solubility_results.csv:row=1055;Lipophilicity_results.csv:row=1056
CHEMBL261772,MECLOCYCLINE SULFOSALICYLATE,C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.55; logP 0.55,repurposing_candidates.csv:rc_row=864;CYP3A4_results.csv:row=772;CYP2C19_results.csv:row=772;CYP2D6_results.csv:row=772;CYP1A2_results.csv:row=772;CYP2C9_results.csv:row=772;hERG_results.csv:row=772;AMES_results.csv:row=772;PGP_results.csv:row=772;PAMPA_results.csv:row=772;BBB_results.csv:row=772;Solubility_results.csv:row=772;Lipophilicity_results.csv:row=773
CHEMBL1200474,DEMECLOCYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.77; logP 0.69,repurposing_candidates.csv:rc_row=109;CYP3A4_results.csv:row=108;CYP2C19_results.csv:row=108;CYP2D6_results.csv:row=108;CYP1A2_results.csv:row=108;CYP2C9_results.csv:row=108;hERG_results.csv:row=108;AMES_results.csv:row=108;PGP_results.csv:row=108;PAMPA_results.csv:row=108;BBB_results.csv:row=108;Solubility_results.csv:row=108;Lipophilicity_results.csv:row=108
CHEMBL685,MEBENDAZOLE,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.21; logP 2.97,repurposing_candidates.csv:rc_row=1486;CYP3A4_results.csv:row=1292;CYP2C19_results.csv:row=1292;CYP2D6_results.csv:row=1292;CYP1A2_results.csv:row=1292;CYP2C9_results.csv:row=1292;hERG_results.csv:row=1292;AMES_results.csv:row=1292;PGP_results.csv:row=1292;PAMPA_results.csv:row=1292;BBB_results.csv:row=1292;Solubility_results.csv:row=1292;Lipophilicity_results.csv:row=1293
CHEMBL522302,VOFOPITANT,COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.00; logP 3.27,repurposing_candidates.csv:rc_row=1368;CYP3A4_results.csv:row=1179;CYP2C19_results.csv:row=1179;CYP2D6_results.csv:row=1179;CYP1A2_results.csv:row=1179;CYP2C9_results.csv:row=1179;hERG_results.csv:row=1179;AMES_results.csv:row=1179;PGP_results.csv:row=1179;PAMPA_results.csv:row=1179;BBB_results.csv:row=1179;Solubility_results.csv:row=1179;Lipophilicity_results.csv:row=1180
CHEMBL1200688,ERYTHROMYCIN ETHYLSUCCINATE,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.90; logP 2.68,repurposing_candidates.csv:rc_row=150;CYP3A4_results.csv:row=149;CYP2C19_results.csv:row=149;CYP2D6_results.csv:row=149;CYP1A2_results.csv:row=149;CYP2C9_results.csv:row=149;hERG_results.csv:row=149;AMES_results.csv:row=149;PGP_results.csv:row=149;PAMPA_results.csv:row=149;BBB_results.csv:row=149;Solubility_results.csv:row=149;Lipophilicity_results.csv:row=149
CHEMBL2219414,ERAVACYCLINE DIHYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12.Cl.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.29; logP 1.14,repurposing_candidates.csv:rc_row=810;CYP3A4_results.csv:row=719;CYP2C19_results.csv:row=719;CYP2D6_results.csv:row=719;CYP1A2_results.csv:row=719;CYP2C9_results.csv:row=719;hERG_results.csv:row=719;AMES_results.csv:row=719;PGP_results.csv:row=719;PAMPA_results.csv:row=719;BBB_results.csv:row=719;Solubility_results.csv:row=719;Lipophilicity_results.csv:row=720
CHEMBL6067484,GENTAMICIN SULFATE,,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources,repurposing_candidates.csv:rc_row=1444;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1090090,VX-702,NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.39; logP 3.62,repurposing_candidates.csv:rc_row=38;CYP3A4_results.csv:row=38;CYP2C19_results.csv:row=38;CYP2D6_results.csv:row=38;CYP1A2_results.csv:row=38;CYP2C9_results.csv:row=38;hERG_results.csv:row=38;AMES_results.csv:row=38;PGP_results.csv:row=38;PAMPA_results.csv:row=38;BBB_results.csv:row=38;Solubility_results.csv:row=38;Lipophilicity_results.csv:row=38
CHEMBL1209734,BMS-986094,COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)Oc2cccc3ccccc23)[C@@H](O)[C@@]1(C)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.71; logP 3.35,repurposing_candidates.csv:rc_row=330;CYP3A4_results.csv:row=293;CYP2C19_results.csv:row=293;CYP2D6_results.csv:row=293;CYP1A2_results.csv:row=293;CYP2C9_results.csv:row=293;hERG_results.csv:row=293;AMES_results.csv:row=293;PGP_results.csv:row=293;PAMPA_results.csv:row=293;BBB_results.csv:row=293;Solubility_results.csv:row=293;Lipophilicity_results.csv:row=294
CHEMBL514201,TALMAPIMOD,C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.16; logP 3.98,repurposing_candidates.csv:rc_row=1360;CYP3A4_results.csv:row=1171;CYP2C19_results.csv:row=1171;CYP2D6_results.csv:row=1171;CYP1A2_results.csv:row=1171;CYP2C9_results.csv:row=1171;hERG_results.csv:row=1171;AMES_results.csv:row=1171;PGP_results.csv:row=1171;PAMPA_results.csv:row=1171;BBB_results.csv:row=1171;Solubility_results.csv:row=1171;Lipophilicity_results.csv:row=1172
CHEMBL513,CARMUSTINE,O=NN(CCCl)C(=O)NCCCl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.90; logP 1.16,repurposing_candidates.csv:rc_row=1359;CYP3A4_results.csv:row=1170;CYP2C19_results.csv:row=1170;CYP2D6_results.csv:row=1170;CYP1A2_results.csv:row=1170;CYP2C9_results.csv:row=1170;hERG_results.csv:row=1170;AMES_results.csv:row=1170;PGP_results.csv:row=1170;PAMPA_results.csv:row=1170;BBB_results.csv:row=1170;Solubility_results.csv:row=1170;Lipophilicity_results.csv:row=1171
CHEMBL6067973,TULATHROMYCIN,,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources,repurposing_candidates.csv:rc_row=1446;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL6068334,SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE,Cl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.01; logP 1.61,repurposing_candidates.csv:rc_row=1448;CYP3A4_results.csv:row=1255;CYP2C19_results.csv:row=1255;CYP2D6_results.csv:row=1255;CYP1A2_results.csv:row=1255;CYP2C9_results.csv:row=1255;hERG_results.csv:row=1255;AMES_results.csv:row=1255;PGP_results.csv:row=1255;PAMPA_results.csv:row=1255;BBB_results.csv:row=1255;Solubility_results.csv:row=1255;Lipophilicity_results.csv:row=1256
CHEMBL1214827,ONALESPIB,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.34; logP 3.12,repurposing_candidates.csv:rc_row=332;CYP3A4_results.csv:row=295;CYP2C19_results.csv:row=295;CYP2D6_results.csv:row=295;CYP1A2_results.csv:row=295;CYP2C9_results.csv:row=295;hERG_results.csv:row=295;AMES_results.csv:row=295;PGP_results.csv:row=295;PAMPA_results.csv:row=295;BBB_results.csv:row=295;Solubility_results.csv:row=295;Lipophilicity_results.csv:row=296
CHEMBL6068336,MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE,Cl.Cl.N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1.O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.23; logP 3.00,repurposing_candidates.csv:rc_row=1449;CYP3A4_results.csv:row=1256;CYP2C19_results.csv:row=1256;CYP2D6_results.csv:row=1256;CYP1A2_results.csv:row=1256;CYP2C9_results.csv:row=1256;hERG_results.csv:row=1256;AMES_results.csv:row=1256;PGP_results.csv:row=1256;PAMPA_results.csv:row=1256;BBB_results.csv:row=1256;Solubility_results.csv:row=1256;Lipophilicity_results.csv:row=1257
CHEMBL1237072,DIRITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.86; logP 2.20,repurposing_candidates.csv:rc_row=348;CYP3A4_results.csv:row=310;CYP2C19_results.csv:row=310;CYP2D6_results.csv:row=310;CYP1A2_results.csv:row=310;CYP2C9_results.csv:row=310;hERG_results.csv:row=310;AMES_results.csv:row=310;PGP_results.csv:row=310;PAMPA_results.csv:row=310;BBB_results.csv:row=310;Solubility_results.csv:row=310;Lipophilicity_results.csv:row=311
CHEMBL1200732,AMCINONIDE,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.01; logP 3.52,repurposing_candidates.csv:rc_row=158;CYP3A4_results.csv:row=156;CYP2C19_results.csv:row=156;CYP2D6_results.csv:row=156;CYP1A2_results.csv:row=156;CYP2C9_results.csv:row=156;hERG_results.csv:row=156;AMES_results.csv:row=156;PGP_results.csv:row=156;PAMPA_results.csv:row=156;BBB_results.csv:row=156;Solubility_results.csv:row=156;Lipophilicity_results.csv:row=157
CHEMBL1200734,FOSAMPRENAVIR CALCIUM,CC(C)CN(C[C@@H](OP(=O)([O-])[O-])[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1.[Ca+2],18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.91; logP 0.88,repurposing_candidates.csv:rc_row=160;CYP3A4_results.csv:row=158;CYP2C19_results.csv:row=158;CYP2D6_results.csv:row=158;CYP1A2_results.csv:row=158;CYP2C9_results.csv:row=158;hERG_results.csv:row=158;AMES_results.csv:row=158;PGP_results.csv:row=158;PAMPA_results.csv:row=158;BBB_results.csv:row=158;Solubility_results.csv:row=158;Lipophilicity_results.csv:row=159
CHEMBL1200948,TRIMIPRAMINE MALEATE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21.O=C(O)/C=C\C(=O)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.96; logP 3.83,repurposing_candidates.csv:rc_row=198;CYP3A4_results.csv:row=196;CYP2C19_results.csv:row=196;CYP2D6_results.csv:row=196;CYP1A2_results.csv:row=196;CYP2C9_results.csv:row=196;hERG_results.csv:row=196;AMES_results.csv:row=196;PGP_results.csv:row=196;PAMPA_results.csv:row=196;BBB_results.csv:row=196;Solubility_results.csv:row=196;Lipophilicity_results.csv:row=197
CHEMBL5095023,LS-104,N#C/C(=C\C=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.41; logP 2.88,repurposing_candidates.csv:rc_row=1351;CYP3A4_results.csv:row=1162;CYP2C19_results.csv:row=1162;CYP2D6_results.csv:row=1162;CYP1A2_results.csv:row=1162;CYP2C9_results.csv:row=1162;hERG_results.csv:row=1162;AMES_results.csv:row=1162;PGP_results.csv:row=1162;PAMPA_results.csv:row=1162;BBB_results.csv:row=1162;Solubility_results.csv:row=1162;Lipophilicity_results.csv:row=1163
CHEMBL2106468,TRICETAMIDE,CCN(CC)C(=O)CNC(=O)c1cc(OC)c(OC)c(OC)c1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.73; logP 1.31,repurposing_candidates.csv:rc_row=718;CYP3A4_results.csv:row=663;CYP2C19_results.csv:row=663;CYP2D6_results.csv:row=663;CYP1A2_results.csv:row=663;CYP2C9_results.csv:row=663;hERG_results.csv:row=663;AMES_results.csv:row=663;PGP_results.csv:row=663;PAMPA_results.csv:row=663;BBB_results.csv:row=663;Solubility_results.csv:row=663;Lipophilicity_results.csv:row=664
CHEMBL304087,MERIMEPODIB,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.09; logP 4.01,repurposing_candidates.csv:rc_row=900;CYP3A4_results.csv:row=807;CYP2C19_results.csv:row=807;CYP2D6_results.csv:row=807;CYP1A2_results.csv:row=807;CYP2C9_results.csv:row=807;hERG_results.csv:row=807;AMES_results.csv:row=807;PGP_results.csv:row=807;PAMPA_results.csv:row=807;BBB_results.csv:row=807;Solubility_results.csv:row=807;Lipophilicity_results.csv:row=808
CHEMBL1200831,SPIRAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.03; logP 2.81,repurposing_candidates.csv:rc_row=180;CYP3A4_results.csv:row=178;CYP2C19_results.csv:row=178;CYP2D6_results.csv:row=178;CYP1A2_results.csv:row=178;CYP2C9_results.csv:row=178;hERG_results.csv:row=178;AMES_results.csv:row=178;PGP_results.csv:row=178;PAMPA_results.csv:row=178;BBB_results.csv:row=178;Solubility_results.csv:row=178;Lipophilicity_results.csv:row=179
CHEMBL625,THIABENDAZOLE,,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources,repurposing_candidates.csv:rc_row=1459;CYP3A4_results.csv;CYP2C19_results.csv;CYP2D6_results.csv;CYP1A2_results.csv;CYP2C9_results.csv;hERG_results.csv;AMES_results.csv;PGP_results.csv;PAMPA_results.csv;BBB_results.csv;Solubility_results.csv;Lipophilicity_results.csv
CHEMBL1200881,MINOCYCLINE HYDROCHLORIDE,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.98; logP 0.61,repurposing_candidates.csv:rc_row=187;CYP3A4_results.csv:row=185;CYP2C19_results.csv:row=185;CYP2D6_results.csv:row=185;CYP1A2_results.csv:row=185;CYP2C9_results.csv:row=185;hERG_results.csv:row=185;AMES_results.csv:row=185;PGP_results.csv:row=185;PAMPA_results.csv:row=185;BBB_results.csv:row=185;Solubility_results.csv:row=185;Lipophilicity_results.csv:row=186
CHEMBL1200909,PREDNISOLONE TEBUTATE,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.20; logP 3.54,repurposing_candidates.csv:rc_row=192;CYP3A4_results.csv:row=190;CYP2C19_results.csv:row=190;CYP2D6_results.csv:row=190;CYP1A2_results.csv:row=190;CYP2C9_results.csv:row=190;hERG_results.csv:row=190;AMES_results.csv:row=190;PGP_results.csv:row=190;PAMPA_results.csv:row=190;BBB_results.csv:row=190;Solubility_results.csv:row=190;Lipophilicity_results.csv:row=191
CHEMBL224436,JOSAMYCIN,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.61; logP 3.01,repurposing_candidates.csv:rc_row=818;CYP3A4_results.csv:row=727;CYP2C19_results.csv:row=727;CYP2D6_results.csv:row=727;CYP1A2_results.csv:row=727;CYP2C9_results.csv:row=727;hERG_results.csv:row=727;AMES_results.csv:row=727;PGP_results.csv:row=727;PAMPA_results.csv:row=727;BBB_results.csv:row=727;Solubility_results.csv:row=727;Lipophilicity_results.csv:row=728
CHEMBL2110814,DELUCEMINE,CNCCC(c1cccc(F)c1)c1cccc(F)c1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.84; logP 3.71,repurposing_candidates.csv:rc_row=782;CYP3A4_results.csv:row=691;CYP2C19_results.csv:row=691;CYP2D6_results.csv:row=691;CYP1A2_results.csv:row=691;CYP2C9_results.csv:row=691;hERG_results.csv:row=691;AMES_results.csv:row=691;PGP_results.csv:row=691;PAMPA_results.csv:row=691;BBB_results.csv:row=691;Solubility_results.csv:row=691;Lipophilicity_results.csv:row=692
CHEMBL341812,IBUFENAC,CC(C)Cc1ccc(CC(=O)O)cc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.43; logP 2.51,repurposing_candidates.csv:rc_row=953;CYP3A4_results.csv:row=857;CYP2C19_results.csv:row=857;CYP2D6_results.csv:row=857;CYP1A2_results.csv:row=857;CYP2C9_results.csv:row=857;hERG_results.csv:row=857;AMES_results.csv:row=857;PGP_results.csv:row=857;PAMPA_results.csv:row=857;BBB_results.csv:row=857;Solubility_results.csv:row=857;Lipophilicity_results.csv:row=858
CHEMBL2146063,CHLORTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.42; logP 0.86,repurposing_candidates.csv:rc_row=788;CYP3A4_results.csv:row=697;CYP2C19_results.csv:row=697;CYP2D6_results.csv:row=697;CYP1A2_results.csv:row=697;CYP2C9_results.csv:row=697;hERG_results.csv:row=697;AMES_results.csv:row=697;PGP_results.csv:row=697;PAMPA_results.csv:row=697;BBB_results.csv:row=697;Solubility_results.csv:row=697;Lipophilicity_results.csv:row=698
CHEMBL550936,BALAPIRAVIR,CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](n2ccc(N)nc2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.25; logP 1.70,repurposing_candidates.csv:rc_row=1407;CYP3A4_results.csv:row=1216;CYP2C19_results.csv:row=1216;CYP2D6_results.csv:row=1216;CYP1A2_results.csv:row=1216;CYP2C9_results.csv:row=1216;hERG_results.csv:row=1216;AMES_results.csv:row=1216;PGP_results.csv:row=1216;PAMPA_results.csv:row=1216;BBB_results.csv:row=1216;Solubility_results.csv:row=1216;Lipophilicity_results.csv:row=1217
CHEMBL53292,ISOXICAM,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.47; logP 1.48,repurposing_candidates.csv:rc_row=1396;CYP3A4_results.csv:row=1205;CYP2C19_results.csv:row=1205;CYP2D6_results.csv:row=1205;CYP1A2_results.csv:row=1205;CYP2C9_results.csv:row=1205;hERG_results.csv:row=1205;AMES_results.csv:row=1205;PGP_results.csv:row=1205;PAMPA_results.csv:row=1205;BBB_results.csv:row=1205;Solubility_results.csv:row=1205;Lipophilicity_results.csv:row=1206
CHEMBL2160007,PSI-352938,CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.30; logP 2.38,repurposing_candidates.csv:rc_row=794;CYP3A4_results.csv:row=703;CYP2C19_results.csv:row=703;CYP2D6_results.csv:row=703;CYP1A2_results.csv:row=703;CYP2C9_results.csv:row=703;hERG_results.csv:row=703;AMES_results.csv:row=703;PGP_results.csv:row=703;PAMPA_results.csv:row=703;BBB_results.csv:row=703;Solubility_results.csv:row=703;Lipophilicity_results.csv:row=704
CHEMBL532,ERYTHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.41; logP 1.79,repurposing_candidates.csv:rc_row=1395;CYP3A4_results.csv:row=1204;CYP2C19_results.csv:row=1204;CYP2D6_results.csv:row=1204;CYP1A2_results.csv:row=1204;CYP2C9_results.csv:row=1204;hERG_results.csv:row=1204;AMES_results.csv:row=1204;PGP_results.csv:row=1204;PAMPA_results.csv:row=1204;BBB_results.csv:row=1204;Solubility_results.csv:row=1204;Lipophilicity_results.csv:row=1205
CHEMBL3287379,CONTEZOLID,O=C1C=CN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)c(F)c2F)CC1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.98; logP 2.82,repurposing_candidates.csv:rc_row=934;CYP3A4_results.csv:row=841;CYP2C19_results.csv:row=841;CYP2D6_results.csv:row=841;CYP1A2_results.csv:row=841;CYP2C9_results.csv:row=841;hERG_results.csv:row=841;AMES_results.csv:row=841;PGP_results.csv:row=841;PAMPA_results.csv:row=841;BBB_results.csv:row=841;Solubility_results.csv:row=841;Lipophilicity_results.csv:row=842
CHEMBL257704,EPLIVANSERIN,CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.90; logP 3.53,repurposing_candidates.csv:rc_row=861;CYP3A4_results.csv:row=769;CYP2C19_results.csv:row=769;CYP2D6_results.csv:row=769;CYP1A2_results.csv:row=769;CYP2C9_results.csv:row=769;hERG_results.csv:row=769;AMES_results.csv:row=769;PGP_results.csv:row=769;PAMPA_results.csv:row=769;BBB_results.csv:row=769;Solubility_results.csv:row=769;Lipophilicity_results.csv:row=770
CHEMBL3039509,TILDIPIROSIN,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2CCCCC2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CN1CCCCC1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.17; logP 4.18,repurposing_candidates.csv:rc_row=895;CYP3A4_results.csv:row=803;CYP2C19_results.csv:row=803;CYP2D6_results.csv:row=803;CYP1A2_results.csv:row=803;CYP2C9_results.csv:row=803;hERG_results.csv:row=803;AMES_results.csv:row=803;PGP_results.csv:row=803;PAMPA_results.csv:row=803;BBB_results.csv:row=803;Solubility_results.csv:row=803;Lipophilicity_results.csv:row=804
CHEMBL1200376,BETAMETHASONE BENZOATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.19; logP 3.76,repurposing_candidates.csv:rc_row=91;CYP3A4_results.csv:row=90;CYP2C19_results.csv:row=90;CYP2D6_results.csv:row=90;CYP1A2_results.csv:row=90;CYP2C9_results.csv:row=90;hERG_results.csv:row=90;AMES_results.csv:row=90;PGP_results.csv:row=90;PAMPA_results.csv:row=90;BBB_results.csv:row=90;Solubility_results.csv:row=90;Lipophilicity_results.csv:row=90
CHEMBL1200543,ANILERIDINE PHOSPHATE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.O=P(O)(O)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.24; logP 2.48,repurposing_candidates.csv:rc_row=122;CYP3A4_results.csv:row=121;CYP2C19_results.csv:row=121;CYP2D6_results.csv:row=121;CYP1A2_results.csv:row=121;CYP2C9_results.csv:row=121;hERG_results.csv:row=121;AMES_results.csv:row=121;PGP_results.csv:row=121;PAMPA_results.csv:row=121;BBB_results.csv:row=121;Solubility_results.csv:row=121;Lipophilicity_results.csv:row=121
CHEMBL5315054,ERTUGLIFLOZIN PIDOLATE,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1.O=C1CC[C@@H](C(=O)O)N1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.49; logP 0.71,repurposing_candidates.csv:rc_row=1390;CYP3A4_results.csv:row=1200;CYP2C19_results.csv:row=1200;CYP2D6_results.csv:row=1200;CYP1A2_results.csv:row=1200;CYP2C9_results.csv:row=1200;hERG_results.csv:row=1200;AMES_results.csv:row=1200;PGP_results.csv:row=1200;PAMPA_results.csv:row=1200;BBB_results.csv:row=1200;Solubility_results.csv:row=1200;Lipophilicity_results.csv:row=1201
CHEMBL2107342,GAMITHROMYCIN,CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.55; logP 2.68,repurposing_candidates.csv:rc_row=726;CYP3A4_results.csv:row=671;CYP2C19_results.csv:row=671;CYP2D6_results.csv:row=671;CYP1A2_results.csv:row=671;CYP2C9_results.csv:row=671;hERG_results.csv:row=671;AMES_results.csv:row=671;PGP_results.csv:row=671;PAMPA_results.csv:row=671;BBB_results.csv:row=671;Solubility_results.csv:row=671;Lipophilicity_results.csv:row=672
CHEMBL1200562,HYDROCORTISONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.60; logP 3.52,repurposing_candidates.csv:rc_row=125;CYP3A4_results.csv:row=124;CYP2C19_results.csv:row=124;CYP2D6_results.csv:row=124;CYP1A2_results.csv:row=124;CYP2C9_results.csv:row=124;hERG_results.csv:row=124;AMES_results.csv:row=124;PGP_results.csv:row=124;PAMPA_results.csv:row=124;BBB_results.csv:row=124;Solubility_results.csv:row=124;Lipophilicity_results.csv:row=124
CHEMBL252164,LUMINESPIB,CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.51; logP 4.13,repurposing_candidates.csv:rc_row=856;CYP3A4_results.csv:row=764;CYP2C19_results.csv:row=764;CYP2D6_results.csv:row=764;CYP1A2_results.csv:row=764;CYP2C9_results.csv:row=764;hERG_results.csv:row=764;AMES_results.csv:row=764;PGP_results.csv:row=764;PAMPA_results.csv:row=764;BBB_results.csv:row=764;Solubility_results.csv:row=764;Lipophilicity_results.csv:row=765
CHEMBL3402567,ITX-5061,COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.20; logP 4.47,repurposing_candidates.csv:rc_row=952;CYP3A4_results.csv:row=856;CYP2C19_results.csv:row=856;CYP2D6_results.csv:row=856;CYP1A2_results.csv:row=856;CYP2C9_results.csv:row=856;hERG_results.csv:row=856;AMES_results.csv:row=856;PGP_results.csv:row=856;PAMPA_results.csv:row=856;BBB_results.csv:row=856;Solubility_results.csv:row=856;Lipophilicity_results.csv:row=857
CHEMBL1200563,CERIVASTATIN SODIUM,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1.[Na+],18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.66; logP 0.55,repurposing_candidates.csv:rc_row=126;CYP3A4_results.csv:row=125;CYP2C19_results.csv:row=125;CYP2D6_results.csv:row=125;CYP1A2_results.csv:row=125;CYP2C9_results.csv:row=125;hERG_results.csv:row=125;AMES_results.csv:row=125;PGP_results.csv:row=125;PAMPA_results.csv:row=125;BBB_results.csv:row=125;Solubility_results.csv:row=125;Lipophilicity_results.csv:row=125
CHEMBL562,GRISEOFULVIN,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.99; logP 2.81,repurposing_candidates.csv:rc_row=1412;CYP3A4_results.csv:row=1221;CYP2C19_results.csv:row=1221;CYP2D6_results.csv:row=1221;CYP1A2_results.csv:row=1221;CYP2C9_results.csv:row=1221;hERG_results.csv:row=1221;AMES_results.csv:row=1221;PGP_results.csv:row=1221;PAMPA_results.csv:row=1221;BBB_results.csv:row=1221;Solubility_results.csv:row=1221;Lipophilicity_results.csv:row=1222
CHEMBL1136,TELITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.87; logP 4.93,repurposing_candidates.csv:rc_row=60;CYP3A4_results.csv:row=59;CYP2C19_results.csv:row=59;CYP2D6_results.csv:row=59;CYP1A2_results.csv:row=59;CYP2C9_results.csv:row=59;hERG_results.csv:row=59;AMES_results.csv:row=59;PGP_results.csv:row=59;PAMPA_results.csv:row=59;BBB_results.csv:row=59;Solubility_results.csv:row=59;Lipophilicity_results.csv:row=59
CHEMBL562967,MERICITABINE,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.49; logP 1.22,repurposing_candidates.csv:rc_row=1413;CYP3A4_results.csv:row=1222;CYP2C19_results.csv:row=1222;CYP2D6_results.csv:row=1222;CYP1A2_results.csv:row=1222;CYP2C9_results.csv:row=1222;hERG_results.csv:row=1222;AMES_results.csv:row=1222;PGP_results.csv:row=1222;PAMPA_results.csv:row=1222;BBB_results.csv:row=1222;Solubility_results.csv:row=1222;Lipophilicity_results.csv:row=1223
CHEMBL5314397,ACUMAPIMOD,Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.47; logP 2.76,repurposing_candidates.csv:rc_row=1383;CYP3A4_results.csv:row=1194;CYP2C19_results.csv:row=1194;CYP2D6_results.csv:row=1194;CYP1A2_results.csv:row=1194;CYP2C9_results.csv:row=1194;hERG_results.csv:row=1194;AMES_results.csv:row=1194;PGP_results.csv:row=1194;PAMPA_results.csv:row=1194;BBB_results.csv:row=1194;Solubility_results.csv:row=1194;Lipophilicity_results.csv:row=1195
CHEMBL2107830,EMPAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.51; logP 1.61,repurposing_candidates.csv:rc_row=739;CYP3A4_results.csv:row=684;CYP2C19_results.csv:row=684;CYP2D6_results.csv:row=684;CYP1A2_results.csv:row=684;CYP2C9_results.csv:row=684;hERG_results.csv:row=684;AMES_results.csv:row=684;PGP_results.csv:row=684;PAMPA_results.csv:row=684;BBB_results.csv:row=684;Solubility_results.csv:row=684;Lipophilicity_results.csv:row=685
CHEMBL1201064,FLUOROMETHOLONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.35; logP 3.49,repurposing_candidates.csv:rc_row=226;CYP3A4_results.csv:row=224;CYP2C19_results.csv:row=224;CYP2D6_results.csv:row=224;CYP1A2_results.csv:row=224;CYP2C9_results.csv:row=224;hERG_results.csv:row=224;AMES_results.csv:row=224;PGP_results.csv:row=224;PAMPA_results.csv:row=224;BBB_results.csv:row=224;Solubility_results.csv:row=224;Lipophilicity_results.csv:row=225
CHEMBL1201051,CIMETIDINE HYDROCHLORIDE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.95; logP 1.02,repurposing_candidates.csv:rc_row=223;CYP3A4_results.csv:row=221;CYP2C19_results.csv:row=221;CYP2D6_results.csv:row=221;CYP1A2_results.csv:row=221;CYP2C9_results.csv:row=221;hERG_results.csv:row=221;AMES_results.csv:row=221;PGP_results.csv:row=221;PAMPA_results.csv:row=221;BBB_results.csv:row=221;Solubility_results.csv:row=221;Lipophilicity_results.csv:row=222
CHEMBL1201047,ANILERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.71; logP 3.83,repurposing_candidates.csv:rc_row=222;CYP3A4_results.csv:row=220;CYP2C19_results.csv:row=220;CYP2D6_results.csv:row=220;CYP1A2_results.csv:row=220;CYP2C9_results.csv:row=220;hERG_results.csv:row=220;AMES_results.csv:row=220;PGP_results.csv:row=220;PAMPA_results.csv:row=220;BBB_results.csv:row=220;Solubility_results.csv:row=220;Lipophilicity_results.csv:row=221
CHEMBL2107186,RESOCORTOL BUTYRATE,CCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.35; logP 4.55,repurposing_candidates.csv:rc_row=723;CYP3A4_results.csv:row=668;CYP2C19_results.csv:row=668;CYP2D6_results.csv:row=668;CYP1A2_results.csv:row=668;CYP2C9_results.csv:row=668;hERG_results.csv:row=668;AMES_results.csv:row=668;PGP_results.csv:row=668;PAMPA_results.csv:row=668;BBB_results.csv:row=668;Solubility_results.csv:row=668;Lipophilicity_results.csv:row=669
CHEMBL3183740,TRELANSERIN,NC(=O)Cn1c(=O)cc(CCN2CCN(c3nccc4sccc34)CC2)c2ccc(F)cc21,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.45; logP 2.60,repurposing_candidates.csv:rc_row=919;CYP3A4_results.csv:row=826;CYP2C19_results.csv:row=826;CYP2D6_results.csv:row=826;CYP1A2_results.csv:row=826;CYP2C9_results.csv:row=826;hERG_results.csv:row=826;AMES_results.csv:row=826;PGP_results.csv:row=826;PAMPA_results.csv:row=826;BBB_results.csv:row=826;Solubility_results.csv:row=826;Lipophilicity_results.csv:row=827
CHEMBL1773,CAPECITABINE,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.01; logP 0.76,repurposing_candidates.csv:rc_row=568;CYP3A4_results.csv:row=514;CYP2C19_results.csv:row=514;CYP2D6_results.csv:row=514;CYP1A2_results.csv:row=514;CYP2C9_results.csv:row=514;hERG_results.csv:row=514;AMES_results.csv:row=514;PGP_results.csv:row=514;PAMPA_results.csv:row=514;BBB_results.csv:row=514;Solubility_results.csv:row=514;Lipophilicity_results.csv:row=515
CHEMBL2263632,ASLAN-003,COc1cccc(-c2cc(F)c(Nc3ncccc3C(=O)O)c(F)c2)c1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.31; logP 4.48,repurposing_candidates.csv:rc_row=820;CYP3A4_results.csv:row=729;CYP2C19_results.csv:row=729;CYP2D6_results.csv:row=729;CYP1A2_results.csv:row=729;CYP2C9_results.csv:row=729;hERG_results.csv:row=729;AMES_results.csv:row=729;PGP_results.csv:row=729;PAMPA_results.csv:row=729;BBB_results.csv:row=729;Solubility_results.csv:row=729;Lipophilicity_results.csv:row=730
CHEMBL2106309,HYDROCORTISONE ACEPONATE,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.20; logP 3.31,repurposing_candidates.csv:rc_row=717;CYP3A4_results.csv:row=662;CYP2C19_results.csv:row=662;CYP2D6_results.csv:row=662;CYP1A2_results.csv:row=662;CYP2C9_results.csv:row=662;hERG_results.csv:row=662;AMES_results.csv:row=662;PGP_results.csv:row=662;PAMPA_results.csv:row=662;BBB_results.csv:row=662;Solubility_results.csv:row=662;Lipophilicity_results.csv:row=663
CHEMBL4297452,YM-543,C[N+](C)(C)CCO.[O-]c1ccc(Cc2cc3cccccc-3c2)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.83; logP 0.66,repurposing_candidates.csv:rc_row=1178;CYP3A4_results.csv:row=1041;CYP2C19_results.csv:row=1041;CYP2D6_results.csv:row=1041;CYP1A2_results.csv:row=1041;CYP2C9_results.csv:row=1041;hERG_results.csv:row=1041;AMES_results.csv:row=1041;PGP_results.csv:row=1041;PAMPA_results.csv:row=1041;BBB_results.csv:row=1041;Solubility_results.csv:row=1041;Lipophilicity_results.csv:row=1042
CHEMBL4297519,NAFITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2[C@H](/C(N)=N/O[C@@H](C)c3nnc(-c4ccccn4)s3)C(=O)O[C@@]21C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.33; logP 4.12,repurposing_candidates.csv:rc_row=1185;CYP3A4_results.csv:row=1048;CYP2C19_results.csv:row=1048;CYP2D6_results.csv:row=1048;CYP1A2_results.csv:row=1048;CYP2C9_results.csv:row=1048;hERG_results.csv:row=1048;AMES_results.csv:row=1048;PGP_results.csv:row=1048;PAMPA_results.csv:row=1048;BBB_results.csv:row=1048;Solubility_results.csv:row=1048;Lipophilicity_results.csv:row=1049
CHEMBL1735,INDINAVIR SULFATE,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.16; logP 2.21,repurposing_candidates.csv:rc_row=533;CYP3A4_results.csv:row=493;CYP2C19_results.csv:row=493;CYP2D6_results.csv:row=493;CYP1A2_results.csv:row=493;CYP2C9_results.csv:row=493;hERG_results.csv:row=493;AMES_results.csv:row=493;PGP_results.csv:row=493;PAMPA_results.csv:row=493;BBB_results.csv:row=493;Solubility_results.csv:row=493;Lipophilicity_results.csv:row=494
CHEMBL1951095,ERAVACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.32; logP 0.29,repurposing_candidates.csv:rc_row=609;CYP3A4_results.csv:row=555;CYP2C19_results.csv:row=555;CYP2D6_results.csv:row=555;CYP1A2_results.csv:row=555;CYP2C9_results.csv:row=555;hERG_results.csv:row=555;AMES_results.csv:row=555;PGP_results.csv:row=555;PAMPA_results.csv:row=555;BBB_results.csv:row=555;Solubility_results.csv:row=555;Lipophilicity_results.csv:row=556
CHEMBL3707376,CADAZOLID,O=C(O)c1cn(C2CC2)c2cc(N3CCC(O)(COc4ccc(N5C[C@H](CO)OC5=O)cc4F)CC3)c(F)cc2c1=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.76; logP 3.04,repurposing_candidates.csv:rc_row=1029;CYP3A4_results.csv:row=906;CYP2C19_results.csv:row=906;CYP2D6_results.csv:row=906;CYP1A2_results.csv:row=906;CYP2C9_results.csv:row=906;hERG_results.csv:row=906;AMES_results.csv:row=906;PGP_results.csv:row=906;PAMPA_results.csv:row=906;BBB_results.csv:row=906;Solubility_results.csv:row=906;Lipophilicity_results.csv:row=907
CHEMBL2103838,DILMAPIMOD,Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.49; logP 2.94,repurposing_candidates.csv:rc_row=669;CYP3A4_results.csv:row=614;CYP2C19_results.csv:row=614;CYP2D6_results.csv:row=614;CYP1A2_results.csv:row=614;CYP2C9_results.csv:row=614;hERG_results.csv:row=614;AMES_results.csv:row=614;PGP_results.csv:row=614;PAMPA_results.csv:row=614;BBB_results.csv:row=614;Solubility_results.csv:row=614;Lipophilicity_results.csv:row=615
CHEMBL376140,TIGECYCLINE,CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.57; logP 0.51,repurposing_candidates.csv:rc_row=1032;CYP3A4_results.csv:row=907;CYP2C19_results.csv:row=907;CYP2D6_results.csv:row=907;CYP1A2_results.csv:row=907;CYP2C9_results.csv:row=907;hERG_results.csv:row=907;AMES_results.csv:row=907;PGP_results.csv:row=907;PAMPA_results.csv:row=907;BBB_results.csv:row=907;Solubility_results.csv:row=907;Lipophilicity_results.csv:row=908
CHEMBL4594382,DEURUXOLITINIB PHOSPHATE,O=P(O)(O)O.[2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H],18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.16; logP 2.54,repurposing_candidates.csv:rc_row=1293;CYP3A4_results.csv:row=1112;CYP2C19_results.csv:row=1112;CYP2D6_results.csv:row=1112;CYP1A2_results.csv:row=1112;CYP2C9_results.csv:row=1112;hERG_results.csv:row=1112;AMES_results.csv:row=1112;PGP_results.csv:row=1112;PAMPA_results.csv:row=1112;BBB_results.csv:row=1112;Solubility_results.csv:row=1112;Lipophilicity_results.csv:row=1113
CHEMBL2103879,GANETESPIB,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.97; logP 3.25,repurposing_candidates.csv:rc_row=677;CYP3A4_results.csv:row=622;CYP2C19_results.csv:row=622;CYP2D6_results.csv:row=622;CYP1A2_results.csv:row=622;CYP2C9_results.csv:row=622;hERG_results.csv:row=622;AMES_results.csv:row=622;PGP_results.csv:row=622;PAMPA_results.csv:row=622;BBB_results.csv:row=622;Solubility_results.csv:row=622;Lipophilicity_results.csv:row=623
CHEMBL4297658,IPRAGLIFLOZIN L-PROLINE,O=C(O)[C@@H]1CCCN1.OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.52; logP 1.97,repurposing_candidates.csv:rc_row=1204;CYP3A4_results.csv:row=1064;CYP2C19_results.csv:row=1064;CYP2D6_results.csv:row=1064;CYP1A2_results.csv:row=1064;CYP2C9_results.csv:row=1064;hERG_results.csv:row=1064;AMES_results.csv:row=1064;PGP_results.csv:row=1064;PAMPA_results.csv:row=1064;BBB_results.csv:row=1064;Solubility_results.csv:row=1064;Lipophilicity_results.csv:row=1065
CHEMBL3989919,FOSNETUPITANT CHLORIDE HYDROCHLORIDE,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-],18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.91; logP 3.79,repurposing_candidates.csv:rc_row=1100;CYP3A4_results.csv:row=969;CYP2C19_results.csv:row=969;CYP2D6_results.csv:row=969;CYP1A2_results.csv:row=969;CYP2C9_results.csv:row=969;hERG_results.csv:row=969;AMES_results.csv:row=969;PGP_results.csv:row=969;PAMPA_results.csv:row=969;BBB_results.csv:row=969;Solubility_results.csv:row=969;Lipophilicity_results.csv:row=970
CHEMBL1689,TOLAZOLINE HYDROCHLORIDE,Cl.c1ccc(CC2=NCCN2)cc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.45; logP 1.65,repurposing_candidates.csv:rc_row=511;CYP3A4_results.csv:row=471;CYP2C19_results.csv:row=471;CYP2D6_results.csv:row=471;CYP1A2_results.csv:row=471;CYP2C9_results.csv:row=471;hERG_results.csv:row=471;AMES_results.csv:row=471;PGP_results.csv:row=471;PAMPA_results.csv:row=471;BBB_results.csv:row=471;Solubility_results.csv:row=471;Lipophilicity_results.csv:row=472
CHEMBL1673408,DELPAZOLID,CN1CCN(c2ccc(N3C[C@H](CO)OC3=O)cc2F)C=N1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.56; logP 0.84,repurposing_candidates.csv:rc_row=504;CYP3A4_results.csv:row=464;CYP2C19_results.csv:row=464;CYP2D6_results.csv:row=464;CYP1A2_results.csv:row=464;CYP2C9_results.csv:row=464;hERG_results.csv:row=464;AMES_results.csv:row=464;PGP_results.csv:row=464;PAMPA_results.csv:row=464;BBB_results.csv:row=464;Solubility_results.csv:row=464;Lipophilicity_results.csv:row=465
CHEMBL2028665,REMOGLIFLOZIN ETABONATE,CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.16; logP 2.51,repurposing_candidates.csv:rc_row=626;CYP3A4_results.csv:row=572;CYP2C19_results.csv:row=572;CYP2D6_results.csv:row=572;CYP1A2_results.csv:row=572;CYP2C9_results.csv:row=572;hERG_results.csv:row=572;AMES_results.csv:row=572;PGP_results.csv:row=572;PAMPA_results.csv:row=572;BBB_results.csv:row=572;Solubility_results.csv:row=572;Lipophilicity_results.csv:row=573
CHEMBL455461,RADEZOLID,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(CNCc4cnn[nH]4)cc3)c(F)c2)C(=O)O1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.34; logP 2.36,repurposing_candidates.csv:rc_row=1280;CYP3A4_results.csv:row=1100;CYP2C19_results.csv:row=1100;CYP2D6_results.csv:row=1100;CYP1A2_results.csv:row=1100;CYP2C9_results.csv:row=1100;hERG_results.csv:row=1100;AMES_results.csv:row=1100;PGP_results.csv:row=1100;PAMPA_results.csv:row=1100;BBB_results.csv:row=1100;Solubility_results.csv:row=1100;Lipophilicity_results.csv:row=1101
CHEMBL454950,TETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.14; logP 0.21,repurposing_candidates.csv:rc_row=1279;CYP3A4_results.csv:row=1099;CYP2C19_results.csv:row=1099;CYP2D6_results.csv:row=1099;CYP1A2_results.csv:row=1099;CYP2C9_results.csv:row=1099;hERG_results.csv:row=1099;AMES_results.csv:row=1099;PGP_results.csv:row=1099;PAMPA_results.csv:row=1099;BBB_results.csv:row=1099;Solubility_results.csv:row=1099;Lipophilicity_results.csv:row=1100
CHEMBL3833371,UPRIFOSBUVIR,CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.71; logP 1.93,repurposing_candidates.csv:rc_row=1046;CYP3A4_results.csv:row=916;CYP2C19_results.csv:row=916;CYP2D6_results.csv:row=916;CYP1A2_results.csv:row=916;CYP2C9_results.csv:row=916;hERG_results.csv:row=916;AMES_results.csv:row=916;PGP_results.csv:row=916;PAMPA_results.csv:row=916;BBB_results.csv:row=916;Solubility_results.csv:row=916;Lipophilicity_results.csv:row=917
CHEMBL2029422,PF-4136309,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.97; logP 3.31,repurposing_candidates.csv:rc_row=627;CYP3A4_results.csv:row=573;CYP2C19_results.csv:row=573;CYP2D6_results.csv:row=573;CYP1A2_results.csv:row=573;CYP2C9_results.csv:row=573;hERG_results.csv:row=573;AMES_results.csv:row=573;PGP_results.csv:row=573;PAMPA_results.csv:row=573;BBB_results.csv:row=573;Solubility_results.csv:row=573;Lipophilicity_results.csv:row=574
CHEMBL2031465,AZD-6703,Cc1ccc(C(=O)NC2CC2)cc1-n1cnc2ccc(N3CCN(C)CC3)cc2c1=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.85; logP 2.34,repurposing_candidates.csv:rc_row=628;CYP3A4_results.csv:row=574;CYP2C19_results.csv:row=574;CYP2D6_results.csv:row=574;CYP1A2_results.csv:row=574;CYP2C9_results.csv:row=574;hERG_results.csv:row=574;AMES_results.csv:row=574;PGP_results.csv:row=574;PAMPA_results.csv:row=574;BBB_results.csv:row=574;Solubility_results.csv:row=574;Lipophilicity_results.csv:row=575
CHEMBL453514,SPIRAMYCIN,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.44; logP 2.33,repurposing_candidates.csv:rc_row=1276;CYP3A4_results.csv:row=1096;CYP2C19_results.csv:row=1096;CYP2D6_results.csv:row=1096;CYP1A2_results.csv:row=1096;CYP2C9_results.csv:row=1096;hERG_results.csv:row=1096;AMES_results.csv:row=1096;PGP_results.csv:row=1096;PAMPA_results.csv:row=1096;BBB_results.csv:row=1096;Solubility_results.csv:row=1096;Lipophilicity_results.csv:row=1097
CHEMBL203567,RO-3201195,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.57; logP 1.56,repurposing_candidates.csv:rc_row=631;CYP3A4_results.csv:row=577;CYP2C19_results.csv:row=577;CYP2D6_results.csv:row=577;CYP1A2_results.csv:row=577;CYP2C9_results.csv:row=577;hERG_results.csv:row=577;AMES_results.csv:row=577;PGP_results.csv:row=577;PAMPA_results.csv:row=577;BBB_results.csv:row=577;Solubility_results.csv:row=577;Lipophilicity_results.csv:row=578
CHEMBL3989686,IFERANSERIN,CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.39; logP 4.76,repurposing_candidates.csv:rc_row=1079;CYP3A4_results.csv:row=948;CYP2C19_results.csv:row=948;CYP2D6_results.csv:row=948;CYP1A2_results.csv:row=948;CYP2C9_results.csv:row=948;hERG_results.csv:row=948;AMES_results.csv:row=948;PGP_results.csv:row=948;PAMPA_results.csv:row=948;BBB_results.csv:row=948;Solubility_results.csv:row=948;Lipophilicity_results.csv:row=949
CHEMBL206031,BRECANAVIR,Cc1nc(COc2ccc(C[C@H](NC(=O)O[C@H]3CO[C@H]4OCC[C@H]43)[C@H](O)CN(CC(C)C)S(=O)(=O)c3ccc4c(c3)OCO4)cc2)cs1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -6.00; logP 3.87,repurposing_candidates.csv:rc_row=634;CYP3A4_results.csv:row=580;CYP2C19_results.csv:row=580;CYP2D6_results.csv:row=580;CYP1A2_results.csv:row=580;CYP2C9_results.csv:row=580;hERG_results.csv:row=580;AMES_results.csv:row=580;PGP_results.csv:row=580;PAMPA_results.csv:row=580;BBB_results.csv:row=580;Solubility_results.csv:row=580;Lipophilicity_results.csv:row=581
CHEMBL1483,ALBENDAZOLE,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.53; logP 3.24,repurposing_candidates.csv:rc_row=429;CYP3A4_results.csv:row=389;CYP2C19_results.csv:row=389;CYP2D6_results.csv:row=389;CYP1A2_results.csv:row=389;CYP2C9_results.csv:row=389;hERG_results.csv:row=389;AMES_results.csv:row=389;PGP_results.csv:row=389;PAMPA_results.csv:row=389;BBB_results.csv:row=389;Solubility_results.csv:row=389;Lipophilicity_results.csv:row=390
CHEMBL450044,SERGLIFLOZIN ETABONATE,CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(OC)cc2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.30; logP 1.65,repurposing_candidates.csv:rc_row=1271;CYP3A4_results.csv:row=1091;CYP2C19_results.csv:row=1091;CYP2D6_results.csv:row=1091;CYP1A2_results.csv:row=1091;CYP2C9_results.csv:row=1091;hERG_results.csv:row=1091;AMES_results.csv:row=1091;PGP_results.csv:row=1091;PAMPA_results.csv:row=1091;BBB_results.csv:row=1091;Solubility_results.csv:row=1091;Lipophilicity_results.csv:row=1092
CHEMBL2103854,OMADACYCLINE TOSYLATE,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cc1ccc(S(=O)(=O)O)cc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.30; logP 2.56,repurposing_candidates.csv:rc_row=673;CYP3A4_results.csv:row=618;CYP2C19_results.csv:row=618;CYP2D6_results.csv:row=618;CYP1A2_results.csv:row=618;CYP2C9_results.csv:row=618;hERG_results.csv:row=618;AMES_results.csv:row=618;PGP_results.csv:row=618;PAMPA_results.csv:row=618;BBB_results.csv:row=618;Solubility_results.csv:row=618;Lipophilicity_results.csv:row=619
CHEMBL2103802,DAPAGLIFLOZIN PROPANEDIOL,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.77; logP 0.38,repurposing_candidates.csv:rc_row=662;CYP3A4_results.csv:row=607;CYP2C19_results.csv:row=607;CYP2D6_results.csv:row=607;CYP1A2_results.csv:row=607;CYP2C9_results.csv:row=607;hERG_results.csv:row=607;AMES_results.csv:row=607;PGP_results.csv:row=607;PAMPA_results.csv:row=607;BBB_results.csv:row=607;Solubility_results.csv:row=607;Lipophilicity_results.csv:row=608
CHEMBL383824,ALVESPIMYCIN,CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.95; logP 1.91,repurposing_candidates.csv:rc_row=1049;CYP3A4_results.csv:row=918;CYP2C19_results.csv:row=918;CYP2D6_results.csv:row=918;CYP1A2_results.csv:row=918;CYP2C9_results.csv:row=918;hERG_results.csv:row=918;AMES_results.csv:row=918;PGP_results.csv:row=918;PAMPA_results.csv:row=918;BBB_results.csv:row=918;Solubility_results.csv:row=918;Lipophilicity_results.csv:row=919
CHEMBL4297502,AVORALSTAT,C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.53; logP 3.77,repurposing_candidates.csv:rc_row=1182;CYP3A4_results.csv:row=1045;CYP2C19_results.csv:row=1045;CYP2D6_results.csv:row=1045;CYP1A2_results.csv:row=1045;CYP2C9_results.csv:row=1045;hERG_results.csv:row=1045;AMES_results.csv:row=1045;PGP_results.csv:row=1045;PAMPA_results.csv:row=1045;BBB_results.csv:row=1045;Solubility_results.csv:row=1045;Lipophilicity_results.csv:row=1046
CHEMBL4297625,LICOGLIFLOZIN,CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.76; logP 1.13,repurposing_candidates.csv:rc_row=1199;CYP3A4_results.csv:row=1059;CYP2C19_results.csv:row=1059;CYP2D6_results.csv:row=1059;CYP1A2_results.csv:row=1059;CYP2C9_results.csv:row=1059;hERG_results.csv:row=1059;AMES_results.csv:row=1059;PGP_results.csv:row=1059;PAMPA_results.csv:row=1059;BBB_results.csv:row=1059;Solubility_results.csv:row=1059;Lipophilicity_results.csv:row=1060
CHEMBL15677,FENCLOFENAC,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.59; logP 4.41,repurposing_candidates.csv:rc_row=462;CYP3A4_results.csv:row=422;CYP2C19_results.csv:row=422;CYP2D6_results.csv:row=422;CYP1A2_results.csv:row=422;CYP2C9_results.csv:row=422;hERG_results.csv:row=422;AMES_results.csv:row=422;PGP_results.csv:row=422;PAMPA_results.csv:row=422;BBB_results.csv:row=422;Solubility_results.csv:row=422;Lipophilicity_results.csv:row=423
CHEMBL1742471,EBROTIDINE,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.13; logP 2.05,repurposing_candidates.csv:rc_row=541;CYP3A4_results.csv:row=501;CYP2C19_results.csv:row=501;CYP2D6_results.csv:row=501;CYP1A2_results.csv:row=501;CYP2C9_results.csv:row=501;hERG_results.csv:row=501;AMES_results.csv:row=501;PGP_results.csv:row=501;PAMPA_results.csv:row=501;BBB_results.csv:row=501;Solubility_results.csv:row=501;Lipophilicity_results.csv:row=502
CHEMBL1257051,TEDIZOLID,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.06; logP 1.40,repurposing_candidates.csv:rc_row=360;CYP3A4_results.csv:row=322;CYP2C19_results.csv:row=322;CYP2D6_results.csv:row=322;CYP1A2_results.csv:row=322;CYP2C9_results.csv:row=322;hERG_results.csv:row=322;AMES_results.csv:row=322;PGP_results.csv:row=322;PAMPA_results.csv:row=322;BBB_results.csv:row=322;Solubility_results.csv:row=322;Lipophilicity_results.csv:row=323
CHEMBL41194,PRATOSARTAN,CCCc1nc2c(n1Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CCCC2,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.71; logP 4.64,repurposing_candidates.csv:rc_row=1135;CYP3A4_results.csv:row=999;CYP2C19_results.csv:row=999;CYP2D6_results.csv:row=999;CYP1A2_results.csv:row=999;CYP2C9_results.csv:row=999;hERG_results.csv:row=999;AMES_results.csv:row=999;PGP_results.csv:row=999;PAMPA_results.csv:row=999;BBB_results.csv:row=999;Solubility_results.csv:row=999;Lipophilicity_results.csv:row=1000
CHEMBL1259059,SOFOSBUVIR,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.63; logP 1.66,repurposing_candidates.csv:rc_row=361;CYP3A4_results.csv:row=323;CYP2C19_results.csv:row=323;CYP2D6_results.csv:row=323;CYP1A2_results.csv:row=323;CYP2C9_results.csv:row=323;hERG_results.csv:row=323;AMES_results.csv:row=323;PGP_results.csv:row=323;PAMPA_results.csv:row=323;BBB_results.csv:row=323;Solubility_results.csv:row=323;Lipophilicity_results.csv:row=324
CHEMBL126,LINEZOLID,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.27; logP 1.12,repurposing_candidates.csv:rc_row=362;CYP3A4_results.csv:row=324;CYP2C19_results.csv:row=324;CYP2D6_results.csv:row=324;CYP1A2_results.csv:row=324;CYP2C9_results.csv:row=324;hERG_results.csv:row=324;AMES_results.csv:row=324;PGP_results.csv:row=324;PAMPA_results.csv:row=324;BBB_results.csv:row=324;Solubility_results.csv:row=324;Lipophilicity_results.csv:row=325
CHEMBL2105669,TEDIZOLID PHOSPHATE,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.25; logP 1.51,repurposing_candidates.csv:rc_row=696;CYP3A4_results.csv:row=641;CYP2C19_results.csv:row=641;CYP2D6_results.csv:row=641;CYP1A2_results.csv:row=641;CYP2C9_results.csv:row=641;hERG_results.csv:row=641;AMES_results.csv:row=641;PGP_results.csv:row=641;PAMPA_results.csv:row=641;BBB_results.csv:row=641;Solubility_results.csv:row=641;Lipophilicity_results.csv:row=642
CHEMBL4297431,HENAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1F,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -5.20; logP 1.50,repurposing_candidates.csv:rc_row=1174;CYP3A4_results.csv:row=1037;CYP2C19_results.csv:row=1037;CYP2D6_results.csv:row=1037;CYP1A2_results.csv:row=1037;CYP2C9_results.csv:row=1037;hERG_results.csv:row=1037;AMES_results.csv:row=1037;PGP_results.csv:row=1037;PAMPA_results.csv:row=1037;BBB_results.csv:row=1037;Solubility_results.csv:row=1037;Lipophilicity_results.csv:row=1038
CHEMBL467399,BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.13; logP 2.13,repurposing_candidates.csv:rc_row=1322;CYP3A4_results.csv:row=1133;CYP2C19_results.csv:row=1133;CYP2D6_results.csv:row=1133;CYP1A2_results.csv:row=1133;CYP2C9_results.csv:row=1133;hERG_results.csv:row=1133;AMES_results.csv:row=1133;PGP_results.csv:row=1133;PAMPA_results.csv:row=1133;BBB_results.csv:row=1133;Solubility_results.csv:row=1133;Lipophilicity_results.csv:row=1134
CHEMBL4129286,ADAFOSBUVIR,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@]1(F)O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(O)[C@@H]1O)Oc1ccccc1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -0.79; logP 0.98,repurposing_candidates.csv:rc_row=1136;CYP3A4_results.csv:row=1000;CYP2C19_results.csv:row=1000;CYP2D6_results.csv:row=1000;CYP1A2_results.csv:row=1000;CYP2C9_results.csv:row=1000;hERG_results.csv:row=1000;AMES_results.csv:row=1000;PGP_results.csv:row=1000;PAMPA_results.csv:row=1000;BBB_results.csv:row=1000;Solubility_results.csv:row=1000;Lipophilicity_results.csv:row=1001
CHEMBL3545309,LEFAMULIN ACETATE,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.CC(=O)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -2.59; logP 3.96,repurposing_candidates.csv:rc_row=987;CYP3A4_results.csv:row=880;CYP2C19_results.csv:row=880;CYP2D6_results.csv:row=880;CYP1A2_results.csv:row=880;CYP2C9_results.csv:row=880;hERG_results.csv:row=880;AMES_results.csv:row=880;PGP_results.csv:row=880;PAMPA_results.csv:row=880;BBB_results.csv:row=880;Solubility_results.csv:row=880;Lipophilicity_results.csv:row=881
CHEMBL42442,OXFENDAZOLE,COC(=O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.77; logP 2.91,repurposing_candidates.csv:rc_row=1150;CYP3A4_results.csv:row=1014;CYP2C19_results.csv:row=1014;CYP2D6_results.csv:row=1014;CYP1A2_results.csv:row=1014;CYP2C9_results.csv:row=1014;hERG_results.csv:row=1014;AMES_results.csv:row=1014;PGP_results.csv:row=1014;PAMPA_results.csv:row=1014;BBB_results.csv:row=1014;Solubility_results.csv:row=1014;Lipophilicity_results.csv:row=1015
CHEMBL1741,CLARITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -1.99; logP 2.44,repurposing_candidates.csv:rc_row=538;CYP3A4_results.csv:row=498;CYP2C19_results.csv:row=498;CYP2D6_results.csv:row=498;CYP1A2_results.csv:row=498;CYP2C9_results.csv:row=498;hERG_results.csv:row=498;AMES_results.csv:row=498;PGP_results.csv:row=498;PAMPA_results.csv:row=498;BBB_results.csv:row=498;Solubility_results.csv:row=498;Lipophilicity_results.csv:row=499
CHEMBL2105711,TOFOGLIFLOZIN,CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -3.62; logP 0.17,repurposing_candidates.csv:rc_row=701;CYP3A4_results.csv:row=646;CYP2C19_results.csv:row=646;CYP2D6_results.csv:row=646;CYP1A2_results.csv:row=646;CYP2C9_results.csv:row=646;hERG_results.csv:row=646;AMES_results.csv:row=646;PGP_results.csv:row=646;PAMPA_results.csv:row=646;BBB_results.csv:row=646;Solubility_results.csv:row=646;Lipophilicity_results.csv:row=647
CHEMBL2105629,VINFLUNINE DITARTRATE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.43; logP 0.83,repurposing_candidates.csv:rc_row=691;CYP3A4_results.csv:row=636;CYP2C19_results.csv:row=636;CYP2D6_results.csv:row=636;CYP1A2_results.csv:row=636;CYP2C9_results.csv:row=636;hERG_results.csv:row=636;AMES_results.csv:row=636;PGP_results.csv:row=636;PAMPA_results.csv:row=636;BBB_results.csv:row=636;Solubility_results.csv:row=636;Lipophilicity_results.csv:row=637
CHEMBL1766582,R-1487 HYDROCHLORIDE,Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,18.333333333333332,10,100.0,35.83333333333333,L,KG-supported from 1 sources; logS -4.24; logP 3.41,repurposing_candidates.csv:rc_row=564;CYP3A4_results.csv:row=510;CYP2C19_results.csv:row=510;CYP2D6_results.csv:row=510;CYP1A2_results.csv:row=510;CYP2C9_results.csv:row=510;hERG_results.csv:row=510;AMES_results.csv:row=510;PGP_results.csv:row=510;PAMPA_results.csv:row=510;BBB_results.csv:row=510;Solubility_results.csv:row=510;Lipophilicity_results.csv:row=511
CHEMBL3039507,SOTAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -5.67; logP 3.17,repurposing_candidates.csv:rc_row=893;CYP3A4_results.csv:row=801;CYP2C19_results.csv:row=801;CYP2D6_results.csv:row=801;CYP1A2_results.csv:row=801;CYP2C9_results.csv:row=801;hERG_results.csv:row=801;AMES_results.csv:row=801;PGP_results.csv:row=801;PAMPA_results.csv:row=801;BBB_results.csv:row=801;Solubility_results.csv:row=801;Lipophilicity_results.csv:row=802
CHEMBL1088751,PH-797804,CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.03; logP 4.43,repurposing_candidates.csv:rc_row=34;CYP3A4_results.csv:row=34;CYP2C19_results.csv:row=34;CYP2D6_results.csv:row=34;CYP1A2_results.csv:row=34;CYP2C9_results.csv:row=34;hERG_results.csv:row=34;AMES_results.csv:row=34;PGP_results.csv:row=34;PAMPA_results.csv:row=34;BBB_results.csv:row=34;Solubility_results.csv:row=34;Lipophilicity_results.csv:row=34
CHEMBL3989754,FLURBIPROFEN SODIUM,CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.94; logP -2.30,repurposing_candidates.csv:rc_row=1085;CYP3A4_results.csv:row=954;CYP2C19_results.csv:row=954;CYP2D6_results.csv:row=954;CYP1A2_results.csv:row=954;CYP2C9_results.csv:row=954;hERG_results.csv:row=954;AMES_results.csv:row=954;PGP_results.csv:row=954;PAMPA_results.csv:row=954;BBB_results.csv:row=954;Solubility_results.csv:row=954;Lipophilicity_results.csv:row=955
CHEMBL176,BEKANAMYCIN,NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -0.64; logP -7.33,repurposing_candidates.csv:rc_row=560;CYP3A4_results.csv:row=506;CYP2C19_results.csv:row=506;CYP2D6_results.csv:row=506;CYP1A2_results.csv:row=506;CYP2C9_results.csv:row=506;hERG_results.csv:row=506;AMES_results.csv:row=506;PGP_results.csv:row=506;PAMPA_results.csv:row=506;BBB_results.csv:row=506;Solubility_results.csv:row=506;Lipophilicity_results.csv:row=507
CHEMBL2348780,VAMOROLONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.45; logP 2.75,repurposing_candidates.csv:rc_row=828;CYP3A4_results.csv:row=737;CYP2C19_results.csv:row=737;CYP2D6_results.csv:row=737;CYP1A2_results.csv:row=737;CYP2C9_results.csv:row=737;hERG_results.csv:row=737;AMES_results.csv:row=737;PGP_results.csv:row=737;PAMPA_results.csv:row=737;BBB_results.csv:row=737;Solubility_results.csv:row=737;Lipophilicity_results.csv:row=738
CHEMBL20883,TEGAFUR,O=c1[nH]c(=O)n(C2CCCO2)cc1F,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.04; logP -0.02,repurposing_candidates.csv:rc_row=648;CYP3A4_results.csv:row=594;CYP2C19_results.csv:row=594;CYP2D6_results.csv:row=594;CYP1A2_results.csv:row=594;CYP2C9_results.csv:row=594;hERG_results.csv:row=594;AMES_results.csv:row=594;PGP_results.csv:row=594;PAMPA_results.csv:row=594;BBB_results.csv:row=594;Solubility_results.csv:row=594;Lipophilicity_results.csv:row=595
CHEMBL1076263,SETROBUVIR,CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.87; logP 2.98,repurposing_candidates.csv:rc_row=25;CYP3A4_results.csv:row=25;CYP2C19_results.csv:row=25;CYP2D6_results.csv:row=25;CYP1A2_results.csv:row=25;CYP2C9_results.csv:row=25;hERG_results.csv:row=25;AMES_results.csv:row=25;PGP_results.csv:row=25;PAMPA_results.csv:row=25;BBB_results.csv:row=25;Solubility_results.csv:row=25;Lipophilicity_results.csv:row=25
CHEMBL3989571,SPECTINOMYCIN HYDROCHLORIDE,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O.Cl.Cl.O.O.O.O.O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -0.89; logP -6.21,repurposing_candidates.csv:rc_row=1075;CYP3A4_results.csv:row=944;CYP2C19_results.csv:row=944;CYP2D6_results.csv:row=944;CYP1A2_results.csv:row=944;CYP2C9_results.csv:row=944;hERG_results.csv:row=944;AMES_results.csv:row=944;PGP_results.csv:row=944;PAMPA_results.csv:row=944;BBB_results.csv:row=944;Solubility_results.csv:row=944;Lipophilicity_results.csv:row=945
CHEMBL3989568,OXYTETRACYCLINE CALCIUM,CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.[Ca+2],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.39; logP -5.26,repurposing_candidates.csv:rc_row=1074;CYP3A4_results.csv:row=943;CYP2C19_results.csv:row=943;CYP2D6_results.csv:row=943;CYP1A2_results.csv:row=943;CYP2C9_results.csv:row=943;hERG_results.csv:row=943;AMES_results.csv:row=943;PGP_results.csv:row=943;PAMPA_results.csv:row=943;BBB_results.csv:row=943;Solubility_results.csv:row=943;Lipophilicity_results.csv:row=944
CHEMBL973,TERIFLUNOMIDE,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.02; logP 3.00,repurposing_candidates.csv:rc_row=1575;CYP3A4_results.csv:row=1381;CYP2C19_results.csv:row=1381;CYP2D6_results.csv:row=1381;CYP1A2_results.csv:row=1381;CYP2C9_results.csv:row=1381;hERG_results.csv:row=1381;AMES_results.csv:row=1381;PGP_results.csv:row=1381;PAMPA_results.csv:row=1381;BBB_results.csv:row=1381;Solubility_results.csv:row=1381;Lipophilicity_results.csv:row=1382
CHEMBL1614702,SCIO-323,COc1cc2c(cc1C(=O)N1CCC(Cc3ccc(F)cc3)CC1)c(C(=O)C(=O)N(C)C)cn2C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.25; logP 3.69,repurposing_candidates.csv:rc_row=476;CYP3A4_results.csv:row=436;CYP2C19_results.csv:row=436;CYP2D6_results.csv:row=436;CYP1A2_results.csv:row=436;CYP2C9_results.csv:row=436;hERG_results.csv:row=436;AMES_results.csv:row=436;PGP_results.csv:row=436;PAMPA_results.csv:row=436;BBB_results.csv:row=436;Solubility_results.csv:row=436;Lipophilicity_results.csv:row=437
CHEMBL393820,VALOPICITABINE,CC(C)[C@H](N)C(=O)O[C@@H]1[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@]1(C)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -0.76; logP -1.64,repurposing_candidates.csv:rc_row=1060;CYP3A4_results.csv:row=929;CYP2C19_results.csv:row=929;CYP2D6_results.csv:row=929;CYP1A2_results.csv:row=929;CYP2C9_results.csv:row=929;hERG_results.csv:row=929;AMES_results.csv:row=929;PGP_results.csv:row=929;PAMPA_results.csv:row=929;BBB_results.csv:row=929;Solubility_results.csv:row=929;Lipophilicity_results.csv:row=930
CHEMBL4208954,AMIKACIN SULFATE,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 1.17; logP -9.73,repurposing_candidates.csv:rc_row=1146;CYP3A4_results.csv:row=1010;CYP2C19_results.csv:row=1010;CYP2D6_results.csv:row=1010;CYP1A2_results.csv:row=1010;CYP2C9_results.csv:row=1010;hERG_results.csv:row=1010;AMES_results.csv:row=1010;PGP_results.csv:row=1010;PAMPA_results.csv:row=1010;BBB_results.csv:row=1010;Solubility_results.csv:row=1010;Lipophilicity_results.csv:row=1011
CHEMBL1607480,OXYTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.Cl,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.27; logP -0.82,repurposing_candidates.csv:rc_row=475;CYP3A4_results.csv:row=435;CYP2C19_results.csv:row=435;CYP2D6_results.csv:row=435;CYP1A2_results.csv:row=435;CYP2C9_results.csv:row=435;hERG_results.csv:row=435;AMES_results.csv:row=435;PGP_results.csv:row=435;PAMPA_results.csv:row=435;BBB_results.csv:row=435;Solubility_results.csv:row=435;Lipophilicity_results.csv:row=436
CHEMBL1200968,HYDROCORTISONE SODIUM PHOSPHATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.03; logP -5.36,repurposing_candidates.csv:rc_row=204;CYP3A4_results.csv:row=202;CYP2C19_results.csv:row=202;CYP2D6_results.csv:row=202;CYP1A2_results.csv:row=202;CYP2C9_results.csv:row=202;hERG_results.csv:row=202;AMES_results.csv:row=202;PGP_results.csv:row=202;PAMPA_results.csv:row=202;BBB_results.csv:row=202;Solubility_results.csv:row=202;Lipophilicity_results.csv:row=203
CHEMBL1200975,CLOCORTOLONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.92; logP 4.60,repurposing_candidates.csv:rc_row=206;CYP3A4_results.csv:row=204;CYP2C19_results.csv:row=204;CYP2D6_results.csv:row=204;CYP1A2_results.csv:row=204;CYP2C9_results.csv:row=204;hERG_results.csv:row=204;AMES_results.csv:row=204;PGP_results.csv:row=204;PAMPA_results.csv:row=204;BBB_results.csv:row=204;Solubility_results.csv:row=204;Lipophilicity_results.csv:row=205
CHEMBL178803,BLONANSERIN,CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.94; logP 4.69,repurposing_candidates.csv:rc_row=573;CYP3A4_results.csv:row=519;CYP2C19_results.csv:row=519;CYP2D6_results.csv:row=519;CYP1A2_results.csv:row=519;CYP2C9_results.csv:row=519;hERG_results.csv:row=519;AMES_results.csv:row=519;PGP_results.csv:row=519;PAMPA_results.csv:row=519;BBB_results.csv:row=519;Solubility_results.csv:row=519;Lipophilicity_results.csv:row=520
CHEMBL2206196,PAROMOMYCIN SULFATE,NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 1.29; logP -9.51,repurposing_candidates.csv:rc_row=804;CYP3A4_results.csv:row=713;CYP2C19_results.csv:row=713;CYP2D6_results.csv:row=713;CYP1A2_results.csv:row=713;CYP2C9_results.csv:row=713;hERG_results.csv:row=713;AMES_results.csv:row=713;PGP_results.csv:row=713;PAMPA_results.csv:row=713;BBB_results.csv:row=713;Solubility_results.csv:row=713;Lipophilicity_results.csv:row=714
CHEMBL1092581,NESBUVIR,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(CCO)S(C)(=O)=O)c(C3CC3)cc12,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.25; logP 3.23,repurposing_candidates.csv:rc_row=41;CYP3A4_results.csv:row=41;CYP2C19_results.csv:row=41;CYP2D6_results.csv:row=41;CYP1A2_results.csv:row=41;CYP2C9_results.csv:row=41;hERG_results.csv:row=41;AMES_results.csv:row=41;PGP_results.csv:row=41;PAMPA_results.csv:row=41;BBB_results.csv:row=41;Solubility_results.csv:row=41;Lipophilicity_results.csv:row=41
CHEMBL109480,TANESPIMYCIN,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.49; logP 2.54,repurposing_candidates.csv:rc_row=43;CYP3A4_results.csv:row=43;CYP2C19_results.csv:row=43;CYP2D6_results.csv:row=43;CYP1A2_results.csv:row=43;CYP2C9_results.csv:row=43;hERG_results.csv:row=43;AMES_results.csv:row=43;PGP_results.csv:row=43;PAMPA_results.csv:row=43;BBB_results.csv:row=43;Solubility_results.csv:row=43;Lipophilicity_results.csv:row=43
CHEMBL1200342,PARAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.47; logP 2.32,repurposing_candidates.csv:rc_row=89;CYP3A4_results.csv:row=88;CYP2C19_results.csv:row=88;CYP2D6_results.csv:row=88;CYP1A2_results.csv:row=88;CYP2C9_results.csv:row=88;hERG_results.csv:row=88;AMES_results.csv:row=88;PGP_results.csv:row=88;PAMPA_results.csv:row=88;BBB_results.csv:row=88;Solubility_results.csv:row=88;Lipophilicity_results.csv:row=88
CHEMBL1200449,TRIAMCINOLONE DIACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.11; logP 1.76,repurposing_candidates.csv:rc_row=103;CYP3A4_results.csv:row=102;CYP2C19_results.csv:row=102;CYP2D6_results.csv:row=102;CYP1A2_results.csv:row=102;CYP2C9_results.csv:row=102;hERG_results.csv:row=102;AMES_results.csv:row=102;PGP_results.csv:row=102;PAMPA_results.csv:row=102;BBB_results.csv:row=102;Solubility_results.csv:row=102;Lipophilicity_results.csv:row=102
CHEMBL1200463,OXAPROZIN POTASSIUM,O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.46; logP -0.30,repurposing_candidates.csv:rc_row=105;CYP3A4_results.csv:row=104;CYP2C19_results.csv:row=104;CYP2D6_results.csv:row=104;CYP1A2_results.csv:row=104;CYP2C9_results.csv:row=104;hERG_results.csv:row=104;AMES_results.csv:row=104;PGP_results.csv:row=104;PAMPA_results.csv:row=104;BBB_results.csv:row=104;Solubility_results.csv:row=104;Lipophilicity_results.csv:row=104
CHEMBL803,CYTARABINE,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.64; logP -2.56,repurposing_candidates.csv:rc_row=1518;CYP3A4_results.csv:row=1324;CYP2C19_results.csv:row=1324;CYP2D6_results.csv:row=1324;CYP1A2_results.csv:row=1324;CYP2C9_results.csv:row=1324;hERG_results.csv:row=1324;AMES_results.csv:row=1324;PGP_results.csv:row=1324;PAMPA_results.csv:row=1324;BBB_results.csv:row=1324;Solubility_results.csv:row=1324;Lipophilicity_results.csv:row=1325
CHEMBL221886,SISOMICIN,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 0.80; logP -3.85,repurposing_candidates.csv:rc_row=807;CYP3A4_results.csv:row=716;CYP2C19_results.csv:row=716;CYP2D6_results.csv:row=716;CYP1A2_results.csv:row=716;CYP2C9_results.csv:row=716;hERG_results.csv:row=716;AMES_results.csv:row=716;PGP_results.csv:row=716;PAMPA_results.csv:row=716;BBB_results.csv:row=716;Solubility_results.csv:row=716;Lipophilicity_results.csv:row=717
CHEMBL1200506,ERYTHROMYCIN LACTOBIONATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 0.35; logP -3.88,repurposing_candidates.csv:rc_row=116;CYP3A4_results.csv:row=115;CYP2C19_results.csv:row=115;CYP2D6_results.csv:row=115;CYP1A2_results.csv:row=115;CYP2C9_results.csv:row=115;hERG_results.csv:row=115;AMES_results.csv:row=115;PGP_results.csv:row=115;PAMPA_results.csv:row=115;BBB_results.csv:row=115;Solubility_results.csv:row=115;Lipophilicity_results.csv:row=115
CHEMBL1200542,DESOXYCORTICOSTERONE ACETATE,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.83; logP 4.27,repurposing_candidates.csv:rc_row=121;CYP3A4_results.csv:row=120;CYP2C19_results.csv:row=120;CYP2D6_results.csv:row=120;CYP1A2_results.csv:row=120;CYP2C9_results.csv:row=120;hERG_results.csv:row=120;AMES_results.csv:row=120;PGP_results.csv:row=120;PAMPA_results.csv:row=120;BBB_results.csv:row=120;Solubility_results.csv:row=120;Lipophilicity_results.csv:row=120
CHEMBL185,FLUOROURACIL,O=c1[nH]cc(F)c(=O)[nH]1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.41; logP -0.80,repurposing_candidates.csv:rc_row=583;CYP3A4_results.csv:row=529;CYP2C19_results.csv:row=529;CYP2D6_results.csv:row=529;CYP1A2_results.csv:row=529;CYP2C9_results.csv:row=529;hERG_results.csv:row=529;AMES_results.csv:row=529;PGP_results.csv:row=529;PAMPA_results.csv:row=529;BBB_results.csv:row=529;Solubility_results.csv:row=529;Lipophilicity_results.csv:row=530
CHEMBL3989966,CONTEZOLID ACEFOSAMIL,CC(=O)OP(=O)([O-])N(C[C@H]1CN(c2cc(F)c(N3C=CC(=O)CC3)c(F)c2F)C(=O)O1)c1ccon1.[Na+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.66; logP -0.75,repurposing_candidates.csv:rc_row=1106;CYP3A4_results.csv:row=975;CYP2C19_results.csv:row=975;CYP2D6_results.csv:row=975;CYP1A2_results.csv:row=975;CYP2C9_results.csv:row=975;hERG_results.csv:row=975;AMES_results.csv:row=975;PGP_results.csv:row=975;PAMPA_results.csv:row=975;BBB_results.csv:row=975;Solubility_results.csv:row=975;Lipophilicity_results.csv:row=976
CHEMBL1200578,THEOPHYLLINE SODIUM GLYCINATE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)[O-].[Na+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 1.74; logP -6.34,repurposing_candidates.csv:rc_row=127;CYP3A4_results.csv:row=126;CYP2C19_results.csv:row=126;CYP2D6_results.csv:row=126;CYP1A2_results.csv:row=126;CYP2C9_results.csv:row=126;hERG_results.csv:row=126;AMES_results.csv:row=126;PGP_results.csv:row=126;PAMPA_results.csv:row=126;BBB_results.csv:row=126;Solubility_results.csv:row=126;Lipophilicity_results.csv:row=126
CHEMBL2364623,PLAZOMICIN SULFATE,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 2.76; logP -6.01,repurposing_candidates.csv:rc_row=840;CYP3A4_results.csv:row=749;CYP2C19_results.csv:row=749;CYP2D6_results.csv:row=749;CYP1A2_results.csv:row=749;CYP2C9_results.csv:row=749;hERG_results.csv:row=749;AMES_results.csv:row=749;PGP_results.csv:row=749;PAMPA_results.csv:row=749;BBB_results.csv:row=749;Solubility_results.csv:row=749;Lipophilicity_results.csv:row=750
CHEMBL2146123,METHACYCLINE HYDROCHLORIDE,C=C1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.Cl,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.45; logP -0.02,repurposing_candidates.csv:rc_row=790;CYP3A4_results.csv:row=699;CYP2C19_results.csv:row=699;CYP2D6_results.csv:row=699;CYP1A2_results.csv:row=699;CYP2C9_results.csv:row=699;hERG_results.csv:row=699;AMES_results.csv:row=699;PGP_results.csv:row=699;PAMPA_results.csv:row=699;BBB_results.csv:row=699;Solubility_results.csv:row=699;Lipophilicity_results.csv:row=700
CHEMBL4297640,VECABRUTINIB,NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.43; logP 2.65,repurposing_candidates.csv:rc_row=1203;CYP3A4_results.csv:row=1063;CYP2C19_results.csv:row=1063;CYP2D6_results.csv:row=1063;CYP1A2_results.csv:row=1063;CYP2C9_results.csv:row=1063;hERG_results.csv:row=1063;AMES_results.csv:row=1063;PGP_results.csv:row=1063;PAMPA_results.csv:row=1063;BBB_results.csv:row=1063;Solubility_results.csv:row=1063;Lipophilicity_results.csv:row=1064
CHEMBL715,OLANZAPINE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.84; logP 3.44,repurposing_candidates.csv:rc_row=1498;CYP3A4_results.csv:row=1304;CYP2C19_results.csv:row=1304;CYP2D6_results.csv:row=1304;CYP1A2_results.csv:row=1304;CYP2C9_results.csv:row=1304;hERG_results.csv:row=1304;AMES_results.csv:row=1304;PGP_results.csv:row=1304;PAMPA_results.csv:row=1304;BBB_results.csv:row=1304;Solubility_results.csv:row=1304;Lipophilicity_results.csv:row=1305
CHEMBL1200636,CYCLOBENZAPRINE HYDROCHLORIDE,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.49; logP 4.98,repurposing_candidates.csv:rc_row=140;CYP3A4_results.csv:row=139;CYP2C19_results.csv:row=139;CYP2D6_results.csv:row=139;CYP1A2_results.csv:row=139;CYP2C9_results.csv:row=139;hERG_results.csv:row=139;AMES_results.csv:row=139;PGP_results.csv:row=139;PAMPA_results.csv:row=139;BBB_results.csv:row=139;Solubility_results.csv:row=139;Lipophilicity_results.csv:row=139
CHEMBL1200649,QUINUPRISTIN,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.56; logP 2.32,repurposing_candidates.csv:rc_row=143;CYP3A4_results.csv:row=142;CYP2C19_results.csv:row=142;CYP2D6_results.csv:row=142;CYP1A2_results.csv:row=142;CYP2C9_results.csv:row=142;hERG_results.csv:row=142;AMES_results.csv:row=142;PGP_results.csv:row=142;PAMPA_results.csv:row=142;BBB_results.csv:row=142;Solubility_results.csv:row=142;Lipophilicity_results.csv:row=142
CHEMBL2018096,IPRAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.18; logP 2.15,repurposing_candidates.csv:rc_row=622;CYP3A4_results.csv:row=568;CYP2C19_results.csv:row=568;CYP2D6_results.csv:row=568;CYP1A2_results.csv:row=568;CYP2C9_results.csv:row=568;hERG_results.csv:row=568;AMES_results.csv:row=568;PGP_results.csv:row=568;PAMPA_results.csv:row=568;BBB_results.csv:row=568;Solubility_results.csv:row=568;Lipophilicity_results.csv:row=569
CHEMBL2023895,HYDROXYSTILBAMIDINE ISETHIONATE,N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1.O=S(=O)(O)CCO.O=S(=O)(O)CCO,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -0.46; logP -0.14,repurposing_candidates.csv:rc_row=624;CYP3A4_results.csv:row=570;CYP2C19_results.csv:row=570;CYP2D6_results.csv:row=570;CYP1A2_results.csv:row=570;CYP2C9_results.csv:row=570;hERG_results.csv:row=570;AMES_results.csv:row=570;PGP_results.csv:row=570;PAMPA_results.csv:row=570;BBB_results.csv:row=570;Solubility_results.csv:row=570;Lipophilicity_results.csv:row=571
CHEMBL1195136,SNX 5422,CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.77; logP 3.37,repurposing_candidates.csv:rc_row=79;CYP3A4_results.csv:row=78;CYP2C19_results.csv:row=78;CYP2D6_results.csv:row=78;CYP1A2_results.csv:row=78;CYP2C9_results.csv:row=78;hERG_results.csv:row=78;AMES_results.csv:row=78;PGP_results.csv:row=78;PAMPA_results.csv:row=78;BBB_results.csv:row=78;Solubility_results.csv:row=78;Lipophilicity_results.csv:row=78
CHEMBL1200729,CHLORAMPHENICOL SODIUM SUCCINATE,O=C([O-])CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1.[Na+],18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.54; logP -3.01,repurposing_candidates.csv:rc_row=157;CYP3A4_results.csv:row=155;CYP2C19_results.csv:row=155;CYP2D6_results.csv:row=155;CYP1A2_results.csv:row=155;CYP2C9_results.csv:row=155;hERG_results.csv:row=155;AMES_results.csv:row=155;PGP_results.csv:row=155;PAMPA_results.csv:row=155;BBB_results.csv:row=155;Solubility_results.csv:row=155;Lipophilicity_results.csv:row=156
CHEMBL3989829,NETILMICIN SULFATE,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 6.20; logP -9.67,repurposing_candidates.csv:rc_row=1091;CYP3A4_results.csv:row=960;CYP2C19_results.csv:row=960;CYP2D6_results.csv:row=960;CYP1A2_results.csv:row=960;CYP2C9_results.csv:row=960;hERG_results.csv:row=960;AMES_results.csv:row=960;PGP_results.csv:row=960;PAMPA_results.csv:row=960;BBB_results.csv:row=960;Solubility_results.csv:row=960;Lipophilicity_results.csv:row=961
CHEMBL1808388,BEXAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -4.31; logP 2.00,repurposing_candidates.csv:rc_row=580;CYP3A4_results.csv:row=526;CYP2C19_results.csv:row=526;CYP2D6_results.csv:row=526;CYP1A2_results.csv:row=526;CYP2C9_results.csv:row=526;hERG_results.csv:row=526;AMES_results.csv:row=526;PGP_results.csv:row=526;PAMPA_results.csv:row=526;BBB_results.csv:row=526;Solubility_results.csv:row=526;Lipophilicity_results.csv:row=527
CHEMBL3989768,LEVORPHANOL TARTRATE,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O.O.O=C(O)C(O)C(O)C(=O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.11; logP -0.69,repurposing_candidates.csv:rc_row=1086;CYP3A4_results.csv:row=955;CYP2C19_results.csv:row=955;CYP2D6_results.csv:row=955;CYP1A2_results.csv:row=955;CYP2C9_results.csv:row=955;hERG_results.csv:row=955;AMES_results.csv:row=955;PGP_results.csv:row=955;PAMPA_results.csv:row=955;BBB_results.csv:row=955;Solubility_results.csv:row=955;Lipophilicity_results.csv:row=956
CHEMBL535650,MEFLOQUINE HYDROCHLORIDE,Cl.OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.48; logP 4.87,repurposing_candidates.csv:rc_row=1399;CYP3A4_results.csv:row=1208;CYP2C19_results.csv:row=1208;CYP2D6_results.csv:row=1208;CYP1A2_results.csv:row=1208;CYP2C9_results.csv:row=1208;hERG_results.csv:row=1208;AMES_results.csv:row=1208;PGP_results.csv:row=1208;PAMPA_results.csv:row=1208;BBB_results.csv:row=1208;Solubility_results.csv:row=1208;Lipophilicity_results.csv:row=1209
CHEMBL3184791,STREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 6.88; logP -18.28,repurposing_candidates.csv:rc_row=921;CYP3A4_results.csv:row=828;CYP2C19_results.csv:row=828;CYP2D6_results.csv:row=828;CYP1A2_results.csv:row=828;CYP2C9_results.csv:row=828;hERG_results.csv:row=828;AMES_results.csv:row=828;PGP_results.csv:row=828;PAMPA_results.csv:row=828;BBB_results.csv:row=828;Solubility_results.csv:row=828;Lipophilicity_results.csv:row=829
CHEMBL3545060,ERYTHROMYCIN GLUCEPTATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -0.49; logP -2.35,repurposing_candidates.csv:rc_row=967;CYP3A4_results.csv:row=868;CYP2C19_results.csv:row=868;CYP2D6_results.csv:row=868;CYP1A2_results.csv:row=868;CYP2C9_results.csv:row=868;hERG_results.csv:row=868;AMES_results.csv:row=868;PGP_results.csv:row=868;PAMPA_results.csv:row=868;BBB_results.csv:row=868;Solubility_results.csv:row=868;Lipophilicity_results.csv:row=869
CHEMBL322241,TELINAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1)C(=O)NC(C)(C)C,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.48; logP 2.76,repurposing_candidates.csv:rc_row=929;CYP3A4_results.csv:row=836;CYP2C19_results.csv:row=836;CYP2D6_results.csv:row=836;CYP1A2_results.csv:row=836;CYP2C9_results.csv:row=836;hERG_results.csv:row=836;AMES_results.csv:row=836;PGP_results.csv:row=836;PAMPA_results.csv:row=836;BBB_results.csv:row=836;Solubility_results.csv:row=836;Lipophilicity_results.csv:row=837
CHEMBL3305901,MK-0812,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.51; logP 3.57,repurposing_candidates.csv:rc_row=944;CYP3A4_results.csv:row=848;CYP2C19_results.csv:row=848;CYP2D6_results.csv:row=848;CYP1A2_results.csv:row=848;CYP2C9_results.csv:row=848;hERG_results.csv:row=848;AMES_results.csv:row=848;PGP_results.csv:row=848;PAMPA_results.csv:row=848;BBB_results.csv:row=848;Solubility_results.csv:row=848;Lipophilicity_results.csv:row=849
CHEMBL1201155,LOXAPINE SUCCINATE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.67; logP 3.71,repurposing_candidates.csv:rc_row=244;CYP3A4_results.csv:row=241;CYP2C19_results.csv:row=241;CYP2D6_results.csv:row=241;CYP1A2_results.csv:row=241;CYP2C9_results.csv:row=241;hERG_results.csv:row=241;AMES_results.csv:row=241;PGP_results.csv:row=241;PAMPA_results.csv:row=241;BBB_results.csv:row=241;Solubility_results.csv:row=241;Lipophilicity_results.csv:row=242
CHEMBL4594217,CANAGLIFLOZIN,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -3.55; logP 2.14,repurposing_candidates.csv:rc_row=1284;CYP3A4_results.csv:row=1104;CYP2C19_results.csv:row=1104;CYP2D6_results.csv:row=1104;CYP1A2_results.csv:row=1104;CYP2C9_results.csv:row=1104;hERG_results.csv:row=1104;AMES_results.csv:row=1104;PGP_results.csv:row=1104;PAMPA_results.csv:row=1104;BBB_results.csv:row=1104;Solubility_results.csv:row=1104;Lipophilicity_results.csv:row=1105
CHEMBL1440,TETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.83; logP -0.21,repurposing_candidates.csv:rc_row=417;CYP3A4_results.csv:row=377;CYP2C19_results.csv:row=377;CYP2D6_results.csv:row=377;CYP1A2_results.csv:row=377;CYP2C9_results.csv:row=377;hERG_results.csv:row=377;AMES_results.csv:row=377;PGP_results.csv:row=377;PAMPA_results.csv:row=377;BBB_results.csv:row=377;Solubility_results.csv:row=377;Lipophilicity_results.csv:row=378
CHEMBL3188576,DIHYDROSTREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 5.38; logP -17.86,repurposing_candidates.csv:rc_row=925;CYP3A4_results.csv:row=832;CYP2C19_results.csv:row=832;CYP2D6_results.csv:row=832;CYP1A2_results.csv:row=832;CYP2C9_results.csv:row=832;hERG_results.csv:row=832;AMES_results.csv:row=832;PGP_results.csv:row=832;PAMPA_results.csv:row=832;BBB_results.csv:row=832;Solubility_results.csv:row=832;Lipophilicity_results.csv:row=833
CHEMBL1446,KANAMYCIN SULFATE,NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS 0.10; logP -7.94,repurposing_candidates.csv:rc_row=420;CYP3A4_results.csv:row=380;CYP2C19_results.csv:row=380;CYP2D6_results.csv:row=380;CYP1A2_results.csv:row=380;CYP2C9_results.csv:row=380;hERG_results.csv:row=380;AMES_results.csv:row=380;PGP_results.csv:row=380;PAMPA_results.csv:row=380;BBB_results.csv:row=380;Solubility_results.csv:row=380;Lipophilicity_results.csv:row=381
CHEMBL1201071,TETRACYCLINE PHOSPHATE COMPLEX,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.O=P(O)(O)O,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.73; logP -1.14,repurposing_candidates.csv:rc_row=229;CYP3A4_results.csv:row=227;CYP2C19_results.csv:row=227;CYP2D6_results.csv:row=227;CYP1A2_results.csv:row=227;CYP2C9_results.csv:row=227;hERG_results.csv:row=227;AMES_results.csv:row=227;PGP_results.csv:row=227;PAMPA_results.csv:row=227;BBB_results.csv:row=227;Solubility_results.csv:row=227;Lipophilicity_results.csv:row=228
CHEMBL1471,APREPITANT,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -5.18; logP 4.95,repurposing_candidates.csv:rc_row=425;CYP3A4_results.csv:row=385;CYP2C19_results.csv:row=385;CYP2D6_results.csv:row=385;CYP1A2_results.csv:row=385;CYP2C9_results.csv:row=385;hERG_results.csv:row=385;AMES_results.csv:row=385;PGP_results.csv:row=385;PAMPA_results.csv:row=385;BBB_results.csv:row=385;Solubility_results.csv:row=385;Lipophilicity_results.csv:row=386
CHEMBL52939,SARPOGRELATE,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.69; logP 3.20,repurposing_candidates.csv:rc_row=1376;CYP3A4_results.csv:row=1187;CYP2C19_results.csv:row=1187;CYP2D6_results.csv:row=1187;CYP1A2_results.csv:row=1187;CYP2C9_results.csv:row=1187;hERG_results.csv:row=1187;AMES_results.csv:row=1187;PGP_results.csv:row=1187;PAMPA_results.csv:row=1187;BBB_results.csv:row=1187;Solubility_results.csv:row=1187;Lipophilicity_results.csv:row=1188
CHEMBL452461,PERZINFOTEL,O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.55; logP -0.92,repurposing_candidates.csv:rc_row=1275;CYP3A4_results.csv:row=1095;CYP2C19_results.csv:row=1095;CYP2D6_results.csv:row=1095;CYP1A2_results.csv:row=1095;CYP2C9_results.csv:row=1095;hERG_results.csv:row=1095;AMES_results.csv:row=1095;PGP_results.csv:row=1095;PAMPA_results.csv:row=1095;BBB_results.csv:row=1095;Solubility_results.csv:row=1095;Lipophilicity_results.csv:row=1096
CHEMBL377559,RETASPIMYCIN HYDROCHLORIDE,C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2.Cl,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.67; logP 4.58,repurposing_candidates.csv:rc_row=1035;CYP3A4_results.csv:row=910;CYP2C19_results.csv:row=910;CYP2D6_results.csv:row=910;CYP1A2_results.csv:row=910;CYP2C9_results.csv:row=910;hERG_results.csv:row=910;AMES_results.csv:row=910;PGP_results.csv:row=910;PAMPA_results.csv:row=910;BBB_results.csv:row=910;Solubility_results.csv:row=910;Lipophilicity_results.csv:row=911
CHEMBL1489,AZACITIDINE,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.04; logP -3.17,repurposing_candidates.csv:rc_row=431;CYP3A4_results.csv:row=391;CYP2C19_results.csv:row=391;CYP2D6_results.csv:row=391;CYP1A2_results.csv:row=391;CYP2C9_results.csv:row=391;hERG_results.csv:row=391;AMES_results.csv:row=391;PGP_results.csv:row=391;PAMPA_results.csv:row=391;BBB_results.csv:row=391;Solubility_results.csv:row=391;Lipophilicity_results.csv:row=392
CHEMBL1517,OXYTETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -2.97; logP -1.24,repurposing_candidates.csv:rc_row=445;CYP3A4_results.csv:row=405;CYP2C19_results.csv:row=405;CYP2D6_results.csv:row=405;CYP1A2_results.csv:row=405;CYP2C9_results.csv:row=405;hERG_results.csv:row=405;AMES_results.csv:row=405;PGP_results.csv:row=405;PAMPA_results.csv:row=405;BBB_results.csv:row=405;Solubility_results.csv:row=405;Lipophilicity_results.csv:row=406
CHEMBL1201782,FOSAPREPITANT DIMEGLUMINE,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.23; logP -2.35,repurposing_candidates.csv:rc_row=318;CYP3A4_results.csv:row=287;CYP2C19_results.csv:row=287;CYP2D6_results.csv:row=287;CYP1A2_results.csv:row=287;CYP2C9_results.csv:row=287;hERG_results.csv:row=287;AMES_results.csv:row=287;PGP_results.csv:row=287;PAMPA_results.csv:row=287;BBB_results.csv:row=287;Solubility_results.csv:row=287;Lipophilicity_results.csv:row=288
CHEMBL3184512,CLINDAMYCIN PHOSPHATE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1,18.333333333333332,10,95.0,34.58333333333333,L,KG-supported from 1 sources; logS -1.29; logP 0.51,repurposing_candidates.csv:rc_row=920;CYP3A4_results.csv:row=827;CYP2C19_results.csv:row=827;CYP2D6_results.csv:row=827;CYP1A2_results.csv:row=827;CYP2C9_results.csv:row=827;hERG_results.csv:row=827;AMES_results.csv:row=827;PGP_results.csv:row=827;PAMPA_results.csv:row=827;BBB_results.csv:row=827;Solubility_results.csv:row=827;Lipophilicity_results.csv:row=828
CHEMBL191413,REPARIXIN,CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1,18.333333333333332,25,70.0,33.58333333333333,L,KG-supported from 1 sources; hERG risk; logS -4.69; logP 2.06,repurposing_candidates.csv:rc_row=597;CYP3A4_results.csv:row=543;CYP2C19_results.csv:row=543;CYP2D6_results.csv:row=543;CYP1A2_results.csv:row=543;CYP2C9_results.csv:row=543;hERG_results.csv:row=543;AMES_results.csv:row=543;PGP_results.csv:row=543;PAMPA_results.csv:row=543;BBB_results.csv:row=543;Solubility_results.csv:row=543;Lipophilicity_results.csv:row=544
CHEMBL960,LEFLUNOMIDE,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,18.333333333333332,25,70.0,33.58333333333333,L,KG-supported from 1 sources; hERG risk; logS -3.73; logP 3.25,repurposing_candidates.csv:rc_row=1567;CYP3A4_results.csv:row=1373;CYP2C19_results.csv:row=1373;CYP2D6_results.csv:row=1373;CYP1A2_results.csv:row=1373;CYP2C9_results.csv:row=1373;hERG_results.csv:row=1373;AMES_results.csv:row=1373;PGP_results.csv:row=1373;PAMPA_results.csv:row=1373;BBB_results.csv:row=1373;Solubility_results.csv:row=1373;Lipophilicity_results.csv:row=1374
CHEMBL6068339,IRBESARTAN HYDROCHLORIDE,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1.Cl,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -3.76; logP 5.20,repurposing_candidates.csv:rc_row=1450;CYP3A4_results.csv:row=1257;CYP2C19_results.csv:row=1257;CYP2D6_results.csv:row=1257;CYP1A2_results.csv:row=1257;CYP2C9_results.csv:row=1257;hERG_results.csv:row=1257;AMES_results.csv:row=1257;PGP_results.csv:row=1257;PAMPA_results.csv:row=1257;BBB_results.csv:row=1257;Solubility_results.csv:row=1257;Lipophilicity_results.csv:row=1258
CHEMBL4802157,ELINZANETANT,Cc1cc(F)ccc1-c1cc(N2C[C@H]3COCCN3C[C@H]2CO)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -5.36; logP 6.06,repurposing_candidates.csv:rc_row=1329;CYP3A4_results.csv:row=1140;CYP2C19_results.csv:row=1140;CYP2D6_results.csv:row=1140;CYP1A2_results.csv:row=1140;CYP2C9_results.csv:row=1140;hERG_results.csv:row=1140;AMES_results.csv:row=1140;PGP_results.csv:row=1140;PAMPA_results.csv:row=1140;BBB_results.csv:row=1140;Solubility_results.csv:row=1140;Lipophilicity_results.csv:row=1141
CHEMBL1200510,ERYTHROMYCIN STEARATE,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -5.41; logP 8.12,repurposing_candidates.csv:rc_row=117;CYP3A4_results.csv:row=116;CYP2C19_results.csv:row=116;CYP2D6_results.csv:row=116;CYP1A2_results.csv:row=116;CYP2C9_results.csv:row=116;hERG_results.csv:row=116;AMES_results.csv:row=116;PGP_results.csv:row=116;PAMPA_results.csv:row=116;BBB_results.csv:row=116;Solubility_results.csv:row=116;Lipophilicity_results.csv:row=116
CHEMBL1938400,PF-03715455,CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -5.91; logP 7.80,repurposing_candidates.csv:rc_row=605;CYP3A4_results.csv:row=551;CYP2C19_results.csv:row=551;CYP2D6_results.csv:row=551;CYP1A2_results.csv:row=551;CYP2C9_results.csv:row=551;hERG_results.csv:row=551;AMES_results.csv:row=551;PGP_results.csv:row=551;PAMPA_results.csv:row=551;BBB_results.csv:row=551;Solubility_results.csv:row=551;Lipophilicity_results.csv:row=552
CHEMBL3545094,ELOCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@@H](C)C/C=C/C(O)(CC)CC)=CCC23)C[C@@H](O)C[C@@H]1O,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -3.64; logP 6.18,repurposing_candidates.csv:rc_row=970;CYP3A4_results.csv:row=870;CYP2C19_results.csv:row=870;CYP2D6_results.csv:row=870;CYP1A2_results.csv:row=870;CYP2C9_results.csv:row=870;hERG_results.csv:row=870;AMES_results.csv:row=870;PGP_results.csv:row=870;PAMPA_results.csv:row=870;BBB_results.csv:row=870;Solubility_results.csv:row=870;Lipophilicity_results.csv:row=871
CHEMBL3707330,ROLAPITANT HYDROCHLORIDE,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -4.12; logP 5.33,repurposing_candidates.csv:rc_row=1022;CYP3A4_results.csv:row=902;CYP2C19_results.csv:row=902;CYP2D6_results.csv:row=902;CYP1A2_results.csv:row=902;CYP2C9_results.csv:row=902;hERG_results.csv:row=902;AMES_results.csv:row=902;PGP_results.csv:row=902;PAMPA_results.csv:row=902;BBB_results.csv:row=902;Solubility_results.csv:row=902;Lipophilicity_results.csv:row=903
CHEMBL256907,MARAVIROC,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -3.44; logP 5.95,repurposing_candidates.csv:rc_row=859;CYP3A4_results.csv:row=767;CYP2C19_results.csv:row=767;CYP2D6_results.csv:row=767;CYP1A2_results.csv:row=767;CYP2C9_results.csv:row=767;hERG_results.csv:row=767;AMES_results.csv:row=767;PGP_results.csv:row=767;PAMPA_results.csv:row=767;BBB_results.csv:row=767;Solubility_results.csv:row=767;Lipophilicity_results.csv:row=768
CHEMBL3989904,CETHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -4.34; logP 5.11,repurposing_candidates.csv:rc_row=1099;CYP3A4_results.csv:row=968;CYP2C19_results.csv:row=968;CYP2D6_results.csv:row=968;CYP1A2_results.csv:row=968;CYP2C9_results.csv:row=968;hERG_results.csv:row=968;AMES_results.csv:row=968;PGP_results.csv:row=968;PAMPA_results.csv:row=968;BBB_results.csv:row=968;Solubility_results.csv:row=968;Lipophilicity_results.csv:row=969
CHEMBL1447,LINCOMYCIN,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -0.53; logP -0.86,repurposing_candidates.csv:rc_row=421;CYP3A4_results.csv:row=381;CYP2C19_results.csv:row=381;CYP2D6_results.csv:row=381;CYP1A2_results.csv:row=381;CYP2C9_results.csv:row=381;hERG_results.csv:row=381;AMES_results.csv:row=381;PGP_results.csv:row=381;PAMPA_results.csv:row=381;BBB_results.csv:row=381;Solubility_results.csv:row=381;Lipophilicity_results.csv:row=382
CHEMBL2403318,DELEOBUVIR,Cn1c(C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Br)cn5)n(C)c4c3)CCC2)nc2ccc(/C=C/C(=O)O)cc21,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -4.83; logP 6.85,repurposing_candidates.csv:rc_row=847;CYP3A4_results.csv:row=755;CYP2C19_results.csv:row=755;CYP2D6_results.csv:row=755;CYP1A2_results.csv:row=755;CYP2C9_results.csv:row=755;hERG_results.csv:row=755;AMES_results.csv:row=755;PGP_results.csv:row=755;PAMPA_results.csv:row=755;BBB_results.csv:row=755;Solubility_results.csv:row=755;Lipophilicity_results.csv:row=756
CHEMBL2105665,ELACYTARABINE,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -6.09; logP 4.03,repurposing_candidates.csv:rc_row=694;CYP3A4_results.csv:row=639;CYP2C19_results.csv:row=639;CYP2D6_results.csv:row=639;CYP1A2_results.csv:row=639;CYP2C9_results.csv:row=639;hERG_results.csv:row=639;AMES_results.csv:row=639;PGP_results.csv:row=639;PAMPA_results.csv:row=639;BBB_results.csv:row=639;Solubility_results.csv:row=639;Lipophilicity_results.csv:row=640
CHEMBL490672,FILIBUVIR,CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -4.54; logP 5.12,repurposing_candidates.csv:rc_row=1339;CYP3A4_results.csv:row=1150;CYP2C19_results.csv:row=1150;CYP2D6_results.csv:row=1150;CYP1A2_results.csv:row=1150;CYP2C9_results.csv:row=1150;hERG_results.csv:row=1150;AMES_results.csv:row=1150;PGP_results.csv:row=1150;PAMPA_results.csv:row=1150;BBB_results.csv:row=1150;Solubility_results.csv:row=1150;Lipophilicity_results.csv:row=1151
CHEMBL3121539,RADALBUVIR,CC1=CC[C@H](C(=O)N(c2cc(C#CC(C)(C)C)sc2C(=O)O)[C@H]2CC[C@](O)(CO[C@H]3CCOC3)CC2)CC1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -5.15; logP 5.40,repurposing_candidates.csv:rc_row=903;CYP3A4_results.csv:row=810;CYP2C19_results.csv:row=810;CYP2D6_results.csv:row=810;CYP1A2_results.csv:row=810;CYP2C9_results.csv:row=810;hERG_results.csv:row=810;AMES_results.csv:row=810;PGP_results.csv:row=810;PAMPA_results.csv:row=810;BBB_results.csv:row=810;Solubility_results.csv:row=810;Lipophilicity_results.csv:row=811
CHEMBL363648,TAK-715,CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -5.60; logP 6.00,repurposing_candidates.csv:rc_row=1007;CYP3A4_results.csv:row=893;CYP2C19_results.csv:row=893;CYP2D6_results.csv:row=893;CYP1A2_results.csv:row=893;CYP2C9_results.csv:row=893;hERG_results.csv:row=893;AMES_results.csv:row=893;PGP_results.csv:row=893;PAMPA_results.csv:row=893;BBB_results.csv:row=893;Solubility_results.csv:row=893;Lipophilicity_results.csv:row=894
CHEMBL2218877,ERYTHROMYCIN ESTOLATE,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C.CCCCCCCCCCCCOS(=O)(=O)O,18.333333333333332,10,90.0,33.33333333333333,L,KG-supported from 1 sources; logS -1.49; logP 6.47,repurposing_candidates.csv:rc_row=808;CYP3A4_results.csv:row=717;CYP2C19_results.csv:row=717;CYP2D6_results.csv:row=717;CYP1A2_results.csv:row=717;CYP2C9_results.csv:row=717;hERG_results.csv:row=717;AMES_results.csv:row=717;PGP_results.csv:row=717;PAMPA_results.csv:row=717;BBB_results.csv:row=717;Solubility_results.csv:row=717;Lipophilicity_results.csv:row=718
CHEMBL573677,ABEQUOLIXRON,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,14.63768115942029,40,50.0,32.35507246376812,L,KG targets NR1H2; clinical phase 1.0; hERG risk; logS -6.17; logP 8.48,repurposing_candidates.csv:rc_row=1422;protein_drug_candidates.csv:rows=1725;CYP3A4_results.csv:row=1231;CYP2C19_results.csv:row=1231;CYP2D6_results.csv:row=1231;CYP1A2_results.csv:row=1231;CYP2C9_results.csv:row=1231;hERG_results.csv:row=1231;AMES_results.csv:row=1231;PGP_results.csv:row=1231;PAMPA_results.csv:row=1231;BBB_results.csv:row=1231;Solubility_results.csv:row=1231;Lipophilicity_results.csv:row=1232
CHEMBL1650595,AR-12,NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,14.63768115942029,40,50.0,32.35507246376812,L,KG targets PDPK1; clinical phase 1.0; hERG risk; logS -6.91; logP 5.76,repurposing_candidates.csv:rc_row=495;protein_drug_candidates.csv:rows=1628;CYP3A4_results.csv:row=455;CYP2C19_results.csv:row=455;CYP2D6_results.csv:row=455;CYP1A2_results.csv:row=455;CYP2C9_results.csv:row=455;hERG_results.csv:row=455;AMES_results.csv:row=455;PGP_results.csv:row=455;PAMPA_results.csv:row=455;BBB_results.csv:row=455;Solubility_results.csv:row=455;Lipophilicity_results.csv:row=456
CHEMBL71,CHLORPROMAZINE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,18.333333333333332,25,65.0,32.33333333333333,L,KG-supported from 1 sources; hERG risk; logS -5.33; logP 4.89,repurposing_candidates.csv:rc_row=1497;CYP3A4_results.csv:row=1303;CYP2C19_results.csv:row=1303;CYP2D6_results.csv:row=1303;CYP1A2_results.csv:row=1303;CYP2C9_results.csv:row=1303;hERG_results.csv:row=1303;AMES_results.csv:row=1303;PGP_results.csv:row=1303;PAMPA_results.csv:row=1303;BBB_results.csv:row=1303;Solubility_results.csv:row=1303;Lipophilicity_results.csv:row=1304
CHEMBL2105667,ORVEPITANT,Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -4.15; logP 6.80,repurposing_candidates.csv:rc_row=695;CYP3A4_results.csv:row=640;CYP2C19_results.csv:row=640;CYP2D6_results.csv:row=640;CYP1A2_results.csv:row=640;CYP2C9_results.csv:row=640;hERG_results.csv:row=640;AMES_results.csv:row=640;PGP_results.csv:row=640;PAMPA_results.csv:row=640;BBB_results.csv:row=640;Solubility_results.csv:row=640;Lipophilicity_results.csv:row=641
CHEMBL2104927,FIGOPITANT,CN(CCc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)[C@H](c1ccccc1)N1CCN(CC2CC2)CC1,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -3.62; logP 5.49,repurposing_candidates.csv:rc_row=680;CYP3A4_results.csv:row=625;CYP2C19_results.csv:row=625;CYP2D6_results.csv:row=625;CYP1A2_results.csv:row=625;CYP2C9_results.csv:row=625;hERG_results.csv:row=625;AMES_results.csv:row=625;PGP_results.csv:row=625;PAMPA_results.csv:row=625;BBB_results.csv:row=625;Solubility_results.csv:row=625;Lipophilicity_results.csv:row=626
CHEMBL206253,NETUPITANT,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -4.47; logP 6.79,repurposing_candidates.csv:rc_row=638;CYP3A4_results.csv:row=584;CYP2C19_results.csv:row=584;CYP2D6_results.csv:row=584;CYP1A2_results.csv:row=584;CYP2C9_results.csv:row=584;hERG_results.csv:row=584;AMES_results.csv:row=584;PGP_results.csv:row=584;PAMPA_results.csv:row=584;BBB_results.csv:row=584;Solubility_results.csv:row=584;Lipophilicity_results.csv:row=585
CHEMBL1200877,FLUMETHASONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -6.39; logP 3.44,repurposing_candidates.csv:rc_row=185;CYP3A4_results.csv:row=183;CYP2C19_results.csv:row=183;CYP2D6_results.csv:row=183;CYP1A2_results.csv:row=183;CYP2C9_results.csv:row=183;hERG_results.csv:row=183;AMES_results.csv:row=183;PGP_results.csv:row=183;PAMPA_results.csv:row=183;BBB_results.csv:row=183;Solubility_results.csv:row=183;Lipophilicity_results.csv:row=184
CHEMBL1200592,DESOXYCORTICOSTERONE PIVALATE,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -5.29; logP 5.29,repurposing_candidates.csv:rc_row=129;CYP3A4_results.csv:row=128;CYP2C19_results.csv:row=128;CYP2D6_results.csv:row=128;CYP1A2_results.csv:row=128;CYP2C9_results.csv:row=128;hERG_results.csv:row=128;AMES_results.csv:row=128;PGP_results.csv:row=128;PAMPA_results.csv:row=128;BBB_results.csv:row=128;Solubility_results.csv:row=128;Lipophilicity_results.csv:row=128
CHEMBL2364626,RALIMETINIB,CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21,18.333333333333332,10,85.0,32.08333333333333,L,KG-supported from 1 sources; logS -5.86; logP 5.55,repurposing_candidates.csv:rc_row=841;CYP3A4_results.csv:row=750;CYP2C19_results.csv:row=750;CYP2D6_results.csv:row=750;CYP1A2_results.csv:row=750;CYP2C9_results.csv:row=750;hERG_results.csv:row=750;AMES_results.csv:row=750;PGP_results.csv:row=750;PAMPA_results.csv:row=750;BBB_results.csv:row=750;Solubility_results.csv:row=750;Lipophilicity_results.csv:row=751
CHEMBL103667,DORAMAPIMOD,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,18.333333333333332,10,80.0,30.833333333333332,L,KG-supported from 1 sources; logS -7.24; logP 5.99,repurposing_candidates.csv:rc_row=13;CYP3A4_results.csv:row=13;CYP2C19_results.csv:row=13;CYP2D6_results.csv:row=13;CYP1A2_results.csv:row=13;CYP2C9_results.csv:row=13;hERG_results.csv:row=13;AMES_results.csv:row=13;PGP_results.csv:row=13;PAMPA_results.csv:row=13;BBB_results.csv:row=13;Solubility_results.csv:row=13;Lipophilicity_results.csv:row=13
CHEMBL222559,TIPRANAVIR,CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,18.333333333333332,10,80.0,30.833333333333332,L,KG-supported from 1 sources; logS -7.23; logP 7.33,repurposing_candidates.csv:rc_row=816;CYP3A4_results.csv:row=725;CYP2C19_results.csv:row=725;CYP2D6_results.csv:row=725;CYP1A2_results.csv:row=725;CYP2C9_results.csv:row=725;hERG_results.csv:row=725;AMES_results.csv:row=725;PGP_results.csv:row=725;PAMPA_results.csv:row=725;BBB_results.csv:row=725;Solubility_results.csv:row=725;Lipophilicity_results.csv:row=726
CHEMBL4303403,LOREDIPLON,CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F,23.333333333333332,10,70.0,30.333333333333336,L,KG-supported from 1 sources; hERG risk; logS -1.69; logP 3.81,repurposing_candidates.csv:rc_row=1252;CYP3A4_results.csv:row=1072;CYP2C19_results.csv:row=1072;CYP2D6_results.csv:row=1072;CYP1A2_results.csv:row=1072;CYP2C9_results.csv:row=1072;hERG_results.csv:row=1072;AMES_results.csv:row=1072;PGP_results.csv:row=1072;PAMPA_results.csv:row=1072;BBB_results.csv:row=1072;Solubility_results.csv:row=1072;Lipophilicity_results.csv:row=1073
CHEMBL2105527,TETRAZEPAM,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,23.333333333333332,10,70.0,30.333333333333336,L,KG-supported from 1 sources; hERG risk; logS -4.00; logP 3.61,repurposing_candidates.csv:rc_row=690;CYP3A4_results.csv:row=635;CYP2C19_results.csv:row=635;CYP2D6_results.csv:row=635;CYP1A2_results.csv:row=635;CYP2C9_results.csv:row=635;hERG_results.csv:row=635;AMES_results.csv:row=635;PGP_results.csv:row=635;PAMPA_results.csv:row=635;BBB_results.csv:row=635;Solubility_results.csv:row=635;Lipophilicity_results.csv:row=636
CHEMBL931,HALOTHANE,FC(F)(F)C(Cl)Br,23.333333333333332,10,70.0,30.333333333333336,L,KG-supported from 1 sources; hERG risk; logS -1.95; logP 2.51,repurposing_candidates.csv:rc_row=1555;CYP3A4_results.csv:row=1361;CYP2C19_results.csv:row=1361;CYP2D6_results.csv:row=1361;CYP1A2_results.csv:row=1361;CYP2C9_results.csv:row=1361;hERG_results.csv:row=1361;AMES_results.csv:row=1361;PGP_results.csv:row=1361;PAMPA_results.csv:row=1361;BBB_results.csv:row=1361;Solubility_results.csv:row=1361;Lipophilicity_results.csv:row=1362
CHEMBL4650336,EMVODODSTAT,COc1ccc([C@H]2c3[nH]c4ccc(Cl)cc4c3CCN2C(=O)Oc2ccc(Cl)cc2)cc1,18.333333333333332,10,75.0,29.583333333333332,L,KG-supported from 1 sources; logS -6.55; logP 6.63,repurposing_candidates.csv:rc_row=1311;CYP3A4_results.csv:row=1125;CYP2C19_results.csv:row=1125;CYP2D6_results.csv:row=1125;CYP1A2_results.csv:row=1125;CYP2C9_results.csv:row=1125;hERG_results.csv:row=1125;AMES_results.csv:row=1125;PGP_results.csv:row=1125;PAMPA_results.csv:row=1125;BBB_results.csv:row=1125;Solubility_results.csv:row=1125;Lipophilicity_results.csv:row=1126
CHEMBL2356023,DIHYDROTACHYSTEROL,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C,18.333333333333332,10,75.0,29.583333333333332,L,KG-supported from 1 sources; logS -6.01; logP 7.72,repurposing_candidates.csv:rc_row=830;CYP3A4_results.csv:row=739;CYP2C19_results.csv:row=739;CYP2D6_results.csv:row=739;CYP1A2_results.csv:row=739;CYP2C9_results.csv:row=739;hERG_results.csv:row=739;AMES_results.csv:row=739;PGP_results.csv:row=739;PAMPA_results.csv:row=739;BBB_results.csv:row=739;Solubility_results.csv:row=739;Lipophilicity_results.csv:row=740
CHEMBL38434,BREQUINAR,Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,18.333333333333332,10,75.0,29.583333333333332,L,KG-supported from 1 sources; logS -6.21; logP 5.85,repurposing_candidates.csv:rc_row=1050;CYP3A4_results.csv:row=919;CYP2C19_results.csv:row=919;CYP2D6_results.csv:row=919;CYP1A2_results.csv:row=919;CYP2C9_results.csv:row=919;hERG_results.csv:row=919;AMES_results.csv:row=919;PGP_results.csv:row=919;PAMPA_results.csv:row=919;BBB_results.csv:row=919;Solubility_results.csv:row=919;Lipophilicity_results.csv:row=920
CHEMBL3991932,PEXMETINIB,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,18.333333333333332,10,75.0,29.583333333333332,L,KG-supported from 1 sources; logS -6.31; logP 6.07,repurposing_candidates.csv:rc_row=1115;CYP3A4_results.csv:row=979;CYP2C19_results.csv:row=979;CYP2D6_results.csv:row=979;CYP1A2_results.csv:row=979;CYP2C9_results.csv:row=979;hERG_results.csv:row=979;AMES_results.csv:row=979;PGP_results.csv:row=979;PAMPA_results.csv:row=979;BBB_results.csv:row=979;Solubility_results.csv:row=979;Lipophilicity_results.csv:row=980
CHEMBL1200419,MOLINDONE HYDROCHLORIDE,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -0.84; logP 2.38,repurposing_candidates.csv:rc_row=98;CYP3A4_results.csv:row=97;CYP2C19_results.csv:row=97;CYP2D6_results.csv:row=97;CYP1A2_results.csv:row=97;CYP2C9_results.csv:row=97;hERG_results.csv:row=97;AMES_results.csv:row=97;PGP_results.csv:row=97;PAMPA_results.csv:row=97;BBB_results.csv:row=97;Solubility_results.csv:row=97;Lipophilicity_results.csv:row=97
CHEMBL4076467,ABT-072,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -6.00; logP 3.37,repurposing_candidates.csv:rc_row=1126;CYP3A4_results.csv:row=990;CYP2C19_results.csv:row=990;CYP2D6_results.csv:row=990;CYP1A2_results.csv:row=990;CYP2C9_results.csv:row=990;hERG_results.csv:row=990;AMES_results.csv:row=990;PGP_results.csv:row=990;PAMPA_results.csv:row=990;BBB_results.csv:row=990;Solubility_results.csv:row=990;Lipophilicity_results.csv:row=991
CHEMBL130,CHLORAMPHENICOL,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.18; logP 0.91,repurposing_candidates.csv:rc_row=378;CYP3A4_results.csv:row=339;CYP2C19_results.csv:row=339;CYP2D6_results.csv:row=339;CYP1A2_results.csv:row=339;CYP2C9_results.csv:row=339;hERG_results.csv:row=339;AMES_results.csv:row=339;PGP_results.csv:row=339;PAMPA_results.csv:row=339;BBB_results.csv:row=339;Solubility_results.csv:row=339;Lipophilicity_results.csv:row=340
CHEMBL2104991,VABICASERIN HYDROCHLORIDE,Cl.c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.09; logP 2.92,repurposing_candidates.csv:rc_row=684;CYP3A4_results.csv:row=629;CYP2C19_results.csv:row=629;CYP2D6_results.csv:row=629;CYP1A2_results.csv:row=629;CYP2C9_results.csv:row=629;hERG_results.csv:row=629;AMES_results.csv:row=629;PGP_results.csv:row=629;PAMPA_results.csv:row=629;BBB_results.csv:row=629;Solubility_results.csv:row=629;Lipophilicity_results.csv:row=630
CHEMBL5314394,SB-773812,COc1cc2c(cc1S(=O)(=O)c1ccc(OCc3ccc(Cl)cc3)cc1)CCN(C)CC2,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.07; logP 4.79,repurposing_candidates.csv:rc_row=1382;CYP3A4_results.csv:row=1193;CYP2C19_results.csv:row=1193;CYP2D6_results.csv:row=1193;CYP1A2_results.csv:row=1193;CYP2C9_results.csv:row=1193;hERG_results.csv:row=1193;AMES_results.csv:row=1193;PGP_results.csv:row=1193;PAMPA_results.csv:row=1193;BBB_results.csv:row=1193;Solubility_results.csv:row=1193;Lipophilicity_results.csv:row=1194
CHEMBL189475,LADARIXIN,C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.86; logP 1.09,repurposing_candidates.csv:rc_row=589;CYP3A4_results.csv:row=535;CYP2C19_results.csv:row=535;CYP2D6_results.csv:row=535;CYP1A2_results.csv:row=535;CYP2C9_results.csv:row=535;hERG_results.csv:row=535;AMES_results.csv:row=535;PGP_results.csv:row=535;PAMPA_results.csv:row=535;BBB_results.csv:row=535;Solubility_results.csv:row=535;Lipophilicity_results.csv:row=536
CHEMBL1770248,ERTUGLIFLOZIN,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.47; logP 1.36,repurposing_candidates.csv:rc_row=566;CYP3A4_results.csv:row=512;CYP2C19_results.csv:row=512;CYP2D6_results.csv:row=512;CYP1A2_results.csv:row=512;CYP2C9_results.csv:row=512;hERG_results.csv:row=512;AMES_results.csv:row=512;PGP_results.csv:row=512;PAMPA_results.csv:row=512;BBB_results.csv:row=512;Solubility_results.csv:row=512;Lipophilicity_results.csv:row=513
CHEMBL2358147,CARPHENAZINE MALEATE,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.85; logP 3.31,repurposing_candidates.csv:rc_row=831;CYP3A4_results.csv:row=740;CYP2C19_results.csv:row=740;CYP2D6_results.csv:row=740;CYP1A2_results.csv:row=740;CYP2C9_results.csv:row=740;hERG_results.csv:row=740;AMES_results.csv:row=740;PGP_results.csv:row=740;PAMPA_results.csv:row=740;BBB_results.csv:row=740;Solubility_results.csv:row=740;Lipophilicity_results.csv:row=741
CHEMBL1375743,ZIPRASIDONE HYDROCHLORIDE,Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.24; logP 3.41,repurposing_candidates.csv:rc_row=398;CYP3A4_results.csv:row=358;CYP2C19_results.csv:row=358;CYP2D6_results.csv:row=358;CYP1A2_results.csv:row=358;CYP2C9_results.csv:row=358;hERG_results.csv:row=358;AMES_results.csv:row=358;PGP_results.csv:row=358;PAMPA_results.csv:row=358;BBB_results.csv:row=358;Solubility_results.csv:row=358;Lipophilicity_results.csv:row=359
CHEMBL116,AMPRENAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.35; logP 2.40,repurposing_candidates.csv:rc_row=65;CYP3A4_results.csv:row=64;CYP2C19_results.csv:row=64;CYP2D6_results.csv:row=64;CYP1A2_results.csv:row=64;CYP2C9_results.csv:row=64;hERG_results.csv:row=64;AMES_results.csv:row=64;PGP_results.csv:row=64;PAMPA_results.csv:row=64;BBB_results.csv:row=64;Solubility_results.csv:row=64;Lipophilicity_results.csv:row=64
CHEMBL529,AZITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -0.40; logP 1.90,repurposing_candidates.csv:rc_row=1375;CYP3A4_results.csv:row=1186;CYP2C19_results.csv:row=1186;CYP2D6_results.csv:row=1186;CYP1A2_results.csv:row=1186;CYP2C9_results.csv:row=1186;hERG_results.csv:row=1186;AMES_results.csv:row=1186;PGP_results.csv:row=1186;PAMPA_results.csv:row=1186;BBB_results.csv:row=1186;Solubility_results.csv:row=1186;Lipophilicity_results.csv:row=1187
CHEMBL1323,DARUNAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.13; logP 2.38,repurposing_candidates.csv:rc_row=382;CYP3A4_results.csv:row=343;CYP2C19_results.csv:row=343;CYP2D6_results.csv:row=343;CYP1A2_results.csv:row=343;CYP2C9_results.csv:row=343;hERG_results.csv:row=343;AMES_results.csv:row=343;PGP_results.csv:row=343;PAMPA_results.csv:row=343;BBB_results.csv:row=343;Solubility_results.csv:row=343;Lipophilicity_results.csv:row=344
CHEMBL1088750,ARRY-797,CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.77; logP 4.05,repurposing_candidates.csv:rc_row=33;CYP3A4_results.csv:row=33;CYP2C19_results.csv:row=33;CYP2D6_results.csv:row=33;CYP1A2_results.csv:row=33;CYP2C9_results.csv:row=33;hERG_results.csv:row=33;AMES_results.csv:row=33;PGP_results.csv:row=33;PAMPA_results.csv:row=33;BBB_results.csv:row=33;Solubility_results.csv:row=33;Lipophilicity_results.csv:row=33
CHEMBL3544974,ASENAPINE MALEATE,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.07; logP 3.97,repurposing_candidates.csv:rc_row=960;CYP3A4_results.csv:row=862;CYP2C19_results.csv:row=862;CYP2D6_results.csv:row=862;CYP1A2_results.csv:row=862;CYP2C9_results.csv:row=862;hERG_results.csv:row=862;AMES_results.csv:row=862;PGP_results.csv:row=862;PAMPA_results.csv:row=862;BBB_results.csv:row=862;Solubility_results.csv:row=862;Lipophilicity_results.csv:row=863
CHEMBL85,RISPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.29; logP 3.59,repurposing_candidates.csv:rc_row=1535;CYP3A4_results.csv:row=1341;CYP2C19_results.csv:row=1341;CYP2D6_results.csv:row=1341;CYP1A2_results.csv:row=1341;CYP2C9_results.csv:row=1341;hERG_results.csv:row=1341;AMES_results.csv:row=1341;PGP_results.csv:row=1341;PAMPA_results.csv:row=1341;BBB_results.csv:row=1341;Solubility_results.csv:row=1341;Lipophilicity_results.csv:row=1342
CHEMBL1200531,ALFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.01; logP 1.81,repurposing_candidates.csv:rc_row=118;CYP3A4_results.csv:row=117;CYP2C19_results.csv:row=117;CYP2D6_results.csv:row=117;CYP1A2_results.csv:row=117;CYP2C9_results.csv:row=117;hERG_results.csv:row=117;AMES_results.csv:row=117;PGP_results.csv:row=117;PAMPA_results.csv:row=117;BBB_results.csv:row=117;Solubility_results.csv:row=117;Lipophilicity_results.csv:row=117
CHEMBL2107779,SEMAPIMOD,C/C(=N\NC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(/C(C)=N/NC(=N)N)cc(/C(C)=N/NC(=N)N)c2)cc(/C(C)=N/NC(=N)N)c1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.23; logP 2.21,repurposing_candidates.csv:rc_row=736;CYP3A4_results.csv:row=681;CYP2C19_results.csv:row=681;CYP2D6_results.csv:row=681;CYP1A2_results.csv:row=681;CYP2C9_results.csv:row=681;hERG_results.csv:row=681;AMES_results.csv:row=681;PGP_results.csv:row=681;PAMPA_results.csv:row=681;BBB_results.csv:row=681;Solubility_results.csv:row=681;Lipophilicity_results.csv:row=682
CHEMBL1200635,HYDROCORTAMATE HYDROCHLORIDE,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C.Cl,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.88; logP 3.10,repurposing_candidates.csv:rc_row=139;CYP3A4_results.csv:row=138;CYP2C19_results.csv:row=138;CYP2D6_results.csv:row=138;CYP1A2_results.csv:row=138;CYP2C9_results.csv:row=138;hERG_results.csv:row=138;AMES_results.csv:row=138;PGP_results.csv:row=138;PAMPA_results.csv:row=138;BBB_results.csv:row=138;Solubility_results.csv:row=138;Lipophilicity_results.csv:row=138
CHEMBL585902,AMG-548,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.16; logP 4.64,repurposing_candidates.csv:rc_row=1429;CYP3A4_results.csv:row=1238;CYP2C19_results.csv:row=1238;CYP2D6_results.csv:row=1238;CYP1A2_results.csv:row=1238;CYP2C9_results.csv:row=1238;hERG_results.csv:row=1238;AMES_results.csv:row=1238;PGP_results.csv:row=1238;PAMPA_results.csv:row=1238;BBB_results.csv:row=1238;Solubility_results.csv:row=1238;Lipophilicity_results.csv:row=1239
CHEMBL1621,PALIPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.39; logP 3.08,repurposing_candidates.csv:rc_row=482;CYP3A4_results.csv:row=442;CYP2C19_results.csv:row=442;CYP2D6_results.csv:row=442;CYP1A2_results.csv:row=442;CYP2C9_results.csv:row=442;hERG_results.csv:row=442;AMES_results.csv:row=442;PGP_results.csv:row=442;PAMPA_results.csv:row=442;BBB_results.csv:row=442;Solubility_results.csv:row=442;Lipophilicity_results.csv:row=443
CHEMBL1200937,DALFOPRISTIN,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.44; logP 2.27,repurposing_candidates.csv:rc_row=196;CYP3A4_results.csv:row=194;CYP2C19_results.csv:row=194;CYP2D6_results.csv:row=194;CYP1A2_results.csv:row=194;CYP2C9_results.csv:row=194;hERG_results.csv:row=194;AMES_results.csv:row=194;PGP_results.csv:row=194;PAMPA_results.csv:row=194;BBB_results.csv:row=194;Solubility_results.csv:row=194;Lipophilicity_results.csv:row=195
CHEMBL2035185,CT-1578,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.69; logP 4.56,repurposing_candidates.csv:rc_row=629;CYP3A4_results.csv:row=575;CYP2C19_results.csv:row=575;CYP2D6_results.csv:row=575;CYP1A2_results.csv:row=575;CYP2C9_results.csv:row=575;hERG_results.csv:row=575;AMES_results.csv:row=575;PGP_results.csv:row=575;PAMPA_results.csv:row=575;BBB_results.csv:row=575;Solubility_results.csv:row=575;Lipophilicity_results.csv:row=576
CHEMBL566534,ARTEMETHER,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.40; logP 2.84,repurposing_candidates.csv:rc_row=1415;CYP3A4_results.csv:row=1224;CYP2C19_results.csv:row=1224;CYP2D6_results.csv:row=1224;CYP1A2_results.csv:row=1224;CYP2C9_results.csv:row=1224;hERG_results.csv:row=1224;AMES_results.csv:row=1224;PGP_results.csv:row=1224;PAMPA_results.csv:row=1224;BBB_results.csv:row=1224;Solubility_results.csv:row=1224;Lipophilicity_results.csv:row=1225
CHEMBL1200774,FLUPREDNISOLONE,C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.80; logP 1.51,repurposing_candidates.csv:rc_row=164;CYP3A4_results.csv:row=162;CYP2C19_results.csv:row=162;CYP2D6_results.csv:row=162;CYP1A2_results.csv:row=162;CYP2C9_results.csv:row=162;hERG_results.csv:row=162;AMES_results.csv:row=162;PGP_results.csv:row=162;PAMPA_results.csv:row=162;BBB_results.csv:row=162;Solubility_results.csv:row=162;Lipophilicity_results.csv:row=163
CHEMBL3989833,ZIPRASIDONE MESYLATE,CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.45; logP 0.84,repurposing_candidates.csv:rc_row=1093;CYP3A4_results.csv:row=962;CYP2C19_results.csv:row=962;CYP2D6_results.csv:row=962;CYP1A2_results.csv:row=962;CYP2C9_results.csv:row=962;hERG_results.csv:row=962;AMES_results.csv:row=962;PGP_results.csv:row=962;PAMPA_results.csv:row=962;BBB_results.csv:row=962;Solubility_results.csv:row=962;Lipophilicity_results.csv:row=963
CHEMBL1257,ENFLURANE,FC(F)OC(F)(F)C(F)Cl,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -1.70; logP 2.35,repurposing_candidates.csv:rc_row=358;CYP3A4_results.csv:row=320;CYP2C19_results.csv:row=320;CYP2D6_results.csv:row=320;CYP1A2_results.csv:row=320;CYP2C9_results.csv:row=320;hERG_results.csv:row=320;AMES_results.csv:row=320;PGP_results.csv:row=320;PAMPA_results.csv:row=320;BBB_results.csv:row=320;Solubility_results.csv:row=320;Lipophilicity_results.csv:row=321
CHEMBL14376,ILOPERIDONE,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.82; logP 4.83,repurposing_candidates.csv:rc_row=416;CYP3A4_results.csv:row=376;CYP2C19_results.csv:row=376;CYP2D6_results.csv:row=376;CYP1A2_results.csv:row=376;CYP2C9_results.csv:row=376;hERG_results.csv:row=376;AMES_results.csv:row=376;PGP_results.csv:row=376;PAMPA_results.csv:row=376;BBB_results.csv:row=376;Solubility_results.csv:row=376;Lipophilicity_results.csv:row=377
CHEMBL1201127,DARUNAVIR ETHANOLATE,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CCO,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.24; logP 2.37,repurposing_candidates.csv:rc_row=239;CYP3A4_results.csv:row=236;CYP2C19_results.csv:row=236;CYP2D6_results.csv:row=236;CYP1A2_results.csv:row=236;CYP2C9_results.csv:row=236;hERG_results.csv:row=236;AMES_results.csv:row=236;PGP_results.csv:row=236;PAMPA_results.csv:row=236;BBB_results.csv:row=236;Solubility_results.csv:row=236;Lipophilicity_results.csv:row=237
CHEMBL1200678,ATAZANAVIR SULFATE,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C.O=S(=O)(O)O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -0.79; logP 3.56,repurposing_candidates.csv:rc_row=148;CYP3A4_results.csv:row=147;CYP2C19_results.csv:row=147;CYP2D6_results.csv:row=147;CYP1A2_results.csv:row=147;CYP2C9_results.csv:row=147;hERG_results.csv:row=147;AMES_results.csv:row=147;PGP_results.csv:row=147;PAMPA_results.csv:row=147;BBB_results.csv:row=147;Solubility_results.csv:row=147;Lipophilicity_results.csv:row=147
CHEMBL1090089,PAMAPIMOD,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.10; logP 1.94,repurposing_candidates.csv:rc_row=37;CYP3A4_results.csv:row=37;CYP2C19_results.csv:row=37;CYP2D6_results.csv:row=37;CYP1A2_results.csv:row=37;CYP2C9_results.csv:row=37;hERG_results.csv:row=37;AMES_results.csv:row=37;PGP_results.csv:row=37;PAMPA_results.csv:row=37;BBB_results.csv:row=37;Solubility_results.csv:row=37;Lipophilicity_results.csv:row=37
CHEMBL729,LOPINAVIR,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.34; logP 4.33,repurposing_candidates.csv:rc_row=1500;CYP3A4_results.csv:row=1306;CYP2C19_results.csv:row=1306;CYP2D6_results.csv:row=1306;CYP1A2_results.csv:row=1306;CYP2C9_results.csv:row=1306;hERG_results.csv:row=1306;AMES_results.csv:row=1306;PGP_results.csv:row=1306;PAMPA_results.csv:row=1306;BBB_results.csv:row=1306;Solubility_results.csv:row=1306;Lipophilicity_results.csv:row=1307
CHEMBL1230065,BMS-582949,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,18.333333333333332,10,70.0,28.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.12; logP 3.12,repurposing_candidates.csv:rc_row=337;CYP3A4_results.csv:row=300;CYP2C19_results.csv:row=300;CYP2D6_results.csv:row=300;CYP1A2_results.csv:row=300;CYP2C9_results.csv:row=300;hERG_results.csv:row=300;AMES_results.csv:row=300;PGP_results.csv:row=300;PAMPA_results.csv:row=300;BBB_results.csv:row=300;Solubility_results.csv:row=300;Lipophilicity_results.csv:row=301
CHEMBL114,SAQUINAVIR,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.73; logP 3.09,repurposing_candidates.csv:rc_row=61;CYP3A4_results.csv:row=60;CYP2C19_results.csv:row=60;CYP2D6_results.csv:row=60;CYP1A2_results.csv:row=60;CYP2C9_results.csv:row=60;hERG_results.csv:row=60;AMES_results.csv:row=60;PGP_results.csv:row=60;PAMPA_results.csv:row=60;BBB_results.csv:row=60;Solubility_results.csv:row=60;Lipophilicity_results.csv:row=60
CHEMBL1108,DROPERIDOL,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.92; logP 3.68,repurposing_candidates.csv:rc_row=51;CYP3A4_results.csv:row=51;CYP2C19_results.csv:row=51;CYP2D6_results.csv:row=51;CYP1A2_results.csv:row=51;CYP2C9_results.csv:row=51;hERG_results.csv:row=51;AMES_results.csv:row=51;PGP_results.csv:row=51;PAMPA_results.csv:row=51;BBB_results.csv:row=51;Solubility_results.csv:row=51;Lipophilicity_results.csv:row=51
CHEMBL1215661,PRUVANSERIN,N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.41; logP 3.18,repurposing_candidates.csv:rc_row=334;CYP3A4_results.csv:row=297;CYP2C19_results.csv:row=297;CYP2D6_results.csv:row=297;CYP1A2_results.csv:row=297;CYP2C9_results.csv:row=297;hERG_results.csv:row=297;AMES_results.csv:row=297;PGP_results.csv:row=297;PAMPA_results.csv:row=297;BBB_results.csv:row=297;Solubility_results.csv:row=297;Lipophilicity_results.csv:row=298
CHEMBL1615372,LURASIDONE HYDROCHLORIDE,Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.44; logP 4.68,repurposing_candidates.csv:rc_row=478;CYP3A4_results.csv:row=438;CYP2C19_results.csv:row=438;CYP2D6_results.csv:row=438;CYP1A2_results.csv:row=438;CYP2C9_results.csv:row=438;hERG_results.csv:row=438;AMES_results.csv:row=438;PGP_results.csv:row=438;PAMPA_results.csv:row=438;BBB_results.csv:row=438;Solubility_results.csv:row=438;Lipophilicity_results.csv:row=439
CHEMBL58510,CHLOROQUINE PHOSPHATE,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O.O=P(O)(O)O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.59; logP 2.95,repurposing_candidates.csv:rc_row=1428;CYP3A4_results.csv:row=1237;CYP2C19_results.csv:row=1237;CYP2D6_results.csv:row=1237;CYP1A2_results.csv:row=1237;CYP2C9_results.csv:row=1237;hERG_results.csv:row=1237;AMES_results.csv:row=1237;PGP_results.csv:row=1237;PAMPA_results.csv:row=1237;BBB_results.csv:row=1237;Solubility_results.csv:row=1237;Lipophilicity_results.csv:row=1238
CHEMBL1112,ARIPIPRAZOLE,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.73; logP 4.86,repurposing_candidates.csv:rc_row=53;CYP3A4_results.csv:row=53;CYP2C19_results.csv:row=53;CYP2D6_results.csv:row=53;CYP1A2_results.csv:row=53;CYP2C9_results.csv:row=53;hERG_results.csv:row=53;AMES_results.csv:row=53;PGP_results.csv:row=53;PAMPA_results.csv:row=53;BBB_results.csv:row=53;Solubility_results.csv:row=53;Lipophilicity_results.csv:row=53
CHEMBL1200588,CLINDAMYCIN HYDROCHLORIDE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1.Cl,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -0.95; logP 0.81,repurposing_candidates.csv:rc_row=128;CYP3A4_results.csv:row=127;CYP2C19_results.csv:row=127;CYP2D6_results.csv:row=127;CYP1A2_results.csv:row=127;CYP2C9_results.csv:row=127;hERG_results.csv:row=127;AMES_results.csv:row=127;PGP_results.csv:row=127;PAMPA_results.csv:row=127;BBB_results.csv:row=127;Solubility_results.csv:row=127;Lipophilicity_results.csv:row=127
CHEMBL42,CLOZAPINE,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.44; logP 3.72,repurposing_candidates.csv:rc_row=1142;CYP3A4_results.csv:row=1006;CYP2C19_results.csv:row=1006;CYP2D6_results.csv:row=1006;CYP1A2_results.csv:row=1006;CYP2C9_results.csv:row=1006;hERG_results.csv:row=1006;AMES_results.csv:row=1006;PGP_results.csv:row=1006;PAMPA_results.csv:row=1006;BBB_results.csv:row=1006;Solubility_results.csv:row=1006;Lipophilicity_results.csv:row=1007
CHEMBL221722,FAVIPIRAVIR,NC(=O)c1nc(F)cnc1O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -1.19; logP -0.58,repurposing_candidates.csv:rc_row=806;CYP3A4_results.csv:row=715;CYP2C19_results.csv:row=715;CYP2D6_results.csv:row=715;CYP1A2_results.csv:row=715;CYP2C9_results.csv:row=715;hERG_results.csv:row=715;AMES_results.csv:row=715;PGP_results.csv:row=715;PAMPA_results.csv:row=715;BBB_results.csv:row=715;Solubility_results.csv:row=715;Lipophilicity_results.csv:row=716
CHEMBL4297147,HALOPERIDOL LACTATE,CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.11; logP 3.88,repurposing_candidates.csv:rc_row=1159;CYP3A4_results.csv:row=1023;CYP2C19_results.csv:row=1023;CYP2D6_results.csv:row=1023;CYP1A2_results.csv:row=1023;CYP2C9_results.csv:row=1023;hERG_results.csv:row=1023;AMES_results.csv:row=1023;PGP_results.csv:row=1023;PAMPA_results.csv:row=1023;BBB_results.csv:row=1023;Solubility_results.csv:row=1023;Lipophilicity_results.csv:row=1024
CHEMBL1205,NELFINAVIR MESYLATE,CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -1.60; logP 4.25,repurposing_candidates.csv:rc_row=326;CYP3A4_results.csv:row=289;CYP2C19_results.csv:row=289;CYP2D6_results.csv:row=289;CYP1A2_results.csv:row=289;CYP2C9_results.csv:row=289;hERG_results.csv:row=289;AMES_results.csv:row=289;PGP_results.csv:row=289;PAMPA_results.csv:row=289;BBB_results.csv:row=289;Solubility_results.csv:row=289;Lipophilicity_results.csv:row=290
CHEMBL2359966,QUININE SULFATE,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.59; logP 4.04,repurposing_candidates.csv:rc_row=832;CYP3A4_results.csv:row=741;CYP2C19_results.csv:row=741;CYP2D6_results.csv:row=741;CYP1A2_results.csv:row=741;CYP2C9_results.csv:row=741;hERG_results.csv:row=741;AMES_results.csv:row=741;PGP_results.csv:row=741;PAMPA_results.csv:row=741;BBB_results.csv:row=741;Solubility_results.csv:row=741;Lipophilicity_results.csv:row=742
CHEMBL1090173,SD-0006,O=C(CO)N1CCC(c2n[nH]c(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.02; logP 2.89,repurposing_candidates.csv:rc_row=39;CYP3A4_results.csv:row=39;CYP2C19_results.csv:row=39;CYP2D6_results.csv:row=39;CYP1A2_results.csv:row=39;CYP2C9_results.csv:row=39;hERG_results.csv:row=39;AMES_results.csv:row=39;PGP_results.csv:row=39;PAMPA_results.csv:row=39;BBB_results.csv:row=39;Solubility_results.csv:row=39;Lipophilicity_results.csv:row=39
CHEMBL1201,THIOTHIXENE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.38; logP 3.47,repurposing_candidates.csv:rc_row=213;CYP3A4_results.csv:row=211;CYP2C19_results.csv:row=211;CYP2D6_results.csv:row=211;CYP1A2_results.csv:row=211;CYP2C9_results.csv:row=211;hERG_results.csv:row=211;AMES_results.csv:row=211;PGP_results.csv:row=211;PAMPA_results.csv:row=211;BBB_results.csv:row=211;Solubility_results.csv:row=211;Lipophilicity_results.csv:row=212
CHEMBL1201060,LOXAPINE HYDROCHLORIDE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.Cl,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.87; logP 4.19,repurposing_candidates.csv:rc_row=225;CYP3A4_results.csv:row=223;CYP2C19_results.csv:row=223;CYP2D6_results.csv:row=223;CYP1A2_results.csv:row=223;CYP2C9_results.csv:row=223;hERG_results.csv:row=223;AMES_results.csv:row=223;PGP_results.csv:row=223;PAMPA_results.csv:row=223;BBB_results.csv:row=223;Solubility_results.csv:row=223;Lipophilicity_results.csv:row=224
CHEMBL2105760,BREXPIPRAZOLE,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.40; logP 4.72,repurposing_candidates.csv:rc_row=711;CYP3A4_results.csv:row=656;CYP2C19_results.csv:row=656;CYP2D6_results.csv:row=656;CYP1A2_results.csv:row=656;CYP2C9_results.csv:row=656;hERG_results.csv:row=656;AMES_results.csv:row=656;PGP_results.csv:row=656;PAMPA_results.csv:row=656;BBB_results.csv:row=656;Solubility_results.csv:row=656;Lipophilicity_results.csv:row=657
CHEMBL1357648,AMODIAQUINE HYDROCHLORIDE,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl.Cl.O.O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.13; logP 4.37,repurposing_candidates.csv:rc_row=391;CYP3A4_results.csv:row=352;CYP2C19_results.csv:row=352;CYP2D6_results.csv:row=352;CYP1A2_results.csv:row=352;CYP2C9_results.csv:row=352;hERG_results.csv:row=352;AMES_results.csv:row=352;PGP_results.csv:row=352;PAMPA_results.csv:row=352;BBB_results.csv:row=352;Solubility_results.csv:row=352;Lipophilicity_results.csv:row=353
CHEMBL1200469,PROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccccc21.Cl,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.95; logP 4.66,repurposing_candidates.csv:rc_row=107;CYP3A4_results.csv:row=106;CYP2C19_results.csv:row=106;CYP2D6_results.csv:row=106;CYP1A2_results.csv:row=106;CYP2C9_results.csv:row=106;hERG_results.csv:row=106;AMES_results.csv:row=106;PGP_results.csv:row=106;PAMPA_results.csv:row=106;BBB_results.csv:row=106;Solubility_results.csv:row=106;Lipophilicity_results.csv:row=106
CHEMBL54,HALOPERIDOL,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.34; logP 4.43,repurposing_candidates.csv:rc_row=1402;CYP3A4_results.csv:row=1211;CYP2C19_results.csv:row=1211;CYP2D6_results.csv:row=1211;CYP1A2_results.csv:row=1211;CYP2C9_results.csv:row=1211;hERG_results.csv:row=1211;AMES_results.csv:row=1211;PGP_results.csv:row=1211;PAMPA_results.csv:row=1211;BBB_results.csv:row=1211;Solubility_results.csv:row=1211;Lipophilicity_results.csv:row=1212
CHEMBL282042,SAQUINAVIR MESYLATE,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -1.68; logP 2.60,repurposing_candidates.csv:rc_row=877;CYP3A4_results.csv:row=785;CYP2C19_results.csv:row=785;CYP2D6_results.csv:row=785;CYP1A2_results.csv:row=785;CYP2C9_results.csv:row=785;hERG_results.csv:row=785;AMES_results.csv:row=785;PGP_results.csv:row=785;PAMPA_results.csv:row=785;BBB_results.csv:row=785;Solubility_results.csv:row=785;Lipophilicity_results.csv:row=786
CHEMBL197194,VIDOFLUDIMUS,COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.87; logP 4.00,repurposing_candidates.csv:rc_row=615;CYP3A4_results.csv:row=561;CYP2C19_results.csv:row=561;CYP2D6_results.csv:row=561;CYP1A2_results.csv:row=561;CYP2C9_results.csv:row=561;hERG_results.csv:row=561;AMES_results.csv:row=561;PGP_results.csv:row=561;PAMPA_results.csv:row=561;BBB_results.csv:row=561;Solubility_results.csv:row=561;Lipophilicity_results.csv:row=562
CHEMBL831,LOXAPINE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.55; logP 3.77,repurposing_candidates.csv:rc_row=1528;CYP3A4_results.csv:row=1334;CYP2C19_results.csv:row=1334;CYP2D6_results.csv:row=1334;CYP1A2_results.csv:row=1334;CYP2C9_results.csv:row=1334;hERG_results.csv:row=1334;AMES_results.csv:row=1334;PGP_results.csv:row=1334;PAMPA_results.csv:row=1334;BBB_results.csv:row=1334;Solubility_results.csv:row=1334;Lipophilicity_results.csv:row=1335
CHEMBL74355,VOLINANSERIN,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.36; logP 3.83,repurposing_candidates.csv:rc_row=1505;CYP3A4_results.csv:row=1311;CYP2C19_results.csv:row=1311;CYP2D6_results.csv:row=1311;CYP1A2_results.csv:row=1311;CYP2C9_results.csv:row=1311;hERG_results.csv:row=1311;AMES_results.csv:row=1311;PGP_results.csv:row=1311;PAMPA_results.csv:row=1311;BBB_results.csv:row=1311;Solubility_results.csv:row=1311;Lipophilicity_results.csv:row=1312
CHEMBL3989824,THIOTHIXENE HYDROCHLORIDE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.19; logP 2.66,repurposing_candidates.csv:rc_row=1089;CYP3A4_results.csv:row=958;CYP2C19_results.csv:row=958;CYP2D6_results.csv:row=958;CYP1A2_results.csv:row=958;CYP2C9_results.csv:row=958;hERG_results.csv:row=958;AMES_results.csv:row=958;PGP_results.csv:row=958;PAMPA_results.csv:row=958;BBB_results.csv:row=958;Solubility_results.csv:row=958;Lipophilicity_results.csv:row=959
CHEMBL1764,LEVOMEPROMAZINE,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.67; logP 4.50,repurposing_candidates.csv:rc_row=562;CYP3A4_results.csv:row=508;CYP2C19_results.csv:row=508;CYP2D6_results.csv:row=508;CYP1A2_results.csv:row=508;CYP2C9_results.csv:row=508;hERG_results.csv:row=508;AMES_results.csv:row=508;PGP_results.csv:row=508;PAMPA_results.csv:row=508;BBB_results.csv:row=508;Solubility_results.csv:row=508;Lipophilicity_results.csv:row=509
CHEMBL1201120,REMIFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1.Cl,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -1.62; logP 2.42,repurposing_candidates.csv:rc_row=237;CYP3A4_results.csv:row=234;CYP2C19_results.csv:row=234;CYP2D6_results.csv:row=234;CYP1A2_results.csv:row=234;CYP2C9_results.csv:row=234;hERG_results.csv:row=234;AMES_results.csv:row=234;PGP_results.csv:row=234;PAMPA_results.csv:row=234;BBB_results.csv:row=234;Solubility_results.csv:row=234;Lipophilicity_results.csv:row=235
CHEMBL13376,CLOMETACIN,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,18.333333333333332,10,65.0,27.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.42; logP 3.93,repurposing_candidates.csv:rc_row=385;CYP3A4_results.csv:row=346;CYP2C19_results.csv:row=346;CYP2D6_results.csv:row=346;CYP1A2_results.csv:row=346;CYP2C9_results.csv:row=346;hERG_results.csv:row=346;AMES_results.csv:row=346;PGP_results.csv:row=346;PAMPA_results.csv:row=346;BBB_results.csv:row=346;Solubility_results.csv:row=346;Lipophilicity_results.csv:row=347
CHEMBL479,THIORIDAZINE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.64; logP 5.89,repurposing_candidates.csv:rc_row=1327;CYP3A4_results.csv:row=1138;CYP2C19_results.csv:row=1138;CYP2D6_results.csv:row=1138;CYP1A2_results.csv:row=1138;CYP2C9_results.csv:row=1138;hERG_results.csv:row=1138;AMES_results.csv:row=1138;PGP_results.csv:row=1138;PAMPA_results.csv:row=1138;BBB_results.csv:row=1138;Solubility_results.csv:row=1138;Lipophilicity_results.csv:row=1139
CHEMBL515966,EZLOPITANT,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.57; logP 6.20,repurposing_candidates.csv:rc_row=1364;CYP3A4_results.csv:row=1175;CYP2C19_results.csv:row=1175;CYP2D6_results.csv:row=1175;CYP1A2_results.csv:row=1175;CYP2C9_results.csv:row=1175;hERG_results.csv:row=1175;AMES_results.csv:row=1175;PGP_results.csv:row=1175;PAMPA_results.csv:row=1175;BBB_results.csv:row=1175;Solubility_results.csv:row=1175;Lipophilicity_results.csv:row=1176
CHEMBL1200599,DIFENOXIN HYDROCHLORIDE,Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.08; logP 5.43,repurposing_candidates.csv:rc_row=131;CYP3A4_results.csv:row=130;CYP2C19_results.csv:row=130;CYP2D6_results.csv:row=130;CYP1A2_results.csv:row=130;CYP2C9_results.csv:row=130;hERG_results.csv:row=130;AMES_results.csv:row=130;PGP_results.csv:row=130;PAMPA_results.csv:row=130;BBB_results.csv:row=130;Solubility_results.csv:row=130;Lipophilicity_results.csv:row=130
CHEMBL1200817,LEVOMETHADYL ACETATE HYDROCHLORIDE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1.Cl,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.21; logP 5.08,repurposing_candidates.csv:rc_row=177;CYP3A4_results.csv:row=175;CYP2C19_results.csv:row=175;CYP2D6_results.csv:row=175;CYP1A2_results.csv:row=175;CYP2C9_results.csv:row=175;hERG_results.csv:row=175;AMES_results.csv:row=175;PGP_results.csv:row=175;PAMPA_results.csv:row=175;BBB_results.csv:row=175;Solubility_results.csv:row=175;Lipophilicity_results.csv:row=176
CHEMBL1956285,DSM-265,Cc1cc(Nc2ccc(S(F)(F)(F)(F)F)cc2)n2nc(C(C)(F)F)nc2n1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.64; logP 5.95,repurposing_candidates.csv:rc_row=612;CYP3A4_results.csv:row=558;CYP2C19_results.csv:row=558;CYP2D6_results.csv:row=558;CYP1A2_results.csv:row=558;CYP2C9_results.csv:row=558;hERG_results.csv:row=558;AMES_results.csv:row=558;PGP_results.csv:row=558;PAMPA_results.csv:row=558;BBB_results.csv:row=558;Solubility_results.csv:row=558;Lipophilicity_results.csv:row=559
CHEMBL9960,AZD-7624,CC[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.83; logP 5.78,repurposing_candidates.csv:rc_row=1581;CYP3A4_results.csv:row=1387;CYP2C19_results.csv:row=1387;CYP2D6_results.csv:row=1387;CYP1A2_results.csv:row=1387;CYP2C9_results.csv:row=1387;hERG_results.csv:row=1387;AMES_results.csv:row=1387;PGP_results.csv:row=1387;PAMPA_results.csv:row=1387;BBB_results.csv:row=1387;Solubility_results.csv:row=1387;Lipophilicity_results.csv:row=1388
CHEMBL3989694,OLANZAPINE PAMOATE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.92; logP 7.01,repurposing_candidates.csv:rc_row=1081;CYP3A4_results.csv:row=950;CYP2C19_results.csv:row=950;CYP2D6_results.csv:row=950;CYP1A2_results.csv:row=950;CYP2C9_results.csv:row=950;hERG_results.csv:row=950;AMES_results.csv:row=950;PGP_results.csv:row=950;PAMPA_results.csv:row=950;BBB_results.csv:row=950;Solubility_results.csv:row=950;Lipophilicity_results.csv:row=951
CHEMBL3544947,BURAPITANT,CC(C)(C(N)=O)C1CCN(CCC2(c3ccc(Cl)c(Cl)c3)CN(C(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CCO2)CC1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.44; logP 6.94,repurposing_candidates.csv:rc_row=958;CYP3A4_results.csv:row=861;CYP2C19_results.csv:row=861;CYP2D6_results.csv:row=861;CYP1A2_results.csv:row=861;CYP2C9_results.csv:row=861;hERG_results.csv:row=861;AMES_results.csv:row=861;PGP_results.csv:row=861;PAMPA_results.csv:row=861;BBB_results.csv:row=861;Solubility_results.csv:row=861;Lipophilicity_results.csv:row=862
CHEMBL1200916,THIORIDAZINE HYDROCHLORIDE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.Cl,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.94; logP 6.31,repurposing_candidates.csv:rc_row=194;CYP3A4_results.csv:row=192;CYP2C19_results.csv:row=192;CYP2D6_results.csv:row=192;CYP1A2_results.csv:row=192;CYP2C9_results.csv:row=192;hERG_results.csv:row=192;AMES_results.csv:row=192;PGP_results.csv:row=192;PAMPA_results.csv:row=192;BBB_results.csv:row=192;Solubility_results.csv:row=192;Lipophilicity_results.csv:row=193
CHEMBL2043025,TMC-647055,COc1ccc2c(c1)C=C1Cn3c-2c(C2CCCCC2)c2ccc(cc23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -6.58; logP 4.16,repurposing_candidates.csv:rc_row=633;CYP3A4_results.csv:row=579;CYP2C19_results.csv:row=579;CYP2D6_results.csv:row=579;CYP1A2_results.csv:row=579;CYP2C9_results.csv:row=579;hERG_results.csv:row=579;AMES_results.csv:row=579;PGP_results.csv:row=579;PAMPA_results.csv:row=579;BBB_results.csv:row=579;Solubility_results.csv:row=579;Lipophilicity_results.csv:row=580
CHEMBL1201052,MESORIDAZINE BESYLATE,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.61; logP 5.83,repurposing_candidates.csv:rc_row=224;CYP3A4_results.csv:row=222;CYP2C19_results.csv:row=222;CYP2D6_results.csv:row=222;CYP1A2_results.csv:row=222;CYP2C9_results.csv:row=222;hERG_results.csv:row=222;AMES_results.csv:row=222;PGP_results.csv:row=222;PAMPA_results.csv:row=222;BBB_results.csv:row=222;Solubility_results.csv:row=222;Lipophilicity_results.csv:row=223
CHEMBL277535,BIFONAZOLE,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.87; logP 5.19,repurposing_candidates.csv:rc_row=873;CYP3A4_results.csv:row=781;CYP2C19_results.csv:row=781;CYP2D6_results.csv:row=781;CYP1A2_results.csv:row=781;CYP2C9_results.csv:row=781;hERG_results.csv:row=781;AMES_results.csv:row=781;PGP_results.csv:row=781;PAMPA_results.csv:row=781;BBB_results.csv:row=781;Solubility_results.csv:row=781;Lipophilicity_results.csv:row=782
CHEMBL2104992,VESTIPITANT MESYLATE,CS(=O)(=O)O.Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,60.0,25.833333333333332,L,KG-supported from 1 sources; hERG risk; logS -0.99; logP 5.44,repurposing_candidates.csv:rc_row=685;CYP3A4_results.csv:row=630;CYP2C19_results.csv:row=630;CYP2D6_results.csv:row=630;CYP1A2_results.csv:row=630;CYP2C9_results.csv:row=630;hERG_results.csv:row=630;AMES_results.csv:row=630;PGP_results.csv:row=630;PAMPA_results.csv:row=630;BBB_results.csv:row=630;Solubility_results.csv:row=630;Lipophilicity_results.csv:row=631
CHEMBL105060,DNK333,CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.26; logP 6.06,repurposing_candidates.csv:rc_row=17;CYP3A4_results.csv:row=17;CYP2C19_results.csv:row=17;CYP2D6_results.csv:row=17;CYP1A2_results.csv:row=17;CYP2C9_results.csv:row=17;hERG_results.csv:row=17;AMES_results.csv:row=17;PGP_results.csv:row=17;PAMPA_results.csv:row=17;BBB_results.csv:row=17;Solubility_results.csv:row=17;Lipophilicity_results.csv:row=17
CHEMBL1257040,TRIFLUOPERAZINE HYDROCHLORIDE,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.92; logP 5.79,repurposing_candidates.csv:rc_row=359;CYP3A4_results.csv:row=321;CYP2C19_results.csv:row=321;CYP2D6_results.csv:row=321;CYP1A2_results.csv:row=321;CYP2C9_results.csv:row=321;hERG_results.csv:row=321;AMES_results.csv:row=321;PGP_results.csv:row=321;PAMPA_results.csv:row=321;BBB_results.csv:row=321;Solubility_results.csv:row=321;Lipophilicity_results.csv:row=322
CHEMBL3544985,DASABUVIR SODIUM MONOHYDRATE,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[n-]c2=O)cc1C(C)(C)C.O.[Na+],18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -7.35; logP -0.17,repurposing_candidates.csv:rc_row=962;CYP3A4_results.csv:row=864;CYP2C19_results.csv:row=864;CYP2D6_results.csv:row=864;CYP1A2_results.csv:row=864;CYP2C9_results.csv:row=864;hERG_results.csv:row=864;AMES_results.csv:row=864;PGP_results.csv:row=864;PAMPA_results.csv:row=864;BBB_results.csv:row=864;Solubility_results.csv:row=864;Lipophilicity_results.csv:row=865
CHEMBL908,CHLORPROTHIXENE,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.43; logP 5.19,repurposing_candidates.csv:rc_row=1549;CYP3A4_results.csv:row=1355;CYP2C19_results.csv:row=1355;CYP2D6_results.csv:row=1355;CYP1A2_results.csv:row=1355;CYP2C9_results.csv:row=1355;hERG_results.csv:row=1355;AMES_results.csv:row=1355;PGP_results.csv:row=1355;PAMPA_results.csv:row=1355;BBB_results.csv:row=1355;Solubility_results.csv:row=1355;Lipophilicity_results.csv:row=1356
CHEMBL3188993,QUETIAPINE FUMARATE,O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.32; logP 5.42,repurposing_candidates.csv:rc_row=926;CYP3A4_results.csv:row=833;CYP2C19_results.csv:row=833;CYP2D6_results.csv:row=833;CYP1A2_results.csv:row=833;CYP2C9_results.csv:row=833;hERG_results.csv:row=833;AMES_results.csv:row=833;PGP_results.csv:row=833;PAMPA_results.csv:row=833;BBB_results.csv:row=833;Solubility_results.csv:row=833;Lipophilicity_results.csv:row=834
CHEMBL447955,SERLOPITANT,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.69; logP 7.68,repurposing_candidates.csv:rc_row=1268;CYP3A4_results.csv:row=1088;CYP2C19_results.csv:row=1088;CYP2D6_results.csv:row=1088;CYP1A2_results.csv:row=1088;CYP2C9_results.csv:row=1088;hERG_results.csv:row=1088;AMES_results.csv:row=1088;PGP_results.csv:row=1088;PAMPA_results.csv:row=1088;BBB_results.csv:row=1088;Solubility_results.csv:row=1088;Lipophilicity_results.csv:row=1089
CHEMBL6067995,BEROTRALSTAT HYDROCHLORIDE,Cl.Cl.N#Cc1cccc([C@@H](NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.39; logP 6.55,repurposing_candidates.csv:rc_row=1447;CYP3A4_results.csv:row=1254;CYP2C19_results.csv:row=1254;CYP2D6_results.csv:row=1254;CYP1A2_results.csv:row=1254;CYP2C9_results.csv:row=1254;hERG_results.csv:row=1254;AMES_results.csv:row=1254;PGP_results.csv:row=1254;PAMPA_results.csv:row=1254;BBB_results.csv:row=1254;Solubility_results.csv:row=1254;Lipophilicity_results.csv:row=1255
CHEMBL1672054,CASOPITANT,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -3.03; logP 6.65,repurposing_candidates.csv:rc_row=503;CYP3A4_results.csv:row=463;CYP2C19_results.csv:row=463;CYP2D6_results.csv:row=463;CYP1A2_results.csv:row=463;CYP2C9_results.csv:row=463;hERG_results.csv:row=463;AMES_results.csv:row=463;PGP_results.csv:row=463;PAMPA_results.csv:row=463;BBB_results.csv:row=463;Solubility_results.csv:row=463;Lipophilicity_results.csv:row=464
CHEMBL1713,CHLORPROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -4.63; logP 5.32,repurposing_candidates.csv:rc_row=524;CYP3A4_results.csv:row=484;CYP2C19_results.csv:row=484;CYP2D6_results.csv:row=484;CYP1A2_results.csv:row=484;CYP2C9_results.csv:row=484;hERG_results.csv:row=484;AMES_results.csv:row=484;PGP_results.csv:row=484;PAMPA_results.csv:row=484;BBB_results.csv:row=484;Solubility_results.csv:row=484;Lipophilicity_results.csv:row=485
CHEMBL1200632,CLINDAMYCIN PALMITATE HYDROCHLORIDE,CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@@H]1SC.Cl,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.20; logP 6.84,repurposing_candidates.csv:rc_row=138;CYP3A4_results.csv:row=137;CYP2C19_results.csv:row=137;CYP2D6_results.csv:row=137;CYP1A2_results.csv:row=137;CYP2C9_results.csv:row=137;hERG_results.csv:row=137;AMES_results.csv:row=137;PGP_results.csv:row=137;PAMPA_results.csv:row=137;BBB_results.csv:row=137;Solubility_results.csv:row=137;Lipophilicity_results.csv:row=137
CHEMBL1423,PIMOZIDE,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.42; logP 5.86,repurposing_candidates.csv:rc_row=409;CYP3A4_results.csv:row=369;CYP2C19_results.csv:row=369;CYP2D6_results.csv:row=369;CYP1A2_results.csv:row=369;CYP2C9_results.csv:row=369;hERG_results.csv:row=369;AMES_results.csv:row=369;PGP_results.csv:row=369;PAMPA_results.csv:row=369;BBB_results.csv:row=369;Solubility_results.csv:row=369;Lipophilicity_results.csv:row=370
CHEMBL1957287,TEGOBUVIR,Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -5.35; logP 6.73,repurposing_candidates.csv:rc_row=613;CYP3A4_results.csv:row=559;CYP2C19_results.csv:row=559;CYP2D6_results.csv:row=559;CYP1A2_results.csv:row=559;CYP2C9_results.csv:row=559;hERG_results.csv:row=559;AMES_results.csv:row=559;PGP_results.csv:row=559;PAMPA_results.csv:row=559;BBB_results.csv:row=559;Solubility_results.csv:row=559;Lipophilicity_results.csv:row=560
CHEMBL190333,RWJ-67657,OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1,18.333333333333332,10,55.0,24.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -2.73; logP 5.12,repurposing_candidates.csv:rc_row=592;CYP3A4_results.csv:row=538;CYP2C19_results.csv:row=538;CYP2D6_results.csv:row=538;CYP1A2_results.csv:row=538;CYP2C9_results.csv:row=538;hERG_results.csv:row=538;AMES_results.csv:row=538;PGP_results.csv:row=538;PAMPA_results.csv:row=538;BBB_results.csv:row=538;Solubility_results.csv:row=538;Lipophilicity_results.csv:row=539
CHEMBL119385,NEFLAMAPIMOD,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,18.333333333333332,10,50.0,23.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -7.09; logP 5.49,repurposing_candidates.csv:rc_row=78;CYP3A4_results.csv:row=77;CYP2C19_results.csv:row=77;CYP2D6_results.csv:row=77;CYP1A2_results.csv:row=77;CYP2C9_results.csv:row=77;hERG_results.csv:row=77;AMES_results.csv:row=77;PGP_results.csv:row=77;PAMPA_results.csv:row=77;BBB_results.csv:row=77;Solubility_results.csv:row=77;Lipophilicity_results.csv:row=77
CHEMBL1200901,HALOFANTRINE HYDROCHLORIDE,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12.Cl,18.333333333333332,10,50.0,23.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -6.47; logP 9.07,repurposing_candidates.csv:rc_row=189;CYP3A4_results.csv:row=187;CYP2C19_results.csv:row=187;CYP2D6_results.csv:row=187;CYP1A2_results.csv:row=187;CYP2C9_results.csv:row=187;hERG_results.csv:row=187;AMES_results.csv:row=187;PGP_results.csv:row=187;PAMPA_results.csv:row=187;BBB_results.csv:row=187;Solubility_results.csv:row=187;Lipophilicity_results.csv:row=188
CHEMBL2107360,PALIPERIDONE PALMITATE,CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O,18.333333333333332,10,50.0,23.333333333333332,L,KG-supported from 1 sources; hERG risk; logS -7.37; logP 9.11,repurposing_candidates.csv:rc_row=727;CYP3A4_results.csv:row=672;CYP2C19_results.csv:row=672;CYP2D6_results.csv:row=672;CYP1A2_results.csv:row=672;CYP2C9_results.csv:row=672;hERG_results.csv:row=672;AMES_results.csv:row=672;PGP_results.csv:row=672;PAMPA_results.csv:row=672;BBB_results.csv:row=672;Solubility_results.csv:row=672;Lipophilicity_results.csv:row=673
CHEMBL38827,LUMEFANTRINE,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,18.333333333333332,10,45.0,22.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -7.11; logP 9.15,repurposing_candidates.csv:rc_row=1054;CYP3A4_results.csv:row=923;CYP2C19_results.csv:row=923;CYP2D6_results.csv:row=923;CYP1A2_results.csv:row=923;CYP2C9_results.csv:row=923;hERG_results.csv:row=923;AMES_results.csv:row=923;PGP_results.csv:row=923;PAMPA_results.csv:row=923;BBB_results.csv:row=923;Solubility_results.csv:row=923;Lipophilicity_results.csv:row=924
CHEMBL303933,PIPERAQUINE,Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,18.333333333333332,10,45.0,22.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -6.22; logP 5.42,repurposing_candidates.csv:rc_row=891;CYP3A4_results.csv:row=799;CYP2C19_results.csv:row=799;CYP2D6_results.csv:row=799;CYP1A2_results.csv:row=799;CYP2C9_results.csv:row=799;hERG_results.csv:row=799;AMES_results.csv:row=799;PGP_results.csv:row=799;PAMPA_results.csv:row=799;BBB_results.csv:row=799;Solubility_results.csv:row=799;Lipophilicity_results.csv:row=800
CHEMBL2219425,ARIPIPRAZOLE LAUROXIL,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,18.333333333333332,10,45.0,22.083333333333332,L,KG-supported from 1 sources; hERG risk; logS -7.79; logP 8.68,repurposing_candidates.csv:rc_row=813;CYP3A4_results.csv:row=722;CYP2C19_results.csv:row=722;CYP2D6_results.csv:row=722;CYP1A2_results.csv:row=722;CYP2C9_results.csv:row=722;hERG_results.csv:row=722;AMES_results.csv:row=722;PGP_results.csv:row=722;PAMPA_results.csv:row=722;BBB_results.csv:row=722;Solubility_results.csv:row=722;Lipophilicity_results.csv:row=723
CHEMBL1200986,HALOPERIDOL DECANOATE,CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,18.333333333333332,10,35.0,19.583333333333332,L,KG-supported from 1 sources; hERG risk; logS -8.70; logP 8.12,repurposing_candidates.csv:rc_row=209;CYP3A4_results.csv:row=207;CYP2C19_results.csv:row=207;CYP2D6_results.csv:row=207;CYP1A2_results.csv:row=207;CYP2C9_results.csv:row=207;hERG_results.csv:row=207;AMES_results.csv:row=207;PGP_results.csv:row=207;PAMPA_results.csv:row=207;BBB_results.csv:row=207;Solubility_results.csv:row=207;Lipophilicity_results.csv:row=208
